<SEC-DOCUMENT>0000939767-17-000137.txt : 20170802
<SEC-HEADER>0000939767-17-000137.hdr.sgml : 20170802
<ACCEPTANCE-DATETIME>20170802161521
ACCESSION NUMBER:		0000939767-17-000137
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170802
DATE AS OF CHANGE:		20170802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		171000075

	BUSINESS ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel2017063010-q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEA79F67C9EEF288DA15D12B9BC574C4F"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </font><font style="font-family:inherit;font-size:10pt;">000-30235</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:22pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:22pt;"><font style="font-family:inherit;font-size:22pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3257395</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">210 East Grand Ave.</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South San Francisco, CA 94080</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(650) 837-7000</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:inherit;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253; </font><font style="font-family:inherit;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:40%;"></td><td style="width:11%;"></td><td style="width:23%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.    </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168; </font><font style="font-family:inherit;font-size:10pt;">No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">July&#160;26, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">293,904,704</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the registrant&#8217;s common stock outstanding.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s21B61A6609634ABEE2D512B9BC6BE703"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:80%;"></td><td style="width:12%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s7AD7AB01191B5A7E246612B9E4D144C1"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">PART I - FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s66A1E3E471F4AE8673B312B9E4EF2A75"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s66A1E3E471F4AE8673B312B9E4EF2A75">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s573FAFE5FC45021B4B7F12B9BC6B76CD"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets &#8211; June 30, 2017 and December 31, 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s573FAFE5FC45021B4B7F12B9BC6B76CD">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3B7F46153532C116506B12B9BC9D430D"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations &#8211; Three and Six Months Ended June 30, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s3B7F46153532C116506B12B9BC9D430D">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9158D482966969F180A12B9BCCF1ED1"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income (Loss) &#8211; Three and Six Months Ended June 30, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sF9158D482966969F180A12B9BCCF1ED1">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1FB0B417C599C6E9A28B12B9BCD9CAB3"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows &#8211; Six Months Ended June 30, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s1FB0B417C599C6E9A28B12B9BCD9CAB3">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85B1DFCA55240F4879CD12B9E61BEFA6"><font style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s85B1DFCA55240F4879CD12B9E61BEFA6">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7DDA023E48BBC6C60E9B12B9E9283360"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7DDA023E48BBC6C60E9B12B9E9283360">23</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s20351FF0BB60FC4CB18912B9C781CC1C"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s20351FF0BB60FC4CB18912B9C781CC1C">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s6D7386C6E937BED144A212B9EA62D018"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s6D7386C6E937BED144A212B9EA62D018">33</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s7D5383119B8E842ADE5512B9EA807790"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">PART II - OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s35A16B64161751E846C912B9EAB2A7B1"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s35A16B64161751E846C912B9EAB2A7B1">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s911FB6EED5FBCE1711B012B9EAD02D13"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s911FB6EED5FBCE1711B012B9EAD02D13">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s5A3550C600779A5C55AD12B9EB027FFC"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s5A3550C600779A5C55AD12B9EB027FFC">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sA5BF62738A838C9AE9B712B9EB209590"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sA5BF62738A838C9AE9B712B9EB209590">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s9E144BFEE04AD56A64EC12B9EB5C71A8"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s9E144BFEE04AD56A64EC12B9EB5C71A8">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s2EC3BEAA468712C1A87512B9EB7AD0B3"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s2EC3BEAA468712C1A87512B9EB7AD0B3">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sEA7FBE1DE3250056379812B9EBACC7DD"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sEA7FBE1DE3250056379812B9EBACC7DD">53</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s0822ADA96F85CEB9DCF312B9CA0F798F"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">SIGNATURES</font></a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;" href="#s69B77D974649F523379412B9EBFCC4E6"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-weight:bold;text-decoration:underline;">EXHIBIT INDEX</font></a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2</font></div></div><hr style="page-break-after:always"><div><a name="s7AD7AB01191B5A7E246612B9E4D144C1"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I - FINANCIAL INFORMATION</font></div><div><a name="s66A1E3E471F4AE8673B312B9E4EF2A75"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;Item 1. Financial Statements</font></div><div><a name="s573FAFE5FC45021B4B7F12B9BC6B76CD"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016*</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402,239</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">469,001</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,532</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,919</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,923</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,663</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 293,727,630 and 289,923,798 at June 30, 2017 and December 31, 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,097,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,072,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(416</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,949,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,983,147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,511</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,532</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div><a name="s3B7F46153532C116506B12B9BC9D430D"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,962</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,679</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,560</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,727</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,823</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring (recovery) charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,895</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income and other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,259</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,228</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing net income (loss) per share, basic </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing net income (loss) per share, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font></div><div><a name="sF9158D482966969F180A12B9BCCF1ED1"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income consisted solely of unrealized gains or losses, net on available-for-sale securities arising during the periods presented. There were nominal or </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities and there was </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;income tax expense related to other comprehensive income during those periods. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these condensed consolidated financial statements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><a name="s1FB0B417C599C6E9A28B12B9BCD9CAB3"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discounts and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual of interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(639</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,087</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(192</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,049</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">519</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,779</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,873</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from maturities of restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,809</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(199,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes paid related to net share settlement of equity awards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of convertible notes and term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185,788</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172,086</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,807</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,212</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental cash flow disclosure - non-cash investing and financing activity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction-in-progress deemed to have been acquired under build-to-suit lease</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,530</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><a name="s85B1DFCA55240F4879CD12B9E61BEFA6"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div><a name="sCE1EA887EB6B9C67EC8312B9BD0B7C26"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the commercial marketplace. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;tablets approved for previously treated advanced renal cell carcinoma (&#8220;RCC&#8221;) and COMETRIQ</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is a formulation of cobimetinib, a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The condensed consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the United States (&#8220;U.S.&#8221;) dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended June 30, 2017 and July 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended June 30, 2017 and June 30, 2016, and the years ended December&#160;31, 2017 and December&#160;31, 2016, respectively.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating results for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Correction of an Immaterial Error</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the third quarter of 2016, we identified errors in the Consolidated Balance Sheets and Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for 2015, 2014, 2013, and 2012, and in the unaudited interim Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for all prior interim fiscal periods from September 30, 2012 through June 30, 2016. Specifically, in 2012 we incorrectly calculated 1) the allocation between Additional paid-in capital and Convertible notes of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$287.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;aggregate principal amount from our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Convertible Senior Subordinated Notes due 2019 (&#8220;2019 Notes&#8221;); and 2) the amortization of the debt discount associated with the 2019 Notes during 2012 and all subsequent periods.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Having evaluated the materiality of these errors from a quantitative and qualitative perspective, management has concluded that although the accumulation of these errors was significant to the three and nine months ended September 30, 2016, the correction of these errors would not be material to any individual prior period, and did not have an effect on the trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 99, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Materiality</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and Staff Accounting Bulletin No. 108, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Because management has concluded that these errors are not material, we will correct them prospectively when the consolidated balance sheets, statements of operations, comprehensive loss and cash flows for such periods are included in future filings.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Comprehensive Loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These errors did not affect any other caption or total in our unaudited condensed consolidated financial statements as of and for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. See &#8220;Note 1 - Organization and Summary of Significant Accounting Policies&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the amounts of the corrections and the amounts that should have been reported for 2015, 2014, 2013, and 2012 in the affected line items of the statements of operations, statements of comprehensive loss and statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in accrued product sales discounts payable to our customers as of December 31, 2016 from Other current liabilities to Trade and other receivables in the accompanying Condensed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Consolidated Balance Sheets. We have also reclassified the related balances between the Changes in assets and liabilities line items in the accompanying Condensed Consolidated Statements of Cash Flows for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We operate as a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">single</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reportable segment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-09,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-09&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, and no prior periods were restated as a result of this change in accounting principle, with a cumulative adjustment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to accumulated deficit and additional paid-in-capital as of January 1, 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-09, we also recorded an increase to the federal and state net operating losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for excess tax benefits previously not included. The resulting increase to the deferred tax assets of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is offset by a corresponding increase to the valuation allowance, resulting in a net </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impact on our income tax expense and our Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on our Condensed Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in cash provided by operating activities by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;along with a corresponding increase in cash used in financing activities in our Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2014-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2014-09&#8221;).&#160;In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which delays the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, but allows us to adopt the standard one year earlier. We will adopt ASU 2014-09 in the first quarter of fiscal year 2018. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have substantially completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of revenue from product sales. We do expect that ASU 2014-09 will impact the timing of recognition of revenue for our collaboration arrangements. We expect to reclassify deferred revenue to retained earnings (a concept known as lost revenue) for amounts associated with certain of our collaboration arrangements upon recording our transition adjustment to accumulated loss on January 1, 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration arrangements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.</font></div><div><a name="sBD0D87116972EC2987DD12B9BD65C1C3"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2: COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement (the &#8220;Ipsen Collaboration Agreement&#8221;) with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ipsen Pharma SAS (&#8220;Ipsen&#8221;) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the commercialization and further development of cabozantinib. Pursuant to the terms of the Ipsen Collaboration Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ipsen </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan (the &#8220;Ipsen Territory&#8221;). The Ipsen Collaboration Agreement was subsequently amended in December 2016 (the &#8220;Amendment&#8221;) to include commercialization rights in Canada in the Ipsen Territory. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the Ipsen Collaboration Agreement, Ipsen paid us an upfront nonrefundable payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in March 2016. Additionally, as a result of the Amendment, we received a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upfront nonrefundable payment from Ipsen in December 2016 and, as a result of the approval of cabozantinib in second-line RCC by the European Commission (&#8220;EC&#8221;) in September 2016, we received a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone in November 2016. We are receiving a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;royalty on the initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of net sales by Ipsen, and are entitled to receive a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;royalty on the next </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of net sales by Ipsen. After the initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of sales, we are entitled to receive a tiered royalty of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">22%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on annual net sales by Ipsen; these tiers will reset each calendar year. We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the Ipsen Collaboration Agreement; global development costs for additional trials will be shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">35%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of such costs, provided Ipsen opts in to participate in such additional trials. Pursuant to the terms of the Ipsen Collaboration Agreement, we will remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities. As part of the collaboration agreement, we entered into a supply agreement pursuant to which we will supply finished, labeled product to Ipsen for distribution in the Ipsen Territories at our cost, as defined in the agreement, which excludes the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;royalty we are required to pay GlaxoSmithKline (&#8220;GSK&#8221;) on Ipsen&#8217;s Net Sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Ipsen Collaboration Agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Ipsen for all development and commercial activities, research and development services, and participation on the joint steering, development and commercialization committees (as defined in the Ipsen Collaboration Agreement). We determined that these deliverables do not have stand-alone value and accordingly, combined these deliverables into a single unit of accounting and allocated the entire arrangement consideration to that combined unit of accounting. As a result, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, received in the first quarter of 2016 and the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upfront payment received in December 2016 in consideration for the development and commercialization rights in Canada are being recognized ratably over the term of the Ipsen Collaboration Agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the European Union. At the time we entered into the Ipsen Collaboration Agreement, we also determined that the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone we achieved upon the approval of cabozantinib by the EC in second-line RCC was not substantive due to the relatively low degree of uncertainty and relatively low amount of effort required on our part to achieve the milestone as of the date of the collaboration agreement; the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was deferred entirely until the date of the European Medicines Agency&#8217;s approval of cabozantinib in second-line RCC in September 2016 and has since been recognized ratably over the remainder of the term of the Ipsen Collaboration Agreement. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestones for the first commercial sales of CABOMETYX in Germany and the United Kingdom were determined to be substantive at the time we entered into the Ipsen Collaboration Agreement and were recognized as collaboration revenues in the fourth quarter of 2016. We determined that the remaining development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. Reimbursements for development costs are classified as revenue as the development services represent our ongoing major or central operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the three months ended March 31, 2017, we reclassified </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of deferred revenue to Accrued collaboration liabilities and Other long-term liabilities, and accordingly adjusted our amortization of the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as a result of a change in operational responsibilities for certain clinical programs in the Ipsen Territory. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;toward the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of reimbursements due to Ipsen for these clinical programs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;Note 2 - Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for additional description of our collaboration agreement with Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of upfront payments and deferred milestone</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of supplied product</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty payable to GSK on net sales by Ipsen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues under the Ipsen Collaboration Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the Ipsen Collaboration Agreement was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$219.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement (the &#8220;Genentech Collaboration Agreement&#8221;). Under the terms of the Genentech Collaboration Agreement for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. The profit and loss share has multiple tiers: we are entitled to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of profits and losses from the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of U.S. actual sales, decreasing to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of profits and losses from U.S. actual sales in excess of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$400.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In addition, we are entitled to low double-digit royalties on ex-U.S. net sales. In November 2013, we exercised an option under the Genentech Collaboration Agreement to co-promote in the U.S. In 2015, we began fielding </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 3, 2016, we filed a Demand for Arbitration before JAMS in San Francisco, California asserting claims against Genentech related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&#8217;s commercialization in the U.S. Our arbitration demand asserted that Genentech breached the Genentech Collaboration Agreement by, amongst other breaches, failing to meet its diligence and good faith obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 13, 2016, Genentech asserted a counterclaim for breach of contract seeking monetary damages and interest related to the cost allocations under the Genentech Collaboration Agreement. On December 29, 2016, however, Genentech withdrew its counterclaim against us and stated that it would unilaterally change its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy, both retrospectively and prospectively. The revised allocation approach substantially reduced our exposure to costs associated with promotion of the COTELLIC plus Zelboraf combination in the U.S. However, other significant issues remained in dispute between the parties as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Genentech&#8217;s action did not address the claims in our demand for arbitration related to Genentech&#8217;s clinical development of cobimetinib, or pricing or promotional costs for COTELLIC in the U.S. and it did not fully resolve claims over revenue allocation. In addition, Genentech&#8217;s unilateral action did not clarify how it intended to allocate promotional costs incurred with respect to the promotion of other combination therapies that include cobimetinib for other indications that may be developed or are in development and may be approved. As a result, we continued to press our position before the arbitral panel to obtain a just resolution of these claims. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 8, 2017, the parties settled the arbitration, which was dismissed with prejudice. The settlement does not provide for payments in settlement of the asserted claims; as part of the settlement, on July 19, 2017, we entered into an amendment to the Genentech Collaboration Agreement (the &#8220;Genentech Amendment&#8221;) which provides for a revised revenue </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and cost-sharing arrangement, effective as of July 1, 2017, that is applicable to current and potential future commercial uses of COTELLIC. See &#8220;Note 13 - Subsequent Event&#8221; for a further description of the Genentech Amendment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. losses included in Selling, general and administrative expenses</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,630</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,923</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">A portion of the accrual for losses for </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech&#8217;s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S. losses under the Genentech Collaboration Agreement include our share of the net loss from the collaboration, as well as personnel and other costs we have incurred to co-promote COTELLIC plus Zelboraf in the U.S.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Royalty revenues from the Genentech Collaboration Agreement are based on amounts reported to us by Genentech and are recorded when such information becomes available to us. For prior periods, from the launch of COTELLIC through December 31, 2016, such information was not available until the following quarter, meaning that historically we recorded royalty revenues on a one quarter lag. Beginning in 2017, such information became available to us in the current quarter. As a result of this change, during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in addition to the royalties reported to us for that period we also recorded </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in royalties for the sales activity related to the three months ended December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2017, we entered into a collaboration and license agreement (the &#8220;Takeda Collaboration Agreement&#8221;) with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the Takeda Collaboration Agreement, Takeda will have exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The companies have also agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration will be governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the Takeda Collaboration Agreement, Takeda paid us an upfront nonrefundable payment of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2017. We will be eligible to receive development, regulatory and first-sales milestones of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$95.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to second-line RCC, first-line RCC and second-line hepatocellular carcinoma (&#8220;HCC&#8221;), as well as additional development, regulatory and first-sales milestone payments for potential future indications. The Takeda Collaboration Agreement also provides that we will be eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;associated with potential sales milestones. We will also receive royalties on net sales of cabozantinib in Japan at an initial tiered rate of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">24%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;on net sales for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of cumulative net sales. Thereafter, the royalty rate will be adjusted to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;on annual net sales.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Takeda will be responsible for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the costs associated with the global&#160;cabozantinib&#160;development plan&#8217;s current and future trials, provided Takeda opts to participate in such future trials, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the Takeda Collaboration Agreement, we will remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration. As part of the collaboration, the parties will enter into appropriate supply agreements for the manufacture and supply of cabozantinib for Takeda&#8217;s territory.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of upfront payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,313</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues under the Takeda Collaboration Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There was no such revenue during the comparable periods in 2016. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the Takeda Collaboration Agreement was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Takeda Collaboration Agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;following the first commercial sale of cabozantinib in Japan shall constitute a material breach of the Takeda Collaboration Agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the Takeda Collaboration Agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the Takeda Collaboration Agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the Takeda Collaboration Agreement upon </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">twelve months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Takeda Collaboration Agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Takeda for all development and commercial activities, research and development services, and participation on the joint executive, development and commercialization committees (as defined in the Takeda Collaboration Agreement). We determined that these deliverables, other than the commercial supply and joint commercialization committee participation, are non-contingent in nature. The commercial supply deliverable was deemed contingent, primarily due to the fact that there is uncertainty around approval in Japan, which is dependent on successful bridging study results. We also determined that the non-contingent deliverables do not have stand-alone value, because each one of them has value only if we meet our obligation as a whole to provide Takeda with research and development services, including clinical supply of cabozantinib under the Takeda Collaboration Agreement. Accordingly, we combined the non-contingent deliverables into a single unit of accounting and allocated the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upfront fee to that combined unit of accounting. We also determined that the level of effort required of us to meet our obligations under the Takeda Collaboration Agreement is not expected to vary significantly over the development period of the Takeda Collaboration Agreement. As a result, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, received in the first quarter of 2017, will be recognized ratably over the development period of the Takeda Collaboration Agreement of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We determined that the development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Bristol-Myers Squibb Collaboration - First-Line Advanced RCC, Bladder Cancer and HCC Combination Studies </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with Bristol-Myers Squibb Company</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(the &#8220;BMS Collaboration Agreement&#8221;) for the purpose of evaluating the combination of cabozantinib with nivolumab or of cabozantinib with nivolumab and ipilimumab in various tumor types, including, in RCC, HCC and bladder cancer. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To date, a phase 3 trial in first-line advanced RCC and a phase 2 trial in HCC evaluating the combination have been initiated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the terms of the BMS Collaboration Agreement, each party will grant to the other a non-exclusive, worldwide (within the collaboration territory as defined in the BMS Collaboration Agreement), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts will be governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the supply agreement entered into between the parties in April 2017, and costs for each such trial will be shared equally between the parties, unless two Bristol-Myers Squibb Company (&#8220;BMS&#8221;) compounds will be utilized in such trial, in which case BMS will bear </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two-thirds</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs for such study treatment arms and we will bear </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one-third</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the costs. Unless earlier terminated, the BMS Collaboration Agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. Ipsen has opted in to participate in the phase 3 pivotal trial in first-line advanced RCC and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at their choosing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The Roche Group Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2017, we established a clinical trial collaboration with The Roche Group (&#8220;Roche&#8221;) for the purpose of evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the mater clinical supply agreement entered into by the parties in February 2017. Based on the dose-escalation results, the trial has the potential to enroll up to four expansion cohorts, including a cohort of patients with previously untreated advanced clear cell RCC and three cohorts of urothelial carcinoma, namely platinum eligible first-line patients, first or second-line platinum ineligible patients and patients previously treated with platinum-containing chemotherapy. The trial was initiated in June 2017 and is open for enrollment. We are the sponsor of the trial, and Roche is responsible for supplying atezolizumab. Ipsen has opted to participate in the study and will have access to the results to support potential future development in its territories.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GlaxoSmithKline Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In October 2002, we established a collaboration with GSK to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under the terms of the product development and commercialization agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. As a result, we retained the rights to develop, commercialize, and license cabozantinib, subject to payment to GSK of a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;royalty on net sales of any product incorporating cabozantinib. The product development and commercialization agreement was terminated during 2014, although GSK will continue to be entitled to a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;royalty on net sales of any product incorporating cabozantinib, including COMETRIQ and CABOMETYX. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties earned by GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Royalties earned by GSK are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen in the accompanying Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in contract revenues from a milestone payment received from BMS related to its ROR gamma program, and during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in contract revenues from a milestone payment received from Merck related to its worldwide license of our phosphoinositide-3 kinase-delta program. There was no such revenue during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. See &#8220;Note 2 - Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for a description of our existing collaboration agreements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><a name="sD5B854B951AC4D3C173812B9BDDD59B5"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3: CASH AND INVESTMENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our cash equivalents and investments are classified as available-for-sale. The following tables summarize cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">214,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">214,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">380,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">380,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">268,234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">268,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">479,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">479,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under our loan and security agreement with Silicon Valley Bank, we were required to maintain compensating balances on deposit in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or more investment accounts with Silicon Valley Bank or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of its affiliates. The total collateral balance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$81.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is reflected in our Condensed Consolidated Balance Sheet in short-term investments; as a result of our repayment of the term loan with Silicon Valley Bank, the compensating balance requirement was terminated as of March 29, 2017. See &#8220;Note 7 - Debt&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information regarding the collateral balance requirements under our Silicon Valley Bank loan and security agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following tables summarize our cash equivalents and investments by security type as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were nominal or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;we did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;investments in an unrealized loss position with gross unrealized losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and an aggregate fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$133.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The investments in an unrealized loss position comprise corporate bonds with an aggregate fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$117.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and securities issued by U.S. Treasury and government sponsored enterprises</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;with an aggregate fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The unrealized losses were not attributed to credit risk, but rather associated with the changes in interest rates. Based on the scheduled maturities of our investments, we concluded that the unrealized losses in our investment securities are not other-than-temporary, as it is more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the fair value of securities classified as available-for-sale by contractual maturity as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mature within One Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">After One Year through Two Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,214</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,986</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash is excluded from the table above. The classification of certain restricted investments is dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. Therefore, certain long-term restricted cash and investments have contractual maturities within one year. </font></div><div><a name="s9E8906ADD2A02D26276F12B9BE57EA7E"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventory consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,919</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,568</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: non-current portion included in Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We generally relieve inventory on a first-expiry, first-out basis. A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and, therefore, was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">revenues. Such write-downs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">; the amount of such write-downs was nominal for the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The non-current portion of inventory is expected to be sold in future periods more than 12 months from the date presented and consists of finished goods as of June 30, 2017 and a portion of the active pharmaceutical ingredient that is included in raw materials and work in process inventories as of December 31, 2016. </font></div><div><a name="sdb11373cceaf416689e0a1e8209588f0"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction-in-progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,953</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,828</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during both the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Build-to-Suit Lease </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with Ascentris 105, LLC (&#8220;Ascentris&#8221;), to lease </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;square feet of space in office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the &#8220;Premises&#8221;). See &#8220;Note 10. Commitments&#8221; for a description of the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Lease, we received a tenant improvement allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Ascentris, for the costs associated with the design, development and construction of tenant improvements for the Premises. We are obligated to fund all costs incurred in excess of the tenant improvement allowance and certain indemnification obligations related to the construction activities. We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises including the building shells did not qualify as &#8220;normal tenant improvements&#8221; under Accounting Standards Codification topic 840, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Accordingly, for accounting purposes, we are the deemed owner of such portions of the Premises during the construction period. As such, we will capitalize the construction costs as a build-to-suit property within property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. The capitalized construction costs will also include the estimated tenant improvements incurred by Ascentris. We will also recognize a corresponding build-to-suit lease obligation included in Other long-term liabilities for the same amount. As of June 30, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of costs were capitalized in construction-in-progress with a corresponding build-to-suit lease obligation recognized related to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once the construction is complete, we will consider the requirements for sale-leaseback accounting treatment, including evaluating whether all risks of ownership have been transferred back to Ascentris, as evidenced by a lack of continuing involvement in the leased property. If the arrangement does not qualify for sale-leaseback accounting treatment, the building assets will remain on our consolidated balance sheets at their historical cost. </font></div><div><a name="s030BC8A49628CD5C85CB12B9BE589E5B"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. DEBT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amortized carrying amount of our debt consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Secured Convertible Notes due 2018 (&#8220;Deerfield Notes&#8221;)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;Note 7 - Debt&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for additional information on the terms of our debt, including a description of the material features of the Deerfield Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Deerfield Notes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. The repayment amount totaled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which comprised </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$113.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in principal, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of interest paid in kind paid through the repayment date, a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prepayment penalty associated with the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">early repayment of the notes and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in accrued and unpaid interest. As a result of the early repayment, there was a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;loss on the extinguishment of the debt which comprised the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prepayment penalty </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and the unamortized fees and costs on the date of the repayment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our early repayment of the notes, the outstanding principal amount of the Deerfield Notes bore interest at the rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per annum to be paid in cash, quarterly in arrears, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per annum to be paid in kind, quarterly in arrears, for a total interest rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per annum. The following is a summary of interest expense for the Deerfield Notes (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stated coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,151</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,484</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The balance of unamortized fees and costs was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which was recorded as a reduction of the carrying amount of the Deerfield Notes on the accompanying Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Silicon Valley Bank Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 29, 2017, we repaid all amounts outstanding under our term loan with Silicon Valley Bank. The repayment included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$80.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in principal plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in accrued and unpaid interest. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;gain or loss on the extinguishment of debt as a result of the repayment of the term loan. Prior to our early repayment of the term loan, the principal amount outstanding under the term loan had accrued interest at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;per annum, which was due and payable monthly. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with the terms of the loan and security agreement, we were required to maintain an amount equal to at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, but not to exceed </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">107%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, of the outstanding principal balance of the term loan on deposit in one or more investment accounts with Silicon Valley Bank or one of its affiliates as support for our obligations under the loan and security agreement. We were entitled to retain income earned on the amounts maintained in such accounts. The total collateral balance as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$81.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and was reflected in our Condensed Consolidated Balance Sheet in Short-term investments as the amounts were not restricted as to withdrawal. As a result of our repayment of the term loan, the compensating balance requirement was terminated as of March 29, 2017.</font></div><div><a name="s8EC638266F5864FB664E12B9BEAE4C21"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and there were no transfers of financial assets or liabilities classified as Level 3 during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The carrying amounts of cash, trade and other receivables, accounts payable, accrued clinical trial liabilities, accrued compensation and benefits, and other liabilities approximate their fair values and are excluded from the tables above.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing, which are Level 2 inputs.</font></div><div><a name="s7D7618F6A53D7471D99B12B9BF3A4F08"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,427</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value of our stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of stock options and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ESPP</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We considered implied volatility as well as our historical volatility in developing our estimate of expected volatility. The expected life computation is based on historical exercise patterns and post-vesting termination behavior. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is presented below (dollars in thousands</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,999,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,242,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,269,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">426,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,181,093</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.72 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">24,237,774</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares were available for grant under our stock option plans.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of restricted stock unit (&#8220;RSU&#8221;) activity for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is presented below (dollars in thousands</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,469,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,272</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sEE168592DA5244D3080E12B9BFD0E50D"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax expense consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recorded income tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which comprises our computed income tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reduced by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of excess benefits associated with equity compensation. The income tax expense for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><a name="s6032b937510e4707921172db493d7d90"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. COMMITMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On May 2, 2017, we entered into the Lease with Ascentris for an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;square feet of space in office and research facilities located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California. We also have the right to make certain tenant improvements to the space leased on the Premises. The Lease has an initial term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;with a target commencement date of March 1, 2018 and rent payments will begin upon the target commencement date. We have </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">five</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year options to extend the Lease and a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-time option to terminate the Lease without cause on the last day of the 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year of the initial term. We are obligated to make lease payments totaling </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;over the Lease term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">170,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;square feet of space, as that additional space becomes available over the remainder of the initial term at 1601, 1701, 1751, and 1801 Harbor Bay Parkway, Alameda, California at a market rate determined according to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are deemed, for accounting purposes only, to be the owner of portions of the Premises, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;building shells, even though we are not the legal owner. See &#8220;Note 5. Property and Equipment - Build-to-Suit Lease&#8221; </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for a further description of the accounting for that portion of the Premises.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the aggregate future minimum lease payments under our leases are as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other financing obligations</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other financing obligations includes payments related to build-to-suit lease arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense and sublease income were as follows for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross rental expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(895</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net rental expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;Letter of Credit</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We obtained a standby letter of credit in May 2017 in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which may be drawn down by Ascentris in the event we fail to fully and faithfully perform all of our obligations under the Lease and to compensate Ascentris for all losses and damages Ascentris may suffer as a result of the occurrence of any default on our part not cured within the applicable cure period. As of June 30, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the standby letter of credit amount has been used.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;Note 13 - Commitments&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for a description of additional letters of credits that were entered into prior to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><a name="sAA5ABA05AD138CF11A1412B9BFDADF18"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares of common stock outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The 2014 Warrants are participating securities and the warrant holders do not have a contractual obligation to share in our losses. See &#8220;Note 8 - Common Stock and Warrants&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for a description of the 2014 Warrants.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth potentially dilutive shares of common stock that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deerfield Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Deerfield Notes were repaid in June 2017. The 2019 Notes were converted and redeemed between August and November 2016. </font></div><div><a name="sB55E061FB88B2FEA9E4C12B9C02000B2"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. CONCENTRATIONS OF CREDIT RISK</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially subject us to concentrations of credit risk are primarily trade and other receivables and investments. Investments consist of money market funds, commercial paper, corporate bonds with high credit quality, and securities issued by the U.S. Treasury and other government sponsored enterprises. All investments are maintained with financial institutions that management believes are creditworthy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Trade and other&#160;receivables are unsecured and are concentrated in the pharmaceutical and biotechnology industries. Accordingly, we may be exposed to credit risk generally associated with pharmaceutical and biotechnology companies. We </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">have incurred no bad debt expense since inception. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">19%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">17%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of our trade receivables are with Diplomat Specialty Pharmacy, Caremark L.L.C., affiliates of McKesson Corporation, and Accredo Health, Incorporated, respectively. All of these customers have historically paid promptly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. We have operations solely in the U.S., while some of our collaboration partners have headquarters outside of the U.S. and some of our clinical trials for cabozantinib are also conducted outside of the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows the revenues earned by geographic region. Net product revenues are attributed to regions based on the delivery location. Collaboration revenues are attributed to regions based on the location of our collaboration partner's headquarters (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Japan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recorded losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;relating to foreign exchange fluctuations for both the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><a name="sc4870410503948e1897de572e10254c6"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 13. SUBSEQUENT EVENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 19, 2017, we and Genentech entered into the Genentech Amendment. The Genentech Amendment was entered into in connection with the settlement of the arbitration concerning claims asserted by us against Genentech related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&#8217;s commercialization in the U.S. See &#8220;Note 2 - Collaboration Agreements - Genentech Collaboration&#8221; for additional information on the Genentech collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Genentech Amendment sets forth the parties&#8217; confirmation and agreement that we have exercised our co-promotion option and that, as such, we have the right to co-promote current and future Genentech combinations that include COTELLIC in the U.S. Pursuant to the terms of the Genentech Amendment, we will continue to be entitled to a share of U.S. profits and losses received in connection with the commercialization of COTELLIC, which share will continue to decrease as sales of COTELLIC increase in accordance with the profit share tiers as originally set forth in the Genentech Collaboration Agreement. However, effective as of July 1, 2017, the revenue for each sale of COTELLIC applied to the profit and loss statement for the Genentech Collaboration Agreement (the &#8220;Collaboration P&amp;L&#8221;) will be calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. While we will also continue to share U.S. commercialization costs for COTELLIC, the Genentech Amendment expressly sets forth that the amount of commercialization costs Genentech is entitled to allocate to the Collaboration P&amp;L will be reduced based on the number of Genentech products in any given combination including COTELLIC. The Genentech Amendment also provides for more detailed communication requirements for the parties related to COTELLIC research, development and commercialization activities and clarifies meeting and escalation procedures for the joint steering committee and the joint commercialization committee, each a body established under the Genentech Collaboration Agreement to coordinate activities with respect to COTELLIC.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><a name="s7DDA023E48BBC6C60E9B12B9E9283360"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The following discussion and analysis contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; &#8220;would,&#8221; &#8220;intend,&#8221; &#8220;continues,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;initiate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;trend,&#8221; or the negative of such terms or other similar expressions identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in Part II, Item&#160;1A of this Form 10-Q, as well as those discussed elsewhere in this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this report and the financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">, filed with the Securities and Exchange Commission, or SEC, on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">. Operating results are not necessarily indicative of results that may occur in future periods. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;tablets approved for previously treated advanced renal cell carcinoma, or RCC, and COMETRIQ</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is a formulation of cobimetinib, a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs for multiple oncology indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While our commercialization efforts for CABOMETYX and COMETRIQ are focused in the U.S., we have licensed development and commercialization rights to cabozantinib outside of the U.S. to Ipsen Pharma SAS, or Ipsen, and Takeda Pharmaceutical Company Ltd., or Takeda. Ipsen has been granted rights to cabozantinib outside of the U.S. and Japan, and Takeda has been granted rights to cabozantinib in Japan. Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we are working closely with them on these activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Beyond the approved indications of cabozantinib, we are engaged in a broad development program composed of over 45 ongoing or planned clinical trials in additional tumor types, many of which are conducted through our Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program, or NCI-CTEP, or our investigator sponsored trial program. The most notable studies at this time are CELESTIAL, our company-sponsored phase 3 trial of cabozantinib in advanced hepatocellular carcinoma, or HCC, for which we anticipate the planned second interim analysis with 75% of all required events to take place in the second half of 2017, and CABOSUN, a randomized phase 2 trial comparing cabozantinib to sunitinib in the first-line treatment of intermediate- or poor-risk RCC, patients, being conducted by The Alliance for Clinical Trials in Oncology, or The Alliance, through our CRADA with NCI-CTEP. In May 2016, The Alliance informed us that CABOSUN met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement of progression-free survival compared with sunitinib. The CABOSUN primary efficacy endpoint results were later confirmed by a blinded independent radiology review committee, or IRC, in June 2017. Based on these results, we are working towards the submission of a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration, or FDA, in the third quarter of 2017 for cabozantinib as a treatment for patients with previously untreated advanced RCC. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also interested in further examining cabozantinib&#8217;s potential in combination with immunotherapies to determine if outcomes for patients may be further improved. Building on preclinical and clinical observations that cabozantinib creates a more immune-permissive tumor environment potentially resulting in the cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of immune checkpoint inhibitors in multiple clinical trials. The most advanced of these combination studies includes a phase 3 trial evaluating cabozantinib with nivolumab (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Opdivo</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) or with nivolumab and ipilimumab (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Yervoy</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in first-line advanced RCC and a phase 2 evaluation of the same combination in HCC, each in collaboration with Bristol-Myers Squibb Company, or BMS. As part of our clinical collaboration with BMS, we also plan to evaluate cabozantinib with nivolumab or with nivolumab and ipilimumab in various other tumor types, including in bladder cancer. We have also initiated phase 1b dose escalation study evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Tecentriq</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in patients with locally advanced or metastatic solid tumors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to these advances connected with cabozantinib, significant progress continues to be made with respect to the clinical development, regulatory status and commercial potential of cobimetinib under our collaboration agreement with Genentech. Genentech is now conducting two phase 3 pivotal trials exploring the combination of cobimetinib with atezolizumab in colorectal carcinoma (IMblaze370) and melanoma (IMspire150 TRILOGY), and has announced plans to initiate a third phase 3 trial of cobimetinib in combination with atezolizumab in a distinct melanoma population (IMspire170) in the third quarter of 2017. Genentech recently announced that enrollment in IMblaze370 was completed in the first quarter of 2017. We believe that cobimetinib has the potential to provide us with a second meaningful source of revenue.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Second Quarter 2017 Business Development Updates and Financial Highlights</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the second quarter of 2017, we continued to build infrastructure intended to support our anticipated growth and evolution beyond our current product pipeline. Significant business development updates and financial highlights for the quarter include:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Development Updates</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, we entered into a lease agreement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for an aggregate of 110,783 square feet of space in office and research facilities in Alameda, California, which will become our corporate headquarters in 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2017, we initiated a phase 1b trial of cabozantinib and atezolizumab in locally advanced or metastatic solid tumors. The trial is divided in two parts: a dose-escalation phase and an expansion cohort phase. The trial will evaluate the optimal dose and schedule of daily oral administration of cabozantinib when given in combination with atezolizumab to inform the trial&#8217;s subsequent expansion stage. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2017, an analysis of CABOSUN conducted </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">on the basis of a blinded IRC review of radiographic images confirmed that cabozantinib demonstrated a clinically meaningful and statistically significant reduction in the rate of disease progression or death as measured by progression-free survival, or PFS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2017, BMS initiated a phase 3 trial, CheckMate 9ER, to evaluate cabozantinib in combination with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nivolumab</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or in combination </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with nivolumab and ipilimumab, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">versus sunitinib in patients with previously untreated, advanced or metastatic RCC. The primary endpoint for the trial is PFS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2017, we entered into an amendment to our collaboration agreement with Genentech in connection with the settlement of our arbitration with Genentech concerning </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">claims&#160;asserted by us against Genentech related to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the development, pricing and commercialization of COTELLIC. The amendment resolves our concerns outlined in the arbitration demand and provides for a revised revenue and cost-sharing arrangement, effective as of July 1, 2017, that is applicable to current and potential future commercial uses of COTELLIC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2017, we announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 10 presentations at the European Society for Medical Oncology, or ESMO, 2017 Congress, including from CABOSUN as a late-breaking abstract. Cabozantinib presentations will also include the phase 1b trial of cabozantinib, nivolumab, and ipilimumab in advanced genitourinary malignancies, as well as additional analyses of the METEOR trial in advanced RCC Cobimetinib presentations will include two data sets concerning forms of metastatic melanoma.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Financial Highlights</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net income for the second quarter 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.06</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, basic and diluted, compared to a net loss of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$(34.8) million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$(0.15)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, basic and fully diluted, for the second quarter of 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total revenues for the second quarter 2017 increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$99.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$36.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the second quarter of 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cost of goods sold for the second quarter 2017 increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the second quarter of 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses for the second quarter 2017 increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$28.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the second quarter of 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Selling, general and administrative expenses for the second quarter 2017 increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$40.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$35.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the second quarter of 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total other expense, net for the second quarter 2017 decreased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$(8.9) million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$(9.7) million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the second quarter of 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and investments decreased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$380.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$479.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2017, we retired a series of Secured Convertible Notes, referred to herein as the Deerfield Notes, originally issued in July 2010 to entities associated with Deerfield Management Company, or the Deerfield Entities, one year ahead of their July 2018 maturity date. We retired the Deerfield Notes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;by making a $123.8 million payment to the Deerfield E</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ntities on June 28, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;below for a discussion of the detailed components and analysis of the amounts above.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we may not be able to maintain or increase profitability on a quarterly or annual basis and we are unable to accurately predict the extent of long-range future profits or losses. Excluding fiscal 2011, our operating expenses have exceeded our revenues for each fiscal year, and we expect to continue to spend significant additional amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to expand our product pipeline through the measured resumption of drug discovery and the evaluation of in-licensing and acquisition opportunities that align with our oncology drug expertise, which efforts could involve substantial costs. As a result, we are unable to predict the extent of any future profits or losses because we expect to continue to incur substantial operating expenses and, consequently, we will need to generate substantial revenues to maintain or increase profitability.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We anticipate that we will continue to face a number of challenges and risks to our business that may impact our ability to execute on our 2017 business objectives. In particular, we anticipate that for the foreseeable future our ability to generate meaningful revenue to fund our commercial operations and our development and discovery programs is dependent upon the successful commercialization of CABOMETYX for the treatment of advanced RCC in territories where it has been or may be approved. The commercial potential of CABOMETYX for the treatment of advanced RCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of advanced RCC. Our ability to generate meaningful product revenue from CABOMETYX is also affected by a number of other factors, including the extent to which coverage and reimbursement for CABOMETYX is available from government and other third-party payers. Obtaining and maintaining appropriate coverage and reimbursement for CABOMETYX is increasingly challenging due to, among other things, efforts by payors to contain and slow increases in healthcare costs in the U.S. and worldwide, as well as increasing policy interest in the U.S. with respect to controlling pharmaceutical drug pricing practices. Our ability to fulfill the commercial potential of cabozantinib also depends on our ability to expand the compound&#8217;s use by generating data in clinical development that will support regulatory approval of cabozantinib in additional indications. Our immediate focus in this regard is the potential regulatory approval of our sNDA for cabozantinib as a treatment for patients with previously untreated advanced RCC based upon data from CABOSUN. Obtaining this approval represents a significant challenge because CABOSUN was not originally designed as a registrational trial. However, given the positive nature of CABOSUN results, combined with the confirming analysis of such results by the IRC, we are planning to submit a sNDA to the FDA during the third quarter of 2017. Achievement of our 2017 business objectives will also depend on our ability to adapt our development and commercialization strategy to navigate the increasing prevalence of immunotherapy, which is both a competitive threat and a potential opportunity due to interest in the use of combination therapy to treat cancer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the challenges we encounter while working toward the achievement of our development and commercial objectives for 2017, we also face significant challenges in our efforts to expand our pipeline through the&#160;measured resumption of internal drug discovery activities and the evaluation of in-licensing and acquisition opportunities. Internal discovery efforts require substantial technical, financial and human resources and may fail to yield product candidates for clinical development. Furthermore, we continue to operate in an environment with significant market competition for relevant product candidates, and, even if we are able to identify an attractive and available product candidate, we may not be able to in-license or acquire it on acceptable terms that would enable our continued growth as an organization.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the pharmaceutical industry with development and commercial operations. For a complete discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div><a name="sAB91DE35EEB0BE7036F212B9E965D395"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal Year Convention</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended June 30, 2017 and July 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended June 30, 2017 and June 30, 2016, and the years ended December&#160;31, 2017 and December&#160;31, 2016, respectively.</font></div><div><a name="s6FD4FEA010DD4390F30012B9C4D433B0"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,049</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,663</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,254</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,431</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,336</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,946</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License revenues</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,571</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,763</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty and product supply revenues, net </font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract revenues</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,962</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,216</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Includes amortization of upfront payments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Includes milestone payments.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,044</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,386</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,164</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, net product revenues increased </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">178%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">285%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in 2016. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the 360% and 715% increase in net product revenues for CABOMETYX as compared to the comparable period in 2016, was primarily due to a 326% and 667% increase, respectively, in the number of CABOMETYX units sold as well as an increase in the average selling price of the product. The increase in CABOMETYX sales volume was due to the commercial launch of CABOMETYX in late April 2016. CABOMETYX was approved by the FDA on April 25, 2016 as a treatment for patients with advanced RCC who have received prior anti-angiogenic therapy. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the 49% and 41% decrease in net product revenues for COMETRIQ as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was primarily due to a 58% and 54% decrease, respectively, in the number of COMETRIQ units sold; the decrease in units sold was partially offset by an increase in the average selling price of the product. The decrease in COMETRIQ sales volume was primarily driven by the adoption of CABOMETYX by our customers.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">License revenues consists of the recognition of the upfront payments and non-substantive milestone received in connection with our February 2016 collaboration agreement with Ipsen and the upfront payment received in connection with our January 2017 collaboration agreement with Takeda. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of such revenue in connection with the Ipsen collaboration agreement, as compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, during the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of such revenue in connection with the Takeda collaboration agreement. No such revenue was recognized for Takeda during the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The increase in such revenues is due to the timing of the execution of those agreements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Royalty and product supply revenues, net, primarily consisted of royalties on ex-U.S. net sales of COTELLIC under our collaboration agreement with Genentech for cobimetinib. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract revenues for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reflect recognition of a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone earned from BMS related to the ROR Gamma program. Contract revenues for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reflect a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone earned from Merck related to its worldwide license of our phosphoinositide-3 kinase-delta program. There was no such revenue for either the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Development cost reimbursements for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;consisted of reimbursements pursuant to our collaboration and license agreements, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, under our agreement with Ipsen and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, under our agreement with Takeda. There were no such development cost reimbursements during the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total revenues by significant customer were as follows (dollars in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caremark L.L.C.</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,137</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,137</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,459</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,459</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Others, individually less than 10% of total revenues for all periods presented</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,658</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,009</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recognize product revenue net of discounts and allowances that are further described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Chargebacks and discounts for prompt payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other customer credits and co-pay assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(718</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. Balances as of December 31, 2016 have been reclassified to reflect that presentation. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The increase in the reserve balance at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was the result of an increase in product sales volume and a shift in payer mix to government programs, which was offset by the prior period adjustments for chargebacks and certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rebates. We expect our discounts and allowances, including rebates, as a percentage of gross product revenue to increase during the remainder of 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as our business evolves and the number of patients participating in government programs increases and the discounts or rebates to government payers increase, as well as engaging in commercial contracting which may result in additional discounts or rebates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The cost of goods sold and our gross margins were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;royalty payable to GlaxoSmithKline on net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, and other third party logistics costs. Portions of the manufacturing costs for inventory were incurred prior to the regulatory approval of CABOMETYX and COMETRIQ and, therefore, were expensed as research and development costs when incurred, rather than capitalized as inventory. The sale of products containing previously expensed materials resulted in an 11% and 8% reduction in the Cost of goods sold during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to a 5% and 4% reduction during the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, our inventory includes approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of materials that were previously expensed, are not capitalized, and will not be charged to Costs of goods sold in future periods. Cost of goods sold also includes write-downs related to excess and expiring inventory. Such write-downs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">; the amount of such write-downs was nominal for the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The increase in Cost of goods sold was primarily related to the growth in sales of CABOMETYX due to the commercial launch of CABOMETYX in late April 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Gross margin percentage is net product revenues less cost of goods sold, divided by net product revenues. The increase in gross margin for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was related to the change in product mix as CABOMETYX tablets have a lower manufacturing cost than COMETRIQ capsules.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total research and development expenses were as follows (dollars in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(486</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial costs, personnel expenses, consulting and outside services, an allocation for general corporate costs, stock-based compensation, and temporary personnel expenses. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The increase in research and development expenses for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was primarily related to an increase in clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials, and increases in personnel expenses and stock-based compensation. The increase in clinical trial costs was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The increase in clinical trial costs was predominantly due to increases in costs related to CABOSUN, a randomized phase 2 trial of cabozantinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease conducted by The Alliance under our CRADA with NCI-CTEP, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">start-up costs associated with CheckMate 9ER, a phase 3 trial to evaluate nivolumab in combination with cabozantinib or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with nivolumab and ipilimumab in combination with cabozantinib </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">versus sunitinib in patients with previously untreated, advanced or metastatic RCC, and start-up costs associated with our phase 1b trial of cabozantinib and atezolizumab in locally advanced </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or metastatic solid tumors; those increases were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">partially offset by decreases in costs related to METEOR, our phase 3 pivotal trial in advanced RCC. The increase in personnel expenses was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily as a result of an increase in headcount associated with the re-launch of our discovery program and the build-out of our medical affairs organization. The increase in stock-based compensation was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to the increase in overall headcount and an increase in the valuation of recently granted options and awards as a result of the increase in the price of our stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The decrease in research and development expenses for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was primarily related to decreases in clinical trial costs and stock-based compensation; these decreases were partially offset by an increase in personnel expenses. The decrease in clinical trial costs was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The decrease in clinical trial costs was predominantly due to a decrease in costs related to METEOR, which was partially offset by increases in costs related to CABOSUN, start-up costs associated with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">CheckMate 9ER, and start-up costs associated with our phase 1b trial of cabozantinib and atezolizumab in locally advanced or metastatic solid tumors</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The decrease in stock-based compensation was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to the 2016 recognition of stock-based compensation expense pertaining to the performance-based stock-options tied to the acceptance and anticipated approval of our CABOMETYX New Drug Application, or NDA, submission to the FDA and a 2016 bonus to our employees in the form of fully-vested restricted stock units. These decreases were partially offset by an increase in personnel expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily as a result of an increase in headcount associated with the re-launch of our discovery program and the build-out of our medical affairs organization.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not track fully-burdened research and development expenses on a project-by-project basis.&#160;We group our research and development expenses into three categories: development, drug discovery and other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Drug discovery expenses relate primarily to personnel expenses and consulting and outside services. The &#8220;Other&#8221; category includes stock-based compensation and the allocation of general corporate costs to research and development. The expenditures for research and development expenses by category were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,404</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,968</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personnel expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting and outside services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,392</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,515</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other development costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,367</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,847</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,293</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Drug discovery</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,424</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, the results of and data from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy, which includes the pursuit of commercial collaborations with major pharmaceutical and biotechnology companies for the development of our drug candidates. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are focusing our development and commercialization efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound, and as a result, we expect our near-term research and development expenses to primarily relate to the clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">approximately 45 ongoing or planned clinical trials across multiple indications. The most notable studies of this program is CELESTIAL, our company-sponsored phase 3 trial of cabozantinib in advanced HCC, our phase 3 study in collaboration with BMS, evaluating cabozantinib in combination with nivolumab or nivolumab and ipilimumab as compared to sunitinib in previously untreated patients with advanced RCC, and our phase 2 study, in collaboration with BMS, evaluating cabozantinib and nivolumab or nivolumab and ipilimumab in advanced HCC, as well as our phase 1b study, in collaboration with Roche, evaluating cabozantinib in combination with atezolizumab in patients with advanced malignancies. In addition, postmarketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication. As a result, we expect our research and development expenses to increase as we continue to develop cabozantinib and our pipeline. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications, and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know how many of those indications we will ultimately pursue regulatory approval for. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to postmarketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any other research and development projects. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total selling, general and administrative expenses were as follows (dollars in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,904</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,307</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation, legal and accounting costs, marketing, travel and entertainment and facility costs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The increase in selling, general and administrative expenses for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was primarily related to increases in personnel expenses, legal and accounting costs, and consulting and outside services; those increases were partially offset by a decrease in marketing costs. Personnel expenses increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to an increase in headcount connected with the build-out and support of our U.S. commercial organization as a result of the launch of CABOMETYX, as well as an increase in headcount for our general and administrative organization, incentive compensation and the accrual for bonuses. Legal and accounting expenses increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to increases in legal costs related to our dispute with Genentech. Consulting and outside services increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">respectively, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to increases in consulting for marketing activities. Marketing costs decreased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to a decrease in losses recognized under our collaboration agreement with Genentech driven by Genentech&#8217;s change in cost allocation approach in January 2017.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Expense, Net</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain historical amounts in Other expense, net have been revised to reflect the correction of the accounting for non-cash interest expense associated with our previously-outstanding 4.25% Convertible Senior Subordinated Notes due 2019, or the 2019 Notes. See &#8220;Note 1 - Organization and Summary of Significant Accounting Policies - Correction of an Immaterial Error&#8221; in the Notes to the Condensed Consolidated Financial Statements for additional information on the correction.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other expense, net, was as follows (dollars in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income and other, net</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,259</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,239</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,239</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,876</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,228</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other expense, net consists primarily of interest expense incurred on our debt, loss on the extinguishment of debt and interest income earned on our cash and investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest expense decreased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, primarily due to conversions and the redemption of the 2019 Notes during the third and fourth quarters of 2016 and the repayment of the Silicon Valley Bank term loan in March 2017. We expect our interest expense will continue to decrease as a result of interest savings from the repayment of the Deerfield Notes in June 2017.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;loss on extinguishment of debt resulting primarily from the prepayment penalty associated with the early the repayment of the Deerfield Notes. See &#8220;Note 6 - Debt&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; for more information on the repayment of our debt during </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest income increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, due to both an increase in our investment balances and an increase in the yield earned on those investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;we recognized a $0.6 million gain on the sale of our 9% interest in Akarna Therapeutics, Ltd, which we acquired in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Tax Expense</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax expense was as follows (dollars in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax expense for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset any federal taxable income.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div><a name="s022CB2953CD7220359F412B9CACD6606"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred net losses in every fiscal year since our inception, with the exception of the 2011 fiscal year, and as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.9 billion</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Although we reported net income of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we may not be able to maintain or increase profitability on a quarterly or annual basis and we are unable to accurately predict the extent of long-range future profits or losses. Excluding fiscal 2011, our operating expenses have exceeded our revenues for each fiscal year, and we expect to continue to spend significant additional amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to expand our product pipeline through the measured resumption of drug discovery and the evaluation of in-licensing and acquisition opportunities that align with our oncology drug expertise, which efforts could involve substantial costs. As a result, we are unable to predict the extent of any future profits or losses because we expect to continue to incur substantial operating expenses and, consequently, we will need to generate substantial revenues to maintain or increase profitability.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since the launch of our first commercial product in January 2013, through&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we have generated an aggregate of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$366.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in net product revenues, including&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$156.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Other than sales of CABOMETYX and COMETRIQ, we have derived substantially all of our revenues since inception from collaborative arrangements, including upfront and milestone payments and research funding we earn from any products developed from the collaborative research. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones and the amount of royalties, if any, from sales of CABOMETYX and COMETRIQ under our collaboration with Ipsen; our share of the net profits and losses for the commercialization of COTELLIC in the U.S. under our collaboration with Genentech; the amount of royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech; other license and contract revenues; and the level of our expenses, including commercialization activities for cabozantinib and any pipeline expansion efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$380.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in cash and investments, which included&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$375.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;available for operations and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of long-term restricted investments. We anticipate that our current cash and cash equivalents, and short-term investments available for operations, product revenues and collaboration revenues, will enable us to maintain our operations for a period of at least 12 months following the filing date of this report. The sufficiency of our cash resources depends on numerous assumptions, including assumptions related to product sales and operating expenses, as well as the other factors set forth in &#8220;Risk Factors&#8221; under the headings &#8220;Risks Related to our Capital Requirements and Financial Results,&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.&#160;Our assumptions may prove to be wrong or other factors may adversely affect our business, and as a result we may not have the cash resources to fund our current and future operating plans. This in turn could require us to raise additional funds, which we may be unable to do, which could have a material adverse effect on our business. We may also choose to raise additional funds through the issuance of equity or debt to meet our business objectives.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our cash flow activities (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,698</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,219</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,510</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by financing activities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172,086</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,474</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,807</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period </font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,212</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income (loss) for: non-cash operating items such as depreciation and amortization, non-cash interest expense and share-based compensation charges; and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Results of Operations. Our operating activities provided cash of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$74.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$131.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the same period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The decrease in cash provided by operating activities was primarily due to the upfront nonrefundable payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;received from Ipsen in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in consideration for the exclusive license and other rights contained in our collaboration and license agreement with Ipsen. That decrease was partially offset by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$116.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;increase in net product revenues and the upfront nonrefundable payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;received from Takeda in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in consideration for the exclusive license and other rights contained in our collaboration and license agreement with Takeda.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our investing activities provided cash of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$81.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$143.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of cash used during the same period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash provided by investing activities for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily due to cash provided by the maturity of investments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$206.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and the sale of investments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$37.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, less cash used for investment purchases of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$161.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash used by investing activities for the six months ended June&#160;30, 2016 was primarily due to investment purchases of $203.5 million, less cash from the maturity of unrestricted and restricted investments of $61.0 million.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash used in financing activities was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$172.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of cash provided during the same period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash used in financing activities for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily a result of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$185.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;paid for all amounts outstanding under the Deerfield Notes and our term loan with Silicon Valley Bank.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash provided by financing activities for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily a result of the issuance of common stock under our equity incentive plans which was almost completely offset by employees&#8217; tax withholding paid to taxing authorities from shares withheld on stock awards. </font></div><div><a name="s93242248AD20C8EB3A2312B9EA1C5F1A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we have contractual obligations in the form of capital and operating leases, purchase obligations and other long-term liabilities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. On March 29, 2017, we repaid all amounts outstanding under our term loan with Silicon Valley Bank. See &#8220;Note 6 - Debt&#8221; in the accompanying Notes to the Condensed Consolidated Financial Statements for more information on the Deerfield Notes and our loan and security agreement with Silicon Valley Bank. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease Agreement, or the Lease, with Ascentris 105, LLC, for an aggregate of 110,783 square feet of space in office and research facilities located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California. We are obligated to make lease payments totaling $24.1 million over the Lease term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. See &#8220;Note 10. Commitments&#8221; in the accompanying Notes to the Condensed Consolidated Financial Statements </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for a description of the Lease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no other material changes outside of the ordinary course of business in our contractual obligations from those as of December 31, 2016.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</font></div><div><a name="sF91551591CA404061B4D12B9EA263C56"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and share based compensation reflect the more significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no significant changes in our critical accounting policies and estimates during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1 - Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in this Quarterly Report on Form 10-Q and &#8220;Note 1 - Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; included in our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div><a name="s20351FF0BB60FC4CB18912B9C781CC1C"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our market risks at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;have not changed significantly from those discussed in Item&#160;7A of our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio, and for prior periods, our debt. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, an increase in the interest rates of one percentage point would have had a net adverse change in the fair value of interest rate sensitive assets and liabilities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$(1.3) million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as compared to a net positive change in the fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we have exposure to fluctuations in certain foreign currencies in countries in which we conduct clinical trials. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of our accrued clinical trial liability was owed in foreign currencies. An adverse change of one percentage point in the foreign currency exchange rates would not have resulted in a material impact as of either of the dates presented. We recorded losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;relating to foreign exchange fluctuations for both the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><a name="s6D7386C6E937BED144A212B9EA62D018"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Controls and Procedures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the effectiveness of controls.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in internal control over financial reporting. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div><a name="s7D5383119B8E842ADE5512B9EA807790"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II. OTHER INFORMATION</font></div><div><a name="s35A16B64161751E846C912B9EAB2A7B1"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 3, 2016, we filed a Demand for Arbitration before JAMS in San Francisco, California asserting claims against Genentech (a member of the Roche Group) related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&#8217;s commercialization in the U.S. Our arbitration demand asserted that Genentech breached the parties&#8217; December 2006 collaboration agreement for the development and commercialization of COTELLIC, by, amongst other breaches, failing to meet its diligence and good faith obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 13, 2016, Genentech asserted a counterclaim for breach of contract seeking monetary damages and interest related to the cost allocations under the collaboration agreement. On December 29, 2016, however, Genentech withdrew its counterclaim against us and stated that it would unilaterally change its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy, both retrospectively and prospectively. The revised allocation approach substantially reduced our exposure to costs associated with promotion of the COTELLIC plus Zelboraf combination in the U.S. However, other significant issues remained in dispute between the parties as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Genentech&#8217;s action did not address the claims in our demand for arbitration related to Genentech&#8217;s clinical development of cobimetinib, or pricing or promotional costs for COTELLIC in the U.S. and it did not fully resolve claims over revenue allocation. In addition, Genentech&#8217;s unilateral action did not clarify how it intended to allocate promotional costs incurred with respect to the promotion of other combination therapies that include cobimetinib for other indications that may be developed or are in development and may be approved. As a result, we continued to press our position before the arbitral panel to obtain a just resolution of these claims. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 8, 2017, the parties settled the arbitration, which was dismissed with prejudice. The settlement was memorialized in a settlement agreement dated July 19, 2017, that included a mutual release of all claims arising out of or related in any way to the causes of actions and/or claims that were asserted or could have been asserted based on the facts alleged in the arbitration. The settlement does not provide for payments in settlement of the asserted claims; as part of the settlement, on July 19, 2017, the parties entered into an amendment to the December 2006 collaboration agreement. Pursuant to the terms of the amendment, we will continue to be entitled to a share of U.S. profits and losses received in connection with the commercialization of COTELLIC, which share will continue to decrease as sales of COTELLIC increase in accordance with the profit share tiers as originally set forth in the collaboration agreement. However, effective as of July 1, 2017, the revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement, or the Collaboration P&amp;L, will be calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. While we will also continue to share U.S. commercialization costs for COTELLIC, the amendment expressly sets forth that the amount of commercialization costs Genentech is entitled to allocate to the Collaboration P&amp;L will be reduced based on the number of Genentech products in any given combination including COTELLIC. In addition, the amendment also sets forth the parties&#8217; confirmation and agreement that we have exercised our co-promotion option and that, as such, we have the right to co-promote current and future Genentech combinations that include COTELLIC in the U.S.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may from time to time become a party to other legal proceedings arising in the ordinary course of business.</font></div><div><a name="s911FB6EED5FBCE1711B012B9EAD02D13"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In addition to the factors discussed elsewhere in this report and our other reports filed with the SEC, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occurs, our business could be harmed.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have marked with an asterisk (*) those risk factors below that reflect substantive changes in risks facing us from the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 30, 2016 filed with the Securities and Exchange Commission on February 27, 2017. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our future prospects are critically dependent upon the commercial success of CABOMETYX for advanced RCC and the further clinical development and commercial success of cabozantinib in additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our mission is to maximize the clinical and commercial potential of cabozantinib and cobimetinib and position Exelixis for future growth through the resumption of our discovery efforts and expansion of our development pipeline. We anticipate that for the foreseeable future our ability to generate meaningful revenue to fund our commercial operations and our development and discovery programs will be dependent upon the successful commercialization of CABOMETYX for the treatment of advanced RCC in territories where it has been or may soon be approved. The commercial potential of CABOMETYX for the treatment of advanced RCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of advanced RCC.&#160;If revenue from CABOMETYX decreases, we may need to reduce our operating expenses or raise additional funds to execute our business plan, which would have a material adverse effect on our business and financial condition, results of operations and growth prospects. Furthermore, as a consequence of our exclusive collaboration agreement with Ipsen, we rely heavily upon Ipsen&#8217;s regulatory, commercial, medical affairs, and other expertise and resources for commercialization of CABOMETYX in territories outside of the U.S. and Japan. If Ipsen is unable to, or does not invest the resources necessary to, successfully commercialize CABOMETYX for the treatment of advanced RCC in the European Union and other international territories where it may be approved, this could reduce the amount of revenue we are due to receive under our collaboration agreement with Ipsen, thus resulting in harm to our business and operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also believe that there are commercial opportunities for cabozantinib in therapeutic indications beyond advanced RCC, and we are dedicating substantial proprietary resources to developing cabozantinib into a potentially broad and significant oncology franchise. Even following the approval of CABOMETYX for the treatment of advanced RCC in the U.S. and European Union, our success remains contingent upon, among other things, successful clinical development, regulatory approval and market acceptance of cabozantinib in additional indications, such as previously treated advanced RCC, advanced HCC, non-small cell lung cancer, and other forms of cancer. With the planned second interim analysis from CELESTIAL anticipated in the second half of 2017, and a final analysis, if needed in 2018, we expect growth of the cabozantinib oncology franchise to be most immediately impacted by the clinical trial results of cabozantinib in advanced HCC. However, the historical rate of failures for product candidates in clinical development is high. Should we prove unsuccessful in the further development of cabozantinib beyond MTC or advanced RCC, we may be unable to execute our business plan and our revenues and financial condition would be materially adversely affected. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are heavily dependent on our partner, Genentech (a member of the Roche group), for the successful development, regulatory approval and commercialization of cobimetinib.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The terms of our collaboration agreement provide Genentech with exclusive authority over the global development and commercialization plans for cobimetinib and the execution of those plans. We have limited effective influence over those plans and are heavily dependent on Genentech&#8217;s decision making. Any significant changes to Genentech&#8217;s business strategy and priorities, over which we have no control, could adversely affect Genentech&#8217;s willingness or ability to complete their obligations under our collaboration agreement and result in harm to our business and operations.&#160;Subject to contractual diligence obligations, Genentech has complete control over and financial responsibility for cobimetinib&#8217;s development program and regulatory strategy and execution, and we are not able to control the amount or timing of resources that Genentech will devote to the product.&#160;Of particular significance are Genentech&#8217;s development efforts with respect to the combination of cobimetinib with immuno-oncology agents, a promising and competitive area of clinical research. Regardless of Genentech&#8217;s efforts and expenditures for the further development of cobimetinib, the results of such additional clinical investigation may not prove positive and may not produce label expansions or approval in additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The commercial success of cabozantinib, as CABOMETYX tablets for advanced RCC and as COMETRIQ capsules for MTC, and if approved for additional indications, will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ability to successfully commercialize cabozantinib, as CABOMETYX tablets for advanced RCC and COMETRIQ capsules for MTC is, and if approved for additional indications, will be, highly dependent upon the extent to which cabozantinib gains market acceptance among physicians, patients, health care payers such as Medicare, Medicaid and commercial plans and the medical community. If cabozantinib does not achieve an adequate level of acceptance, we may not generate significant future product revenues. The degree of market acceptance of CABOMETYX and COMETRIQ will depend upon a number of factors, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the effectiveness, or perceived effectiveness, of cabozantinib in comparison to competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the safety of cabozantinib, including the existence of serious side effects of cabozantinib and their severity in comparison to those of any competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cabozantinib&#8217;s relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unexpected results connected with analysis of data from future or ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of cabozantinib label expansions for additional indications, if any, relative to competitive treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the price of cabozantinib relative to competitive therapies and any new government initiatives affecting pharmaceutical pricing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the strength of CABOMETYX sales efforts, marketing, medical affairs and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the sufficiency of commercial and government insurance coverage and reimbursement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights with respect to cabozantinib.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or scale adequate sales, marketing, market access and distribution capabilities or enter into or maintain agreements with third parties to do so, we may be unable to maximize product revenues and our business, financial condition, results of operations and prospects may be adversely affected.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the FDA&#8217;s approval of CABOMETYX for the treatment of patients with advanced RCC, we substantially increased our sales, marketing, market access, medical affairs and product distribution capabilities. Establishing and maintaining these capabilities requires significant resources. If we cannot maintain effective sales, marketing, market access, medical affairs and product distribution capabilities, we may be unable to maximize the commercial potential of cabozantinib in its approved indications. Also, to the extent that the commercial opportunities for cabozantinib grow over time, we may not properly judge the requisite size and experience of the commercialization teams or the scale of distribution necessary to market and sell cabozantinib successfully. If we are unable to maintain or scale our organization appropriately, we may not be able to maximize product revenues and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently rely on third party providers to handle storage and distribution for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. While we have expanded our U.S. distribution and pharmacy channels in connection with the approval of CABOMETYX by the FDA for the treatment of patients with advanced RCC in the U.S., we still rely on a relatively limited distribution network to dispense COMETRIQ in fulfillment of prescriptions in the U.S. Furthermore, we rely on our collaboration partners for the commercialization and distribution of CABOMETYX and COMETRIQ in territories outside of the U.S., as well as for access and distribution activities for the approved products under the Named Patient Use program or a similar program with the effect of introducing earlier patient access to COMETRIQ and CABOMETYX. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance, of third parties, may adversely affect our ability to supply cabozantinib to the marketplace on a timely and competitive basis. These third parties may not provide services in the time required to meet our commercial timelines and objectives or to meet regulatory requirements. We may not be able to maintain or renew our arrangements with third parties, or enter into new arrangements, on acceptable terms, or at all. Third parties could terminate or decline to renew our arrangements based on their own business priorities. If we are unable to contract for these third party services related to the distribution of cabozantinib on acceptable terms, our commercialization efforts may be delayed or otherwise adversely affected, which could have material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the impact of improper conduct, the laws that may affect our ability to operate include, without limitation:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, or AKS, which governs our business activities, including our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities. The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. Remuneration is not </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">defined in the AKS and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. The AKS has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Food, Drug, and Cosmetic Act, or FDCA, and its regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any food, drug, device, or cosmetic that is adulterated or misbranded;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">federal and state government price reporting laws that require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs (participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and could potentially affect our ability to offer certain marketplace discounts);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">federal and state financial transparency laws, which generally require certain types of expenditures in the U.S. to be tracked and reported (compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships with healthcare providers and healthcare entities, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">federal and state healthcare fraud and abuse laws, FDA rules and regulations, as well as false claims laws, including the civil False Claims Act, which govern certain mar</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">keting practices, including off-label promotion. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. Such individuals, commonly known as &#8220;whistleblowers,&#8221; may potentially then share in amounts paid by the entity to the government in fines or settlement. The filing of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend civil False Claims Act actions. When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification. These laws could create liability for us or increase our cost of doing business. International laws, such as the EU Data Privacy Directive (95/46/EC) and Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the U.S. Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain both adequate coverage and adequate reimbursement from third-party payers for CABOMETYX or COMETRIQ, our revenues and prospects for profitability will suffer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ability to commercialize CABOMETYX or COMETRIQ successfully is highly dependent on the extent to which coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Patients may not be capable of paying for CABOMETYX or COMETRIQ themselves and may rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and prospects for profitability will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford cabozantinib. There has been negative publicity regarding, and increasing legislative and enforcement interest in the U.S. with respect to, drug pricing and the use of specialty pharmacies, which may result in physicians being less willing to participate in our patient access programs and thereby limit our ability to increase patient access and adoption of cabozantinib. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, and reform government program reimbursement methodologies for drugs. If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial results. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, in some foreign countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control under the respective national health system. In these countries, price negotiations with governmental authorities or payers can take six to twelve months or longer after marketing authorization is granted for a product, which has the potential to substantially delay broad availability of the product in some of those countries. To obtain reimbursement and/or pricing approval in some countries, we and our collaboration partner, Ipsen, may be required to conduct a clinical trial that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a clinical trial could be expensive and result in delays in the commercialization of CABOMETYX. Third-party payers are challenging the prices charged for medicinal products and services, and many third-party payers limit reimbursement for newly-approved health care products. In particular, third-party payers may limit the indications for which they will reimburse patients who use CABOMETYX or COMETRIQ. Cost-control initiatives could decrease the price we and our collaboration partner, Ipsen, might establish for CABOMETYX, which would result in lower license revenues to us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may affect our ability to sell CABOMETYX and COMETRIQ profitably.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell CABOMETYX and COMETRIQ profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the PPACA. The Budget Resolution is not a law; however, it marked the first step toward the passage of legislation that would repeal certain aspects of PPACA. Congress is currently considering legislation that would repeal and replace elements of PPACA. The legislation that is under consideration also makes several reforms to the Medicaid program, including shifting Medicaid financing from a federal match to states, known as the federal medical assistance percentage, to a per capita allotment or block grant approach. The bill passed the U.S. House of Representatives on May 14, 2017, and the Senate is currently considering legislation. It remains uncertain whether the House or Senate bill will become law. Further, if passed, it is difficult to project the scope and subject of any further changes to the legislation. It is also possible that Congress could consider legislation that retains PPACA, and is intended to stabilize the health insurance markets. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with responsibilities under PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Moreover, certain politicians, including the President, have announced plans to regulate the prices of pharmaceutical products. Congress has also signaled an intent to address pharmaceutical pricing, with a Senate hearing to examine the cost of prescription drugs held on June 13, 2017. We cannot know what form any such legislation may take or the market&#8217;s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may limit our ability to generate revenue or commercialize our current products and/or those for which we may receive regulatory approval in the future.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Congress is also considering legislation that would reauthorize the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars. The reauthorization bill passed the House on July 12, 2017, but it has not been voted on by the Senate. The legislation is expected to include, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">inter alia,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;measures to expedite the development and approval of generic products, but it is unclear what form the final legislation could take and how such legislation would affect us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the U.S., third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. These entities could refuse or limit coverage for CABOMETYX and COMETRIQ, such as by using tiered reimbursement, which would adversely affect demand for CABOMETYX and COMETRIQ. They may also refuse to provide coverage for uses of CABOMETYX and COMETRIQ for medical indications other than those for which the FDA has granted market approval. As a result, significant uncertainty exists as to whether and how much third-party payers will cover newly approved drugs, which in turn will put pressure on the pricing of drugs. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, third-party payer or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on our revenues and prospects for profitability.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many companies in our industry have received a governmental request for documents and information relating to drug pricing and patient support programs. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, such findings could further harm our business, reputation and/or prospects. It is possible that such inquiries could result in negative publicity or other negative actions that could harm our reputation; changes in our product pricing and distribution strategies; reduced demand for our approved products and/or reduced reimbursement of approved products, including by federal health care programs such as Medicare and Medicaid and state health care programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the Trump Administration has indicated interest in taking measures pertaining to drug pricing, including potential proposals relating to Medicare price negotiations, importation of drugs from other countries, and facilitating value-based arrangements between manufacturers and payers. At this time, it is unclear whether any of these proposals will be pursued and how they would impact our products or our future product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the value of cabozantinib, cobimetinib and any future product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The pharmaceutical, biopharmaceutical and biotechnology industries are highly diversified and are characterized by rapid technological change. In particular, the area of novel oncology therapies is a rapidly evolving and competitive field. Specifically, the indication of advanced RCC is highly competitive and several novel therapies and combinations of therapies are in advanced stages of clinical development in this indication, and may compete with or displace cabozantinib. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Some of our competitors have entered into collaborations with leading companies within our target markets, including some of our existing collaborators. Some of our competitors are further along in the development of their products than we are. Delays in the development of cabozantinib or cobimetinib for the treatment of additional tumor types, for example, could allow our competitors to bring products to market before us. Our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. Our products may become less marketable if we are unable to successfully adapt our development strategy to address the likelihood that this new approach to treating cancer with immuno-oncology agents will become prevalent in indications for which our products are approved, most notably advanced RCC, and in additional indications where we may seek regulatory approval. Furthermore, the complexities of such a strategy has and may continue to require collaboration with some of our competitors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The markets for which we intend to pursue regulatory approval of cabozantinib and for which Roche and Genentech intend to pursue regulatory approval for cobimetinib are highly competitive. Further, our competitors may be more effective at using their technologies to develop commercial products. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do. As a result, our competitors may be able to more easily develop technologies and products that would render our technologies and products, and those of our collaborators, obsolete and noncompetitive. There may also be drug candidates of which we are not aware at an earlier stage of development that may compete with cabozantinib, cobimetinib, and our other product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If competitors use litigation and regulatory means to obtain approval for generic versions of cabozantinib, our business will suffer.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#160; </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an Abbreviated New Drug Application, or&#160;ANDA, for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a 505(b)(2) NDA that relies on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. The filing of an ANDA or 505(b)(2) NDA with respect to cabozantinib could have an adverse impact on our stock price.&#160;Moreover, if any such ANDAs or 505(b)(2) NDAs were to be approved and the patents covering cabozantinib were not upheld in litigation, or if a generic competitor is found not to infringe these patents, the resulting generic competition would negatively affect our business, financial condition and results of operations. In this regard, generic equivalents, which must meet the same quality standards as the branded drugs, would be significantly less costly than ours to bring to market. Companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, regardless of the regulatory approval pathway, after the introduction of a generic competitor, a significant percentage of the sales of any branded product are typically lost to the generic product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of product candidates is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that a product candidate, even if it is approved for other indications, is ineffective or has an unacceptable safety profile that may significantly decrease the likelihood of regulatory approval in a new indication. For example, COMET-1 and COMET-2, our two phase 3 pivotal trials of cabozantinib in metastatic castration-resistant prostate cancer, or mCRPC, failed to meet their respective primary endpoints of demonstrating a statistically significant increase in OS for patients treated with cabozantinib as compared to prednisone and to demonstrate improvement in pain response for patients treated with cabozantinib as compared to mitoxantrone/prednisone. Based on the outcome of the COMET trials, we deprioritized the clinical development of cabozantinib in mCRPC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The results of preliminary studies do not necessarily predict clinical or commercial success, and later-stage clinical trials may fail to confirm the results observed in earlier-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of our product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of our product candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">lack of efficacy or harmful side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results may require us to conduct further testing or to abandon projects that we had expected to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our competitors may discover or commercialize other compounds or therapies that show significantly improved safety or efficacy compared to our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">patient registration or enrollment in our clinical testing may be lower than we anticipate, resulting in the delay or cancellation of clinical testing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">failure by our collaborators to supply us on a timely basis with the product required for a combination trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">failure of our third-party contract research organization or investigators to satisfy their contractual obligations, including deviating from trial protocol; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulators or institutional review boards may withhold authorization to commence or conduct clinical trials of a product candidate, or delay, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their determination that participating patients are being exposed to unacceptable health risks.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we were to have significant delays in or termination of our clinical testing of our product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to rapidly or effectively continue the further development of our product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions, including those identified based on our discussions with the FDA or such other regulatory authorities. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of the product candidate. The duration and the cost of clinical trials may vary significantly over the life of a project as a result of factors relating to the clinical trial, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number of patients </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">who ultimately participate in the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number of clinical sites included in the trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the length of time required to enroll suitable patie</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nt subjects.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain, and may not result in regulatory approvals for our product candidates, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of our products and product candidates, are subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. We have only limited experience in preparing and filing the applications necessary to gain regulatory approvals. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the European Medicines Agency or any application or submission to regulatory </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual, additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for our product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more indications beyond advanced RCC and MTC, or one of our other product candidates, the approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, advertising, promotion, marketing and/or production of the product and could impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. For example, in connection with the FDA&#8217;s approval of COMETRIQ for the treatment of progressive, metastatic MTC, we are subject to post-marketing requirement to conduct a clinical study comparing a lower dose of cabozantinib to the approved dose of 140 mg daily cabozantinib in progressive, metastatic MTC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or eliminate the commercialization of cabozantinib. Further, these agencies may also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are committed to the discovery, development and promotion of new medicines with the potential to improve care and outcomes for people with cancer. In this regard, we have resumed internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including the research methodology used may not be successful in identifying potential product candidates, or potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profile or other characteristics suggesting that they are unlikely to be effective products. Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive.&#160;Established companies, in particular, may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160; We may also be unable to in-license or acquire a relevant product candidate on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to develop suitable product candidates through internal discovery effort or if we are unable to successfully obtain rights to suitable product candidates, our business, financial condition and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs.&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements and Financial Results</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be forced to limit the expansion of our product development programs or commercialization efforts.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$380.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$375.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;available for operations and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of long-term restricted investments. Our business operations grew substantially during 2016 and experienced further development during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In order to maintain business growth and maximize the clinical and commercial opportunities for cabozantinib and cobimetinib, we plan to continue to execute on the U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib, research and development activities, as well as through in-licensing and acquisition efforts. Our ability to execute on these business objectives will depend on many factors including but not limited to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, medical affairs and distribution capabilities for CABOMETYX in advanced RCC and COMETRIQ in the approved MTC indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones under our collaboration with Ipsen; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commercial success of COTELLIC and the revenues generated through our share of related profits and losses for the commercialization of COTELLIC in the U.S. and royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the potential regulatory approval of cabozantinib as a treatment for patients with previously untreated advanced RCC and in other indications, both in the U.S. and abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">future clinical trial results, notably the results from CELESTIAL, our phase 3 pivotal trial in patients with advanced HCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and corporate development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to control costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of clinical drug supply for our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the European Union;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the filing,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib, continued research and development activities as well as through in-licensing and acquisition efforts, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations, licensing arrangements, and public or private debt or equity financings. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to limit the expansion of our product development programs or commercialization efforts, which could have a material adverse effect on our business and growth prospects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have a history of net losses and may incur net losses in the future, and may be unable to achieve and maintain profitability.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred net losses in every fiscal year since our inception, with the exception of the 2011 fiscal year, and as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.9 billion</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Although we reported net income of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we may not be able to maintain or increase profitability on a quarterly or annual basis and we are unable to accurately predict the extent of long-range future profits or losses. Excluding fiscal 2011, our operating expenses have exceeded our revenues for each fiscal year, and we expect to continue to spend significant additional amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to expand our product pipeline through the measured resumption of drug discovery and the evaluation of in-licensing and acquisition opportunities that align with our oncology drug expertise, which efforts could involve substantial costs. As a result, we are unable to predict </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the extent of any future profits or losses because we expect to continue to incur substantial operating expenses and, consequently, we will need to generate substantial revenues to maintain or increase profitability.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since the launch of our first commercial product in January 2013, through&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we have generated an aggregate of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$366.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in net product revenues, including&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$156.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Other than sales of CABOMETYX and COMETRIQ, we have derived substantially all of our revenues since inception from collaborative arrangements, including upfront and milestone payments and research funding we earn from any products developed from the collaborative research. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones and the amount of royalties, if any, from sales of CABOMETYX and COMETRIQ under our collaboration with Ipsen; our share of the net profits and losses for the commercialization of COTELLIC in the U.S. under our collaboration with Genentech; the amount of royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech; other license and contract revenues; and the level of our expenses, including commercialization activities for cabozantinib and any pipeline expansion efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are exposed to risks related to foreign currency exchange rates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Most of our foreign expenses incurred are associated with establishing and conducting clinical trials for cabozantinib. The amount of these expenses will be impacted by fluctuations in the currencies of those countries in which we conduct clinical trials. Our agreements with the foreign sites that conduct such clinical trials generally provide that payments for the services provided will be calculated in the currency of that country, and converted into U.S. dollars using various exchange rates based upon when services are rendered or the timing of invoices. When the U.S. dollar weakens against foreign currencies, the U.S. dollar value of the foreign-currency denominated expense increases, and when the U.S. dollar strengthens against these currencies, the U.S. dollar value of the foreign-currency denominated expense decreases. Consequently, changes in exchange rates may affect our financial position and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Global credit and financial market conditions could negatively impact the value of our current portfolio of cash equivalents, short-term investments or long-term investments and our ability to meet our financing objectives.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our cash and cash equivalents are maintained in highly liquid investments with remaining maturities of 90 days or less at the time of purchase. Our short-term and long-term investments consist primarily of readily marketable debt securities with remaining maturities of more than 90 days at the time of purchase. While as of the date of this report we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents, short-term investments or long-term investments since </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, no assurance can be given that a deterioration in conditions of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or investments or our ability to meet our financing objectives.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods and certain assumptions and estimates.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. The preparation of our financial statements requires us to make significant estimates, assumptions and judgments that affect the amounts of assets, liabilities, revenues and expenses and related disclosures. Significant estimates that may be made by us include assumptions used in the determination of revenue recognition, discounts and allowances from gross revenue, inventory and stock-based compensation. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and as a result we </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, prospects for profitability or financial position. For example, in May 2014, the Financial Accounting Standards Board issued an Accounting Standards Update entitled Accounting Standards Update No. 2014-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or ASU 2014-09, which will replace existing revenue recognition guidance in U.S. generally accepted accounting pronouncements when it becomes effective for us in the first quarter of fiscal year 2018. We do not expect that ASU 2014-09 will have a material impact on the recognition of revenue from product sales. We do expect that ASU 2014-09 will impact the timing of recognition of revenue for our collaboration arrangements. We expect to reclassify deferred revenue to retained earnings (a concept known as lost revenue) for amounts associated with our collaboration arrangements with Ipsen and Takeda upon recording our transition adjustment to accumulated loss on January 1, 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration arrangements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. In any event, we will continue to evaluate the impact of the new standard on all of our revenues, including those mentioned above, and our preliminary assessments may change in the future based on our continuing evaluation. The application of existing or future financial accounting standards, particularly those relating to the way we account for revenues and costs, could have a significant impact on our reported results. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subjects us to a number of risks.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have established collaborations with leading pharmaceutical and biotechnology companies, including, Ipsen, Takeda, Genentech, Daiichi Sankyo, Merck (known as MSD outside of the U.S. and Canada), BMS and Sanofi for the development and ultimate commercialization of certain compounds generated from our research and development efforts. Our dependence on our relationships with existing collaborators for the development and commercialization of compounds under the collaborations subjects us to, and our dependence on future collaborators for development and commercialization of additional compounds will subject us to, a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we are not able to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we are not able to control the U.S. commercial resourcing decisions made and resulting costs incurred by Genentech for cobimetinib, which costs we are obligated to share, in part, under our collaboration agreement with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">collaborators may delay clinical trials, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">fail to supply us on a timely basis with the product required for a combination trial, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">collaborators may experience financial difficulties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">collaborators may not be successful in their efforts to obtain regulatory approvals in a timely manner, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">collaborators may not comply with applicable healthcare regulatory laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we may be precluded from entering into additional collaboration arrangements with other parties in an area or field of exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of development of our drug candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts could be delayed and our business, operating results and financial condition could be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib for the treatment of additional indications beyond advanced RCC and MTC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib independently, including our post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib for additional indications beyond the advanced RCC and MTC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack the manufacturing capabilities necessary for us to produce cabozantinib for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not own or operate manufacturing or distribution facilities for clinical or commercial production and distribution of CABOMETYX and COMETRIQ. Instead, we have multiple contractual agreements in place with third party contract manufacturing organizations who, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ, and will continue to do so for the foreseeable future. To establish and manage this supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties. Although we maintain significant resources to directly oversee the activities and relationships with companies in our supply chain effectively, we do not have direct control over their operations. Our third party manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. Additionally, as part of our collaboration with Ipsen, we are responsible for the manufacturing and supply of finished, labeled cabozantinib products to Ipsen. Failure to meet our supply obligations under the collaboration could impair Ipsen&#8217;s ability to successfully commercialize cabozantinib and generate revenues to which we are entitled under the collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our third party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach, and their failure to supply us could impair or preclude our ability to meet our and/or Ipsen&#8217;s commercial needs, or our supply needs for clinical trials.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">information) and confidential information with respect to our customers, clinical trial patients and our business partners. We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation. We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks continue to become more prevalent and much harder to detect and defend against. Our network and storage applications and those of our vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others. Cyber-attacks could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. Our network security and data recovery measures and those of our vendors may not be adequate to protect against such security breaches and disruptions. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties. As a result, we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation may be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and negatively impact our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives. Such compulsory licenses could be extended to include our products or product candidates, which could limit our potential revenue opportunities. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to obtain or could require substantial time and expense. Third parties may accuse us of employing their proprietary technology without authorization. In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical personnel, in defending ourselves against any such claims or enforcing our patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from third parties. We may not be able to obtain these licenses at a reasonable cost, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain product candidates, which could severely harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. In addition, the physical expansion of our operations may lead to significant costs and may divert our management and capital resources. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plan. Retaining and, where necessary, recruiting qualified clinical, commercial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and scientific personnel will be critical to support activities related to advancing the development program for cabozantinib and our other compounds, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial and scientific personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our collaborations with outside scientists may be subject to restriction and change.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts. These advisors and collaborators are not our employees and may have other commitments that limit their availability to us. Although these advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. In such a circumstance, we may lose work performed by them, and our development efforts with respect to the matters on which they were working may be significantly delayed or otherwise adversely affected. In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our headquarters are located near known earthquake fault zones, and the occurrence of an earthquake or other disaster could damage our facilities and equipment, which could harm our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our headquarters are located in the San Francisco Bay Area, California and, therefore our facilities are vulnerable to damage from earthquakes. We do not carry earthquake insurance. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events since any insurance we may maintain may not be adequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired. In addition, the unique nature of our research activities could cause significant delays in our programs and make it difficult for us to recover from a disaster. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We plan to move our headquarters and may face disruption and turnover of employees.*</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2018, we plan to move our corporate headquarters from South San Francisco, California to Alameda, California. As a result, we expect to incur additional expenses, including those related to tenant improvements to and furniture for the new corporate headquarters, as well as moving and exit costs, and may encounter disruption of operations related to the move, all of which could have an adverse effect on our financial condition and results of operations. In addition, relocation of our corporate headquarters may make it more difficult to retain certain of our employees, and any resulting need to recruit and train new employees could be disruptive to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, could subject us to liability and have a material adverse impact on our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and radioactive and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">release of, these hazardous materials used by these parties. Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaborators develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical, biopharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline, causing investor losses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commerci</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">al success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">customer ordering patterns for CABOMETYX and COMETRIQ, which may vary significantly from period to period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the overall level of demand for CABOMETYX and COMETRIQ, including the impact of any competitive products and the duration of therapy for patients receiving CABOMETYX or COMETRIQ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commercial success of COTELLIC and the revenues generated through our share of related profits and losses for the commercialization of COTELLIC in the U.S. and royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs associated with maintaining our sales, marketing, medical affairs and distribution capabilities for CABOMETYX, COMETRIQ and COTELLIC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to obtain regulatory approval for cabozantinib as a treatment for patients with previously untreated advanced RCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones, under our collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the progress and scope of other development and commercialization activities for cabozantinib and our other compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">future clinical trial results, notably the results from CELESTIAL, our phase 3 pivotal trial in patients with advanced HCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and corporate development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">recognition of upfront licensing or other fees or revenues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the introduction of new technologies or products by our competitors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing and willingness of collaborators to further develop or, if approved, commercialize our product candidates out-licensed to them;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the termination or non-renewal of existing collaborations or third party vendor relationships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adjustments to expenses accrued in prior periods based on management&#8217;s estimates after the actual level of activity relating to such expenses becomes more certain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additions and departures of key personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general and industry-specific economic conditions that may affect our or our collaborators&#8217; research and development expenditures; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other factors described in this &#8220;Risk Factors&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance. As a result, in some future quarters, our operating results may not meet the expectations of securities analysts and investors, which could result in a decline in the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price may be extremely volatile.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adverse results or delay</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">s in our or our collaborators&#8217; clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process, of cabozantinib or our collaborators&#8217; product candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators&#8217; or our competitors&#8217; clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for cabozantinib or any of our other programs or compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actions taken by regulatory agencies with respect to cabozantinib or our clinical trials for cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the announcement of new products by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">developments in our relationships with our collaborators, including the termination or modification of our agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">conflicts or litigation with our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">failure to achieve operating results projected by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the entry into new financing arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">departures of key personnel or board members;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">FDA or international regulatory actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">third-party coverage and reimbursement policies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disposition of any of our technologies or compounds; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general market, economic and politica</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">l conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of the United Kingdom&#8217;s pending withdrawal from the European Union and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and health care spending and delivery, including the potential repeal and/or replacement of all or portions of PPACA or greater restrictions on free trade stemming from Trump Administration policies, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Future sales of our common stock or the perception that such sales or conversions may occur, may depress our stock price.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A substantial number of shares of our common stock are reserved for issuance upon the exercise of stock options, upon vesting of restricted stock unit awards, upon a purchase under our employee stock purchase program and upon exercise of certain outstanding warrants. The issuance and sale of substantial amounts of our common stock or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or equity-related securities in the future at a time and price that we deem appropriate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a classified Boar</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the inability of our stockholders to call special meetings of stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limitations on the removal of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">advance notice requirements for d</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">irector nominations and stockholder proposals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Internal Revenue Code, or the Code, and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carry-forwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carry-forwards before utilization. We concluded, as of December 31, 2016, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses, or NOLs. Furthermore, our ability to utilize our NOLs, other than the NOLs expected to be utilized to offset income in 2017, is conditioned upon our attaining profitability and generating U.S. federal taxable income. We have incurred significant cumulative operating losses since our inception; thus, we do not know whether or when we will generate the U.S. federal taxable income necessary to utilize our remaining NOLs. A full valuation allowance has been provided for the entire amount of our remaining NOLs.</font></div><div><a name="s5A3550C600779A5C55AD12B9EB027FFC"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sA5BF62738A838C9AE9B712B9EB209590"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s9E144BFEE04AD56A64EC12B9EB5C71A8"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s2EC3BEAA468712C1A87512B9EB7AD0B3"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Other Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sEA7FBE1DE3250056379812B9EBACC7DD"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Exhibits</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(a) Exhibits</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See the Exhibit Index immediately following the signature page to this Quarterly Report on Form 10-Q, which is incorporated by reference here.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div><a name="s0822ADA96F85CEB9DCF312B9CA0F798F"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">E</font><font style="font-family:inherit;font-size:8pt;">XELIXIS, </font><font style="font-family:inherit;font-size:10pt;">I</font><font style="font-family:inherit;font-size:8pt;">NC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;2, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:inherit;font-size:9pt;">HRISTOPHER</font><font style="font-family:inherit;font-size:10pt;">&#160;J. S</font><font style="font-family:inherit;font-size:9pt;">ENNER</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief&#160;Financial&#160;Officer </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Duly Authorized Officer and Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><a name="s69B77D974649F523379412B9EBFCC4E6"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5/25/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12/5/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Specimen Common Stock Certificate.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">S-1,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">333-96335</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4/7/2000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Registration Rights Agreement dated January 22, 2014 by and among Exelixis, Inc., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1/22/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Form of Warrant to Purchase Common Stock of Exelixis, Inc. issued to OTA LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11/10/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exelixis, Inc. 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5/25/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Form of Agreements used in connection with the Exelixis, Inc. 2017 Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5/25/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Non-Employee Director Equity Compensation Policy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Amendment dated July 19, 2017, to Collaboration Agreement between Exelixis, Inc. and Genentech dated December 22, 2006</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Statement Re Computation of Earnings to Fixed Charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certification required by Rule 13a-14(a) or Rule 15d-14(a).</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certification required by Rule 13a-14(a) or Rule 15d-14(a).</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">32.1&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certification by the Chief Executive Officer and the Chief Financial Officer of Exelixis, Inc., as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s21B61A6609634ABEE2D512B9BC6BE703"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Labels Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment requested for certain portions of this exhibit.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8225;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel20170630exhibit101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sd9f97bf5727445248e8a85d8f126e031"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY </font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ALAMEDA, CA</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEASE AGREEMENT</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">between</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ASCENTRIS 105, LLC,</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">as Landlord, and</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXELIXIS, INC.,</font><font style="font-family:inherit;font-size:10pt;">&#32;<br> <br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">as Tenant</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s394d9160de8040a7ae32719763ad5979"></a></div><div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:606px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BASIC LEASE DEFINITIONS, EXHIBITS AND ADDITIONAL DEFINITIONS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Basic Lease Definitions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibits and Riders</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Definitions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">7</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">GRANT OF LEASE.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Demise</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acceptance of Premises</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quiet Enjoyment</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">13</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord and Tenant Covenants</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">14</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Reserved Rights</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">14</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rentable Area Adjustments</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">14</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">RENT.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">15</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Base Rent</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">15</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Rent</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">15</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms of Payment</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interest on Late Payments, Late Charge</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Right to Accept Payments</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">17</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">USE AND OCCUPANCY</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Use</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Occupancy</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Hazardous Material</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">18</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Civil Code Section&#160;1938 Disclosure</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">22</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SERVICES AND UTILITIES; REPAIR AND MAINTENANCE OBLIGATIONS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">22</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Standard Services (and Repair and Maintenance Responsibilities) for Multi User Buildings</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">22</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Services in Multi User Buildings.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">23</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Standard Services (and Repair, Maintenance and Replacement Responsibilities) For Single User Buildings</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">24</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s Services (and Repair, Maintenance and Replacement Responsibilities) For Single User Buildings</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">25</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC For Single User Buildings</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">26</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Elevators For Single User Buildings</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">26</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contactors and Contracts for Tenant&#8217;s Maintenance Obligations.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">26</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:606px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Request for Major Replacement; Reimbursement of Major Replacement Expenditures</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">27</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interruption of Services</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">27</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Security</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">28</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amenities</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">28</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TENANT&#8217;S REPAIR AND MAINTENANCE OBLIGATIONS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">28</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Repairs Within the Premises</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">28</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Failure to Maintain Premises</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">29</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notice of Damage</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">29</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ALTERATIONS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">29</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alterations by Tenant</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">29</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">7.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alterations by Landlord</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">30</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LIENS</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">31</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INSURANCE.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">31</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Insurance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">31</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s Insurance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">32</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">9.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Subrogation</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">34</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DAMAGE OR DESTRUCTION.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">35</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination Options</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">35</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Repair Obligations</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">35</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">10.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rent Abatement</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">36</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WAIVERS AND INDEMNITIES</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">36</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">11.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s Waivers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">36</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">11.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Indemnity</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">36</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">11.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s Indemnity</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">36</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CONDEMNATION.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">37</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">12.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Full Taking</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">37</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">12.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Partial Taking.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">37</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">12.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Awards</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">38</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ASSIGNMENT AND SUBLETTING.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">38</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Limitation</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">38</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notice of Proposed Transfer; Landlord&#8217;s Options</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">38</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consent Not to be Unreasonably Withheld</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">39</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Form of Transfer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">39</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payments to Landlord</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">40</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Change of Ownership</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">40</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Effect of Transfers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">40</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Applicability to Subsequent Transfers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">40</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">13.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Letter of Credit</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">41</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:606px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PERSONAL PROPERTY.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">41</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">14.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Installation and Removal</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">41</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">14.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Responsibility</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">41</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">END OF TERM.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">41</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Surrender</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">41</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">15.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Holding Over</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">42</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ESTOPPEL CERTIFICATES</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">42</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TRANSFERS OF LANDLORD&#8217;S INTEREST.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">43</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sale, Conveyance and Assignment</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">43</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Effect of Sale, Conveyance or Assignment</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">43</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subordination and Nondisturbance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">43</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">17.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attornment</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">44</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">RULES AND REGULATIONS</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">44</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PARKING</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">44</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DEFAULT AND REMEDIES.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">45</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">20.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s Default</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">45</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">20.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Remedies</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">46</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">20.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Intentionally Omitted.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">50</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">20.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Default and Tenant&#8217;s Remedies.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">50</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">20.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Non-waiver of Default</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">51</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SIGNAGE.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">51</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">21.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signage Provided by Landlord</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">51</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">21.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Monument Signage</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">51</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">21.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exterior Building Signage</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">51</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">21.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">52</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SECURITY DEPOSIT.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">52</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">22.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amount</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">52</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">22.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Use and Restoration</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">52</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">22.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Transfers</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">53</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">22.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Refund</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">53</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">BROKERS</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">53</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LIMITATIONS ON LANDLORD&#8217;S LIABILITY</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">53</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOTICES</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">54</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TELECOMMUNICATIONS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">54</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Certain Definitions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">54</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Installation and Use of Telecommunications Technologies</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">54</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Limitation of Responsibility</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">54</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:606px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Necessary Service Interruptions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">55</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interference</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">55</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Removal of Telecom Equipment, Wiring and Other Facilities</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">55</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">26.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Third Party Beneficiary</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MISCELLANEOUS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Binding Effect</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Complete Agreement; Modification</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Delivery for Examination</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Air Rights</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Enforcement Expenses</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Intentionally Omitted.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Project Name</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.8</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Press Release; Recording; Confidentiality</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">56</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.9</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Captions</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.10</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Invoices</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.11</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severability</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.12</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jury Trial</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.13</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Only Landlord/Tenant Relationship</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.14</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Covenants Independent</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.15</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Force Majeure</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">57</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.16</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Governing Law</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">58</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.17</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Financial Reports</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">58</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.18</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint and Several Liability</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">58</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.19</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Signing Authority</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">58</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.20</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dates and Time</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">58</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">27.21</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Counterparts; Electronic Execution</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">59</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LETTER OF CREDIT.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">59</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Generally</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">59</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Use and Restoration</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">59</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Transfers by Tenant</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">60</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Transfers and Assignments by Landlord</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">60</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Replacement</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">60</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s Ability to Draw</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">61</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">28.7</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Return</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">61</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TERMINATION OPTION.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">61</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">29.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Grant of Option</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">61</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">29.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Conditions for Exercise</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">61</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">29.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Early Termination</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">62</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">29.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Limitations on Tenant&#8217;s Rights</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">62</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">RIGHT OF FIRST OFFER.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">62</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">30.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms of Right</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">62</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Table of Contents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:606px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">30.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Limitations on Tenant&#8217;s Rights</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">63</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">RENEWAL OPTIONS.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">63</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">31.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Grant of Rights</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">63</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">31.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exercise</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">63</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">31.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Determination of Market Rental Rate</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">64</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">31.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Market Rental Rate Defined</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">65</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">31.5</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">After Exercise</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">65</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">31.6</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Limitations on Tenant&#8217;s Rights</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">66</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">32.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">LANDLORD&#8217;S HVAC WORK AND ALLOWANCE.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">66</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">32.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord&#8217;s HVAC Work</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">66</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">32.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1801 HVAC Allowance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">66</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">32.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Completion of Landlord&#8217;s HVAC Work</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">67</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">32.4</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">67</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">33.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TENANT&#8217;S HVAC WORK AND ALLOWANCE.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">67</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">33.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s HVAC Work</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">67</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">33.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1851 HVAC Allowance</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">67</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">33.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title and Liability</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">67</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;A - PLAN DELINEATING THE PREMISES AND TENANT MAINTAINED OUTDOOR AREAS</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A-1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;B - POSSESSION AND LEASEHOLD IMPROVEMENTS EXHIBIT</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;C - OCCUPANCY ESTOPPEL CERTIFICATE</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C-1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;D - RULES AND REGULATIONS</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D-1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;E - INTENTIONALLY OMITTED</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">E-1</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;F - FORM OF LETTER OF CREDIT</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">F-1</font></div></td></tr></table><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXHIBIT&#160;G - HVAC EQUIPMENT LIST</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">G-1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sf509eca249114d4c83258710b6227dc6"></a></div><div><br></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LEASE AGREEMENT</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ALAMEDA, CALIFORNIA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS LEASE AGREEMENT (&#8220;Lease&#8221;) is entered into as of the Lease Date, and by and between Landlord and Tenant, identified in Section&#160;1.1 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;BASIC LEASE DEFINITIONS, EXHIBITS AND ADDITIONAL DEFINITIONS</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Basic Lease Definitions</font><font style="font-family:inherit;font-size:12pt;">.  In this Lease, the following defined terms have the meanings indicated:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#8220;Lease Date&#8221; means that date set forth under Landlord&#8217;s signature at the end of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#8220;Landlord&#8221; means Ascentris 105, LLC, a Colorado limited liability company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#8220;Tenant&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#8220;Premises&#8221; means the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Temporary Space; 1751 Space</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding anything to the contrary in this Lease, Landlord shall deliver possession of Suite&#160;225 located on the second floor of the 1751 Building and identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Temporary Space&#8221;) on the Lease Date.  Tenant may use and occupy the Temporary Space, including conducting business therein, from the Lease Date until the Commencement Date (as defined in Paragraph&#160;1(a) of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">) occurs (the &#8220;Temporary Space Period&#8221;), at no cost to Tenant, including payment of Rent, but on all of the other terms and conditions of this Lease.  The parties acknowledge that upon the Commencement Date, the Temporary Space Period will end and the Temporary Space will become part of the Premises in accordance with the terms and conditions of this Lease and the Work Letter and shall, upon becoming part of the Premises, be referred to as the &#8220;1751 Space,&#8221; which contains approximately 11,965 square feet of Rentable Area, which shall not be subject to re-measurement except as set forth in Section&#160;2.6 below;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">1801 Space</font><font style="font-family:inherit;font-size:12pt;">.  Premises known as Suites&#160;100, 150, 175, 200 and 210 located on the first and second floors of the 1801 Building and identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;1801 Space&#8221;), which contains approximately 41,342&#160;square feet of Rentable Area, which shall not be subject to re-measurement except as set forth in Section&#160;2.6 below; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">1851 Space</font><font style="font-family:inherit;font-size:12pt;">.  Premises known as Suites&#160;1000, 125, 150, 200 and 210 located on the first and second floors of the 1851 Building identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;1851 Space&#8221;), which constitute the entire Building and contain approximately 57,476 square feet of the Rentable Area, which shall not be subject to re&#8209;measurement except as set forth in Section&#160;2.6 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Premises contains a total of 110,783 square feet of Rentable Area, which shall not be subject to re-measurement except as set forth in Section&#160;2.6 below.  The Premises do not include any areas above the finished ceiling or below the finished floor covering installed in the Premises or any other areas not shown on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">&#32;as being part of the Premises.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#8220;Buildings&#8221; or &#8220;Building&#8221; means the office buildings in which the Premises is located.  A &#8220;Multi User Building&#8221; means a Building occupied by Tenant and one or more other tenants or includes vacant space that could be marketed for lease to other tenants.  A &#8220;Single User Building&#8221; means a Building occupied by Tenant and no other tenants and does not include vacant space that could be marketed for lease to other tenants.  The Buildings are further described as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;1751 Harbor Bay Parkway, Alameda, California, in which the Temporary Space is located (the &#8220;1751 Building&#8221;), which Building contains 74,170 square feet of Rentable Area and is a Multi User Building;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;1801 Harbor Bay Parkway, Alameda, California, in which the 1801 Space is located (the &#8220;1801 Building&#8221;), which Building currently contains 57,685 square feet of Rentable Area and is a Multi User Building; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;1851 Harbor Bay Parkway, Alameda, California, in which the 1851 Space is located (the &#8220;1851 Building&#8221;), which Building contains 57,476 square feet of Rentable Area and is a Single User Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#8220;Project&#8221; means the multiple building project, of which the Buildings are a part, known as of the Lease Date as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California, and related parking areas, walkways, landscaping areas and other common areas, less any portions that may be owned separately from the Buildings by a party other than Landlord from time to time.  On the Lease Date, the Project contains 384,579 square feet of Rentable Area.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;&#8220;Use&#8221; means general office uses throughout the Premises, research and development uses throughout the Premises, vivarium in the 1801 Building and the 1851 Building only, manufacturing in the 1801 Building and the 1851 Building only, and ancillary uses related to the foregoing uses, subject to obtaining any required approvals.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;&#8220;Term&#8221; means the duration of this Lease, which will be approximately 120&#160;months, beginning on the &#8220;Commencement Date&#8221; (as defined in Paragraph&#160;1(a) of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">) and ending on the &#8220;Expiration Date&#8221; (as defined below), unless terminated earlier or extended further as provided in this Lease.  The &#8220;Expiration Date&#8221; means (i)&#160;if the Commencement Date is the first day of a month, the date which is 120&#160;months from the date preceding the Commencement Date; or (ii)&#160;if the Commencement Date is not the first day of a month, the date which is 120&#160;months from the last day of the month in which the Commencement Date occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#8220;Base Rent&#8221; means the Rent payable according to Section&#160;3.1, which will be in an amount per month or portion thereof during the Term as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:54px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.38775510204081%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:42%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Months</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monthly Rental Rate</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Rent Payable Per Month</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 1 &#8211; 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$182,791.95*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 13** &#8211; 24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$188,275.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 25 &#8211; 36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$193,923.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 37 &#8211; 48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$199,741.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 49 &#8211; 60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$205,733.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 61 &#8211; 72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$211,905.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 73 &#8211; 84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$218,263.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 85 &#8211; 96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$224,811.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 97 &#8211; 108</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$231,555.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 109 &#8211; 120</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$238,502.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">* </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12 Month</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rent Abatement Period.</font><font style="font-family:inherit;font-size:12pt;">&#32;Base Rent for this period will be partially abated in the amount of $83,791.95 per month (the &#8220;Rent Abatement&#8221;) beginning on the Commencement Date and ending on the date that is 12&#160;calendar months after the Commencement Date (the &#8220;Rent Abatement Period&#8221;).  By way of example, if the Commencement Date occurs on October&#160;10, 2017, then the Rent Abatement Period shall expire on October&#160;9, 2018.  However, if Landlord terminates this Lease as a result of a &#8220;Default&#8221; (as defined in Section&#160;20.1) at any time during the Term, in addition to all other remedies available to Landlord, the unamortized portion of any Rent that is abated pursuant to this Section&#160;1.1(i) will automatically become immediately due and payable.  At any time on or before the Rent Abatement Period, upon notice to Tenant, Landlord shall have the right to purchase any Rent Abatement relating to the remaining Rent Abatement Period by paying to Tenant an amount equal to the &#8220;Rent Abatement Purchase Price&#8221; (as defined below).  As used herein, &#8220;Rent Abatement Purchase Price&#8221; shall mean the aggregate amount of the Rent Abatement remaining during the Rent Abatement Period, as of the date of payment of the Rent Abatement Purchase Price by Landlord.  Upon Landlord&#8217;s payment of the Rent Abatement Purchase Price to Tenant, Tenant shall be required to pay Rent in accordance with the provisions of Sections&#160;1.1(i) and 3.1 and there shall be no further Rent Abatement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">**</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proration for Partial Months</font><font style="font-family:inherit;font-size:12pt;">.  If the Commencement Date is not the first day of the month, then for purposes of this Section&#160;1.1(i), &#8220;Month&#160;13&#8221; of the Term will be the first full calendar month after the expiration of the Rent Abatement Period, together with the days in the prior calendar month after the expiration of the Rent Abatement Period (the &#8220;Partial Month&#8221;), and Rent for the Partial Month will be payable at the same rate as set forth in this Section&#160;1.1(i) for Month&#160;13, prorated based on the number of days in the Partial Month and the number of days in such prior calendar month.  Except for the increase immediately following the Rent Abatement Period, all increases will occur on the first day of the applicable month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;&#8220;Building Shares&#8221; or &#8220;Building Share&#8221; means, with respect to the calculation of Operating Expenses according to Section&#160;1.3(j), the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;With respect to the 1751 Building, percentage obtained by dividing the Rentable Area of the 1751 Space by the total Rentable Area of the 1751 Building and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1751 Building Share&#8221;).  As of the Commencement Date, upon which the Temporary Space becomes part of the Premises (and is thereafter referred to as the 1751 Space), the 1751 Building Share will be 16.13%, subject to adjustment pursuant to Section&#160;2.6 below.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;With respect to the 1801&#160;Building, percentage obtained by dividing the Rentable Area of the 1801 Space which has been Delivered by Landlord by the total Rentable Area of the 1801 Building and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1801 Building Share&#8221;).  As of the Lease Date, the 1801 Building Share will be 71.67%, subject to adjustment pursuant to Section&#160;2.6 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;With respect to the 1851&#160;Building, percentage obtained by dividing the Rentable Area of the 1851 Space which has been Delivered by Landlord by the total Rentable Area of the 1851 Building and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1851 Building Share&#8221;).  As of the Lease Date, the 1851 Building Share will be 100%, subject to adjustment pursuant to Section&#160;2.6 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;&#8220;Project Shares&#8221; or &#8220;Project Share&#8221; means, with respect to the calculation of Operating Expenses according to Section&#160;1.3(j), the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;With respect to the 1751 Building, percentage obtained by dividing the Rentable Area of the 1751 Space by the total rentable square footage of the Project and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1751 Project Share&#8221;).  As of the Commencement Date, upon which the Temporary Space becomes part of the Premises (and is thereafter referred to as the 1751 Space), the 1751 Project Share will be 3.11%, subject to adjustment pursuant to Section&#160;2.6 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;With respect to the 1801 Building, percentage obtained by dividing the Rentable Area of the 1801 Space that has been Delivered by Landlord by the total rentable square footage of the Project and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1801 Project Share&#8221;).  As of the Lease Date, the 1801 Project Share will be 10.75%, subject to adjustment pursuant to Section&#160;2.6 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;With respect to the 1851 Building, percentage obtained by dividing the Rentable Area of the 1851 Space which has been Delivered by Landlord by the total rentable square footage of the Project and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1851 Project Share&#8221;).  As of the Lease Date, the 1851 Project Share will be 14.95%, subject to adjustment pursuant to Section&#160;2.6 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Rentable Area of the Project (and therefore, Project Shares) will be subject to adjustment based on the number of buildings in the Project that Landlord may own, from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)&#160;&#160;&#160;&#160;&#8220;Security Deposit&#8221; means $0.00.  See, however, Sections&#160;1.1(r) and 28 regarding the &#8220;Letter of Credit.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)&#160;&#160;&#160;&#160;&#8220;Landlord&#8217;s Manager&#8217;s Address&#8221; means: </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Jones Lang LaSalle Americas, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1601 Harbor Bay Parkway Suite 110</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alameda, CA  94502</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Chris Wakefield &#8211; General Manager</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)&#160;&#160;&#160;&#160;&#8220;Landlord&#8217;s General Address&#8221; means: </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ascentris 105, LLC</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1401 17th Street, 12th Floor</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Denver, Colorado  80202</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:  Robert A. Toomey, Jr., Manager</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)&#160;&#160;&#160;&#160;&#8220;Landlord&#8217;s Payment Address&#8221; means: </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ascentris 105, LLC</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o Jones Lang LaSalle</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">P.O. Box 748365</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Los Angeles, CA  90074-8365</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Notice Address&#8221; means:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">for notices given before the Commencement Date:</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">210 East Grand Avenue</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">South San Francisco CA 94080</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:  Executive Vice President, General Counsel and Secretary</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and for notices given after the Commencement Date:</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1851 Harbor Bay Parkway</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alameda, California  94502</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:  Executive Vice President, General Counsel and Secretary </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In each case, with a copy to: </font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cooley LLP</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">101 California Street, 5</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Floor</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">San Francisco, California 94111-5800</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn: Anna B. Pope</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(q)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Invoice Address&#8221; means:</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1851 Harbor Bay Parkway</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alameda, California  94502</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Accounts Payable APGroup@exelixis.com</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(r)&#160;&#160;&#160;&#160;&#8220;Letter of Credit&#8221; means a single irrevocable, standby letter of credit as security for the performance of the obligations of Tenant hereunder in a form substantially similar to that attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;F</font><font style="font-family:inherit;font-size:12pt;">&#32;and consistent with the terms of Section&#160;28 of this Lease in the initial amount of $500,000.00 (the &#8220;L/C Amount&#8221;).  Within two (2) business days following mutual execution of this Lease (the &#8220;Deposit Date&#8221;), Tenant will deliver the Letter of Credit to Landlord, as additional consideration to induce Landlord to enter into this Lease.  Provided that no default of the Lease by Tenant has occurred beyond any applicable cure period (unless transmittal of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">notice of a default of the Lease by Tenant is barred by applicable Laws, in which case no such notice or cure period will be required with respect to such default), the L/C Amount shall periodically decrease in accordance with this Section&#160;1.1(r), including the schedule set forth below, with each period during which the L/C Amount is at a certain level being a &#8220;L/C Amount Period&#8221; and the months set forth below being the months after the Commencement Date.  Notwithstanding the foregoing, until the last L/C Amount Period, upon the occurrence of any monetary or insolvency Default during a L/C Amount Period (without limiting Landlord&#8217;s other remedies under this Lease), the next applicable reduction of the L/C Amount will automatically be extended one full L/C Amount Period, and all subsequent reductions will be postponed for a corresponding period of time.  For instance, if Tenant first commits a monetary or insolvency Default, in Month&#160;28 of the Term, the L/C Amount will not be decreased from $405,000.00 to $364,500.00 until Month&#160;49 of the Term, and will not be decreased from $364,500.00 to $328,050.00 until Month&#160;61 of the Term.</font></div><div style="line-height:120%;padding-left:54px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75.91836734693878%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:37%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">L/C Amount Period</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">(Months after the Commencement Date)</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">L/C Amount</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Deposit Date** through Month&#160;12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$500,000.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 13 through 24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$450,000.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 25 through 36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$405,000.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 37 through 48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$364,500.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 49 through 60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$328,050.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 61 through 72</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$295,245.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 73 through 84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$265,720.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Months 85 through 120</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$252,698.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:42px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">* These changes in the L/C Amount may be delayed as set forth above, and Tenant will be responsible for causing any such modifications of the applicable Letter of Credit to be made at Tenant&#8217;s sole cost.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:42px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">** The first L/C Amount Period will begin on the date Tenant deposits the Letter of Credit with Landlord and end on Month&#160;12 of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(s)&#160;&#160;&#160;&#160;&#8220;Brokers&#8221; means the following brokers who will be paid by Landlord:  Kidder Matthews and Cushman Wakefield; and the following brokers who will be paid by Tenant:  None.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibits and Riders</font><font style="font-family:inherit;font-size:12pt;">.  The Exhibits and Riders listed below are attached to and incorporated in this Lease.  In the event of any inconsistency between such Exhibits or Riders and the terms and provisions of this Lease, the terms and provisions of the Exhibits and Riders will control.  The Exhibits to this Lease are:</font></div><div style="line-height:120%;padding-left:162px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:70%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:5%;"></td><td style="width:75%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Plan Delineating the Premises and Tenant Maintained Outdoor Areas</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;B</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Possession and Leasehold Improvements Exhibit</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;C</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Occupancy Estoppel Certificate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;D</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rules and Regulations</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;E</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Intentionally Omitted</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;F</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Form of Letter of Credit</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit&#160;G</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8211;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC Equipment List</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Additional Definitions</font><font style="font-family:inherit;font-size:12pt;">.  In addition to those terms defined in Section&#160;1.1 and other sections of this Lease, the following defined terms when used in this Lease have the meanings indicated:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#8220;Additional Rent&#8221; means the Rent payable according to Section&#160;3.2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#8220;Affiliates&#8221; of a party means that party&#8217;s parent, subsidiary and affiliated corporations and its and their managers, members, partners, venturers, directors, officers, shareholders, agents, servants and employees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#8220;Building Standard&#8221; means the scope and quality of leasehold improvements, Building systems or Building services, as the context may require, generally offered from time to time to all office tenants of the Buildings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#8220;Business Hours&#8221; means the hours from 7:00&#160;a.m. to 7:00&#160;p.m. on Monday through Friday.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#8220;Common Areas&#8221; means certain interior and exterior common and public areas located on the Project and in the respective Buildings as may be designated by Landlord for the nonexclusive use in common by Tenant, Landlord and other tenants, and their employees, guests, customers, agents and invitees, including any fitness center in the Project made available to tenants; it being understood that the Common Areas will not include the Tenant Maintained Outdoor Areas.  With respect to Single User Buildings, there will be no interior Common Areas within such Buildings; provided, however, Landlord will have access to the Single User Buildings in accordance with this Lease, including, without limitation, Sections&#160;2.4 and 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#8220;Costs&#8221; means the aggregate of all ordinary and customary real property operating costs (other than those expressly excluded below) incurred or accrued during each calendar year according to standard real estate accounting principles for operating, managing, administering, equipping, securing and protecting (to the extent such services are provided by Landlord), insuring, heating, cooling, ventilating, lighting, repairing, replacing, renewing, cleaning, maintaining, decorating, inspecting, and providing water, sewer and other energy and utilities to, any portion of the Project, Buildings and Common Areas (any of which may be furnished by Landlord, an Affiliate of Landlord, or a third party, including an owners&#8217; association or declarant under a Declaration); the total amounts paid by or due from Landlord in satisfaction of any charges or assessments made by any association or other party in connection with providing any services or benefits to the Premises, Buildings or the Project pursuant to any Declaration, but excluding the costs of electricity used in the Premises, which will be paid by Tenant pursuant to Section&#160;5.2(f); management fees calculated according to the management agreement between Landlord and its managing agent, which management fees will be at a then&#8209;current market rate) and shall never exceed 3% of gross revenues with respect to the portion of the Premises located in a Multi User Building and 2% of gross revenues with respect to the portion of the Premises located in a Single User Building (and the percentage will be adjusted accordingly if a Multi User Building is converted into a Single User Building and vice versa) and shall never exceed rates charged by third party commercial real estate property managers for comparable services at comparable business parks in the San Francisco Bay Area; reasonable fees and expenses incurred in connection with Landlord&#8217;s registration of the Buildings and/or Project with the Environmental Protection Agency&#8217;s Energy Star&#174; Portfolio Manager system (the &#8220;Portfolio Manager System&#8221;) and with Landlord&#8217;s collection, tracking and disclosure of energy consumption information with respect to the Buildings and/or Project as may be reasonably </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">necessary to comply with California Public Resources Code Section 25402.10; fees and expenses (including reasonable attorneys&#8217; fees) incurred in contesting, in good faith, the validity of any Laws that would cause an increase in Costs, provided that Landlord believes, in good faith, that the cost savings will be greater than the fees required to pursue such contest; depreciation and amortization on materials, tools, supplies and vendor type equipment purchased by Landlord to enable Landlord to supply services Landlord might otherwise contract for with a third party where such depreciation and amortization would otherwise have been included in the charge for such third party&#8217;s services, all as determined in accordance with generally accepted accounting principles, consistently applied, and when depreciation or amortization is permitted or required, the item shall be amortized over its reasonably anticipated useful life (&#8220;Permitted Depreciation and Amortization&#8221;); and, except as otherwise expressly set forth in this Lease, costs (whether capital or not) that (i) are incurred in order to conform to changes subsequent to the Lease Date in any Laws, or (ii) have been or are incurred with the reasonably expectation of a substantial reduction in Costs or the rate of increase in Costs (the costs described in clauses (i) and (ii) will be charged to Costs in annual installments over the useful life of the items for which such costs are incurred [in the case of items required by changes in Laws] or over the period Landlord reasonably estimates that it will take for the savings in Costs achieved by such items to equal their cost [in the case of items intended to reduce Costs or their rate of increase], and in either case together with interest, at the average Prime Rate in effect during each calendar year that such costs are charged to Costs, on the unamortized balance) (collectively, &#8220;Permitted Capital Expenditures&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Costs will not include (1) principal, interest, points or fee on debt or amortization on any mortgage or mortgages or any other debt instrument encumbering the Building or Project; (2) ground lease payments; (3) leasing commissions; (4) costs of advertising space for lease in the Project; (5) costs for which Landlord is reimbursed by insurance proceeds or from tenants of the Project (other than such tenants&#8217; regular contributions to Costs); (6) any amortization or depreciation, except for Permitted Depreciation and Amortization and Permitted Capital Expenditures, (7) and capital expenditures as determined in accordance with generally accepted accounting principles, except for Permitted Capital Expenditures; (8) legal fees and other costs incurred in connection with negotiating leases or collecting rents, (9) legal fees and other costs incurred in connection with disputes with present or prospective tenants, other occupants of the Building or Project, or other third parties; (10) costs directly and solely related to the maintenance and operation of the entity that constitutes Landlord, such as accounting fees incurred solely for the purpose of reporting Landlord&#8217;s financial condition; (11) any fines, costs, penalties or interest resulting from Landlord&#8217;s failure to comply with Laws, except as expressly provided above; (12) expenses in connection with services or other benefits which are exclusively offered to one tenant in the Project but not offered to Tenant or other tenants generally or for which Tenant is charged directly but which are not provided to another tenant or occupant of the Building or Project; (13) costs incurred by Landlord due to the violation by Landlord or any other tenant other than Tenant of the terms and conditions of any lease of space in the Building or Project; (14) any compensation paid to clerks, attendants, or other persons in commercial concessions operated by Landlord other than reasonable payments to food trucks to meet sales minimums; (15) (intentionally omitted); (16) all items and services for which Tenant or any other tenant of the Building or Project reimburses or is obligated to reimburse Landlord and which Landlord provides selectively to one or more tenants in the Project but not offered to Tenant or other tenants generally; (17) (intentionally omitted); (18) electric power costs for which any tenant directly contracts with the local public service company; (19) services provided and costs incurred in connection with any operation of any retail, restaurant or deli in the Building, if any; (20) (intentionally omitted); </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(21) (intentionally omitted); (22) wages, salaries, fees and fringe benefits paid to administrative or executive personnel or officers or partners of Landlord or management agent or anyone else over the level of Project supervisor; (23) the cost of correcting defects in the original construction of the Buildings; (24) the cost of any repair made by Landlord because of the total or partial destruction of the Building or Project, or the condemnation of a portion of the Building or Project that is reimbursed by insurance or condemnation award; (25) the cost of overtime or other expense to Landlord due to Landlord&#8217;s defaults or incurred while performing work expressly provided in this lease to be borne at Landlord&#8217;s expense (but not including overtime related to emergencies or required weekend work); (26) allowances, concessions, permits, licensees, inspections, and other costs and expenses incurred in completing, fixturing, renovating, decorating or redecorating space for tenants (including Tenant), prospective tenants or other occupants or prospective occupants of the Building or Project, or vacant leasable space in the Building or Project, or constructing or finishing demising walls (but not including paint touch-up) and public corridors with respect to any such space whether such work or alteration is performed for the initial occupancy by such tenant or occupant or thereafter; (27) after hours or overtime HVAC costs or electricity costs if chargeable or charged separately to other Building tenants; (28) expenses incurred by Landlord with respect to a tenant&#8217;s space located in another project in connection with such tenant&#8217;s leasing of space in the Project; (29) any cost representing an amount paid for first-class services or materials to a related person, firm, or entity to the extent such amount exceeds the amount that would be paid for such first-class services or materials at the then-existing market rates to an unrelated person, firm, or entity; (30) costs incurred due to the late payment of taxes, utility bills or other amounts owing, so long as Landlord was obligated to make such payments and did not in good faith dispute the amount of such payments; (31) general corporate overhead and general administrative expenses and accounting, record-keeping and clerical support of Landlord or the management agent, except as otherwise included in Landlord&#8217;s management fees; (32) any increase in insurance premiums caused by Landlord&#8217;s or any tenant&#8217;s acts (other than Tenant&#8217;s acts) with respect to &#8220;Hazardous Material&#8221; (as defined in Section&#160;4.4); (33) moving expense costs of tenants of the Building or Project; (34) costs incurred for any items to the extent Landlord recovers under a manufacturer&#8217;s, materialmen&#8217;s vendor&#8217;s or contractor&#8217;s warranty; (35) costs of acquisition (but not maintenance and repair) of sculpture, paintings, or other objects of art; (36) any rent or expenses for storage space or other facilities that solely benefits Landlord; (37) costs incurred to test, survey, clean up, contain, abate, remove or otherwise remedy Hazardous Material and/or indoor air quality problems from the Building or Project, subject, however, to Tenant&#8217;s obligations with respect to Hazardous Material as set forth in Section&#160;4.4; (38) costs directly resulting from the gross negligence or intentional misconduct of Landlord, or its Affiliates; (39) costs or fees relating to the defense of Landlord&#8217;s title or interest in the real estate containing the Building or Project, or any part thereof; (40) costs or expenses incurred by Landlord in financing, refinancing, pledging, selling, granting or otherwise transferring or encumbering ownership rights in the Building or Project; (41) (intentionally omitted); (42) the cost of installing, operating and maintaining any specialty service operated by the Landlord, such as an athletic or recreational club in the Building, unless Tenant has access to the same; (43) any bad debt loss; (44) costs and expenses incurred in connection with any transfer of an interest in the Landlord, the Building or the Project; and (45) any other expenses that under standard real estate accounting principles consistently applied would not be considered normal maintenance, repair, management or operation expenses.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For each calendar year during the Term, the amount by which those Costs that vary with occupancy (such as cleaning costs and utilities) would have increased had the Project been 100% occupied </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and operational and had all Project services been provided to all tenants will be reasonably determined and the amount of such increase will be included in Costs for such calendar year. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Costs shall be reduced by all cash discounts, trade discounts or quantity discounts received by Landlord or its Affiliates in the purchase of any goods, utilities or services in connection with the prudent operation of the Buildings and Project.  In the calculation of any expenses hereunder, it is understood that the same exact expense shall not be charged more than once. Landlord shall use its best efforts in good faith to effect an equitable proration of bills for services rendered to a Building and to any other property owned by Landlord or its Affiliates.  In the event there exists a conflict as to an expense which is specified to be included in Costs and is also specified to be excluded from Costs within the above list, the exclusions listed above shall prevail and the expenses shall be deemed excluded.  Landlord shall not recover more than 100% of the Costs actually incurred by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;&#8220;Declarations&#8221; means any declaration, reciprocal easement agreement or other similar instrument or agreement relating to access, use and/or maintenance of the Project and improvements thereon that now affect or in the future may affect the Project and is recorded in the real property records of Alameda County, California, as they may be recorded, amended and otherwise modified.  This Lease and all of Tenant&#8217;s rights hereunder are and will be subject and subordinate to all Declarations.  While such subordination will occur automatically, Tenant agrees to execute and deliver to Landlord or the applicable association or party contemplated by the applicable Declaration, within 10 days after request and without cost to Landlord, such commercially reasonable instrument(s) as may be reasonably required to evidence such subordination.  Notwithstanding the foregoing, from and after the Lease Date, Landlord shall not voluntarily create or acquiesce to the creation of any new Declaration or a modification of any existing Declaration which would materially diminish the rights of Tenant under this Lease, materially increase Tenant&#8217;s costs under this Lease, materially reduce the available parking spaces for Tenant&#8217;s use at the Buildings or Project, or materially interfere with Tenant&#8217;s access to the Buildings or parking areas in the Project.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;&#8220;Delivers&#8221; (or &#8220;Deliver&#8221; or &#8220;Delivered&#8221;, as the context may require) means Landlord tenders possession of the applicable portion of the Premises in the condition required by Section&#160;2.2 of this Lease and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#8220;Laws&#8221; means any and all present or future federal, state or local laws, statutes, ordinances, rules, regulations or orders of any and all governmental or quasi-governmental authorities having jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;&#8220;Operating Expenses&#8221; means the sum of (i)&#160;the 1751 Building Share multiplied by the Costs and Taxes incurred by Landlord in such calendar year in connection with the 1751 Building, (ii)&#160;the 1801 Building Share multiplied by the Costs and Taxes incurred by Landlord in such calendar year in connection with the 1801 Building, (iii)&#160;the 1851 Building Share multiplied by the Costs and Taxes incurred by Landlord in such calendar year in connection with the 1851 Building, (iv)&#160;the 1751 Project Share multiplied by all Costs and Taxes incurred by Landlord in such calendar year in connection with the Project, (v)&#160;the 1801 Project Share multiplied by all Costs and Taxes incurred by Landlord in such calendar year in connection with the Project, (vi)&#160;the 1851 Project Share multiplied by all Costs and Taxes incurred by Landlord in such calendar year in connection with the Project; the Project Shares shall include a share of all Costs and Taxes incurred by Landlord in connection with the Common Areas of the Project, but shall exclude Costs and Taxes incurred by Landlord with respect to any particular building </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in the Project, as equitably and reasonably determined by Landlord in accordance with sound property management accounting principles.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;&#8220;Portfolio Manager System&#8221; has the meaning set forth in Section&#160;1.3(f).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)&#160;&#160;&#160;&#160;&#8220;Prime Rate&#8221; means the rate of interest announced from time to time by Wells Fargo Bank, or any successor to it, as its prime rate.  If Wells Fargo Bank or any successor to it ceases to announce a prime rate, Landlord will designate a reasonably comparable financial institution for purposes of determining the Prime Rate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)&#160;&#160;&#160;&#160;&#8220;Rent&#8221; means the Base Rent, Additional Rent and all other amounts required to be paid by Tenant under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)&#160;&#160;&#160;&#160;&#8220;Rentable Area&#8221; means the rentable area, measured in square feet, of any described space within the respective Buildings or Project, as applicable, as determined pursuant to a Standard Method for Measuring Floor Area in Office Buildings, ANSI/BOMA Z65.1-1996.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)&#160;&#160;&#160;&#160;&#8220;Taxes&#8221; means the amount incurred or accrued during each calendar year according to generally accepted accounting principles for:  all ad valorem real and personal property taxes and assessments, special or otherwise, levied upon or with respect to the respective Buildings or Project, the personal property used in operating the respective Buildings or Project, and the rents and additional charges payable by tenants of the respective Buildings or Project, and imposed by any taxing authority having jurisdiction; all taxes, levies and charges which may be assessed, levied or imposed in replacement of, or in addition to, all or any part of ad valorem real or personal property taxes or assessments as revenue sources, and which in whole or in part are measured or calculated by or based upon the respective Buildings or Project, the leasehold estate of Landlord or the tenants of the respective Buildings or Project, or the rents and other charges payable by such tenants; capital and place-of-business taxes, and other similar taxes assessed relating to the Common Areas; and any reasonable expenses incurred by Landlord in attempting to reduce or avoid an increase in Taxes, including, without limitation, reasonable legal fees and costs.  Notwithstanding the foregoing, if a reassessment of the respective Buildings or Project for ad valorem property tax purposes, including any reassessment pursuant to California Constitution Article&#160;13A and Sections&#160;60 through 67 of the California Revenue &amp; Taxation Code, occurs, then Tenant will be obligated to pay the Building Shares and/or the Project Shares of any such additional Taxes resulting from any such reassessment with respect to the respective Buildings or Project.  Notwithstanding the foregoing, Taxes shall not include any tax upon Landlord&#8217;s net income or profits and shall also not include: business professional, occupational and license taxes (BPOL), federal, state or local income taxes, franchise, gift, transfer, excise, capital stock, estate, succession, or inheritance taxes (collectively, &#8220;Excluded Taxes&#8221;).  Landlord shall pay all real property taxes and assessments by the date due, and shall, upon Tenant&#8217;s written request, furnish Tenant with evidence of such payment. Taxes shall not include any interest, late fees or other changes incurred as a result of Landlord&#8217;s failure to pay Taxes as and when due. Landlord shall not include in taxes any interest or penalties incurred by Landlord by reason of Landlord&#8217;s failure to pay in a timely manner any real property taxes and assessments.  Landlord shall not recover more than 100% of the Taxes actually incurred by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)&#160;&#160;&#160;&#160;&#8220;Tenant Maintained Outdoor Areas&#8221; means certain exterior areas located outside of the 1801 Building and the 1851 Building as depicted in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:inherit;font-size:12pt;">, as may be adjusted by Landlord from time to time, that will be maintained by Tenant for the use by Tenant and its employees, guests, customers, agents and invitees; provided, however, that the exterior areas </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">surrounding the 1801 Building will not be considered part of the Tenant Maintained Outdoor Areas until the time, if ever, the 1801 Building is converted into a Single User Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;GRANT OF LEASE</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Demise</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms, covenants, conditions and provisions of this Lease, Landlord leases to Tenant and Tenant leases from Landlord the Premises, together with the exclusive right to use the Tenant Maintained Outdoor Areas and the non-exclusive right to use the Common Areas, for the Term.  Subject to the terms and conditions of this Lease and Landlord&#8217;s right to close the Buildings or Project in the event of an emergency, Tenant shall have access to the Premises 24 hours per day, seven days per week.  Tenant&#8217;s exclusive right to use the Tenant Maintained Outdoor Areas will mean Tenant can erect and maintain fences and hedges to exclude others from the Tenant Maintained Outdoor Areas and may reasonably request that such persons leave the Tenant Maintained Outdoor Areas.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;Acceptance of Premises</font><font style="font-family:inherit;font-size:12pt;">.  On the applicable &#8220;Start Dates&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">), Landlord will deliver the Premises to Tenant in a clean condition, with the roof of each Building in good condition and repair, with all base building and Premises systems in good working order and condition, and, to the extent expressly required by the City of Alameda, with the path of travel to the applicable portion of the Premises and Common Areas in each Building in compliance with all regulatory/municipal requirements, including Americans with Disabilities Act of 1990, 42 U.S.C. &#167;12101 et seq.  Any capital expenditures required exclusively for such work to the base building systems, path of travel, or the Common Areas will be the responsibility of Landlord, at Landlord&#8217;s cost, and shall not be included as a Cost.  Except as expressly set forth in this Lease, Tenant acknowledges that Landlord has not made any representation or warranty with respect to the condition of the Premises, the Buildings or the Project or with respect to the suitability or fitness for the conduct of the Use or for any other purpose.  On the applicable Start Dates, Tenant agrees to accept the Premises in its &#8220;as is&#8221; physical condition without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements (or to provide any allowance for same), except as expressly set forth in this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;Quiet Enjoyment</font><font style="font-family:inherit;font-size:12pt;">.  Landlord covenants that during the Term, Tenant will have quiet and peaceable possession of the Premises free from claims by, through and under Landlord, subject to the terms, covenants, conditions and provisions of this Lease, and Landlord will not disturb such possession except as expressly provided in this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;Landlord and Tenant Covenants</font><font style="font-family:inherit;font-size:12pt;">.  Landlord covenants to observe and perform all of the terms, covenants and conditions applicable to Landlord in this Lease.  Tenant covenants to pay the Rent when due, and to observe and perform all of the terms, covenants and conditions applicable to Tenant in this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.5&#160;&#160;&#160;&#160;Landlord&#8217;s Reserved Rights</font><font style="font-family:inherit;font-size:12pt;">.  With respect to Multi User Buildings, Landlord reserves, for Landlord&#8217;s exclusive use, any of the following (other than those installed for Tenant&#8217;s exclusive use) that may be located in such Multi User Buildings: janitor closets, stairways and stairwells; fan, mechanical, electrical, telephone and similar rooms; and elevator, pipe and other vertical shafts, flues and ducts.  With respect to Single User Buildings, Landlord will have access to the roofs, all structural elements, the heating, ventilation and air conditioning (&#8220;HVAC&#8221;) systems and elevators located in such Single User Buildings for the purposes of inspection and performance of Landlord&#8217;s obligations under this Lease.  In connection with the foregoing, and in addition to other rights in favor of Landlord set forth herein, Landlord, its agents and employees will have the right to enter the Premises from time to time at reasonable times and upon at least 24 hours&#8217; written notice (which may be by email), unless a </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shorter time frame is agreed to by Tenant on a case-by-case basis, and except in case of emergency, in which case, Landlord shall endeavor to provide notice to Tenant as soon as practicable, to examine the same, obtain ingress to and egress from the portions of the Premises to which Landlord has a right to access under this Lease, show them to prospective purchasers, lenders, investors, employees or consultants (and during the last 24 months of the Term or any time during the Term if Tenant is in Default, to prospective tenants), to supply janitorial services or any other services to be provided by Landlord to Tenant, to inspect or cause a consultant to inspect all portions of the Premises to ensure Tenant&#8217;s compliance with its maintenance and operational obligations under this Lease, to post notices of non-responsibility, to record any amendments to the Declarations and to create any related associations; without liability to Tenant for any loss or damage incurred as a result of such entry, provided that Landlord will take reasonable steps in connection with such entry to minimize any disruption to Tenant&#8217;s business or its use of the Premises. In any entrance into the Premises pursuant to the provisions of this Section&#160;2.5, Landlord shall ensure compliance with Tenant&#8217;s reasonable security and operational procedures previously detailed by Tenant to Landlord, except to the extent Landlord or its agents determine that an emergency makes compliance with such procedures impracticable.  Tenant may from time to time upon five days&#8217; advance written notice to Landlord designate, as secured areas of the Premises, areas where unusually confidential information is kept; provided that such secured areas must be reasonably located so that such secured areas do not interfere with Landlord performing its obligations under this Lease.  Except in the case of emergency (as determined by Landlord in good faith), Landlord shall not enter such secured areas unless accompanied by a representative of Tenant. Tenant agrees to make such representative available to Landlord during Business Hours upon reasonable advance written request by Landlord (which may be by email) at least 24 hours&#8217; in advance. Landlord shall at all times be provided with a means of entry to the secured areas in the event of an emergency.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.6&#160;&#160;&#160;&#160;Rentable Area Adjustments</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of all amounts, percentages and figures appearing or referred to in this Lease (including, without limitation, Building Shares and Project Shares), the Rentable Area of the Project, Buildings or Premises shall not be subject to remeasurement, except as follows: if the Premises, Building or Project shall be materially physically expanded or contracted, Landlord may cause its architect to measure and certify to Landlord and Tenant the Rentable Area of the Project, Buildings or Premises pursuant to standards set forth in Section&#160;1.3(n) and, upon the request of Landlord, Landlord and Tenant will execute an amendment to this Lease to modify all amounts, percentages and figures appearing or referred to in this Lease (including, without limitation, Building Shares and Project Shares) as may be necessary to conform to such remeasurement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;RENT</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Base Rent</font><font style="font-family:inherit;font-size:12pt;">.  Commencing on the Commencement Date and then throughout the Term, Tenant agrees to pay Landlord Base Rent according to the following provisions.  Base Rent during each month (or portion of a month) described in Section&#160;1.1(i) will be payable in equal monthly installments for such month (or portion), in advance, on or before the first day of each and every month during the Term; provided, however, that the first full months&#8217; Base Rent payment due (less applicable Rent Abatement) will be made upon execution of this Lease by Tenant.  However, if the Term commences on a date other than the first day of a month or the Term ends on a date other than the last day of a month, Base Rent for such month will be appropriately adjusted on a prorated basis.  Notwithstanding anything to the contrary contained in this Lease, in no event shall Tenant be obligated to pay Base Rent on a given portion of the Premises prior to the date Landlord has delivered such portion of the Premises.  No Base Rent shall be payable on the Temporary Space until the Commencement Date occurs.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;Additional Rent</font><font style="font-family:inherit;font-size:12pt;">.  Commencing on the Commencement Date and then throughout the Term, Tenant agrees to pay Landlord, as Additional Rent, in the manner provided below, Operating Expenses.</font></div><div style="line-height:120%;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Estimated Payments</font><font style="font-family:inherit;font-size:12pt;">.  Prior to the Commencement Date and as soon as practicable after the beginning of each calendar year thereafter, Landlord will notify Tenant in writing of Landlord&#8217;s estimate of the Operating Expenses for the ensuing calendar year.  On or before the first day of each month during the Term, commencing on the applicable Commencement Date for each portion of the Premises, Tenant will pay to Landlord, in advance, 1/12th of such estimated amounts, provided that until such notice is given with respect to the ensuing calendar year, Tenant will continue to pay on the basis of the prior calendar year&#8217;s estimate until the month after the month in which such notice is given.  However, if a Commencement Date falls on a date other than the first day of a month or the Term ends on other than the last day of a month, Operating Expenses for such month will be appropriately adjusted on a prorated basis.  In the month Tenant first pays based on Landlord&#8217;s new estimate, Tenant will pay to Landlord 1/12th of the difference between the new estimate and the prior year&#8217;s estimate for each month which has elapsed since the beginning of the current calendar year.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Annual Settlement</font><font style="font-family:inherit;font-size:12pt;">.  As soon as practicable after the close of each calendar year, but by no later than May&#160;1 following the close of such calendar year, Landlord will deliver to Tenant its written statement setting forth in reasonable detail the Operating Expenses for such calendar year.  If on the basis of such statement Tenant owes an amount that is less than the estimated payments previously made by Tenant for such calendar year, Landlord will either refund such excess amount to Tenant or credit such excess amount against the next payment(s), if any, due from Tenant to Landlord.  If on the basis of such statement Tenant owes an amount that is more than the estimated payments previously made by Tenant for such calendar year, Tenant will pay the deficiency to Landlord within 30 days after the delivery of such statement.  If this Lease commences on a day other than the first day of a calendar year or terminates on a day other than the last day of a calendar year, Operating Expenses applicable to the calendar year in which such commencement or termination occurs will be prorated on the basis of the number of days within such calendar year that are within the Term.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Final Payment</font><font style="font-family:inherit;font-size:12pt;">.  Tenant&#8217;s obligation to pay the Additional Rent provided for in this Section&#160;3.2 which is accrued but not paid for periods prior to the expiration or early termination of the Term will survive such expiration or early termination.  Prior to or as soon as practicable after the expiration or early termination of the Term, Landlord may submit an invoice to Tenant stating Landlord&#8217;s estimate of the amount by which Operating Expenses through the date of such expiration or early termination will exceed Tenant&#8217;s estimated payments of Additional Rent for the calendar year in which such expiration or termination has occurred or will occur.  Tenant will pay the amount of any such excess to Landlord within 30 days after the date of Landlord&#8217;s invoice.  Notwithstanding the foregoing, in the event that Landlord shall fail to invoice Tenant for any Additional Rent pursuant to this Section&#160;3.2 by May&#160;1 following the close of the calendar year in which the expiration or earlier termination of the Term occurs, then Landlord shall be deemed to have waived its right to collect such Additional Rent.  In the event that Tenant is entitled to a refund pursuant to this Section&#160;3.2, Landlord shall pay such amount within 30&#160;days after the end of the Term and Landlord&#8217;s obligation to refund any such amounts will survive termination or expiration of the Term.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tenant&#8217;s Right to Audit</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will have the right to inspect and audit Landlord&#8217;s books and records with respect to Operating Expenses covered by such annual statement (an &#8220;Audit&#8221;), provided that Tenant provides Landlord 10 days&#8217; prior notice of Tenant&#8217;s intention to conduct such Audit, which notice must be delivered to Landlord on or before the date that is 90 days after Tenant&#8217;s receipt of the applicable annual statement (including an annual statement received after the expiration or earlier termination of the Term).  In the event Tenant does not give Landlord notice of its election to conduct an Audit within such 90-day period, the terms and amounts set forth in such annual statement will be conclusive and final, and Tenant shall have no further right to conduct an Audit with respect to such annual statement or the Operating Expenses related thereto.  Tenant may only use a private accounting firm retained on an hourly or fixed-fee basis or Tenant&#8217;s internal accounting staff to conduct an Audit; in no event may Tenant use any auditor paid on a contingency fee or result-based basis.  If the conclusion of the Audit (which conclusion must be reasonably supported by the documentation reviewed in connection with the Audit) reveals that the amount charged by Landlord for Operating Expenses was greater than actual Operating Expenses, Landlord will credit against Rent next coming due after the completion of the Audit (or if the Term has expired, Landlord will pay to Tenant within 30 days after the completion of the Audit) the amount due to Tenant based on such difference, and if such conclusion of the Audit is that the amount charged by Landlord for Operating Expenses was less than actual Operating Expenses, Tenant will pay to Landlord the amount due from Tenant based on such difference within 30 days after the completion of the Audit.  If the conclusion of the Audit reveals that the amount charged by Landlord for Operating Expenses was greater than 105% of the actual Operating Expenses, Landlord will be responsible for its own costs and expenses related to the Audit and will reimburse Tenant for the actual and reasonable costs charged by the accounting firm retained by Tenant, if any, to conduct the Audit, excluding travel and lodging expenses within 30 days after Landlord&#8217;s receipt of Tenant&#8217;s request and evidence of such costs.  A permitted assignee of Tenant&#8217;s interest in this Lease may conduct an Audit, but only with respect to annual statements delivered after the effective date of the applicable assignment of the Tenant&#8217;s interest in this Lease.  No subtenant of the Premises will be permitted to conduct an Audit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;Other Taxes</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will reimburse Landlord upon demand for any and all taxes payable by Landlord (other than Excluded Taxes and taxes included in the definition of Taxes) whether or not now customary or within the contemplation of Landlord and Tenant:  (a)&#160;upon, measured by or reasonably attributable to the cost or value of Tenant&#8217;s equipment, furniture, fixtures and other personal property located in the Premises; (b)&#160;upon or measured by Rent; (c)&#160;upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion of the Premises; and (d)&#160;upon this transaction or any document to which Tenant is a party creating or transferring an interest or an estate in the Premises.  If it is not lawful for Tenant to reimburse Landlord, the Base Rent payable to Landlord under this Lease will be revised to yield to Landlord the same net rental after the imposition of any such tax upon Landlord as would have been payable to Landlord prior to the imposition of any such tax.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;Terms of Payment</font><font style="font-family:inherit;font-size:12pt;">.  All Base Rent, Additional Rent and other Rent will be paid to Landlord in lawful money of the United States of America, at Landlord&#8217;s Payment Address or to such other person or at such other place as Landlord may from time to time designate in writing, without notice or demand and without right of deduction, abatement or set-off, except as otherwise expressly provided in this Lease.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.5&#160;&#160;&#160;&#160;Interest on Late Payments, Late Charge</font><font style="font-family:inherit;font-size:12pt;">.  Tenant hereby acknowledges that the late payment by Tenant to Landlord of any amount payable under this Lease will cause Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult to ascertain.  All amounts payable under this Lease by Tenant to Landlord, if not paid within five days after such amounts are past due, will bear interest from the due date until paid at the lesser of the highest interest rate permitted by law or 4% in excess of the then-current Prime Rate.  Landlord, at Landlord&#8217;s option, in addition to past due interest, may charge Tenant a late charge for all payments not paid within five days after such amounts are past due, equal to the lesser of 4% of the amount of said late payment or the maximum amount permitted by law.  The parties hereby agree that such late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant.  Acceptance of such late charge by Landlord will in no event constitute a waiver of Tenant&#8217;s default with respect to such overdue amount, nor prevent Landlord from exercising any of the other rights and remedies granted hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.6&#160;&#160;&#160;&#160;Right to Accept Payments</font><font style="font-family:inherit;font-size:12pt;">.  No receipt by Landlord of an amount less than Tenant&#8217;s full amount due will be deemed to be other than payment &#8220;on account&#8221;, nor will any endorsement or statement on any check or any accompanying letter effect or evidence an accord and satisfaction.  Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance or pursue any right of Landlord.  No payments by Tenant to Landlord:  (a)&#160;after the expiration or other termination of the Term, or after termination of Tenant&#8217;s right to possession of the Premises, will reinstate, continue or extend the Term; or (b)&#160;will invalidate or make ineffective any notice (other than a demand for payment of money) given prior to such payment by Landlord to Tenant.  After notice or commencement of a suit, or after final judgment granting Landlord possession of the Premises, Landlord may receive and collect any sums of Rent due under this Lease, and such receipt will not void any notice or in any manner affect any pending suit or any judgment obtained.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;USE AND OCCUPANCY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;Use</font><font style="font-family:inherit;font-size:12pt;">.  Tenant agrees to use and occupy the Premises only for the Use described in Section&#160;1.1(g), or for such other purpose as Landlord expressly authorizes in writing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Compliance</font><font style="font-family:inherit;font-size:12pt;">.  Tenant agrees to use the Premises and the Tenant Maintained Areas in compliance with all Laws applicable to Tenant&#8217;s use, occupancy or alteration of the Premises and the Tenant Maintained Areas or the condition of the Premises and the Tenant Maintained Areas resulting from such use, occupancy or alteration, at Tenant&#8217;s sole cost and expense.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;Occupancy</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not do or permit anything which obstructs or unreasonably interferes with other tenants&#8217; rights or with Landlord&#8217;s providing Building or Project services, or which injures or annoys other tenants, as determined by Landlord in good faith.  Tenant will not cause, maintain or permit any nuisance in or about the Premises and will keep the Premises free of debris, and anything (other than the &#8220;Permitted Hazardous Materials&#8221; [as defined in Section&#160;4.4(b) below]) of a dangerous, noxious, toxic or offensive nature or which could create a fire hazard or undue vibration, heat or noise.  If any item of equipment, building material or other property (other than the Permitted Hazardous Materials) brought into the Project by Tenant or on Tenant&#8217;s request causes a dangerous, noxious, toxic or offensive effect (including an environmental effect) and in Landlord&#8217;s reasonable opinion such effect will not be permanent but will only be temporary and is able to be eliminated, then Tenant will not be required to remove such item, provided that Tenant promptly and diligently causes such effect to be eliminated, pays for all costs of elimination and indemnifies Landlord against all liabilities arising from such effect.  Tenant will not make or permit any use of the Premises which would be reasonably expected to cause the cancellation of any insurance coverage, increase the cost of insurance or require additional </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">insurance coverage.  If by reason of Tenant&#8217;s failure to comply with the provisions of this Section&#160;4.3, (a)&#160;any insurance coverage becomes unavailable, then Landlord will have the option to terminate this Lease; or (b)&#160;any insurance premiums increase, then Landlord may, upon written notice to Tenant, require Tenant to promptly pay to Landlord as Rent the amount of the increase in insurance premiums.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;Hazardous Material.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;The term &#8220;Hazardous Material&#8221; as used in this Lease means any product, substance, chemical, material, or waste whose presence, nature, quantity and/or intensity of existence, use, manufacture, disposal, transportation, spill, release, or effect, either by itself or in combination with other materials expected to be owned or about the Premises is either: (i)&#160;potentially injurious to the public health, safety, or welfare, the environment, or the Premises, (ii) regulated or monitored by any governmental authority, or (iii) a basis for liability of Landlord to any governmental agency or third party under applicable statute or common law theory.  Hazardous Material will include, but not be limited to, hydrocarbons, petroleum, gasoline, crude oil, or any products, by-products or fractions thereof, asbestos, chlorofluorocarbons, polychlorinated biphenyls (PCBs) and formaldehyde.  Tenant will not bring, place, hold, treat, or dispose of any Hazardous Material on, under, or about the Premises, the Buildings, or the Project except in compliance with &#8220;Applicable Environmental Laws&#8221; (as defined below). The term &#8220;Hazardous Materials&#8221; does not include office supplies (such as cleaning materials and toner ink) used in the ordinary course of business in compliance with Applicable Environmental Laws. Except as permitted pursuant to Section&#160;4.4(b) below, Tenant will not cause or allow any Hazardous Material to be incorporated into any improvements or alterations which it makes or causes to be made to the Premises.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Tenant may utilize certain Hazardous Materials in the designated laboratory and manufacturing areas of the Premises in connection with Tenant&#8217;s research and development operations that (i) are necessary or useful to Tenant&#8217;s business, (ii) will be used, kept, and stored in a safe manner consistent with then-current best practices and in compliance with all Applicable Environmental Laws, and (iii) for which Tenant obtains, at Tenant&#8217;s sole cost and expense, any environmental permits, plans or approvals required for its operations under this Lease and for the Premises, including, but not limited to Hazardous Materials Business Plans, Storm Water Pollution Prevention Plans, Spill Response Plans, Air Pollution Control Permits, and Waste Discharge Requirements (Hazardous Materials meeting the criteria in this sentence are &#8220;Permitted Hazardous Materials&#8221;).  Upon Landlord&#8217;s request, Tenant shall promptly provide to Landlord copies of any Safety Data Sheets (as required by the Occupational Safety and Health Act) relating to such Permitted Hazardous Materials.  Tenant will be solely liable for any damages due to or arising from the Permitted Hazardous Materials.  Tenant will indemnify, defend and hold harmless Landlord, its managers, members, partners, officers, directors, subsidiaries, affiliates, employees and agents and Property Manager from and against any and all liability, loss, claims, demands, damages or expenses (including reasonable attorneys&#8217; fees) due to or arising from the Permitted Hazardous Materials.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Tenant will promptly comply with the requirements of Section&#160;25359.7(b) of the California Health and Safety Code and/or any successor or similar statute.  Accordingly, if Tenant knows, or has reasonable cause to believe, that Hazardous Material, or a condition involving or resulting from same, has come to be located in, on, under, or about the Premises, in violation of Applicable Environmental Laws, Tenant will promptly give written notice of such fact to Landlord.  Tenant will also promptly give Landlord a copy of any written statement, report, notice, registration, application, permit, business plan, license, claim, action, or proceeding given </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to, or received from, any governmental authority or private party, or persons entering or occupying the Premises, concerning the presence, spill, release, discharge off, or exposure to, any Hazardous Material, or contamination in, on, under, or about the Premises in violation of Applicable Environmental Laws.  Should Tenant fail to so notify Landlord, Landlord will have all rights and remedies provided for such a failure by such Section&#160;25359.7(b) in addition to all other rights and remedies which Landlord may have under this Lease or otherwise.  Additionally, Tenant will immediately notify Landlord in writing of (i) any enforcement, clean-up, removal, or other governmental action instituted, completed, or threatened with regard to Hazardous Material involving the Premises, the Buildings, or the Project, (ii) any claim made or threatened by any person against Tenant, Landlord, the Premises, the Buildings, or the Project related to damage, contribution, cost recovery, compensation, loss, or injury resulting from or claimed to result from any Hazardous Material, (iii) any reports made to any environmental agency arising out of or in connection with any Hazardous Material at or removed from the Premises, the Buildings, or the Project, including any complaints, notices, warnings, or assertions of any violation in connection therewith, and (iv) any spill, release, discharge, or disposal of Hazardous Material that occurs with respect to the Premises or Tenant&#8217;s operations, including, without limitation, those that would constitute a violation of California Health and Safety Code Section&#160;25249.5 or any other Applicable Environmental Law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Tenant will promptly and diligently abate any Hazardous Material brought, placed, or leaked onto, or under, the Premises during the Term by Tenant or any of Tenant&#8217;s employees, agents, representatives, licensees, guests, contractors or invitees, in violation of Applicable Environmental Laws.  Additionally, to the extent Tenant brings, places, holds, treats, disposes of, or utilizes any chlorofluorocarbons on or about the Premises, Tenant will remove all such chlorofluorocarbons prior to, or upon, termination of the Lease, regardless of whether such chlorofluorocarbons are then defined, recognized, known or supposed to be Hazardous Material.  Tenant, however, will not take any remedial action related to Hazardous Material located in or about the Premises, the Buildings or the Project in violation of Applicable Environmental Laws and will not enter into a settlement, consent decree, or compromise in response to any claim related to Hazardous Material, without first notifying Landlord in writing of Tenant&#8217;s proposed action and affording Landlord a reasonable opportunity to appear, intervene, or otherwise participate in any discussion or proceeding for the purposes of protecting Landlord&#8217;s interest in the Premises, the Buildings and the Project.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;In addition to any other indemnity contained in this Lease, Tenant hereby will protect, defend, indemnify, and hold Landlord, its partners, managers, members, officers, directors, subsidiaries, affiliates, lenders, employees and agents, and Landlord&#8217;s property manager (&#8220;Property Manager&#8221;) and ground lessor, if any (individually a &#8220;Landlord Party&#8221; and collectively &#8220;Landlord Parties&#8221;), and the Premises, harmless, unless due to the gross negligence or willful misconduct of any Landlord Party, from and against any and all losses, liabilities, general, special, consequential and/or incidental damages, injuries, costs, expenses, claims of any and every kind whatsoever (including, without limitation, court costs, reasonable attorneys&#8217; fees, damages to any person, the Premises, the Buildings, the Project, or any other property or loss of rents) which at any time or from time to time may be paid, incurred, or suffered by or asserted against Landlord with respect to, or as a result of: (i) breach by Tenant of any of the covenants set forth in this Section&#160;4.4, and/or (ii) to the extent caused or allowed by Tenant, or any agent, employee, contractor, invitee, or licensee of Tenant, the presence on, under, or the escape, seepage, leakage, spillage, discharge, emission, release from, onto, or into the Premises, the Buildings, the Project, any land, the atmosphere, or any watercourse, body of water, or ground </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">water, of any Hazardous Material (including, without limitation, any losses, liabilities, damages, injuries, costs, expenses, or claims asserted or arising under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 (42 U.S.C. &#167;&#167; 9601 et seq.), any so-called &#8220;Superfund&#8221; or &#8220;Superlien&#8221; law, the Resource Conservation and Recovery Act of 1980 (42 U.S.C. &#167;&#167; 6901 et seq.), the Federal Water Pollution Control Act (33 U.S.C. &#167;&#167; 1251 et seq.), the Safe Drinking Water Act (42 U.S.C.  &#167;&#167; 300f et seq.), the Toxic Substances Control Act (15 U.S.C.  &#167;&#167; 2601 et seq.), the Clean Air Act (42 U.S.C. &#167;&#167; 7401 et seq.), California Health &amp; Safety Code &#167;&#167; 25100 et seq. and &#167;&#167; 39000 et seq., the California Safe Drinking Water &amp; Toxic Enforcement Act of 1986 (California Health &amp; Safety Code &#167;&#167; 25249.5 et seq.), the Porter-Cologne Water Quality Control Act (California Water Code &#167;&#167; 13000 et seq.), any and all amendments and recodifications of the foregoing statutes, or any other federal, state, local, or other statute, law, ordinance, code, rule, regulation, permit, order, or decree regulating, relating to or imposing liability or standards of conduct concerning Hazardous Material; all of the foregoing will collectively be referred to as &#8220;Applicable Environmental Laws&#8221;).  The undertaking and indemnification set forth in this Section&#160;4.4 will survive the termination of this Lease and will continue to be the personal liability and obligation of Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;Landlord represents and warrants to Tenant that to the actual knowledge of Jake Rome, who is the individual in Landlord&#8217;s organization in the best position to have knowledge of such matters, as of the Lease Date, Landlord has not received any written notice from any governmental entity of any violations of Applicable Environmental Laws affecting or applicable to the Premises or Buildings that have not been cured as of the Lease Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;Tenant will obtain insurance or other evidence of financial capability satisfactory to Landlord (in its reasonable discretion) to assure compliance with the indemnity and other obligations of Tenant related to Hazardous Material set forth in this Lease or otherwise now or in the future required by Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;Subject to the limitations set forth in Section&#160;2.5, Landlord and Landlord&#8217;s lender(s) will have the right to enter the Premises for the purpose of inspecting the condition of the Premises and for verifying compliance by Tenant with this Lease and with all Applicable Environmental Laws, and to employ experts and/or consultants in connection therewith and/or to advise Landlord with respect to Tenant&#8217;s activities including but not limited to the installation, operation, use, monitoring, maintenance, or removal of any Hazardous Material from the Premises.  The costs and expenses of such inspection will be paid by the party requesting same, unless a Default of this Lease, violation of Applicable Environmental Law, or a contamination, caused or contributed to by Tenant is found to exist or be imminent, or unless the inspection is required or ordered by governmental authority as the result of any such existing or imminent violation or contamination.  In any such case, Tenant will upon request reimburse Landlord or Landlord&#8217;s lender(s), as the case may be, for the costs and expenses of such inspections.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.5&#160;&#160;&#160;&#160;Civil Code Section&#160;1938 Disclosure</font><font style="font-family:inherit;font-size:12pt;">.  California law requires the following disclosure:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;A Certified Access Specialist (&#8220;CASp&#8221;) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.  Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">requested by the lessee or tenant.  The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant will only be permitted to have a CASp conduct an inspection as required by applicable Laws, and Landlord will only be required to contribute to the cost of repairs (as contemplated by this Section&#160;4.5) to the extent required by applicable Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;SERVICES AND UTILITIES; REPAIR AND MAINTENANCE OBLIGATIONS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Landlord&#8217;s Standard Services (and Repair and Maintenance Responsibilities) for Multi User Buildings</font><font style="font-family:inherit;font-size:12pt;">.  During the Term, Landlord will operate and maintain the Multi User Buildings and the Project in compliance with all applicable Laws and according to those standards from time to time prevailing for comparable office buildings in the Alameda, California market area.  Landlord will provide the following services according to such standards, the costs of which will be included in Costs to the extent provided in Section&#160;1.3(f):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;repair, maintenance and replacement of the Common Areas, including the fitness center, the roofs and all structural elements of the Multi User Buildings and all general mechanical, plumbing and electrical systems installed in the Project serving the Multi User Buildings, but excluding those portions of any mechanical, plumbing or electrical systems that exceed Building Standard and exclusively serve the Premises;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;HVAC in any Multi User Building (except any HVAC components exclusively serving the Premises, for which Tenant shall have maintenance, repair and replacement responsibility) for the Premises located therein and interior Common Areas during Business Hours, at temperatures and in amounts as may be reasonably required for comfortable use and occupancy under normal business office and research and development laboratory operations with &#8220;Customary Equipment&#8221; (as used in this Lease, &#8220;Customary Equipment&#8221; includes typewriters, calculators, dictation recorders, desk top personal computers, printers and similar devices and equipment, but will not include any machines, devices or equipment that materially and adversely affect the temperature otherwise maintained in the Premises or that require a voltage other than 120 volts, single phase, such as, for instance, data processing or heavy-duty computer or reproduction equipment);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;electricity for lighting and operating Customary Equipment in the Premises located in a Multi User Building during Business Hours;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;water for Tenant&#8217;s laboratory, small kitchens, washrooms and drinking fountains located in a Multi User Building, 24 hours per day, 7 days per week;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;janitorial services to the Premises located in a Multi User Building and Common Areas, Monday through Friday, excluding national holidays;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;passenger elevators in a Multi User Building for access to and from the floor(s) on which the Premises, 24 hours per day, 7 days per week;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;toilet facilities in or serving any portion of the Premises located in a Multi User Building, including necessary washroom supplies sufficient for Tenant&#8217;s normal use, 24 hours per day, 7 days per week;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;electric lighting for all Common Areas in a Multi User Building that require electric light during the day or are open at night, including replacement of tubes and ballasts in lighting fixtures, 24 hours per day, 7 days per week; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;replacement of tubes and ballasts in those Building Standard lighting fixtures installed in the Premises located in a Multi User Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Additional Services in Multi User Buildings</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;If Tenant requires HVAC for the Premises located in Multi User Building during hours other than Business Hours, Landlord will furnish the same for the hours specified in a request from Tenant, provided the request is made in the manner reasonably designated by Landlord for such requests from time to time and by 3:00 p.m. of the business day before the day that the additional service is required.  Tenant will pay for such additional services at the standard hourly rate reasonably determined by Landlord from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;If Tenant requires electric current, water or any other energy at times or in amounts in excess of those provided by Landlord in Multi User Buildings according to Section&#160;5.1, such excess electric, water or other energy requirements will be supplied only with Landlord&#8217;s consent, which consent will not be unreasonably withheld, conditioned or delayed.  If Landlord grants such consent, Tenant will pay all reasonable costs of meter service and installation of facilities or professional services necessary to measure and/or furnish the excess requirements and the entire cost of such additional electricity, water or other energy so required, which costs will be reasonably determined by Landlord and charged to Tenant (i)&#160;by metering at applicable rates, where meters exist or are installed at Landlord&#8217;s direction, including all service and meter installation and/or reading charges; and/or (ii)&#160;by use and engineering surveys identifying all costs relating to consumption of such additional electricity, water or other energy (including, without limitation, survey costs, labor, utility rates and Landlord&#8217;s administrative fees to the extent allowed by applicable Laws and not in excess of 5% of such costs).  For purposes of this Section&#160;5.2(b), and subject to the limitations set forth in Section&#160;2.5, from time to time during the Term, Landlord may enter the Premises located in a Multi User Building to install, maintain, replace or read meters for such excess requirements and/or to evaluate Tenant&#8217;s consumption of and demand for them.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;If Tenant installs any machines, equipment or devices in the Premises located in a Multi User Building that do not constitute Customary Equipment and such machines, equipment or devices cause the temperature in any part of the Premises to exceed the temperature the mechanical system of the respective Building would be able to maintain in the Premises were it not for such machines, equipment or devices, then Landlord reserves the right to install supplementary air conditioning units in the Premises located in a Multi User Building, and Tenant will pay Landlord all actual costs of installing, operating and maintaining such supplementary units.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;If Tenant requires any janitorial or cleaning services for Premises located in a Multi User Building in excess of the amounts provided by Landlord according to Section&#160;5.1 (such as cleaning services beyond normal office janitorial services for kitchens, computer rooms </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or other special use areas), Landlord will provide such excess services to Tenant within a reasonable period after Tenant&#8217;s request made to Property Manager, provided that such excess services are available from Landlord&#8217;s regular janitorial or cleaning contractor.  Tenant will pay the cost of such excess services.  Landlord will also provide, within a reasonable period after Tenant&#8217;s request made to Property Manager, at Tenant&#8217;s cost and to the extent available to Landlord, replacement of bulbs, tubes or ballasts in any non-Building Standard lighting fixtures in the Premises located in a Multi User Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Tenant will pay as Rent, within 30 days after the date of Landlord&#8217;s invoice, all costs which may become payable by Tenant to Landlord under this Section&#160;5.2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary set forth in this Section&#160;5.2, Landlord may determine, during its review of the &#8220;Preliminary Plans&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">) or other plans for Alterations, in its reasonable discretion, to have the Premises separately submetered by Landlord, as opposed to the utility company, for electricity serving the lights and convenience outlets in the Premises located in a Multi User Building.  The costs for installing such separate submeter will be included in &#8220;Tenant&#8217;s Work&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;">), and Landlord will pay the applicable utility company for such electricity.  During the Term, Tenant will reimburse Landlord, as Additional Rent and at the same rate as charged by the utility company, for all costs incurred by Landlord for such electricity used in the Premises located in a Multi User Building, as reflected by such submeter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.3&#160;&#160;&#160;&#160;Landlord&#8217;s Standard Services (and Repair, Maintenance and Replacement Responsibilities) For Single User Buildings</font><font style="font-family:inherit;font-size:12pt;">.  During the Term, Landlord will operate and maintain the Single User Buildings as follows, in compliance with all applicable Laws and in a manner consistent with those standards from time to time prevailing for comparable office and laboratory buildings in the Alameda, California market area; provided, however, that such operational and maintenance obligations for Single User Buildings will be limited to those matters contemplated in this Section&#160;5.3, with the understanding that Tenant will have significant operational and maintenance obligations with respect to Single User Buildings under Section&#160;5.4, and the foregoing standard will not apply to matters that are the subject of such obligations.  Landlord will provide the following services to Single User Buildings according to such standards, the costs of which will be included in Costs to the extent provided in Section&#160;1.3(f) except as otherwise expressly provided below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;repair, maintenance and replacement of the exterior Common Areas, the roofs and all structural elements of the Single User Buildings;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;electricity for lighting and operating Customary Equipment in the Premises located in a Single User Building, provided, however, that Landlord will cooperate with Tenant if Tenant desires to arrange for the electricity in the Single User Buildings to be separately metered by the utility company.  The costs for installing such separate meter will be included in &#8220;Tenant&#8217;s Work&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">), and Tenant will directly pay the applicable utility company for such electricity, as reflected by such meter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;water for Tenant&#8217;s laboratory, kitchens, washrooms and drinking fountains, 24 hours per day, 7 days per week;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;electric lighting for all exterior Common Areas that require electric light during the day or are open at night, including replacement of tubes and ballasts in lighting fixtures, 24 hours per day, 7 days per week; and</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;repair and replacement of the building systems serving any Single User Buildings, including, without limitation, general mechanical, plumbing and electrical systems, HVAC systems, elevators and any other component of the Single User Building (excluding any portion of Tenant&#8217;s Work or any &#8220;Tenant Alterations&#8221; [as defined in Section&#160;7.1]), to the extent that any single repair or replacement exceeds $75,000.00 (each, a &#8220;Major Replacement&#8221; and the costs incurred by Landlord in connection with a Major Replacement being a &#8220;Major Replacement Expenditure&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.4&#160;&#160;&#160;&#160;Tenant&#8217;s Services (and Repair, Maintenance and Replacement Responsibilities) For Single User Buildings</font><font style="font-family:inherit;font-size:12pt;">.  During the Term, Tenant will, at its cost and expense, operate and maintain the Single User Buildings in compliance with all applicable Laws and according to those standards from time to time prevailing for comparable Class A buildings in the Alameda, California market area; provided, however, that the foregoing will not limit Landlord&#8217;s obligations under Section&#160;5.3. Tenant will be responsible for the following services according to such standards:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;repair, maintenance and replacement of all portions of the Single User Buildings (except as otherwise set forth in this Lease) and all general mechanical, plumbing and electrical systems installed within the Single User Building (other than Major Replacement Expenditures);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;landscaping, maintenance, repair and replacement of the Tenant Maintained Outdoor Areas.  Tenant will construct any signage, fencing or hedges (which will be subject to Landlord&#8217;s approval, not to be unreasonably withheld, conditioned or delayed) to indicate Tenant&#8217;s exclusive right to use the Tenant Maintained Outdoor Areas in accordance with Section&#160;7.1  below;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;HVAC in accordance with Section&#160;5.5 below;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;janitorial services to any Single User Building, Monday through Friday, excluding national holidays;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;elevators in accordance with Section&#160;5.6, 24 hours per day, 7 days per week;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;toilet facilities in the Premises located in any Single User Building, including necessary washroom supplies sufficient for Tenant&#8217;s normal use, 24 hours per day, 7 days per week; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;replacement of tubes and ballasts in those Building Standard lighting fixtures installed in any Single User Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.5&#160;&#160;&#160;&#160;HVAC For Single User Buildings</font><font style="font-family:inherit;font-size:12pt;">.  Other than Major Replacement Expenditures, Tenant will pay the cost for all HVAC service provided to a Single User Building, including the cost of maintenance, repair and replacement of the equipment, ducting and other connections providing the same, subject to Sections&#160;5.7 and 5.8.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.6&#160;&#160;&#160;&#160;Elevators For Single User Buildings</font><font style="font-family:inherit;font-size:12pt;">.  Other than Major Replacement Expenditures, Tenant will pay the cost for any elevators located in a Single User Building, including the cost of maintenance, repair and replacement of the equipment, ducting and other connections providing the same, subject to Sections&#160;5.7 and 5.8.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.7&#160;&#160;&#160;&#160;Contactors and Contracts for Tenant&#8217;s Maintenance Obligations</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Maintenance Contractors</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will engage one or more third-party contractors to perform the repair, maintenance and replacement obligations of Tenant under Sections&#160;5.4, 5.5 and 5.6 with respect to the Single User Building(s) (each, a &#8220;Maintenance Contractor&#8221;).  Each Maintenance Contractor will be selected by Tenant and approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed.  In the event Tenant&#8217;s Maintenance Contractor fails to perform its obligations in a commercially reasonable manner, Landlord, at its option, may remove the applicable Maintenance Contractor and arrange for a replacement Maintenance Contractor; provided, however, Landlord has notified Tenant of the failure of the applicable Maintenance Contractor to comply with the maintenance requirements set forth herein and Tenant has failed to cure such noncompliance within 10 business days from receipt by Tenant of Landlord&#8217;s notice.  Any replacement Maintenance Contractor will be subject to Tenant&#8217;s approval, which approval will not be unreasonably withheld, conditioned or delayed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Preventative Maintenance Contracts</font><font style="font-family:inherit;font-size:12pt;">.  In connection with its obligations under Sections&#160;5.5 and 5.6, Tenant will enter into and keep in place preventative maintenance contracts on such equipment as is reasonably prudent under the circumstances, including, without limitation, the HVAC and elevator equipment serving each Single User Building (each, a &#8220;Preventative Maintenance Contract&#8221;).  Such Preventative Maintenance Contracts will provide for periodic maintenance in accordance with the manufacturer&#8217;s specifications, and such maintenance will be performed by a licensed Maintenance Contractor in a manner which is consistent with and will not void, limit or impair any warranty then in effect for the applicable equipment or any other element of the Building such as, by way of example only, the roof.  In the event Tenant fails to maintain such Preventative Maintenance Contract, Landlord, at its option, may arrange for a replacement Preventative Maintenance Contract for the applicable equipment, which Replacement Preventative Contract will be subject to Tenant&#8217;s approval, which will not be unreasonably withheld, conditioned or delayed; provided, however, Landlord has notified Tenant of such failure of Tenant to maintain a Preventative Maintenance Contract as set forth herein and Tenant has failed to cure such noncompliance within 10 business days from receipt by Tenant of Landlord&#8217;s notice, in which event the cost of such Preventative Maintenance Contract will be billed directly to Tenant and will be paid within 10 days of receipt of invoice therefor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.8&#160;&#160;&#160;&#160;Request for Major Replacement; Reimbursement of Major Replacement Expenditures</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will provide notice to Landlord if a Major Replacement is required.  Landlord will have the right to review and inspect the equipment requiring the Major Replacement and to approve the Major Replacement, which approval will not be unreasonably withheld, conditioned or delayed.  Upon such approval, Landlord will cause such Major Replacement to be performed.  Notwithstanding anything to the contrary contained in this Lease, Landlord will be permitted to include in Costs annual installments for the amortization of each Major Replacement Expenditure over the useful life of the applicable Major Replacement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.9&#160;&#160;&#160;&#160;Interruption of Services</font><font style="font-family:inherit;font-size:12pt;">.  If any of the services provided for in Sections&#160;5.1, 5.2 or 5.3 are interrupted or stopped, Landlord will use due diligence to resume the service; provided, however, no irregularity or stoppage of any of these services will create any liability for Landlord (including, without limitation, any liability for damages to Tenant&#8217;s personal property caused by any such irregularity or stoppage), constitute an actual or constructive eviction or, except as expressly provided below, cause any abatement of the Rent payable under this Lease or in any manner or for any purpose relieve Tenant from any of its obligations under this Lease.  If, due to reasons within Landlord&#8217;s reasonable control, any of the services required to be provided by Landlord under this Section&#160;5 should become unavailable </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and should remain unavailable for a period in excess of 60 hours after notice of such unavailability from Tenant to Landlord, and if such unavailability should render all or any portion of the Premises untenantable, then commencing upon the expiration of such 60-hour period, Tenant&#8217;s Rent will equitably abate in proportion to the portion of the Premises so rendered untenantable for so long as such services remain unavailable for such reasons.  Without limiting those reasons for an irregularity or stoppage of services that may be beyond Landlord&#8217;s control, any such irregularity or stoppage that is required in order to comply with any Laws or that is required or recommended by governmental agencies for health or safety reasons will be deemed caused by a reason beyond Landlord&#8217;s control.  Tenant hereby waives the provisions of Sections&#160;1932, 1933(4) and 1942 of the Civil Code of California or any similar or successor statutes to the fullest extent permitted by Laws, and Tenant acknowledges that, except as specifically provided herein, in the event Landlord fails to make a repair or perform maintenance, Tenant&#8217;s sole remedy for such breach by Landlord will be an action for damages, and that Tenant will not be entitled to terminate this Lease, withhold Rent, or make any repair and deduct the cost of repair from Rent payable under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.10&#160;&#160;&#160;&#160;Security</font><font style="font-family:inherit;font-size:12pt;">.  Only Landlord will determine the type and amount of any security services to be provided to the Project.  Tenant may utilize any existing card readers installed at the entrance of the Premises; provided, however, that Tenant, at Tenant&#8217;s sole cost and expense, shall be obligated to install its own security system software for managing such card readers and controlling access and shall maintain and repair the software, hardware and firmware with respect to the card readers.  In no event will Landlord be liable to Tenant, and Tenant hereby waives any claim against Landlord, for (a) any entry of third parties into the Premises, the Buildings and/or the Project; (b) any damage or injury to persons or property; or (c) any loss of property in or about the Premises, the Buildings and/or the Project, if the subject event described in the foregoing clause&#160;(a), (b) or (c) occurs as a result of any unauthorized or criminal acts of third parties, regardless of any action, inaction, failure, breakdown, malfunction or insufficiency of the security services provided by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.11&#160;&#160;&#160;&#160;Amenities</font><font style="font-family:inherit;font-size:12pt;">.  Throughout the Term, the fitness center located in the Project will remain part of the Common Areas, and Landlord will endeavor to maintain such fitness center in a condition that is substantially the same as the condition that exists as of the Lease Date.  The caf&#233; located in the Project is currently leased by a third-party tenant.  In the event that such tenant no longer operates the caf&#233;, Landlord will endeavor to obtain a new caf&#233; tenant and cause such caf&#233; to be maintained in a condition that is substantially the same as the condition that exists as of the Lease Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;TENANT&#8217;S REPAIR AND MAINTENANCE OBLIGATIONS</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.1&#160;&#160;&#160;&#160;Repairs Within the Premises</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms of Sections&#160;3.6, 5, 10 and 12, and except to the extent Landlord is required to perform or pay for certain maintenance or repairs according to those sections, Tenant will, at Tenant&#8217;s own expense:  (a)&#160;at all times during the Term, maintain the Premises, all fixtures and equipment in the Premises and those portions of any mechanical, plumbing or electrical systems that exceed Building Standard and exclusively serve portions of the Premises located in Multi User Building, or are located in Single User Buildings, in good order and repair and in a condition that complies with all applicable Laws; and (b)&#160;promptly and adequately repair all damage to the Premises and replace or repair all of such fixtures, equipment and portions of the mechanical, plumbing or electrical systems that are damaged or broken, all under the supervision of Landlord (provided that in the event of a conflict between the foregoing clause and the provisions of Section&#160;10, Section&#160;10 shall control).  All work done by Tenant or its contractors (which contractors will be subject to Landlord&#8217;s reasonable approval) will be done in a first-class workmanlike manner using only grades of materials at least equal in quality to Building Standard materials and will comply with all insurance requirements and all applicable Laws.  Tenant will not place any object or series of objects on the floors of the Premises in </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such a manner as to exceed the load capacity of the floors on a per square foot basis as determined by any architect, engineer, or other consultant of Landlord, or as otherwise limited by any applicable Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.2&#160;&#160;&#160;&#160;Failure to Maintain Premises</font><font style="font-family:inherit;font-size:12pt;">.  If Tenant fails to perform any of its obligations under Section&#160;6.1, and Tenant fails to commence performance of its obligations within five business days after receipt of written notice from Landlord of the need for repairs or thereafter fails to diligently pursue the applicable repair to completion, then Landlord may perform such obligations and Tenant will pay as Rent to Landlord the cost of such performance, including an amount sufficient to reimburse Landlord for overhead and supervision, within 30&#160;days after the date of Landlord&#8217;s invoice.  For purposes of performing such obligations, or to inspect the Premises, Landlord may enter the Premises subject to the terms and conditions in Section&#160;2.5; provided that if the time is of the essence for making a repair (for instance, if the cost of repair or risk associated with not making the repair increases with time), it shall be deemed an emergency.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.3&#160;&#160;&#160;&#160;Notice of Damage</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will notify Landlord promptly after Tenant learns of (a)&#160;any fire or other casualty in the Premises; (b)&#160;any damage to or defect in the Premises, including the fixtures and equipment in the Premises, for the repair of which Landlord might be responsible; and (c)&#160;any damage to or defect in any parts or appurtenances of the sanitary, electrical, heating, air conditioning, elevator or other systems located in or passing through the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;ALTERATIONS</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.1&#160;&#160;&#160;&#160;Alterations by Tenant</font><font style="font-family:inherit;font-size:12pt;">.  Tenant may, from time to time, at its own expense make changes, additions and improvements to the Premises to better adapt the same to its business (each a &#8220;Tenant Alteration&#8221;), provided that any such Tenant Alteration will (a)&#160;comply with all applicable Laws; (b)&#160;be made only with the prior written consent of Landlord, which consent will not be unreasonably withheld, conditioned or delayed; (c)&#160;equal or exceed Building Standard; and (d)&#160;be carried out only by persons selected by Tenant and approved in writing by Landlord (such approval to not be unreasonably withheld, conditioned or delayed).  Notwithstanding the foregoing, Tenant may, without Landlord&#8217;s consent but upon at least 10&#160;business days&#8217; prior notice to Landlord (and provided that all other provisions of this Section&#160;7.1 will otherwise apply), make Tenant Alterations which (a)&#160;do not exceed $5.00 per square foot of Rentable Area of the Premises affected by such change, addition or improvement, (b)&#160;do not affect the structural components of such Building, (c)&#160;do not materially affect the mechanical, electrical, plumbing, HVAC, fire suppression or similar Building systems, (d)&#160;do not affect the exterior of such Building and (e) do not cause any part of the Premises to become non-compliant with applicable Laws (&#8220;Permitted Alterations&#8221;).  Landlord will have the right to post notices of non-responsibility or similar notices on the Premises, and to record such notices in the real property records of Alameda County, California, all in accordance with Section&#160;8844 of the California Civil Code in order to protect the Premises, Buildings and Project against any liens resulting from such Work.  Tenant will maintain, and will contractually cause the persons performing any such work relating to a Tenant Alteration to maintain (and Tenant&#8217;s contract with such persons will so provide that such person is obligated to maintain), worker&#8217;s compensation insurance and public liability and property damage insurance (with Landlord named as an additional insured), in amounts, with companies and in a form reasonably satisfactory to Landlord, which insurance will remain in effect during the entire period in which the work will be carried out and for such additional time as may be further required for completed operations coverage.  If requested by Landlord, Tenant will deliver to Landlord proof of all such insurance.  In addition to the foregoing, Tenant will cause the persons performing such work relating to such Tenant Alterations to execute agreements relating to reasonable rules and regulations, whereby such persons will agree to maintain insurance as set forth in such rules and regulations and to provide proof of such insurance upon request of Landlord.  Landlord has the right to deny entry to the Premises to any persons performing </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">work in the Premises relating to such Tenant Alterations until such persons have executed and delivered to Landlord such agreements relating to rules and regulations.  Tenant will indemnify, defend and hold harmless Landlord, its managers, members, partners, officers, directors, subsidiaries, affiliates, employees and agents and Property Manager from and against any and all liability, loss, claims, demands, damages or expenses (including reasonable attorneys&#8217; fees) due to or arising out of Tenant&#8217;s failure to cause any persons performing work in the Premises relating to such Tenant Alterations to obtain the insurance required by this Lease.  Subject to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">, Tenant will promptly pay, when due, the cost of all such work and, upon completion, Tenant will deliver to Landlord, to the extent not previously received by Landlord, evidence of payment, contractors&#8217; affidavits and full and final waivers of all liens for labor, services or materials.  Tenant will also pay any increase in property taxes on, or fire or casualty insurance premiums for, the Project attributable to such Tenant Alteration and the cost of any modifications to the Project outside the Premises that are required to be made in order to make the Tenant Alteration to the Premises.  Tenant, at its expense, will have promptly prepared and submitted to Landlord reproducible as-built plans of any such Tenant Alteration upon its completion.  Within 10 days after the completion of such Tenant Alteration, Tenant will, at its expense, record in the real property records of Alameda County, California a notice of completion in accordance with Section&#160;8182 of the California Civil Code and provide Landlord with a copy of the same.  All Tenant Alterations, whether temporary or permanent in character, will be Tenant&#8217;s property throughout the Term of this Lease and shall automatically become Landlord&#8217;s property upon termination of this Lease, or termination of Tenant&#8217;s right to possession of the Premises, without compensation to Tenant.  If at the time Landlord consents to their installation (or in the case of Permitted Alterations, Landlord makes the request 10 business days prior to the expiration of the Term), Landlord requests or approves the removal by Tenant of any such Tenant Alterations upon termination of this Lease or the termination of Tenant&#8217;s right to possession of the Premises, Tenant will remove the same upon termination of this Lease, or termination of Tenant&#8217;s right to possession of the Premises, as provided in Section&#160;15.1; provided that under no circumstances shall Tenant be required to remove any portion of the Leasehold Improvements (other than Specialized Tenant Improvements) constructed in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">.  All other Tenant Alterations and the Leasehold Improvements shall be Landlord&#8217;s property upon termination of this Lease, or termination of Tenant&#8217;s right to possession of the Premises, and will be relinquished to Landlord in good condition, ordinary wear and tear and casualty excepted.  Any and all Tenant Alterations that are &#8220;Telecom Equipment&#8221; (as defined below) will also be governed by the terms and conditions of Section&#160;26, and if there is any conflict between the requirements of this Section&#160;7.1 and those of Section&#160;26 with respect to Telecom Equipment, Section&#160;26 will govern.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.2&#160;&#160;&#160;&#160;Alterations by Landlord</font><font style="font-family:inherit;font-size:12pt;">.  Landlord may from time to time make repairs, changes, additions and improvements to the Project, the Buildings, Common Areas and those Project and Building systems necessary to provide the services described in Section&#160;5, and for such purposes, Landlord may enter the Premises subject to the terms and conditions in Section&#160;2.5, without liability to Tenant for any loss or damage incurred as a result of such entry, provided that in doing so Landlord will not disturb or interfere with Tenant&#8217;s use of the Premises and operation of its business any more than is reasonably necessary in the circumstances and will repair any damage to the Premises caused by such entry, nor will Landlord unreasonably restrict or impair Tenant&#8217;s access to the Premises or parking areas.  No change, addition or improvement made by Landlord will materially impair Tenant&#8217;s use of the Premises for the Use, materially impair Tenant&#8217;s access to the Premises or reduce the amount of available parking Tenant is entitled to pursuant to this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;LIENS.  </font><font style="font-family:inherit;font-size:12pt;">Tenant agrees to pay before delinquency all costs for work, services or materials furnished to Tenant for the Premises, the nonpayment of which could result in any lien against the Project or Buildings.  Tenant will keep title to the Project and Buildings free and clear of any such lien.  Tenant </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">will promptly notify Landlord of the filing of any such lien or any pending claims or proceedings relating to any such lien and will protect, defend, indemnify and hold Landlord harmless from and against all loss, damages and expenses (including reasonable attorneys&#8217; fees) suffered or incurred by Landlord as a result of such lien, claims and proceedings.  In case any such lien attaches, Tenant agrees to cause it to be immediately released and removed of record (failing which Landlord may do so at Tenant&#8217;s sole expense), unless Tenant has a good faith dispute as to such lien in which case Tenant may contest such lien by appropriate proceedings so long as Tenant deposits with Landlord a bond or other security in an amount reasonably acceptable to Landlord (but not more than 150% of the amount in dispute) which may be used by Landlord to release such lien if Tenant&#8217;s contest is abandoned or is unsuccessful.  Upon final determination of any permitted contest, Tenant will promptly pay any judgment rendered and cause the lien to be released.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;INSURANCE</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.1&#160;&#160;&#160;&#160;Landlord&#8217;s Insurance</font><font style="font-family:inherit;font-size:12pt;">.  During the Term, Landlord will provide and keep in force the following insurance:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;commercial general liability insurance relating to Landlord&#8217;s operation of the Project, including coverage for personal and bodily injury and death, and damage to others&#8217; property;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#8220;special causes of loss&#8221; property insurance relating to the Project (but excluding Tenant&#8217;s fixtures, furnishings, equipment, personal property, inventory, stock in trade, documents, files and work products and all leasehold improvements in the Premises that are owned by Landlord during the Term; for purposes of this Section&#160;9.1(b) and Section&#160;9.2(d) below, unless this Lease provides that certain leasehold improvements, including, without limitation, equipment installed to serve the Premises, are owned by Tenant, then they will be deemed to be owned by Landlord);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;loss of rental income insurance or loss of insurable gross profits commonly insured against by prudent landlords; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;such other insurance (including boiler and machinery insurance) as Landlord reasonably elects to obtain or any Project or Building mortgagee requires.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insurance effected by Landlord under this Section&#160;9.1 will be in amounts which Landlord from time to time reasonably determines sufficient or any Project or Building mortgagee requires; will be subject to such deductibles and exclusions as Landlord reasonably determines; and will otherwise be on such terms and conditions as Landlord from time to time reasonably determines sufficient.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.2&#160;&#160;&#160;&#160;Tenant&#8217;s Insurance</font><font style="font-family:inherit;font-size:12pt;">.  The insurance carried by Tenant or such insurance carried by Tenant&#8217;s contractors or subcontractors pursuant to this Lease will be primary and non&#8209;contributory insurance over any insurance carried by Landlord.  During the Term, Tenant will provide, pay for, and maintain in full force and effect, the insurance outlined herein, covering claims arising out of or in connection with the use, occupancy or maintenance of the Premises, and all areas appurtenant thereto, by Tenant, its agents, representatives, employees, contractors or subcontractors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial General Liability</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will maintain commercial general liability insurance covering liability arising out of the use, occupancy or maintenance of the Premises and the Tenant Maintained Outdoor Areas on an occurrence basis against claims for bodily injury, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">property damage and personal injury. Such insurance will provide minimum limits and coverage as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Minimum Limits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1,000,000 Each Occurrence (Bodily Injury and Property Damage per location or project, as applicable).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2,000,000 General Aggregate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2,000,000 Products / Completed Operations Aggregate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(D)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1,000,000 Personal and Advertising Injury.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(E)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$300,000 Fire Damage.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Coverages</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1986 (or current equivalent) ISO Commercial General Liability Form (Occurrence Form)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Insured, but only with respects to occurrences within the Premises and all areas appurtenant thereto:  Landlord, its partners, managers, members, officers and directors, employees, agents, subsidiaries, affiliates, lender and Property Manager.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Subrogation in favor of Landlord and Property Manager.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Automobile Liability</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will maintain business auto liability covering liability arising out of any owned, hired and non-owned autos.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Minimum Limits</font><font style="font-family:inherit;font-size:12pt;">.  $1,000,000 Combined Single Limit for each accident.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Workers Compensation</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will maintain workers compensation and employers liability insurance applicable to its operations in the State of California.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Minimum Limits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Workers Compensation:  Statutory Limits.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employers Liability:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">(I)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bodily Injury for Each Accident &#8211; $500,000.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">(II)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bodily Injury by Disease for Each Employee &#8211; $500,000.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:240px;"><font style="font-family:inherit;font-size:12pt;">(III)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bodily Injury Disease Aggregate &#8211; $500,000.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Coverages</font><font style="font-family:inherit;font-size:12pt;">.  Waiver of Subrogation in favor of Landlord and Property Manager.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Personal Property</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will maintain property insurance covering all personal property and equipment (including, but not limited to Tenant&#8217;s fixtures, furnishings, equipment, personal property, inventory, stock in trade, documents, files and work products and all leasehold improvements not required to be insured by the Landlord pursuant to Section&#160;9.1(b)) in the Premises on a full replacement cost basis in amounts sufficient to prevent Tenant from becoming a coinsurer and insuring against Special Causes of Loss, including an amount of no less than $1,000 for money and securities (inside and outside of the Premises) and vandalism and malicious mischief.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Umbrella/Excess Liability</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will maintain umbrella/excess liability insurance as shown below.  The insurance will be on an occurrence basis in excess of the underlying insurance described in Sections&#160;9.2(a), (b) and (c)(i)(B) and will be at least as broad as each and every one of the underlying policies. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Minimum Limits</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$5,000,000 per Occurrence.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$5,000,000 Aggregate.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Other Insurance Provisions</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will name, and will cause its contractors to name, Landlord, Property Manager, their Affiliates and their respective partners, managers, members, officers, directors and employees as additional insureds with respect to liability arising out of Tenant&#8217;s or its contractors&#8217; or subcontractors&#8217; use, occupancy, or maintenance of the Premises or activities performed thereon, on all liability policies carried by Tenant and/or Tenant&#8217;s contractors and subcontractors.  All liability insurance policies carried by Tenant will include provisions for contractual liability coverage.  It is expressly understood and agreed that the coverages required represent Landlord&#8217;s minimum requirements and such are not to be construed to void or limit Tenant&#8217;s indemnity obligations contained in this Lease.  Neither (i) the insolvency, bankruptcy or failure of any insurance company covering Tenant, (ii) the failure of any insurance company to pay claims occurring nor (iii) any exclusion from or insufficiency of coverage will be held to affect, negate or waive any of Tenant&#8217;s indemnity obligations under Sections&#160;4.3, 4.4(e), 7.1, 8, 11.3, 23 or 26.5 hereof or any other provision of this Lease.  The amount of liability insurance under insurance policies maintained by Tenant shall not be reduced by the existence of insurance coverage under policies separately maintained by Landlord.  Tenant shall be solely responsible for any premiums, assessments, penalties, deductible assumptions, retentions, audits, retrospective adjustments or any other kind of payment due under its policies.  Tenant&#8217;s occupancy of the Premises without delivering the certificates and/or other evidence of insurance, will not constitute a waiver of Tenant&#8217;s obligations to provide the required coverages.  If Tenant provides to Landlord a certificate that does not evidence the coverages required herein, or that is faulty in any respect, Landlord&#8217;s acceptance of such certificate will not constitute a waiver of Tenant&#8217;s obligations to provide the proper insurance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proof of Insurance</font><font style="font-family:inherit;font-size:12pt;">.  Prior to execution of this Lease, Tenant will furnish Property Manager with certificates of insurance evidencing the coverage outlined above and the Other Insurance Provisions outlined above.  Insurance is to be placed with insurers with a Best&#8217;s rating of no less than A&#8209;IX by carriers authorized to furnish insurance in the State of California.  No such policy will be cancelable, non renewed or modified except after 30 days&#8217; written notice to Property Manager.  Tenant will maintain all of the foregoing insurance coverages in full force and effect until the expiration or earlier termination of this Lease.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.3&#160;&#160;&#160;&#160;Waiver of Subrogation</font><font style="font-family:inherit;font-size:12pt;">.  Landlord and Tenant agree that all insurance required to be carried under Sections&#160;9.1(b), (c) and (d) and 9.2(d) and other property damage insurance which may be carried by either of them will be endorsed with a clause providing that any release from liability of, or waiver of claim for, recovery from the other party entered into in writing by the insured thereunder prior to any loss or damage will not affect the validity of such policy or the right of the insured to recover under such policy, and providing further that the insurer waives all rights of subrogation which such insurer might have against the other party (and, when the &#8220;other party&#8221; is Landlord, such waiver will apply to Property Manager as well).  Without limiting any release or waiver of liability or recovery set forth elsewhere in this Lease, and notwithstanding anything in this Lease which may appear to be to the contrary, each of the parties hereto waives all claims for recovery from the other party for any loss or damage to any of its property insured (or required by the terms of this Lease to be insured) under valid and collectible insurance policies to the extent of any recovery collectible (or would have been collectible if the insurance required under this Lease had been maintained) under such insurance policies, and this waiver will expressly apply to any amount that is not reimbursable or paid by the damaged party&#8217;s insurer because of the deductible or self-insured retention portion of the damaged party&#8217;s insurance coverage.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;DAMAGE OR DESTRUCTION</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.1&#160;&#160;&#160;&#160;Termination Options</font><font style="font-family:inherit;font-size:12pt;">.  If any portion of the Premises, the respective Buildings or a portion of the Project reasonably necessary for the continued use of each Building and/or the Premises are damaged by fire or other casualty Landlord will, promptly after learning of such damage, notify Tenant in writing of the time necessary to repair or restore such damage, as estimated by Landlord&#8217;s architect, engineer or contractor.  If such estimate states that repair or restoration of all of such damage that was caused to a portion of the Premises or to any other portion of the Buildings or Project necessary for Tenant&#8217;s occupancy cannot be completed within 365 days from the date of such damage (or within 30 days from the date of such damage if such damage occurred within the last 12 months of the Term), then Tenant will have the option to terminate this Lease with respect to the applicable portion of the Premises affected by such damage.  If such estimate states that repair or restoration of all of such damage that was caused to the Buildings or applicable portion of the Project cannot be completed within 365 days from the date of such damage, or if such damage occurred within the last 12 months of the Term and such estimate states that repair or restoration of all such damage that was caused to a portion of the Premises or to any other portion of the Buildings or the Project necessary for Tenant&#8217;s occupancy cannot be completed within 60 days from the date of such damage (provided that if Tenant has exercised, or proceeds to validly exercise an option to extend the Term within 15 business days of the occurrence of such damage, the &#8220;Term&#8221; for the purposes of the foregoing clause shall refer to the Term so extended), or if such damage is not insured against by the insurance policies required to be maintained by Landlord according to Section&#160;9.1 (and Tenant does not agree to pay the shortfall in the cost of restoration), then Landlord or Tenant will have the option to terminate this Lease with respect to the applicable portion of the Premises affected by such damage.  Any option to terminate granted above must be exercised by written notice to the other party given within 10&#160;business days after Landlord delivers to Tenant the notice of estimated repair time.  If either party exercises its option to terminate this Lease with respect to a portion of the Premises, such termination will occur 30&#160;days after notice of termination is delivered; provided, however, that Rent for the period commencing on the date of such damage until the date this Lease terminates will be reduced to the reasonable value of any use or occupation of any portion of the Premises by Tenant during such period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.2&#160;&#160;&#160;&#160;Repair Obligations</font><font style="font-family:inherit;font-size:12pt;">.  If the Premises, the Buildings and/or Project are damaged by fire or other casualty and neither party terminates this Lease according to Section&#160;10.1, then Landlord will repair and restore such damage with reasonable promptness, subject to delays for insurance adjustments </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and delays caused by matters beyond Landlord&#8217;s control.  Landlord will have no liability to Tenant and Tenant will not be entitled to terminate this Lease if such repairs and restoration are not in fact completed within the estimated time period, provided that Landlord promptly commences and diligently pursues such repairs and restoration to completion.  In no event will Landlord be obligated to repair, restore or replace any of the property required to be insured by Tenant according to Section&#160;9.2.  Notwithstanding anything to the contrary contained herein, Tenant hereby waives the provisions of the California Civil Code, Section&#160;1932, Subsection&#160;2, and Section&#160;1933, Subsection&#160;4 (and any other successor statutes thereof permitting Tenant to terminate this Lease as a result of any damage or destruction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.3&#160;&#160;&#160;&#160;Rent Abatement</font><font style="font-family:inherit;font-size:12pt;">.  If any fire or casualty damage renders all or a portion of the Premises untenantable and if this Lease is not terminated with respect to all or a portion of the Premises according to Section&#160;10.1, then Rent attributable to the untenantable portion of the Premises will abate beginning on the date of such damage.  Such abatement will end on the date Landlord has substantially completed the repairs and restoration Landlord is required to perform according to Section&#160;10.1 and Tenant has had a reasonable period of time to substantially complete any repairs and restoration Tenant is required to perform according to Section&#160;10.1.  Such abatement will be in an amount bearing the same ratio to the total amount of Rent for such period as the untenantable portion of the Premises bears to the entire Premises.  In no event will Landlord be liable for any inconvenience or annoyance to Tenant or injury to the business of Tenant resulting in any way from damage caused by fire or other casualty or the repair of such damage, provided however that, to the extent Tenant remains in possession of any portion of the Premises, Landlord will take all reasonable steps to minimize the disruption to Tenant&#8217;s business and use of such portion of the Premises during the period of repair. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;WAIVERS AND INDEMNITIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.1&#160;&#160;&#160;&#160;Tenant&#8217;s Waivers</font><font style="font-family:inherit;font-size:12pt;">.  Except to the extent caused by the willful or negligent act or omission or breach of this Lease by Landlord or anyone for whom Landlord is legally responsible, Landlord and its Affiliates will not be liable or in any way responsible for, and Tenant waives all claims against Landlord and its Affiliates for, any loss, injury or damage suffered by Tenant or others relating to (a)&#160;loss or theft of, or damage to, property of Tenant or others; (b)&#160;subject to Section&#160;9.3, injury or damage to persons or property resulting from fire, explosion, falling plaster, escaping steam or gas, electricity, water, rain or snow, or leaks from any part of the Buildings or Project or from any pipes, appliances or plumbing, or from dampness; or (c)&#160;damage caused by other tenants, occupants or persons in the Premises or other premises in the Buildings or Project, or caused by the public or by construction of any private or public work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.2&#160;&#160;&#160;&#160;Landlord&#8217;s Indemnity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to Sections&#160;5.9, 5.10, 9.3 and 11.1 and except to the extent caused by the willful misconduct or grossly negligent act or omission by Tenant, to the fullest extent permitted by applicable Laws, Landlord will indemnify, defend and hold harmless Tenant from and against any and all liability, loss, claims, demands, damages or expenses (including reasonable attorneys&#8217; fees) due to or arising out of (a)&#160;Landlord&#8217;s maintenance, operation and management of the Common Areas as required by this Lease, (b)&#160;the gross negligence or willful misconduct of Landlord or its Affiliates, and (c)&#160;any claim arising directly from Landlord&#8217;s material breach of this Lease.  Landlord&#8217;s obligations under this Section&#160;11.2 will survive the expiration or early termination of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.3&#160;&#160;&#160;&#160;Tenant&#8217;s Indemnity</font><font style="font-family:inherit;font-size:12pt;">.  Subject to Section&#160;9.3 and except to the extent caused by the willful misconduct or grossly negligent act or omission by Landlord, to the fullest extent permitted by applicable Laws, Tenant will indemnify, defend and hold harmless Landlord, Property Manager, their Affiliates and their respective partners, managers, members, officers, directors and employees from and against </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any and all liability, loss, claims, demands, damages or expenses (including reasonable attorneys&#8217; fees) due to or arising out of (a)&#160;Tenant&#8217;s use and occupancy of the Premises and/or the Tenant Maintained Outdoor Areas, (b)&#160;the gross negligence or willful misconduct of Tenant or its Affiliates and (c)&#160;any claim arising directly from Tenant&#8217;s material breach of this Lease.  Tenant&#8217;s obligations under this Section&#160;11.3 will survive the expiration or early termination of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;CONDEMNATION</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.1&#160;&#160;&#160;&#160;Full Taking</font><font style="font-family:inherit;font-size:12pt;">.  If all or substantially all of the Project, Buildings or Premises are taken for any public or quasi-public use under any applicable Laws or by right of eminent domain, or are sold to the condemning authority in lieu of condemnation, then this Lease will terminate as of the date when the condemning authority takes physical possession of the Project, Buildings or Premises. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.2&#160;&#160;&#160;&#160;Partial Taking</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Landlord&#8217;s Termination of Lease</font><font style="font-family:inherit;font-size:12pt;">.  If only part of the Project, a Building or Premises is thus taken or sold, and such partial taking materially impairs Tenant&#8217;s use of the Premises, and if after such partial taking, in Landlord&#8217;s reasonable judgment, alteration or reconstruction is not economically justified, then Landlord (whether or not the Premises are affected) may terminate this Lease by giving notice to Tenant within 60 days after the taking.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tenant&#8217;s Termination of Lease</font><font style="font-family:inherit;font-size:12pt;">.  If over 20% of the 1801 Space and/or the 1851 Space is thus taken or sold and Landlord is unable to provide Tenant with comparable replacement premises in the Buildings or Project, Tenant may terminate this Lease if in Tenant&#8217;s reasonable judgment such portion of the Premises cannot be operated by Tenant in an economically viable fashion because of such partial taking.  Such termination by Tenant must be exercised by notice to Landlord given not later than 60 days after Tenant is notified of the taking of such portion of the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date of Termination</font><font style="font-family:inherit;font-size:12pt;">.  Termination by Landlord or Tenant will be effective as of the date when physical possession of the applicable portion of the Project, Buildings or Premises is taken by the condemning authority.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Election to Continue Lease</font><font style="font-family:inherit;font-size:12pt;">.  If neither Landlord nor Tenant elects to terminate this Lease upon a partial taking of a portion of the Premises, the Rent payable under this Lease will be diminished by an amount allocable to the portion of the Premises which was so taken or sold.  If this Lease is not terminated upon a partial taking of the Project, Buildings or Premises, Landlord will, at Landlord&#8217;s sole expense, promptly restore and reconstruct the Project, Buildings and Premises to substantially their former condition to the extent the same is feasible.  However, Landlord will not be required to spend for such restoration or reconstruction an amount in excess of the net amount received by Landlord as compensation or damages for the part of the Project, the Buildings or Premises so taken.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;">.  Tenant hereby waives any and all rights it might otherwise have pursuant to Section&#160;1265.130 of the California Code of Civil Procedure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.3&#160;&#160;&#160;&#160;Awards</font><font style="font-family:inherit;font-size:12pt;">.  As between the parties to this Lease, Landlord will be entitled to receive, and Tenant assigns to Landlord, all of the compensation awarded upon taking of any part or all of the Project, Buildings or Premises, including any award for the value of the unexpired Term.  However, Tenant may assert a claim in a separate proceeding against the condemning authority for any damages resulting from </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the taking of Tenant&#8217;s trade fixtures or personal property, or for moving expenses, business relocation expenses or damages to Tenant&#8217;s business incurred as a result of such condemnation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;ASSIGNMENT AND SUBLETTING</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.1&#160;&#160;&#160;&#160;Limitation</font><font style="font-family:inherit;font-size:12pt;">.  Without Landlord&#8217;s prior written consent, Tenant will not assign all or any of its interest under this Lease, sublet all or any part of the Premises or permit the Premises to be used by any parties other than Tenant and its employees, subject, however, to the terms and conditions of this Section&#160;13, which terms and conditions Tenant and Landlord agree are reasonable.  Notwithstanding anything contained herein to the contrary, any assignment or sublease to an entity which controls, is controlled by, or is under common control with Tenant, or which is the result of a merger or consolidation with Tenant, or which acquires all or substantially all of Tenant&#8217;s assets will not require the consent of Landlord (a &#8220;Permitted Transfer&#8221;), provided that Tenant will provide prior written notice to Landlord, unless such notice is prohibited by law, in which case it will be provided as soon as reasonably possible, and deliver to Landlord any documents or information reasonably required by Landlord regarding such assignment or sublease, the proposed assignee or sublessee has a net worth equal to or greater than the net worth of Tenant as of the Lease Date, and such an assignment or sublease is not an effort by Tenant to avoid any of its obligations under this Lease, including, without limitation, the obligations under this Section&#160;13.  For purposes of this Section&#160;13.1, in order for an entity to control another, the controlling entity must have voting control of and own greater than 50% of every class of voting stock and/or other voting equity interest of the entity, when the controlled entity is a corporation; the controlling entity must be the owner of greater than 50% of the partnership or limited liability company interests in the assets, liabilities, income, loss and distributions of the controlled entity, when the controlled entity is a partnership or limited liability company; or the controlling entity must be the sole beneficiary of the controlled entity, when the controlled entity is a trust.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.2&#160;&#160;&#160;&#160;Notice of Proposed Transfer; Landlord&#8217;s Options</font><font style="font-family:inherit;font-size:12pt;">.  Other than a Permitted Transfer, if Tenant desires to enter into any assignment of this Lease or a sublease of all or any part of the Premises, Tenant will first give Landlord notice of the proposed assignment or sublease, which notice will contain the name and address of the proposed transferee, the proposed use of the Premises, statements reflecting the proposed transferee&#8217;s current financial condition and income and expenses for the past two years, and the principal terms of the proposed assignment or sublease.  Landlord will have the following options, which must be exercised, if at all, by notice given to Tenant within 10 business days after Landlord&#8217;s receipt of Tenant&#8217;s notice of the proposed transfer (other than a Permitted Transfer): </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;if Tenant&#8217;s notice relates to an assignment of this Lease, to cancel and terminate this Lease.  If Landlord exercises its option to terminate this Lease, this Lease will cancel and terminate on the last day of the month following such 10 business day period and Tenant will be released from any further liability under this Lease, and Landlord may, at its option, lease the Premises to the proposed assignee, or to any other person or entity, without liability to Tenant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;if Tenant&#8217;s notice relates to a subletting for the remainder of the Term, to cancel and terminate this Lease with respect to such portion of the Premises that would be subject to the proposed sublease.  If this Lease shall be terminated with respect to less than the entire Premises pursuant to this Section&#160;13.2(b), the Base Rent and Operating Expenses shall be adjusted on the basis of the number of square feet of Rentable Area retained by Tenant in proportion to the number of square feet of Rentable Area contained in the original Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of same.  In addition to the foregoing, Landlord </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">shall construct and erect, at its sole cost, such partitions as may be required to separate the space to be retained by Tenant from the space recaptured by Landlord.  Landlord may, at its option, lease any recaptured portion of the Premises to the proposed subtenant or to any other person or entity without liability to Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary, if Landlord elects to terminate this Lease pursuant to the terms of this Section&#160;13.2, provided that Tenant is not in default under this Lease, Tenant will have the right to revoke its request for Landlord&#8217;s consent by giving Landlord notice within five&#160;business days after Landlord&#8217;s delivery of its termination notice, thereby nullifying Landlord&#8217;s exercise of its termination right, and no assignment or sublease, as the case may be, will then occur.  Except in the event of termination of this Lease by Landlord as provided in this Section&#160;13.2, no provision of this Section&#160;will be construed to relieve Tenant of the obligations as set forth in this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.3&#160;&#160;&#160;&#160;Consent Not to be Unreasonably Withheld</font><font style="font-family:inherit;font-size:12pt;">.  To the extent Landlord&#8217;s consent is required, and if Landlord does not exercise any of its applicable options under Section&#160;13.2, then Landlord will not unreasonably withhold, condition or delay its consent to the proposed assignment or subletting, except with respect to a proposed assignment or sublease to an existing tenant or other occupant in the Project or to a party who has been engaged in negotiations with Landlord for a lease in the Project within six months prior to Tenant&#8217;s request for Landlord&#8217;s approval of such assignment or sublease, for which Landlord may withhold its consent in its sole and absolute discretion.  Landlord shall send written notice to Tenant exercising one of its applicable options under Section&#160;13.2 within 15 business days of Landlord&#8217;s receipt of the information required under Section&#160;13.2. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.4&#160;&#160;&#160;&#160;Form of Transfer</font><font style="font-family:inherit;font-size:12pt;">.  If Landlord consents to a proposed assignment or sublease, Landlord&#8217;s consent will not be effective unless and until Tenant delivers to Landlord an original duly executed assignment or sublease, as the case may be, that provides, in the case of a sublease, that the sublease is subject and subordinate to this Lease and the subtenant will comply with all applicable terms and conditions of this Lease and, in the case of an assignment, an assumption by the assignee of all of the obligations which this Lease requires Tenant to perform and an acknowledgment by Tenant that it remains liable for the performance of all of such obligations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.5&#160;&#160;&#160;&#160;Payments to Landlord</font><font style="font-family:inherit;font-size:12pt;">.  If Landlord does not exercise its applicable option under Section&#160;13.2 and Tenant effects an assignment or sublease or in case of a Permitted Transfer, then Landlord will be entitled to receive and collect, either from Tenant or directly from the transferee, 50% of the amount by which the consideration required to be paid by the transferee for the use and enjoyment of Tenant&#8217;s rights under this Lease (after deducting from such consideration Tenant&#8217;s reasonable costs incurred in effecting the assignment or sublease, including, without limitation, tenant improvements, rent abatements and similar concessions, as well as market brokerage and legal fees) exceeds the Rent payable by Tenant to Landlord allocable to the transferred space or interest.  Such percentage of such amount will be payable to Landlord at the time(s) Tenant receives the same from its transferee (whether in monthly installments, in a lump sum or otherwise).  Tenant shall reimburse Landlord for any costs incurred in the review of a sublease of the Premises or assignment of this Lease, not to exceed $2,000 per request.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.6&#160;&#160;&#160;&#160;Change of Ownership</font><font style="font-family:inherit;font-size:12pt;">.  Except for a Permitted Transfer, any change by Tenant in the form of its legal organization (such as, for example, a change from a general to a limited partnership), any transfer of 51% or more of Tenant&#8217;s assets, and any other transfer of interest effecting a change in identity of persons exercising effective control of Tenant will be deemed an &#8220;assignment&#8221; of this Lease requiring Landlord&#8217;s prior written consent.  The transfer of any outstanding capital stock of a corporation </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">whose stock is publicly traded will not, however, be deemed a &#8220;transfer of interest&#8221; under this Section&#160;13.6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.7&#160;&#160;&#160;&#160;Effect of Transfers</font><font style="font-family:inherit;font-size:12pt;">.  Unless Landlord agrees to the contrary in writing, no subletting or assignment (including a Permitted Transfer) will release Tenant from any of its obligations under this Lease and such obligations of Tenant will continue in full force and effect as if no subletting or assignment had been made, regardless of any action taken by or on behalf of a subtenant or assignee, or limitations imposed on remedies against a subtenant or assignee, in any bankruptcy, insolvency, receivership, reorganization or dissolution proceeding instituted by or against such subtenant or assignee.  Acceptance of Rent by Landlord from any person other than Tenant will not be deemed a waiver by Landlord of any provision of this Section&#160;13.  Consent to one assignment or subletting will not be deemed a consent to any subsequent assignment or subletting.  In the event of any default by any assignee or subtenant or any successor of Tenant in the performance of any Lease obligation, Landlord may proceed directly against Tenant without exhausting remedies against such assignee, subtenant or successor.  The voluntary or other surrender of this Lease by Tenant or the cancellation of this Lease by mutual agreement of Tenant and Landlord will not work a merger and will, at Landlord&#8217;s option, terminate all or any subleases or operate as an assignment to Landlord of all or any subleases; such option will be exercised by notice to Tenant and all known subtenants in the Premises.  The discovery of the fact that any financial statement relied upon by Landlord in giving its consent to an assignment or subletting was materially false or misleading will, at Landlord&#8217;s election, render Landlord&#8217;s said consent null and void.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.8&#160;&#160;&#160;&#160;Applicability to Subsequent Transfers</font><font style="font-family:inherit;font-size:12pt;">.  If Tenant assigns its rights under this Lease or subleases any portion of the Premises, and subsequently (a)&#160;the applicable assignee desires to either sublease a portion of the Premises or further assign its interest in this Lease, or (b)&#160;the applicable subtenant desires to sub-sublease any portion of the Premises, then Landlord&#8217;s rights under this Section&#160;13 will apply to any such subsequent assignment, sublease or sub-sublease, as well as to any other subsequent transfer of Tenant&#8217;s interest in this Lease and/or the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.9&#160;&#160;&#160;&#160;Letter of Credit</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding anything to the contrary in this Lease, it will be a condition precedent to any assignment of Tenant&#8217;s interest in this Lease or any sublease of all or a portion of the Premises (including a Permitted Transfer) that, after the consummation of such assignment or sublease, Landlord will continue to have full and unaltered access to the Letter of Credit provided by Tenant under Section&#160;1.1(r) and Section&#160;28, or a replacement letter of credit from such assignee or subtenant in the amount and form required pursuant to this Lease, issued by financial institution acceptable to Landlord, in its reasonable discretion, and any such assignment or subletting will be void and of no force or effect if it adversely affects Landlord&#8217;s ability to obtain the full benefits of the Letter of Credit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;PERSONAL PROPERTY</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.1&#160;&#160;&#160;&#160;Installation and Removal</font><font style="font-family:inherit;font-size:12pt;">.  Tenant may install in the Premises its personal property (including Tenant&#8217;s usual trade fixtures) in a proper manner, provided that no such installation will materially and adversely  interfere with or damage the mechanical, plumbing or electrical systems or the structure of the Buildings and/or Project, and provided further, that if such installation would require any Tenant Alteration, such installation will be subject to Section&#160;7.1.  If neither a Default nor any fact or circumstance that would constitute a Default with the giving of notice and/or the passage of time then exists, any such personal property installed in the Premises by Tenant (a)&#160;may be removed from the Premises from time to time in the ordinary course of Tenant&#8217;s business or in the course of making any Tenant Alterations permitted under Section&#160;7.1, and (b)&#160;will be removed by Tenant at the end of the Term </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">36</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">according to Section&#160;15.1.  Tenant will promptly repair at its expense any damage to the Buildings and/or Project resulting from such installation or removal.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.2&#160;&#160;&#160;&#160;Responsibility</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will be solely responsible for all costs and expenses related to personal property used or stored in the Premises.  Tenant will pay any taxes or other governmental impositions levied upon or assessed against such personal property, or upon Tenant for the ownership or use of such personal property, on or before the due date for payment.  Such personal property taxes or impositions are not included in Taxes.  Tenant agrees that all personal property of whatever kind, including, without limitation, inventory and/or goods stored at or about the Premises, Tenant&#8217;s trade fixtures, and Tenant&#8217;s interest in tenant improvements which may be at any time located in, on or about the Premises or the Buildings, whether owned by Tenant or third parties, will be at the sole risk or at the risk of those claiming through Tenant, and that Landlord will not be liable for any damage to or loss of such property except for loss or damage arising from or caused by the sole gross negligence or willful misconduct of Landlord or any of Landlord&#8217;s officers, employees, agents, or authorized representatives.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;END OF TERM</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.1&#160;&#160;&#160;&#160;Surrender</font><font style="font-family:inherit;font-size:12pt;">.  Upon the expiration or other termination of the Term, or termination of Tenant&#8217;s right to possession of the Premises, Tenant will immediately vacate and surrender possession of the Premises, in good order, repair and condition, except for ordinary wear and tear, any portion of the Premises for which Landlord is responsible for repair and maintenance under the terms of this Lease, and casualty damage governed by Section&#160;10.  Upon the expiration or other termination of the Term, or termination of Tenant&#8217;s right to possession of the Premises, Tenant agrees to remove (a) all Tenant Alterations (other than the Leasehold Improvements) the removal of which Landlord requested or approved according to Section&#160;7.1 at the time Landlord consented to their installation, and (b) all Specialized Tenant Improvements which Tenant designated for removal according to Paragraph&#160;20 of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">,  (c) all of Tenant&#8217;s trade fixtures, office furniture, office equipment and other personal property, and (d) any other specialized tenant improvements installed by and paid for by Tenant, as identified and mutually agreed to in writing by Landlord and Tenant prior to installation.  Tenant will repair any damage to the Premises, Buildings and/or Project caused by the installation or removal of any such items or, if Tenant fails to make sure repairs within a reasonable time, Landlord may, at its option, make sure repairs and Tenant will reimburse Landlord for the reasonable cost of such repair following receipt of demand and reasonable back-up.  Notwithstanding the foregoing, (i) except pursuant to the express provisions of this Lease (including, without limitation, Sections&#160;10.1, 12.2(b) and Section&#160;29), Tenant may not unilaterally terminate this Lease prior to the expiration of the Term and (ii) Tenant will be responsible for removing all Telecom Equipment installed by or at Tenant&#8217;s request at the expiration or earlier termination of the Term, or termination of Tenant&#8217;s right to possession of the Premises,  in accordance with Section&#160;26.6 below.  Any of Tenant&#8217;s property remaining in the Premises after the expiration or earlier termination of the Term, or termination of Tenant&#8217;s right to possession of the Premises, will be conclusively deemed to have been abandoned by Tenant and may be appropriated, stored, sold, destroyed or otherwise disposed of by Landlord without notice or obligation to account to or compensate Tenant, and Tenant will pay Landlord on demand all reasonable costs incurred by Landlord relating to such abandoned property, including the cost to remove or demolish such property.  Tenant&#8217;s obligations under this Section&#160;15.1 will survive the expiration or early termination of this Lease and no surrender of possession of the Premises by Tenant will limit Tenant&#8217;s liability under this Lease.  No act or thing done by Landlord or Landlord&#8217;s agents during the Term of this Lease will be deemed an acceptance of a surrender of the Premises, unless in writing signed by Landlord.  The delivery of the keys to an employee or agent of Landlord will not operate as a termination of this Lease or a surrender of the Premises.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">37</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.2&#160;&#160;&#160;&#160;Holding Over</font><font style="font-family:inherit;font-size:12pt;">.  Tenant understands that it does not have the right to hold over at any time and Landlord may exercise any and all remedies at law or in equity to recover possession of the Premises, as well as any damages incurred by Landlord, due to Tenant&#8217;s failure to vacate the Premises and deliver possession to Landlord as required by this Lease.  If Tenant holds over after the Expiration Date, Tenant will be deemed to be a tenant from month-to-month, at a monthly Base Rent, payable in advance, equal to 150% of monthly Base Rent payable during the last year of the Term, and Tenant will be bound by all of the other terms, covenants and agreements of this Lease as the same may apply to a tenancy at sufferance.  If Tenant fails to surrender the Premises upon expiration of this Lease despite demand to do so by Landlord, Tenant will indemnify and hold Landlord harmless from all loss, cost, expense, or liability, including without limitation, any claim made by any succeeding tenant founded on or resulting from such failure to surrender and any attorneys&#8217; fees and other costs of legal proceedings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;ESTOPPEL CERTIFICATES</font><font style="font-family:inherit;font-size:12pt;">.  Promptly upon Landlord&#8217;s request after Tenant has occupied the Premises, Tenant will execute and deliver to Landlord an Occupancy Estoppel Certificate in the form of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;C</font><font style="font-family:inherit;font-size:12pt;">.  In addition, Tenant agrees that at any time and from time to time (but on not less than 10 business days&#8217; prior request by Landlord), Tenant will execute, acknowledge and deliver to Landlord a certificate indicating any or all of the following:  (a) the Commencement Date and Expiration Date; (b) that this Lease is unmodified and in full force and effect (or, if there have been modifications, that this Lease is in full force and effect, as modified, and stating the date and nature of each modification); (c) the date, if any, through which Base Rent, Additional Rent and any other Rent payable have been paid; (d) that, to Tenant&#8217;s actual knowledge, no default by Landlord or Tenant exists which has not been cured, except as to defaults stated in such certificate; (e) that, to Tenant&#8217;s actual knowledge, Tenant has no existing defenses or set-offs to enforcement of this Lease, except as specifically stated in such certificate; (f) provided such events have occurred, that Tenant has accepted the Premises and that all improvements required to be made to the Premises by Landlord have been completed according to this Lease; (g) that, except as specifically stated in such certificate, Tenant, and only Tenant, currently occupies the Premises; and (h) such other factual matters as may be reasonably requested by Landlord.  Any such certificate may be relied upon by Landlord and any prospective purchaser or present or prospective mortgagee, deed of trust beneficiary or ground lessor of all or a portion of the Buildings and/or Project.  Tenant&#8217;s failure to deliver such certificate will be deemed to establish conclusively that this Lease is in full force and effect and that the statements set forth in Landlord&#8217;s proposed certificate are true and correct.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;TRANSFERS OF LANDLORD&#8217;S INTEREST</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.1&#160;&#160;&#160;&#160;Sale, Conveyance and Assignment</font><font style="font-family:inherit;font-size:12pt;">.  Subject only to Tenant&#8217;s rights under this Lease, nothing in this Lease will restrict Landlord&#8217;s right to sell, convey, assign or otherwise deal with the Project, Buildings or Landlord&#8217;s interest under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.2&#160;&#160;&#160;&#160;Effect of Sale, Conveyance or Assignment</font><font style="font-family:inherit;font-size:12pt;">.  A sale, conveyance or assignment of Landlord&#8217;s interest in the leases of the Buildings and/or the Project (when coupled with the transfer of the Letter of Credit,  and Security Deposit, if any, to Landlord&#8217;s transferee) will automatically release Landlord from liability under this Lease from and after the effective date of the transfer, except for any liability relating to the period prior to such effective date; and Tenant will look solely to Landlord&#8217;s transferee for performance of Landlord&#8217;s obligations relating to the period after such effective date.  This Lease will not be affected by any such sale, conveyance or assignment and Tenant will attorn to Landlord&#8217;s transferee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.3&#160;&#160;&#160;&#160;Subordination and Nondisturbance</font><font style="font-family:inherit;font-size:12pt;">.  This Lease is and will be subject and subordinate in all respects to any ground lease, first mortgage or first deed of trust now or later encumbering the Buildings or Project, and to all their renewals, modifications, supplements, consolidations and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">replacements (an &#8220;Encumbrance&#8221;).  With respect to any Encumbrance first encumbering the Buildings or Project subsequent to the Lease Date of this Lease, Landlord will use its commercially reasonable efforts to cause the holder of such Encumbrance to agree (by delivery of a commercially reasonable subordination, non-disturbance and attornment agreement) that so long as Tenant is not in Default of its obligations under this Lease, this Lease will not be terminated and Tenant&#8217;s possession of the Premises will not be disturbed by the termination or foreclosure, or proceedings for enforcement, of such Encumbrance.  While such subordination will occur automatically, Tenant agrees, upon request by and without cost to Landlord or any successor in interest, to execute and deliver to Landlord or the holder of an Encumbrance such commercially reasonable instrument(s) as may be reasonably required to evidence such subordination within 10 business days after Landlord&#8217;s request therefor.  In the alternative, however, the holder of an Encumbrance may unilaterally elect to subordinate such Encumbrance to this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.4&#160;&#160;&#160;&#160;Attornment</font><font style="font-family:inherit;font-size:12pt;">.  If the interest of Landlord is transferred to any person (a &#8220;Transferee&#8221;) by reason of the termination or foreclosure, or proceedings for enforcement, of an Encumbrance, or by delivery of a deed in lieu of such foreclosure or proceedings, Tenant will immediately and automatically attorn to the Transferee.  Upon attornment this Lease will continue in full force and effect as a direct lease between the Transferee and Tenant, upon all of the same terms, conditions and covenants as stated in this Lease, except the Transferee (a) will not be subject to any set offs or claims which Tenant might have against any prior landlord; (b) will not be liable for any act or omission of any prior landlord (except to the extent any non-performance of this Lease continues after such transfer); (c) will not be bound by any payment of Rent for more than one month in advance, unless such amounts are actually transferred to the Transferee; and (d) will not be bound by any amendment or modification of this Lease made without the express written consent of Transferee.  Tenant agrees, upon request by and without cost to the Transferee, to promptly execute and deliver to the Transferee such commercially reasonable instrument(s) as may be reasonably required to evidence such attornment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;RULES AND REGULATIONS</font><font style="font-family:inherit;font-size:12pt;">.  Tenant agrees to observe and comply with the Rules and Regulations set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;D</font><font style="font-family:inherit;font-size:12pt;">&#32;and with all reasonable, nondiscriminatory modifications and additions to such Rules and Regulations and/or Telecommunications Rules from time to time adopted by Landlord and of which Tenant is notified in writing.  No such modification or addition will contradict or abrogate any right expressly granted to Tenant under this Lease.  Landlord&#8217;s enforcement of the Rules and Regulations and/or Telecommunications Rules will be uniform and nondiscriminatory, but Landlord will not be responsible to Tenant for the failure of any person to comply with the Rules and Regulations and/or Telecommunications Rules.  In the event of any conflict between the Rules and Regulations and the terms, covenants and conditions of this Lease, this Lease will control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;PARKING</font><font style="font-family:inherit;font-size:12pt;">.  Tenant may utilize up to 410 unassigned parking spaces within the Project at no charge.  Landlord reserves the right to specify the areas or portions of the Project in which Tenant&#8217;s employees and agents must park, and if so specified, Tenant&#8217;s employees and agents will only park in such specified area or portion; provided that Landlord will use best efforts to designate such areas within reasonable walking distance to the Premises.  Tenant&#8217;s rights to use the Project&#8217;s parking areas are nonexclusive, and are conditioned upon this Lease being in full force and effect.  Tenant will not abuse its privileges with respect to such parking areas and will use the same in accordance with Landlord&#8217;s reasonable directions.  Landlord&#8217;s inability to make any of the parking spaces available at any time during the Term for reasons beyond Landlord&#8217;s reasonable control will not be deemed a default by Landlord giving rise to any claim by Tenant; provided, however, if any event or action or omission by Landlord renders Tenant&#8217;s parking space allocation for the Premises for whatever reason inaccessible, unusable, unsafe, or which causes the number of parking spaces for the Buildings or Tenant&#8217;s parking </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">39</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">space allocation for the Premises to be reduced below applicable local code requirements (which reasons may include but are not limited to repairs, maintenance, casualty, condemnation, or displacement or dislocation caused by future construction), Landlord shall immediately provide substitute parking areas for Tenant&#8217;s use and its invitees which areas shall (i) unless required by Laws, cause no net reduction in Tenant&#8217;s parking space allocation, (ii) be similarly convenient in terms of location, quality and safety, as reasonably determined based on the circumstances, and (iii) except in the case of an emergency, be designated by prior written notice to Tenant with the exact location and anticipated duration of such substitute parking areas.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.&#160;&#160;&#160;&#160;DEFAULT AND REMEDIES</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.1&#160;&#160;&#160;&#160;Tenant&#8217;s Default</font><font style="font-family:inherit;font-size:12pt;">.  The occurrence of any one or more of the following events if uncured before the expiration of the cure periods set forth below, if any, will be a material default and breach of this Lease by Tenant (&#8220;Default&#8221;).  Any notice required by the terms of this Lease in connection with any such default will be in lieu of, and not in addition to, any notice required under Sections&#160;1161, et seq., of the California Code of Civil Procedure:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Tenant fails to pay any Rent payment or other sum due under this Lease after the same will be due and payable, and such failure continues for a period of five days after written notice thereof from Landlord to Tenant.  Without limiting the foregoing, Tenant will only be given one such notice and/or cure period per calendar year; after such notice given to Tenant by Landlord, any subsequent failure by Tenant to pay amounts when due during such calendar year will constitute a Default without Landlord providing further notice or opportunity to cure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Tenant fails to perform or observe any term, condition, covenant, or obligation required to be performed or observed by it under this Lease for a period of 30 days (or such shorter time provided herein) after notice thereof from Landlord; provided, however, that if the term, condition, covenant, or obligation to be performed by Tenant is of such nature that the same cannot reasonably be cured within 30 days and if Tenant commences such performance within said 30-day period and thereafter diligently undertakes to complete the same, then such failure will not be a Default hereunder if it is cured within 60 days following Landlord&#8217;s notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;A trustee, disbursing agent, or receiver is appointed to take possession of all or substantially all of Tenant&#8217;s assets in, on or about the Premises or of Tenant&#8217;s interest in this Lease (and Tenant or any guarantor of Tenant&#8217;s obligations under this Lease does not regain possession within 90 days after such appointment); or Tenant makes an assignment for the benefit of creditors; or all or substantially all of Tenant&#8217;s assets in, on or about the Premises or Tenant&#8217;s interest in this Lease are attached or levied upon under execution (and Tenant does not discharge the same within 90 days thereafter).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;A petition in bankruptcy, insolvency, or for reorganization or arrangement is filed by or against Tenant or any guarantor of Tenant&#8217;s obligations under this Lease pursuant to any federal or state statute, and, with respect to any such petition filed against it, Tenant or such guarantor fails to secure a stay or discharge thereof within 90&#160;days after the filing of the same.  In the event that any provision of this Section&#160;20.1(d) is contrary to any applicable Laws, such provision will be of no force or effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Any assignment, subletting, or other transfer for which the prior written consent of the Landlord was required pursuant to Section&#160;13, but was not obtained.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">40</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;Discovery of any knowingly false or misleading statement of material fact concerning financial information submitted by Tenant to Landlord in connection with obtaining this Lease or any other consent or agreement by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;Tenant&#8217;s admission in writing of its inability to pay its debts as they mature.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;Suspension of Tenant&#8217;s right to conduct its business, caused by the order, judgment, decree, decision, or other act of any court or governmental agency for more than 60&#160;days.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to execute, acknowledge, and deliver to Landlord, within the 10 business day period specified in Section&#160;17, any documents required to effectuate an attornment, a subordination, or to make this Lease or any option granted herein prior to the lien of any mortgage, deed of trust, or ground lease, or any estoppel certificate, as the case may be, where such failure continues for more than five business days following Tenant&#8217;s receipt of a written notice from Landlord stating that &#8220;Tenant&#8217;s failure to respond to this notice within five business days will constitute a breach of the Lease.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;Intentionally deleted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;Any default by Tenant (after the expiration of any applicable cure period) under a written agreement with Landlord relating to Telecom Equipment, if applicable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to timely replace the Letter of Credit as required by, and in accordance with, Section&#160;28.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.2&#160;&#160;&#160;&#160;Landlord&#8217;s Remedies</font><font style="font-family:inherit;font-size:12pt;">.  Upon the occurrence of any Default, Landlord will have the following rights and remedies, in addition to those allowed by law or in equity, any one or more of which may be exercised or not exercised without precluding the Landlord from exercising any other remedy provided in this Lease or otherwise allowed by law or in equity:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Landlord may terminate this Lease and Tenant&#8217;s right to possession of the Premises.  If Tenant has abandoned and vacated the Premises, the mere entry onto the Premises by Landlord in order to perform acts of maintenance, cure defaults, preserve the Premises, or attempt to relet the Premises, or the appointment of a receiver in order to protect the Landlord&#8217;s interest under this Lease, will not be deemed a termination of Tenant&#8217;s right to possession or a termination of this Lease unless Landlord has notified Tenant in writing that this Lease is terminated.  If Landlord terminates this Lease and Tenant&#8217;s right to possession of the Premises pursuant to this Section&#160;20.2(a), then Landlord may recover from Tenant:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;The worth at the time of the award of unpaid Rent, including, without limitation, Operating Expenses, which had been earned at the time of termination; plus</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;The worth at the time of the award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;The worth at the time of the award of the amount by which the unpaid Rent for the balance of the term after the time of the award exceeds the amount of such rental loss that Tenant proves could be reasonably avoided; plus</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">41</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)&#160;&#160;&#160;&#160;Any other amounts necessary to compensate Landlord for all of the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease which in the ordinary course of things would be likely to result therefrom, including, without limitation, recovery of Base Rent, Additional Rent, and additional or other forms of Rent, for any unamortized period of free Rent theretofore enjoyed by Tenant (with amortization for the Term calculated including an interest factor of 10% per annum); recovery of the unamortized portion (with amortization for the Term calculated including an interest factor of 10% per annum) of any tenant improvement allowance or other leasehold improvement costs paid by Landlord to install leasehold improvements on the Premises which is applicable to that portion of the Term, including option periods, which is unexpired as of the date on which this Lease terminated; any legal expenses, brokers&#8217; commissions, or finders&#8217; fees in connection with reletting the Premises, and the unamortized portion of any leasing commission paid by Landlord in connection with this Lease which is applicable to the portion of the Term, including option periods, which is unexpired as of the date on which this Lease terminated; the costs of repairs, cleanup, refurbishing, removal, and storage or disposal of Tenant&#8217;s personal property, equipment, fixtures, and anything else that Tenant is required under this Lease to remove but does not remove (including those alterations which Tenant is required to remove pursuant to an election by Landlord, and which Landlord actually removes, whether or not notice to remove will be delivered to Tenant); and any costs for alterations, additions, and renovations incurred by Landlord in regaining possession of and reletting (or attempting to relet) the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All computations of the &#8220;worth at the time of the award&#8221; of amounts recoverable by Landlord under Sections&#160;20.2(a)(i) and (ii) hereof will be computed by allowing interest at the 10% plus the Prime Rate as of the date on which the Default occurred.  The &#8220;worth at the time of the award&#8221; recoverable by Landlord under Section&#160;20.2(a)(iii) and the discount rate for purposes of determining any amounts recoverable under Section&#160;20.2(a)(iv), if applicable, will be computed by discounting the amount recoverable by Landlord at the discount rate of the Federal Reserve Bank of California San Francisco at the time of the award plus 1%.  If Tenant tenders to Landlord in an offer of settlement all sums due under this Section&#160;20.2(a) after Landlord has notified Tenant of exercise of the remedies under this Section&#160;20.2(a), then the &#8220;worth at the time of the award&#8221; will be determined at the time of the tender of payment of the entire amount of such sums by Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Upon termination of this Lease, whether by lapse of time or otherwise, Tenant will immediately vacate the Premises and deliver possession to Landlord.  If Tenant has vacated the Premises and Landlord or any of its agents has reason to believe that Tenant does not intend to reoccupy the Premises, and current or past Rent has been due or unpaid for at least 14 consecutive days, then Landlord will have the right to send Tenant a notice of belief of abandonment pursuant to Section&#160;1951.3 of the California Civil Code.  The Premises will be deemed abandoned, and the Tenant&#8217;s right to possession of the Premises will terminate on the date set forth in such notice, unless Landlord receives (at its address for notices pursuant to this Lease) before such date a notice from Tenant stating (i)&#160;Tenant&#8217;s intent not to abandon the Premises, and (ii)&#160;an address at which Tenant may be served in any action for unlawful detainer of the Premises and/or damages or other relief available at law or in equity.  If the Premises are deemed abandoned (either through the aforementioned procedure or due to any statement by Tenant to that effect), or if Landlord or any of its agents acts pursuant to a court order, then </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">42</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord or any of its agents will have the right, without terminating this Lease, to re-enter the Premises and remove all persons therefrom and any or all of Tenant&#8217;s fixtures, equipment, furniture, and other personal property (herein collectively referred to as &#8220;Unclaimed Property&#8221;) from the Premises, without being deemed in any manner liable for trespass, eviction, or forcible entry or detainer, or conversion of Unclaimed Property, and without relinquishing any right given to Landlord under this Lease or by operation of law.  If Landlord re-enters the Premises in such situation, all Unclaimed Property removed from the Premises by Landlord or any of its agents and not claimed by the owner may be handled, removed, or stored, in a commercial warehouse or otherwise by Landlord at Tenant&#8217;s risk and expense, and Landlord will in no event be responsible for the value, preservation, or safekeeping thereof.  Before the retaking of any such Unclaimed Property from storage, Tenant will pay to Landlord, upon demand, all expenses incurred in such removal and all storage charges against such Unclaimed Property.  Any such Unclaimed Property of Tenant not so retaken from storage by Tenant within 30 days after such Unclaimed Property is removed from the Premises will be deemed abandoned and may be either disposed of by Landlord pursuant to Section&#160;1988 of the California Civil Code or retained by Landlord as its own property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Notwithstanding Landlord&#8217;s right to terminate this Lease pursuant to Section&#160;20.2(a), Landlord may, at its option, even though Tenant has breached this Lease and abandoned the Premises, continue this Lease in full force and effect and not terminate Tenant&#8217;s right to possession, and enforce all of Landlord&#8217;s rights and remedies under this Lease.  In such event, Landlord will have the remedy described in California Civil Code Section&#160;1951.4 (Landlord may continue this Lease in effect after Tenant&#8217;s breach and abandonment and recover Rent as it becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations).  Further, in such event, Landlord will be entitled to recover from Tenant all costs of maintenance and preservation of the Premises, and all costs, including reasonable attorneys&#8217; fees and receivers&#8217; fees, incurred in connection with appointment of and performance by a receiver to protect the Premises and Landlord&#8217;s interest under this Lease.  No reentry or taking possession of the Premises by Landlord pursuant to this Section&#160;20.2(c) will be construed as an election to terminate this Lease unless a written notice (signed by a duly authorized representative of Landlord) of intention to terminate this Lease is given to Tenant.  Landlord may at any time after default by Tenant elect to terminate this Lease pursuant to Section&#160;20.2(a), notwithstanding Landlord&#8217;s prior continuance of this Lease in effect for any period of time, and upon and after Tenant&#8217;s default under this Lease, Landlord may, but need not, relet the Premises or any part thereof for the account of Tenant to any person, firm, partnership, corporation, or other business entity for such Rent, for such time, and upon such terms as Landlord, in its sole discretion, will determine.  Subject to the provisions of this Lease regarding assignment and subletting in Section&#160;13, Landlord will not be required to accept any substitute tenant offered by Tenant or to observe any instructions given by Tenant regarding such reletting.  Landlord may remove (and repair any damage caused by such removal) and store (or dispose of) any of Tenant&#8217;s personal property, equipment, fixtures, and anything else Tenant is required (under this Lease at the election of Landlord or otherwise) to remove but does not remove, and Landlord may also make repairs, renovations, alterations, and/or additions to the Premises to the extent deemed by Landlord necessary or desirable in connection with any attempt to relet the Premises.  Tenant will upon demand pay the cost of such repairs, alterations, additions, removal, storage and renovations, together with any reasonable legal expenses, brokers&#8217; commissions or finders&#8217; fees and any other expenses incurred by Landlord in connection with its entry upon the Premises and attempt to relet the Premises.  If Landlord is able to relet the Premises for Tenant&#8217;s account during the remaining portion of the Term and the consideration collected by Landlord from any reletting is </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">43</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">not sufficient to pay monthly the full amount of Base Rent and Additional Rent payable by Tenant under this Lease, together with any reasonable legal expenses, brokers&#8217; commissions or finders&#8217; fees, any cost for repairs, alterations, additions, removal, storage and renovations, and any other cost and expense incurred by Landlord in re-entering the Premises and reletting the Premises, then Tenant will pay to Landlord the amount of each monthly deficiency upon demand.  Any rentals received by Landlord from any such reletting will be applied as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;First, to the payment of any costs of reentry and reletting the Premises;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;Second, to the payment of costs of any such alterations, repairs, additions, removal, storage, and renovations to the Premises;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;Third, to the payment of any other Rent due and unpaid under this Lease; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)&#160;&#160;&#160;&#160;The residue, if any, will be held by Landlord and applied as payment of future Rent as the same may become due and payable under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;No act or omission by Landlord or its agents during the Term will be an acceptance of a surrender of the Premises, and no agreement to accept a surrender of the Premises will be valid, unless made in writing and signed by a duly authorized representative of Landlord.  Neither any remedy set forth in this Lease nor pursuit of any particular remedy will preclude Landlord from any other remedy set forth in this Lease or otherwise available at law or in equity.  Landlord will be entitled to a restraining order or injunction to prevent Tenant from breaching or defaulting under any of its obligations under this Lease other than the payment of Rent or other sums due hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Neither the termination of this Lease nor the exercise of any remedy under this Lease or otherwise available at law or in equity will affect the right of Landlord to any right of indemnification set forth in this Lease or otherwise available at law or in equity by reason of Tenant&#8217;s occupancy of the Premises, and all rights to indemnification or other obligations of Tenant will survive termination of this Lease and termination of Tenant&#8217;s right to possession under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;Landlord may, at Landlord&#8217;s option but without obligation to do so, and without releasing Tenant from any obligations under this Lease, make any payment or take any action as Landlord deems necessary or desirable to cure any Default in such manner and to such extent as Landlord deems necessary or desirable.  Landlord may do so without additional demand on, or additional written notice to, Tenant and without giving Tenant an additional opportunity to cure such Default.  Tenant covenants and agrees to pay Landlord, upon demand, all advances, costs and expenses of Landlord in connection with making any such payment or taking any such action, including reasonable attorneys&#8217; fees, together with interest at the rate described in Section&#160;3.5, from the date of payment of any such advances, costs and expenses by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.3&#160;&#160;&#160;&#160;Intentionally Omitted</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.4&#160;&#160;&#160;&#160;Landlord&#8217;s Default and Tenant&#8217;s Remedies</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;It will be a default and breach of this Lease by Landlord if it fails to perform or observe any term, condition, covenant or obligation required to be performed or observed by it under this Lease for a period of 30 days after written notice thereof from Tenant; provided, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">44</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">however, that if the term, condition, covenant or obligation to be performed by Landlord is of such nature that the same cannot reasonably be performed within such 30&#8209;day period, such default will be deemed to have been cured if Landlord commences such performance within said 30&#8209;day period and thereafter diligently undertakes to complete the same.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Tenant will not have the right based upon a default of Landlord to terminate this Lease or to withhold, offset or abate Rent, Tenant&#8217;s sole recourse for Landlord&#8217;s default being an action for damages against Landlord for the period of Landlord&#8217;s default, which is proximately caused by Landlord&#8217;s default and/or an injunction or other equitable remedy.  Tenant will not have the right to terminate this Lease or to withhold, offset or abate the payment of Rent based upon the unreasonable or arbitrary withholding by Landlord of its consent or approval of any matter requiring Landlord&#8217;s consent or approval, including, but not limited to, any proposed assignment or subletting, Tenant&#8217;s remedies in such instance being limited to a declaratory relief action, specific performance, injunctive relief or an action of actual damages.  Tenant will not in any case be entitled to any consequential or punitive damages based upon any Landlord default or withholding of consent or approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.5&#160;&#160;&#160;&#160;Non-waiver of Default</font><font style="font-family:inherit;font-size:12pt;">.  The failure or delay by Landlord to enforce or exercise at any time any of its rights or remedies or other provisions of this Lease will not be construed to be a waiver thereof, nor affect the validity of any part of this Lease or the right of Landlord thereafter to enforce each and every such right or remedy or other provision.  No waiver by Landlord of any Default or breach of this Lease will be held to be a waiver of any other or subsequent Default or breach.  The receipt by Landlord of less than the full Rent due will not be construed to be other than a payment on account of Rent then due, no statement on Tenant&#8217;s check or any letter accompanying Tenant&#8217;s check be deemed an accord and satisfaction, and Landlord may accept any payment without prejudice to Landlord&#8217;s right to recover the balance of the Rent due or to pursue any other remedies provided in this Lease or available at law or in equity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.&#160;&#160;&#160;&#160;SIGNAGE</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.1&#160;&#160;&#160;&#160;Signage Provided by Landlord</font><font style="font-family:inherit;font-size:12pt;">.  Landlord, at its sole cost and expense, will provide in Multi User Buildings (a)&#160;identification of Tenant in the main floor lobby directory of each Building and (b)&#160;Building Standard identification signage at the designated suite entrances to the Premises.  Notwithstanding the foregoing, Tenant, at its sole cost and expense, may install custom signage at the entrances to the Premises with Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.  Any subsequent changes to the suite identification will be at Tenant&#8217;s sole cost.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.2&#160;&#160;&#160;&#160;Monument Signage</font><font style="font-family:inherit;font-size:12pt;">.  Subject to approval of a signage package by the City of Alameda and the Harbor Bay Business Park Association and the terms of this Section&#160;21.2, Tenant may, at its sole cost and expense, install a monument sign in a location mutually designated by Landlord and Tenant (the &#8220;Monument Sign&#8221;).  The size, design and method of attachment of the Monument Sign must be approved in writing by Landlord prior to installation, which approval shall not be unreasonably withheld, conditioned or delayed, and the Monument Sign must comply with all applicable Laws, Landlord&#8217;s signage and design criteria, any Declarations and any applicable association and/or any related architectural control committee.  Tenant, at its sole cost and expense, will obtain all necessary permits with respect to the Monument Sign.  Tenant will maintain the Monument Sign in good and operating condition.  If the Monument Sign is damaged or inoperative, Tenant will commence repair of such Monument Sign as soon as practicable, but in no event later than 48&#160;hours (exclusive of Saturdays, Sundays and nationally recognized bank holidays) after receipt of notice from Landlord, and thereafter, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">45</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant will diligently pursue completion of such repair.  Upon vacation of the Premises, or the removal or alteration of the Monument Sign for any reason, Tenant will be responsible for the repair, maintenance and/or replacement of the land where the applicable Monument Sign is removed from, if applicable.  Landlord, at Landlord&#8217;s option after reasonable notice to Tenant, may perform any of Tenant&#8217;s obligations to install, repair, maintain and/or replace the Monument Sign and the applicable land where such Monument Sign is located, and Landlord will be entitled to reimbursement from Tenant for the costs and expenses related thereto.  Tenant&#8217;s obligations under this Section&#160;21.2 will survive expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.3&#160;&#160;&#160;&#160;Exterior Building Signage</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms of this Section&#160;21.3, Tenant may, at its sole cost and expense, install signage on the exterior of the 1801 Building and the 1851 Building in locations designated by Landlord (the &#8220;Exterior Signs&#8221;).  The size, design and method of attachment of the Exterior Signs must be approved in writing by Landlord prior to installation, and the Exterior Signs must comply with all applicable Laws, Landlord&#8217;s signage and design criteria, any Declarations and any applicable association and/or any related architectural control committee.  Tenant, at its sole cost and expense, will obtain all necessary permits with respect to the Exterior Signs.  Tenant will maintain the Exterior Signs in good and operating condition.  If either Exterior Sign is damaged or inoperative, Tenant will commence repair of such Exterior Sign as soon as practicable, but in no event later than 48&#160;hours (exclusive of Saturdays, Sundays and nationally recognized bank holidays) after receipt of notice from Landlord, and thereafter, Tenant will diligently pursue completion of such repair.  Upon vacation of the Premises, or the removal or alteration of the Exterior Signs for any reason, Tenant will be responsible for the repair, maintenance and/or replacement of the Building fascia surface where the applicable Exterior Sign is removed from, if applicable.  Landlord, at Landlord&#8217;s option after reasonable notice to Tenant, may perform any of Tenant&#8217;s obligations to install, repair, maintain and/or replace each Exterior Sign and the applicable Building fascia surface where such Exterior Sign is attached, if applicable, and Landlord will be entitled to reimbursement from Tenant for the costs and expenses related thereto.  Except as set forth above, Tenant will not, without Landlord&#8217;s prior written consent, (a)&#160;make any changes to or paint the exterior of the Building, (b)&#160;affix signs, advertisements, banners or other materials to the inside or outside of exterior windows or to any doors, columns or storefront walls.  Tenant&#8217;s obligations under this Section&#160;21.3 will survive expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.4&#160;&#160;&#160;&#160;General</font><font style="font-family:inherit;font-size:12pt;">.  All signs, whether erected by Landlord or Tenant, will conform to Landlord&#8217;s Building Standard signage and to all Laws.  In the event of a violation of the foregoing by Tenant, Landlord may remove same without any liability, and may charge the expense incurred in such removal to Tenant.  Tenant will remove all approved signs which it has erected upon the termination of this Lease, or termination of Tenant&#8217;s right to possession of the Premises, and repair all damage caused by such removal.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.&#160;&#160;&#160;&#160;SECURITY DEPOSIT</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.1&#160;&#160;&#160;&#160;Amount</font><font style="font-family:inherit;font-size:12pt;">.  Upon execution of this Lease, Tenant will deposit the Security Deposit with Landlord in the amount described in Section&#160;1.1(l), if any.  Landlord and Tenant intend the Security Deposit to be used solely as security for Tenant&#8217;s faithful and diligent performance of all of Tenant&#8217;s obligations under this Lease.  The Security Deposit will remain in Landlord&#8217;s possession for the entire Term, and Landlord will not be required to segregate it from Landlord&#8217;s general funds.  Tenant will not be entitled to any interest on the Security Deposit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.2&#160;&#160;&#160;&#160;Use and Restoration</font><font style="font-family:inherit;font-size:12pt;">.  If Tenant fails to perform any of its obligations under this Lease, Landlord may, at its option, use, apply or retain all or any part of the Security Deposit for the payment of (a)&#160;any Rent in arrears; (b)&#160;any expenses Landlord may incur as a direct or indirect result of Tenant&#8217;s </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">46</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">failure to perform; and (c)&#160;any other losses or damages Landlord may suffer as a direct or indirect result of Tenant&#8217;s failure to perform.  If Landlord so uses or applies all or any portion of the Security Deposit, Landlord will notify Tenant of such use or application and Tenant will, within 10 business days after the date of Landlord&#8217;s notice, deposit with Landlord a sum sufficient to restore the Security Deposit to the amount held by Landlord immediately prior to such use or application.  Tenant&#8217;s failure to so restore the Security Deposit will constitute a Default.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.3&#160;&#160;&#160;&#160;Transfers</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not assign or encumber the Security Deposit without Landlord&#8217;s express written consent.  Neither Landlord nor its successors or assigns will be bound by any assignment or encumbrance unless Landlord has given its consent.  Landlord will have the right, at any time and from time to time, to transfer the Security Deposit to any purchaser or lessee of an entire Building and/or Project and deliver to Tenant the notice required by Section&#160;1950.7 of the Civil Code of California.  Upon any such transfer, Tenant agrees to look solely to the new owner or lessee for the return of the Security Deposit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.4&#160;&#160;&#160;&#160;Refund</font><font style="font-family:inherit;font-size:12pt;">.  Provided that Tenant has fully and faithfully performed all of its obligations under this Lease, Landlord will refund the Security Deposit, or any balance remaining, to Tenant or, at Landlord&#8217;s option, to the latest assignee of Tenant&#8217;s interest under this Lease, within 45 days after the expiration or early termination of the Term and Tenant&#8217;s vacation and surrender of the Premises to Landlord in the condition required by Section&#160;15.1.  If Tenant fails to make any final estimated payment of Additional Rent required by Landlord according to Section&#160;3.2(c), Landlord may withhold such final payment from the amount of the Security Deposit refund.  Tenant hereby waives the provisions of Section&#160;1950.7 of the California Civil Code and all other provisions of law, now or hereafter in effect, which provide that Landlord may claim from a Security Deposit only those sums reasonably necessary to remedy defaults in the payment of Rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that Landlord may, in addition, claim those sums specified in this Section&#160;22 above and/or those sums reasonably necessary to compensate Landlord for any other loss or damage, foreseeable or unforeseeable, caused by the acts or omissions of Tenant or any officer, employee, agent, contractor or invitee of Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">23.&#160;&#160;&#160;&#160;BROKERS</font><font style="font-family:inherit;font-size:12pt;">.  Landlord and Tenant represent and warrant that no broker or agent negotiated or was instrumental in negotiating or consummating this Lease except the Brokers.  Neither party knows of any other real estate broker or agent who is or might be entitled to a commission or compensation in connection with this Lease.  Landlord will pay all fees, commissions or other compensation payable to the Brokers to be paid by Landlord according to Section&#160;1.1(s) and Tenant will pay all fees, commissions or other compensation payable to the Brokers to be paid by Tenant according to Section&#160;1.1(s).  Tenant and Landlord will indemnify and hold each other harmless from all damages paid or incurred by the other resulting from any claims asserted against either party by brokers or agents claiming through the other party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">24.&#160;&#160;&#160;&#160;LIMITATIONS ON LANDLORD&#8217;S LIABILITY</font><font style="font-family:inherit;font-size:12pt;">.  Any liability for damages, breach or nonperformance by Landlord, or arising out of the subject matter of, or the relationship created by, this Lease, will be collectible only out of Landlord&#8217;s interest in the Project and no personal liability is assumed by, or will at any time be asserted against, Landlord, its parent and affiliated corporations, its and their partners, venturers, directors, officers, shareholders, members, managers, agents and employees, or any of its or their successors or assigns; all such liability, if any, being expressly waived and released by Tenant.  In no event will Landlord be liable to Tenant or any other person for consequential, special or punitive damages, including, without limitation lost profits.  Landlord&#8217;s review, supervision, commenting on or approval of any aspect of work to be done by or for Tenant (under Section&#160;7, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">&#32;or otherwise) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">47</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">are solely for Landlord&#8217;s protection and, except as expressly provided, create no warranties or duties to Tenant or to third parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">25.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:inherit;font-size:12pt;">.  Unless specifically permitted otherwise by the terms of this Lease, all notices required or permitted under this Lease must be in writing and will only be deemed properly given and received (a)&#160;when actually given and received, if delivered in person to a party who acknowledges receipt in writing; or (b)&#160;one business day after deposit with a private courier or overnight delivery service, if such courier or service confirms delivery; or (c)&#160;two business days after deposit in the United States mails, certified or registered mail with return receipt requested and postage prepaid.  All such notices must be transmitted by one of the methods described above to the party to receive the notice at, in the case of notices to Landlord, both Landlord&#8217;s Manager&#8217;s Address and Landlord&#8217;s General Address, and in the case of notices to Tenant, the applicable Tenant&#8217;s Notice Address, or, in either case, at such other address(es) as either party may notify the other of according to this Section&#160;25.  Any notice to be given by Landlord under this Lease will be effective if given by Landlord or its agents or attorneys.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.&#160;&#160;&#160;&#160;TELECOMMUNICATIONS</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.1&#160;&#160;&#160;&#160;Certain Definitions</font><font style="font-family:inherit;font-size:12pt;">.  The following definitions are applicable to this Section&#160;26:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#8220;Telecom Equipment&#8221; means telephone, internet and any other communications equipment, all Connections (as defined below) and any technological evolution or replacement thereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#8220;Connections&#8221; means any wires, cables, fiber optic lines, antennas, switches and other equipment or infrastructure located in the Project, but outside the Premises, that are installed by or on behalf of Tenant for, or related to, the operation of other Telecom Equipment.  All Connections are also Telecom Equipment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#8220;Telecom Provider&#8221; means a provider of Telecom Equipment or services using Telecom Equipment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#8220;Telecom Services&#8221; means services provided by a Telecom Provider using Telecom Equipment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.2&#160;&#160;&#160;&#160;Installation and Use of Telecommunications Technologies</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will install Telecom Equipment, including WiMax systems, antennae and satellite dishes, within the Premises and/or within or on the Project in compliance with Section&#160;7.1.  Tenant may not utilize the services of a Telecom Provider whose equipment is not then servicing the Project, nor may Tenant require or request that a Telecom Provider materially expand the Telecom Services or Connections it currently provides or has provided in or to the Project, without first securing the prior written approval of Landlord, which approval will not be unreasonably withheld, conditioned or delayed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.3&#160;&#160;&#160;&#160;Limitation of Responsibility</font><font style="font-family:inherit;font-size:12pt;">.  Tenant acknowledges and agrees that all Telecom Equipment will be obtained, installed, maintained, repaired, replaced and removed at the sole expense of Tenant.  Landlord will have no responsibility for the operation, maintenance, repair or replacement of Tenant&#8217;s Telecom Equipment, including, without limitation, Tenant&#8217;s Connections.  Tenant agrees that, to the extent any Telecom Services are interrupted, curtailed or discontinued, Landlord will have no obligation or liability with respect thereto, and it will be the sole obligation of Tenant at its expense to obtain substitute Telecom Services.  No approval by Landlord under this Section&#160;26 will be deemed any kind of warranty or representation by Landlord, including, without limitation, any warranty or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">48</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">representation as to the suitability, competence or financial strength of any Telecom Provider or the quality or fitness for any particular purpose of any Telecom Equipment or Telecom Services.  Landlord does not make, and expressly disclaims, any representation, warranty or endorsement regarding or relating to any Telecom Provider, Telecom Services or Telecom Equipment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.4&#160;&#160;&#160;&#160;Necessary Service Interruptions</font><font style="font-family:inherit;font-size:12pt;">.  With respect to Multi User Buildings, Landlord will have the right to interrupt Tenant&#8217;s telecommunications services or disable Tenant&#8217;s Telecom Equipment in the event of emergency or as necessary in connection with repairs to any portion of the Project or installation of Telecom Equipment for other tenants or occupants of the Project.  Landlord will provide Tenant with at least 48 hours&#8217; prior notice of any such interruption or disabling (or less time in case of emergency or if approved by Tenant), except in the event of an emergency, in which case Landlord will provide Tenant as much advance notice as reasonably possible.  Landlord will exercise commercially reasonable efforts to perform any scheduled interruptions outside of Business Hours.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.5&#160;&#160;&#160;&#160;Interference</font><font style="font-family:inherit;font-size:12pt;">.  In the event that Telecom Equipment, including, without limitation, wiring, cabling or satellite and antenna equipment of any type installed by or at the request of Tenant within the Premises, on the roof of a Building or elsewhere within or on the Project causes interference to equipment (including Telecom Equipment) used by another party, Tenant will be responsible for, and indemnify and defend Landlord against, all liability related to such interference.  Tenant will use reasonable efforts, and will cooperate with Landlord and other parties, to promptly eliminate such interference.  In the event that Tenant is unable to eliminate such interference, Tenant will substitute alternative equipment.  If such interference persists after such alternative equipment is installed, Tenant will discontinue the use of its Telecom Equipment as necessary to discontinue such interference, and, at Landlord&#8217;s discretion, remove such Telecom Equipment according to specifications required by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.6&#160;&#160;&#160;&#160;Removal of Telecom Equipment, Wiring and Other Facilities</font><font style="font-family:inherit;font-size:12pt;">.  Prior to the expiration or earlier termination of the Term, Tenant will remove any and all Telecom Equipment installed in the Premises or elsewhere in the Project by or on behalf of Tenant, including all connections once the Telecom Equipment is no longer in use, at Tenant&#8217;s sole cost or, if Landlord so elects, Landlord may perform such removal at Tenant&#8217;s sole cost, with the cost thereof to be paid to Landlord as Additional Rent.  Such costs may also include, if Tenant has not provided plans and specifications, location of such Telecom Equipment and/or preparation of as-built plans or drawings of the Telecom Equipment serving the Premises and located in the Project.  Landlord will have the right, however, upon written notice to Tenant, given at least 45&#160;days prior to the expiration or earlier termination of the Term, to require Tenant to abandon and leave in place, without additional payment to Tenant or credit against Rent, any and all connections or selected components thereof, whether located in the Premises or elsewhere in the Project.  The terms and conditions of this Section&#160;26.6 will survive expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.7&#160;&#160;&#160;&#160;No Third Party Beneficiary</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding any provision of the preceding paragraphs to the contrary, the provisions of this Lease, including this Section&#160;26, may be enforced solely by Tenant and Landlord, are not for the benefit of any other party (including any subtenant), and specifically, but without limitation, no Telecom Provider will be deemed a third party beneficiary of this Lease or this Section&#160;26.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.&#160;&#160;&#160;&#160;MISCELLANEOUS</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.1&#160;&#160;&#160;&#160;Binding Effect</font><font style="font-family:inherit;font-size:12pt;">.  Each of the provisions of this Lease will extend to, bind or inure to the benefit of, as the case may be, Landlord and Tenant and their respective heirs, successors and assigns, provided that this clause will not permit any transfer by Tenant contrary to the provisions of Section&#160;13.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">49</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.2&#160;&#160;&#160;&#160;Complete Agreement; Modification</font><font style="font-family:inherit;font-size:12pt;">.  All of the representations and obligations of the parties are contained in this Lease and no modification, waiver or amendment of this Lease or of any of its conditions or provisions will be binding upon a party unless it is in writing signed by such party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.3&#160;&#160;&#160;&#160;Delivery for Examination</font><font style="font-family:inherit;font-size:12pt;">.  Submission of the form of this Lease for examination will not bind Landlord in any manner, and no obligations will arise under this Lease until it is signed by both Landlord and Tenant and delivery is made to each.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.4&#160;&#160;&#160;&#160;No Air Rights</font><font style="font-family:inherit;font-size:12pt;">.  This Lease does not grant any easements or rights for light, air or view.  Any diminution or blockage of light, air or view by any structure or condition now or later erected will not affect this Lease or impose any liability on Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.5&#160;&#160;&#160;&#160;Enforcement Expenses</font><font style="font-family:inherit;font-size:12pt;">.  Each party agrees to pay, upon demand, all of the other party&#8217;s costs, charges and expenses, including the fees and out-of-pocket expenses of counsel, agents and others retained incurred in successfully enforcing the other party&#8217;s obligations under this Lease and any other disputes arising out of this Lease (with successful enforcement being determined by the presiding judge or tribunal).  In addition, Landlord will be entitled to recover from Tenant those reasonable costs, charges and expenses related to preparation, delivery and/or service of notices pursuant to applicable forcible entry and detainer statutes in anticipation of commencing litigation, even if litigation is not commenced or pursued to final judgment after such notices are delivered and/or served.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.6&#160;&#160;&#160;&#160;Intentionally Omitted</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.7&#160;&#160;&#160;&#160;Project Name</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not, without Landlord&#8217;s consent, use Landlord&#8217;s or the Project&#8217;s name, or any facsimile or reproduction of the Project (or any portion thereof), for any purpose; except that Tenant may use the Project&#8217;s name in the address of the business to be conducted by Tenant in the Premises.  Landlord reserves the right, upon reasonable prior notice to Tenant, to change the name or address of the Building and/or the Project.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.8&#160;&#160;&#160;&#160;Press Release; Recording; Confidentiality</font><font style="font-family:inherit;font-size:12pt;">.  Landlord, with the prior consent of Tenant, which shall not be unreasonably withheld, conditioned or delayed, may issue a press release or otherwise communicate to the media the existence of the leasing arrangement between Landlord and Tenant under this Lease, provided that the language in such press release will be reasonably approved by Tenant.  Tenant will not record this Lease, or a short form memorandum, without Landlord&#8217;s written consent and any such recording without Landlord&#8217;s written consent will be a Default.  Tenant agrees to keep this Lease&#8217;s terms, provisions and conditions confidential and will not disclose them to any other person without Landlord&#8217;s prior written consent.  However, Tenant may disclose this Lease&#8217;s terms, provisions and conditions to Tenant&#8217;s accountants, attorneys, managing employees and others in privity with Tenant, as reasonably necessary for Tenant&#8217;s business purposes, without such prior consent, provided that, upon such disclosure, Tenant&#8217;s accountants, attorneys, managing employees and others in privity with Tenant will be bound by the terms of this Section&#160;27.8.  Notwithstanding the foregoing, Tenant may file, post or distribute this Lease as required by applicable Laws, including, without limitation, in full compliance with the filing and reporting requirements of the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.9&#160;&#160;&#160;&#160;Captions</font><font style="font-family:inherit;font-size:12pt;">.  The captions of sections are for convenience only and will not be deemed to limit, construe, affect or alter the meaning of such sections.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.10&#160;&#160;&#160;&#160;Invoices</font><font style="font-family:inherit;font-size:12pt;">.  All bills or invoices to be given by Landlord to Tenant will be sent to Tenant&#8217;s Invoice Address.  Tenant may change Tenant&#8217;s Invoice Address by notice to Landlord given according to Section&#160;25.  If Tenant fails to give Landlord specific notice of its objections within 60 days after </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">50</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">receipt of any bill or invoice from Landlord, such bill or invoice will be deemed true and correct and Tenant may not later question the validity of such bill or invoice or the underlying information or computations used to determine the amount stated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.11&#160;&#160;&#160;&#160;Severability</font><font style="font-family:inherit;font-size:12pt;">.  If any provision of this Lease is declared void or unenforceable by a final judicial or administrative order, this Lease will continue in full force and effect, except that the void or unenforceable provision will be deemed deleted and replaced with a provision as similar in terms to such void or unenforceable provision as may be possible and be valid and enforceable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.12&#160;&#160;&#160;&#160;Jury Trial</font><font style="font-family:inherit;font-size:12pt;">.  LANDLORD AND TENANT WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY LANDLORD OR TENANT AGAINST THE OTHER WITH RESPECT TO ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS LEASE, TENANT&#8217;S USE AND OCCUPANCY OF THE PREMISES, OR THE RELATIONSHIP OF LANDLORD AND TENANT.  However, such waiver of jury trial will not apply to any claims for personal injury.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.13&#160;&#160;&#160;&#160;Only Landlord/Tenant Relationship</font><font style="font-family:inherit;font-size:12pt;">.  Landlord and Tenant agree that neither any provision of this Lease nor any act of the parties will be deemed to create any relationship between Landlord and Tenant other than the relationship of landlord and tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.14&#160;&#160;&#160;&#160;Covenants Independent</font><font style="font-family:inherit;font-size:12pt;">.  The parties intend that this Lease be construed as if the covenants between Landlord and Tenant are independent and not dependent and that the Rent will be payable without offset, reduction or abatement for any cause except as otherwise specifically provided in this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.15&#160;&#160;&#160;&#160;Force Majeure</font><font style="font-family:inherit;font-size:12pt;">.  Except for Tenant&#8217;s obligation to pay Rent, neither party shall incur liability to the other party with respect to, and shall not be responsible for any failure to perform, any of its obligations hereunder if such failure is caused by any reason beyond the control of such party including, but not limited to, strike, labor trouble, governmental rule, regulations, ordinance, statute or interpretation, or by fire, earthquake, civil commotion, war, shortages of labor or materials, or failure or disruption of utility services.  The amount of time for either party to perform any of its obligations (including, without limitation, delivery of the Premises to Tenant, but not including the payment of Rent) shall be extended by the amount of time such party is delayed in performing such obligation by reason of any force majeure occurrence whether similar to or different from the foregoing types of occurrences.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.16&#160;&#160;&#160;&#160;Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Lease will be governed by and construed according to the laws of the State of California.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.17&#160;&#160;&#160;&#160;Financial Reports</font><font style="font-family:inherit;font-size:12pt;">.  If Tenant&#8217;s financials are not publicly available, within 15 days after Landlord&#8217;s request, Tenant will furnish Tenant&#8217;s most recent audited financial statements (including any notes to them) to Landlord, or, if no such audited statements have been prepared, such other financial statements (and notes to them) as may have been prepared by an independent certified public accountant or, if those are not so prepared, Tenant&#8217;s internally prepared financial statements.  Tenant will discuss its financial statements with Landlord and will give Landlord access to Tenant&#8217;s books and records in order to enable Landlord to verify the financial statements.  Landlord will not disclose any aspect of Tenant&#8217;s financial statements that Tenant designates to Landlord as confidential except (a)&#160;to Landlord&#8217;s Affiliates, attorneys, accountants and consultants, subject to the foregoing confidentiality requirements; (b)&#160;to Landlord&#8217;s lenders or prospective purchasers of the project, (c)&#160;in litigation between Landlord and Tenant, and (d) if required by court order.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">51</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.18&#160;&#160;&#160;&#160;Joint and Several Liability</font><font style="font-family:inherit;font-size:12pt;">.  If two or more parties execute this Lease as Tenant, the liability of each such party to pay all Rent and other amounts due hereunder and to perform all the other covenants of this Lease will be joint and several.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.19&#160;&#160;&#160;&#160;Signing Authority</font><font style="font-family:inherit;font-size:12pt;">.  If either Tenant or Landlord is a corporation, partnership or limited liability company, each individual executing this Lease on behalf of said entity represents and warrants that he or she is duly authorized to execute and deliver this Lease on behalf of said entity in accordance with:  (a) if it is a corporation, a duly adopted resolution of the Board of Directors of said corporation or in accordance with the by-laws of said corporation, (b) if it is a partnership, the terms of the partnership agreement, and (c) if it is a limited liability company, the terms of its operating or limited liability company agreement, and that this Lease is binding upon said entity in accordance with its terms.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.20&#160;&#160;&#160;&#160;Dates and Time</font><font style="font-family:inherit;font-size:12pt;">.  As used herein, the term &#8220;business day&#8221; shall mean all days, excluding Saturdays, Sundays and all days observed by either the State of California or the United States government as legal holidays.  All references to &#8220;days&#8221; that do not specifically refer to &#8220;business days&#8221; will refer to calendar days.  For purposes of determining dates under this Lease (a) a day that is a specified number of days after a given date will be the day that occurs the specified number of days after (but not including) the given date (so that, for example, the day that is 10 days after January 1 will be January 11); and (b) a day that is a specified number of months after a given date will be the day that occurs on the same day of the calendar month as the given date the specified number of months later (so that, for example, the day that is three months after January 15 will be April 15), except that if the day is the last day of a month, it will also be the last day of the month that is the specified number of months later (so that, for example, the day that is three months after January 31 will be April 30).  If any date set forth in this Lease for the delivery of any document or the happening of any event should, under the terms hereof, fall on a day that is not a business day, then such date will be automatically extended to the next succeeding business day.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.21&#160;&#160;&#160;&#160;Counterparts; Electronic Execution</font><font style="font-family:inherit;font-size:12pt;">.  This Lease may be executed in counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one agreement.  Executed copies hereof may be delivered by telecopier, email or other electronic means and upon receipt will be deemed originals and binding upon the parties hereto, regardless of whether originals are delivered thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.&#160;&#160;&#160;&#160;LETTER OF CREDIT</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.1&#160;&#160;&#160;&#160;Generally</font><font style="font-family:inherit;font-size:12pt;">.  Within two (2) business days following mutual execution of this Lease and as a condition precedent to Landlord&#8217;s obligations under this Lease, Tenant will deliver to Landlord the Letter of Credit issued in Landlord&#8217;s favor by a bank or other financial institution acceptable to Landlord in Landlord&#8217;s commercially reasonable discretion (the &#8220;Issuer&#8221;) in the applicable L/C Amount, as determined pursuant to Section&#160;1.1(r) in substantially the form attached to this Lease as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;F</font><font style="font-family:inherit;font-size:12pt;">.  Landlord hereby approves Wells Fargo as the initial Issuer.  If Tenant fails to deliver the Letter of Credit when due, Landlord will have the right to terminate this Lease at any time prior to Tenant&#8217;s delivery of the Letter of Credit as required by this Lease, and upon such termination, all rights and obligations under this Lease will no longer be in force and effect except to the extent that they expressly survive the expiration or earlier termination of this Lease.  The Letter of Credit may be replaced from time to time pursuant to this Section&#160;28.  Any Letter of Credit will be in a form reasonably acceptable to Landlord and consistent with the terms of Section&#160;1.1(r) and this Section&#160;28.  In advance of the issuance of any Letter of Credit, Tenant will deliver a draft of the form of the applicable Letter of Credit to Landlord, and Landlord will have the right to review and require modifications to such form to ensure that it </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">52</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">conforms to the requirements of Section&#160;1.1(r) and this Section&#160;28 prior to issuance of the final Letter of Credit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.2&#160;&#160;&#160;&#160;Use and Restoration</font><font style="font-family:inherit;font-size:12pt;">.  If Tenant fails to perform any of its obligations under this Lease beyond applicable notice and cure periods (unless transmittal of notice of a default of the Lease by Tenant is barred by applicable Laws, in which case no such notice or cure period will be required with respect to such default), Landlord may, at its option, use, apply or retain all or any portion of the Letter of Credit proceeds for the payment of (a) any Rent in arrears; (b)&#160;any expenses Landlord may incur as a direct or indirect result of Tenant&#8217;s failure to perform; and (c) any other losses or damages Landlord may suffer as a direct or indirect result of Tenant&#8217;s failure to perform its obligations under this Lease.  If Landlord so uses or applies all or any portion of the Letter of Credit, Landlord shall notify Tenant of such use or application in writing, and Tenant will, within five business days after its receipt of Landlord&#8217;s notice, restore the Letter of Credit to the amount required under this Lease.  Tenant&#8217;s failure to so restore the Letter of Credit will constitute a Default by Tenant without an additional notice or cure period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.3&#160;&#160;&#160;&#160;Transfers by Tenant</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not assign or encumber the Letter of Credit, except as may be expressly contemplated by this Section&#160;28, without Landlord&#8217;s express prior written consent.  Neither Landlord nor its successors or assigns will be bound by any assignment or encumbrance by Tenant unless Landlord has given such consent in advance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.4&#160;&#160;&#160;&#160;Transfers and Assignments by Landlord</font><font style="font-family:inherit;font-size:12pt;">.  This Section&#160;28 will also apply to subsequent grantees and transferees of Landlord.  The Letter of Credit will provide both that it will be transferable and that the proceeds of the Letter of Credit will be assignable, in each case, one or more times by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Landlord will have the right, at any time and from time to time, to transfer the Letter of Credit to any purchaser or lessee of Landlord&#8217;s interest in this Lease (or a lender of Landlord or of any such purchaser or lessee).  Tenant will be responsible for the payment of any fees charged by the Issuer in connection with such transfer.  Upon any such transfer, Tenant agrees to look solely to the new owner or lessee for the return of the Letter of Credit or any funds resulting from a draw thereon.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Further, Tenant will, from time to time, cooperate with Landlord and any lender of Landlord to collaterally assign Landlord&#8217;s rights to receive the proceeds of the Letter of Credit to such lender or to secure the debt owed by Landlord to such lender with Landlord&#8217;s interest in the Letter of Credit or the proceeds thereof.  Landlord or its lender will be responsible for customary fees charged by the Issuer in connection with any such collateral assignment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.5&#160;&#160;&#160;&#160;Replacement</font><font style="font-family:inherit;font-size:12pt;">.  If necessary and without notice from Landlord, Tenant will provide for replacements of the Letter of Credit to be issued and delivered to Landlord at least 30 days prior to the expiration of the then-effective Letter of Credit, time being of the essence and any such failure will constitute a Default by Tenant without an additional cure period, and Landlord will be entitled, without notice to Tenant, to draw the entire Letter of Credit prior to its expiration if the Letter of Credit is not timely replaced or renewed as set forth above.  If Landlord draws the entire Letter of Credit due to Tenant&#8217;s failure to timely replace or renew the Letter of Credit, Tenant will provide a replacement Letter of Credit within 10 business days after Landlord&#8217;s draw.  To the extent that Landlord is holding the proceeds of a Letter of Credit because of Tenant&#8217;s failure to timely replace or renew such Letter of Credit, Landlord may apply such proceeds to any Default of the Lease by Tenant.  Landlord will have the right, at any time and from time to time, to transfer Landlord&#8217;s rights to such funds to any successor to Landlord&#8217;s interest as landlord under this Lease, and upon any such transfer, Tenant agrees to look solely to the new </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">53</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">owner for the return of such funds.  Notwithstanding the foregoing, Tenant shall deliver a replacement Letter of Credit in the same form and in the amount of the then-effective Letter of Credit from a bank or other financial institution acceptable to Landlord in Landlord&#8217;s commercially reasonable discretion (the &#8220;Substitute Issuer&#8221;), within 10 business days after any of the following occur:  (a) the original Issuer enters into or becomes subject to any form of regulatory or governmental receivership or other similar regulatory or governmental proceeding, including any receivership instituted or commenced by the Federal Deposit Insurance Corporation or any other governmental agency responsible for the regulation and/or oversight of the original Issuer (in each instance, the &#8220;Bank Regulator&#8221;), is otherwise declared insolvent or downgraded by the Bank Regulator, or is placed on a Bank Regulator &#8220;watchlist&#8221;; or (b) the Bank Regulator repudiates the Letter of Credit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.6&#160;&#160;&#160;&#160;Landlord&#8217;s Ability to Draw</font><font style="font-family:inherit;font-size:12pt;">.  Subject to this Section&#160;28, if a Default of this Lease by Tenant has occurred beyond any applicable notice and cure period, including a failure to timely provide a replacement Letter of Credit, Landlord may, but will not be obligated to, draw on the Letter of Credit and apply the proceeds of any such draw to cure the Default of this Lease by Tenant or to apply such funds as otherwise permitted under this Section&#160;28.  Tenant will not have the right to call upon Landlord to draw upon all or any part of the Letter of Credit to cure any Default of this Lease by Tenant or to fulfill any obligation of Tenant, but instead, the decision to draw on the Letter of Credit will be solely in the discretion of Landlord.  The Letter of Credit will be payable to Landlord upon presentation at the Issuer&#8217;s offices of a sight draft signed by Landlord, together with a separate certification of Landlord:  (a) that the person signing the certification is duly authorized to do so, and (b) that (i) a default of this Lease by Tenant exists and has continued beyond any applicable notice and cure period under this Lease, (ii) Tenant has committed a default under this Lease and the transmittal of notice of such default is barred by applicable Laws, or (iii) Tenant has failed to deliver a replacement Letter of Credit to Landlord at least 30 days prior to the expiration date of the Letter of Credit.  Notwithstanding the foregoing, if the terms or requirements of the applicable Letter of Credit with respect to certifications, drafts or other documentation necessary for Landlord to draw on the Letter of Credit differ from that otherwise required by this Section&#160;28, then Landlord will only be required to comply with the terms of the Letter of Credit and will not be required to comply with the terms of this Section&#160;28 except to the extent consistent with the Letter of Credit.  Nothing in this Section&#160;28 will require Landlord to submit, or prohibit Landlord from submitting, partial draws of the Letter of Credit, it being acknowledged that Landlord may (but is in no way required to) draw the entire amount of the Letter of Credit to protect its interest in the funds resulting from such draw, provided that notwithstanding such right, the Letter of Credit will not be considered a security deposit upon Landlord&#8217;s receipt of such funds.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">28.7&#160;&#160;&#160;&#160;Return</font><font style="font-family:inherit;font-size:12pt;">.  Provided that Tenant has fully and faithfully performed all of its obligations under this Lease, if Landlord has not drawn on the Letter of Credit, Landlord will deliver the Letter of Credit to Tenant or the Issuer, as Tenant may direct, after the expiration of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.&#160;&#160;&#160;&#160;TERMINATION OPTION</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.1&#160;&#160;&#160;&#160;Grant of Option</font><font style="font-family:inherit;font-size:12pt;">.  Tenant shall have a one-time option to terminate this Lease with regard to all of the Premises subject to this Lease at the time of exercise (the &#8220;Termination Option&#8221;) pursuant to the provisions of this Section&#160;29.  If properly exercised, the termination of this Lease pursuant to the Termination Option shall be effective on the last day of Month&#160;96 of the Term of this Lease (the &#8220;Early Termination Date&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.2&#160;&#160;&#160;&#160;Conditions for Exercise</font><font style="font-family:inherit;font-size:12pt;">.  The Termination Option is granted on and subject to the following terms and conditions:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">54</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;No earlier than the first day of Month&#160;78 of the Term, but not later than the last day of Month&#160;84 of the Term, Tenant must give Landlord written notice of Tenant&#8217;s election to exercise the Termination Option; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;No Default exists either on the date that Tenant exercises the Termination Option or at any time thereafter up to and including the Early Termination Date; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Tenant pays to Landlord a fee equal to the sum of (i)&#160;the amount of Base Rent and Additional Rent that would have been due for Months 97 through 102 of the Term had this Lease not been terminated, plus (ii) the unamortized transaction costs incurred by Landlord in connection with this Lease for tenant improvement costs and leasing commissions, amortized at an annual interest rate of 10% over the Term (collectively, the &#8220;Termination Fee&#8221;).  After receipt of Tenant&#8217;s timely notice of election to exercise the Termination Option, Landlord will notify Tenant in writing of the amount of the Termination Fee.  Tenant will pay 50% of the Termination Fee within five business days after receipt of Landlord&#8217;s notice of the Termination Fee amount and the other 50% of the Termination Fee on the Early Termination Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.3&#160;&#160;&#160;&#160;Early Termination</font><font style="font-family:inherit;font-size:12pt;">.  If the conditions described in Section&#160;29.2 have been met, then this Lease will terminate on the Early Termination Date, whereupon Tenant will surrender the Premises in accordance with Section&#160;15.1 and both parties will thereafter be relieved of any obligations under this Lease that would otherwise have accrued subsequent to the Early Termination Date, except those that survive the expiration or early termination of this Lease.  Notwithstanding Tenant&#8217;s payment of the Termination Fee, all Rent will continue to be due as provided in Section&#160;3 through the Early Termination Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">29.4&#160;&#160;&#160;&#160;Limitations on Tenant&#8217;s Rights</font><font style="font-family:inherit;font-size:12pt;">.  Any assignment of this Lease or subletting of the Premises by Tenant (excluding an assignment that is a Permitted Transfer) terminates Tenant&#8217;s rights with respect to the Termination Option, unless Landlord consents to the contrary in writing at the time of such subletting or assignment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">30.&#160;&#160;&#160;&#160;RIGHT OF FIRST OFFER</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">30.1&#160;&#160;&#160;&#160;Terms of Right</font><font style="font-family:inherit;font-size:12pt;">.  If at any time during the Term, any office space in the 1751 Building, the 1801 Building, the 1851 Building and the office buildings located at 1601 and 1701 Harbor Bay Parkway, Alameda, California to the extent owned by Landlord (the &#8220;ROFO Space&#8221;) becomes available or is becoming available for lease, Landlord will notify Tenant in writing that such ROFO Space is available for lease or is becoming available, and such notice will set forth the terms upon which Landlord is willing to lease the ROFO Space to prospective tenants (the &#8220;Offer Notice&#8221;).  The ROFO Space shall not be deemed available or becoming available for lease to the extent (a) that it is subject to, or becomes subject to, any rights or options in favor of any other parties that are superior to Tenant&#8217;s with respect to the ROFO Space as of the Lease Date, and/or (b) the ROFO Space is subject to a then-existing lease, as such lease may be modified, amended, extended or renewed.  Provided that a Default does not then exist, and subject to the provisions of this Section&#160;30, Tenant will have 10 business days after the receipt of the Offer Notice in which to deliver a written notice to Landlord exercising Tenant&#8217;s right to lease all, but not less than all, of the ROFO Space subject to the applicable Offer Notice (the &#8220;ROFO Acceptance Notice&#8221;).  If Tenant delivers the ROFO Acceptance Notice to Landlord within such 10 business-day period, then Landlord and Tenant will promptly amend this Lease to include the ROFO Space on the terms stated in the Offer Notice.  If Tenant fails to deliver the ROFO Acceptance Notice within such 10 business-day period, Tenant will be deemed to have rejected the Offer Notice.  If Tenant rejects or is deemed to have rejected the Offer Notice, Tenant&#8217;s right of first offer with respect to the ROFO Space </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">55</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">which is the subject of the Offer Notice will terminate and be of no further force or effect, and Landlord will be free to lease any or all of the ROFO Space that is the subject of such Offer Notice to any prospective tenant at any time after the earlier of the date Tenant rejects the Offer Notice or the expiration of such 10 business day period; provided, however, if Landlord has not entered into a lease for all or any portion of such ROFO Space with a third party within 270&#160;days following the delivery by Landlord to Tenant of the Offer Notice, then, so long as Landlord is not engaged in good faith negotiations with a third party to lease all or a portion of such Offered Space, Landlord agrees that Tenant&#8217;s rights under this Section&#160;30 with respect to such ROFO Space shall be reinstated and Landlord shall provide Tenant with an Offer Notice if, as, and to the extent, required under the terms of this Section&#160;30.  Tenant&#8217;s right of first offer will be deemed a continuing right and will apply to each ROFO Space that becomes available or is becoming available for lease; provided, however, that, except as expressly provided in this Section&#160;30.1, upon Tenant&#8217;s rejection or deemed rejection of an Offer Notice, Tenant will have no rights under this Section&#160;30 with respect to the ROFO Space subject to such Offer Notice until after the expiration of the term of any lease (and any applicable renewals) by and between Landlord and a third party relating to such ROFO Space.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">30.2&#160;&#160;&#160;&#160;Limitations on Tenant&#8217;s Rights</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will have no right to lease any ROFO Space and its ROFO Acceptance Notice will be ineffective if a Default exists at the time such notice is given or at the time the amendment to this Lease is scheduled to be executed by Landlord and Tenant.  Any termination of this Lease terminates all rights under this Section&#160;30.  Any assignment or subletting by Tenant of this Lease or of all or a portion of the Premises (including a Permitted Transfer) terminates Tenant&#8217;s rights with respect to the ROFO Space, unless Landlord consents to the contrary in writing at the time of such subletting or assignment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.&#160;&#160;&#160;&#160;RENEWAL OPTIONS</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.1&#160;&#160;&#160;&#160;Grant of Rights</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the terms and provisions of this Section&#160;31, Tenant, at its option, may extend the Term of this Lease for a period of 60&#160;months at the end of the initial Term (the &#8220;First Renewal Term&#8221;) with respect to the Premises as it exists as of the last day of the Term (the &#8220;First Renewal Option&#8221;), and if Tenant exercises the First Renewal Option, Tenant may further extend the Term of this Lease for another period of 60&#160;months at the end of the First Renewal Term (the &#8220;Second Renewal Term&#8221;) with respect to the Premises as it exists as of the last day of the First Renewal Term (the &#8220;Second Renewal Option&#8221;).  The First Renewal Term and the Second Renewal Term will be referred to individually as a &#8220;Renewal Term&#8221; or, collectively, as the &#8220;Renewal Terms.&#8221;  The First Renewal Option and the Second Renewal Option will be referred to individually as a &#8220;Renewal Option&#8221; or, collectively, as the &#8220;Renewal Options.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.2&#160;&#160;&#160;&#160;Exercise</font><font style="font-family:inherit;font-size:12pt;">.  To exercise either such Renewal Option, Tenant must deliver notice of the exercise thereof (a &#8220;Renewal Notice&#8221;) to Landlord no earlier than 15&#160;months and no later than 9&#160;months prior to the expiration of the initial Term, with respect to the exercise of the First Renewal Option, and prior to the expiration of the First Renewal Term, with respect to the exercise of the Second Renewal Option.  Tenant&#8217;s delivery of a Renewal Notice will constitute Tenant&#8217;s irrevocable election to renew the Lease for the applicable Renewal Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.3&#160;&#160;&#160;&#160;Determination of Market Rental Rate</font><font style="font-family:inherit;font-size:12pt;">.  Within 10&#160;days after Tenant delivers a Renewal Notice, Landlord will notify Tenant in writing (the &#8220;Rate Notice&#8221;) of the &#8220;Market Rental Rate&#8221; (as defined below).  If Tenant agrees that the rental rate set forth in the Rate Notice is the Market Rental Rate, such rental rate will be the Market Rental Rate for the purposes of this Section&#160;31, and Base Rent for the applicable Renewal Term will be the Market Rental Rate.  If Tenant disagrees with the Market Rental Rate in the Rate Notice, then Tenant will have 30&#160;days after receipt of the Rate Notice to object </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">56</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to the rental rate in the Rate Notice by giving notice to Landlord.  If Tenant fails to object within such 30&#160;day period, Tenant will be deemed to have agreed that the Rate Notice contains the Market Rental Rate.  If Tenant timely notifies Landlord of Tenant&#8217;s objection to the rate set forth in the Rate Notice, then Landlord and Tenant will, for a period of 20&#160;days from and after Tenant gives its objection to the Rate Notice, negotiate to determine a Market Rental Rate acceptable to both Landlord and Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Parties&#8217; Brokers</font><font style="font-family:inherit;font-size:12pt;">.  If the parties are unable to agree upon the Market Rental Rate during such 20&#160;day period, then, within five business days after the expiration of such 20&#160;day period, Landlord and Tenant will each appoint their own licensed real estate broker who has at least 10&#160;years&#8217; full-time experience in commercial office and lab/research and development leasing in the Alameda, California market area (the &#8220;Parties&#8217; Brokers&#8221;).  The Parties&#8217; Brokers will negotiate in good faith for 10&#160;days after the date that both Parties&#8217; Brokers have been appointed to determine a Market Rental Rate acceptable to both Landlord and Tenant.  If the Parties&#8217; Brokers cannot reach agreement on the Market Rental Rate within such 10&#160;day period, then within five days after the expiration of such 10&#160;day period, Landlord will deliver to Tenant a written determination of the Market Rental Rate as determined by Landlord and its broker using the criteria set forth below (&#8220;Landlord&#8217;s Determination&#8221;).  Tenant will have five business days from the date of Landlord&#8217;s delivery of Landlord&#8217;s Determination to notify Landlord of Tenant&#8217;s acceptance of Landlord&#8217;s Determination or deliver to Landlord Tenant&#8217;s written determination of the Market Rental Rate using the criteria set forth below (&#8220;Tenant&#8217;s Determination&#8221;).  If Tenant does not deliver Tenant&#8217;s Determination to Landlord within such five business day period, Tenant will be deemed to have accepted Landlord&#8217;s Determination and the rental rate set forth in Landlord&#8217;s Determination will be the Market Rental Rate.  If Tenant does deliver Tenant&#8217;s Determination within such five business day period, then the Parties&#8217; Brokers will have an additional seven days from the date of delivery of Tenant&#8217;s Determination to negotiate a Market Rental Rate acceptable to both Landlord and Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Broker</font><font style="font-family:inherit;font-size:12pt;">.  If no agreement can be reached as to the Market Rental Rate within such seven day period, then, within five days after such seven day period expires, the Parties&#8217; Brokers shall cooperate to appoint a third broker (the &#8220;Third Broker&#8221;).  The Third Broker will be a person who has not previously acted in any capacity for either party and who meets the same experience qualifications as required for the Parties&#8217; Brokers.  If Parties&#8217; Brokers cannot agree on the Third Broker within such five-day period, either of the Parties&#8217; Brokers may submit a request to the Chairman of the Board of Governors of the California Commercial Brokers Association to appoint the Third Broker, and such appointment will be binding on Landlord, Tenant and the Parties&#8217; Brokers.  Within 10&#160;days of his or her appointment, the Third Broker will review Landlord&#8217;s Determination and Tenant&#8217;s Determination of the Market Rental Rate and such other information as he or she deems necessary and will select either Landlord&#8217;s Determination or Tenant&#8217;s Determination of the Market Rental Rate (but no other rate) as being more reasonable.  The Third Broker will be instructed, in deciding whether Landlord&#8217;s Determination or Tenant&#8217;s Determination is more reasonable, to use the criteria as to the Market Rental Rate set forth below.  The Third Broker will immediately notify the parties of his or her selection of the Landlord&#8217;s Determination or the Tenant&#8217;s Determination as being more reasonable, and then such selected determination will be the Market Rental Rate.  Each of the parties will bear the entire cost of their own broker and 1/2 of the cost of the Third Broker.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interim Rate</font><font style="font-family:inherit;font-size:12pt;">.  Notwithstanding anything in this Lease to the contrary, if no agreement can be reached as to the Market Rental Rate prior to the expiration of the Term, with respect to the exercise of the First Renewal Option, and/or prior to the expiration of the First </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">57</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Renewal Term, with respect to the exercise of the Second Renewal Option, Tenant shall pay Base Rent to Landlord in accordance with the rental rate set forth in Landlord&#8217;s Rate Notice (the &#8220;Interim Rate&#8221;) for the period (the &#8220;Interim Period&#8221;) beginning on the day immediately following the last day of the Term and/or the First Renewal Term, as applicable, and ending on the date the Market Rental Rate is determined pursuant to this Section&#160;31 (the &#8220;Determination Date&#8221;).  If the amount of Base Rent Tenant paid to Landlord during the Interim Period, prorated based on the number of days in such period (the &#8220;Interim Base Rent&#8221;), is more than the amount Tenant would have paid if the Market Rental Rate had been in effect during such Interim Period, Landlord will credit such excess amount against the next payment(s) of Base Rent due from Tenant to Landlord.  If the Interim Base Rent is less than the amount Tenant would have paid if the Market Rental Rate had been in effect during such Interim Period, Tenant will pay the deficiency to Landlord within 30&#160;days after the Determination Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.4&#160;&#160;&#160;&#160;Market Rental Rate Defined</font><font style="font-family:inherit;font-size:12pt;">.  &#8220;Market Rental Rate&#8221; means the prevailing renewal rate and periodic increases thereof, if any, then charged by landlords of similar buildings in the Alameda, California market area of comparable quality, amenities and age as the Building for similar space to tenants similar to Tenant in size, credit quality and stature, taking into account the length of the applicable Renewal Term, as well as the project amenities, views, parking ratios, concessions and inducements offered at comparable properties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.5&#160;&#160;&#160;&#160;After Exercise</font><font style="font-family:inherit;font-size:12pt;">.  During each Renewal Term, all of the terms and provisions of this Lease will apply, except that (a)&#160;after the Second Renewal Term there will be no further right of renewal; and (b)&#160;during each Renewal Term, Base Rent will be payable at the applicable Market Rental Rate, as determined pursuant to this Section&#160;31, multiplied by the rentable square feet of the Premises as of the commencement of the applicable Renewal Term.  The &#8220;Term&#8221; of this Lease will include any properly exercised Renewal Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">31.6&#160;&#160;&#160;&#160;Limitations on Tenant&#8217;s Rights</font><font style="font-family:inherit;font-size:12pt;">.  At Landlord&#8217;s option, Tenant will have no right to extend the Term, and Tenant&#8217;s Renewal Notice will be ineffective, if a Default exists at the time a Renewal Notice is given or at the time the applicable Renewal Term is scheduled to commence.  Any termination of this Lease terminates all rights under this Section&#160;31.  Any assignment of this Lease or subletting of Premises by Tenant (excluding an assignment that is a Permitted Transfer) terminates Tenant&#8217;s rights under this Section&#160;31, unless Landlord consents to the contrary in writing at the time of such subletting or assignment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">32.&#160;&#160;&#160;&#160;LANDLORD&#8217;S HVAC WORK AND ALLOWANCE</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">32.1&#160;&#160;&#160;&#160;Landlord&#8217;s HVAC Work</font><font style="font-family:inherit;font-size:12pt;">.  Landlord shall update the base building HVAC and boiler systems in the 1801 Building (the &#8220;1801 HVAC Systems&#8221;) by replacing the existing equipment listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;G</font><font style="font-family:inherit;font-size:12pt;">&#32;attached hereto (the &#8220;HVAC Equipment List&#8221;) in the 1801 Building with new, substantially similar equipment, which work will be referred to herein as &#8220;Landlord&#8217;s HVAC Work&#8221;.  Landlord will work with Tenant collaboratively to produce the plans and specifications for Landlord&#8217;s HVAC Work so that it is designed and constructed to maximize efficiency and meet the needs of Tenant.  Landlord shall perform Landlord&#8217;s HVAC Work in a good and workmanlike manner, in compliance with applicable Laws and in compliance with plans and specifications approved by Tenant, which approval shall not be unreasonably withheld, conditioned or delayed.  The parties acknowledge that the performance of Landlord&#8217;s HVAC Work will not affect the Start Dates or the Commencement Date as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">.  Tenant shall not be required to remove the 1801 HVAC Systems (or pay the costs therefor) at the expiration or earlier termination of the Lease.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">58</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Landlord and Tenant acknowledge that Landlord&#8217;s HVAC Work is anticipated to be conducted in accordance with a schedule to be agreed upon by Landlord and Tenant with Tenant&#8217;s Work in the 1801 Building.  Landlord may enter the 1801 Building to the extent necessary to perform Landlord&#8217;s HVAC Work.  Landlord will work in harmony with Tenant and use reasonable commercial efforts to avoid unreasonable interference with Tenant&#8217;s Work or Tenant&#8217;s operations during the performance of Landlord&#8217;s HVAC Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Tenant acknowledges that, despite Landlord&#8217;s efforts, Tenant may experience interference with and/or interruption of Tenant&#8217;s Work in the 1801 Building.  Unless caused by the negligence or intentional misconduct (including material noncompliance with Laws or plans and specifications approved by Tenant) of Landlord or its employees, Tenant will hold Landlord harmless from any and all claims, damages and liability against Landlord, either by Tenant or Tenant&#8217;s employees, customers, contractors, agents or invitees resulting from Landlord&#8217;s HVAC Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">32.2&#160;&#160;&#160;&#160;1801 HVAC Allowance</font><font style="font-family:inherit;font-size:12pt;">.  Landlord shall pay for the cost of Landlord&#8217;s HVAC Work up to a maximum of $600,000.00 (the &#8220;1801 HVAC Allowance&#8221;), and Tenant shall pay for Landlord&#8217;s HVAC Work to the extent that the cost of Landlord&#8217;s HVAC Work exceeds the 1801 HVAC Allowance within 30 days of Landlord&#8217;s request.  A condition precedent to Tenant&#8217;s reimbursement of the excess costs of Landlord&#8217;s HVAC Work will be that Tenant has received written notice from Landlord&#8217;s contractor (or other evidence satisfactory to Tenant) that Landlord&#8217;s HVAC Work has been completed.  Tenant will not be entitled to any credit if Landlord&#8217;s HVAC Allowance exceeds the cost of Landlord&#8217;s HVAC Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">32.3&#160;&#160;&#160;&#160;Completion of Landlord&#8217;s HVAC Work</font><font style="font-family:inherit;font-size:12pt;">.  Landlord will begin performing Landlord&#8217;s HVAC Work after the last Start Date for the 1801 Space (as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">) and use commercially reasonable efforts to complete Landlord&#8217;s HVAC Work on or before the Commencement Date.  If Landlord is unable to complete Landlord&#8217;s HVAC Work by such date, then Landlord will continue to use commercially reasonable efforts to complete Landlord&#8217;s HVAC Work as soon as reasonably feasible.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">32.4&#160;&#160;&#160;&#160;Title</font><font style="font-family:inherit;font-size:12pt;">.  Once installed, title in and to the 1801 HVAC Systems and all equipment related thereto will be vested in Landlord throughout the Term and upon expiration or earlier termination of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">33.&#160;&#160;&#160;&#160;TENANT&#8217;S HVAC WORK AND ALLOWANCE</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">33.1&#160;&#160;&#160;&#160;Tenant&#8217;s HVAC Work.  </font><font style="font-family:inherit;font-size:12pt;">As part of Tenant&#8217;s Work in the 1851 Space, Tenant shall update the base building HVAC and boiler systems in the 1851 Building (the &#8220;1851 HVAC Systems&#8221;) by replacing the existing equipment listed on the HVAC Equipment List in the 1851 Building with new, substantially similar equipment, which work shall be referred to herein as &#8220;Tenant&#8217;s HVAC Work.&#8221;  Tenant will work with Landlord collaboratively to produce the plans and specifications for Tenant&#8217;s HVAC Work so that it is designed and constructed to maximize efficiency and meet the needs of Tenant.  Tenant and &#8220;Contractor&#8221; (as defined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">) shall perform or cause to be performed Tenant&#8217;s HVAC Work in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">, including, without limitation, Paragraphs 10 through 14 of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">.  Tenant may begin performing Tenant&#8217;s HVAC Work after the last Start Date for the 1851 Space (as set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">) and use commercially reasonable efforts to complete Tenant&#8217;s HVAC Work on or before the Commencement Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">33.2&#160;&#160;&#160;&#160;1851 HVAC Allowance</font><font style="font-family:inherit;font-size:12pt;">.  Throughout the Term, Tenant will be solely responsible for all costs and expenses incurred in updating, operating, maintaining, repairing and replacing the 1851 HVAC </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">59</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Systems in accordance with Section&#160;5; provided, however, that Landlord will pay for the cost of Tenant&#8217;s HVAC Work up to a maximum of $600,000.00 (&#8220;1851 HVAC Allowance&#8221;), and Tenant shall pay for Tenant&#8217;s HVAC Work to the extent that the cost of Tenant&#8217;s HVAC Work exceeds the 1851 HVAC Allowance.  A condition precedent to Landlord&#8217;s payment of the 1851 HVAC Allowance will be that Landlord has received from Tenant the following: (a)&#160;written notice from Contractor (or other evidence satisfactory to Landlord) that Tenant&#8217;s HVAC Work has been completed; (b)&#160;final and unconditional lien waivers from Contractor and all subcontractors, suppliers, materialmen and other parties who performed labor at, or supplied materials to, the 1851 Building in connection with Tenant&#8217;s HVAC Work.  Tenant will not be entitled to any credit if the 1851 HVAC Allowance exceeds the cost of Tenant&#8217;s HVAC Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">33.3&#160;&#160;&#160;&#160;Title and Liability</font><font style="font-family:inherit;font-size:12pt;">.  Without limiting Tenant&#8217;s obligations under this Section&#160;33, once installed, title in and to the 1851 HVAC Systems and all equipment related thereto will be Tenant&#8217;s property throughout the Term of this Lease and shall automatically become Landlord&#8217;s property upon termination of this Lease, or termination of Tenant&#8217;s right to possession of the 1851 Space, without compensation to Tenant.  Subject to this Section&#160;33 and except to the extent caused by the willful misconduct or grossly negligent act or omission by Landlord, to the fullest extent permitted by applicable laws, codes, rules and regulations, Tenant will indemnify and hold Landlord, its affiliates, its property manager and their respective managers, members, officers, directors, employees and agents harmless from and against any and all claims, costs and liabilities (including reasonable attorneys&#8217; fees) arising out of or in connection with Tenant&#8217;s installation, use, operation, maintenance, repair and replacement of the 1851 HVAC Systems.  This Section&#160;33 will survive the expiration or earlier termination of the Term.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">(Signatures on the Following Page)</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">60</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Having read and intending to be bound by the terms and provisions of this Lease, Landlord and Tenant have signed it as of the Lease Date.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.55102040816327%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TENANT:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LANDLORD:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXELIXIS, INC.,</font></div><div style="padding-bottom:48px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Delaware corporation</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Michael M. Morrissey</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Printed Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Michael M. Morrissey, Ph.D.</font></div><div style="padding-bottom:24px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">President and CEO</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">And By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Christopher J. Senner</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Printed Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Christopher J. Senner</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EVP and CFO</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ASCENTRIS 105, LLC, </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;">a Colorado limited liability company</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Gabe L. Finke</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Printed Name: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Gabe L. Finke</font></div><div style="padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manager</font></div><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">5/2/2017</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="sB6BEA69B9B9A43C8FBBF99F6DFDFDE43"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;A</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PLAN DELINEATING THE PREMISES AND TENANT MAINTAINED OUTDOOR AREAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ex101170630image1a03.jpg" alt="ex101170630image1a03.jpg" style="height:454px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ex101170630image2a02.jpg" alt="ex101170630image2a02.jpg" style="height:437px;width:577px;"><img src="ex101170630image3a02.jpg" alt="ex101170630image3a02.jpg" style="height:414px;width:558px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A-2</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ex101170630image4a02.jpg" alt="ex101170630image4a02.jpg" style="height:425px;width:562px;"><img src="ex101170630image5a02.jpg" alt="ex101170630image5a02.jpg" style="height:429px;width:570px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A-3</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ex101170630image6a02.jpg" alt="ex101170630image6a02.jpg" style="height:665px;width:408px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A-4</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TENANT MAINTAINED OUTDOOR AREAS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ex101170630image7a02.jpg" alt="ex101170630image7a02.jpg" style="height:398px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A-5</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s13D3D5974288C40200F999F6E012C2BF"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;B</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">POSSESSION AND LEASEHOLD IMPROVEMENTS EXHIBIT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Conflicts; Terms.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If there is any conflict or inconsistency between the provisions of the Lease Agreement to which this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">&#32;is attached and those of this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:inherit;font-size:12pt;">&#32;(&#8220;Work Letter&#8221;), the provisions of this Work Letter will control.  Except for those terms expressly defined in this Work Letter, all initially capitalized terms will have the meanings stated for such terms in the Lease.  The following terms, which are not defined in the Lease, have the meanings indicated:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#8220;Commencement Date&#8221; with respect to the Premises means the first day of the Term, which will be six months after the last Start Date for the entire Premises (other than the Temporary Space).  Notwithstanding the foregoing, if Tenant takes possession of any part of the Premises (other than the Temporary Space) for the conduct of business prior to the Commencement Date, Tenant will pay Landlord Base Rent according to Section&#160;3.1 at the rates applicable to Months 1 &#8211; 12 of the Term of the Lease (not including the Rent Abatement) and Additional Rent according to Section&#160;3.2, prorated for the time and portion of the Premises so occupied.&#160; No early occupancy will change the Commencement Date or the Expiration Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#8220;Start Date&#8221; with respect to each portion of the Premises means the date that Landlord will &#8220;Deliver&#8221; (as defined in Section&#160;1.3(h) of the Lease) such portion to Tenant, unless the applicable Start Date is extended according to Paragraph&#160;2 below.  The estimated Start Dates are as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:102px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.84615384615384%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:39%;"></td><td style="width:61%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Premises</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Start Date</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1751 Space</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Temporary Space &#8211; Suite 225</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lease Date</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1801 Space</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 200</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 210</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 150</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5 days after Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 175</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within five business days after the relocation of BizWorld, estimated to be four months after the Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 100</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within five business days after the relocation of Metaswitch, estimated to be four months after the Lease Date</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1851 Space</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 200</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 210</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within five business days after the vacation of PINC Solutions, estimated to be June 1, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 1000</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 125</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within five business days after the vacation of AbsolutData, estimated to be 45 days after the Lease Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Suite 150</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lease Date</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#8220;Temporary Space Period&#8221; is defined in Section&#160;1.1(d)(i) of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#8220;Tenant Finish Period&#8221; means with respect to each portion of the Premises, the period beginning on the Start Date applicable to such portion and ending on the Commencement Date applicable to such portion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#8220;Submission Date&#8221; means July&#160;31, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#8220;Landlord&#8217;s Representative&#8221; means Jones Lang LaSalle Americas, Inc. and NV5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Representative&#8221; means Dana Aftab.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Architect&#8221; means DGA, or such other licensed or registered professional architect, designer or space planner as may be selected by Tenant and reasonably approved by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Engineers&#8221; means the licensed or registered professional engineers selected by Tenant and reasonably approved by Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)&#160;&#160;&#160;&#160;&#8220;Maximum Allowance Amount&#8221; means $5,539,150.00 (which is approximately $50.00 per rentable square foot);  provided, however, that if Tenant elects to complete Tenant&#8217;s Work on a multi-phase basis, Landlord will advance the applicable </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">prorated portion of the Maximum Allowance Amount based on the area of the portion of the Premises in each such phase.  In addition to the Maximum Allowance Amount, Landlord, at its sole cost and expense, will pay up to $15,000.00 for two initial test plans for the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)&#160;&#160;&#160;&#160;&#8220;Leasehold Improvements&#8221; means all alterations, leasehold improvements and installations to be constructed or installed by Landlord or Tenant in the Premises according to this Work Letter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)&#160;&#160;&#160;&#160;&#8220;Landlord&#8217;s Work&#8221; means those Leasehold Improvements to be constructed or installed by Landlord according to Paragraph&#160;4 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Work&#8221; means all Leasehold Improvements other than Landlord&#8217;s Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)&#160;&#160;&#160;&#160;&#8220;Preliminary Plans&#8221; means space plans and general specifications for Tenant&#8217;s Work prepared by Tenant&#8217;s Architect in such form (and on such scale in the case of plans and drawings) as Landlord may reasonably specify.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)&#160;&#160;&#160;&#160;&#8220;Construction Documents&#8221; means complete construction plans and specifications for Tenant&#8217;s Work prepared by Tenant&#8217;s Architect and Tenant&#8217;s Engineers in such form (and on such scale in the case of plans and drawings) as Landlord may reasonably specify and detailing all aspects of Tenant&#8217;s Work, including, without limitation, the location of libraries, safes and other heavy objects, stairwells, walls, doors, computer equipment, telephone and related equipment, and electrical, plumbing, heating, ventilation and air conditioning equipment (including equipment in excess of that required for normal use).  Tenant&#8217;s Engineers will perform all mechanical and electrical design work included in the Construction Documents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)&#160;&#160;&#160;&#160;&#8220;Tenant&#8217;s Costs&#8221; means all costs required to be expended by Tenant under this Work Letter in connection with Tenant&#8217;s Work, including, without limitation, the costs of:  preparing the Preliminary Plans, Construction Documents and the as-built plans described in Paragraph&#160;8; performing Tenant&#8217;s Work; obtaining all required insurance, licenses and permits; satisfying all requirements of Laws; letting all contracts; all services provided by or for Landlord under Paragraph&#160;14; the costs of Tenant&#8217;s construction manager, if any; all required electrical and telephone panels and/or meters; and Landlord&#8217;s construction management fee (as described in Paragraph&#160;14 below.  Tenant&#8217;s Costs will not, however, include any costs incurred by Tenant for furniture or other personal property, for fixtures or equipment (unless such fixtures or equipment will constitute permanent additions to the Premises and are shown on the Construction Documents), or for moving to the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Tenant Finish Period.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The Tenant Finish Period with respect to each portion of the Premises will begin on the applicable Start Dates specified in Paragraph&#160;1(b) above with respect to each portion of the Premises identified there, unless such Start Dates are extended according to the following provisions.  If on or before the applicable Start Date specified in Paragraph&#160;1(b), (i)&#160;Landlord&#8217;s Work has not been completed in the applicable portion of the Premises to the extent </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">that Tenant&#8217;s Work may begin (except for any Landlord&#8217;s Work which has been delayed, hindered or prevented by Tenant); or (ii)&#160;Tenant has not been permitted entry to the applicable portion of the Premises for the conduct of Tenant&#8217;s Work, then such Start Date will be extended until the date on which both such events have occurred; provided, however, that Landlord shall have no other liability to Tenant for its failure to deliver a portion of the Premises to Tenant on the applicable Start Date if such delay is caused by a tenant&#8217;s holding over in a portion of the Premises, so long as Landlord is using commercially reasonable efforts to cause such tenant to vacate the portion of the Premises, which commercially reasonable efforts shall include filing an unlawful detainer action if such holdover continues for a period in excess of 30 days.  If the Start Date for a specified portion of the Premises has not occurred within 120&#160;days after the date specified in Paragraph&#160;1(b), then Tenant will have the right to terminate the Lease with respect to such undelivered portion of the Premises (the &#8220;Terminated Space&#8221;) by delivering written notice of termination to Landlord not more than 30&#160;days after the end of such 120&#8209;day period.  Upon such termination, each party will, upon the other&#8217;s request, execute and deliver an agreement in recordable form containing a release and surrender of all right, title and interest in and to the Terminated Space or the Premises as a whole, as applicable; neither Landlord nor Tenant will have any further obligations to each other with respect to the Terminated Space or the Premises as a whole, as applicable, including, without limitation, any obligations to pay for work previously performed in the Terminated Space or the Premises as a whole, as applicable; all improvements to the Terminated Space will become and remain the property of Landlord; Landlord will refund to Tenant any sums paid to Landlord by Tenant for the Terminated Space or the Premises as a whole, as applicable, in connection with the Lease; and the Letter of Credit shall be terminated or returned to Tenant, if the Lease is terminated in its entirety.  Such postponement of a Start Date and the Commencement Date and such termination and refund right, will be Tenant&#8217;s sole and exclusive remedies for Landlord&#8217;s failure to deliver any portion of the Premises by the dates described above, and Tenant expressly waives any other rights, claims or remedies that Tenant might otherwise have against Landlord by reason of Landlord&#8217;s failure to deliver any portion of the Premises or any delay in commencing or completing any of Landlord&#8217;s Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Representatives.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Landlord appoints Landlord&#8217;s Representative to act for Landlord in all matters covered by this Work Letter.  Tenant appoints Tenant&#8217;s Representative to act for Tenant in all matters covered by this Work Letter.  All inquiries, requests, instructions, authorizations and other communications with respect to the matters covered by this Work Letter will be made to Landlord&#8217;s Representative or Tenant&#8217;s Representative, as the case may be.  Tenant will not make any inquiries of or requests to, and will not give any instructions or authorizations to, any other employee or agent of Landlord, including Landlord&#8217;s architect, engineers and contractors or any of their agents or employees, with regard to matters covered by this Work Letter.  Either party may change its Representative under this Work Letter at any time by three days&#8217; prior written notice to the other party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Landlord&#8217;s Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Landlord, at its expense and as Landlord&#8217;s Work, will complete in or for the Premises, in a good and workmanlike manner and according to all Laws, the following:  None (other than Landlord&#8217;s HVAC Work in accordance with Section&#160;32 of the Lease).</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord will pay for the design costs associated with Landlord&#8217;s Work; provided that to the extent Landlord&#8217;s Work requires design information (such as heating or air conditioning load factors) that would be prepared in connection with the preparation of the Preliminary Plans or the Construction Documents, Tenant will be responsible for the cost of such design information.  The Premises will be delivered to Tenant when Landlord has substantially completed Landlord&#8217;s Work, subject only to completion of minor construction details which would not materially interfere with Tenant&#8217;s Work, and Tenant will accept the Premises upon notice from Landlord that Landlord&#8217;s Work has been substantially completed.  Landlord and Tenant agree that all alterations, improvements and additions made to the Premises according to this Work Letter, whether paid for by Landlord or Tenant, will, without compensation to Tenant, become Landlord&#8217;s property upon installation and will remain Landlord&#8217;s property at the expiration or earlier termination of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Landlord&#8217;s Punch List.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Upon substantial completion of Landlord&#8217;s Work, Landlord&#8217;s Representative and Tenant&#8217;s Representative will inspect the Premises and prepare and sign a punch list identifying all items of Landlord&#8217;s Work which require correction or completion.  Landlord will, within 10 days after execution of such punch list, begin correction or completion of any items identified on such punch list and will complete such work in a prompt and diligent manner.  Landlord will not be responsible for any items of damage caused by Tenant, its agents, independent contractors or suppliers.  Except for any items identified on such punch list, and except for any latent defects in Landlord&#8217;s Work in a specified portion of the Premises of which Tenant notifies Landlord within one year after the Commencement Date applicable to such portion of the Premises, Tenant&#8217;s taking possession of any portion of the Premises will be conclusive evidence that such portion of the Premises was in good order and satisfactory condition when Tenant took possession.  No promises to alter, remodel or improve the Premises or Building and no representations concerning the condition of the Premises or Building have been made by Landlord to Tenant other than as may be expressly stated in the Lease (including this Work Letter).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Early Access.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Tenant will not be entitled to exclusive possession of portions of the Premises until Landlord&#8217;s Work is completed in such portions.  Landlord shall permit Tenant to enter certain portions of the Premises at least 30 days prior to the applicable Start Date so that Tenant may do such work as may be required to prepare the Premises for Tenant&#8217;s Work.  If Tenant makes such entry prior to the Start Date, Tenant will work in harmony with Landlord and will not interfere with the performance of Landlord&#8217;s Work, or with the work of any other tenant or occupant.  If at any time such access causes or threatens to cause disharmony or interference, including labor disharmony, Landlord will have the right to immediately terminate such early access.  At all times when Tenant enters any portion of the Premises prior to the Commencement Date (including the Tenant Finish Period) applicable to such portion, Tenant will be subject to and will comply with all of the terms and provisions of the Lease, except that no Base Rent or Costs will be payable by Tenant prior to such applicable Commencement Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Landlord&#8217;s Approval.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All Preliminary Plans and Construction Documents, and any revisions to the same (whether in the form of a change order or otherwise) are expressly subject to Landlord&#8217;s prior written approval, which shall not be unreasonably withheld, conditioned or delayed.  Landlord may engage architects and/or engineers as it deems reasonably necessary to review the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-5</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Preliminary Plans and Construction Documents and advise Landlord with respect to such approval.  Landlord may withhold its approval of any such items that require work which:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;exceeds or adversely affects the capacity or integrity of the Building&#8217;s structure or any of its heating, ventilating, air conditioning, plumbing, mechanical, electrical, communications or other systems;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;is not approved by the holder of any Encumbrance, if such approval is required;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;would not be approved by a prudent owner of property similar to the Building;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;violates any agreement which affects the Building or binds Landlord;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Landlord reasonably believes will substantially increase the cost of operating or maintaining any of the Building&#8217;s systems;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;Landlord reasonably believes will materially reduce the market value of the Premises or the Building at the end of the Term;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;does not conform to applicable building code or is not approved by any governmental authority having jurisdiction over the Premises;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)&#160;&#160;&#160;&#160;does not meet or exceed Building Standard; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Landlord reasonably believes will infringe on the architectural integrity of the Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Tenant&#8217;s Plans.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;On or before the Submission Date, Tenant, at its expense, will cause the Preliminary Plans to be prepared and submitted to Landlord for its approval, which shall not be unreasonably withheld, conditioned or delayed.  Landlord, at its sole cost and expense, will pay up to $15,000.00 for two initial test plans for the Premises.   If the submitted materials are not acceptable to Landlord, Landlord will so notify Tenant by returning the Preliminary Plans with required changes noted within 10 business days following Landlord&#8217;s receipt.  If Landlord so notifies Tenant of any required change to the Preliminary Plans, Tenant will cause the same to be revised according to the returned Preliminary Plans and resubmitted to Landlord.  After Landlord notifies Tenant of Landlord&#8217;s approval of the Preliminary Plans, Tenant, at its expense, will cause, using commercially reasonable efforts, the Construction Documents to be prepared and submitted to Landlord for its approval, which shall not be unreasonably withheld, conditioned or delayed.  Such submittal will include a complete color and finish board for Tenant&#8217;s Work.  The Construction Documents must substantially conform to the Preliminary Plans approved by Landlord and must be in all respects sufficient for the purpose of obtaining a building permit for Tenant&#8217;s Work.  If required by Landlord, Tenant will cause the Construction Documents to be resubmitted to Landlord for its approval after Landlord notifies Tenant of any required changes.  Tenant&#8217;s Work will not commence prior to Landlord&#8217;s approval of the Construction Documents.  If Landlord fails to deliver to Tenant Landlord&#8217;s written approval or its written request for revisions within 15 days after Landlord receives </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-6</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">any submittal by Tenant of Preliminary Plans, Construction Documents or any required revisions to them, or Tenant&#8217;s request for approval of its Contractor (defined below in Section&#160;11) Tenant will receive a credit against Base Rent beginning on the first day of the Term equal to one day&#8217;s Base Rent for each day subsequent to the 15th day after Tenant&#8217;s submittal until the day of Landlord&#8217;s response.  Except as provided in Paragraph 2 above, no delays in the design or performance of Tenant&#8217;s Work will change the applicable Start Dates or the Commencement Date with respect to any of various portions of the Premises.  Upon completion of Tenant&#8217;s Work in the Premises as a whole, Tenant will provide Landlord a complete set of reproducible as-built plans of the Premises.  If Tenant fails to provide such plans, Landlord may obtain them, directly or by field verification, and charge Tenant for all costs incurred by Landlord in doing so.  No approval by Landlord of the Preliminary Plans, the Construction Documents or any revisions to them will constitute a representation or warranty by Landlord or its architects or engineers as to the adequacy or sufficiency of such plans, or the improvements to which they relate, for any use, purpose or condition, but such approval will merely be the consent of Landlord to the construction or installation of improvements in the Premises according to such plans.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Tenant&#8217;s Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;During the Tenant Finish Period, Tenant, at its expense (but subject to reimbursement from the Allowance), will construct or cause to be constructed in the Premises all of Tenant&#8217;s Work according to the Construction Documents approved by Landlord.  Tenant, at its expense (but subject to reimbursement from the Allowance), will obtain: (i) all permits (including, without limitation, building permits) required for construction of Tenant&#8217;s Work; (ii) all contracts and insurance required under this Work Letter; and (iii) all certificates required for occupancy of the Premises from the appropriate governmental authorities.  Tenant will cause all Tenant&#8217;s Work to be diligently completed in a good and workmanlike manner, according to the approved Construction Documents and all Laws, and free and clear of any liens or claims for liens.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Tenant&#8217;s Contractor.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Landlord will have the right to approve Tenant&#8217;s contractor (&#8220;Contractor&#8221;) and all subcontractors, which approvals will not be unreasonably withheld, conditioned or delayed.  Landlord will provide Tenant with a list of contractors and subcontractors that are acceptable to Landlord.  Tenant may select its Contractor and subcontractors from such list or may request Landlord&#8217;s approval of a Contractor or subcontractors not on such list.  Tenant will not execute any contract for the performance of Tenant&#8217;s Work until Landlord&#8217;s approvals of the Contractor and subcontractors have been obtained, and Tenant will cause its proposed Contractor and subcontractors (if the proposed Contractor or subcontractors are other than those set forth on such list) to submit such information, including financial information, as may be reasonably required by Landlord to determine whether such Contractor and subcontractors should be approved.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;Construction Contract.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Tenant&#8217;s construction contract for Tenant&#8217;s Work  will provide (and Tenant will deliver a copy of it to Landlord so that Landlord may confirm it provides) that:  (i)&#160;construction of Tenant&#8217;s Work will not interfere with Landlord&#8217;s or Landlord&#8217;s tenants&#8217; activities in, or use or enjoyment of, any of the Buildings, as determined by Landlord in good faith; (ii) Contractor will cooperate with other contractors in the Buildings in a commercially reasonable manner to insure harmonious working relationships, including, without limitation, coordinating with other contractors in the Buildings concerning use of elevators, trash removal and water and utility usage; (iii)&#160;Contractor will leave all Common Areas in a neat, clean, orderly and safe condition </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-7</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">at the end of each day during construction of Tenant&#8217;s Work; (iv) Contractor will procure and maintain, and will cause its subcontractors to procure and maintain the insurance and to execute such documents evidencing such obligation to procure and maintain such insurance, as described in Paragraph&#160;12 below; (v) upon completion of Tenant&#8217;s Work, Contractor will provide to Landlord and Tenant as-built drawings together with mechanical balance reports and any maintenance manuals on equipment installed in the Premises as part of Tenant&#8217;s Work; (vi) any purchased materials remaining after completion of the subject portion of Tenant&#8217;s Work (such as, for example, extra paint, wall coverings or carpet) will be given by Contractor to Tenant for use in subsequent repairs; and (vii) all labor and material supplied according to the contract will be fully warranted by Contractor for a period of not less than one year from substantial completion of Tenant&#8217;s Work and such warranty will provide that it is for the benefit of both Landlord and Tenant and may be enforced by either.  The construction contract will also contain the following indemnification and defense provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;To the fullest extent permitted by law, Contractor will indemnify, defend and hold harmless Ascentris 105, LLC, a Colorado limited liability company, and its successors, assigns, property manager, partners, managers, members, officers and directors, subsidiaries, affiliates, employees and agents (collectively, the &#8220;Indemnitees&#8221;) from and against any and all claims, damages, losses and expenses, including, but not limited to, attorneys&#8217; fees, arising out of or resulting from performance of the work contemplated by this contract by Contractor or any of its subcontractors, except that the foregoing will not apply to any Indemnitee to the extent such Indemnitee&#8217;s negligence caused such claim, damage, loss or expense.  Such obligations will not be construed to negate, abridge or otherwise reduce any other right or obligation of indemnity which would otherwise exist as to any party or person described in this paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Contractor agrees to protect, defend, hold harmless and indemnify the Indemnitees from and against any and all claims, actions, liabilities, damages, losses, costs and expenses (including attorneys&#8217; fees) arising out of or resulting from Contractor&#8217;s failure to purchase all insurance required under Paragraph&#160;12 of the Possession and Leasehold Improvements Agreement attached to and made a part of the Lease Agreement dated ____</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">[insert date of Lease]</font><font style="font-family:inherit;font-size:12pt;">_____ between Ascentris 105, LLC, a Colorado limited liability company, and Exelixis, Inc., a Delaware corporation, and from Contractor&#8217;s failure to require and obtain proper insurance coverage from its subcontractors.  In any and all claims against the Indemnitees or any employee of Contractor or anyone directly or indirectly employed by it or anyone for whose acts it may be liable, the indemnification obligation under this provision will not be limited in any way by any limitation on the amount or type of damages, compensation or benefits payable by or for Contractor or any subcontractor under Workers&#8217; or Workmen&#8217;s Compensation Acts, disability benefit acts, or other employee benefit acts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The indemnification and defense obligations stated above will not apply to any claims, actions, liabilities, damages, losses, costs or expenses caused directly by the negligence or intentional tortious acts of the Indemnitees.&#8221;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-8</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;Contractor&#8217;s Insurance.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Contractor&#8217;s insurance or such insurance carried by Contractor&#8217;s subcontractors or sub-subcontractors pursuant to this Work Letter will be primary and non-contributory insurance over any insurance carried by Landlord.  Beginning on the Start Date and thereafter during the Term of the Lease, and for such additional time as may be further required, Tenant will cause Contractor to provide, pay for, and maintain in full force and effect, the insurance outlined herein, covering claims arising out of or in connection with the work or service performed by or on behalf of Contractor for Tenant.  Further, Tenant will cause Contractor and any and all subcontractors and sub&#8209;subcontractors to execute documentation satisfactory to Landlord, whereby each such subcontractor and/or sub&#8209;subcontractors will agree to maintain such types of insurance with limits required by Landlord during the entire period that they conduct any work in the Premises, and to provide proof of such insurance in a form satisfactory to Landlord.  Contractor will cause all subcontracts and sub-subcontracts to include these provisions (with applicable insurance limits) and to provide evidence thereof to Landlord promptly after request.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Commercial General Liability.  Contractor will maintain commercial general liability insurance covering all operations by or on behalf of Contractor on an occurrence basis against claims for bodily injury, property damage, and personal injury.  Such insurance will provide minimum limits and coverage as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Minimum Limits.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1,000,000 Each Occurrence (Combined Single Limit Bodily Injury and Property Damage);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2,000,000 General Aggregate per project site; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$2,000,000 Products / Completed Operations Aggregate.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;Coverages.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Products and Completed Operations coverage maintained for at least 3 years from completion of work or warranty period, whichever is greater;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Insured status including Products and Completed Operations:  Landlord, its partners, managers, members, officers and directors, employees, agents, subsidiaries, affiliates and Property Manager;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insured status for Landlord if Additional Insured status is not available for Products and Completed Operations coverage;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">D)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Subrogation in favor of Landlord and Property Manager; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">E)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subcontractor exception to their work exclusion.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-9</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;Unacceptable Exclusions.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Residential (if applicable)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Condominiums or condominium conversions (if applicable)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EIFS (if applicable)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">D)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subsidence exclusion</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">E)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Damage to work performed by subcontractors on Contractor&#8217;s behalf (e.g. CG 22 94 or CG 22 95)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">F)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Known loss</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">G)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Design professionals</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Automobile Liability.  Contractor will maintain business auto liability covering liability arising out of any auto (including owned, hired and non-owned autos).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Minimum Limits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;$1,000,000 Combined Single Limit Each Accident.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;Coverages.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Insured: Landlord, its partners, managers, members, officers and directors, employees, agents, subsidiaries, affiliates and Property Manager; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Subrogation in favor of Landlord and Property Manager.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Workers Compensation.  Contractor will maintain workers compensation and employers liability insurance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Minimum Limits.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Workers Compensation:  Statutory Limits; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Employers Liability:  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:240px;"><font style="font-family:inherit;font-size:11pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Bodily Injury for Each Accident:  $1,000,000;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:240px;"><font style="font-family:inherit;font-size:11pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Bodily Injury by Disease for  Each Employee:  $1,000,000; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:288px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:240px;"><font style="font-family:inherit;font-size:11pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Bodily Injury Disease Aggregate:  $1,000,000.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Coverage</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-10</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Subrogation in favor of Landlord and Property Manager.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Umbrella/Excess Liability.  Contractor will maintain umbrella/excess liability insurance as shown below.  The insurance will be on an occurrence basis in excess of the underlying insurance described in Paragraphs&#160;12(a), 12(b), 12(c)(i)B) and will be at least as broad as each and every one of the underlying policies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Minimum Limits.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Greater of $5,000,000 or Total Hard Costs of Contract per Occurrence</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:240px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:192px;"><font style="font-family:inherit;font-size:12pt;">B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Greater of $5,000,000 or Total Hard Costs of Contract Aggregate</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Property Insurance</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Contractor and any subcontractor or sub-subcontractor will maintain property insurance covering all personal property, materials and equipment that are used in connection to this Lease.  If Contractor or any of its subcontractors or sub-subcontractors elects not to carry this insurance, Landlord&#8217;s property insurance will not cover Contractor&#8217;s or any subcontractor&#8217;s or sub-subcontractor&#8217;s personal property, materials or equipment including scaffolding, and Contractor, for itself and its subcontractors and sub-subcontractors, hereby waives all claims against Landlord and Property Manager on account of any loss or damage to personal property, materials, equipment or scaffolding used or stored on the property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;Proof of Insurance.  Prior to execution of this Lease, or before Contractor performs work at or on the Premises or delivers supplies or materials to the Building, whichever comes first, Contractor will furnish, and will cause the applicable subcontractors and sub&#8209;subcontractors to furnish, Property Manager with certificates of insurance evidencing the types of coverage outlined above, and with regard to the subcontractors and sub&#8209;subcontractors, with the limits required by Landlord, and all in compliance with the Other Insurance Provisions outlined below.  Neither Contractor nor any subcontractor will have the right to enter the Premises or perform any of Tenant&#8217;s Work unless and until appropriate certificates of insurance and other related documentation, as requested by Landlord and/or Property Manager, has been delivered to Property Manager.  Insurance is to be placed with insurers with a Best&#8217;s rating of no less than A-IX.  No such policy will be cancelable, non-renewed or modified except after 30&#160;days&#8217; written notice to Property Manager.  Except for the provisions of Paragraph&#160;12(a)(ii)A) hereof, Contractor will maintain all of the foregoing insurance coverages in full force and effect until the work or service under this Agreement is fully completed.  The requirements for carrying the foregoing insurance will not release Contractor from the provision for indemnification of Landlord by Contractor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;Other Insurance Provisions.  Contractor will name, will cause its subcontractors and sub-subcontractors to name and will cause the applicable contracts with </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-11</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such subcontractors and sub-subcontractors to provide that each such subcontractor and sub-subcontractor will name, Landlord, Landlord&#8217;s partners, managers, members, officers and directors, employees, agents, subsidiaries, affiliates and the Property Manager as additional insureds with respect to liability arising out of the activities performed by or on behalf of Contractor or its subcontractors or sub-subcontractors on all policies carried by Contractor and/or Contractor&#8217;s subcontractors or sub-subcontractors, except Workers Compensation.  Contractor&#8217;s and its subcontractor&#8217;s and sub-subcontractor&#8217;s Workers&#8217; Compensation insurers will agree to waive all rights of subrogation against Landlord, its partners, managers, members, officers and directors, employees and agents, subsidiaries and affiliates and Property Manager, for losses arising from work or activities performed by Contractor or its subcontractor or sub-subcontractor, as applicable.  All liability insurance policies carried by Contractor will include provisions for contractual liability coverage insuring Contractor for the performance of its indemnity obligations set forth herein.  Contractor is solely responsible for causing its subcontractors and sub-subcontractors to obtain the types of insurance and applicable coverages set forth herein.  It is expressly understood and agreed that the coverages required represent Landlord&#8217;s minimum requirements and such are not to be construed to void or limit Contractor&#8217;s indemnity obligations contained in this Work Letter.  Neither (i)&#160;the insolvency, bankruptcy or failure of any insurance company covering Contractor or its subcontractors or sub-subcontractors, (ii)&#160;the failure of any insurance company to pay claims occurring nor (iii)&#160;any exclusion from or insufficiency of coverage will be held to affect, negate or waive any of Contractor&#8217;s indemnity obligations set forth herein or under any other provision of this Work Letter.  The amount of liability insurance under insurance policies maintained by Contractor or any of its subcontractors or sub-subcontractors will not be reduced by the existence of insurance coverage under policies separately maintained by Landlord.  Contractor and each of its subcontractors and sub-subcontractors will be solely responsible for any premiums, assessments, penalties, deductible assumptions, retentions, audits, retrospective adjustments or any other kind of payment due under their respective policies.  The entry by Contractor or any subcontractor or sub-subcontractor onto, or the performance of any work by Contractor or any subcontractor or sub-subcontractor in, the Premises without delivering the required certificates and/or other evidence of insurance, will not constitute a waiver of the obligations of Contractor or the applicable subcontractor or sub-subcontractor (as the case may be) to provide the required coverages.  If Contractor or any subcontractor or sub-subcontractor provides to Landlord or Property Manager a certificate that does not evidence the coverages required herein, or that is faulty in any respect, acceptance of such certificate by Landlord or Property Manager will not constitute a waiver of the obligations of Contractor or any subcontractor or sub-subcontractor (as the case may be) to provide the proper insurance.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;Additional Requirements Concerning Tenant&#8217;s Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The following additional requirements will apply to Tenant&#8217;s Work:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;All of Tenant&#8217;s Work will be:  (i) of a quality at least equal to Class A buildings in the Alameda, California market area; (ii) completed only according to the Construction Documents approved by Landlord; (iii) conducted in a manner so as to maintain harmonious labor relations and not to interfere with or delay any other work or activities being carried </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-12</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">on by Landlord or Landlord&#8217;s contractors or other tenants; (iv) designed, performed and completed in substantial compliance with all applicable reasonable standards and reasonable regulations established by Landlord and provided to Tenant in advance of the commencement of construction of Tenant&#8217;s Work as well as all safety, fire, plumbing and electrical and other codes and governmental and insurance requirements; (v) completed only by the Contractor approved by Landlord; (vi) coordinated by the approved Contractor so as to ensure timely completion; and (vii) performed and conducted in such a manner so as not to alter the structure or systems of the Building without Landlord&#8217;s prior written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;With respect to any Multi User Buildings, under no circumstances will Tenant, Contractor or any of their authorized representatives ever alter or modify or in any manner disturb any &#8220;Central&#8221; (as defined below) system or installation of the Building, including, without limitation, the Central plumbing system, Central electrical system, Central heating, ventilating and air conditioning system, Central fire protection and fire alert system, Central Building maintenance systems, Central structural system, elevators and anything located within the Central core of the Building, without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.  Only with Landlord&#8217;s express written permission will Tenant, Contractor or their authorized representatives alter or modify or in any manner disturb any &#8220;Branch&#8221; (as defined below) of any Central system or installation of the Building which serves or is located within the Premises.  &#8220;Central&#8221; means that portion of any Building system or component which is within the core of the Building or common to or serves or exists for the benefit of other tenants in the Building, and &#8220;Branch&#8221; means that portion of any Building system or component which serves to connect or extend Central systems to the Premises.  Any and all interfacing with, or tie-ins to, any Central Building systems or Branches will be scheduled with Landlord not later than five days prior to the commencement of any such work.  Any such interfacing with, or tie-ins to, any such Building systems, and any checks of such interfacing or tie-ins, will be performed only after the same have been scheduled with, and reasonably approved by, Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;At Tenant&#8217;s election, Contractor may submit to Landlord written requests for use of any Building Standard materials which have been prestocked by Landlord.  Any such request will indicate the quantity and description of the prestocked materials needed.  Contractor will be responsible for the relocation and allocation of any such materials to the Premises under the supervision of, and only with the consent of, Landlord&#8217;s Representative or contractor.  Contractor will be solely and exclusively responsible for signing for and verifying any such prestocked materials so used.  Landlord will deduct from the amount of the Allowance described in Paragraph&#160;17 below the value of any prestocked materials so requested by Contractor from Landlord.  The value of any such prestocked materials will be determined by the quantities required in accordance with generally accepted costs in the metropolitan area in which the Building is located.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;If there is a freight elevator, all construction personnel engaged in the performance of Tenant&#8217;s Work must use the Building&#8217;s freight elevator, if applicable, and not the passenger elevators for access to any portion of the Premises in any Multi User </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-13</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Building.  All deliveries of materials for use in connection with the construction of Tenant&#8217;s Work requiring a freight elevator of a Multi User Building must be scheduled reasonably in advance with Landlord.  In addition, any of Tenant&#8217;s Work which is to be performed in a Multi User Building during hours other than the Business Hours must be scheduled in advance with Landlord.  With respect to any of Tenant&#8217;s Work which is to be performed in a Single User Building during hours other than the Business Hours, Tenant will provide reasonable advance notice to Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;Tenant agrees that if Contractor fails to leave all Common Areas in a neat, clean, orderly and safe condition at the end of each day during construction of Tenant&#8217;s Work, Landlord will have the right to immediately take such action as Landlord deems appropriate to render the Common Areas neat, clean, orderly and safe and Tenant will, upon Landlord&#8217;s written demand, reimburse Landlord for all Landlord&#8217;s costs of taking such action.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;Landlord&#8217;s Services; Construction Administration.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;During construction of Tenant&#8217;s Work, Landlord will provide the following services related to such construction, the cost of which will be paid by Tenant as a part of Tenant&#8217;s Costs:  all electricity and other utilities (provided that Tenant will only be responsible for the cost of electricity beginning during the Tenant Finish Period); refuse removal (including dumpsters); and any other services requested by Tenant or Contractor that Landlord agrees to provide (such as engineering, maintenance or housekeeping services).  In addition, Landlord will provide construction administration with respect to Tenant&#8217;s Work which will include providing Landlord&#8217;s personnel.  Landlord shall not interfere with the progress of the construction of Tenant&#8217;s Work.  Tenant, at its option, will have the right to hire its own construction manager with Landlord&#8217;s approval, which approval will not be unreasonably withheld, conditioned or delayed.  Tenant or its construction manager will be responsible for coordinating all aspects of Tenant&#8217;s Work from the design process through construction; assistance in obtaining any approvals required from Landlord and any governmental authorities; and assistance in scheduling Tenant&#8217;s deliveries to the Premises (including Tenant&#8217;s move to the Premises).  Tenant will pay Landlord, as a part of Tenant&#8217;s Costs, a fee for Landlord&#8217;s supervision of Tenant&#8217;s Work in an amount equal to Landlord&#8217;s actual out-of-pocket costs with no mark-up, in an amount not to exceed $5,000.00 per month during the Tenant Finish Period.  All Tenant&#8217;s Costs that are payable to Landlord will be paid by Tenant within 10 days after the date of Landlord&#8217;s invoice or, at Landlord&#8217;s election, shall be subtracted from the Maximum Allowance Amount prior to payment to Tenant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;Inspection; Stop Work; Noncomplying Work.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Landlord reserves the right to inspect Tenant&#8217;s Work in the Premises at all reasonable times, provided that such inspection(s) will in no way make Landlord responsible for any of Tenant&#8217;s Work and will not constitute a representation or warranty by Landlord as to the adequacy or sufficiency of Tenant&#8217;s Work.  Landlord reserves the right to stop any and all work performed (or to be performed) if Landlord reasonably considers any such work, or its performance, to be dangerous or creating a nuisance, or otherwise injurious to Tenant, Landlord or any other Building tenants.  If any inspection by Landlord reveals any item of Tenant&#8217;s Work that does not materially comply with Tenant&#8217;s obligations under this Work Letter, Landlord may so notify Tenant and require that the item be corrected to so comply.  Within 10 days after the date of any such notice from Landlord, Tenant will begin correction of any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-14</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such noncomplying item and will then promptly and diligently pursue such correction to completion.  If  any such item is not so corrected, Landlord may enter the Premises at any time and correct the item at Tenant&#8217;s expense (to be paid by Tenant promptly upon demand).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;Mechanics&#8217; Liens.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;In the conduct of Tenant&#8217;s Work, Tenant will take all action necessary to ensure that no mechanic&#8217;s or other liens attach to the Premises or Building.  Without limitation, Tenant will post notices, with form and content and in the manner as specified by Laws, notifying all persons or entities which may supply labor or materials in connection with Tenant&#8217;s Work that Landlord&#8217;s interest in the Premises and Building will not be subject to any lien for the same.  If any such lien should be filed, the provisions of Section&#160;8 of the Lease will apply.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;Landlord&#8217;s Allowance</font><font style="font-family:inherit;font-size:12pt;">.  Landlord agrees to pay Tenant the &#8220;Allowance,&#8221; to be applied to the cost of designing and performing Tenant&#8217;s Work, equal to the lesser of (a)&#160;Tenant&#8217;s Costs, or (b)&#160;the Maximum Allowance Amount (which may be prorated in accordance with Paragraph&#160;1(j) of this Work Letter).  As used below, &#8220;Landlord&#8217;s Percentage&#8221; means that percentage obtained by dividing the Maximum Allowance Amount (which may be prorated in accordance with Paragraph&#160;1(j) of the Work Letter) by the then-current estimate of the total Tenant&#8217;s Costs (based on Tenant&#8217;s contracts with Tenant&#8217;s Architect, Tenant&#8217;s Engineers and Contractor); provided that Landlord&#8217;s Percentage will never exceed 100%.  Landlord will pay the amount of the Allowance to Tenant in progress payments no more than on a monthly basis upon the completion of Tenant&#8217;s Work in each Building.  Such progress payments will be made not later than 30&#160;days after receipt by Landlord from Tenant of copies of Tenant&#8217;s invoices from Contractor (and, where applicable, copies of Contractor&#8217;s invoices from its subcontractors or suppliers) together with a certificate from Tenant&#8217;s Architect (or other evidence satisfactory to Landlord) indicating that the work to which such invoices relate has been substantially completed and/or the materials to which such invoices relate have been installed in, or delivered to, the Premises, and such work is for the completion of Tenant&#8217;s Work in the applicable Building.  Such progress payments will be made payable to Tenant or Contractor, and will be for Landlord&#8217;s Percentage of the amount of the submitted invoices, less a 10% retainage.  As a condition precedent to Landlord delivering the first such progress payment, Tenant will deliver to Landlord original conditional lien waivers for the work completed or materials supplied as of the date of such lien waiver.  As a condition precedent to Landlord&#8217;s issuing any such progress payment subsequent to the first such progress payment, Tenant will deliver to Landlord both original lien waivers from Contractor and any applicable subcontractor or supplier indicating that claims for mechanics&#8217; or materialmen&#8217;s liens with respect to the labor and materials reflected in the invoices submitted for the immediately preceding progress payment have been unconditionally waived and original conditional lien waivers for the work completed or materials supplied as of the date of each such lien waiver subsequent to such preceding progress payment.  A further condition precedent to Landlord&#8217;s issuing the last such payment for the amount of the retainage will be that Landlord has received from Tenant (either prior to or simultaneously with the issuance of such final payment) the following: (i)&#160;written notice from Contractor and Tenant&#8217;s Architect (or other evidence satisfactory to Landlord) that Tenant&#8217;s Work has been completed (including completion of any punch list items); (ii)&#160;final and unconditional original lien waivers from Contractor and all subcontractors, suppliers, materialmen and other parties who performed labor at, or supplied materials to, the Premises in connection with Tenant&#8217;s Work; and (iii)&#160;a copy of the certificate of occupancy for the Premises issued by the appropriate governmental authorities.  Landlord will have no obligation to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-15</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">make any such progress payment at any time that a Default exists under the Lease and the total of all such progress payments will in no event exceed the amount of the Allowance.  Landlord will have no obligation to disburse any portion of the Allowance, including any retainage, after the date that is one year following the Start Date.  Tenant will not be entitled to any credit if the Maximum Allowance Amount exceeds Tenant&#8217;s Cost.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;General.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Failure by Tenant to pay any amounts due under this Work Letter beyond the notice and cure period set forth in Section&#160;20.1(a) of the Lease will have the same effect as failure to pay Rent under the Lease, and such failure or Tenant&#8217;s failure to perform any of its other obligations under this Work Letter beyond the notice and cure period set forth in Section&#160;20.1(b) of the Lease will constitute a Default under Section&#160;20.1(b) of the Lease, entitling Landlord to all of its remedies under the Lease as well as all remedies otherwise available to Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;Specialized Tenant Improvements; Removal of Tenant Improvements</font><font style="font-family:inherit;font-size:12pt;">.  Tenant shall designate on the Preliminary Plans and/or Construction Documents those certain specialized trade fixtures and equipment installed by Tenant which Tenant wishes to designate as &#8220;Specialized Tenant Improvements.&#8221;  Tenant shall indicate which Specialized Tenant Improvements, if any, it wishes to remove from the Premises upon the expiration or sooner termination of the Term.  Landlord shall indicate its approval or modification of Tenant&#8217;s selection of Tenant&#8217;s Specialized Tenant Improvements by noting the same on its approval of the Preliminary Plans and/or the Construction Documents.  Notwithstanding anything to the contrary contained in this Lease, Landlord shall not require that Tenant remove any of the Leasehold Improvements.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">B-16</font></div></div><hr style="page-break-after:always"><div><a name="s5A102823BAF24618DCEC99F6E04871A5"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;C</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OCCUPANCY ESTOPPEL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS OCCUPANCY ESTOPPEL CERTIFICATE (&#8220;Certificate&#8221;) is given by EXELIXIS, INC., a Delaware corporation (&#8220;Tenant&#8221;), to ASCENTRIS 105, LLC (&#8220;Landlord&#8221;), with respect to that certain Lease Agreement dated _______________, 2017 (&#8220;Lease&#8221;), under which Tenant has leased from Landlord certain premises located in the buildings in the Harbor Bay office project located at 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California (&#8220;Building&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In consideration of the mutual covenants and agreements stated in the Lease, and intending that this Certificate may be relied upon by Landlord and any prospective purchaser or present or prospective mortgagee, deed of trust beneficiary or ground lessor of all or a portion of the Building, Tenant certifies as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Except for those terms expressly defined in this Certificate, all initially capitalized terms will have the meanings stated for such terms in the Lease.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Landlord first delivered possession of the Premises to Tenant (either for occupancy by Tenant or for the commencement of construction by Tenant) and the Start Dates are as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suites&#160;225 of the 1751 Space, Suites&#160;200 and 210 of the 1801 Space, Suites 1000, 150 and 200 of the 1851 Space, on [____________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;150 of the 1801 Space, on ____________, 201___;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;210 of the 1851 Space, on [________________,201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;125 of the 1851 Space, on [________________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;175 of the 1801 Space, on [______________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;100 of the 1801 Space, on [______________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other than the Temporary Space, Tenant moved into the Premises (or otherwise first occupied the Premises for Tenant&#8217;s business purposes ) as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;200 of the 1801 Space, on [________________,201___];</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;210 of the 1801 Space, on [________________,201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite 1000 of the 1851 Space, on [________________,201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;150 of the 1851 Space, on [________________,201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;200 of the 1851 Space, on [____________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;150 of the 1801 Space, on [____________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;210 of the 1851 Space, on [________________,201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;125 of the 1851 Space, on [________________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;175 of the 1801 Space, on [______________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to Suite&#160;100 of the 1801 Space, on [______________, 201___];</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Commencement Date occurred on ____________, 201___, and the Expiration Date will occur on _____________, 20____.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s obligation to make monthly payments of Base Rent under the Lease began (or will begin) on ____________, 201___.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tenant&#8217;s obligation to make monthly estimated payments of Operating Expenses under the Lease began (or will begin) on ____________, 201___.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Executed this _____ day of _____________, 201___.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">TENANT:</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">EXELIXIS, INC.,</font></div><div style="line-height:120%;padding-bottom:48px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">a Delaware corporation</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Printed Name:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">C-2</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sFD908137FB3B0A2A064399F6E05DB8A2"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;D </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RULES AND REGULATIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Rights of Entry</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will have the right to enter the Premises at any time, but outside of Business Hours Tenant will be required to furnish proper and verifiable identification when entering any Multi User Building.  Landlord will have the right to enter the Premises after Business Hours in any Multi User Building to perform janitorial services and other Landlord services, at all reasonable hours to clean windows and also at any time during the last three months of the Term, with reasonable prior notice to Tenant, to show the Premises to prospective tenants. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Right of Exclusion</font><font style="font-family:inherit;font-size:12pt;">.  Landlord reserves the right to exclude or expel from the Project any person who, in Landlord&#8217;s judgment, is intoxicated or under the influence of alcohol or drugs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Obstructions</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not obstruct or place anything in or on the sidewalks or driveways outside the building, or in the lobbies in a Multi User Building, corridors in a Multi User Building, stairwells in a Multi User Building or other exterior Common Areas or interior Common Areas in Multi User Buildings.  Landlord may remove, at Tenant&#8217;s expense, any such obstruction or thing without notice or obligation to Tenant.  Tenant shall not cause any portion of the Buildings to be in non-compliance with applicable fire codes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Refuse</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will place all refuse in the Premises in proper receptacles provided and paid for by Tenant, or in receptacles provided by Landlord for the Project, and will not place any litter or refuse on or in the sidewalks or driveways outside the Building, or the Common Areas, lobbies, corridors, stairwells, ducts or shafts of the Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Public Safety</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not throw anything out of doors, windows or skylights, down passageways or over walls.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Keys; Locks</font><font style="font-family:inherit;font-size:12pt;">.  Landlord may from time to time install and change locks on entrances to any Multi User Building and Common Areas in Multi User Buildings and, with the prior consent of Tenant, the Premises, and will provide Tenant a reasonable number of keys to meet Tenant&#8217;s requirements.  If Tenant desires additional keys  they will be furnished by Landlord and Tenant will pay a reasonable charge for them.  Tenant will not add or change existing locks on any door in or to the Premises without Landlord&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.  If with Landlord&#8217;s consent, Tenant installs lock(s) incompatible with the Building master locking system:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;Landlord, without abatement of Rent, will be relieved of any obligation under the Lease to provide any service that requires access to the affected areas;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;Tenant will indemnify Landlord against any expense as a result of forced entry to the affected areas which may be required in an emergency; and</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D-1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;Tenant will, at the end of the Term and at Landlord&#8217;s request, remove such lock(s) at Tenant&#8217;s expense.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At the end of the Term, Tenant will promptly return to Landlord all keys for the Building and Premises which are in Tenant&#8217;s possession.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Aesthetics</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not attach any awnings, signs, displays or projections to the outside or inside walls or windows of the Building which are visible from outside the Premises by an ordinary person at ground level without Landlord&#8217;s prior written approval, which may be withheld in Landlord&#8217;s sole but reasonable discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Window Treatment</font><font style="font-family:inherit;font-size:12pt;">.  If Tenant desires to attach or hang any curtains, blinds, shades or screens to or in any window or door of the Premises, Tenant must obtain Landlord&#8217;s prior written approval, which shall not be unreasonably withheld, conditioned or delayed.  Tenant will not coat or sunscreen the interior or exterior of any windows without Landlord&#8217;s express written consent.  Tenant will not place any objects on the window sills that cause, in Landlord&#8217;s reasonable opinion, an aesthetically unacceptable appearance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Directory Boards</font><font style="font-family:inherit;font-size:12pt;">.  Landlord will make every reasonable effort to accommodate Tenant&#8217;s requirements for the Building directory boards in any Multi User Building in which a portion of the Premises is located.  The cost of any changes to the directory board information identifying Tenant requested by Tenant subsequent to the initial installation of such information will be paid for by Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Project Control</font><font style="font-family:inherit;font-size:12pt;">.  Landlord reserves the right to control and operate the exterior Common Areas, and interior Common Areas in any Multi User Building, as well as facilities furnished for the common use of tenants in such manner as Landlord deems best for the benefit of tenants generally.  Landlord reserves the right to prevent access to the Project or any portion thereof during an emergency by closing the doors or otherwise, for the safety of tenants and protection of the Project and property in the Project.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;Engineering Consent</font><font style="font-family:inherit;font-size:12pt;">.  All plumbing, electrical and HVAC work for and in the Premises located in a Multi User Building requires Landlord&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed) to maintain the integrity of the Project&#8217;s electrical, plumbing and HVAC systems.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;HVAC Interference</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not place objects or other obstructions on the HVAC convectors or diffusers and will not permit any other interference with the HVAC system.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;Plumbing</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will only use plumbing fixtures for the purpose for which they are constructed.  Tenant will pay for all damages resulting from any misuse by Tenant of plumbing fixtures.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;Equipment Location</font><font style="font-family:inherit;font-size:12pt;">.  Landlord reserves the right to specify where Tenant&#8217;s business machines, mechanical equipment and heavy objects will be placed in the Premises in order to best absorb and prevent vibration, noise and annoyance to other tenants, and to prevent damage </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D-2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to the Buildings and/or the Project.  Tenant will pay the cost of any required professional engineering certification or assistance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;Animals</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will not bring into, or keep about, any portion of the Premises located in a Multi User Building any vehicles, birds, animals (other than service animals and laboratory testing animals).  Vehicles may only be parked in Project areas designated for such purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;Carpet Protection</font><font style="font-family:inherit;font-size:12pt;">.  In those portions of the Premises where carpet has been provided by Landlord, Tenant will at its own expense install and maintain pads to protect the carpet under all furniture having castors other than carpet castors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;Proper Conduct</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will conduct itself in a manner which is consistent with the character of the Project and will ensure that Tenant&#8217;s conduct will not impair the comfort or convenience of other tenants in the Project.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;Elevators</font><font style="font-family:inherit;font-size:12pt;">.  Except as may be expressly permitted by Landlord, in Multi User Buildings, only freight elevators may be used for deliveries.  Use of freight elevators in Multi User Buildings after Business Hours must be scheduled through the office of Property Manager.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;Deliveries</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will ensure that deliveries of materials and supplies to any portion of the Premises located in a Multi User Building are made through such entrances, elevators and corridors and at such times as may from time to time be reasonably designated by Landlord.  Tenant will use or cause to be used, in any Multi User Building, hand trucks or other conveyances equipped with rubber tires and rubber side guards to prevent damage to such Multi User Building or property in such Multi User Building.  Tenant will promptly pay Landlord the cost of repairing any damage to the Building and/or the Project caused by any person making deliveries to the Premises at the direction or request of Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">20.&#160;&#160;&#160;&#160;Moving</font><font style="font-family:inherit;font-size:12pt;">.  Tenant will ensure that furniture and equipment and other bulky matter being moved to or from the Premises located in a Multi User Building are moved through such entrances, elevators and corridors and at such times as may from time to time be reasonably designated by Landlord, and by movers or a moving company reasonably approved by Landlord.  Tenant will promptly pay Landlord the cost of repairing any damage to such Building and/or the Project caused by any person moving any such furniture, equipment or matter to or from the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">21.&#160;&#160;&#160;&#160;Solicitations</font><font style="font-family:inherit;font-size:12pt;">.  Canvassing, soliciting and peddling in the Project are prohibited and Tenant will cooperate in preventing the same.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">22.&#160;&#160;&#160;&#160;Food</font><font style="font-family:inherit;font-size:12pt;">.  Tenant may order food to be delivered to the Premises for consumption by its employees and guests within the Premises.  Except for the activity described in the preceding sentence, only persons approved from time to time by Landlord may prepare, solicit orders for, sell, serve or distribute food in or around the Project.  Except as may be specified in the Lease or in construction drawings for the Premises approved by Landlord, and except for microwave cooking, Tenant will not use the Premises for preparing or dispensing food, or soliciting of orders for sale, serving or distribution of food.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D-3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">23.&#160;&#160;&#160;&#160;Smoking</font><font style="font-family:inherit;font-size:12pt;">.  The smoking of cigarettes, cigars, pipes, etc. is STRICTLY PROHIBITED anywhere in the interior of the Building including the Premises.  The ONLY designated smoking areas will be specifically designated by Landlord.  STANDING ASH TRAYS WILL BE PROVIDED.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">24.&#160;&#160;&#160;&#160;Chemical Storage</font><font style="font-family:inherit;font-size:12pt;">.  All chemicals, paints or other similar materials must be stored in compliance with all Laws, including all applicable fire codes.  Nothing in this paragraph will permit Tenant to violate Section&#160;3.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">25.&#160;&#160;&#160;&#160;Storage Near Ceiling</font><font style="font-family:inherit;font-size:12pt;">.  Tenant may not store any materials within 18&#160;inches (or any greater distance prescribed, from time to time, by Laws, including applicable fire codes) of the ceiling of the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">26.&#160;&#160;&#160;&#160;Weapons</font><font style="font-family:inherit;font-size:12pt;">.  Possession of a firearm or other weapon is STRICTLY PROHIBITED anywhere in the interior of the Building including the Premises.  Nothing in this paragraph will prohibit Tenant from carrying Mace or pepper spray for personal defense.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">27.&#160;&#160;&#160;&#160;Employees, Agents and Invitees</font><font style="font-family:inherit;font-size:12pt;">.  In these Rules and Regulations, &#8220;Tenant&#8221; includes Tenant&#8217;s employees, agents, invitees, licensees and others permitted by Tenant to access, use or occupy the Premises.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">D-4</font></div></div><hr style="page-break-after:always"><div><a name="s5E10E2A45D6312B604B499F6E0805851"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;E</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTENTIONALLY OMITTED</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">E-1</font></div></div><hr style="page-break-after:always"><div><a name="s72CD349D6EF5EAA784DE99F6E0B21EF4"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;F</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM OF LETTER OF CREDIT</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Wells Fargo Bank, N.A.</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">U. S. TRADE SERVICES &#8211; Standby Letters of Credit</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">MAC xxxxx-xxx</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Address Line 1</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Address Line 2</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Phone: 1(800) 776-3862 Option 2</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">E-Mail: StandbyLC@wachovia.com</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">IRREVOCABLE STANDBY LETTER OF CREDIT</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">NUMBER </font><font style="font-family:inherit;font-size:9pt;color:#3366ff;font-weight:bold;">_______________</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;text-indent:-48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issue Date:</font><font style="font-family:inherit;font-size:9pt;color:#3366ff;font-weight:bold;">______________</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BENEFICIARY:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;APPLICANT:</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ascentris 105, LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#0000ff;font-style:italic;">Applicant Name</font><font style="font-family:inherit;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1401 17</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:inherit;font-size:9pt;">&#32;Street, 12</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:inherit;font-size:9pt;">&#32;Floor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#0000ff;font-style:italic;">Address</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denver, Colorado  80202&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;color:#0000ff;font-style:italic;">City, State Zip</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Attention: Robert A. Toomey, Jr.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">LETTER OF CREDIT ISSUE AMOUNT:  $500,000.00&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXPIRY DATE: </font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">[Confirm the Expiry Date.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ladies and Gentlemen:</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">At the request and for the account of the above referenced Applicant, we hereby issue our Irrevocable Standby Letter of Credit (the &#8220;Wells Credit&#8221;) in your favor in the amount of Five Hundred Thousand and 00/100 Dollars ($500,000.00) available with us at our above office by payment against presentation of the following documents: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1. A draft drawn on us at sight marked &#8220;Drawn under Wells Fargo Bank, N.A. Standby Letter of Credit No. _____________.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#32;<br>2. The original of this Letter of Credit and any amendments thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3. Beneficiary&#8217;s signed and dated statement worded as follows (with the instructions in brackets therein complied with): </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The undersigned, an authorized representative of the beneficiary of Wells Fargo Bank Letter of Credit No. _________, certifies (a)  that the amount of the draft accompanying this statement represents the amount due to Beneficiary pursuant to and in connection with that certain Lease Agreement dated </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">[insert date]</font><font style="font-family:inherit;font-size:9pt;">, including any amendments thereto (collectively, the &#8220;Lease&#8221;), between Applicant, as tenant (&#8220;Tenant&#8221;), and Beneficiary, as landlord (&#8220;Landlord&#8221;), and (b)  that (i) a default of the Lease by Tenant exists and has continued beyond any applicable notice and cure period under the Lease, (ii) Tenant has committed a default under the Lease and the transmittal of notice of such default is barred by applicable laws, or (iii) Tenant has failed to deliver a replacement letter of credit to Landlord at least 30 days prior to the expiration date of the letter of credit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Multiple drawings are permitted.  In the event of partial drawings, Wells Fargo Bank, N.A. shall endorse the original of this Letter of Credit and return it to the beneficiary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If any instructions accompanying a drawing under this Letter of Credit request that payment is to be made by transfer to an account with us or at another bank, we and/or such other bank may rely on an account number specified in such instructions as that of the beneficiary&#8217;s without any further validation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">This Letter of Credit is transferable one or more times to any entity that has succeeded Beneficiary as Landlord under the Lease, but in each instance only to a single transferee and only in the full amount available to be drawn under the Letter of Credit at the time of such transfer.  Any such transfer may be effected only through Wells Fargo Bank, N.A. and only upon presentation to us at our presentation office specified herein of a duly executed transfer request in the form attached hereto as Exhibit&#160;A, with instructions therein in brackets complied with, together with the original of this Letter of Credit and any amendments thereto and payment of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">F-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">our transfer fee.  Each transfer shall be evidenced by our endorsement on the reverse of the original of this Letter of Credit, and we shall deliver such original to the transferee.  The transferee&#8217;s name shall automatically be substituted for that of the Beneficiary wherever such Beneficiary&#8217;s name appears within this Letter of Credit.  All charges in connection with any transfer of this Letter of Credit are for the Applicant&#8217;s account.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">This Letter of Credit is assignable in its entirety, but not in part, by Beneficiary, as Landlord, to its lender, or by any person or entity who or that succeeds to Landlord&#8217;s interest under the Lease to its lender, without limit as to the number of assignments;  provided, however, that an assignment of proceeds will not be deemed an assignment &#8220;in part.&#8221;  Such assignment shall be effected by presentation to us at our presentation office specified herein of a duly executed assignment request, together with the original of this Letter of Credit, and any amendments thereto, and payment of our assignment fee.  All charges in connection with any assignment of this Letter of Credit are for the Beneficiary&#8217;s or the Beneficiary&#8217;s lender&#8217;s account.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">We are subject to various laws, regulations and executive and judicial orders (including economic sanctions, embargoes, anti-boycott, anti-money laundering, anti-terrorism, and anti-drug trafficking laws and regulations) of the U.S. and other countries that are enforceable under applicable law.  We will not be liable for our failure to make, or our delay in making, payment under this Letter of Credit or for any other action we take or do not take, or any disclosure we make, under or in connection with this Letter of Credit (including, without limitation, any refusal to transfer this Letter of Credit) that is required by such laws, regulations, or orders, provided that any failure, delay, action or disclosure is made in good faith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">We hereby engage with you that each draft drawn under and in compliance with the terms and conditions of this Letter of Credit will be duly honored if presented together with the documents specified in this Letter of Credit at our office located at </font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">[Insert San Leandro address.]</font><font style="font-family:inherit;font-size:9pt;">&#32;Attention: U.S. Trade Services, Standby Letters of Credit, on or before the above stated expiry date, or any extended expiry date if applicable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">This Letter of Credit sets forth in full the terms of our undertaking.  This undertaking is independent of and shall not in any way be modified, amended, amplified or incorporated by reference to any document, contract or agreement referenced herein other than the stipulated ICC rules and governing laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Except as otherwise expressly stated herein, this Letter of Credit is subject to The International Standby Practice 1998, International Chamber of Commerce Publication No. 590 (the &#8220;ISP98&#8221;).  For matters not addressed by the ISP98, this Letter of Credit will be governed by and construed in accordance with the laws of the State of California;  provided, however, that in the event of any conflict between the ISP98 and the laws of the State of California, the ISP98 will control. </font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Very truly yours</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">WELLS FARGO BANK, N.A.</font></div><div style="line-height:120%;text-align:justify;text-indent:336px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BY:        _____________________________ </font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;(AUTHORIZED SIGNATURE)</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">The original of this Letter of Credit contains an embossed seal over the Authorized Signature.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Please direct any written correspondence or inquires regarding this Letter of Credit, always quoting our reference number, to Wells Fargo Bank, N.A., Attn:  U.S. Trade Services, Standby Letters of Credit,</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">&#32;[Insert San Leandro address.]</font><font style="font-family:inherit;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">All phone inquiries regarding this credit should be directed to our Standby Customer Connection Professionals at</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1-800-776-3862, Option 2.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">F-2</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="s75D46A6AB41F3871A43399F6E10C9DA4"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WATERFRONT AT HARBOR BAY </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT&#160;G</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">HVAC EQUIPMENT LIST</font></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">1801 Building</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1801 AC-1</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SXHFC5040U67C7AD600</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L23825M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1801 AC-6</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SXHFC5040U67C7AD600</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L23824M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1801 AC-11</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SXHFC5040U67C7AD600</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L23828M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1801 AC-12</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SXHFC5040U67C7AD600</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L23829M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Boiler 1801 B-1</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: RITE</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WA180W</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">27337</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">1851 Building</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1851 1801 AC-1</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHFC5040U77C8B</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C9925795M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1851 AC-6</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SCHFC5040U77C8B</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L25796M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1851 AC-11</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SXHFC5040U88C8</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L25806M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HVAC 1851 AC-12</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: Trane</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: S</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">XHFC5040U88C8</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Rating: 50 ton pkg unit</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">C99L25805M</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Boiler 1851 B-1</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturer: RITE</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Model: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WA180W</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Serial: </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">27405</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">G-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exel20170630exhibit104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE2DB575EB2A08F70240D99E3C352AB12"></a></div><div></div><div><br></div><div style="line-height:138%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION POLICY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  FEBRUARY 23, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each member of the board of directors (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of Exelixis, Inc. (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;) who is not an Employee (as defined in the Exelixis, Inc. 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Plan</font><font style="font-family:inherit;font-size:10pt;">&#8221;)) (each, a &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:inherit;font-size:10pt;">&#8221;) will be eligible to receive equity compensation as set forth in this Exelixis, Inc. Non-Employee Director Equity Compensation Policy (this &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Initial Option Grants, Initial RSU Grants, Annual Option Grants and Annual RSU Grants (each as defined below) described in this Policy will be granted automatically and without further action of the Board to each Non-Employee Director who is eligible to receive such equity compensation, unless such Non-Employee Director declines the receipt of such equity compensation by written notice to the Company; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:10pt;">, that notwithstanding the foregoing or anything in this Policy to the contrary, any equity grants scheduled to be granted on a certain date pursuant to this Policy will not be granted automatically if (i) the number of shares available for issuance under the 2017 Plan is insufficient to make all such grants on such date or (ii) making any such grants would exceed any applicable limits in the 2017 Plan.  This Policy will become effective on the date of the annual meeting of the Company&#8217;s stockholders held in 2017 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), provided that the 2017 Plan is approved by the Company&#8217;s stockholders at such annual meeting, and will remain in effect until it is revised or rescinded by further action of the Board.  Upon this Policy becoming effective on the Effective Date, (i) this Policy will replace and supersede in its entirety the Exelixis, Inc. Non-Employee Director Equity Compensation Policy adopted by the Board on February 28, 2014, as amended (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prior Policy</font><font style="font-family:inherit;font-size:10pt;">&#8221;), which provided for equity grants under the Exelixis, Inc. 2014 Equity Incentive Plan, and (ii) the Prior Policy will be rescinded and no longer in effect as of the Effective Date, provided that any equity grants made pursuant to the Prior Policy will remain subject to the terms of the Prior Policy.  Capitalized terms not explicitly defined in this Policy but defined in the 2017 Plan will have the same definitions as in the 2017 Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The equity grants described in this Policy will be granted under the 2017 Plan and will be subject to the terms and conditions of (i) the 2017 Plan, (ii) the forms of grant notices and agreements approved by the Board for the grant of equity to Non-Employee Directors and (iii) this Policy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Initial Grants.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Each person who is elected or appointed for the first time to be a Non-Employee Director automatically will be granted, upon the date of his or her initial election or appointment to be a Non-Employee Director, equity grants with a combined total dollar value of $400,000, which will be divided between approximately 50% in the form of a nonstatutory stock option (an &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Option Grant</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and approximately 50% in the form of a restricted stock unit award (an &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial RSU Grant</font><font style="font-family:inherit;font-size:10pt;">&#8221;), based on the valuation methodology established by the Board.  The number of shares of Common Stock subject to each Initial Option Grant and Initial RSU Grant will be based on such methodology and the average of the daily closing sales prices of the Common Stock for all of the trading days during the 30 calendar day period ending on (and including) the last calendar day immediately prior to the grant date of such Initial Option Grant and Initial RSU Grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Grants.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;On the day following each annual meeting of the Company&#8217;s stockholders, each person who is then a Non-Employee Director automatically will be granted equity grants with a combined total dollar value of $250,000, which will be divided between approximately 50% in the form of a nonstatutory stock option (an &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual Option Grant</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and approximately 50% in the form of a restricted stock unit award (an &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual RSU Grant</font><font style="font-family:inherit;font-size:10pt;">&#8221;), based on the valuation methodology established by the Board; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:inherit;font-size:10pt;">, that each Non-Employee Director may instead elect to receive 100% of such equity grants in the form of a nonstatutory stock option (in which case, the term &#8220;Annual Option Grant&#8221; will refer to such nonstatutory stock option).  Any such election must be made by a Non-Employee Director by the date required by the Company and will remain in effect until revoked by such Non-Employee Director, provided that any such revocation is made by the date required by the Company.  The number of shares of Common Stock subject to each Annual Option Grant and Annual RSU Grant, if any, will be based on such methodology and the average of the daily closing sales prices of the Common Stock for all of the trading days during the 30 calendar day period ending on (and including) the last calendar day immediately prior to the grant date of such Annual Option Grant and Annual RSU Grant, if any.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Terms of Options.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise Price</font><font style="font-family:inherit;font-size:10pt;">.  The exercise price of each Initial Option Grant and Annual Option Grant will be equal to 100% of the Fair Market Value of the Common Stock subject to such option on the date such option is granted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercisability and Vesting</font><font style="font-family:inherit;font-size:10pt;">.  Subject to Section (e) below, each Initial Option Grant and Annual Option Grant will be fully exercisable upon grant and will vest as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(A) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Each Initial Option Grant will provide for vesting of 1/4th of the shares subject to such option on the first anniversary of the date of grant and 1/48th of the shares subject to such option each month thereafter, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Each Annual Option Grant will provide for vesting of 1/12th of the shares subject to such option each month after the date of grant, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Terms of RSUs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Vesting</font><font style="font-family:inherit;font-size:10pt;">.  Subject to Section (e) below, each Initial RSU Grant and Annual RSU Grant will vest as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(A) </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Each Initial RSU Grant will provide for vesting of 1/4th of the shares subject to such award on each of the first four anniversaries of the date of grant, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Each Annual RSU Grant will provide for vesting of 100% of the shares subject to such award on the first anniversary of the date of grant, subject to the Non-Employee Director&#8217;s Continuous Service through such date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Delivery of Shares</font><font style="font-family:inherit;font-size:10pt;">.  The shares subject to each Initial RSU Grant and Annual RSU Grant will be delivered on the applicable vesting date or as soon as administratively practicable thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Transaction.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The provisions in this Section (e) will apply to each Initial Option Grant, Initial RSU Grant, Annual Option Grant, Annual RSU Grant and any other equity award granted to a Non-Employee Director under the 2017 Plan (an &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Equity Grant</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and will supersede Section 9(c) of the 2017 Plan in its entirety. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Asset Sale, Merger, Consolidation or Reverse Merger</font><font style="font-family:inherit;font-size:10pt;">.  In the event of (i) a sale, lease or other disposition of all or substantially all of the assets of the Company, (ii) a merger or consolidation in which the Company is not the surviving corporation or (iii) a reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, then any surviving corporation or acquiring corporation shall assume any Stock Awards outstanding under the 2017 Plan or shall substitute similar stock awards (including awards to acquire the same consideration paid to the stockholders in the transaction described in this Section (e)(i) for those outstanding under the 2017 Plan).  In the event any surviving corporation or acquiring corporation refuses to assume such Stock Awards or to substitute similar stock awards for those outstanding under the 2017 Plan, then with respect to Stock Awards held by Participants whose Continuous Service has not terminated prior to consummation of such event, the vesting of such Stock Awards and any shares of Common Stock acquired under such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full, and the Stock Awards shall terminate if not exercised at or prior to consummation of such event.  With respect to any other Stock Awards outstanding under the 2017 Plan, such Stock Awards shall terminate if not exercised prior to consummation of such event.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Securities Acquisition</font><font style="font-family:inherit;font-size:10pt;">.  In the event of an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Exchange Act, or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or an Affiliate) of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of Directors and provided that such acquisition is not a result of, and does not constitute a transaction described in, Section (e)(i) above, then with respect to Stock Awards held by Participants whose Continuous Service has not terminated prior to consummation of such event, the vesting of such Stock Awards and any shares of Common Stock acquired under such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in Control.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Section 9(d)(i) of the 2017 Plan will not apply to any Initial Option Grant, Initial RSU Grant, Annual Option Grant, Annual RSU Grant or Other Equity Grant.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>exel20170630exhibit105.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9E6EC9BB087CD9091DB39F627B79CAA8"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 10.5</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Third Amendment to the Collaboration Agreement</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This third amendment (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to the Collaboration Agreement dated December 22, 2006, as amended, (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) between Exelixis, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and Genentech, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Genentech</font><font style="font-family:inherit;font-size:10pt;">&#8221;) is made and entered into by Exelixis and Genentech effective July 19, 2017 (the&#183;&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;). All capitalized terms not expressly defined in this Amendment shall have the meaning assigned to them in the Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Whereas</font><font style="font-family:inherit;font-size:10pt;">, Exelixis and Genentech are parties to the Agreement, as amended by the First Amendment to the Collaboration Agreement, dated March 13, 2008, and the Second Amendment to the Collaboration Agreement, dated April 30, 2010;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Whereas</font><font style="font-family:inherit;font-size:10pt;">, Exelixis and Genentech have agreed on a term sheet, dated June 8, 2017 (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term Sheet</font><font style="font-family:inherit;font-size:10pt;">&#8221;), in connection with a settlement between Exelixis and Genentech of the arbitration proceeding entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, Inc. v. Genentech, Inc.</font><font style="font-family:inherit;font-size:10pt;">, JAMS Ref No. 110084603;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Whereas</font><font style="font-family:inherit;font-size:10pt;">, Exelixis and Genentech wish to amend the terms of the Agreement as set forth herein; and</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Whereas</font><font style="font-family:inherit;font-size:10pt;">, Exelixis and Genentech have executed a settlement agreement (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Settlement Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of even date herewith.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Now, therefore</font><font style="font-family:inherit;font-size:10pt;">, in consideration of the foregoing premises the Parties do hereby agree to amend the Agreement, effective as of the Amendment Effective Date (unless otherwise stated below), as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;JSC Meetings.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Section 2.1(e) of the Agreement is hereby amended and restated as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;JSC meetings shall be held [ * ] on a date mutually agreed by the Parties,  with ad hoc meetings as necessary, particularly to address issues described in Sections 2.1(b) and 3.2(d).  Meetings will be scheduled for [ * ] or such additional time as may be necessary to the subject matter of the meeting, at the option of either Party.  A proposed agenda prepared by the hosting Party shall be circulated in advance of each meeting.  The Parties agree that attendees appropriate to the subject matter of the meeting will be in attendance.  Either Party may also raise additional topics for discussion at the meeting even if not included on the original agenda.  With the consent of the representatives of each Party serving on the JSC, other representatives of each Party may attend meetings as nonvoting observers (provided such nonvoting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement).  A JSC meeting may be held by audio, video or internet teleconference with the consent of each Party, but at least one-half (1/2) of the minimum number of meetings shall be held in person, in South San Francisco or Alameda, California, or elsewhere with the consent of each party.  Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating.  Each Party shall be responsible for all of its own expenses of participating in the JSC meetings.  The Parties will alternate hosting of the meeting, and the Party hosting is responsible for preparing and circulating the minutes of such JSC meeting.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;JCC Meetings.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The first sentence of Section 2.3(d) of the Agreement is hereby replaced by the following sentence:</font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;JCC meetings shall be held at least [ * ] on a date mutually agreed by the Parties, and each meeting will be scheduled for [ * ], or such additional time as may be necessary to the subject matter of the meeting, at the option of either Party.&#8221;</font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Escalation.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;New Section 2.4 is hereby added to the agreement as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;2.4&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Escalation.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;From time to time, issues may arise before the JSC or JCC wherein, after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter, the representatives of the Parties cannot reach an agreement as to such matter.  Such disputed matter shall be reflected in </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the minutes for such JSC or JCC meeting, as the case may be.  If, within [ * ] after the date such minutes are prepared by the responsible Party and provided to the other Party, the Parties remain unable to resolve such disputed matter, then at the request of either Party such disputed matter will be escalated to [ * ] for Genentech and [ * ] for Exelixis for discussion and resolution.  If such officers cannot resolve such disputed matter within [ * ] after receiving written notice (by electronic mail or other written communication) from the officer of the other Party requesting resolution of such disputed matter, then the Decision Making provisions of Sections 2.1(d) for the JSC and 2.3(c) for the JCC shall control, notwithstanding whether the [ * ] period set forth in Section 2.1(d) or 2.3(c), as applicable, has or has not expired.&#8221;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Exelixis&#8217; Co-Promotion Option</font><font style="font-family:inherit;font-size:10pt;">.  The following sentences are hereby added and inserted at the end of Section 5.6 of the Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;The Parties confirm and agree that Exelixis has exercised the Co-Promotion option set forth in this Section 5.6.  As such, Exelixis shall have the right, but not the obligation, to co-promote all current and future Genentech Combinations (as defined in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">), regardless of the then-current label of Licensed Product, therapeutic components of combination, indication, or the Genentech division to which the sales effort has been assigned.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Progress Information</font><font style="font-family:inherit;font-size:10pt;">.  Section 6.2 of the Agreement is hereby amended and restated as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Each Party shall use Diligent Efforts to keep the other Party informed of its research, development and commercialization (including promotional) activities hereunder, and shall provide to the other Party&#8217;s representatives on the JCC or JSC, as appropriate, regular summary updates at each meeting, and as necessary between meetings, including copies of presentations and other materials presented at such meeting.  [ * ]  Neither Party is required to generate additional data or prepare additional reports to comply with the obligations set forth in this Section 6.2.  All reports, information and data provided by a Party shall be considered the providing Party&#8217;s Confidential Information.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">With regard to development activities, Genentech will provide to Exelixis&#8217; representatives on the JSC updates with regard to (i) ongoing Clinical Trials, (ii) notification of [ * ], (iii) notification of [ * ], (iv) status of [ * ], (v) anticipated dates for [ * ] and (vi) such further milestones as the Parties may mutually agree.  Key development milestones that may occur in between JSC meetings that would require additional updates shall include: (i) [ * ] and (ii) [ * ], to the extent that updates on such intent were not provided at the last prior JSC, and [ * ] may occur before the next scheduled JSC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">With regard to commercialization (including promotional) activities, each Party will provide to the other Party&#8217;s representatives on the JCC or JSC, as applicable, the following information to the extent available: (i) key [ * ]; (ii) updates on [ * ]; (iii) key [ * ], including but not limited to a summary of [ * ] (e.g. [ * ]); (iv) summary of [ * ]; (v) [ * ]; (vi) [ * ] plans and (vii) significant changes to [ * ].  In addition, Genentech will provide to Exelixis: [ * ].  For clarity, any of the foregoing may be redacted in part to protect confidential information unrelated to the Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">If reasonably necessary for a Party to perform its work under this Agreement or to exercise its rights under this Agreement, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier provided, and the other Party shall [ * ] provide the requesting Party with information and data as is reasonably available and reasonably related to the work under this Agreement.&#8221;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Profit Share in the Profit-Share Territory</font><font style="font-family:inherit;font-size:10pt;">.  Section 8.4(a) of the Agreement is hereby amended and restated as follows:</font></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">2.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Profit Share in the Profit-Share Territory</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Profit-Share Ratio</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">The Parties shall share Operating Profit (Loss) for Licensed Product(s) sold for the Profit-Share Territory as follows:  </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">[ * ]Total Adjusted Actual Sales of a Licensed Product in the Profit-Share Territory for a Particular Calendar Year</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Genentech&#8217;s Share of Operating Profit (Loss)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exelixis&#8217; Share of Operating Profit (Loss)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">First $200 million</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]%</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Above $400 million</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Quarterly Calculations</font><font style="font-family:inherit;font-size:10pt;">.  Each Party&#8217;s share of Operating Profit (Loss) will be determined on a calendar quarterly basis using the profit share ratio set forth in clause (i) above.  For example, in a calendar year where the Total Adjusted Actual Sales of a Licensed Product is $[ * ] in each calendar quarter (or a total of $[ * ] for the calendar year), Exelixis&#8217; initial share of Operating Profit would be calculated based on the following profit-share ratios:  [ * ]   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Quarterly True-Up Process and Annual Reconciliation</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">In the event [ * ] are not available for the purpose of determining the Total Adjusted Actual Sales for the current quarterly settlement, then [ * ] shall be used to determine the current quarter Total Adjusted Actual Sales. The current quarterly settlement shall be trued-up using [ * ] after the end of the subsequent calendar quarter. If the true-up amount is in Exelixis&#8217; favor, then Genentech shall make a catch-up payment with the subsequent quarterly settlement payment. If the true-up amount is in Genentech&#8217;s favor, then Genentech shall reduce the respective amount from the subsequent quarterly profit-share. If there will be no further or insufficient payment obligations under this Agreement from Genentech to Exelixis, then Exelixis shall, at the request of Genentech, refund such overpaid amount within [ * ] of receiving such request.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annually, together with the true-up of the Q4 Total Adjusted Actual Sales, based on [ * ], each Party&#8217;s actual share of Operating Profit (Loss) for the calendar year will be calculated and reconciled based on the weighted average profit share ratio for the full year.  For example, if there were $[ * ] annual Total Adjusted Actual Sales in the Profit-Share Territory, the weighted average profit share ratio of [ * ]%, would be applied to calculate Exelixis&#8217; share of the annual Operating Profit (Loss) for such calendar year as set forth in the following table (for illustration purposes only).   [ * ]    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the reconciliation payment based on the above calculation is in Exelixis&#8217; favor, then Genentech shall make a catch-up payment with the next quarterly settlement payment. If the reconciliation payment is in Genentech&#8217;s favor, then Genentech shall reduce the respective amount from the next quarterly profit-share payment(s). If there will be no further or insufficient payment obligations under this Agreement from Genentech to Exelixis, then Exelixis shall, at the request of Genentech, refund such overpaid amount within [ * ] of receiving such request.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Budget Overrun.  </font><font style="font-family:inherit;font-size:10pt;">If, for any calendar quarter: (A) Exelixis&#8217; share of the budgeted cost for the Operating Profit (Loss) [ * ] for such calendar quarter [ * ] is in the aggregate [ * ] (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Budget Overrun</font><font style="font-family:inherit;font-size:10pt;">&#8221;) by at least [ * ] dollars ($[ * ]); and (B) a [ * ] for such calendar quarter, then Exelixis shall [ * ] for the amount of such Budget Overrun [ * ] Exelixis to Genentech [ * ].  If Exelixis&#8217; share of the budgeted cost for the Operating Profit (Loss) [ * ] for such calendar year [ * ] is in the aggregate [ * ] what Genentech [ * ] for such calendar year, then the [ * ] the budget used in the calculation of the Budget Overrun above.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">3.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Financial Appendix</font><font style="font-family:inherit;font-size:10pt;">.  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">&#32;(Financial Appendix) of the Agreement is hereby amended and restated as attached with effect as of July 1, 2017.</font></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Miscellaneous</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Except as expressly and unambiguously stated herein, no other changes are made to the Agreement and all other terms and conditions of the Agreement shall remain in full force and effect. In the event of a conflict between the provisions hereof and the Agreement, the provisions of this Amendment shall control. The Agreement, this Amendment and Settlement Agreement, contain the entire understanding between the Parties hereto with respect to the subject matter hereof and supersede and terminate all prior agreements, understandings and arrangements (including the Term Sheet) between the Parties, whether written or oral with respect to such subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">This Amendment shall be governed by and construed under the substantive laws of the State of California, without regard to conflicts of law rules requiring the application of different law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">The headings of this Agreement are for ease of reference only and are not part of this Agreement for the purpose of construction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:240%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[remainder of page intentionally left blank]</font></div><div style="line-height:240%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">4.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:10pt;">, Exelixis and Genentech have executed this Third Amendment to the Collaboration Agreement by their respective duly authorized representative(s).</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GENENTECH, INC. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;text-indent:-144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: /s/ Michael Morrissey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By: /s/ Bill Anderson&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: Michael Morrissey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name: Bill Anderson&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: President and Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title: Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="line-height:240%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">5.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><a name="s80C3E07D6FFA55C942139F627BD3762C"></a></div><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit A</font></div><div style="line-height:240%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Appendix</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Principles of Reporting and Profit/Loss Sharing Statement.  </font><font style="font-family:inherit;font-size:10pt;">Determination of Operating Profit (Loss) for a Licensed Product in the Profit-Share Territory will be based on each Party&#8217;s respective financial information.  The interpretation of the defined terms in such report shall be in accordance with GAAP and this Agreement. Each calendar quarter Genentech shall determine the Operating Profit (Loss) as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Adjusted Actual Sales</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less [ * ]</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">= Operating Profit (Loss)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, Genentech shall [ * ]: (a) [ * ] and (b) [ * ]:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the [ * ] associated with [ * ], the total [ * ] for the Licensed Product will be allocated [ * ].</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Together with each profit and loss statement, Genentech will provide, on a quarterly basis, a breakdown of [ * ] separated by (i) [ * ] and (ii) [ * ]. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For clarity, Genentech will not include [ * ] that do not include the Licensed Product, in any such profit and loss statement.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All [ * ] incurred by Exelixis for [ * ] may be applied to the Operating Profit (Loss).&#160; Exelixis shall provide to Genentech [ * ].  For clarity, other than its share of the Operating Profit (Loss), Exelixis is not entitled to any further reimbursement by Genentech for any costs, including [ * ], incurred in co-promoting Genentech Combinations.  </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If necessary, a Party will make the appropriate adjustments to the financial information it supplies under the Agreement to conform to the above format of reporting results of operations.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Accounting and Cost Categories.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Definitions of the various categories of revenues, costs and expenses included in Operating Profit (Loss) shall be interpreted in accordance with GAAP.  Any costs included in the calculation under one cost category may not be included in the calculation of another cost category.  Where the terms of this Financial Appendix would permit inclusion of a cost within more than one cost category, that cost will be allocated to a single cost category consistent with GAAP and the other provisions of this Agreement.  [ * ]. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;References to &#8220;Collaboration&#8221;.  </font><font style="font-family:inherit;font-size:10pt;">References in this Financial Appendix to the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration</font><font style="font-family:inherit;font-size:10pt;">&#8221; are references to those activities related to the Licensed Product that would form the basis for Operating Profit (Loss) under this Agreement.  The Parties may consolidate accounting of operations related to Licensed Products, and the activities subject to that consolidated accounting also will be referred to the &#8220;Collaboration.&#8221;  However, the Collaboration is not a legal entity for financial accounting, income tax reporting or any other purposes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Reporting.  </font><font style="font-family:inherit;font-size:10pt;">The fiscal year for the Collaboration will be a calendar year.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Party is responsible for providing the other Party reports as set forth in the table below, for activities for which it is responsible and costs it incurred and revenue obtained that forms a component of Operating Profit (Loss) for Licensed Products in the Profit-Share Territory.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reporting will be at the times set forth in the following Report Table, with submissions due on the date indicated or the next business day if such date is a weekend or U.S. holiday: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Parties agree to use [ * ] (or another [ * ] as mutually agreed by the Parties) as the basis for making Adjusted Actual Sales calculations as set forth in this </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">.  For the purposes of calculating Adjusted Actual Sales in the Draft Consolidated Operating Profit (Loss), Genentech will use the [ * ].  For the purposes of calculating Adjusted Actual Sales in the Final Consolidated Operating Profit (Loss), Genentech will use the [ * ].  For the purposes of </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">calculating Adjusted Actual Sales for the True-up of the Consolidated Operating Profit (Loss), Genentech will use the [ * ].</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Report Table [ * ]</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">[ * ]</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Parties may agree to modify the foregoing reporting cycles and deadlines.  In the event that a Party substantially or materially changes its internal reporting cycles and deadlines generally, then the Parties shall discuss, in good faith, appropriate revisions to the foregoing reporting cycles and deadlines to reasonably accommodate such change.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise agreed by the Parties consistent with their responsibilities for sales and marketing, Genentech shall record sales.  Without limiting the Parties&#8217; reporting obligations as set forth in the Report Table above, on a calendar quarterly basis, Exelixis will supply Genentech with a statement setting forth that quarter&#8217;s Operating Profit (Loss) obtained by Exelixis for Licensed Products in the Profit-Share Territory, including the basis for calculation of such amounts.  Genentech shall consolidate any Operating Profit (Loss) reported by Exelixis with those obtained directly by Genentech.  Each such report shall be provided as early as possible, on the schedule in the chart above. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each Party will make available a financial representative to coordinate regarding financial aspects of planning, reporting and information sharing, at the request of the other Party:  Upon the reasonable request of either Party, the other Party shall answer any question and address any comment from the other Party pertaining to such financial planning and reporting.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Budgets.  </font><font style="font-family:inherit;font-size:10pt;">Genentech will prepare a consolidated budget for Operating Profit (Loss) for the Collaboration on [ * ] basis; Exelixis shall provide input for that budget regarding its sales force activities. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Budgets are provided for information and planning purposes; final sharing of Operating Profit (Loss) on a calendar year basis are based on actual amounts, subject to Section 8.4(a)(v) of the Agreement.   </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ILLUSTRATIVE EXAMPLES OF PROFIT SHARE CALCULATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following examples are intended to illustrate how Genentech will determine the Actual Adjusted Sales as well as the Operating Profits (Losses) in the Profit-Share Territory.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">{Redacted content comprises approximately 2 pages.}</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definitions for Financial Appendix.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual Sales</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">means, with respect to a particular Licensed Product, the Gross Sales less [ * ].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">B.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Actual Sales</font><font style="font-family:inherit;font-size:10pt;">&#8221; means, (i) with respect to any Genentech Combination, Adjusted Actual Combo Sales or (ii) with respect to any Licensed Product Monotherapy, Adjusted Actual Mono Sales.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">C.&#160;&#160;&#160;&#160;&#8220;Adjusted Actual Combo Sales&#8221; </font><font style="font-family:inherit;font-size:10pt;">shall, with respect to a particular Licensed Product, be calculated by multiplying Actual Sales by the Adjusted Price Factor for each Genentech Combination.  The [ * ] quarterly Actual Sales of Licensed Product allocated to each Genentech Combination shall be based on [ * ], pursuant to the methodology in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit G</font><font style="font-family:inherit;font-size:10pt;">. As described in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit G</font><font style="font-family:inherit;font-size:10pt;">, [ * ]. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D.&#160;&#160;&#160;&#160;&#8220;Adjusted Actual Mono Sales&#8221; </font><font style="font-family:inherit;font-size:10pt;">shall, with respect to a particular Licensed Product, be the Actual Sales for Licensed Product Monotherapies. The percentage of quarterly Actual Sales of Licensed Product allocated to Licensed Product Monotherapies shall be based on [ * ], pursuant to the methodology in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit G</font><font style="font-family:inherit;font-size:10pt;">. As described in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit G</font><font style="font-family:inherit;font-size:10pt;">, [ * ].</font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted Price Factor</font><font style="font-family:inherit;font-size:10pt;">&#8220; shall be calculated on a quarterly basis as the percentage calculated as A divided by B divided by C, where:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A is the sum of the Net Prices of Licensed Product and the Other Genentech Product(s) in a Genentech Combination;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B is the sum of 1 (i.e. the Licensed Product) plus the number of Other Genentech Products in the respective Genentech Combination; and</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C is the Net Price of the Licensed Product.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">F.&#160;&#160;&#160;&#160;&#8220;Allocable Overhead&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means costs incurred by each Party that are attributable to that Party&#8217;s [ * ].  The Allocable Overhead shall not include [ * ], and shall not duplicate General &amp; Administrative Expenses hereunder.  </font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Actual Gross to Net Percentage</font><font style="font-family:inherit;font-size:10pt;">&#8221; means with respect to a particular Licensed Product or Other Genentech Product, the percentage calculated as A divided by B, where</font></div><div style="line-height:120%;text-align:justify;padding-left:66px;text-indent:-19px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A is the all Actual Sales for such product in the respective calendar quarter; and</font></div><div style="line-height:120%;text-align:justify;padding-left:66px;text-indent:-19px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">B is the all Gross Sales for such product in the respective calendar quarter.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">H.&#160;&#160;&#160;&#160;&#8220;Cost of Sales&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means the sum of: (i) Fully Burdened Manufacturing Cost (or &#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FBMC</font><font style="font-family:inherit;font-size:10pt;">&#8221;, as defined below) of a Licensed Product in the Profit-Share Territory (in whatever form), to the extent included pursuant to Section 4.1 of the Agreement; (ii)&#160;freight, insurance, customs charges, duty, and other costs of shipping Licensed Products in the Profit-Share Territory to customers (to the extent actually incurred by the shipping Party and not reimbursed by the customer); (iii) temporary storage; and (iv)&#160;the actual costs associated with the technology transfer to a Third Party manufacturer to enable Manufacturing of that Licensed Product, including without limitation any upfront and milestone based payments and startup costs associated therewith.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I.&#160;&#160;&#160;&#160;&#8220;Distribution Costs&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means the costs, including applicable Allocable Overhead, specifically identifiable to the distribution of a Licensed Product in the Profit-Share Territory, including customer services, collection of data about sales to hospitals and other end users, order entry, billing, shipping, logistics, credit and collection and other such activities.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">J.&#160;&#160;&#160;&#160;&#8220;Fully Burdened Manufacturing Cost&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8220;FBMC&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means one hundred percent (100%) of each Party&#8217;s actual manufacturing cost (as defined in each Party&#8217;s accounting policies consistently applied) of goods produced, as determined by each Party manufacturing or contracting with a Third Party for each stage of the manufacturing process, in accordance with GAAP (as used in this definition of FBMC, the &#8220;Cost of Goods&#8221;), including product quality assurance/control costs, plus applicable Allocable Overhead.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">K.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Genentech Combination</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any therapeutic combination of Licensed Product sold by Genentech or its Affiliates with one or more Other Genentech Products [ * ].  </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">L.&#160;&#160;&#160;&#160;&#8220;General and Administrative Costs&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8220;G&amp;A Costs&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means costs equal to [ * ] (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G&amp;A Rate</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of the sum of [ * ].  [ * ] both Parties shall use such revised G&amp;A Rate going forward in calculating General and Administrative Costs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">M.&#160;&#160;&#160;&#160;&#8220;Gross Sales&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means the gross amount invoiced by Genentech, its Affiliates or sublicensees (for the purpose of this definition only, the term sublicensee shall include entities to which Genentech sells a Licensed Product in a form other than final form, including without limitation OEM manufacturer and distributors, whether or not a sublicense is expressly granted) for sales of Licensed Products (such products being in final form intended for use by the end user) in the Profit-Share Territory to any Third Party in arms-length transactions.  Consideration for sales of Licensed Products in the Profit-Share Territory for other than cash shall be valued at fair market value at the time of final sale.  Sales between Genentech and its Affiliates or sublicensees shall be disregarded for purposes of calculating Gross Sales, except if the purchasing entity is the end-user. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensed Product Monotherapy&#8221; or &#8220;Licensed Product Monotherapies&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means with respect to a particular Licensed Product, the use in any therapy other than in a Genentech Combination. For clarity, both the use of Licensed Product in a monotherapy and the use in a therapeutic combination without an Other Genentech Product shall be considered a Licensed Product Monotherapy.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">O.&#160;&#160;&#160;&#160;&#8220;Marketing Costs&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means the specific direct costs incurred by Genentech for marketing a Licensed Product and/or Genentech Combination in the Profit-Share Territory, including costs incurred for marketing, promotion, advertising, promotional materials, professional education, product related public relations, relationships with opinion leaders and professional societies, market research (before and after product approval), healthcare economics studies, and other similar activities conducted to benefit the Licensed Product and/or Genentech Combination in the Profit-Share Territory, but excluding the portion of such costs for which Genentech is getting reimbursed from any Third Party.  Such costs will include internal costs (e.g., salaries, benefits, travel, supplies and materials), applicable Allocable Overhead, and outside services and expenses (e.g., consultants, agency fees, meeting costs), in all cases only as directly applicable to a specific Licensed Product and/or Genentech Combination in the Profit-Share Territory.  The Marketing Costs shall also include activities related to obtaining reimbursement from payers and costs of sales and marketing data, in all cases only as directly applicable to a specific Licensed Product and/or Genentech Combination in the Profit-Share Territory.  The Marketing Costs will specifically exclude the costs of activities that promote either Party&#8217;s business as a whole without being product specific (e.g., corporate image advertising). Should the Licensed Product be sold as part of a Genentech Combination, Genentech shall allocate the costs incurred for marketing the Genentech Combination in the Profit-Share Territory as described above to the Licensed Product as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;[ * ]% for Genentech Combinations with one Other Genentech Product (irrespective of combinations with further products);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;[ * ]% for Genentech Combinations with two Other Genentech Products (irrespective of combinations with further products);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;[ * ]% for Genentech Combination with X number of Other Genentech Products (irrespective of further combinations with further products).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For clarity, 100% of Genentech&#8217;s costs incurred for marketing a Licensed Product Monotherapy in the Profit-Share Territory shall be allocated to such Licensed Product Monotherapy. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Monthly WAC</font><font style="font-family:inherit;font-size:10pt;">&#8221; means with respect to a particular Licensed Product or an Other Genentech Product used in a particular Genentech Combination, the monthly wholesale acquisition cost for treatment with such product in a month, as calculated by multiplying:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;the wholesale acquisition cost per tablet (vial or other single unit as applicable) for a particular Licensed Product or Other Genentech Product, by </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;the monthly average number of tablets (vial or other single unit as applicable) of such particular Licensed Product or Other Genentech Product as indicated per the relevant product label for the respective Genentech Combination.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Illustrative Example: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Monthly WAC</font><font style="font-family:inherit;font-size:10pt;">&#32;Calculation for COTELLIC&#174; and [ * ]</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">COTELLIC&#174;  </font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82.47863247863248%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:23%;"></td><td style="width:49%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffff;padding-left:2px;padding-top:1px;padding-bottom:1px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;font-weight:bold;">NDC #</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffff;padding-left:2px;padding-top:1px;padding-bottom:1px;padding-right:8px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffff;padding-left:2px;padding-top:1px;padding-bottom:1px;padding-right:8px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;font-weight:bold;">WAC&#160;effective January 1, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:1px;padding-right:8px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">50242-0717-01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:8px;padding-top:2px;padding-bottom:2px;padding-right:8px;border-right:1px solid #000000;"><div style="padding-bottom:1px;padding-top:1px;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">COTELLIC&#174; (cobimetinib)</font></div><div style="padding-bottom:1px;padding-top:1px;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">63 count 20 mg tablets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:1px;padding-right:8px;border-right:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">$[ * ]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Labeled dosage (Source FDA &#8211; COTELLIC&#174; Label): </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;The recommended dose is </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">60 mg orally once daily for the first 21 days of each 28-day cycle</font><font style="font-family:inherit;font-size:10pt;">&#32;until disease progression or unacceptable toxicity.&#8221; (section 2.2)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Q.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Price</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall, with respect to a particular Licensed Product or an Other Genentech Product used in a particular Genentech Combination, be calculated by multiplying Monthly WAC by the Average Actual Gross to Net Percentage.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R.&#160;&#160;&#160;&#160;&#8220;Operating Profit (Loss)&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means Total Adjusted Actual Sales of all Licensed Products in the Profit-Share Territory less the following items with respect to each Licensed Product in the Profit-Share Territory, all for a given period: [ * ], all of which as properly chargeable and allocable on a Licensed Product-by-Licensed Product basis.  All calculations will be made using, and all defined and undefined terms will be construed in accordance with GAAP and consistent with generally accepted costing methods (including appropriate Allocable Overhead) for similar products in the pharmaceutical industry.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Genentech Product</font><font style="font-family:inherit;font-size:10pt;">&#8221; means a branded pharmaceutical product (other than a Licensed Product) for which Genentech or its Affiliates [ * ].  When the terms Gross Sales, Actual Sales or Sales Returns and Allowances are used with respect to an Other Genentech Product, any references to Licensed Product in such definitions shall be considered references to such Other Genentech Product.  Genentech or its Affiliates shall not undertake any corporate restructuring or enter into a transaction with a Third Party for the purpose of removing a pharmaceutical product from the definition of &#8220;Other Genentech Product.&#8221;  [ * ] shall not be deemed an Affiliate for purposes of this definition, except that if [ * ] becomes fully owned by Genentech or its Affiliates, then [ * ] would at that time be deemed an Affiliate for the purposes of this definition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Operating Income/Expense</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any of the following: (i) [ * ] of any Licensed Product in the Profit-Share Territory, to the extent not previously captured; (ii) amounts with respect to [ * ] that will be shared pursuant to Article&#160;[ * ] of this Agreement; (iii) costs of [ * ] with respect to the Licensed Product (provided that if such costs are allocated between products the Parties will discuss the method of such allocation, which method must be reasonable); (iv)&#160;costs of [ * ] that, pursuant to Article [ * ], will be included in Operating Profit (Loss); (v)&#160;costs to [ * ]; (vi) any [ * ] of Licensed Products in the Profit-Share Territory, excluding any [ * ] already accounted for in Fully Burdened Manufacturing Cost, and (vii) the annual Branded Prescription Drug Fee to the United States government pursuant to Section 9008 of the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (as may be amended).   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.&#160;&#160;&#160;&#160;&#8220;Report Table&#8221; </font><font style="font-family:inherit;font-size:10pt;">means the table set forth in this Appendix that specifies the frequency and timing of submissions for specific reporting events.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">V.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales Costs</font><font style="font-family:inherit;font-size:10pt;">&#8221; means costs, including Allocable Overhead, incurred by a Party pursuant to sales activities pursuant to a Promotion Plan or otherwise authorized under this Agreement for a Licensed Product and/or Genentech Combination in the Profit-Share Territory, , but excluding costs to the extent that Genentech receives payment or reimbursement for such costs from any third party which costs are specifically identifiable with such authorized sales efforts for Licensed Products and/or Genentech Combination in the Profit-Share Territory, with respect to all customer types, including the managed care market.  Should the Licensed Product be sold as part of a Genentech Combination, Genentech shall allocate the costs incurred as described above for sales activities for the Genentech Combination in the Profit-Share Territory to the Licensed Product as follows:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;[ * ]% for Genentech Combinations with one Other Genentech Product (irrespective of combinations with further products);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;[ * ]% for Genentech Combinations with two Genentech Products (irrespective of combinations with further products);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;[ * ]% for Genentech Combinations with X number of Genentech Products (irrespective of further combinations with further products).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For clarity, 100% of Genentech&#8217;s costs incurred for sales of a Licensed Product Monotherapy in the Profit-Share Territory shall be allocated to such Licensed Product Monotherapy.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">W.&#160;&#160;&#160;&#160;&#8220;Sales Returns and Allowances&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;means the sum of (x) and (y), where: </font></div><div style="line-height:120%;text-align:justify;padding-left:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(x) is a provision, determined by a Party under GAAP for sales of Licensed Products in the Profit-Share Territory for (i) trade, cash and quantity discounts on Licensed Products in the Profit-Share Territory granted and which are included in the determination of Gross Sales; (ii)&#160;credits or allowances given or made for rejection or return of previously sold Licensed Products in the Profit-Share Territory or for retroactive price reductions (including rebates similar to Medicare and/or Medicaid); (iii) sales tax, VAT taxes, and other taxes, duties or other governmental charges levied on or measured by the billing amount for Licensed Products in the Profit-Share Territory, as adjusted for rebates or refunds, that are borne by the seller thereof and that are not refundable; and (iv) discounts pursuant to indigent patient programs and patient discount programs, including the impact of price caps and patient assistance programs; and </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(y) is a periodic adjustment of the provision determined in clause (x) to reflect amounts actually incurred by each Party in the Territory for items (i), (ii), (iii), and (iv) in clause (x).  The provision allowed in clause (x) and adjustments made in clause&#160;(y) (if any) will be reviewed by the financial representatives from the Parties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">X.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Y.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Adjusted Actual Sales</font><font style="font-family:inherit;font-size:10pt;">&#8221; means the sum of (x) all Adjusted Actual Combo Sales and (y) all Adjusted Actual Mono Sales.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div><a name="sB21B4A4E89DCB0BA6AE69F627C23F9E3"></a></div><div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit G</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">{Redacted content comprises approximately 2.5 pages}</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This [ * ] Exhibit illustrates how Genentech will calculate [ * ] Actual Sales by Genentech Combination and Licensed Product Monotherapies using [ * ].</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>exel20170630exhibit121.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s038E80251FA0563132AC12B9C706B26B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 12.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT RE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our earnings were insufficient to cover fixed charges for the periods presented except for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The following table sets forth our ratio of earnings to fixed charges for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and our deficiency of earnings to cover fixed charges for the other periods presented.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed charges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest portion of rental expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,979</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings available for fixed charges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(261,479</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed charges per above</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,781</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,714</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total earnings available for fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,441</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219,231</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(198,574</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ratio of earnings to fixed charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deficiency of earnings available to cover fixed charges</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(261,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exel20170630exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB0C0B7F3CED31CD3E79612B9E1AE5023"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:42.96875%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">/s/ M</font><font style="font-family:inherit;font-size:8pt;text-align:center;">ICHAEL</font><font style="font-family:inherit;font-size:10pt;text-align:center;">&#160;M. M</font><font style="font-family:inherit;font-size:8pt;text-align:center;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">August&#160;2, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exel20170630exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9D33395A39B991DA431612B9E262A626"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:42.96875%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:inherit;font-size:8pt;">HRISTOPHER</font><font style="font-family:inherit;font-size:10pt;">&#160;J. S</font><font style="font-family:inherit;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">August&#160;2, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exel20170630exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s29DFE5E7C66CF3DA47A912B9E3022D1C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly  Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2nd</font><font style="font-family:inherit;font-size:10pt;">&#32;day of </font><font style="font-family:inherit;font-size:10pt;">August 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:inherit;font-size:8pt;">ICHAEL</font><font style="font-family:inherit;font-size:10pt;">&#160;M. M</font><font style="font-family:inherit;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:inherit;font-size:8pt;">HRISTOPHER</font><font style="font-family:inherit;font-size:10pt;">&#160;J. S</font><font style="font-family:inherit;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>exel-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:2d678b4bdcc1464195b33c6df048795f,x:560f6ed44bbf4dc99b4b56375ea5222b-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:exel="http://www.exelixis.com/20170630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="exel-20170630.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul26">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">exel:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">exel:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:ProductsDerivedfromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">exel:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_TradeandOtherReceivablesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:TradeandOtherReceivablesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">exel:CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">exel:CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:GlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:SecondMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_StatementGeographicalAxis_country_DE_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Mar01-31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4November_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-01</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_MajorCustomersAxis_exel_GlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_dei_LegalEntityAxis_exel_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">exel:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_exel_PeriodGeneratedAxis_exel_Q416Member_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:PeriodGeneratedAxis">exel:Q416Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_dei_LegalEntityAxis_exel_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">exel:BristolMyersSquibbMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_StatementGeographicalAxis_country_GB_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:LongTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:RestrictedCashAndInvestmentsLongTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:RestrictedCashAndInvestmentsLongTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:LongTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:CapitalLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:CapitalLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-28</xbrli:startDate>
			<xbrli:endDate>2017-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_exel_InterestPaymentTypeAxis_exel_CouponInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:InterestPaymentTypeAxis">exel:CouponInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exel:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exel:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-29</xbrli:startDate>
			<xbrli:endDate>2017-03-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exel:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_exel_InterestPaymentTypeAxis_exel_PaymentinKindInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:InterestPaymentTypeAxis">exel:PaymentinKindInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exel:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exel:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exel:FinancingLeaseObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:CapitalLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-02</xbrli:startDate>
			<xbrli:endDate>2017-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_BuildingShellsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:CapitalLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:BuildingShellsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May31_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:MerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:MerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:MerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:MerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="option">
		<xbrli:measure>exel:option</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="property">
		<xbrli:measure>exel:property</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="milestone">
		<xbrli:measure>exel:milestone</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="account">
		<xbrli:measure>exel:account</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="affiliate">
		<xbrli:measure>exel:affiliate</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q2YTD" id="Fact-599ACA12FA2AE249AE5512B9AF9707FD">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q2YTD" id="Fact-290D7AB056ED00961DBF12B9AF97ADA2">--12-29</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q2YTD" id="Fact-C44D592F0946ECA769D312B9AFABDAE2">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q2YTD" id="Fact-4E9FD7AE672CFADA85D212B9AFABC9FF">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q2YTD" id="Fact-74FFD4AB0E0CF486770312B9AF972333">2017-06-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q2YTD" id="Fact-303544135A540AEEBF2312B9AF972539">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q2YTD" id="Fact-55E0E6EA09CAC47DCDAC12B9AFB5C663">0000939767</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q3Jul26" decimals="INF" id="Fact-932789C398F51D59CDF912B9AFAB4A08" unitRef="shares">293904704</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q2YTD" id="Fact-870BB8839C29580BBCA412B9AFB5F6DA">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q2YTD" id="Fact-F5ACCA7D4F83F5B7DFCE12B9AFAB80E8">EXELIXIS, INC.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2017Q2YTD" id="Fact-6994FF549909D547519012B9AFA11493">exel</dei:TradingSymbol>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1FCECA99A01BCD4E81DB12B9AF650E9E" unitRef="usd">14131000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-379B5EE45D4784E4AB5912B9B04BBD03" unitRef="usd">14680000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-4E45FF7240D057BC929C12B9AF299E4F" unitRef="usd">2046000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-116F4EAC6AA4DC48589612B9ADF3E97A" unitRef="usd">7919000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:CapitalLeasesFutureMinimumPaymentsDueAfterYearSix contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-52FD6824F96A52C07227898E3670F752" unitRef="usd">10441000</exel:CapitalLeasesFutureMinimumPaymentsDueAfterYearSix>
	<exel:CapitalLeasesFutureMinimumPaymentsDueAfterYearSix contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-F672BA837825FE0325628985E3A19138" unitRef="usd">3465000</exel:CapitalLeasesFutureMinimumPaymentsDueAfterYearSix>
	<exel:CapitalLeasesFutureMinimumPaymentsDueinSixYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-EE71CBADA296E89D9B42898D951BDA72" unitRef="usd">1814000</exel:CapitalLeasesFutureMinimumPaymentsDueinSixYears>
	<exel:CapitalLeasesFutureMinimumPaymentsDueinSixYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-186FECF6F1D2C38443D18986B1B9E57E" unitRef="usd">646000</exel:CapitalLeasesFutureMinimumPaymentsDueinSixYears>
	<exel:CapitalLeasesNumberofOptionstoTerminate contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="INF" id="Fact-2B9FD587019BB5C9F71698EFDCEF7CBE" unitRef="option">1</exel:CapitalLeasesNumberofOptionstoTerminate>
	<exel:CapitalLeasesNumberofRenewalOptions contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="INF" id="Fact-3E982044EF213810F55D89B33D6593C7" unitRef="option">2</exel:CapitalLeasesNumberofRenewalOptions>
	<exel:CapitalLeasesOptionAdditionalAreaofRealEstateProperty contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="0" id="Fact-B2D5B28197E3946660A789BB268B9356" unitRef="sqft">170000</exel:CapitalLeasesOptionAdditionalAreaofRealEstateProperty>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2016Q4" decimals="-3" id="Fact-73325666F15FC64BC6E712B9AEEDD441" unitRef="usd">479554000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-628C0EA0D54BC3CD343312B9AEF74475" unitRef="usd">55601000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-A6E0B9480D6F1762F22312B9AEE30805" unitRef="usd">4150000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-B78810C1A2406245E01F12B9AEE329EF" unitRef="usd">151686000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-07BB8CE06CCC0BF5AFC512B9AEF76261" unitRef="usd">268117000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2017Q2" decimals="-3" id="Fact-45A12A7A947B2EE802A312B9B0607185" unitRef="usd">380319000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-9890F17CBBBCCD27414512B9B04C9132" unitRef="usd">26413000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-E00BC592648ED6EAC20512B9AD121B06" unitRef="usd">4650000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-FC258BB91FF723E87BDA12B9B0600DC3" unitRef="usd">135212000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-2B9C703D82AF0810A66F12B9AD1CC386" unitRef="usd">214044000</exel:CashCashEquivalentsandAvailableforsaleSecurities>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-3" id="Fact-4CF64D9B672A73F7EB1E12B9AEF7B949" unitRef="usd">479862000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-C50A5448AAEE492697AE12B9AEEDBC08" unitRef="usd">55792000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-2C87830811B685063EF212B9AEED243A" unitRef="usd">4150000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-3981398414FF35C64F1712B9AEED9B51" unitRef="usd">151686000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-F44CC3EF51F44E4BE05C12B9AEF70B2F" unitRef="usd">268234000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2017Q2" decimals="-3" id="Fact-592040D26C7FC0A84E0D12B9B0606726" unitRef="usd">380438000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-9B58AE843D501601C34D12B9B04C265A" unitRef="usd">26404000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-424971F3AACE0322DB3212B9B060C326" unitRef="usd">4650000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-4F91CAE4FD9CF88E578812B9B0604AEB" unitRef="usd">135212000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-AF057DBC09C7C900309212B9B060E45A" unitRef="usd">214172000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-4AF9F8BAF3B6EF0CD02312B9AEF736A2" unitRef="usd">14000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-158D909F059F8194674B12B9AEED7933" unitRef="usd">1000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-D206D5029D30F6DCE33212B9AEEDEDA8" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-5D9D69924EB0B602BB7312B9AEF7312C" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-2D2EB0491663BB9D9BBB12B9AEF71B94" unitRef="usd">13000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2017Q2" decimals="-3" id="Fact-3F60EF366EA50C9741B312B9AD128BBB" unitRef="usd">41000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-3330F1AAEF0115DA148812B9B04CFCF8" unitRef="usd">26000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-C659C182A8B3645537BE12B9B06013E5" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-6B378547258A0FCC4CB912B9B04C75D8" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-24030F2718E670ABD4BF12B9B0606167" unitRef="usd">15000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-5CB12494F2A28291130112B9AEED2541" unitRef="usd">322000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-3C23CCEEF1B94306F73912B9AEF75A13" unitRef="usd">192000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-4D410C8C460AF52690BE12B9AEED48EE" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-9EC7961F1AC752C2276D12B9AEF7665D" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-2A3D3B1578AEBB22FAD612B9AEEDFABB" unitRef="usd">130000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2017Q2" decimals="-3" id="Fact-D77A71E1633DE922EF4512B9B04C48EA" unitRef="usd">160000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_LongTermInvestmentsMember" decimals="-3" id="Fact-991A728F28799F9CDF9012B9B06002F7" unitRef="usd">17000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_exel_RestrictedCashAndInvestmentsLongTermMember" decimals="-3" id="Fact-B28162F0E47189E01F8512B9B04C9365" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="Fact-1C603D2E5B5E450DEA0512B9B04C7D52" unitRef="usd">0</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments contextRef="FI2017Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-6E8FBB82DC069FD2294112B9B04C2185" unitRef="usd">143000</exel:CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-7D89F8C8044EBA0B710E12B9AFFB96D0">P6Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-DF796F323B8B456EE6E4858A885F89C6" unitRef="usd">0</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-0816258BA393B763D3B712B9AE61DF25" unitRef="usd">0</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-EA05E59F137D2913AF37858A8242ECF3" unitRef="usd">862000</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-511F765B8D389A46A8A5859718F91D68" unitRef="usd">1313000</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-22303994A1E931536EA912B9AE5740CC" unitRef="usd">1199000</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-F44B06D1EEF341390D0C12B9AD44FB3E" unitRef="usd">2108000</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-E306A75124D9AE38991E8593989FB5B8" unitRef="usd">-4630000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-6EA8B65B9A48B69B0C3412B9AD1C2CEB" unitRef="usd">-11923000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-3E7C2E86B95C2917707885938F8A7B42" unitRef="usd">-781000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-5C30A3361911C9DC320A12B9AFE78ED6" unitRef="usd">-1407000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-9357654C089B2932AD5C12B9AECFEA0C" unitRef="usd">95000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementShareinCostsPercentage contextRef="FD2017Q2YTD_dei_LegalEntityAxis_exel_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" decimals="4" id="Fact-6DABC7F9FA1896B3FE2A12B9B04B34ED" unitRef="number">0.6667</exel:CollaborativeArrangementShareinCostsPercentage>
	<exel:CollaborativeArrangementShareinCostsPercentage contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" decimals="4" id="Fact-58B52AE39ACE69E86AB412B9AF8D40FE" unitRef="number">0.3333</exel:CollaborativeArrangementShareinCostsPercentage>
	<exel:ContractTerminationPeriodforWrittenNotice contextRef="FD2017Q2YTD_dei_LegalEntityAxis_exel_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-6457E23CB3F498C1F13312B9AD9EB23C">P12M</exel:ContractTerminationPeriodforWrittenNotice>
	<exel:DebtCollateralNumberOfAffiliateBanks contextRef="FD2017Q2YTD" decimals="INF" id="Fact-8683B7E388822C9CED3F12B9AE89A48E" unitRef="affiliate">1</exel:DebtCollateralNumberOfAffiliateBanks>
	<exel:DebtCollateralNumberOfRequiredInvestmentAccounts contextRef="FD2017Q2YTD" decimals="INF" id="Fact-9F117630C8307D16F5B512B9AE89AA3F" unitRef="account">1</exel:DebtCollateralNumberOfRequiredInvestmentAccounts>
	<exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection contextRef="FI2017Q2_exel_InterestPaymentTypeAxis_exel_CouponInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-4DE0D2F693D1464E2D2012B9ADE97C9F" unitRef="number">0.075</exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection>
	<exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection contextRef="FI2017Q2_exel_InterestPaymentTypeAxis_exel_PaymentinKindInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-77BA9040853ECDA7602F12B9ADDF8ABF" unitRef="number">0.075</exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection>
	<exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-45CC588EC8D94E5CC83C12B9ADDF924F" unitRef="number">0.15</exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection>
	<exel:DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="INF" id="Fact-FC38277331C0D64BEF0B12B9ADD5EEFF" unitRef="number">1</exel:DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations>
	<exel:DebtInstrumentPrepaymentPenalty contextRef="I2017Q2Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-D877AEBA498DC492D1988B09FC863D42" unitRef="usd">5800000</exel:DebtInstrumentPrepaymentPenalty>
	<exel:DebtInstrumentsUnamortizedClosingFeesAndExpenses contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-0E4A81D8BD6D2F5DD70912B9ADD5F7D8" unitRef="usd">400000</exel:DebtInstrumentsUnamortizedClosingFeesAndExpenses>
	<exel:DeferredRevenueRecognitionPeriod contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-3888BD9FE2BAFBBA446312B9AF5126BE">P4Y</exel:DeferredRevenueRecognitionPeriod>
	<exel:ExcessTaxBenefitsSharebasedCompensation contextRef="FD2017Q2YTD" decimals="-5" id="Fact-E0D4FC3E5B357CBD816966474D85C31C" unitRef="usd">1000000</exel:ExcessTaxBenefitsSharebasedCompensation>
	<exel:ExtinguishmentofDebtIncludingPaidinKindInterest contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-3C857D6CE3641A37F10F8B005668D0A5" unitRef="usd">113900000</exel:ExtinguishmentofDebtIncludingPaidinKindInterest>
	<exel:ExtinguishmentofDebtincludingInterestandPenalties contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-3A6631226772BCA17CF98B13BF799B2B" unitRef="usd">123800000</exel:ExtinguishmentofDebtincludingInterestandPenalties>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-29E0155F6BE244D707CE12B9ADC110B5" unitRef="usd">-2390000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-60705EC23D63369861C312B9AD9E497D" unitRef="usd">549000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BAD6FFAE758A5255148B12B9AD80876C" unitRef="usd">6055000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="FD2017Q2YTD" decimals="-3" id="Fact-8D1B04302E7CAF6B8F4E12B9ADD50454" unitRef="usd">5873000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:InterestExpenseCouponInterest contextRef="FD2016Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-108CE1F02D101887878112B9AD94FD85" unitRef="usd">1972000</exel:InterestExpenseCouponInterest>
	<exel:InterestExpenseCouponInterest contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-8FBD5A8F9CC34302B39A12B9B04B4D82" unitRef="usd">3908000</exel:InterestExpenseCouponInterest>
	<exel:InterestExpenseCouponInterest contextRef="FD2017Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-5D75047D9CDD421D7C9112B9AD628351" unitRef="usd">2083000</exel:InterestExpenseCouponInterest>
	<exel:InterestExpenseCouponInterest contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-E23E3A2476DF0F86BE9112B9AE4DC282" unitRef="usd">4151000</exel:InterestExpenseCouponInterest>
	<exel:LesseeLeasingArrangementsCapitalLeasesRenewalTerm contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" id="Fact-71CB152520B36BAFDD3489B660F5984E">P5Y</exel:LesseeLeasingArrangementsCapitalLeasesRenewalTerm>
	<exel:LesseeLeasingArrangementsCapitalLeasesTermofContract contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" id="Fact-D95CB630FF0A49FE364689B168E41985">P10Y</exel:LesseeLeasingArrangementsCapitalLeasesTermofContract>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-3F2EEF263A452ABFCF0812B9AFFBF7B7" unitRef="usd">83000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:Maximumpercentagerequiredforcollateralbalance contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="INF" id="Fact-9DCAE29463DAC6C7758712B9ADD54B8C" unitRef="number">1.07</exel:Maximumpercentagerequiredforcollateralbalance>
	<exel:NumberofProductsinCommercialMarket contextRef="FD2017Q2YTD" decimals="INF" id="Fact-4C6CAAF1760C0307616512B9ADE9F379" unitRef="product">3</exel:NumberofProductsinCommercialMarket>
	<exel:NumberofProductsinCommercialMarket contextRef="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember" decimals="INF" id="Fact-C31F62F84881663BAF3212B9ADE90381" unitRef="product">2</exel:NumberofProductsinCommercialMarket>
	<exel:PaymentOfReimbursementsFromCollaborationArrangement contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-122C76F09F818A7C9F8E12B9B04B7741" unitRef="usd">2100000</exel:PaymentOfReimbursementsFromCollaborationArrangement>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-8C88A3D0BA1FDFBCAAA412B9AF3DC141" unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-6C0F44C3973696A20FDF12B9ADC1DF7A" unitRef="number">0.3</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-0888769BFCFE6CCC950B12B9AF8D42A8" unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-DE578BEB0AD9FCAF606412B9AF3DDCB8" unitRef="number">0.2</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-BACCE3293BFAE4C8D7CB12B9AFFB600A" unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-0D978627C01DC70BE44E12B9ADFD0D0C" unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-EE428D9FE2FB280A748512B9AFA1E022" unitRef="number">0.02</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-667780BAE913F623860F12B9AFA110B5" unitRef="number">0.12</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="FD2017Q2YTD_us-gaap_MajorCustomersAxis_exel_GlaxoSmithKlineMember" decimals="INF" id="Fact-DBA8DCE2A9C71567E91412B9AF3DBE06" unitRef="number">0.03</exel:PercentOfRoyaltyOnNetSale>
	<exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-04002E2CA5BC7760693C12B9AECF2F29" unitRef="number">0.25</exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce>
	<exel:ProfitSharingAgreementPercentOfProfits contextRef="FD2017Q2YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-358753F46028BF087BAD12B9AF47E57A" unitRef="number">0.5</exel:ProfitSharingAgreementPercentOfProfits>
	<exel:ProfitSharingAgreementPercentOfProfits contextRef="FD2017Q2YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-D3924AFA2D6F54D7497212B9AF47485A" unitRef="number">0.3</exel:ProfitSharingAgreementPercentOfProfits>
	<exel:ProfitSharingAgreementProfitThreshold contextRef="FD2017Q2YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-9267370DC6DE585258C612B9AF97CF09" unitRef="usd">200000000</exel:ProfitSharingAgreementProfitThreshold>
	<exel:ProfitSharingAgreementProfitThreshold contextRef="FD2017Q2YTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-A879197C4BA4BD83277B12B9AF33508C" unitRef="usd">400000000</exel:ProfitSharingAgreementProfitThreshold>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="FD2017Q2YTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-85F5E66B47984024390912B9ADB7953D" unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="FD2017Q2YTD_us-gaap_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-D7F3B596A9AB43B750E012B9AFA1BF1A" unitRef="number">0.2</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-23C94A6B874D3562012912B9ADA880F8" unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" decimals="INF" id="Fact-1EF37F74F0C0F586F37612B9B023130E" unitRef="milestone">2</exel:RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved>
	<exel:RoyaltyTier contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-4A2768D4F93C33B3ED9412B9B005375F" unitRef="usd">150000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-77C29FEA29B0D905DF1A12B9AEC5FE4A" unitRef="usd">50000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-4E92406B538A8F7998A612B9B04BBF25" unitRef="usd">300000000.0</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="FD2017Q2YTD_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-02EDCE5CE424F2A2400512B9AF155A8F" unitRef="usd">100000000</exel:RoyaltyTier>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-6D3867286C74B65127E812B9AE07A2DD" unitRef="usd">58173000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-A514C13E9A0CDD081CBA12B9AE1158FD" unitRef="shares">280657</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-936050088464CFB81BC212B9ADFD3E23" unitRef="usdPerShare">4.24</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue>
	<exel:TenantLeaseImprovementsAllowance contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="-5" id="Fact-6A8AC8044EBFA588CD95862D60C88960" unitRef="usd">6700000</exel:TenantLeaseImprovementsAllowance>
	<exel:UpfrontAndMilestonePayments contextRef="D2016Q1Mar01-31_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-A95014A83E69259A283812B9AFF1EEB4" unitRef="usd">200000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontAndMilestonePayments contextRef="D2017Q1Feb_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-5B14F824C8B64A571C3E12B9B04BE613" unitRef="usd">50000000</exel:UpfrontAndMilestonePayments>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AFE26984752D607804C412B9AF837F4B" unitRef="usd">6565000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-CAD932406B601DDCA7F712B9AF65C83F" unitRef="usd">7037000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C27A991BD8FF632DCF8A12B9AF517045" unitRef="usd">20334000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-F9FCD969369ABCEB852912B9AF6F5305" unitRef="usd">15555000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedMarketingCostsCurrent contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_exel_TradeandOtherReceivablesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-5" id="Fact-384456063B9E76B254449920FED5745C" unitRef="usd">1800000</us-gaap:AccruedMarketingCostsCurrent>
	<us-gaap:AccruedMarketingCostsCurrent contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-5" id="Fact-427D131F66638C45A70612B9ADFDA108" unitRef="usd">-1800000</us-gaap:AccruedMarketingCostsCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-9553EDAFEDEDE6A69C3F12B9AF8D0E3B" unitRef="usd">24882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q2" decimals="-3" id="Fact-9342022BC43F1E73A16912B9AF974C09" unitRef="usd">22828000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-C04ABD4CDEFA54B8A0B212B9B04B295C" unitRef="usd">-416000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q2" decimals="-3" id="Fact-D4A7C9C628A445D975EC12B9AF6F7AD4" unitRef="usd">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-18FB613B834ADF9056A512B9AFFB0AC2" unitRef="usd">2072591000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q2" decimals="-3" id="Fact-1FAB8BA67B942F980FB212B9AF5B8DC3" unitRef="usd">2097379000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-179D108BCD2AB15014E212B9AFBF797E" unitRef="usd">3558000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-CC2EF8AD192F65337E1C12B9AFB528D7" unitRef="usd">1165000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-0565D95B6BCAA5BF8CE112B9AFD31E4B" unitRef="usd">2393000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C63B5545F57E5990F1C612B9AD8A1561" unitRef="usd">14743000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-5AF9D73EFB68091B396E12B9AD801346" unitRef="usd">6729000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-F2C58F69B6124281A44E12B9AD8002AF" unitRef="usd">8014000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-342607996C064788702712B9AFBF36B2" unitRef="usd">5027000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-55D2BF65C4BED00CC30A12B9AFBF3440" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-48356BD53AD19BE0171712B9AFC9BBE4" unitRef="usd">3427000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-CD61867B7F7F98A0AF6D12B9AD80DB91" unitRef="usd">9740000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-2F99E48BC77FFCA387EC12B9AD76545E" unitRef="usd">3078000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-D23423837E037C6F1A3512B9AD80182E" unitRef="usd">6662000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-B6DEB9F010D9CEEBC37E89F87A1EF25D" unitRef="usd">113000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q2YTD" decimals="-3" id="Fact-502ABB3A3BF7C1EB13FA12B9AD8A1C13" unitRef="usd">6411000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-D425C50953F164C3D50B12B9AD127DFC" unitRef="usd">206000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-7BEBFF1497C539FF872512B9B00590A3" unitRef="usd">-4301000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-C1245001F598C542418A89F87A0CA612" unitRef="usd">93000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q2YTD" decimals="-3" id="Fact-3818BC7531B51BF62C6212B9ADDFAE51" unitRef="usd">182000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-CA1A6A0D5D0215BEE06712B9AE93F922" unitRef="usd">182000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD" decimals="-3" id="Fact-900739BEF0FEB0099B5D89D431B947DB" unitRef="shares">119645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-6799FB7D8C5BA613231C89D43185548A" unitRef="shares">54118000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-1E3C408E567EC9FA4FEC89D46AFF27F8" unitRef="shares">33890000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-A267C7F7FFAF1CEC9FCB89D4599B6A52" unitRef="shares">30637000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-A2948CCDC387144EFA5089D4318D3466" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD" decimals="-3" id="Fact-7D789EB60E0CD686E81C12B9B0418ADE" unitRef="shares">119645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-5CACA8FC959C384F49EA12B9ADC13831" unitRef="shares">54118000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-BC387500402E3799092412B9AF3D09D8" unitRef="shares">33890000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-9DB27E0E2BB3EAE9C2D212B9ADABE74B" unitRef="shares">30637000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-54DBEA59D42C2F4ECB6E12B9AE9D5288" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD" decimals="-3" id="Fact-29AE805D37735893FE9789D431B23E51" unitRef="shares">1747000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-21A64EADBBCC20399BDD89D431DC82F0" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-0C71CFB02D885C37A9E189D4660E41D4" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-EA263C140DC1AE88DA7B89D451EAF7ED" unitRef="shares">1747000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-FE5850C6B1ACAE8D44BF89D431E9CAAD" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2YTD" decimals="-3" id="Fact-2E75224EF46143439C2012B9AEF716C8" unitRef="shares">1633000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-6927E3ADD892FDD5AE4E12B9AE89DB6C" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-95C2752A2AC0CD0FC7A612B9AEF728D4" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-EA2230DD3AAA4EFD7C9712B9AF15165D" unitRef="shares">1633000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-E0314058DAE91EF3A9DA12B9B060EB05" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="0" id="Fact-F7E93F385447817E8A01861B37B808B9" unitRef="sqft">110783</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-F84D1B7CCDE0A236088E12B9AF335A8B" unitRef="usd">595739000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q2" decimals="-3" id="Fact-066707B5674089D5AB7E12B9AF8322DA" unitRef="usd">516532000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-39BC6E4186082A0C74ED12B9AF83BB30" unitRef="usd">469001000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-A7BF4781E8C016DBA22812B9AFF17826" unitRef="usd">402239000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4" decimals="-3" id="Fact-ECDE52B69D07F2C804DF12B9AD4EDB09" unitRef="usd">459966000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-834EBF6A8B407CBC235B12B9AE617933" unitRef="usd">71457000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-997C3CC32182BB6FFF7C12B9AE4D9BBB" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-1E190E2823EAB163A5E412B9AE4D12FF" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-34E0AA775A476C26C5D812B9AE75E58B" unitRef="usd">71457000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-37D7B959DEC2F142925912B9AD6287CF" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-CEE885B2FA3CC5966FD512B9AE5755D3" unitRef="usd">388509000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B56F9E68584C958E238312B9AD622282" unitRef="usd">165375000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-CC435E29481F7602C9EF12B9AE75F08B" unitRef="usd">152407000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-DE8F47057E2FA02FB78C12B9AE750A6B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-592A232C1E4E0366646812B9AE6B1B80" unitRef="usd">70727000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-9CDA77E94D33E6CE860812B9AD62212F" unitRef="usd">165375000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-03334A8DE9A21E523B7B12B9AE57EE4C" unitRef="usd">152407000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-290B4DA70E84F6AD4C9B12B9AE575C91" unitRef="usd">71457000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-9E89F5AC58705F008F1B12B9AE4D511D" unitRef="usd">70727000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2" decimals="-3" id="Fact-9328FE84134F491EC66112B9ADDF0F5C" unitRef="usd">368225000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-597FB5627373B3F0B7D112B9AD944FD4" unitRef="usd">48253000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-7D036EB1F107C4F56C6012B9AD8A731A" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-469167B16EFDABF712A512B9AD8AD2F3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-1FB8CE0B299362F35BE112B9AD94247A" unitRef="usd">48253000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-8A57EFA79CF0286F984C12B9AD9E1DB0" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-0A3B730F579726ADD91112B9AD8AC02A" unitRef="usd">319972000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C3569653B3B1FF40F06B12B9AD94A4ED" unitRef="usd">303786000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-C1B53F451A7DE5301D9912B9ADA8DAB2" unitRef="usd">550000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-B4D055A45EF5E7190B3F12B9AD94267D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-9DE067B92FE46C27F4BA12B9ADA8FBE5" unitRef="usd">15636000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-D8B17A6F8E12230D730D12B9ADDF9A54" unitRef="usd">303786000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-56A1B9959EF140A1F93E12B9AD80242D" unitRef="usd">550000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-E7542DE31D2E9E7D78BD12B9AD8AA813" unitRef="usd">48253000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-84545C5156676AD3AE0212B9ADD57215" unitRef="usd">15636000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4" decimals="-3" id="Fact-F5D671176A0BCFE3713612B9AD6216B3" unitRef="usd">459966000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-AA69DDD43B02805F4D1D12B9AD620A20" unitRef="usd">165375000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-0179B2C57A0BE1272CE812B9AD588B77" unitRef="usd">152407000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-F9910D9642F55EDACFE112B9AD4EAB60" unitRef="usd">71457000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-245EF97AC03DE77DB67112B9AD44EABF" unitRef="usd">70727000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q2" decimals="-3" id="Fact-0FA7FA8AB51E8E8966E212B9ADFD2BC3" unitRef="usd">368225000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-5615A6BC4BAA39B39C7112B9AE1B5F3D" unitRef="usd">303786000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-4DCFD9673FD88339396E12B9AE07E32D" unitRef="usd">550000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-45C3335850EF7306B52F12B9ADFD243F" unitRef="usd">48253000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-4F558FBE262FE2B3291112B9AE11B791" unitRef="usd">15636000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-247E53F98A92C09BDF5612B9AE6B49AA" unitRef="usd">14000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-46025B2C53FFBE23382812B9AD3AD139" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E397813B7F7AD9F08FF612B9AD44E535" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7AB8CFB2FDD02596C37612B9AD6C9E16" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-41EFD02E61C51D91CCED12B9AD44E0ED" unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q2" decimals="-3" id="Fact-6D5824B926CAE30E242D12B9AFABC3F4" unitRef="usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B41E5656ED2A3FBA027412B9AFB507C9" unitRef="usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-24024330AE232855180412B9AFB54A6F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-574C940C0C5B8BFC23D612B9AFB5DDC9" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-D4E038297569D4C3F95B12B9AFB51974" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-34D42DE4D5190B13DC2A12B9AD3A2349" unitRef="usd">322000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-CF2B982AB2E4B2880C1E12B9AD626CF5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-F6848D214FB3ADA05A2612B9AD301C28" unitRef="usd">308000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-4549AC688BB5C7EB857F12B9AD441737" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-E8DBBE57D34A5995DA1512B9AD4EAA0B" unitRef="usd">14000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q2" decimals="-3" id="Fact-54FDC840AD3811E1585112B9AE89C32F" unitRef="usd">160000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2E501A33786AE329E8A212B9AFB59785" unitRef="usd">132000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-4E29576D4CC5E0A55DA112B9AFA1EF54" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-C9EFFED7B79F672CA62D12B9AFA1C96F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-F0E9790B7A14EEF89F2912B9AFB50C01" unitRef="usd">28000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4" decimals="-3" id="Fact-F0DA3AC66AE52C4CE83712B9AD628A7D" unitRef="usd">460274000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2434ACCCFFF91B304C6012B9AFB556A6" unitRef="usd">165375000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-2507EA12AC41AFEAC32C12B9AE393211" unitRef="usd">152712000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-65C10D14EDA838AD374312B9AD62774E" unitRef="usd">71457000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-CA7C5F3497CB1CD5D16A12B9AD3AA5B5" unitRef="usd">70730000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q2" decimals="-3" id="Fact-C597FD8F0F2091D99DE112B9AFABEFE8" unitRef="usd">368344000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-855BB8B1F3EB4274D7CD12B9AFABCAEE" unitRef="usd">303877000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-49587DF53AFDB63998E912B9AFAB6A38" unitRef="usd">550000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-AE02DB01A3A0EC40D5C412B9AFA14C77" unitRef="usd">48253000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-F8D6582E2B11910496EF12B9AFB5D7D2" unitRef="usd">15664000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="FI2017Q2" decimals="-5" id="Fact-0FCE88103736DBFF7A9312B9AE8910E4" unitRef="usd">133200000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-5" id="Fact-9C51B7F48B989BC37F0C12B9AE7F9350" unitRef="usd">117500000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-5" id="Fact-3D03D18C959D7BD089F985D4290FF7D8" unitRef="usd">15700000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q2" decimals="-3" id="Fact-56063A4190E15F13EB5712B9AE07299A" unitRef="usd">24414000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-A102EF1C7831FC81058012B9AE074F86" unitRef="usd">22214000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-122791612BC1B373F58912B9AE070D88" unitRef="usd">550000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-55CBC0A9835359EE4C3412B9AE1B647D" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-2EC5F8180AD5F30BD5FC12B9AE11EA66" unitRef="usd">1650000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q2" decimals="-3" id="Fact-4BB25A19620E9332F65712B9AE07A8C3" unitRef="usd">343811000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-347AF26BA2B3395BCA6D12B9AE073671" unitRef="usd">281572000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-17D99077C9BDD274510612B9AE117111" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-37479CFA2619753FC7EE12B9AE11032E" unitRef="usd">48253000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-C46EAE4B8207BE84A49312B9AE115A32" unitRef="usd">13986000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="FD2017Q2QTD" decimals="-5" id="Fact-FD0ACBFC1DD856CC4EB112B9AE893F07" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="FD2017Q2YTD" decimals="-5" id="Fact-04D2187C26252D475D1E12B9AD268002" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
	<us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear contextRef="FI2017Q2" decimals="INF" id="Fact-7F66B0411E5378BD547C12B9AE93DC58" unitRef="investment">75</us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-F3AFD415928C7330732D898FB0025C4D" unitRef="usd">17728000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-BC542FA4E5F176737FDC12B9ADABD032" unitRef="usd">10775000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-67B6FEC16390E8CE579F898C60362006" unitRef="usd">1745000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-E780F1C31C71F640545089858036A4E8" unitRef="usd">637000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-F255AB68F8569380D160898C54952B02" unitRef="usd">1685000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-B39F033381CA77D36DD1898533C38361" unitRef="usd">630000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-476F92D10A3023261E4A898C425CA7A4" unitRef="usd">1477000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-97DA4BDEBCDFEEC0C76512B9AF297935" unitRef="usd">605000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-22EC3FD28CA33E27E7E6898C1D846DF7" unitRef="usd">566000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-21706482C2D35825579612B9ADA9A610" unitRef="usd">2802000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="-5" id="Fact-EA2F359635508C2B09A489B7E172C643" unitRef="usd">24100000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_FinancingLeaseObligationMember" decimals="-3" id="Fact-5A2EBCDB9CC9FF0F6BC7898AA23B6E0C" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_CapitalLeaseObligationsMember" decimals="-3" id="Fact-0BF8B7A35749F03C516D12B9ADB77318" unitRef="usd">1990000</us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-7A4AD6E6B9195C21AFB312B9ADB7022A" unitRef="usd">141634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-3" id="Fact-F8E7A6D82B4C9288EA9B12B9ADD5A54E" unitRef="usd">129827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-CBBC51EA3090ACE238D512B9B0193F90" unitRef="usd">151686000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q2" decimals="-3" id="Fact-DCE3153BE3E165148AE712B9AF6507E4" unitRef="usd">135212000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A17231D124644EB9376212B9ADA99BD4" unitRef="usd">-11807000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q2YTD" decimals="-3" id="Fact-5D61DBA95A34072019C112B9ADA82DB8" unitRef="usd">-16474000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-8CF5A84EF7153701CC7212B9AF5B8354" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q2" id="Fact-AE9F1E2627664BB418CB12B9AF6FA6D2" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-70A8ECBF70DE7C075C3412B9B019635B" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q2" decimals="INF" id="Fact-2DC2084BB5567E2A7C3012B9AF0152D5" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-E18500D0D90A02AFA3B812B9B005DC6A" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q2" decimals="INF" id="Fact-E63F91C878E5728C349012B9AF1F051A" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-B6B8C4C9A134081874D412B9AF012E07" unitRef="shares">289923798</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q2" decimals="INF" id="Fact-25CA549FA589C5E0B66612B9AFF1CD90" unitRef="shares">293727630</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-C7A0AB356DE43FC68BC112B9AFF1F18A" unitRef="shares">289923798</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q2" decimals="INF" id="Fact-650ED18B76E434AB8AD812B9AF015BAF" unitRef="shares">293727630</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-664CE6541B82523E0E0912B9B04C3D69" unitRef="usd">290000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q2" decimals="-3" id="Fact-9E5FBDC160E97FFD909912B9AF6F8F82" unitRef="usd">294000</us-gaap:CommonStockValue>
	<us-gaap:CompensatingBalanceAmount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember" decimals="-5" id="Fact-7C89096D08AE4321F1E112B9ADD55D56" unitRef="usd">81600000</us-gaap:CompensatingBalanceAmount>
	<us-gaap:CompensatingBalanceAmount contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember" decimals="-3" id="Fact-F0B1F1D96A6DE403261212B9AE89660C" unitRef="usd">81600000</us-gaap:CompensatingBalanceAmount>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q2QTD" decimals="-3" id="Fact-1DB3BE4A040A9DE3A90512B9AECFD511" unitRef="usd">-34667000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q2QTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-8AC2EFEC743E4C2C3752856C4DB0F976" unitRef="usd">2177000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q2YTD" decimals="-3" id="Fact-520D4064AC54D20B06D412B9AF1F003B" unitRef="usd">-93700000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-9815F5FF640440DE74B512B9B019BC74" unitRef="usd">4301000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q2QTD" decimals="-3" id="Fact-5CBEF1BCBBEEA286986412B9AED99630" unitRef="usd">17863000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q2YTD" decimals="-3" id="Fact-D1A6409404E231E8928012B9AF1F35B9" unitRef="usd">34653000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-E457BF2DD360BBB444EB89DB8B8A425A" unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-88DA209591B751599CE589DB90138F62" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-CC31F20DB38FD93BC96789DB86B3C379" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-5C966364457C1DE2B76A89DB81E9CF0F" unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember" decimals="2" id="Fact-9B8333D223252B7BD25189DB94BC3F13" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-DA5941BE863791B701CD12B9AD6C4C75" unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-7E0FD5B23D91995E466C12B9AD80F4E9" unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-0894542337B0CEC5A7F512B9AD76681F" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-F2F239DEC5785DE0732512B9B04C2B1F" unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember" decimals="2" id="Fact-13EC68DF7128D2BA4E8012B9B04CA491" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-7632140287B4F5FCF9C789DB88E4611A" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-8CF591FD94091E9955A589DB8D7EF3FD" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-508891972C42B4EF319D89DB83D651B3" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-353495363D423F19908589DB7F4E7753" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember" decimals="2" id="Fact-023037B6F3E6FD056C3B89DB921056F9" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-ABCB03FC581F59BD0E5B12B9AF5B3077" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-49CA0897F2F8A62254C412B9ADD5A0B0" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-38168B2736347034D4B312B9AF831C51" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-C6C32D2F8BC115BFD4AF12B9AD9428EE" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-B7D584C9DDF02D35051D12B9B04B8771" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-AE168C0CADCA1371D61912B9AD6CA2B6" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-635BA00C1C812B615D2012B9AD8A8183" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-247EB14EDBBFFE5FD7F812B9B04B8AA6" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_MerckMember" decimals="2" id="Fact-0A17326D62D376B983FE12B9AD7641C6" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="FD2016Q2YTD" decimals="-3" id="Fact-3185C159C55747576187854E89CC5943" unitRef="usd">0</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="FD2017Q2YTD" decimals="-3" id="Fact-02E77C7B15572958F3609FB7683F765C" unitRef="usd">14530000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q2_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="-5" id="Fact-F13CD92DDB0182FD561B854E89AA04BC" unitRef="usd">14500000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2QTD" decimals="-3" id="Fact-C5921416BAA45A2E069612B9AD306C99" unitRef="usd">4634000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP" decimals="-3" id="Fact-B717A0A6D27DB971BF1789DC84BDDF23" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-F39CB1323699D0DD3BB289DC5208A030" unitRef="usd">32192000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-9A9A1C63B2EEE3B3C0D789DC7D3ADA38" unitRef="usd">4060000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-F8EAA5B85F303A1FEC62858ABA90BA9C" unitRef="usd">3592000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2YTD" decimals="-3" id="Fact-9AC0021A3432B6E4A9A112B9AF5B3086" unitRef="usd">10962000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP" decimals="-3" id="Fact-DDA575D6BA0FA3C2BA6212B9AFD31727" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-9C32BF96E681A6AA7A7412B9AFD36BCF" unitRef="usd">45786000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-2CF81458EB751E08089F12B9AFD32B50" unitRef="usd">5893000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-C910705D2D6E3003883E12B9ADDFAC10" unitRef="usd">4790000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD" decimals="-3" id="Fact-C6B2339D0C39846933CA12B9AD44446D" unitRef="usd">11004000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP" decimals="-3" id="Fact-6E19D3310E935247311889DC7F6470E9" unitRef="usd">4143000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-06B53EE2BF58F241082989DC520B47D3" unitRef="usd">89371000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-EAEB8AE28A0966AE022489DC7AD3D44C" unitRef="usd">5494000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-36A92F35B7FCB11D64EC858AB0E0A085" unitRef="usd">5494000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-07EC315ACA822953F37785971CB0C7C9" unitRef="usd">4143000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2YTD" decimals="-3" id="Fact-BC6D0EBE6A12A26F39A512B9AE6BB372" unitRef="usd">23014000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_JP" decimals="-3" id="Fact-A379F187327540D7176A12B9AFD37DF2" unitRef="usd">6825000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-4011475D4F2175890C8B12B9AFC97C1C" unitRef="usd">163046000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-4E4F6D64F59C5F3B4A6F12B9AFDD360C" unitRef="usd">10024000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-8816A9913746D5188A1812B9AE6B4DEE" unitRef="usd">10024000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-C1856D19EFB50FB2744B12B9AD1CA880" unitRef="usd">6825000</us-gaap:ContractsRevenue>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6656B6EF4A5F7299A78812B9B0057236" unitRef="usd">109122000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-65945203AD69BF0F7D5212B9AE25FADC" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q2QTD" decimals="-3" id="Fact-A3F38B126A174076082812B9AD4ED6C5" unitRef="usd">1560000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-3A7607CE783210127E51858A99B6D33F" unitRef="usd">0</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q2YTD" decimals="-3" id="Fact-DD7BA9DB479606AF91E412B9AEE3345A" unitRef="usd">2245000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-7F400A6E2AFB84D2E6C912B9AE4D2FA5" unitRef="usd">0</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q2QTD" decimals="-3" id="Fact-ACABB91956CA54D34CE712B9AED9D53A" unitRef="usd">3014000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-D903351F99DD4EDFDC1D858A9563512C" unitRef="usd">811000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q2YTD" decimals="-3" id="Fact-92E3305940CC863B6FA512B9AD8A0EF9" unitRef="usd">6217000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-51869858751B59CA40F412B9AE570EF9" unitRef="usd">1802000</us-gaap:CostOfGoodsSold>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-6445E2BA6A6518263F2112B9ADFD4F9D" unitRef="usd">300000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q2YTD" decimals="-5" id="Fact-60CE7A3A2805859DA9CF66486AAB5A0C" unitRef="usd">1700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2012Q4_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="INF" id="Fact-B0C5E26B1522EF61BDDD12B9ADF31D9C" unitRef="usd">287500000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2012Q4_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="INF" id="Fact-C29BB20EAC97E8CE706012B9ADFDECAD" unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="INF" id="Fact-855651375548FD99645812B9ADDF4971" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredIncomeTaxAssetsNet contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member" decimals="INF" id="Fact-EC7AF83AC5A6E918A55012B9ADE9A5CD" unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
	<us-gaap:DeferredRevenue contextRef="FI2017Q1_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-C15DFFB41876A35816DB12B9AD8AA798" unitRef="usd">9000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-69DD75F9ED68A53884A612B9B00578CD" unitRef="usd">19665000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-D4483B7CABADE365602D12B9AFF1CFAA" unitRef="usd">31255000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-451DA915851B79459A3212B9AF83D3E5" unitRef="usd">19000000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-84548F038A5017BBDC4B12B9AF15BA87" unitRef="usd">11300000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9215018D2BF4EF98A92F12B9B00585B2" unitRef="usd">237094000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-15540F27D5DB929E238C12B9AF659143" unitRef="usd">253663000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-1C25CEAE4C7AA179D52712B9AF8D90E2" unitRef="usd">219700000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-5E21F0AB438B5451CEAD12B9AD1C7B48" unitRef="usd">34000000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-5E579C4C0EEFE7C019DE12B9ADF3AE2B" unitRef="usd">21200000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-5C9FF4BE2409F44E663C85777841C42B" unitRef="usd">21200000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:Depreciation contextRef="FD2016Q2YTD" decimals="-5" id="Fact-CA019C80DFDA5729F0F38AFC1F92FDA4" unitRef="usd">500000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q2YTD" decimals="-5" id="Fact-A5DEDCD726ADD49B45B912B9B0052DEA" unitRef="usd">500000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q2YTD" decimals="-3" id="Fact-DF6C8ADB4C2E1014835F12B9AD8A8910" unitRef="usd">456000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A1468395F44D7DD254EC12B9AE7F2D64" unitRef="usd">563000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2QTD" decimals="2" id="Fact-C99CD50A65A1A2AECD0A12B9AD58F072" unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2YTD" decimals="2" id="Fact-6C8921E6CEABFCA77D6712B9B060B7D2" unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-768F13C6067FDE487DC912B9AF296745" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2YTD" decimals="2" id="Fact-8CEBEC20DA6EADB7AC2912B9AD942F08" unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-F5EB7C3EBE3699857B39855E659DCD28" unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="2" id="Fact-389A4916859CBB43CDB9856C4DB2485E" unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2YTD" decimals="2" id="Fact-BA14818DC7D615911C30855E659B26D5" unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="2" id="Fact-35DC66F772E0CC48EF2512B9B019594F" unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-423242D9FFB1D3E509AE852E51411CBD" unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q2YTD" decimals="2" id="Fact-2E6EFB8C2F4B184CBC6612B9ADD58FD7" unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-C66CBE3439F23E374A4B852E502C2FA0" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2YTD" decimals="2" id="Fact-016CD752FA1A7BBB63B112B9AE393B03" unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
	<us-gaap:ExtinguishmentOfDebtAmount contextRef="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="-5" id="Fact-4369ED24873E308C2B1E8B2BA7B3A881" unitRef="usd">80000000</us-gaap:ExtinguishmentOfDebtAmount>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q2YTD" decimals="-5" id="Fact-0E4C48C609BBD592C29E89E13E0DC503" unitRef="usd">-100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q2YTD" decimals="-5" id="Fact-DE45B8F858E03E301D4312B9ADA954E7" unitRef="usd">-100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="FD2016Q2YTD" decimals="-3" id="Fact-DF6C2A9459DE8470D79E12B9ADCB6BB4" unitRef="usd">0</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6B56D64C4B6CBF9110A112B9AF7916CB" unitRef="usd">639000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="INF" id="Fact-9DCF7E5A3A950B7E32D212B9ADDFCD6F" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-7B20CA7199765E7D859E8B01997C5065" unitRef="usd">-6200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q2QTD" decimals="-3" id="Fact-344DE0DAFA7319D555E912B9AD302AA1" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-79F3A5ADD821C0EF849312B9AF0B62EB" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q2QTD" decimals="-3" id="Fact-F79FBAB2B3CEDB6A619112B9AEE39E31" unitRef="usd">-6239000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-7C195398422C504F4B2312B9AF1FF584" unitRef="usd">-6239000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-3" id="Fact-BC5BBA3E746156119CD512B9AF65BB9F" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q2" decimals="-3" id="Fact-1B51E598C87CE6299D8712B9AE251E31" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q2QTD" decimals="-3" id="Fact-F866BE3E5E7E69CCF84412B9AD80411E" unitRef="usd">-34838000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q2YTD" decimals="-3" id="Fact-23397FFCF68D0800312F12B9AF157613" unitRef="usd">-94061000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q2QTD" decimals="-3" id="Fact-5C2613EEBBE59325443512B9AD7605D4" unitRef="usd">18237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q2YTD" decimals="-3" id="Fact-E8065D3E51EA640AC4CD12B9AF657181" unitRef="usd">35071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q2QTD" decimals="-3" id="Fact-A5C41B3295F54D026A3612B9AF1F1EBC" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q2YTD" decimals="-3" id="Fact-CD9BAB8EF2FDC1630BCC12B9AE39AE73" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9BA5DAF0D3C09D154F4E12B9AF0BC977" unitRef="usd">581000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6184A7E08F675D29659212B9AFBF74D4" unitRef="usd">715000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="FD2016Q2YTD" decimals="-3" id="Fact-E124CF32B5832AD5876612B9ADC142A0" unitRef="usd">11550000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="FD2017Q2YTD" decimals="-3" id="Fact-2664462D67C80ADB2D8712B9ADCB7569" unitRef="usd">2581000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C0CBAA5231270C6DE4F512B9AE4D3F91" unitRef="usd">-966000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q2YTD" decimals="-3" id="Fact-5069CB6E4D4D35DC4D0C12B9AD76EA2E" unitRef="usd">472000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q2YTD" decimals="-3" id="Fact-9DA0B92A92FE18D93F09854096985322" unitRef="usd">195469000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q2YTD" decimals="-3" id="Fact-1E9727EEB3FF2B649E4C8540969135AF" unitRef="usd">28159000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-AE82BFACBF5B283B071812B9ADABCC4F" unitRef="usd">6678000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-81BC18FBE71AEB2F01C612B9ADA988E4" unitRef="usd">-4779000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q2YTD" decimals="-3" id="Fact-B9426EECDF8AA3B12B4712B9ADC1E24F" unitRef="usd">192000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A6D994632683E4D85EE612B9ADC1E86E" unitRef="usd">2087000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BCE858D456C37B8E170C12B9ADCBF3E6" unitRef="usd">-99000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6C6133B445BABA1A5F9312B9AD943C77" unitRef="usd">-519000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-488D97145B06829DF9EE12B9AD8A3076" unitRef="usd">6346000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A6ACB12E2A5CCA4F180112B9ADC11368" unitRef="usd">7457000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q2YTD" decimals="-3" id="Fact-212683CA6C6F45ABE82E12B9ADDF082B" unitRef="usd">851000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6F2C7BF37EBCC2CB4B4F12B9AD9E8F90" unitRef="usd">-1049000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="FD2016Q2YTD" decimals="-3" id="Fact-E56E20BFCE46F21F649E12B9B0238159" unitRef="usd">-2650000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
	<us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0A41875AC3B03CD0845012B9AE6BC427" unitRef="usd">-5650000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
	<us-gaap:InterestExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-7F518EBB598EFEA6DE6112B9ADA8FC5A" unitRef="usd">10451000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q2QTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-2AACD8E0104DE38E1448856C4DB5DCDC" unitRef="usd">-2177000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-947590F8CD12AC849C0812B9AE07172C" unitRef="usd">20741000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-DB02D3690F7107AB0C3112B9AF83EBAC" unitRef="usd">-4301000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-CBC3F1781CCD6DB9A35E12B9AD8AAAA1" unitRef="usd">4259000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6B3B6FD3C1129872279A12B9AF7936CD" unitRef="usd">8679000</us-gaap:InterestExpense>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-809821D2A3F749F25C3B12B9AD3ADD18" unitRef="usd">4057000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-1B87032053B47BBF2CB812B9AD2649B0" unitRef="usd">8022000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-177B9C6CBAF5F88C1DD312B9AD447140" unitRef="usd">4259000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-F8D65BA8130350971B3312B9AE4DDA3B" unitRef="usd">8484000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestPaid contextRef="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="-5" id="Fact-29D790727FD3BFE00C7512B9ADCBA2D1" unitRef="usd">100000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-445D9BE64AC2F21084168B26B97D8F63" unitRef="usd">4200000</us-gaap:InterestPaid>
	<us-gaap:InventoryFinishedGoods contextRef="FI2016Q4" decimals="-3" id="Fact-88BFFFC0B6BF6D31E53212B9AE2F1F98" unitRef="usd">738000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="FI2017Q2" decimals="-3" id="Fact-E93C7C237A14E094204312B9AE2F3C46" unitRef="usd">1121000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="FI2016Q4" decimals="-3" id="Fact-A82F9121A10E9C04AA3312B9AE1BC625" unitRef="usd">3944000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="FI2017Q2" decimals="-3" id="Fact-DC42DBD511A2331B003F12B9AE255B6B" unitRef="usd">5568000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-B980456760C22C5122B712B9AFF1C4F3" unitRef="usd">3338000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q2" decimals="-3" id="Fact-E6FD608240E4FB7CA6BA12B9AF79396C" unitRef="usd">5425000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-CB8968077D571952796812B9AE2FB1C5" unitRef="usd">606000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-4E63A1F058E67E04ECDE12B9AE250747" unitRef="usd">143000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterials contextRef="FI2016Q4" decimals="-3" id="Fact-B32B14BD92DFC71198EC12B9AE259CE2" unitRef="usd">863000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials contextRef="FI2017Q2" decimals="-3" id="Fact-ECECE96274153C6D97A412B9AE1B8C21" unitRef="usd">528000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess contextRef="FI2016Q4" decimals="-3" id="Fact-4372D4133E4348918A1812B9AE111735" unitRef="usd">2343000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="FI2017Q2" decimals="-3" id="Fact-734F772267AE31C06FC412B9AE11838E" unitRef="usd">3919000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWriteDown contextRef="FD2016Q2YTD" decimals="-5" id="Fact-FC93D4A544BC1C3BEA5D9487C19FBF3B" unitRef="usd">0</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2017Q2YTD" decimals="-5" id="Fact-E08D9E9139686B11EDB012B9ADE976D6" unitRef="usd">500000</us-gaap:InventoryWriteDown>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-863F672FBC53104ADC9989A8E7A8981F" unitRef="usd">3194000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0CC8C2E442B45E08C4DC89A8E7B77BA4" unitRef="usd">5453000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-3A7DDE262890C473751289A8E798B0AA" unitRef="usd">1493000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-1576A59D61877E7B890389A8E7E67C6B" unitRef="usd">3771000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="FI2017Q2" decimals="0" id="Fact-1E9DEC96367C6A6A383B89AE90A3F36B" unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-3C60E2F8E35772BAB1D512B9AFF1E2AB" unitRef="usd">506421000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q2" decimals="-3" id="Fact-3C6149FE3F938D4DA5CE12B9B0239DCA" unitRef="usd">368021000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-326FA193E9D455781BCF12B9AF838775" unitRef="usd">595739000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q2" decimals="-3" id="Fact-5D5D671E4C8E701A34C112B9B037479D" unitRef="usd">516532000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-2F73F715ADCCCB96A25D12B9AFDD4040" unitRef="usd">268786000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-BBE787214ACCC7EE6E3B12B9ADA9531A" unitRef="usd">97671000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2017Q2May31_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" decimals="INF" id="Fact-59E67A5C76ADE18C4EAA89ABFE5EF800" unitRef="usd">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-3" id="Fact-2AAED5B2FEBC2C67EEC712B9AF0B8DEC" unitRef="usd">189122000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-67FA5F8E84F69318DBCF12B9AF0184C7" unitRef="usd">109122000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="-3" id="Fact-D538245C21AF077179A112B9AF017412" unitRef="usd">80000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q2" decimals="-3" id="Fact-6D895D52399C5C27413B12B9AF01E2B3" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-C29C1C9F9D3CE1BA200112B9AF0B69C7" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_exel_TermLoanMember" decimals="-3" id="Fact-065B888D3743AD63797C12B9AF01A1E0" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-0CD59B9C3D4824E885B412B9B00F4A90" unitRef="usd">55601000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="FI2017Q2" decimals="-3" id="Fact-C8045293D960B5C0ED6C12B9AFFBB414" unitRef="usd">26413000</us-gaap:LongTermInvestments>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-6E12140D4C0D857613A012B9ADCB5011" unitRef="usd">627000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q2YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-92AB22901C726E4AFFB78577BB6D329A" unitRef="usd">-2100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-10C09E78800CDC050CA812B9AD9EEE8A" unitRef="usd">-172086000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-4010C328E304B116A0C712B9AD8AEE40" unitRef="usd">-143510000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9198C158A9C2AC882CFA12B9ADE9F3A4" unitRef="usd">81219000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-943E6CA46B48CBD17CEB12B9ADC1452F" unitRef="usd">131076000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q2YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-3D318B6203F33BEDC23812B9ADE91763" unitRef="usd">2100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0951CF5352627C6EF56D12B9ADA827AF" unitRef="usd">74393000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-D607826BDE19D788189212B9AD4EBA96" unitRef="usd">-34838000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-5D43B0975E7A4036DDE612B9AE43B5C1" unitRef="usd">2177000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2YTD" decimals="-3" id="Fact-5BD1C9D3CE457CC0CB2B12B9B0238E6A" unitRef="usd">-94061000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-195E684967D50450DFFC12B9B019394B" unitRef="usd">4301000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-F1A4C9469FDE2F8C69D212B9AE116597" unitRef="usd">17656000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2YTD" decimals="-3" id="Fact-499162BD915E6E879EC812B9ADA8803F" unitRef="usd">34356000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q2QTD" decimals="-3" id="Fact-088208615BEA4C0A47E289D355E04545" unitRef="usd">-34838000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q2YTD" decimals="-3" id="Fact-41D076CFDFCA4C15298F12B9AE2F9C4E" unitRef="usd">-94061000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-F52E8CA9B4AF6BBD0C8789D352C15994" unitRef="usd">17596000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q2YTD" decimals="-3" id="Fact-5A3120DF95407B54AC9A12B9AF1548C3" unitRef="usd">34239000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2016Q2QTD" decimals="-3" id="Fact-38800CE6AF412802908F89D360483B2D" unitRef="usd">-34838000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2016Q2YTD" decimals="-3" id="Fact-888AF8F83663CD9ECFB512B9ADFDE1EE" unitRef="usd">-94061000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2017Q2QTD" decimals="-3" id="Fact-E2BEFD2F34F485ED29F989D35BAC30CC" unitRef="usd">17600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2017Q2YTD" decimals="-3" id="Fact-80CD7EE4C81DAA41D49312B9AD44E470" unitRef="usd">34246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-FFB1C7E368F6D784D46E12B9AF3D3921" unitRef="usd">-9702000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q2QTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-2CE5D14EEB6B71F902DD856C4DBB0ADE" unitRef="usd">2177000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-94345501B15E9488276612B9AD9E14A8" unitRef="usd">-19790000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q2YTD_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-CEAB3D924E7D6A050BBC12B9B00531B1" unitRef="usd">4301000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-68C7CDEEDDD41EB8266D12B9AD6223AC" unitRef="usd">-8876000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4226E1F2B0EFF116F17912B9AE93F285" unitRef="usd">-12228000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BA63247507A7E656178E12B9AF65350D" unitRef="usd">80000000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-1CFCDA6DC8DAEE10424812B9AF65C787" unitRef="usd">0</us-gaap:NotesPayableCurrent>
	<us-gaap:NumberOfRealEstateProperties contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_BuildingShellsMember" decimals="INF" id="Fact-158031EE71EF4449901489C4AC8A2239" unitRef="property">2</us-gaap:NumberOfRealEstateProperties>
	<us-gaap:NumberOfReportableSegments contextRef="FD2017Q2YTD" decimals="INF" id="Fact-8737EA29F6C0A7849D2E12B9B0418FF7" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q2QTD" decimals="-3" id="Fact-9FE172D7412FDE74A05E12B9AD76DD81" unitRef="usd">61388000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q2YTD" decimals="-3" id="Fact-1BB244A6A2C11643FC4C12B9B04C3B9B" unitRef="usd">125950000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2QTD" decimals="-3" id="Fact-D7761B15FFF1576E389712B9AD6C31E9" unitRef="usd">71895000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2YTD" decimals="-3" id="Fact-52491AA8970C4CA3A46512B9AF3D4D5B" unitRef="usd">132596000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-AB59FDAB938716D7977512B9AED94E19" unitRef="usd">-25136000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A32066554B1BB4A7213312B9B00FFE0C" unitRef="usd">-74271000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-52B12625CF3CCC82E84012B9AD3AA6BA" unitRef="usd">27113000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2YTD" decimals="-3" id="Fact-3CA93C68989814FEEDE412B9B005DB1F" unitRef="usd">47299000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-74EC17649BC45DD31ACD89A461464CA0" unitRef="usd">2299000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C15545A34EFF78A033DB12B9AF3361BE" unitRef="usd">3723000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-80AA2CA5FB50523F749B89A461454125" unitRef="usd">1187000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q2YTD" decimals="-3" id="Fact-47C967592E963A177F8C12B9AF1FE7EC" unitRef="usd">2546000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="FD2016Q2QTD" decimals="-3" id="Fact-04108CB7BA7C007F194389A5F6909524" unitRef="usd">895000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0E766156245AEEB9228712B9AF1585A5" unitRef="usd">1730000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="FD2017Q2QTD" decimals="-3" id="Fact-F6D04BAA17A2D9145B8B89A5F690B9FF" unitRef="usd">306000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6A92F5835C93D3FADE1912B9AF0BF4F2" unitRef="usd">1225000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_exel_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-8006A43B7567939FE1D512B9ADF37140" unitRef="usd">56900000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E4521F4862DCB7D364C512B9B00FF4A5" unitRef="usd">16923000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-0EECE5B56229BCF7414512B9AD942535" unitRef="usd">21225000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-96626B98DE631FF62ABF12B9ADA907FE" unitRef="usd">1232000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-D12E9A32A7BA16CBEF6C12B9B0418936" unitRef="usd">862000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q2QTD" decimals="-3" id="Fact-C3F3967703CF3162C06612B9AF0BD45C" unitRef="usd">171000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q2YTD" decimals="-3" id="Fact-03676565BA4D3F98722612B9AF29B914" unitRef="usd">361000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q2QTD" decimals="-3" id="Fact-8D5CDCA9E64053F621B812B9AEEDAB51" unitRef="usd">207000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0BAA4692E051DCD8024612B9AF1F8CCD" unitRef="usd">297000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2016Q2QTD" decimals="-3" id="Fact-341998F368D7D65059148A0A72261C42" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2016Q2YTD" decimals="-3" id="Fact-7B3BCA70E21A771A3ABB12B9AED9E744" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2017Q2QTD" decimals="-3" id="Fact-A8BC8C3C90013FFA96B68A0A708EDB11" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2017Q2YTD" decimals="-3" id="Fact-C278E1A0437080F7A6FC12B9AD26F021" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="FD2016Q2QTD" decimals="-3" id="Fact-33216E6E9794C7037EB18A0A96AD396B" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="FD2016Q2YTD" decimals="-3" id="Fact-14974DCA939768EB2B9112B9AD266FD5" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="FD2017Q2QTD" decimals="-3" id="Fact-75225E3136D1EE2107D58A0A946978C1" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="FD2017Q2YTD" decimals="-3" id="Fact-C825A78B3A7AE210463512B9AF29AEF8" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-970CFF796E9A412A46D7852A1FC18BBC" unitRef="usd">541000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-6ED16108BB1B43EC714B852A1FC60DB9" unitRef="usd">16687000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-1722403477FCAEB2C6F012B9AD766831" unitRef="usd">-921000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-729EAAD0DCF4D5F7957B12B9ADE9C64F" unitRef="usd">-1146000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-262402440DEFC3D7DD5F12B9AD8A5BCA" unitRef="usd">749000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A2EFEBB4AE9310917CD212B9B0374283" unitRef="usd">951000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-6B067FF12F4BFDF33F4012B9AD585358" unitRef="usd">1622000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0A020BC94F972E92A08212B9AF33D334" unitRef="usd">2690000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2016Q2YTD" decimals="INF" id="Fact-D6D3F460D38AA692DECA12B9B019936C" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2017Q2YTD" decimals="INF" id="Fact-B48E19DC6BBF8A4B692E12B9AE898725" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaidInKindInterest contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-26AC483173719C240BCF8B0860DF8D6F" unitRef="usd">13900000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2016Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-3439E174E05723B1EC728B1911B8FEC8" unitRef="usd">1972000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A72E781CD0ABBD4A6D4285409687A137" unitRef="usd">3908000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2016Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-E3E19C3CB1C4F20EDDB112B9ADDFA1FA" unitRef="usd">3908000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2017Q2QTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-537D7777FBFB703AC1D08B1910748612" unitRef="usd">2083000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2017Q2YTD" decimals="-3" id="Fact-45B4CA94860EC5972A6E8540969F7B45" unitRef="usd">-11825000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-9EE5406C9E9ED1AE9DE512B9ADCB5FEE" unitRef="usd">4151000</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BD1C350DB5F0654F7A9212B9ADA818BB" unitRef="usd">2059000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q2YTD" decimals="-3" id="Fact-8376334A8E333B17557812B9ADDF2655" unitRef="usd">2331000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-E3B2FAB71B34EEEB0E6412B9AE7F556A" unitRef="usd">199396000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-951FC01E6DDD3D42B1CD12B9ADA95D17" unitRef="usd">154809000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q2YTD" decimals="-3" id="Fact-02E343CCC5049070E9FD12B9ADF32750" unitRef="usd">1083000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q2YTD" decimals="-3" id="Fact-CB9C1A22FADB12353CC412B9ADD59B90" unitRef="usd">2312000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0BA3C45A3911A0560FD412B9AE4D3DC0" unitRef="usd">4150000</us-gaap:PaymentsToAcquireRestrictedInvestments>
	<us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="FD2017Q2YTD" decimals="-3" id="Fact-06887F9446776F94314B12B9ADA9A79C" unitRef="usd">6150000</us-gaap:PaymentsToAcquireRestrictedInvestments>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-155BB72BFDDD85EE9F3F12B9AD1C616E" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q2" decimals="INF" id="Fact-B8FF0B26FA77E863438D12B9B00F64B4" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-12D2659C4F2C10715F5112B9AFFB3E86" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q2" decimals="INF" id="Fact-4A614138D0552CB7103B12B9AFFBF8B8" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-93013BA471331D802EBB12B9AEF79A83" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q2" decimals="INF" id="Fact-5319ECF3D0078DCE903C12B9AFF17F77" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-B28420361CFB0060F46B12B9AF5BEF8A" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q2" decimals="-3" id="Fact-9B4ECA08C2D0F03D926F12B9B0370F8E" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-92711195944ACFBF0DE512B9AF79C239" unitRef="usd">5416000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-CA7BC1F90A0D2D482ED112B9B037DEF8" unitRef="usd">4433000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0BC2AFBE1ACAC9F04B8D12B9ADCB362E" unitRef="usd">58340000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-82E40BBC4B1A2493329D12B9ADD5873C" unitRef="usd">200893000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="FD2016Q2YTD" decimals="-3" id="Fact-11B5D335EE8FA068B06D12B9AF65B9D4" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9F3000AA5FB088E6DF378548E900D291" unitRef="usd">639000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-08FC419603EAF434C86912B9ADA8EFFD" unitRef="usd">17000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-621801D7A6FA65BA072E12B9ADA8EACF" unitRef="usd">37294000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F529E8B66682FCA6538D12B9ADD51653" unitRef="usd">112000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2017Q2YTD" decimals="-3" id="Fact-B2630745F4BE0F3B678512B9AE4D412A" unitRef="usd">14000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q2YTD" decimals="-3" id="Fact-EEA0A703DADCB14EED6D12B9ADD51371" unitRef="usd">2207000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q2YTD" decimals="-3" id="Fact-72208E62ADBF61A80A5912B9AD9EBC0C" unitRef="usd">12980000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockPlans contextRef="FD2016Q2YTD" decimals="-3" id="Fact-18D00A1A25DA4F612F78854B55578440" unitRef="usd">479000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="FD2017Q2YTD" decimals="-3" id="Fact-68627D883676A3A60F1312B9AF7902F4" unitRef="usd">3053000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-842696DB832957936C0F85E76968627F" unitRef="usd">26953000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-D2E4A58BC0AC21E7817812B9AEC50CAE" unitRef="usd">13738000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-D7BDA30611314384466F12B9AF97E419" unitRef="usd">4310000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-BD32C537B4546F3C2C5212B9AF8D7AAA" unitRef="usd">19000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-54464E967DF95A3AABA112B9AEBB9E21" unitRef="usd">2240000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-C42227F8DE3295138E6612B9AEBBD104" unitRef="usd">6646000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q2" decimals="-3" id="Fact-622A0489956AAD357EAC85E769612966" unitRef="usd">41512000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-79E4A48590F171F546CD12B9AF8D2F7D" unitRef="usd">13803000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-4D91CECAFA40F031AC2012B9AF97E02F" unitRef="usd">4286000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-CA9EDED7DDF13460A34012B9AF8DAA85" unitRef="usd">16787000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-CE8B8EE7F9F054EC119512B9AEC572F4" unitRef="usd">1921000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-33BFF50A110F8E592DAE12B9AEC52802" unitRef="usd">4715000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-A73E2E66D93866277FAE12B9AFFBE5C5" unitRef="usd">2071000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q2" decimals="-3" id="Fact-0B716D89FECC5F6A867512B9AF83C7A6" unitRef="usd">18684000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-34472AB658ADE6497EA012B9AF6F59C7" unitRef="usd">40444000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-8EF08736AB4C1CBD9DA712B9AF6F15A0" unitRef="usd">43125000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-5B25DE3E69663F8D9C8C858A7834ECE2" unitRef="usd">3592000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-2F16E81F944734FE234712B9AE6BA362" unitRef="usd">4790000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-5DCDD62388A83B5CAAF7858A74011855" unitRef="usd">4741000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-8F816BD969361AB878458597160BDB6E" unitRef="usd">2830000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-B5D2A97360CA30E6C68712B9AE7FA98A" unitRef="usd">9046000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-A58C05448AAAAFC4261712B9AFD32560" unitRef="usd">4717000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A1C91231B3467902D16212B9AD80479F" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9E31E28817821CBC35D212B9AD803750" unitRef="usd">185788000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-11E67B16A47E792E2E3512B9AD260A64" unitRef="usd">22984000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-582F9AB616B9DF627C1312B9AD8A6960" unitRef="usd">51910000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-521894385A5CC036457C12B9AD808EF4" unitRef="usd">28214000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-CDA3497B2328EF1B09C112B9B0410489" unitRef="usd">51424000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-20ABEEB9057C89AA43AC12B9AF794458" unitRef="usd">4150000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-54C142946F114FF7FAF812B9AF6FACB7" unitRef="usd">4650000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestructuringCharges contextRef="FD2016Q2QTD" decimals="-3" id="Fact-EE7F11404FD796D3754E12B9AD6C9D0E" unitRef="usd">1021000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q2YTD" decimals="-3" id="Fact-663C1E23FB81B8F3AF3312B9AD8ACC3D" unitRef="usd">1115000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q2QTD" decimals="-3" id="Fact-E71949449033F717FB5212B9AF0BAAF8" unitRef="usd">-60000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q2YTD" decimals="-3" id="Fact-83EF655F0318406849CC12B9AEE322F7" unitRef="usd">-32000</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-D3A7CD293102088A66A412B9B00F9170" unitRef="usd">-1983147000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q2" decimals="-3" id="Fact-DD1F94B6AAA8FF4C478512B9AF652A7B" unitRef="usd">-1949043000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4Dec_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember" decimals="-5" id="Fact-466909D9713B763CF77012B9ADA882E0" unitRef="usd">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4November_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" decimals="-5" id="Fact-A3D19AC41C995C7886A712B9ADA9BE71" unitRef="usd">60000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="INF" id="Fact-643163BA39D26ADBE2D785ABB46CB1F3" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="-5" id="Fact-CEF7F4176CD2F99E598612B9AECF37F5" unitRef="usd">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q4QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_StatementGeographicalAxis_country_GB_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" decimals="-5" id="Fact-A70E7E953CF35D082F0593E74CC52142" unitRef="usd">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_StatementGeographicalAxis_country_DE_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" decimals="INF" id="Fact-4F30CE0FCF547AB28DB412B9AFB52FF5" unitRef="usd">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="INF" id="Fact-FDDEEC3A613495F31B9F85ABA17F51BE" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-CCEB1ABEFD69968311DF12B9AF016168" unitRef="usd">2500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-3" id="Fact-AE1F5B6C9A43FB42239712B9AFFB84C9" unitRef="usd">36252000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2YTD" decimals="-3" id="Fact-156D204812AAF01CA06E12B9AED92CC6" unitRef="usd">51679000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-3" id="Fact-91CE852B67E596D29D3012B9AEEDBE28" unitRef="usd">99008000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2YTD" decimals="-3" id="Fact-31A4980735300581301812B9AD800400" unitRef="usd">179895000</us-gaap:Revenues>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-377507C33B735011C8BE85A671274507" unitRef="usd">946000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-0C3A952F8B743107DEDA858AAA0DD3AC" unitRef="usd">0</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-FDEDC9A1DE4EFBEC504C12B9AF3D16A5" unitRef="usd">1218000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-B7622B0DA381AB8B7BF712B9AE4D996C" unitRef="usd">0</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-2F1C5C6E45496EB2A31885A66C9B72D6" unitRef="usd">2962000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-25BF998D12740D22CC6D858A9E531C52" unitRef="usd">328000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-07CD13FDB34B2B8DA09912B9B0411737" unitRef="usd">5363000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-350641233789D4FF996412B9AE892BB1" unitRef="usd">664000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-24C6C418636D3B459D7585938ABB463E" unitRef="usd">1042000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-97A42D70FBF889DD1F01858A7EDD3A41" unitRef="usd">0</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-CDB61987B0BD1B9459BA85932A3FEFCF" unitRef="usd">1172000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-B3646600C22AF1C83FEB12B9ADDFCB55" unitRef="usd">0</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-5E4EE00C34AC7107194B859382B5CD0E" unitRef="usd">1367000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-9FA4E3712E46F1581C17858A7B7B73DA" unitRef="usd">219000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2YTD_exel_PeriodGeneratedAxis_exel_Q416Member_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-32CBBC9E7929EEC8A83712B9AFABF249" unitRef="usd">1100000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-09D2C8CFFC8B3C3B1DB785932A50E913" unitRef="usd">3665000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-D43D749527DAF92C8AA712B9AE75483C" unitRef="usd">443000</us-gaap:RoyaltyRevenue>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-FD3E04242E2301C102F312B9AEE3EDE1" unitRef="usd">31618000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-85811BA471055733AD34858A91C432EE" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q2YTD" decimals="-3" id="Fact-59A397ED3B4ADA33622F12B9ADCB1767" unitRef="usd">40717000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-1F1FED14CBDA53536CF512B9ADDF070B" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-CFC2CD02F0D3FF627C7112B9AF1F21FD" unitRef="usd">88004000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-1E3ED10CFEB24D47F1BD858A8CCDF1D7" unitRef="usd">811000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A60D44BE5DD36DFFFC3712B9B0050AF1" unitRef="usd">156881000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-CBEEBC35599C49A677DB12B9AE4D8346" unitRef="usd">1802000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-65CEA22169E4DC15155112B9AD8A2728" unitRef="usd">35823000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-3BAE2C4A37F679BFD54E12B9AD9E3F2B" unitRef="usd">70680000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-D1614CB74A6FB2BA562F12B9AD30E416" unitRef="usd">40727000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-B402AABEB86A677D8C9612B9B00559F6" unitRef="usd">74987000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q2YTD" decimals="-3" id="Fact-33E604F7D40CE17B86B212B9ADDF9D00" unitRef="usd">14743000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4B6C2BDD38D175478D8B12B9ADCBABF7" unitRef="usd">9740000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-9A8F8E53DCAB5DFF2BCB12B9ADFD148C" unitRef="shares">85543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-4A09A1F68630B88D963812B9AE076B21" unitRef="usdPerShare">10.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-1687B34B8DD7667842F112B9AE11404C" unitRef="shares">258272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-1F212EB0EF11223286B712B9AE11618B" unitRef="usdPerShare">20.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-621C99086FEF53D0A22812B9ADFDC22F" unitRef="shares">2469791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-2765834285758444E45212B9AE0727F6" unitRef="shares">2361863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-DDCA93B6B90452F32B3E12B9AE071038" unitRef="usdPerShare">8.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-4EBDD54361DAA2C9367B12B9AE11CA81" unitRef="usdPerShare">10.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-BCAB0A480434044B9B6112B9AE074575">P1Y8M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-291A7B31F2ADEDFBEAA712B9AE433FB1" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-7F4928A9854EDB7C421612B9AD448A70" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-9F57E962E7827051D51A12B9AED98F8C" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-5248A7E50792803B554D12B9AF8D623A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-53BDE2812D5F33DF5E3912B9AE61E8A0" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-E9C7380A6D22D3458EEA12B9AD30A8C5" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-D8EC4859F5862944E8EF12B9AF1FA8C4" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-563803169C1EE3A4510C12B9AF97BDA9" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-A9231E471A3A49AF4FB012B9AE39128F" unitRef="number">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-D0D0F710483168B361E212B9AD447B8E" unitRef="number">0.0090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-3E502AAB4F4069FF99E812B9AF014D2F" unitRef="number">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-8258C943745E9EF6BB6812B9AF97A52D" unitRef="number">0.0110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-AC445701F708A9A9499412B9AE43A41C" unitRef="number">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-E2C2B6997BFEA2F2EED412B9AD30FE80" unitRef="number">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-7A07D961D056A29D388E12B9AEA76F48" unitRef="number">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-DE341F03878EA9EFF62F12B9AFA1EC5A" unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-B114A03110FE8F98AD7512B9AE5798D1" unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-9C8EBC6C6ECE27CE4F4012B9AD44F947" unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-47CD990C5367E064D82412B9AEC56232" unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-CB51C88978A5C8BB9E7012B9AF8D9FF7" unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-1D82C2DC24B8B96F03EF12B9B0377FFD" unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2AB55A3F0EA5F25D2B5E12B9AD302E5A" unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-20FC5985C33B4168EF6412B9AEED72C1" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5C70C48047DE246365B412B9AF977D61" unitRef="number">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-D3D14B11C9B7027F0D7212B9AD58600E" unitRef="shares">24237774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q2" decimals="INF" id="Fact-9C35EB14CFC21CB22C3D12B9AE11252D" unitRef="shares">16181093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q2" decimals="2" id="Fact-A4A17AE4440C649549F112B9AE2F73D2" unitRef="usdPerShare">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q2YTD" decimals="INF" id="Fact-6227417D43097F71889212B9AE1B8F85" unitRef="shares">161836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q2YTD" decimals="INF" id="Fact-283EBB5C9071EB2E855A12B9AE2FDD7E" unitRef="shares">674110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-26BA07EEBBDC75DFA23912B9AD9ED183" unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-77BE50C6836ED532BDA412B9AD6C4514" unitRef="usdPerShare">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-9C2CEFF88879980188DD12B9AE39FA77" unitRef="usdPerShare">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-77A9AE3A1C0757E1746112B9AE2FFADE" unitRef="usdPerShare">2.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-1080225C2FE9D2C27C8A12B9ADD5B537" unitRef="usdPerShare">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-333B003CE3CC76BD4BF412B9AD947DBE" unitRef="usdPerShare">10.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-411CFCA3075143DCC60E12B9AE391872" unitRef="usdPerShare">4.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-7EA5E05655466CB716F412B9AE2F3672" unitRef="usdPerShare">10.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q2" decimals="-3" id="Fact-FFC3B8EE561D7AD5850D12B9AE1BCA86" unitRef="usd">426081000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-72F23140466146B0596812B9AE254199" unitRef="shares">24999665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q2" decimals="INF" id="Fact-B40976A8CF80729AB79312B9AE073ACB" unitRef="shares">22269913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-A6D08FC69E5CC2536C8D12B9AE1B75FC" unitRef="usdPerShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q2" decimals="2" id="Fact-6FD28637E0EBC5F186AB12B9AE25DD2B" unitRef="usdPerShare">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q2YTD" decimals="2" id="Fact-031A0A264ED62729E6DD12B9AE1B0834" unitRef="usdPerShare">4.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q2YTD" decimals="2" id="Fact-84899CC03F795A43BE9912B9AE1B8BE7" unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q2YTD" decimals="2" id="Fact-2B235996E9C9C7CDDADE12B9AE2FF359" unitRef="usdPerShare">20.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-CE2EF4137F58BBEA2CA112B9AE758B5B">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-671E17E37D0565097ED412B9AD3A3389">P4Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-0E79E3864E97A4B6B0DF12B9AECFB79C">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-ABCB4F70351CD33DA59D12B9AF8D5065">P4Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-93E099003D4ED2BA500A12B9AD6C621E">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-04CCB2F4A5A53FFFD89B12B9AD4EAFBC">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-A92F279B7644F45F454912B9AE7F0567">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-EC70466223FFF77131CC12B9AF972B87">P4Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q2" decimals="-3" id="Fact-919BA585146DA1E3073512B9AE11B0E1" unitRef="usd">331770000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q2YTD" id="Fact-730A4BB8E0005B9B0E2B12B9AE2F4181">P3Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q2YTD" id="Fact-2426A6ADF9BCECEE109612B9AE110C21">P4Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:ShortTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-75802E985BDB30507A5712B9B02DD716" unitRef="usd">268117000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2017Q2" decimals="-3" id="Fact-4225565000835353D6F112B9AF33F7E2" unitRef="usd">214044000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q2YTD" decimals="INF" id="Fact-AF54CCF035DA2E05E31312B9AE2F8613" unitRef="shares">3242026</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-3" id="Fact-2AA56751459A3E1E127D12B9AFFB3CDF" unitRef="usd">89318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q2" decimals="-3" id="Fact-02007B6DE52B862477C312B9B02DDB7D" unitRef="usd">148511000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="FD2016Q2QTD" decimals="-3" id="Fact-3A6CE30FF365F8856B1989D3501F09AA" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C230B2FF3ABC8FE6D60712B9AE7FF1BB" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9AF3C267DB512F598A0089D34CE49995" unitRef="usd">60000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9FACF46429684BB5C8C012B9AFBF2585" unitRef="usd">117000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="FD2016Q2QTD" decimals="-3" id="Fact-05DBEB0E2391C015DD0089D35A415E42" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D639222AD8BD3A57C37712B9AF9758E1" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="FD2017Q2QTD" decimals="-3" id="Fact-F03757092606E3BE7B5C89D357B860B5" unitRef="usd">-4000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9F031489DBF02D7EE9BB12B9ADD54A1B" unitRef="usd">-7000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q2QTD" decimals="-3" id="Fact-3CD2E59FF08C7F7DB38489D37569BF25" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q2YTD" decimals="-3" id="Fact-672E2461C494EDB4E28E12B9AD62E6FD" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q2QTD" decimals="-3" id="Fact-18A13236D92CC27E2F6189D36A7F040A" unitRef="shares">18031000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q2YTD" decimals="-3" id="Fact-F0922BD5C4622C5D7F5212B9AFABF524" unitRef="shares">18730000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q2QTD" decimals="-3" id="Fact-B4CC0C10A797ECCBC11112B9AF515B6A" unitRef="shares">229310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q2YTD" decimals="-3" id="Fact-B686EC0DE331A478B72812B9B023A032" unitRef="shares">228860000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q2QTD" decimals="-3" id="Fact-A7B65E8C5FE2FFC8404112B9AE6BD9F7" unitRef="shares">311219000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q2YTD" decimals="-3" id="Fact-C171A3BC4359E88C8CED12B9AE07400C" unitRef="shares">310759000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q2QTD" decimals="-3" id="Fact-D3C6A5646C714D41324F12B9AD94BD43" unitRef="shares">229310000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q2YTD" decimals="-3" id="Fact-B6B695EBE923EC095B6D12B9AD76791E" unitRef="shares">228860000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-2F2F9861C77C7667E51A12B9AEE38849" unitRef="shares">293188000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q2YTD" decimals="-3" id="Fact-769A001AA99AA3D6028712B9AF8353B4" unitRef="shares">292029000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<exel:AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-5B84AF4F9D786CE252D912B9ADE96EC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Correction of an Immaterial Error&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the third quarter of 2016, we identified errors in the Consolidated Balance Sheets and Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for 2015, 2014, 2013, and 2012, and in the unaudited interim Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for all prior interim fiscal periods from September 30, 2012 through June 30, 2016. Specifically, in 2012 we incorrectly calculated 1) the allocation between Additional paid-in capital and Convertible notes of the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$287.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; aggregate principal amount from our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4.25%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; Convertible Senior Subordinated Notes due 2019 (&amp;#8220;2019 Notes&amp;#8221;); and 2) the amortization of the debt discount associated with the 2019 Notes during 2012 and all subsequent periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Having evaluated the materiality of these errors from a quantitative and qualitative perspective, management has concluded that although the accumulation of these errors was significant to the three and nine months ended September 30, 2016, the correction of these errors would not be material to any individual prior period, and did not have an effect on the trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 99, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Materiality&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and Staff Accounting Bulletin No. 108, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Because management has concluded that these errors are not material, we will correct them prospectively when the consolidated balance sheets, statements of operations, comprehensive loss and cash flows for such periods are included in future filings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statement of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statements of Comprehensive Loss:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(93,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statements of Cash Flows &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss, overstated by $4,301 for the six months ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Not reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Not reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;These errors did not affect any other caption or total in our unaudited condensed consolidated financial statements as of and for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. See &amp;#8220;Note 1 - Organization and Summary of Significant Accounting Policies&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the amounts of the corrections and the amounts that should have been reported for 2015, 2014, 2013, and 2012 in the affected line items of the statements of operations, statements of comprehensive loss and statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</exel:AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock>
	<exel:CashCashEquivalentsAndInvestmentsTextBlock contextRef="FD2017Q2YTD" id="Fact-7B5F6BEDF6AE11D74DE512B9AE899922">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;CASH AND INVESTMENTS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;All of our cash equivalents and investments are classified as available-for-sale. The following tables summarize cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;135,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;135,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;214,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;214,044&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;380,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;380,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;268,234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;268,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;55,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;55,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;479,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;479,554&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under our loan and security agreement with Silicon Valley Bank, we were required to maintain compensating balances on deposit in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or more investment accounts with Silicon Valley Bank or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of its affiliates. The total collateral balance of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;$81.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is reflected in our Condensed Consolidated Balance Sheet in short-term investments; as a result of our repayment of the term loan with Silicon Valley Bank, the compensating balance requirement was terminated as of March 29, 2017. See &amp;#8220;Note 7 - Debt&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information regarding the collateral balance requirements under our Silicon Valley Bank loan and security agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following tables summarize our cash equivalents and investments by security type as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;460,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investments available-for-sale were nominal or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;All of our investments are subject to a quarterly impairment review. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; we did &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;75&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position with gross unrealized losses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and an aggregate fair value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$133.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The investments in an unrealized loss position comprise corporate bonds with an aggregate fair value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$117.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and securities issued by U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; with an aggregate fair value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The unrealized losses were not attributed to credit risk, but rather associated with the changes in interest rates. Based on the scheduled maturities of our investments, we concluded that the unrealized losses in our investment securities are not other-than-temporary, as it is more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes the fair value of securities classified as available-for-sale by contractual maturity as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (in thousands):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Mature within One Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;After One Year through Two Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;343,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash is excluded from the table above. The classification of certain restricted investments is dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. Therefore, certain long-term restricted cash and investments have contractual maturities within one year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</exel:CashCashEquivalentsAndInvestmentsTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-EC8240692AD97CBE586712B9ADF38C65">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-C421FCE668DF52709DB112B9AF1501F5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COLLABORATION AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement (the &amp;#8220;Ipsen Collaboration Agreement&amp;#8221;) with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Ipsen Pharma SAS (&amp;#8220;Ipsen&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;for the commercialization and further development of cabozantinib. Pursuant to the terms of the Ipsen Collaboration Agreement, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Ipsen &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan (the &amp;#8220;Ipsen Territory&amp;#8221;). The Ipsen Collaboration Agreement was subsequently amended in December 2016 (the &amp;#8220;Amendment&amp;#8221;) to include commercialization rights in Canada in the Ipsen Territory. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the Ipsen Collaboration Agreement, Ipsen paid us an upfront nonrefundable payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in March 2016. Additionally, as a result of the Amendment, we received a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; upfront nonrefundable payment from Ipsen in December 2016 and, as a result of the approval of cabozantinib in second-line RCC by the European Commission (&amp;#8220;EC&amp;#8221;) in September 2016, we received a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone in November 2016. We are receiving a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; royalty on the initial &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of net sales by Ipsen, and are entitled to receive a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; royalty on the next &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of net sales by Ipsen. After the initial &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of sales, we are entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; on annual net sales by Ipsen; these tiers will reset each calendar year. We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the Ipsen Collaboration Agreement; global development costs for additional trials will be shared between the parties, with Ipsen reimbursing us for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of such costs, provided Ipsen opts in to participate in such additional trials. Pursuant to the terms of the Ipsen Collaboration Agreement, we will remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities. As part of the collaboration agreement, we entered into a supply agreement pursuant to which we will supply finished, labeled product to Ipsen for distribution in the Ipsen Territories at our cost, as defined in the agreement, which excludes the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (&amp;#8220;GSK&amp;#8221;) on Ipsen&amp;#8217;s Net Sales of any product incorporating cabozantinib.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Ipsen Collaboration Agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Ipsen for all development and commercial activities, research and development services, and participation on the joint steering, development and commercialization committees (as defined in the Ipsen Collaboration Agreement). We determined that these deliverables do not have stand-alone value and accordingly, combined these deliverables into a single unit of accounting and allocated the entire arrangement consideration to that combined unit of accounting. As a result, the upfront payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, received in the first quarter of 2016 and the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; upfront payment received in December 2016 in consideration for the development and commercialization rights in Canada are being recognized ratably over the term of the Ipsen Collaboration Agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the European Union. At the time we entered into the Ipsen Collaboration Agreement, we also determined that the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone we achieved upon the approval of cabozantinib by the EC in second-line RCC was not substantive due to the relatively low degree of uncertainty and relatively low amount of effort required on our part to achieve the milestone as of the date of the collaboration agreement; the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was deferred entirely until the date of the European Medicines Agency&amp;#8217;s approval of cabozantinib in second-line RCC in September 2016 and has since been recognized ratably over the remainder of the term of the Ipsen Collaboration Agreement. The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestones for the first commercial sales of CABOMETYX in Germany and the United Kingdom were determined to be substantive at the time we entered into the Ipsen Collaboration Agreement and were recognized as collaboration revenues in the fourth quarter of 2016. We determined that the remaining development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. Reimbursements for development costs are classified as revenue as the development services represent our ongoing major or central operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the three months ended March 31, 2017, we reclassified &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of deferred revenue to Accrued collaboration liabilities and Other long-term liabilities, and accordingly adjusted our amortization of the upfront payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as a result of a change in operational responsibilities for certain clinical programs in the Ipsen Territory. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, we had paid &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; toward the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of reimbursements due to Ipsen for these clinical programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 2 - Collaboration Agreements&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for additional description of our collaboration agreement with Ipsen.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of upfront payments and deferred milestone&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalty revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Product supply agreement revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of supplied product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalty payable to GSK on net sales by Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenues under the Ipsen Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, short-term and long-term deferred revenue relating to the Ipsen Collaboration Agreement was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$19.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$219.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Genentech Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement (the &amp;#8220;Genentech Collaboration Agreement&amp;#8221;). Under the terms of the Genentech Collaboration Agreement for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. The profit and loss share has multiple tiers: we are entitled to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of profits and losses from the first &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of U.S. actual sales, decreasing to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of profits and losses from U.S. actual sales in excess of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. In addition, we are entitled to low double-digit royalties on ex-U.S. net sales. In November 2013, we exercised an option under the Genentech Collaboration Agreement to co-promote in the U.S. In 2015, we began fielding &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On June 3, 2016, we filed a Demand for Arbitration before JAMS in San Francisco, California asserting claims against Genentech related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&amp;#8217;s commercialization in the U.S. Our arbitration demand asserted that Genentech breached the Genentech Collaboration Agreement by, amongst other breaches, failing to meet its diligence and good faith obligations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On July 13, 2016, Genentech asserted a counterclaim for breach of contract seeking monetary damages and interest related to the cost allocations under the Genentech Collaboration Agreement. On December 29, 2016, however, Genentech withdrew its counterclaim against us and stated that it would unilaterally change its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy, both retrospectively and prospectively. The revised allocation approach substantially reduced our exposure to costs associated with promotion of the COTELLIC plus Zelboraf combination in the U.S. However, other significant issues remained in dispute between the parties as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Genentech&amp;#8217;s action did not address the claims in our demand for arbitration related to Genentech&amp;#8217;s clinical development of cobimetinib, or pricing or promotional costs for COTELLIC in the U.S. and it did not fully resolve claims over revenue allocation. In addition, Genentech&amp;#8217;s unilateral action did not clarify how it intended to allocate promotional costs incurred with respect to the promotion of other combination therapies that include cobimetinib for other indications that may be developed or are in development and may be approved. As a result, we continued to press our position before the arbitral panel to obtain a just resolution of these claims. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On June 8, 2017, the parties settled the arbitration, which was dismissed with prejudice. The settlement does not provide for payments in settlement of the asserted claims; as part of the settlement, on July 19, 2017, we entered into an amendment to the Genentech Collaboration Agreement (the &amp;#8220;Genentech Amendment&amp;#8221;) which provides for a revised revenue and cost-sharing arrangement, effective as of July 1, 2017, that is applicable to current and potential future commercial uses of COTELLIC. See &amp;#8220;Note 13 - Subsequent Event&amp;#8221; for a further description of the Genentech Amendment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. losses included in Selling, general and administrative expenses&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;A portion of the accrual for losses for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt; were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech&amp;#8217;s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The U.S. losses under the Genentech Collaboration Agreement include our share of the net loss from the collaboration, as well as personnel and other costs we have incurred to co-promote COTELLIC plus Zelboraf in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Royalty revenues from the Genentech Collaboration Agreement are based on amounts reported to us by Genentech and are recorded when such information becomes available to us. For prior periods, from the launch of COTELLIC through December 31, 2016, such information was not available until the following quarter, meaning that historically we recorded royalty revenues on a one quarter lag. Beginning in 2017, such information became available to us in the current quarter. As a result of this change, during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, in addition to the royalties reported to us for that period we also recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in royalties for the sales activity related to the three months ended December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On January 30, 2017, we entered into a collaboration and license agreement (the &amp;#8220;Takeda Collaboration Agreement&amp;#8221;) with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Takeda Pharmaceutical Company Ltd. (&amp;#8220;Takeda&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the Takeda Collaboration Agreement, Takeda will have exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The companies have also agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&amp;#8217; collaboration will be governed through a joint executive committee and appropriate subcommittees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the Takeda Collaboration Agreement, Takeda paid us an upfront nonrefundable payment of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2017. We will be eligible to receive development, regulatory and first-sales milestones of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$95.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to second-line RCC, first-line RCC and second-line hepatocellular carcinoma (&amp;#8220;HCC&amp;#8221;), as well as additional development, regulatory and first-sales milestone payments for potential future indications. The Takeda Collaboration Agreement also provides that we will be eligible to receive pre-specified payments of up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$83.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;associated with potential sales milestones. We will also receive royalties on net sales of cabozantinib in Japan at an initial tiered rate of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;on net sales for the first &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of cumulative net sales. Thereafter, the royalty rate will be adjusted to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;on annual net sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Takeda will be responsible for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the costs associated with the global&amp;#160;cabozantinib&amp;#160;development plan&amp;#8217;s current and future trials, provided Takeda opts to participate in such future trials, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the Takeda Collaboration Agreement, we will remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration. As part of the collaboration, the parties will enter into appropriate supply agreements for the manufacture and supply of cabozantinib for Takeda&amp;#8217;s territory.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of upfront payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenues under the Takeda Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;There was no such revenue during the comparable periods in 2016. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, short-term and long-term deferred revenue relating to the Takeda Collaboration Agreement was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$11.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Takeda Collaboration Agreement may be terminated for cause by&amp;#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&amp;#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; following the first commercial sale of cabozantinib in Japan shall constitute a material breach of the Takeda Collaboration Agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the Takeda Collaboration Agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the Takeda Collaboration Agreement if Japan&amp;#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the Takeda Collaboration Agreement upon &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;twelve months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Takeda Collaboration Agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Takeda for all development and commercial activities, research and development services, and participation on the joint executive, development and commercialization committees (as defined in the Takeda Collaboration Agreement). We determined that these deliverables, other than the commercial supply and joint commercialization committee participation, are non-contingent in nature. The commercial supply deliverable was deemed contingent, primarily due to the fact that there is uncertainty around approval in Japan, which is dependent on successful bridging study results. We also determined that the non-contingent deliverables do not have stand-alone value, because each one of them has value only if we meet our obligation as a whole to provide Takeda with research and development services, including clinical supply of cabozantinib under the Takeda Collaboration Agreement. Accordingly, we combined the non-contingent deliverables into a single unit of accounting and allocated the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; upfront fee to that combined unit of accounting. We also determined that the level of effort required of us to meet our obligations under the Takeda Collaboration Agreement is not expected to vary significantly over the development period of the Takeda Collaboration Agreement. As a result, the upfront payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, received in the first quarter of 2017, will be recognized ratably over the development period of the Takeda Collaboration Agreement of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. We determined that the development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Bristol-Myers Squibb Collaboration - First-Line Advanced RCC, Bladder Cancer and HCC Combination Studies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2017, we entered into a clinical trial collaboration agreement with Bristol-Myers Squibb Company&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(the &amp;#8220;BMS Collaboration Agreement&amp;#8221;) for the purpose of evaluating the combination of cabozantinib with nivolumab or of cabozantinib with nivolumab and ipilimumab in various tumor types, including, in RCC, HCC and bladder cancer. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;To date, a phase 3 trial in first-line advanced RCC and a phase 2 trial in HCC evaluating the combination have been initiated. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Pursuant to the terms of the BMS Collaboration Agreement, each party will grant to the other a non-exclusive, worldwide (within the collaboration territory as defined in the BMS Collaboration Agreement), non-transferable, royalty-free license to use the other party&amp;#8217;s compounds in the conduct of each clinical trial. The parties&amp;#8217; efforts will be governed through a joint development committee established to guide and oversee the collaboration&amp;#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the supply agreement entered into between the parties in April 2017, and costs for each such trial will be shared equally between the parties, unless two Bristol-Myers Squibb Company (&amp;#8220;BMS&amp;#8221;) compounds will be utilized in such trial, in which case BMS will bear &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two-thirds&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the costs for such study treatment arms and we will bear &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one-third&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the costs. Unless earlier terminated, the BMS Collaboration Agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. Ipsen has opted in to participate in the phase 3 pivotal trial in first-line advanced RCC and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at their choosing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;The Roche Group Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2017, we established a clinical trial collaboration with The Roche Group (&amp;#8220;Roche&amp;#8221;) for the purpose of evaluating the safety and tolerability of cabozantinib in combination with Roche&amp;#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the mater clinical supply agreement entered into by the parties in February 2017. Based on the dose-escalation results, the trial has the potential to enroll up to four expansion cohorts, including a cohort of patients with previously untreated advanced clear cell RCC and three cohorts of urothelial carcinoma, namely platinum eligible first-line patients, first or second-line platinum ineligible patients and patients previously treated with platinum-containing chemotherapy. The trial was initiated in June 2017 and is open for enrollment. We are the sponsor of the trial, and Roche is responsible for supplying atezolizumab. Ipsen has opted to participate in the study and will have access to the results to support potential future development in its territories.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;GlaxoSmithKline Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In October 2002, we established a collaboration with GSK to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under the terms of the product development and commercialization agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. As a result, we retained the rights to develop, commercialize, and license cabozantinib, subject to payment to GSK of a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; royalty on net sales of any product incorporating cabozantinib. The product development and commercialization agreement was terminated during 2014, although GSK will continue to be entitled to a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; royalty on net sales of any product incorporating cabozantinib, including COMETRIQ and CABOMETYX. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalties earned by GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Royalties earned by GSK are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen in the accompanying Condensed Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Collaborations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in contract revenues from a milestone payment received from BMS related to its ROR gamma program, and during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in contract revenues from a milestone payment received from Merck related to its worldwide license of our phosphoinositide-3 kinase-delta program. There was no such revenue during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. See &amp;#8220;Note 2 - Collaboration Agreements&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for a description of our existing collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-2D9A2A1A16F1D829E09F8610EFBAEB19">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COMMITMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On May 2, 2017, we entered into the Lease with Ascentris for an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;110,783&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; square feet of space in office and research facilities located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California. We also have the right to make certain tenant improvements to the space leased on the Premises. The Lease has an initial term of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; with a target commencement date of March 1, 2018 and rent payments will begin upon the target commencement date. We have &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;five&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year options to extend the Lease and a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-time option to terminate the Lease without cause on the last day of the 8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;th&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; year of the initial term. We are obligated to make lease payments totaling &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$24.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; over the Lease term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;170,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; square feet of space, as that additional space becomes available over the remainder of the initial term at 1601, 1701, 1751, and 1801 Harbor Bay Parkway, Alameda, California at a market rate determined according to the Lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We are deemed, for accounting purposes only, to be the owner of portions of the Premises, including &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; building shells, even though we are not the legal owner. See &amp;#8220;Note 5. Property and Equipment - Build-to-Suit Lease&amp;#8221; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;for a further description of the accounting for that portion of the Premises.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the aggregate future minimum lease payments under our leases are as follows (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Capital leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other financing obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Remainder of 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;Other financing obligations includes payments related to build-to-suit lease arrangements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Rent expense and sublease income were as follows for the periods presented (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: Sublease income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,723&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt; Letter of Credit&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We obtained a standby letter of credit in May 2017 in the amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which may be drawn down by Ascentris in the event we fail to fully and faithfully perform all of our obligations under the Lease and to compensate Ascentris for all losses and damages Ascentris may suffer as a result of the occurrence of any default on our part not cured within the applicable cure period. As of June 30, 2017, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;none&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the standby letter of credit amount has been used.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 13 - Commitments&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for a description of additional letters of credits that were entered into prior to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-E1383084330C29244B4512B9AFFB59FC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;CONCENTRATIONS OF CREDIT RISK&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially subject us to concentrations of credit risk are primarily trade and other receivables and investments. Investments consist of money market funds, commercial paper, corporate bonds with high credit quality, and securities issued by the U.S. Treasury and other government sponsored enterprises. All investments are maintained with financial institutions that management believes are creditworthy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Trade and other&amp;#160;receivables are unsecured and are concentrated in the pharmaceutical and biotechnology industries. Accordingly, we may be exposed to credit risk generally associated with pharmaceutical and biotechnology companies. We have incurred no bad debt expense since inception. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;19%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;17%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of our trade receivables are with Diplomat Specialty Pharmacy, Caremark L.L.C., affiliates of McKesson Corporation, and Accredo Health, Incorporated, respectively. All of these customers have historically paid promptly.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Merck&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. We have operations solely in the U.S., while some of our collaboration partners have headquarters outside of the U.S. and some of our clinical trials for cabozantinib are also conducted outside of the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table shows the revenues earned by geographic region. Net product revenues are attributed to regions based on the delivery location. Collaboration revenues are attributed to regions based on the location of our collaboration partner's headquarters (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;163,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Japan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We recorded losses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; relating to foreign exchange fluctuations for both the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-427570BBA0D9D41E11B712B9ADFD0FFE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The condensed consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the United States (&amp;#8220;U.S.&amp;#8221;) dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-09A73BB4392A6F03195412B9ADDFCBC9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The amortized carrying amount of our debt consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Secured Convertible Notes due 2018 (&amp;#8220;Deerfield Notes&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;189,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;See &amp;#8220;Note 7 - Debt&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for additional information on the terms of our debt, including a description of the material features of the Deerfield Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Deerfield Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. The repayment amount totaled &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$123.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; which comprised &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$113.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in principal, including &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of interest paid in kind paid through the repayment date, a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;prepayment penalty associated with the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;early repayment of the notes and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in accrued and unpaid interest. As a result of the early repayment, there was a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; loss on the extinguishment of the debt which comprised the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;prepayment penalty &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;and the unamortized fees and costs on the date of the repayment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to our early repayment of the notes, the outstanding principal amount of the Deerfield Notes bore interest at the rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per annum to be paid in cash, quarterly in arrears, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per annum to be paid in kind, quarterly in arrears, for a total interest rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per annum. The following is a summary of interest expense for the Deerfield Notes (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stated coupon interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest paid in kind&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The balance of unamortized fees and costs was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which was recorded as a reduction of the carrying amount of the Deerfield Notes on the accompanying Condensed Consolidated Balance Sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Silicon Valley Bank Loan and Security Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On March 29, 2017, we repaid all amounts outstanding under our term loan with Silicon Valley Bank. The repayment included &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in principal plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in accrued and unpaid interest. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; gain or loss on the extinguishment of debt as a result of the repayment of the term loan. Prior to our early repayment of the term loan, the principal amount outstanding under the term loan had accrued interest at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;per annum, which was due and payable monthly. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with the terms of the loan and security agreement, we were required to maintain an amount equal to at least &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, but not to exceed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;107%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, of the outstanding principal balance of the term loan on deposit in one or more investment accounts with Silicon Valley Bank or one of its affiliates as support for our obligations under the loan and security agreement. We were entitled to retain income earned on the amounts maintained in such accounts. The total collateral balance as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$81.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and was reflected in our Condensed Consolidated Balance Sheet in Short-term investments as the amounts were not restricted as to withdrawal. As a result of our repayment of the term loan, the compensating balance requirement was terminated as of March 29, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q2YTD" id="Fact-17EAB168431D5D06307512B9AD808DA3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;) as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value of our stock options and ESPP purchases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of stock options and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We considered implied volatility as well as our historical volatility in developing our estimate of expected volatility. The expected life computation is based on historical exercise patterns and post-vesting termination behavior. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is presented below (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,999,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;674,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,242,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(161,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,269,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;426,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,181,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.72 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a total of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;24,237,774&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares were available for grant under our stock option plans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of restricted stock unit (&amp;#8220;RSU&amp;#8221;) activity for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is presented below (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSUs outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,469,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;258,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(280,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSUs outstanding at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,361,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.72 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q2YTD" id="Fact-85963EC16003E647997A12B9AD3A989B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NET INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income allocable to common stock for basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income allocable to common stock for diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;293,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;229,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;229,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The 2014 Warrants are participating securities and the warrant holders do not have a contractual obligation to share in our losses. See &amp;#8220;Note 8 - Common Stock and Warrants&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for a description of the 2014 Warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth potentially dilutive shares of common stock that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deerfield Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Deerfield Notes were repaid in June 2017. The 2019 Notes were converted and redeemed between August and November 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2017Q2YTD" id="Fact-799A0224628BAC7DF39B12B9AD121E92">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q2YTD" id="Fact-C820C5F66846880AB6B312B9AF65996E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth the classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and there were no transfers of financial assets or liabilities classified as Level 3 during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or the year ended December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The carrying amounts of cash, trade and other receivables, accounts payable, accrued clinical trial liabilities, accrued compensation and benefits, and other liabilities approximate their fair values and are excluded from the tables above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing, which are Level 2 inputs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FiscalPeriod contextRef="FD2017Q2YTD" id="Fact-D54C0A43D2DDA0369D8F12B9ADE98E5D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended June 30, 2017 and July 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended June 30, 2017 and June 30, 2016, and the years ended December&amp;#160;31, 2017 and December&amp;#160;31, 2016, respectively.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-B92842A1416015C50A9212B9AD76D71C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Income tax expense consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, we recorded income tax expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which comprises our computed income tax expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reduced by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of excess benefits associated with equity compensation. The income tax expense for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-A76996A8B28054226F1812B9AF0B7676">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INVENTORY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Inventory consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: non-current portion included in Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We generally relieve inventory on a first-expiry, first-out basis. A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and, therefore, was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;; the amount of such write-downs was nominal for the comparable period in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The non-current portion of inventory is expected to be sold in future periods more than 12 months from the date presented and consists of finished goods as of June 30, 2017 and a portion of the active pharmaceutical ingredient that is included in raw materials and work in process inventories as of December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2017Q2YTD" id="Fact-1525A66CC13308869B8212B9AE7F8066">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes the fair value of securities classified as available-for-sale by contractual maturity as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (in thousands):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Mature within One Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;After One Year through Two Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;343,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-EB72650F744B5B558C1D12B9ADE9A4C9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2014-09&amp;#8221;).&amp;#160;In August 2015, the FASB issued ASU No. 2015-14, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which delays the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, but allows us to adopt the standard one year earlier. We will adopt ASU 2014-09 in the first quarter of fiscal year 2018. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have substantially completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of revenue from product sales. We do expect that ASU 2014-09 will impact the timing of recognition of revenue for our collaboration arrangements. We expect to reclassify deferred revenue to retained earnings (a concept known as lost revenue) for amounts associated with certain of our collaboration arrangements upon recording our transition adjustment to accumulated loss on January 1, 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration arrangements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2017Q2YTD" id="Fact-FE7871B1BEB558BF99BD12B9ADFDB595">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (&amp;#8220;Exelixis,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our&amp;#8221; or &amp;#8220;us&amp;#8221;) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; products discovered at&amp;#160;Exelixis&amp;#160;have progressed through clinical development, received regulatory approval, and entered the commercial marketplace. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;tablets approved for previously treated advanced renal cell carcinoma (&amp;#8220;RCC&amp;#8221;) and COMETRIQ&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is a formulation of cobimetinib, a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The condensed consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the United States (&amp;#8220;U.S.&amp;#8221;) dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended June 30, 2017 and July 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended June 30, 2017 and June 30, 2016, and the years ended December&amp;#160;31, 2017 and December&amp;#160;31, 2016, respectively.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating results for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, included in our Annual Report on Form 10-K filed with the SEC on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;February&amp;#160;27, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Correction of an Immaterial Error&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the third quarter of 2016, we identified errors in the Consolidated Balance Sheets and Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for 2015, 2014, 2013, and 2012, and in the unaudited interim Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for all prior interim fiscal periods from September 30, 2012 through June 30, 2016. Specifically, in 2012 we incorrectly calculated 1) the allocation between Additional paid-in capital and Convertible notes of the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$287.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; aggregate principal amount from our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4.25%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; Convertible Senior Subordinated Notes due 2019 (&amp;#8220;2019 Notes&amp;#8221;); and 2) the amortization of the debt discount associated with the 2019 Notes during 2012 and all subsequent periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Having evaluated the materiality of these errors from a quantitative and qualitative perspective, management has concluded that although the accumulation of these errors was significant to the three and nine months ended September 30, 2016, the correction of these errors would not be material to any individual prior period, and did not have an effect on the trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 99, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Materiality&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and Staff Accounting Bulletin No. 108, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Because management has concluded that these errors are not material, we will correct them prospectively when the consolidated balance sheets, statements of operations, comprehensive loss and cash flows for such periods are included in future filings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statement of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statements of Comprehensive Loss:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(93,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statements of Cash Flows &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss, overstated by $4,301 for the six months ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Not reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Not reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;These errors did not affect any other caption or total in our unaudited condensed consolidated financial statements as of and for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. See &amp;#8220;Note 1 - Organization and Summary of Significant Accounting Policies&amp;#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the amounts of the corrections and the amounts that should have been reported for 2015, 2014, 2013, and 2012 in the affected line items of the statements of operations, statements of comprehensive loss and statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in accrued product sales discounts payable to our customers as of December 31, 2016 from Other current liabilities to Trade and other receivables in the accompanying Condensed Consolidated Balance Sheets. We have also reclassified the related balances between the Changes in assets and liabilities line items in the accompanying Condensed Consolidated Statements of Cash Flows for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We operate as a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;single&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reportable segment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, we adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2016-09,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt; Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-09&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, and no prior periods were restated as a result of this change in accounting principle, with a cumulative adjustment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to accumulated deficit and additional paid-in-capital as of January 1, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASU 2016-09, we also recorded an increase to the federal and state net operating losses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for excess tax benefits previously not included. The resulting increase to the deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is offset by a corresponding increase to the valuation allowance, resulting in a net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impact on our income tax expense and our Condensed Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on our Condensed Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in cash provided by operating activities by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; along with a corresponding increase in cash used in financing activities in our Condensed Consolidated Statement of Cash Flows for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2014-09&amp;#8221;).&amp;#160;In August 2015, the FASB issued ASU No. 2015-14, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which delays the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, but allows us to adopt the standard one year earlier. We will adopt ASU 2014-09 in the first quarter of fiscal year 2018. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have substantially completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of revenue from product sales. We do expect that ASU 2014-09 will impact the timing of recognition of revenue for our collaboration arrangements. We expect to reclassify deferred revenue to retained earnings (a concept known as lost revenue) for amounts associated with certain of our collaboration arrangements upon recording our transition adjustment to accumulated loss on January 1, 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration arrangements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2017Q2YTD" id="Fact-6D4F238E2210288C909B12B9ADFDDF71">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in accrued product sales discounts payable to our customers as of December 31, 2016 from Other current liabilities to Trade and other receivables in the accompanying Condensed Consolidated Balance Sheets. We have also reclassified the related balances between the Changes in assets and liabilities line items in the accompanying Condensed Consolidated Statements of Cash Flows for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-A2147A2D28CD00126E4E85E631B5881A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction-in-progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; during both the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Build-to-Suit Lease &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On May 2, 2017, we entered into a Lease Agreement (the &amp;#8220;Lease&amp;#8221;) with Ascentris 105, LLC (&amp;#8220;Ascentris&amp;#8221;), to lease &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;110,783&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; square feet of space in office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the &amp;#8220;Premises&amp;#8221;). See &amp;#8220;Note 10. Commitments&amp;#8221; for a description of the Lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Lease, we received a tenant improvement allowance of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6.7 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Ascentris, for the costs associated with the design, development and construction of tenant improvements for the Premises. We are obligated to fund all costs incurred in excess of the tenant improvement allowance and certain indemnification obligations related to the construction activities. We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises including the building shells did not qualify as &amp;#8220;normal tenant improvements&amp;#8221; under Accounting Standards Codification topic 840, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Accordingly, for accounting purposes, we are the deemed owner of such portions of the Premises during the construction period. As such, we will capitalize the construction costs as a build-to-suit property within property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. The capitalized construction costs will also include the estimated tenant improvements incurred by Ascentris. We will also recognize a corresponding build-to-suit lease obligation included in Other long-term liabilities for the same amount. As of June 30, 2017, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of costs were capitalized in construction-in-progress with a corresponding build-to-suit lease obligation recognized related to the Lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Once the construction is complete, we will consider the requirements for sale-leaseback accounting treatment, including evaluating whether all risks of ownership have been transferred back to Ascentris, as evidenced by a lack of continuing involvement in the leased property. If the arrangement does not qualify for sale-leaseback accounting treatment, the building assets will remain on our consolidated balance sheets at their historical cost.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2017Q2YTD" id="Fact-4A7F4FDF31A36E38EB5A85EA69B3597C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction-in-progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q2YTD" id="Fact-90E1FD34DF6FCBC90C0512B9AD308C51">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth potentially dilutive shares of common stock that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deerfield Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="FD2017Q2YTD" id="Fact-9E6113E0C8EEA1E421EE12B9AE899CC4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following tables summarize cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;135,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;135,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;214,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;214,044&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;26,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;380,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;380,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;151,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;268,234&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;268,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;55,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;55,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term restricted cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Total cash and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;479,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;479,554&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" id="Fact-447EBD955CC75ECCD15612B9AED9BA30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. losses included in Selling, general and administrative expenses&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;A portion of the accrual for losses for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt; were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech&amp;#8217;s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" id="Fact-6CE39ED690C63A5342DF85B092A74078">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalties earned by GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-3A972CECCE9F029747BA12B9B019443B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of upfront payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenues under the Takeda Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="FD2017Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" id="Fact-0425A64E2D8F1F0DDECF12B9AFF1A225">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of upfront payments and deferred milestone&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalty revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Product supply agreement revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of supplied product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalty payable to GSK on net sales by Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaboration revenues under the Ipsen Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2017Q2YTD" id="Fact-36295D3361F6F51CC677993980158C6A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Income tax expense consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="FD2017Q2YTD" id="Fact-584FAD50E7A8D7A3283F12B9ADE9C8FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is a summary of interest expense for the Deerfield Notes (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stated coupon interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest paid in kind&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,259&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,057&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2017Q2YTD" id="Fact-EB8EB45F2E80140FC6C112B9ADD5E8C3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The amortized carrying amount of our debt consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Secured Convertible Notes due 2018 (&amp;#8220;Deerfield Notes&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;189,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q2YTD" id="Fact-FF5E9CD0E96B9B2C9BA612B9AD441175">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income allocable to common stock for basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,596&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income allocable to common stock for diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;293,188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;229,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;229,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q2YTD" id="Fact-EC1F3782C3D0DEF6DEB812B9AD58A56C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;) as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="FD2017Q2YTD" id="Fact-D13BF3F1EF286987F1F312B9ADE97621">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statement of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statements of Comprehensive Loss:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(93,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Statements of Cash Flows &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss, overstated by $4,301 for the six months ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Not reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(94,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Not reported&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
	<us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="FD2017Q2YTD" id="Fact-A2D7725A8C96225C64768613DA1B0767">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the aggregate future minimum lease payments under our leases are as follows (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Capital leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other financing obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Remainder of 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,814&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:9pt;color:#000000;"&gt;Other financing obligations includes payments related to build-to-suit lease arrangements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2017Q2YTD" id="Fact-EC583BAEAA93204A882512B9B0609B53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Inventory consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: non-current portion included in Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2017Q2YTD" id="Fact-295C874FCADFD9BB277512B9AD94C272">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of restricted stock unit (&amp;#8220;RSU&amp;#8221;) activity for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is presented below (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSUs outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,469,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;258,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(280,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;RSUs outstanding at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,361,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.72 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="FD2017Q2YTD" id="Fact-A0F70794006933439B1A89C9AF037A87">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Rent expense and sublease income were as follows for the periods presented (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: Sublease income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,723&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q2YTD" id="Fact-B91950BD445639C15AD312B9AECF6FF0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is presented below (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,999,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;674,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,242,026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(161,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,269,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;426,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,181,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.72 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q2YTD" id="Fact-B0BD4E5094F9401E24EF12B9AD803CC5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of stock options and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2017Q2YTD" id="Fact-8AEA34BE6C1BB839677F12B9AF658D45">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table shows the revenues earned by geographic region. Net product revenues are attributed to regions based on the delivery location. Collaboration revenues are attributed to regions based on the location of our collaboration partner's headquarters (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;163,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Japan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Merck&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-3A084E2103431BABD17C12B9ADF341A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We operate as a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;single&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reportable segment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="FD2017Q2YTD" id="Fact-A7D935B0BE01CB3B1E6512B9AD4E55F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value of our stock options and ESPP purchases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q2YTD" id="Fact-88DF661D9B5428DDFC1512B9ADFDE178">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, we adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2016-09,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt; Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-09&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, and no prior periods were restated as a result of this change in accounting principle, with a cumulative adjustment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to accumulated deficit and additional paid-in-capital as of January 1, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASU 2016-09, we also recorded an increase to the federal and state net operating losses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for excess tax benefits previously not included. The resulting increase to the deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is offset by a corresponding increase to the valuation allowance, resulting in a net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impact on our income tax expense and our Condensed Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on our Condensed Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in cash provided by operating activities by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; along with a corresponding increase in cash used in financing activities in our Condensed Consolidated Statement of Cash Flows for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months ended&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q2YTD" id="Fact-68013FB0B8AE4F25F74F861866462727">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SUBSEQUENT EVENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On July 19, 2017, we and Genentech entered into the Genentech Amendment. The Genentech Amendment was entered into in connection with the settlement of the arbitration concerning claims asserted by us against Genentech related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&amp;#8217;s commercialization in the U.S. See &amp;#8220;Note 2 - Collaboration Agreements - Genentech Collaboration&amp;#8221; for additional information on the Genentech collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Genentech Amendment sets forth the parties&amp;#8217; confirmation and agreement that we have exercised our co-promotion option and that, as such, we have the right to co-promote current and future Genentech combinations that include COTELLIC in the U.S. Pursuant to the terms of the Genentech Amendment, we will continue to be entitled to a share of U.S. profits and losses received in connection with the commercialization of COTELLIC, which share will continue to decrease as sales of COTELLIC increase in accordance with the profit share tiers as originally set forth in the Genentech Collaboration Agreement. However, effective as of July 1, 2017, the revenue for each sale of COTELLIC applied to the profit and loss statement for the Genentech Collaboration Agreement (the &amp;#8220;Collaboration P&amp;amp;L&amp;#8221;) will be calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. While we will also continue to share U.S. commercialization costs for COTELLIC, the Genentech Amendment expressly sets forth that the amount of commercialization costs Genentech is entitled to allocate to the Collaboration P&amp;amp;L will be reduced based on the number of Genentech products in any given combination including COTELLIC. The Genentech Amendment also provides for more detailed communication requirements for the parties related to COTELLIC research, development and commercialization activities and clarifies meeting and escalation procedures for the joint steering committee and the joint commercialization committee, each a body established under the Genentech Collaboration Agreement to coordinate activities with respect to COTELLIC.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2017Q2YTD" id="Fact-C04929B2E50F2C90C30612B9AE89D917">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following tables summarize our cash equivalents and investments by security type as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;303,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;460,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q2YTD" id="Fact-673E7148A541034C4CDD12B9ADE9458D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-03676565BA4D3F98722612B9AF29B914" xlink:label="Fact-03676565BA4D3F98722612B9AF29B914_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-0BAA4692E051DCD8024612B9AF1F8CCD" xlink:label="Fact-0BAA4692E051DCD8024612B9AF1F8CCD_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-0CD59B9C3D4824E885B412B9B00F4A90" xlink:label="Fact-0CD59B9C3D4824E885B412B9B00F4A90_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-18FB613B834ADF9056A512B9AFFB0AC2" xlink:label="Fact-18FB613B834ADF9056A512B9AFFB0AC2_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-1FCECA99A01BCD4E81DB12B9AF650E9E" xlink:label="Fact-1FCECA99A01BCD4E81DB12B9AF650E9E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-20ABEEB9057C89AA43AC12B9AF794458" xlink:label="Fact-20ABEEB9057C89AA43AC12B9AF794458_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2AA56751459A3E1E127D12B9AFFB3CDF" xlink:label="Fact-2AA56751459A3E1E127D12B9AFFB3CDF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2F73F715ADCCCB96A25D12B9AFDD4040" xlink:label="Fact-2F73F715ADCCCB96A25D12B9AFDD4040_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-326FA193E9D455781BCF12B9AF838775" xlink:label="Fact-326FA193E9D455781BCF12B9AF838775_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-34472AB658ADE6497EA012B9AF6F59C7" xlink:label="Fact-34472AB658ADE6497EA012B9AF6F59C7_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-39BC6E4186082A0C74ED12B9AF83BB30" xlink:label="Fact-39BC6E4186082A0C74ED12B9AF83BB30_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3C60E2F8E35772BAB1D512B9AFF1E2AB" xlink:label="Fact-3C60E2F8E35772BAB1D512B9AFF1E2AB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4E45FF7240D057BC929C12B9AF299E4F" xlink:label="Fact-4E45FF7240D057BC929C12B9AF299E4F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-664CE6541B82523E0E0912B9B04C3D69" xlink:label="Fact-664CE6541B82523E0E0912B9B04C3D69_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6656B6EF4A5F7299A78812B9B0057236" xlink:label="Fact-6656B6EF4A5F7299A78812B9B0057236_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-69DD75F9ED68A53884A612B9B00578CD" xlink:label="Fact-69DD75F9ED68A53884A612B9B00578CD_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-75802E985BDB30507A5712B9B02DD716" xlink:label="Fact-75802E985BDB30507A5712B9B02DD716_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8CF5A84EF7153701CC7212B9AF5B8354" xlink:label="Fact-8CF5A84EF7153701CC7212B9AF5B8354_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8D5CDCA9E64053F621B812B9AEEDAB51" xlink:label="Fact-8D5CDCA9E64053F621B812B9AEEDAB51_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9215018D2BF4EF98A92F12B9B00585B2" xlink:label="Fact-9215018D2BF4EF98A92F12B9B00585B2_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-92711195944ACFBF0DE512B9AF79C239" xlink:label="Fact-92711195944ACFBF0DE512B9AF79C239_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-96626B98DE631FF62ABF12B9ADA907FE" xlink:label="Fact-96626B98DE631FF62ABF12B9ADA907FE_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-970CFF796E9A412A46D7852A1FC18BBC" xlink:label="Fact-970CFF796E9A412A46D7852A1FC18BBC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A73E2E66D93866277FAE12B9AFFBE5C5" xlink:label="Fact-A73E2E66D93866277FAE12B9AFFBE5C5_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-AFE26984752D607804C412B9AF837F4B" xlink:label="Fact-AFE26984752D607804C412B9AF837F4B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B28420361CFB0060F46B12B9AF5BEF8A" xlink:label="Fact-B28420361CFB0060F46B12B9AF5BEF8A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B980456760C22C5122B712B9AFF1C4F3" xlink:label="Fact-B980456760C22C5122B712B9AFF1C4F3_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BA63247507A7E656178E12B9AF65350D" xlink:label="Fact-BA63247507A7E656178E12B9AF65350D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BC5BBA3E746156119CD512B9AF65BB9F" xlink:label="Fact-BC5BBA3E746156119CD512B9AF65BB9F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C04ABD4CDEFA54B8A0B212B9B04B295C" xlink:label="Fact-C04ABD4CDEFA54B8A0B212B9B04B295C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C27A991BD8FF632DCF8A12B9AF517045" xlink:label="Fact-C27A991BD8FF632DCF8A12B9AF517045_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C3F3967703CF3162C06612B9AF0BD45C" xlink:label="Fact-C3F3967703CF3162C06612B9AF0BD45C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-CBBC51EA3090ACE238D512B9B0193F90" xlink:label="Fact-CBBC51EA3090ACE238D512B9B0193F90_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D3A7CD293102088A66A412B9B00F9170" xlink:label="Fact-D3A7CD293102088A66A412B9B00F9170_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E4521F4862DCB7D364C512B9B00FF4A5" xlink:label="Fact-E4521F4862DCB7D364C512B9B00FF4A5_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F84D1B7CCDE0A236088E12B9AF335A8B" xlink:label="Fact-F84D1B7CCDE0A236088E12B9AF335A8B_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-03676565BA4D3F98722612B9AF29B914_lbl" xlink:to="Footnote-7B58FA3CD51DCFE3E5E512B9AEED674F_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-0BAA4692E051DCD8024612B9AF1F8CCD_lbl" xlink:to="Footnote-7B58FA3CD51DCFE3E5E512B9AEED674F_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-0CD59B9C3D4824E885B412B9B00F4A90_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-18FB613B834ADF9056A512B9AFFB0AC2_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1FCECA99A01BCD4E81DB12B9AF650E9E_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-20ABEEB9057C89AA43AC12B9AF794458_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2AA56751459A3E1E127D12B9AFFB3CDF_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2F73F715ADCCCB96A25D12B9AFDD4040_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-326FA193E9D455781BCF12B9AF838775_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-34472AB658ADE6497EA012B9AF6F59C7_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-39BC6E4186082A0C74ED12B9AF83BB30_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3C60E2F8E35772BAB1D512B9AFF1E2AB_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4E45FF7240D057BC929C12B9AF299E4F_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-664CE6541B82523E0E0912B9B04C3D69_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6656B6EF4A5F7299A78812B9B0057236_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-69DD75F9ED68A53884A612B9B00578CD_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-75802E985BDB30507A5712B9B02DD716_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8CF5A84EF7153701CC7212B9AF5B8354_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8D5CDCA9E64053F621B812B9AEEDAB51_lbl" xlink:to="Footnote-7B58FA3CD51DCFE3E5E512B9AEED674F_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9215018D2BF4EF98A92F12B9B00585B2_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-92711195944ACFBF0DE512B9AF79C239_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-96626B98DE631FF62ABF12B9ADA907FE_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-970CFF796E9A412A46D7852A1FC18BBC_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A73E2E66D93866277FAE12B9AFFBE5C5_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-AFE26984752D607804C412B9AF837F4B_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B28420361CFB0060F46B12B9AF5BEF8A_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B980456760C22C5122B712B9AFF1C4F3_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BA63247507A7E656178E12B9AF65350D_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BC5BBA3E746156119CD512B9AF65BB9F_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C04ABD4CDEFA54B8A0B212B9B04B295C_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C27A991BD8FF632DCF8A12B9AF517045_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C3F3967703CF3162C06612B9AF0BD45C_lbl" xlink:to="Footnote-7B58FA3CD51DCFE3E5E512B9AEED674F_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-CBBC51EA3090ACE238D512B9B0193F90_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D3A7CD293102088A66A412B9B00F9170_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E4521F4862DCB7D364C512B9B00FF4A5_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F84D1B7CCDE0A236088E12B9AF335A8B_lbl" xlink:to="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-3EB5A3098394B7A1B82712B9ADA97017_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</link:footnote>
		<link:footnote xlink:label="Footnote-7B58FA3CD51DCFE3E5E512B9AEED674F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other comprehensive income consisted solely of unrealized gains or losses, net on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income during those periods.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>exel-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20170630" xmlns:exel="http://www.exelixis.com/20170630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2104100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails">
        <link:definition>2404405 - Disclosure - Cash and Investments (Available for Sale by Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2404403 - Disclosure - Cash and Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails">
        <link:definition>2404402 - Disclosure - Cash and Investments (Summary by Balance Sheet Line Item) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsSummaryBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails">
        <link:definition>2404404 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2304301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsBristolMyersSquibbCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements (Bristol-Myers Squibb Collaboration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements (Collaboration Revenues - Takeda) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsGenentechCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements (Genentech Collaboration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsGlaxosmithklineCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails">
        <link:definition>2403409 - Disclosure - Collaboration Agreements (GlaxoSmithKline Collaboration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails">
        <link:definition>2403410 - Disclosure - Collaboration Agreements (Other Collaborations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements (Takeda Collaboration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.exelixis.com/role/Commitments">
        <link:definition>2111100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails">
        <link:definition>2411404 - Disclosure - Commitments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>2411402 - Disclosure - Commitments (Schedule of Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails">
        <link:definition>2411403 - Disclosure - Commitments (Schedule of Rental Expenses and Sublease Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://www.exelixis.com/role/CommitmentsTables">
        <link:definition>2311301 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfCreditRisk" roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRisk">
        <link:definition>2113100 - Disclosure - Concentrations of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfCreditRiskNarrativeDetails" roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails">
        <link:definition>2413402 - Disclosure - Concentrations of Credit Risk (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfCreditRiskRevenuesByCustomerDetails" roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails">
        <link:definition>2413403 - Disclosure - Concentrations of Credit Risk (Revenues by Customer) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails">
        <link:definition>2413404 - Disclosure - Concentrations of Credit Risk (Revenues by Geographic Region) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfCreditRiskTables" roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables">
        <link:definition>2313301 - Disclosure - Concentrations of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical">
        <link:definition>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exelixis.com/role/Debt">
        <link:definition>2106100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDeerfieldNotesDetails" roleURI="http://www.exelixis.com/role/DebtDeerfieldNotesDetails">
        <link:definition>2406403 - Disclosure - Debt (Deerfield Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseOnDeerfieldNotesDetails" roleURI="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails">
        <link:definition>2406404 - Disclosure - Debt (Interest Expense on Deerfield Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfDebtDetails" roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails">
        <link:definition>2406402 - Disclosure - Debt (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSiliconValleyBankLoanAndSecurityAgreementDetails" roleURI="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails">
        <link:definition>2406405 - Disclosure - Debt (Silicon Valley Bank Loan and Security Agreement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.exelixis.com/role/DebtTables">
        <link:definition>2306301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2107100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>2407402 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2110100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails">
        <link:definition>2410402 - Disclosure - Income Taxes (Schedule of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exelixis.com/role/IncomeTaxesTables">
        <link:definition>2310301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2105100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryDetails" roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails">
        <link:definition>2405402 - Disclosure - Inventory (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryDetailsCalc2" roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2">
        <link:definition>2405402 - Disclosure - Inventory (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2305301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare">
        <link:definition>2112100 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails">
        <link:definition>2412403 - Disclosure - Net Income (Loss) Per Share (Potentially Dilutive Shares) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>2412402 - Disclosure - Net Income (Loss) Per Share (Reconciliation of Basic and Diluted Net Income (Loss) Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails">
        <link:definition>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies (Error Correction) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails">
        <link:definition>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies (Error Correction, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails">
        <link:definition>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies (Organization) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails">
        <link:definition>2401406 - Disclosure - Organization and Summary of Significant Accounting Policies (Reclassifications) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>2401407 - Disclosure - Organization and Summary of Significant Accounting Policies (Segment Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>2401408 - Disclosure - Organization and Summary of Significant Accounting Policies (Stock-Based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2105100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2405403 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>2405402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2305301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2108100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2408406 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails">
        <link:definition>2408402 - Disclosure - Stock-Based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails">
        <link:definition>2408404 - Disclosure - Stock-Based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAllRsuActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails">
        <link:definition>2408407 - Disclosure - Stock-Based Compensation (Summary of All RSU Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails">
        <link:definition>2408405 - Disclosure - Stock-Based Compensation (Summary of All Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2308301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails">
        <link:definition>2408403 - Disclosure - Stock-Based Compensation (Weighted Average Grant Date Fair Values) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.exelixis.com/role/SubsequentEvent">
        <link:definition>2114100 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock" name="AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AccountingStandardsUpdate201609Member" name="AccountingStandardsUpdate201609Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_BuildingShellsMember" name="BuildingShellsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CapitalLeaseandOtherFinancingLeaseMember" name="CapitalLeaseandOtherFinancingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix" name="CapitalLeasesFutureMinimumPaymentsDueAfterYearSix" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears" name="CapitalLeasesFutureMinimumPaymentsDueinSixYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CapitalLeasesNumberofOptionstoTerminate" name="CapitalLeasesNumberofOptionstoTerminate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalLeasesNumberofRenewalOptions" name="CapitalLeasesNumberofRenewalOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty" name="CapitalLeasesOptionAdditionalAreaofRealEstateProperty" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CaremarkL.L.C.Member" name="CaremarkL.L.C.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsAndInvestmentsTextBlock" name="CashCashEquivalentsAndInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsandAvailableforsaleSecurities" name="CashCashEquivalentsandAvailableforsaleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" name="CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments" name="CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments" name="CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementDevelopmentCostReimbursements" name="CollaborativeArrangementDevelopmentCostReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossfromAgreement" name="CollaborativeArrangementIncomeLossfromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementShareinCostsPercentage" name="CollaborativeArrangementShareinCostsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithBMSMember" name="CollaborativeArrangementwithBMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" name="CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember" name="CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" name="CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithMerckMember" name="CollaborativeArrangementwithMerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" name="CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractTerminationPeriodforWrittenNotice" name="ContractTerminationPeriodforWrittenNotice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" name="ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember" name="CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CotellicMember" name="CotellicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CouponInterestMember" name="CouponInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtCollateralNumberOfAffiliateBanks" name="DebtCollateralNumberOfAffiliateBanks" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtCollateralNumberOfRequiredInvestmentAccounts" name="DebtCollateralNumberOfRequiredInvestmentAccounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" name="DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations" name="DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtInstrumentPrepaymentPenalty" name="DebtInstrumentPrepaymentPenalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" name="DebtInstrumentsUnamortizedClosingFeesAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DeferredRevenueRecognitionPeriod" name="DeferredRevenueRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiplomatSpecialtyPharmacyMember" name="DiplomatSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ExcessTaxBenefitsSharebasedCompensation" name="ExcessTaxBenefitsSharebasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ExtinguishmentofDebtIncludingPaidinKindInterest" name="ExtinguishmentofDebtIncludingPaidinKindInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ExtinguishmentofDebtincludingInterestandPenalties" name="ExtinguishmentofDebtincludingInterestandPenalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinalTierMember" name="FinalTierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinancingLeaseObligationMember" name="FinancingLeaseObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlobalMember" name="GlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseAccruedClinicalLiabilities" name="IncreaseDecreaseAccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseinAccruedCollaborationLiability" name="IncreaseDecreaseinAccruedCollaborationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InitialMember" name="InitialMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_InterestExpenseCouponInterest" name="InterestExpenseCouponInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InterestPaymentTypeAxis" name="InterestPaymentTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InterestPaymentTypeDomain" name="InterestPaymentTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm" name="LesseeLeasingArrangementsCapitalLeasesRenewalTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeLeasingArrangementsCapitalLeasesTermofContract" name="LesseeLeasingArrangementsCapitalLeasesTermofContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LongTermInvestmentsMember" name="LongTermInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_Maximumpercentagerequiredforcollateralbalance" name="Maximumpercentagerequiredforcollateralbalance" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MerckMember" name="MerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PaymentOfReimbursementsFromCollaborationArrangement" name="PaymentOfReimbursementsFromCollaborationArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PaymentinKindInterestMember" name="PaymentinKindInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PercentOfRoyaltyOnNetSale" name="PercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PeriodGeneratedAxis" name="PeriodGeneratedAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PeriodGeneratedDomain" name="PeriodGeneratedDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedfromCabozantinibMember" name="ProductsDerivedfromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" name="ProfitSharingAgreementOptionalPercentOfTotalSalesForce" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementPercentOfProfits" name="ProfitSharingAgreementPercentOfProfits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementProfitThreshold" name="ProfitSharingAgreementProfitThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierOneMember" name="ProfitSharingTierOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierThreeMember" name="ProfitSharingTierThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersAxis" name="ProfitSharingTiersAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersDomain" name="ProfitSharingTiersDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_Q416Member" name="Q416Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RestrictedCashAndInvestmentsLongTermMember" name="RestrictedCashAndInvestmentsLongTermMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved" name="RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RoyaltyTier" name="RoyaltyTier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierAxis" name="RoyaltytierAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierDomain" name="RoyaltytierDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SecondMember" name="SecondMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SecuredConvertibleNotesDueJune2018Member" name="SecuredConvertibleNotesDueJune2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SiliconValleyBankLoanAndSecurityAgreementMember" name="SiliconValleyBankLoanAndSecurityAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_TenantLeaseImprovementsAllowance" name="TenantLeaseImprovementsAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_TradeandOtherReceivablesMember" name="TradeandOtherReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontAndMilestonePayments" name="UpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>exel-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20170630.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20170630.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20170630.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsGenentechCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20170630.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20170630.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20170630.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="exel-20170630.xsd#CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:href="exel-20170630.xsd#CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20170630.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRisk" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20170630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20170630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt" xlink:href="exel-20170630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtDeerfieldNotesDetails" xlink:href="exel-20170630.xsd#DebtDeerfieldNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails" xlink:href="exel-20170630.xsd#DebtInterestExpenseOnDeerfieldNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:href="exel-20170630.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:href="exel-20170630.xsd#DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTables" xlink:href="exel-20170630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20170630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20170630.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20170630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20170630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:href="exel-20170630.xsd#IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20170630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20170630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20170630.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2" xlink:href="exel-20170630.xsd#InventoryScheduleOfInventoryDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20170630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20170630.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:href="exel-20170630.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20170630.xsd#NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20170630.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20170630.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20170630.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20170630.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20170630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20170630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20170630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvent" xlink:href="exel-20170630.xsd#SubsequentEvent" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_6823a784-9391-11db-204e-e1be3381cfb7" xlink:type="locator" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_B0CE26677E4A910FAA247127C899EE44" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_6823a784-9391-11db-204e-e1be3381cfb7" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_B0CE26677E4A910FAA247127C899EE44" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_0F21435C4B9F819BE4857126375ED203" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_6823a784-9391-11db-204e-e1be3381cfb7" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_0F21435C4B9F819BE4857126375ED203" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_8c4e8298-c248-614f-7713-e1be3400b652" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_6823a784-9391-11db-204e-e1be3381cfb7" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_8c4e8298-c248-614f-7713-e1be3400b652" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_86cff74f-f6f6-19a8-2f7a-9014c6119804" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_86cff74f-f6f6-19a8-2f7a-9014c6119804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_f8ec0914-845d-a2a8-d865-8dc286cfe5de" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:to="loc_us-gaap_RoyaltyRevenue_f8ec0914-845d-a2a8-d865-8dc286cfe5de" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_565369E1C866F634D44187328E95A74E" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_565369E1C866F634D44187328E95A74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_065deb92-7092-46c8-89c6-aef4f67f9809" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:to="loc_us-gaap_RoyaltyExpense_065deb92-7092-46c8-89c6-aef4f67f9809" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_978bf54f-94f4-6d95-31d0-cc33097dd6a0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_978bf54f-94f4-6d95-31d0-cc33097dd6a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_74608514-6c9e-8537-59a6-0d935b66d87e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_74608514-6c9e-8537-59a6-0d935b66d87e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_31e1482a-2c65-1330-9267-1f3e05ceda5f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_31e1482a-2c65-1330-9267-1f3e05ceda5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_c9e6708b-c7a2-02bd-ecf0-5193aecad28d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_c9e6708b-c7a2-02bd-ecf0-5193aecad28d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_e5ad3cbd-26fd-1084-dbb7-f0db97dcab88" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_e5ad3cbd-26fd-1084-dbb7-f0db97dcab88" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_532E954C0F8B5DE130728986A21C3726" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_532E954C0F8B5DE130728986A21C3726" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_8F44878DEE890224B2388F961C312E1E" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_af22c084-5dfa-db11-1d14-662ebdcdba41" xlink:to="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_8F44878DEE890224B2388F961C312E1E" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_33c266f5-bd01-1c2e-0668-6cb139d14728" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_36e8e150-2a67-2084-6e01-836ebe4bdbd4" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_33c266f5-bd01-1c2e-0668-6cb139d14728" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_36e8e150-2a67-2084-6e01-836ebe4bdbd4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_c3466533-009e-4fad-f2f2-2a94f4e9ef5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_33c266f5-bd01-1c2e-0668-6cb139d14728" xlink:to="loc_us-gaap_LeaseAndRentalExpense_c3466533-009e-4fad-f2f2-2a94f4e9ef5e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRisk" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_cba84dc8-4958-54c2-1b6f-e02bffbabe75" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_ShortTermInvestments_cba84dc8-4958-54c2-1b6f-e02bffbabe75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_bbf813cd-8531-daad-0362-0abcbe609fb5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_ReceivablesNetCurrent_bbf813cd-8531-daad-0362-0abcbe609fb5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_540af1b9-194c-7bf7-d9d0-6027d94a429e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_540af1b9-194c-7bf7-d9d0-6027d94a429e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_3c67d026-8a2e-6845-efcf-9ef1a83fd83f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_LongTermInvestments_3c67d026-8a2e-6845-efcf-9ef1a83fd83f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_B3539E6AF28E3BCF799F383BA293717C" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_B3539E6AF28E3BCF799F383BA293717C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b1838057-d66f-5a3a-6991-d5ab898b2fba" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b1838057-d66f-5a3a-6991-d5ab898b2fba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_6743ba80-ee40-7fb3-fa59-4c41257a91a1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_6743ba80-ee40-7fb3-fa59-4c41257a91a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_98cdc03b-64f8-7886-0fc1-c262f8c109bb" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_NotesPayableCurrent_98cdc03b-64f8-7886-0fc1-c262f8c109bb" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_25103f4e-fe95-5927-3b44-e1be3385f056" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_25103f4e-fe95-5927-3b44-e1be3385f056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_df1d0e15-f5f3-c915-376e-e664e6611fd4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_PaidInKindInterest_df1d0e15-f5f3-c915-376e-e664e6611fd4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_96572710-82f1-1b2a-13b2-99b2b2ebc8e0" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_96572710-82f1-1b2a-13b2-99b2b2ebc8e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7c8a7ed5-e324-f4d1-e0f2-1bef47015198" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7c8a7ed5-e324-f4d1-e0f2-1bef47015198" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_9a562a6b-8815-4673-e0ad-e1be347edc9a" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_9a562a6b-8815-4673-e0ad-e1be347edc9a" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_8DB7A25DDA25288F079E386A8BD578CB" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_8DB7A25DDA25288F079E386A8BD578CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_04170815-b2b6-fb8f-5ca6-e1c62554f777" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_04170815-b2b6-fb8f-5ca6-e1c62554f777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3d9deaaa-b8c7-3c73-8534-5cd0fb0fcdbc" xlink:type="locator" />
    <link:calculationArc order="17" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_3d9deaaa-b8c7-3c73-8534-5cd0fb0fcdbc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="18" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_6c22d20f-54f5-facd-9317-47b49be0288b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromStockPlans_6c22d20f-54f5-facd-9317-47b49be0288b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_11ed54de-8651-64ce-6bd2-47983535a6d4" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_11ed54de-8651-64ce-6bd2-47983535a6d4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_90cd6d89-f315-788f-d750-05a68667e398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da5d3613-0426-0efc-e877-f02868c1f6ef" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da5d3613-0426-0efc-e877-f02868c1f6ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_288fc970-1897-a3d1-921d-4c298f012d75" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_288fc970-1897-a3d1-921d-4c298f012d75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_deec9633-9b66-f72b-a9df-3d2e95e18907" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_deec9633-9b66-f72b-a9df-3d2e95e18907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_37f1e565-0f5b-d294-1fab-1f43106882e2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_37f1e565-0f5b-d294-1fab-1f43106882e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_8537a914-fea0-e31b-4574-5efbd321ed57" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_8537a914-fea0-e31b-4574-5efbd321ed57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5eef41ab-a09e-58ba-6708-d9dbc2498316" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5eef41ab-a09e-58ba-6708-d9dbc2498316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_c34e9512-39f1-0d42-dfd0-be8eb08f5a1e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_c34e9512-39f1-0d42-dfd0-be8eb08f5a1e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtDeerfieldNotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_b9b203b7-ff42-afaa-638c-417b649aa4c7" xlink:type="locator" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestExpenseCouponInterest" xlink:label="loc_exel_InterestExpenseCouponInterest_292c7333-379a-8140-564e-e1be33f24aff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_b9b203b7-ff42-afaa-638c-417b649aa4c7" xlink:to="loc_exel_InterestExpenseCouponInterest_292c7333-379a-8140-564e-e1be33f24aff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_b9b203b7-ff42-afaa-638c-417b649aa4c7" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_df1d0e15-f5f3-c915-376e-e664e6611fd4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_b9b203b7-ff42-afaa-638c-417b649aa4c7" xlink:to="loc_us-gaap_PaidInKindInterest_df1d0e15-f5f3-c915-376e-e664e6611fd4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_20825d20-4b8f-c4ab-f4d2-ed28965d741d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryRawMaterials_20825d20-4b8f-c4ab-f4d2-ed28965d741d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_6d5597db-4bd4-7d0e-9946-68f22d2ba196" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryWorkInProcess_6d5597db-4bd4-7d0e-9946-68f22d2ba196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_58a767dc-544b-b9e2-38ae-a5daf42f4bd2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryFinishedGoods_58a767dc-544b-b9e2-38ae-a5daf42f4bd2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_26DBE30FFD2865AB89C5945DBCE8EF53_614208db-429d-6b0c-c478-94024260bd46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_26DBE30FFD2865AB89C5945DBCE8EF53_5ffb5cef-7295-abb0-b6bb-26f3ef612fd8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_26DBE30FFD2865AB89C5945DBCE8EF53_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryNoncurrent_26DBE30FFD2865AB89C5945DBCE8EF53_5ffb5cef-7295-abb0-b6bb-26f3ef612fd8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_26DBE30FFD2865AB89C5945DBCE8EF53_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_26DBE30FFD2865AB89C5945DBCE8EF53_614208db-429d-6b0c-c478-94024260bd46" xlink:to="loc_us-gaap_InventoryNet_26DBE30FFD2865AB89C5945DBCE8EF53_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1735fe31-9766-d222-70d1-60b3f7021819" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1735fe31-9766-d222-70d1-60b3f7021819" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_d4bfb08a-5eda-c7c1-1bb4-002253d6e87d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_d4bfb08a-5eda-c7c1-1bb4-002253d6e87d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_452a2c1c-cb0d-618d-ae52-6e537eace427" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1735fe31-9766-d222-70d1-60b3f7021819" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_452a2c1c-cb0d-618d-ae52-6e537eace427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_935fce52-c22c-b328-8ef2-ac103d3c71ac" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_935fce52-c22c-b328-8ef2-ac103d3c71ac" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_935fce52-c22c-b328-8ef2-ac103d3c71ac" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SubsequentEvent" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>exel-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20170630.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20170630.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20170630.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsGenentechCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20170630.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20170630.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20170630.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="exel-20170630.xsd#CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:href="exel-20170630.xsd#CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20170630.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRisk" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20170630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20170630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt" xlink:href="exel-20170630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtDeerfieldNotesDetails" xlink:href="exel-20170630.xsd#DebtDeerfieldNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails" xlink:href="exel-20170630.xsd#DebtInterestExpenseOnDeerfieldNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:href="exel-20170630.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:href="exel-20170630.xsd#DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTables" xlink:href="exel-20170630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20170630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20170630.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20170630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20170630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:href="exel-20170630.xsd#IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20170630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20170630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20170630.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20170630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20170630.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:href="exel-20170630.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20170630.xsd#NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20170630.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20170630.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20170630.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20170630.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20170630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20170630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20170630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvent" xlink:href="exel-20170630.xsd#SubsequentEvent" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:to="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C2D7830918D5FC81D7508550E8283126" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C2D7830918D5FC81D7508550E8283126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_3317E751ECF2D7D548128550E829DB23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_CommercialPaperMember_3317E751ECF2D7D548128550E829DB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5CDD1146191DC1F1DCC68550E8294F49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5CDD1146191DC1F1DCC68550E8294F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DDC4CC78CF749EA84B368550E8295D24" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DDC4CC78CF749EA84B368550E8295D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:to="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:to="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_92A7B991C86D2583B9948550E8327B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_92A7B991C86D2583B9948550E8327B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_BA7C54A5DF14595F575F85D51046C639" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_BA7C54A5DF14595F575F85D51046C639" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtCollateralNumberOfRequiredInvestmentAccounts" xlink:label="loc_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtCollateralNumberOfAffiliateBanks" xlink:label="loc_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LongTermInvestmentsMember" xlink:label="loc_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RestrictedCashAndInvestmentsLongTermMember" xlink:label="loc_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:to="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_80AFBB32669BAA1A32E112B9C2B061E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_80AFBB32669BAA1A32E112B9C2B061E0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:to="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:to="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:to="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_BristolMyersSquibbMember" xlink:label="loc_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669" xlink:to="loc_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" xlink:label="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9" xlink:to="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementShareinCostsPercentage" xlink:label="loc_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_80AFBB32669BAA1A32E112B9C2B061E0" xlink:to="loc_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:to="loc_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:to="loc_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_D380AF3389B2DB09CAA793BFF9D88E07" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_D380AF3389B2DB09CAA793BFF9D88E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_436C9384A456F300AC4B93BFF9D8487B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_ContractsRevenue_436C9384A456F300AC4B93BFF9D8487B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_1ADA6886CD6B3817036B945DBD58622F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2" xlink:to="loc_exel_CotellicMember_1ADA6886CD6B3817036B945DBD58622F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedAxis" xlink:label="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:to="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:to="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_Q416Member" xlink:label="loc_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:to="loc_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_1FB2822FD7ED1B2E9298945DBD583DC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_1FB2822FD7ED1B2E9298945DBD583DC7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:to="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:to="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:to="loc_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:to="loc_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_29D9B0FD436E0C6916C6945DBD58470D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_us-gaap_RoyaltyRevenue_29D9B0FD436E0C6916C6945DBD58470D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:to="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057" xlink:to="loc_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_5AB75EDEC963CB99D8C5A3DDDBDA3E52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_5AB75EDEC963CB99D8C5A3DDDBDA3E52" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_17CCDEF6DE06B6812832A3DDDBDA75DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_17CCDEF6DE06B6812832A3DDDBDA75DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:to="loc_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_5077F2F71BF72F54928993BF26B40D1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_5077F2F71BF72F54928993BF26B40D1F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_GB" xlink:label="loc_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:to="loc_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:to="loc_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87" xlink:to="loc_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:to="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:to="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_DC9F673D06A77E3D529493BF26B51B29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:to="loc_exel_InitialMember_DC9F673D06A77E3D529493BF26B51B29" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:to="loc_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:to="loc_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:to="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:to="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C5C549387DA25A56DDDF93BF26B5E476" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:to="loc_us-gaap_MinimumMember_C5C549387DA25A56DDDF93BF26B5E476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9F0E8C55D04485F582F393BF26B58DAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:to="loc_us-gaap_MaximumMember_9F0E8C55D04485F582F393BF26B58DAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_80BA8B0CBFAE275E8FE293BF26B5377A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE" xlink:to="loc_exel_GlaxoSmithKlineMember_80BA8B0CBFAE275E8FE293BF26B5377A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_F18BC5CDDA5DDE777F2C93BF26B551BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD" xlink:to="loc_us-gaap_RestatementAdjustmentMember_F18BC5CDDA5DDE777F2C93BF26B551BF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_5CD04E578F752EDBFC0493DD8564CB45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_UpfrontAndMilestonePayments_5CD04E578F752EDBFC0493DD8564CB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_8F6FD2D1F1EBD1C0537193BF26B69B1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_8F6FD2D1F1EBD1C0537193BF26B69B1F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_712EECC320C4F105CD5693BF26B6F2C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_712EECC320C4F105CD5693BF26B6F2C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_11EA60308BEDAF29090693BF26B6989F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_11EA60308BEDAF29090693BF26B6989F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved" xlink:label="loc_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PaymentOfReimbursementsFromCollaborationArrangement" xlink:label="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B89C8E0F840D9147753093BF26B64ED9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B89C8E0F840D9147753093BF26B64ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_0C2A83A08E2D77BE1EAF93BF26B6D0C0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_0C2A83A08E2D77BE1EAF93BF26B6D0C0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14CA60DBC0CA82B4D4E193BEFD375B7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14CA60DBC0CA82B4D4E193BEFD375B7A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14CA60DBC0CA82B4D4E193BEFD375B7A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_D254334D188A28C656288550E879D612" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_D254334D188A28C656288550E879D612" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_D05849C13F6EDB583E128550E879CD96" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_D05849C13F6EDB583E128550E879CD96" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:to="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:to="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:to="loc_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:to="loc_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_792CC9184DC2758E25C393BF1340B8BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_792CC9184DC2758E25C393BF1340B8BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:to="loc_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_JP" xlink:label="loc_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:to="loc_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:to="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:to="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:to="loc_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:to="loc_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:to="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:to="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="loc_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:to="loc_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_A50ACCAF3D85E1380BD193BF13C283E1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_us-gaap_DeferredRevenueCurrent_A50ACCAF3D85E1380BD193BF13C283E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_D97C4C161BDA8A18700B93BF13C2A812" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_D97C4C161BDA8A18700B93BF13C2A812" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ContractTerminationPeriodforWrittenNotice" xlink:label="loc_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DeferredRevenueRecognitionPeriod" xlink:label="loc_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:to="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_BuildingShellsMember" xlink:label="loc_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:to="loc_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:to="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:to="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LesseeLeasingArrangementsCapitalLeasesTermofContract" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesNumberofOptionstoTerminate" xlink:label="loc_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty" xlink:label="loc_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfRealEstateProperties" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_FinancingLeaseObligationMember" xlink:label="loc_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:to="loc_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRisk" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:to="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B" xlink:to="loc_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1142605EC0E27BD32FED89D773C87175" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1142605EC0E27BD32FED89D773C87175" xlink:to="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_F5E04429C5584FAF980789D773C7A51F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_F5E04429C5584FAF980789D773C7A51F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_C7A25D1884852F9A776E89D773C7742E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_C7A25D1884852F9A776E89D773C7742E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_131E48EA24BB63C4F6AE89D773C8DF18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_131E48EA24BB63C4F6AE89D773C8DF18" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_7FA554BED636B920E2EA89D773C81621" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_CaremarkL.L.C.Member_7FA554BED636B920E2EA89D773C81621" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_EAD1C8E00F356B431C1C89D773C8AF53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_AccredoHealthIncorporatedMember_EAD1C8E00F356B431C1C89D773C8AF53" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_8C834BA66DDDB955770789D773C8C198" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_8C834BA66DDDB955770789D773C8C198" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_MerckMember" xlink:label="loc_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_959AE1BA69ED4180898389D773C84E74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1142605EC0E27BD32FED89D773C87175" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_959AE1BA69ED4180898389D773C84E74" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:to="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:to="loc_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:to="loc_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_JP" xlink:label="loc_country_JP_2FE4BDD08B41125B4C0789D773C00415" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:to="loc_country_JP_2FE4BDD08B41125B4C0789D773C00415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:to="loc_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtDeerfieldNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:to="loc_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeAxis" xlink:label="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:to="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:to="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CouponInterestMember" xlink:label="loc_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:to="loc_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PaymentinKindInterestMember" xlink:label="loc_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:to="loc_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ExtinguishmentofDebtincludingInterestandPenalties" xlink:label="loc_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ExtinguishmentofDebtIncludingPaidinKindInterest" xlink:label="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentPrepaymentPenalty" xlink:label="loc_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" xlink:label="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" xlink:label="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_D8A8AD4C6F8CA023C3D68B0138373636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334" xlink:to="loc_us-gaap_SecuredDebtMember_D8A8AD4C6F8CA023C3D68B0138373636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:to="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_C92F610011FE90111BCB8B013838A026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_C92F610011FE90111BCB8B013838A026" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestExpenseCouponInterest" xlink:label="loc_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_5BE87F1BB31FEDC0978C8B0138395B5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_PaidInKindInterest_5BE87F1BB31FEDC0978C8B0138395B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_92557DAED89657929C1F8B01383A7507" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_92557DAED89657929C1F8B01383A7507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F8CB2BC3FBF3908227DA945DBCC864BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F8CB2BC3FBF3908227DA945DBCC864BD" xlink:to="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_5CB9CC7AE31FE58BC82B945DBCC83E0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:to="loc_us-gaap_SecuredDebtMember_5CB9CC7AE31FE58BC82B945DBCC83E0C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TermLoanMember" xlink:label="loc_exel_TermLoanMember_F4B1168243A5847D275E945DBCC8D933" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:to="loc_exel_TermLoanMember_F4B1168243A5847D275E945DBCC8D933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:to="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_535A37494630000E3C83945DBCC84848" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_535A37494630000E3C83945DBCC84848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F8CB2BC3FBF3908227DA945DBCC864BD" xlink:to="loc_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TermLoanMember" xlink:label="loc_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0" xlink:to="loc_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:to="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_EB7C9D9FF18AA7127DB58B0136210D3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_EB7C9D9FF18AA7127DB58B0136210D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_CF71201C88DDEAD9DE608B2EFF034AE2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_InterestPaid_CF71201C88DDEAD9DE608B2EFF034AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations" xlink:label="loc_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_Maximumpercentagerequiredforcollateralbalance" xlink:label="loc_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_057C8DCAC3980E73A5C18B0136228714" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_CompensatingBalanceAmount_057C8DCAC3980E73A5C18B0136228714" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:to="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_AAC315749298B3F82C758550E7F98665" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_MoneyMarketFundsMember_AAC315749298B3F82C758550E7F98665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0867E6967F4D31DFE31E8550E7F9854C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0867E6967F4D31DFE31E8550E7F9854C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:to="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="loc_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="loc_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:to="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:to="loc_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember" xlink:label="loc_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:to="loc_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:to="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E152C6C388DAF23229212B9C2ECA8E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E152C6C388DAF23229212B9C2ECA8E5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:to="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:to="loc_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0E2A3873101EA966CE9398EBF3A2DF2A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0E2A3873101EA966CE9398EBF3A2DF2A" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TradeandOtherReceivablesMember" xlink:label="loc_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:to="loc_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:to="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF" xlink:to="loc_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0E2A3873101EA966CE9398EBF3A2DF2A" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccountingStandardsUpdate201609Member" xlink:label="loc_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:to="loc_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:to="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:to="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:to="loc_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_2AD72C00D97B1C59AB2E9FB80539AA42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E" xlink:to="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_2AD72C00D97B1C59AB2E9FB80539AA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E75EF01AEC4D3FC9D1889FB805395C25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_Depreciation_E75EF01AEC4D3FC9D1889FB805395C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_4B5A43BA6B0189554F159FB80539EEA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_4B5A43BA6B0189554F159FB80539EEA8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_DC683065BF224D1666BD9FB8053943CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_DC683065BF224D1666BD9FB8053943CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E1A6E020FFF0252360818B1CDC9C323D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E1A6E020FFF0252360818B1CDC9C323D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:to="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6DC30D9906EBD4D1C348B1CDC9B8C4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B6DC30D9906EBD4D1C348B1CDC9B8C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E1A6E020FFF0252360818B1CDC9C323D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_078E6338D7132A235EB912B9C1464BB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_078E6338D7132A235EB912B9C1464BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:to="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:to="loc_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:to="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11727D8653717E25B5FD12B9C37B67AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11727D8653717E25B5FD12B9C37B67AB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:to="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_621C9032F6B5DA33645712B9C37B43EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_621C9032F6B5DA33645712B9C37B43EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:to="loc_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11727D8653717E25B5FD12B9C37B67AB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEvent" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>exel-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618_label_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618_documentation_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="lab_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB_terseLabel_en-US" xlink:label="lab_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB_label_en-US" xlink:label="lab_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:to="lab_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD_label_en-US" xlink:label="lab_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:to="lab_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:to="lab_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:to="lab_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8_label_en-US" xlink:label="lab_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:to="lab_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC_label_en-US" xlink:label="lab_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:to="lab_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:to="lab_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90_label_en-US" xlink:label="lab_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:to="lab_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:to="lab_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:to="lab_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:type="arc" />
    <link:label id="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40_terseLabel_en-US" xlink:label="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:label id="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40_label_en-US" xlink:label="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:label id="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40_documentation_en-US" xlink:label="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_AccountingStandardsUpdate201609Member" xlink:label="loc_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:to="lab_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:to="lab_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:to="lab_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative adjustment</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in federal and state net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:to="lab_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net impact on provision for income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period, Aggregate Intrinsic Value, in dollars</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period, Aggregate Intrinsic Value, in dollars</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8_terseLabel_en-US" xlink:label="lab_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8_label_en-US" xlink:label="lab_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:to="lab_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:to="lab_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:to="lab_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:to="lab_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government sponsored enterprises [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40_terseLabel_en-US" xlink:label="lab_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40_label_en-US" xlink:label="lab_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="lab_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701" xlink:to="lab_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="lab_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured notes [Member]</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:to="lab_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:to="lab_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:type="arc" />
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77_terseLabel_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77_label_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77_documentation_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:to="lab_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:type="arc" />
    <link:label id="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4_terseLabel_en-US" xlink:label="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Axis]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4_label_en-US" xlink:label="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Axis]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4_documentation_en-US" xlink:label="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeAxis" xlink:label="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:to="lab_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:type="arc" />
    <link:label id="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E_terseLabel_en-US" xlink:label="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Domain]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E_label_en-US" xlink:label="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Domain]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E_documentation_en-US" xlink:label="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Interest Payment Type [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:to="lab_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:type="arc" />
    <link:label id="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C_terseLabel_en-US" xlink:label="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coupon Interest [Member]</link:label>
    <link:label id="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C_label_en-US" xlink:label="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coupon Interest [Member]</link:label>
    <link:label id="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C_documentation_en-US" xlink:label="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coupon Interest [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CouponInterestMember" xlink:label="loc_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:to="lab_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:type="arc" />
    <link:label id="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439_terseLabel_en-US" xlink:label="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment-in-kind interest [Member]</link:label>
    <link:label id="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439_label_en-US" xlink:label="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment-in-Kind Interest [Member]</link:label>
    <link:label id="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439_documentation_en-US" xlink:label="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment-in-Kind Interest [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_PaymentinKindInterestMember" xlink:label="loc_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:to="lab_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="lab_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:type="arc" />
    <link:label id="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18_terseLabel_en-US" xlink:label="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of notes payable</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18_label_en-US" xlink:label="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, including Interest and Penalties</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18_documentation_en-US" xlink:label="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, including Interest and Penalties</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ExtinguishmentofDebtincludingInterestandPenalties" xlink:label="loc_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:to="lab_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:type="arc" />
    <link:label id="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84_terseLabel_en-US" xlink:label="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of principal, including paid in kind interest</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84_label_en-US" xlink:label="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Including Paid in Kind Interest</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84_documentation_en-US" xlink:label="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Including Paid in Kind Interest</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ExtinguishmentofDebtIncludingPaidinKindInterest" xlink:label="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:to="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5_verboseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest paid in kind</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:to="lab_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment penalty amount</link:label>
    <link:label id="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507_label_en-US" xlink:label="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty</link:label>
    <link:label id="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507_documentation_en-US" xlink:label="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentPrepaymentPenalty" xlink:label="loc_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:to="lab_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43_label_en-US" xlink:label="lab_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:to="lab_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate after extension option election (as a percent)</link:label>
    <link:label id="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA_label_en-US" xlink:label="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election</link:label>
    <link:label id="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA_documentation_en-US" xlink:label="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" xlink:label="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:to="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance of unamortized closing fees and expenses</link:label>
    <link:label id="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5_label_en-US" xlink:label="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments, Unamortized Closing Fees And Expenses</link:label>
    <link:label id="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5_documentation_en-US" xlink:label="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instruments, unamortized closing fees and expenses.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" xlink:label="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:to="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross rental expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:to="lab_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less: Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net rental expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:type="arc" />
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F_verboseLabel_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Term Loan and Line of Credit [Member]</link:label>
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F_label_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F_documentation_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:to="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:type="arc" />
    <link:label id="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23_verboseLabel_en-US" xlink:label="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of required investment accounts</link:label>
    <link:label id="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23_label_en-US" xlink:label="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Collateral, Number of Required Investment Accounts</link:label>
    <link:label id="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23_documentation_en-US" xlink:label="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Collateral, Number of Required Investment Accounts</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtCollateralNumberOfRequiredInvestmentAccounts" xlink:label="loc_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:to="lab_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:type="arc" />
    <link:label id="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4_terseLabel_en-US" xlink:label="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of affiliate banks</link:label>
    <link:label id="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4_label_en-US" xlink:label="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Collateral, Number of Affiliate Banks</link:label>
    <link:label id="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4_documentation_en-US" xlink:label="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Collateral, Number of Affiliate Banks</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtCollateralNumberOfAffiliateBanks" xlink:label="loc_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:to="lab_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collateral balance</link:label>
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE_label_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensating Balance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:to="lab_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss position, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:to="lab_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:to="lab_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA_verboseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of upfront payment</link:label>
    <link:label id="lab_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA_label_en-US" xlink:label="lab_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition of Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:to="lab_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development cost reimbursements</link:label>
    <link:label id="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B_label_en-US" xlink:label="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Development Cost Reimbursements</link:label>
    <link:label id="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Development Revenue</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:to="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA_totalLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues under the collaboration agreement</link:label>
    <link:label id="lab_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA_label_en-US" xlink:label="lab_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:to="lab_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE_terseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of upfront payments and deferred milestone</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:to="lab_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:to="lab_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product supply agreement revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of supplied product</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:to="lab_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable to GSK on net sales by Ipsen</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:to="lab_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:type="arc" />
    <link:label id="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791_terseLabel_en-US" xlink:label="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan [Member]</link:label>
    <link:label id="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791_label_en-US" xlink:label="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791_documentation_en-US" xlink:label="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_TermLoanMember" xlink:label="loc_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:to="lab_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding principal amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:to="lab_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain or loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of security deposit on outstanding obligations</link:label>
    <link:label id="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815_label_en-US" xlink:label="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Collateral Security Deposit On Outstanding Obligations</link:label>
    <link:label id="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815_documentation_en-US" xlink:label="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument, percentage of collateral security deposit on outstanding obligations.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations" xlink:label="loc_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:to="lab_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:type="arc" />
    <link:label id="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508_terseLabel_en-US" xlink:label="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage required for collateral balance</link:label>
    <link:label id="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508_label_en-US" xlink:label="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum percentage required for collateral balance</link:label>
    <link:label id="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508_documentation_en-US" xlink:label="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum percentage required for collateral balance.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_Maximumpercentagerequiredforcollateralbalance" xlink:label="loc_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:to="lab_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:to="lab_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:type="arc" />
    <link:label id="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092_terseLabel_en-US" xlink:label="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing obligations</link:label>
    <link:label id="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092_label_en-US" xlink:label="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Lease Obligation [Member]</link:label>
    <link:label id="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092_documentation_en-US" xlink:label="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Lease Obligation [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_FinancingLeaseObligationMember" xlink:label="loc_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:to="lab_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2017</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB_terseLabel_en-US" xlink:label="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB_label_en-US" xlink:label="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Six Years</link:label>
    <link:label id="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB_documentation_en-US" xlink:label="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Six Years</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:to="lab_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220_terseLabel_en-US" xlink:label="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220_label_en-US" xlink:label="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due After Year Six</link:label>
    <link:label id="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220_documentation_en-US" xlink:label="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due After Year Six</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:to="lab_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Future minimum payments due, capital</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mature within One Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After One Year through Two Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:to="lab_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE" xlink:to="lab_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="lab_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="lab_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:to="lab_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:to="lab_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A_label_en-US" xlink:label="lab_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:to="lab_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:to="lab_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:to="lab_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44_label_en-US" xlink:label="lab_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:to="lab_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5_label_en-US" xlink:label="lab_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:to="lab_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:to="lab_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:to="lab_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:to="lab_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:to="lab_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E_label_en-US" xlink:label="lab_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:to="lab_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:to="lab_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="lab_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:to="lab_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 293,727,630 and 289,923,798 at June 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:to="lab_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:to="lab_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36_terseLabel_en-US" xlink:label="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Lease and Other Financing Lease [Member]</link:label>
    <link:label id="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36_label_en-US" xlink:label="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease and Other Financing Lease [Member]</link:label>
    <link:label id="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36_documentation_en-US" xlink:label="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Lease and Other Financing Lease [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:to="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:type="arc" />
    <link:label id="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75_terseLabel_en-US" xlink:label="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building shells [Member]</link:label>
    <link:label id="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75_label_en-US" xlink:label="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Shells [Member]</link:label>
    <link:label id="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75_documentation_en-US" xlink:label="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Building Shells [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_BuildingShellsMember" xlink:label="loc_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:to="lab_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:to="lab_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:to="lab_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby letters of credit [Member]</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of lease property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:type="arc" />
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A_terseLabel_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of lease contract</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A_label_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital Leases, Term of Contract</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A_documentation_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital Leases, Term of Contract</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_LesseeLeasingArrangementsCapitalLeasesTermofContract" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:to="lab_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A_terseLabel_en-US" xlink:label="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A_label_en-US" xlink:label="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Number of Renewal Options</link:label>
    <link:label id="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A_documentation_en-US" xlink:label="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Leases, Number of Renewal Options</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:to="lab_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:type="arc" />
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA_terseLabel_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal option term</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA_label_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital Leases, Renewal Term</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA_documentation_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital Leases, Renewal Term</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:to="lab_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06_terseLabel_en-US" xlink:label="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to terminate</link:label>
    <link:label id="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06_label_en-US" xlink:label="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Number of Options to Terminate</link:label>
    <link:label id="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06_documentation_en-US" xlink:label="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Leases, Number of Options to Terminate</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesNumberofOptionstoTerminate" xlink:label="loc_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:to="lab_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future minimum payments due</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED_terseLabel_en-US" xlink:label="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option for additional area of lease (in sqft)</link:label>
    <link:label id="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED_label_en-US" xlink:label="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Option, Additional Area of Real Estate Property</link:label>
    <link:label id="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED_documentation_en-US" xlink:label="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Leases, Option, Additional Area of Real Estate Property</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty" xlink:label="loc_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:to="lab_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leased properties</link:label>
    <link:label id="lab_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9_label_en-US" xlink:label="lab_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Real Estate Properties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfRealEstateProperties" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:to="lab_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Interest Expense on Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:to="lab_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604_verboseLabel_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604_label_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:to="lab_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:type="arc" />
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for Error Corrections [Axis]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Error Corrections [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for Error Correction [Domain]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Error Correction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:to="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:type="arc" />
    <link:label id="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6_terseLabel_en-US" xlink:label="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Correction of Amortization of Debt Discount Associated with the 2019 Notes [Member]</link:label>
    <link:label id="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6_label_en-US" xlink:label="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Correction of Amortization of Debt Discount Associated with the 2019 Notes [Member]</link:label>
    <link:label id="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6_documentation_en-US" xlink:label="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Correction of Amortization of Debt Discount Associated with the 2019 Notes [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember" xlink:label="loc_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:to="lab_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Operations:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="lab_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57_label_en-US" xlink:label="lab_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:to="lab_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:to="lab_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statements of Comprehensive Loss:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statements of Cash Flows:</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accretion of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:to="lab_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:to="lab_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:to="lab_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:type="arc" />
    <link:label id="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C_terseLabel_en-US" xlink:label="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COTELLIC [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C_label_en-US" xlink:label="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C_documentation_en-US" xlink:label="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:to="lab_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:to="lab_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. losses included in Selling, general and administrative expenses</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:to="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330_label_en-US" xlink:label="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330_documentation_en-US" xlink:label="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:to="lab_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412_label_en-US" xlink:label="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:to="lab_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:type="arc" />
    <link:label id="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27_terseLabel_en-US" xlink:label="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27_label_en-US" xlink:label="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27_documentation_en-US" xlink:label="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:to="lab_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7_verboseLabel_en-US" xlink:label="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7_label_en-US" xlink:label="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7_documentation_en-US" xlink:label="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:to="lab_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:to="lab_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:to="lab_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:type="arc" />
    <link:label id="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316_terseLabel_en-US" xlink:label="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316_label_en-US" xlink:label="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316_documentation_en-US" xlink:label="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:to="lab_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:type="arc" />
    <link:label id="lab_country_JP_AE8327710E326B56AF7A93BF13429CF9_terseLabel_en-US" xlink:label="lab_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan [Member]</link:label>
    <link:label id="lab_country_JP_AE8327710E326B56AF7A93BF13429CF9_label_en-US" xlink:label="lab_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_JP" xlink:label="loc_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:to="lab_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31_label_en-US" xlink:label="lab_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:to="lab_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749_label_en-US" xlink:label="lab_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:to="lab_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70_label_en-US" xlink:label="lab_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:to="lab_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793_label_en-US" xlink:label="lab_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:to="lab_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377_label_en-US" xlink:label="lab_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:to="lab_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723_label_en-US" xlink:label="lab_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:to="lab_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:type="arc" />
    <link:label id="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224_terseLabel_en-US" xlink:label="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224_label_en-US" xlink:label="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224_documentation_en-US" xlink:label="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="loc_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:to="lab_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8_terseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8_label_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8_documentation_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:to="lab_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum pre-specified payments</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7_netLabel_en-US" xlink:label="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Cumulative net sales</link:label>
    <link:label id="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7_label_en-US" xlink:label="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7_documentation_en-US" xlink:label="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:to="lab_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:type="arc" />
    <link:label id="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742_terseLabel_en-US" xlink:label="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination of collaboration agreement, period for written notice</link:label>
    <link:label id="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742_label_en-US" xlink:label="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination, Period for Written Notice</link:label>
    <link:label id="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742_documentation_en-US" xlink:label="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Termination, Period for Written Notice</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ContractTerminationPeriodforWrittenNotice" xlink:label="loc_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:to="lab_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:type="arc" />
    <link:label id="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E_terseLabel_en-US" xlink:label="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, recognition period</link:label>
    <link:label id="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E_label_en-US" xlink:label="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Recognition Period</link:label>
    <link:label id="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E_documentation_en-US" xlink:label="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Recognition Period</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DeferredRevenueRecognitionPeriod" xlink:label="loc_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:to="lab_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Subordinated Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175_label_en-US" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Subordinated Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:to="lab_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:type="arc" />
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5_terseLabel_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Senior Subordinated Notes due August 15, 2019, 4.25% [Member]</link:label>
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5_label_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Subordinated Notes due August 15, 2019, 4.25% [Member]</link:label>
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5_documentation_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Subordinated Notes due 2019, 4.25% [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:to="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235_label_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235_documentation_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:to="lab_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:to="lab_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:to="lab_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:to="lab_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:to="lab_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:to="lab_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929_label_en-US" xlink:label="lab_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:to="lab_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: non-current portion included in Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:to="lab_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244" xlink:to="lab_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:to="lab_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:type="arc" />
    <link:label id="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9_terseLabel_en-US" xlink:label="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMS [Member]</link:label>
    <link:label id="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9_label_en-US" xlink:label="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9_documentation_en-US" xlink:label="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member].</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_BristolMyersSquibbMember" xlink:label="loc_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:to="lab_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, 2 BMS Compound Utilized [Member] [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" xlink:label="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:to="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share in costs, percentage</link:label>
    <link:label id="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66_label_en-US" xlink:label="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Share in Costs, Percentage</link:label>
    <link:label id="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Share in Costs, Percentage</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementShareinCostsPercentage" xlink:label="loc_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:to="lab_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments to net income (loss) resulting from realized gains or losses on sale of securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:to="lab_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:to="lab_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:to="lab_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:to="lab_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock for basic net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock for diluted net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:to="lab_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:to="lab_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:to="lab_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:type="arc" />
    <link:label id="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456_terseLabel_en-US" xlink:label="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Generated [Axis]</link:label>
    <link:label id="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456_label_en-US" xlink:label="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Generated [Axis]</link:label>
    <link:label id="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456_documentation_en-US" xlink:label="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Generated [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedAxis" xlink:label="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:to="lab_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:type="arc" />
    <link:label id="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD_terseLabel_en-US" xlink:label="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Generated [Domain]</link:label>
    <link:label id="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD_label_en-US" xlink:label="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Generated [Domain]</link:label>
    <link:label id="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD_documentation_en-US" xlink:label="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Period Generated [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:to="lab_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:type="arc" />
    <link:label id="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174_terseLabel_en-US" xlink:label="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Q4 '16 [Member]</link:label>
    <link:label id="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174_label_en-US" xlink:label="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Q4 '16 [Member]</link:label>
    <link:label id="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174_documentation_en-US" xlink:label="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Q4 '16 [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_Q416Member" xlink:label="loc_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:to="lab_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74_label_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:to="lab_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135_label_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:to="lab_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3_label_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:to="lab_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762_label_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:to="lab_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:to="lab_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:to="lab_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9_verboseLabel_en-US" xlink:label="lab_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Profit threshold</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:to="lab_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903_verboseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share of the Company in promotions</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Optional Percent of Total Sales Force</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Optional Percent of Total Sales Force</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:to="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash Equivalents and Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Available-for-Sale Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:to="lab_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discounts and debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual of interest paid in kind</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24" xlink:to="lab_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of other equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D_label_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Accrued Clinical Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) accrued clinical liabilities</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:to="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7_label_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:to="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of other equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash and Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:to="lab_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible notes and term loan payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure - non-cash investing and financing activity:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress deemed to have been acquired under build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:to="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="lab_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:type="arc" />
    <link:label id="lab_country_US_A698E8A78B4C8923E7F789D773C0D3C9_terseLabel_en-US" xlink:label="lab_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_country_US_A698E8A78B4C8923E7F789D773C0D3C9_label_en-US" xlink:label="lab_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:to="lab_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:label id="lab_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52_label_en-US" xlink:label="lab_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:to="lab_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:to="lab_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:to="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:to="lab_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:to="lab_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:type="arc" />
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234_terseLabel_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234_label_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234_documentation_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:to="lab_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:type="arc" />
    <link:label id="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2_terseLabel_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2_label_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2_documentation_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:to="lab_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:to="lab_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk (as a percentage)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange fluctuations loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:to="lab_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress [Member]</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:to="lab_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1_label_en-US" xlink:label="lab_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:to="lab_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:type="arc" />
    <link:label id="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11_terseLabel_en-US" xlink:label="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables [Member]</link:label>
    <link:label id="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11_label_en-US" xlink:label="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Receivables [Member]</link:label>
    <link:label id="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11_documentation_en-US" xlink:label="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade and Other Receivables [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_TradeandOtherReceivablesMember" xlink:label="loc_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:to="lab_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B_terseLabel_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:to="lab_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued product sales discounts, reclassified</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computed income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:type="arc" />
    <link:label id="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F_terseLabel_en-US" xlink:label="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess benefits associated with equity compensation</link:label>
    <link:label id="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F_label_en-US" xlink:label="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefits - Share-based Compensation</link:label>
    <link:label id="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F_documentation_en-US" xlink:label="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess Tax Benefits - Share-based Compensation</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ExcessTaxBenefitsSharebasedCompensation" xlink:label="loc_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:to="lab_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7_periodEndLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period, Aggregate Intrinsic Value, in dollars</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D_label_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:to="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMS [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:to="lab_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:to="lab_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized, milestones</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:to="lab_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:to="lab_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:type="arc" />
    <link:label id="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A_terseLabel_en-US" xlink:label="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Correction of an Immaterial Error</link:label>
    <link:label id="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A_label_en-US" xlink:label="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections, Policy [Policy Text Block]</link:label>
    <link:label id="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A_documentation_en-US" xlink:label="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock" xlink:label="loc_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:to="lab_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:to="lab_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:to="lab_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:to="lab_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:to="lab_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvements allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:to="lab_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Consideration for Commercialization Rights [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Consideration for Commercialization Rights [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Consideration for Commercialization Rights [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:to="lab_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Approval of Product by EC in Second-Line RCC [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:to="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:to="lab_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:type="arc" />
    <link:label id="lab_country_GB_741E51710ACA69B4CD9C93E7508BA75C_terseLabel_en-US" xlink:label="lab_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom [Member]</link:label>
    <link:label id="lab_country_GB_741E51710ACA69B4CD9C93E7508BA75C_label_en-US" xlink:label="lab_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_GB" xlink:label="loc_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:to="lab_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:type="arc" />
    <link:label id="lab_country_DE_41C264C7E2791A60BB2793BF26B4331C_terseLabel_en-US" xlink:label="lab_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany [Member]</link:label>
    <link:label id="lab_country_DE_41C264C7E2791A60BB2793BF26B4331C_label_en-US" xlink:label="lab_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:to="lab_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4_label_en-US" xlink:label="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4_documentation_en-US" xlink:label="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:to="lab_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:type="arc" />
    <link:label id="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576_terseLabel_en-US" xlink:label="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:label id="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576_label_en-US" xlink:label="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:label id="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576_documentation_en-US" xlink:label="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:to="lab_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial and Second [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:to="lab_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:to="lab_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:type="arc" />
    <link:label id="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F_terseLabel_en-US" xlink:label="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F_label_en-US" xlink:label="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number of Milestones Achieved</link:label>
    <link:label id="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F_documentation_en-US" xlink:label="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Number of Milestones Achieved</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved" xlink:label="loc_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:to="lab_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue reclassified</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:to="lab_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:type="arc" />
    <link:label id="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF_terseLabel_en-US" xlink:label="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursements of certain clinical programs paid</link:label>
    <link:label id="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF_label_en-US" xlink:label="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Reimbursements From Collaboration Arrangement</link:label>
    <link:label id="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF_documentation_en-US" xlink:label="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Reimbursements From Collaboration Arrangement</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_PaymentOfReimbursementsFromCollaborationArrangement" xlink:label="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:to="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:to="lab_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [Member]</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:to="lab_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:type="arc" />
    <link:label id="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5_terseLabel_en-US" xlink:label="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments [Member]</link:label>
    <link:label id="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5_label_en-US" xlink:label="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5_documentation_en-US" xlink:label="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_LongTermInvestmentsMember" xlink:label="loc_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:to="lab_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:type="arc" />
    <link:label id="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08_terseLabel_en-US" xlink:label="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments [Member]</link:label>
    <link:label id="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08_label_en-US" xlink:label="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Long-term [Member]</link:label>
    <link:label id="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08_documentation_en-US" xlink:label="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Long-term [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_RestrictedCashAndInvestmentsLongTermMember" xlink:label="loc_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:to="lab_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71_label_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:to="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497_label_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:to="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21_label_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities, Gross Unrealized Loss Accumulated in Investments</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities, Gross Unrealized Loss Accumulated in Investments</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:to="lab_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA_label_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Available-for-sale Securities</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:to="lab_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:type="arc" />
    <link:label id="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1_terseLabel_en-US" xlink:label="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1_label_en-US" xlink:label="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1_documentation_en-US" xlink:label="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck [Member].</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_MerckMember" xlink:label="loc_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:to="lab_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:type="arc" />
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4_verboseLabel_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2019 Notes [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:to="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:type="arc" />
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843_netLabel_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Deerfield Notes [Member]</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:to="lab_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions [Member]</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:to="lab_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt [Member]</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF_label_en-US" xlink:label="lab_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:to="lab_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total potentially dilutive shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:to="lab_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69_label_en-US" xlink:label="lab_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:to="lab_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:to="lab_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9" xlink:to="lab_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring (recovery) charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:to="lab_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:to="lab_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:to="lab_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income and other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088" xlink:to="lab_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:type="arc" />
    <link:label id="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008_terseLabel_en-US" xlink:label="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated coupon interest</link:label>
    <link:label id="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008_label_en-US" xlink:label="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Coupon Interest</link:label>
    <link:label id="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008_documentation_en-US" xlink:label="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coupon Interest on Debt</link:label>
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestExpenseCouponInterest" xlink:label="loc_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:to="lab_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:to="lab_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>exel-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20170630.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20170630.xsd#CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20170630.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20170630.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsGenentechCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20170630.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20170630.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20170630.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20170630.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="exel-20170630.xsd#CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:href="exel-20170630.xsd#CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20170630.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRisk" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables" xlink:href="exel-20170630.xsd#ConcentrationsOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20170630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20170630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="exel-20170630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt" xlink:href="exel-20170630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtDeerfieldNotesDetails" xlink:href="exel-20170630.xsd#DebtDeerfieldNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails" xlink:href="exel-20170630.xsd#DebtInterestExpenseOnDeerfieldNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:href="exel-20170630.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:href="exel-20170630.xsd#DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTables" xlink:href="exel-20170630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20170630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20170630.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20170630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20170630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:href="exel-20170630.xsd#IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20170630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20170630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20170630.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20170630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20170630.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:href="exel-20170630.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20170630.xsd#NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20170630.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20170630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20170630.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20170630.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20170630.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20170630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20170630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20170630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:href="exel-20170630.xsd#StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvent" xlink:href="exel-20170630.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2BF98E8F0A40AC22C589860CCB0DC962" xlink:type="locator" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2BF98E8F0A40AC22C589860CCB0DC962" xlink:to="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D1FB78F94907DB106736860CCB0D3E9D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26BD3B795255B2CEE9DA8550E8285D5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26BD3B795255B2CEE9DA8550E8285D5E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:to="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_54BC1CB859B7BA4537448550E828F2DB" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C2D7830918D5FC81D7508550E8283126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C2D7830918D5FC81D7508550E8283126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_3317E751ECF2D7D548128550E829DB23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_CommercialPaperMember_3317E751ECF2D7D548128550E829DB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5CDD1146191DC1F1DCC68550E8294F49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5CDD1146191DC1F1DCC68550E8294F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DDC4CC78CF749EA84B368550E8295D24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A4D781CA09C93FCF07ED8550E8280936" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_DDC4CC78CF749EA84B368550E8295D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_86014BBCA855ACBF52148550E828AEF1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06A4EBC7A0C76D7A49588550E829F500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D02D2770A52CEA24E1808550E8294A5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8942857805802A1687768550E829F14A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_133521AD2C5FDB574DDE8550E829FC32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2DD047D981D380639F698550E8313AFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2DD047D981D380639F698550E8313AFA" xlink:to="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:to="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_27E5D53800AED7F0DC348550E8328F96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9F2BD023CF82BB8E12228550E83203E4" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_80C875394910E0A52ADB8550E8327E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:to="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_709E60CBFEA2C5C3FEC78550E83270C4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_92A7B991C86D2583B9948550E8327B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_92A7B991C86D2583B9948550E8327B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_BA7C54A5DF14595F575F85D51046C639" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EBAF327039B8DEF979A18550E832ACB7" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_BA7C54A5DF14595F575F85D51046C639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_4ECEA60CB4D441F3A3FC8550E83185D3" xlink:to="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtCollateralNumberOfRequiredInvestmentAccounts" xlink:label="loc_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_exel_DebtCollateralNumberOfRequiredInvestmentAccounts_D3B89045689C434A111B8550E8325F23" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtCollateralNumberOfAffiliateBanks" xlink:label="loc_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_exel_DebtCollateralNumberOfAffiliateBanks_FDD833EDF465968690FB8550E83278E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_CompensatingBalanceAmount_E554D276767DE70689F58550E8321CAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_2AC264367C99B8F81AC48550E832DD51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_45F5B6902B584AAC56E28550E832D428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_46ED8E8C819234BA39918550E8330C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_83D471193A48FBCC79838550E8331F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_C30243D121DFC2992DD18550E8328AB7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_5DEA089099E2AAF00BE28550E835D292" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C1ECD77A1FC7AF26037A8550E83A3E3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C1ECD77A1FC7AF26037A8550E83A3E3E" xlink:to="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C2EF1FAD3D9DA400F4228550E83A00FB" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_us-gaap_CashEquivalentsMember_021B8E234AB02E29ACFD8550E83B29F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_55147548B5024D05739C8550E83B93A4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LongTermInvestmentsMember" xlink:label="loc_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_exel_LongTermInvestmentsMember_9FA29F781F549744F35B8550E83B56A5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RestrictedCashAndInvestmentsLongTermMember" xlink:label="loc_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D041A72FFBB4FC4812D68550E83A4D9F" xlink:to="loc_exel_RestrictedCashAndInvestmentsLongTermMember_B55B016EA9F617BC46EA8550E83BCF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_FDA1D63E964462ED73B28550E83A9044" xlink:to="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C5138473673B1EFE1B68550E83B6E71" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments_F042AFDDE057C59FD3208550E83BD497" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments_F328911D901ADC088DC18550E83B4C21" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_0FC593A36AA96C7410DE8550E83B999F" xlink:to="loc_exel_CashCashEquivalentsandAvailableforsaleSecurities_2002C660A55A253917A28550E83BB3FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_FF91C9C85B19149B9DA58550E82DBB38" xlink:to="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:to="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_70D6E81C4964373401AC8550E82D9185" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_394730A70C81BD67801A8550E82DD828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_CommercialPaperMember_DB6BBA7DC485E30E28C78550E82DCA15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_A407F9A24B2EE0DCD8228550E82D97FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2D80FD4548F8F30D9FFB8550E82D3ADF" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_7AD504B64F18169789D38550E82DE747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_1E916C99CB3B83C4F6A48550E82DA8E8" xlink:to="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6081AA82C17B8B663A1D8550E82D9315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9ADDD1CE996A1EEC74808550E82DF228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E42DF84B347B1A8344F18550E82D7B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_1194991828C31A1ACE7F8550E82D5F40" xlink:to="loc_us-gaap_AvailableForSaleSecurities_806C5444B2BC562551638550E82D9D2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58874FC3797A637A4B5F8550E83E02EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58874FC3797A637A4B5F8550E83E02EF" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04479529EF8F8658B2668550E83E3B4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58874FC3797A637A4B5F8550E83E02EF" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_E7755F574C5E165E5DC38550E83E366A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58874FC3797A637A4B5F8550E83E02EF" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6442949DD24F67C93F2A8550E83EE87F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F51661513B778E3092F860C8D594A14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F51661513B778E3092F860C8D594A14" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6B63D21E1305D60D5375860C8D5AC248" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F3CF774CEE0A1EDCDFC12B9C2B02CF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7F3CF774CEE0A1EDCDFC12B9C2B02CF1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:to="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7F26F629BC6EA0FCCECB12B9C2B0C623" xlink:to="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_BristolMyersSquibbMember" xlink:label="loc_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_BE79F363A698ECA1B26612B9C2B0A669" xlink:to="loc_exel_BristolMyersSquibbMember_292BEA9981DE3FC959D312B9C2B0F8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_53264F393B873BE1AD2D12B9C2B08CBF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" xlink:label="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E59D0CD81A2F13948AB12B9C2B077C9" xlink:to="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_D65037B460A680FBBBDF12B9C2B0DE26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_80AFBB32669BAA1A32E112B9C2B061E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55E0B5E81944C287779712B9C2B014C1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_80AFBB32669BAA1A32E112B9C2B061E0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementShareinCostsPercentage" xlink:label="loc_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_80AFBB32669BAA1A32E112B9C2B061E0" xlink:to="loc_exel_CollaborativeArrangementShareinCostsPercentage_904B3B1926C084BE1B2112B9C2B0AA66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8200E541BBB919F725A393BFF9B9944E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8200E541BBB919F725A393BFF9B9944E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CC008E04357B617A91393BFF9B9660A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6E6264C992D373A422A593BFF9B9E804" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_BEDBB501CA80FB81BC5693BFF9B9B303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_7D6BD98ACACE596E665993BFF9B9D69C" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AB15587BDFBBECCDAC8D93BFF9B9E903" xlink:to="loc_exel_CotellicMember_299E86E234B611274FB893BFF9B97C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1F69FBE918A51068987493BFF9C9D7C2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC38CBF02B27C0317D5B93BFF9C98D84" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D35A6A37E00701A1EA4E93BFF9C9A678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2C5E16482EB627E53D0193BFF9B9350F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:to="loc_us-gaap_RoyaltyRevenue_7292B7399C3CD191311893BFF9C9DD76" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CE41C55025C28DC4CF5F93BFF9C95B09" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_6C9EB54C639F474CD8B893BFF9C94336" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ED825F9061DB5224226193BFF9C98460" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ED825F9061DB5224226193BFF9C98460" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C6DB3F0A55FE6548F88093BFF9C95D2E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FC94B64603C303C4CF5A93BFF9C93552" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_4919D5A09092C7E8A05B93BFF9C93EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30852C71F3CD6E41F5ED93BFF9C962EA" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_F4F96364AEDCCCDFD3A493BFF9D853BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_RoyaltyRevenue_3AC87E4A0986C8E498DA93BFF9D87B56" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_D380AF3389B2DB09CAA793BFF9D88E07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_D380AF3389B2DB09CAA793BFF9D88E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1F6A67DEFC5E0084FDC993EB62C6A734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_CostOfGoodsSold_E5F545DD6B377B9170FC93EB62F68BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_RoyaltyExpense_C1649616F50749588D2193BFF9D82BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_436C9384A456F300AC4B93BFF9D8487B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931A868DFDC78A97892993BFF9C9ED11" xlink:to="loc_us-gaap_ContractsRevenue_436C9384A456F300AC4B93BFF9D8487B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5493527F7C8214F7B6298B1CDD6E6009" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5493527F7C8214F7B6298B1CDD6E6009" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05128C3A0B6B0998BCB68B1CDD6F929D" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A4F5B2AF869488F35498B1CDD6F1024" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_8CF597B864B20EBAEFBE8B1CDD6FE3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_417DC5F4EA9EF70F35DC8B1CDD6E1B2D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_4A1F7E20A3674DB1AE138B1CDD6F95FA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_9089D86327250FE5C8628B1CDD6F6D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F05B81D82771736444698B1CDD6F40CB" xlink:to="loc_us-gaap_ContractsRevenue_826AEF8D055AECDAA6C08B4236ABACEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F3868D86E9BA67ABCD24945DBD58A285" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F3868D86E9BA67ABCD24945DBD58A285" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_41C560BF3872F3FBD911945DBD580CFC" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_1ADA6886CD6B3817036B945DBD58622F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AC4FFED3F793D30E9643945DBD58A5A2" xlink:to="loc_exel_CotellicMember_1ADA6886CD6B3817036B945DBD58622F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedAxis" xlink:label="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PeriodGeneratedDomain" xlink:label="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_PeriodGeneratedAxis_E85F825E149EF0EF4566945DBD588456" xlink:to="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_Q416Member" xlink:label="loc_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_PeriodGeneratedDomain_1C57EEF5E00E546A9408945DBD5897DD" xlink:to="loc_exel_Q416Member_2C053CA5BB3F99F1ABBF945DBD581174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A1DB44A10E1D1CE431C9945DBD58E83B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_1FB2822FD7ED1B2E9298945DBD583DC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E6935236E7CA9C76AA14945DBD580176" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_1FB2822FD7ED1B2E9298945DBD583DC7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersAxis_F84B8842B7783E3AD59F945DBD580F74" xlink:to="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:to="loc_exel_ProfitSharingTierOneMember_B9A7868DFB2472924429945DBD5803C3" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_EAC6277C16F28C4637D9945DBD589135" xlink:to="loc_exel_ProfitSharingTierThreeMember_AE9C8374580341956A2A945DBD581762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D6E4012EAD7BD7A591C945DBD588482" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_D8B15B1DB395E0BC2F70945DBD58FDB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_C5DB56F5F623741C2366945DBD5888E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_RoyaltyTier_AFDE03175FFBC309F419945DBD58F3D9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_F5FCD86FCCDD62C3C010945DBD58B903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_29D9B0FD436E0C6916C6945DBD58470D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F9975EBCE11E4182BFEC945DBD5820F5" xlink:to="loc_us-gaap_RoyaltyRevenue_29D9B0FD436E0C6916C6945DBD58470D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17AF383D92F287F59716A3DDDBD76DC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17AF383D92F287F59716A3DDDBD76DC1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:to="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_CC4B679E2EE3D7E0A558A3DDDBD938C6" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_F2C0AC93396A1E2D80F3A3DDDBD95057" xlink:to="loc_exel_GlaxoSmithKlineMember_F72EFAC35C7383D69866A3DDDBDA7BA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C5E5FCE618EE6BB95958A3DDDBDABF65" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_5AB75EDEC963CB99D8C5A3DDDBDA3E52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_96B22B0E0AADF6EF44CCA3DDDBDA98C9" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_5AB75EDEC963CB99D8C5A3DDDBDA3E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1816BC18DEDC8ED318D0A3DDDBD9692A" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_17CCDEF6DE06B6812832A3DDDBDA75DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_17CCDEF6DE06B6812832A3DDDBDA75DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06485CDFDCC2D2C407C0A3DDDBDA1612" xlink:to="loc_us-gaap_RoyaltyExpense_3D44CDD968687855CBA4A3DDDBDAEF50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C41A3B48BF85B8B10D4993BF26B4A581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C41A3B48BF85B8B10D4993BF26B4A581" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_764691C155F26325AF4993BF26B4A620" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_5077F2F71BF72F54928993BF26B40D1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_5077F2F71BF72F54928993BF26B40D1F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember_33DE3D7178C16BFB36F593F2F24E5FE0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_54C02CE8955F8C95A7A093F3333E25C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2771D840B47BB63FA29A93BF26B47BD9" xlink:to="loc_exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember_2E9342D8F6A2B3FD835E93BF26B4D6FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_3346A331EA221D31277793BF26B4153C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_GB" xlink:label="loc_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:to="loc_country_GB_741E51710ACA69B4CD9C93E7508BA75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_FA27666D88027B0A713B93BF26B4BE85" xlink:to="loc_country_DE_41C264C7E2791A60BB2793BF26B4331C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_4111D5602708111EAAF793BF26B47807" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8F370720DAB286ACFAD293BF26B58A87" xlink:to="loc_exel_CabometyxMember_2BD4B38865A82D81D4A793BF26B542A4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierAxis_F184CE82D7BFBC441D1693BF26B581F0" xlink:to="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_DC9F673D06A77E3D529493BF26B51B29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:to="loc_exel_InitialMember_DC9F673D06A77E3D529493BF26B51B29" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:to="loc_exel_SecondMember_5A515F4A4665B047FB6493BF26B51576" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_06A30F4D87D41991A19E93BF26B5A278" xlink:to="loc_exel_FinalTierMember_D36F33F8BF0C7F6D434193BF26B575A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FF779C542876D2F3A87A93BF26B5EC7B" xlink:to="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C5C549387DA25A56DDDF93BF26B5E476" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:to="loc_us-gaap_MinimumMember_C5C549387DA25A56DDDF93BF26B5E476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9F0E8C55D04485F582F393BF26B58DAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E1A1A39A6881FD8193CD93BF26B53C20" xlink:to="loc_us-gaap_MaximumMember_9F0E8C55D04485F582F393BF26B58DAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_16EC8BE343A36DD85DD893BF26B574A1" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_80BA8B0CBFAE275E8FE293BF26B5377A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_A44B447ED97CED9BFBE793BF26B52EAE" xlink:to="loc_exel_GlaxoSmithKlineMember_80BA8B0CBFAE275E8FE293BF26B5377A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_A1974C94439E5932BD8F93BF26B55562" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_F18BC5CDDA5DDE777F2C93BF26B551BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6DB73239D6536841B87293BF26B51BDD" xlink:to="loc_us-gaap_RestatementAdjustmentMember_F18BC5CDDA5DDE777F2C93BF26B551BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C2F9DF1877CD0E17FE093BF26B461B5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_5CD04E578F752EDBFC0493DD8564CB45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_UpfrontAndMilestonePayments_5CD04E578F752EDBFC0493DD8564CB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_8F6FD2D1F1EBD1C0537193BF26B69B1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_8F6FD2D1F1EBD1C0537193BF26B69B1F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_712EECC320C4F105CD5693BF26B6F2C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_712EECC320C4F105CD5693BF26B6F2C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_RoyaltyTier_4FBBDAC04AB12BB177D693BF26B65957" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_11EA60308BEDAF29090693BF26B6989F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_11EA60308BEDAF29090693BF26B6989F" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved" xlink:label="loc_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved_CDE92D6C139F1CF087D693BF26B6478F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_DeferredRevenue_D7A2C58E11C7A688378593BF26B61FB6" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PaymentOfReimbursementsFromCollaborationArrangement" xlink:label="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_DB699A237C7D3E4C0FD493BF26B656FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B89C8E0F840D9147753093BF26B64ED9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B89C8E0F840D9147753093BF26B64ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_0C2A83A08E2D77BE1EAF93BF26B6D0C0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8110AD551901223F290C93BF26B59A87" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_0C2A83A08E2D77BE1EAF93BF26B6D0C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E587B046313308EE14E93BEFD379F83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E587B046313308EE14E93BEFD379F83" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5DAC732CD3F71841548D93BEFD3773E2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_1DA5C5339868E993D9CD93BEFD37EDA5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F14B00038CE08C5D2D193BEFD374A4B" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_93CE06B61AF6D53B9CEF93BEFD3708B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14CA60DBC0CA82B4D4E193BEFD375B7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_496EF6FC2BEC59C85EE593BEFD37961A" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14CA60DBC0CA82B4D4E193BEFD375B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14CA60DBC0CA82B4D4E193BEFD375B7A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_05809742690253F968CA93BEFD374FB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15BFB5AB29C7DE430F608550E8791F18" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15BFB5AB29C7DE430F608550E8791F18" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B7DD82DA971CB31B7DD8550E879EA7B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_D254334D188A28C656288550E879D612" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_D254334D188A28C656288550E879D612" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_A6B4B4A9F8D854FD8A518550E87959D4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_D05849C13F6EDB583E128550E879CD96" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_D05849C13F6EDB583E128550E879CD96" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_003FC4243CEA1799AC318550E879B859" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_E0BDFAFF2F882B52A74685B38B7ADBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_264F27D1CAF8A0E568328550E879C33E" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_C2C06555F0B1D1BDBEF78550E879BDDA" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3CF71D65806CA7FE4A0E8550E879217E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_098D6190B661DDA0BDF393BF13409E73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_098D6190B661DDA0BDF393BF13409E73" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierAxis_A63ED02A95A6B622AEAE93BF13403330" xlink:to="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:to="loc_exel_InitialMember_816A8CD487A3543063D193BF13406E27" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_E33F521DC00BEE5FD43093BF1340A412" xlink:to="loc_exel_FinalTierMember_79E140E79B72FC6280AD93BF1340AFF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C16FA3B4D9C981A9AC1093BF13405D2C" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_792CC9184DC2758E25C393BF1340B8BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6DF530BC97728805170893BF1340DDFF" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_792CC9184DC2758E25C393BF1340B8BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_32284F519E85AD97DBD193BF134034E8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:to="loc_exel_GlobalMember_F72F97D8CFF4F372B9C993BF13400316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_JP" xlink:label="loc_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_DFD350AB694AB75C578C93BF1340CCAC" xlink:to="loc_country_JP_AE8327710E326B56AF7A93BF13429CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_EFD07CF07E3536426E3393BF1342BC31" xlink:to="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:to="loc_us-gaap_MinimumMember_97E19329D528F1EB3C5693BF13433F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F94B8F0F7CEF61B8343193BF13427749" xlink:to="loc_us-gaap_MaximumMember_E252B66546D2411F222093BF13433793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_EE1DAB9D09FCA2ABFA8693BF1343D377" xlink:to="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="loc_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_62CCEEE3E5EF7F29496D93BF13434723" xlink:to="loc_exel_TakedaPharmaceuticalCompanyLimitedMember_A3DC1416AA42BCB059B493BF1343A224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5ECE9EEA8AD45773216693BF13406791" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_UpfrontAndMilestonePayments_EEDABE32BAD68001559193F07A9C64D8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_5258895E2084F9922B3D93BF13437885" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F9EF332C821E7F68A393BF1343A5FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_ACD207A567BD8EDD113693BF134315EA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_RoyaltyTier_CD9FE461AAB32933487B93BF134394D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_53BBBCB21C14FE1CA3AC93BF1343F5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_A50ACCAF3D85E1380BD193BF13C283E1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_us-gaap_DeferredRevenueCurrent_A50ACCAF3D85E1380BD193BF13C283E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_D97C4C161BDA8A18700B93BF13C2A812" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_D97C4C161BDA8A18700B93BF13C2A812" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_4426AA072D6010DD90C693BF13C2FD89" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ContractTerminationPeriodforWrittenNotice" xlink:label="loc_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_ContractTerminationPeriodforWrittenNotice_3F58AA5097B7E8A9B68A93BF13C2D742" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DeferredRevenueRecognitionPeriod" xlink:label="loc_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8448E0B2F35040840EF693BF13430787" xlink:to="loc_exel_DeferredRevenueRecognitionPeriod_E8D406BBDF78366F487193BF13C2BD4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98BB4D9E00812FCBA47A8610CB879D27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_98BB4D9E00812FCBA47A8610CB879D27" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_F9B7717453D27EC67F118610EFA9E317" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75FA78D9898E9F40FAE0A39C67A5E9FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75FA78D9898E9F40FAE0A39C67A5E9FC" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_1BCDA51B7611A1F18537A39C67A51E2B" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_49262530AA876A339C6BA39C67A6F3CF" xlink:to="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_18FD07FE3CC971CC4262A39C67A6CA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8396CAC0FDF0D0F10820A39C67A6CA4C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_BuildingShellsMember" xlink:label="loc_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_377F2915EA2A20940171A39C67A642D7" xlink:to="loc_exel_BuildingShellsMember_2D25BD55526200DD11F9A39C67A60E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_318537ABD97B94E18DBFA39C67A61B78" xlink:to="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_29F729A65ECDF14B81C0A39C67A6F05B" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_853E1967085BEA578DA6A39C67A753B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0C46D67B56D041D4C066A39C67A58D99" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_E12B935A9380C59DCE06A39C67A79C39" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LesseeLeasingArrangementsCapitalLeasesTermofContract" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract_B8A036BDEBFDFE1FA4FDA39C67A7C24A" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_CapitalLeasesNumberofRenewalOptions_56CF2363DFFB9C0A16D8A39C67A7A65A" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm_89619DA9D764BB734001A39C67A71FDA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesNumberofOptionstoTerminate" xlink:label="loc_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_CapitalLeasesNumberofOptionstoTerminate_4265CF786C017B3CA287A39C67A8AF06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_086ADFDCD6CC41FF73ACA3AC73CDBCC0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty" xlink:label="loc_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty_61D15FA4BB318CCB72E9A39C67A8ABED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfRealEstateProperties" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_58A46D791011C7B81997A39C67A88FF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1198F4C95F46517D9BF8A39C67A93A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_561B4201152B0439A104A39C67A753B3" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_6C5FE169212994337BC4A39C67A97476" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FE0DA73BCB1B90B7B6F48FA52AC90D2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FE0DA73BCB1B90B7B6F48FA52AC90D2F" xlink:to="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57816D9AB51CF520E67D8FA52AC91F7B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsMember" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_0DAB3B87F219375EF2428FA52AC9E5A2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_FinancingLeaseObligationMember" xlink:label="loc_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_10C3B3D27D03237D0E808FA52AC94891" xlink:to="loc_exel_FinancingLeaseObligationMember_ED2C9CE903EE0E6767458FA52AC91092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3B2D3CD8D1CF3D0E9ABB8FA52AC948FC" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_029C688AA2445EB43F708FA52AC91E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_990F6132C4AA82D6AA478FA52AC96729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_70E2C22B6777E68627B18FA52AC94500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_B6D5179CDBDF251ED2AA8FA52AC94E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_7B60CCEBD40150255D4D8FA52AC933E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears_62F3DF1AF0226C4BD3F68FA52ACB8FEB" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix" xlink:label="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix_725A0A5C0E5109444C7A8FA52ACB4220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ACC518B940796867951A8FA52AC98D80" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_7BDEC102CC68598CFDF78FA52ACBB1F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:to="loc_us-gaap_LeaseAndRentalExpense_B96E3961B79F7632436598F6EE8AF48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_EC70A40B59748B5382F698F70A6FF8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDDDB86C6F8249F0927898EBF28B3F2B" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_A100103AFDF48A72952198F7296EEEA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDAAF0FA6A8D30FC59C2897D0134EC4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDAAF0FA6A8D30FC59C2897D0134EC4B" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_CBEA3C12B20ECA178ECD897D0134AD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDAAF0FA6A8D30FC59C2897D0134EC4B" xlink:to="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_0A244C64450DCB9B0C4A89C9AE822B6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRisk" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0AE3BF8AD3684A60078912B9C3AD0B49" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_F3A5AF298F07D8AB3C5412B9C3AD46A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_D1F4A705D856103A77C498EBF2308A6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_D1F4A705D856103A77C498EBF2308A6A" xlink:to="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_56C09709F5B279D688EB98EBF2311B7F" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_604C4141E2F1E89AA74598EBF231DCD6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_AB46D5AE81FA16B331F698EBF231ED83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7CF8B2F885798FAE937698EBF231BD78" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_45A864469F5F409B3AFA98EBF231FA8B" xlink:to="loc_us-gaap_AccountsReceivableMember_323E6BF740567BB5405D98EBF231E94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_FC5E688489CE3AF588AC98EBF2312513" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_37ABDEBD7E956F13F3CC98EBF2316234" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_CaremarkL.L.C.Member_81733F4AA6F3D5DB4F4798EBF231FDD2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_DA5855E0C8978E52B1F698EBF23103C2" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_C89DC047862BB0249E1398EBF23182B8" xlink:to="loc_exel_AccredoHealthIncorporatedMember_39B0AD473E85250F9B0A98EBF2313491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_EDD0A3BB961FF7B72DB898EBF23125B8" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8D19CF743F6599BCF48F98EBF2327FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_904FF8E63613E56F5CA798EBF2315B90" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A167B33F495FC39F684498EBF232FDB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_828E092C32052E7C13C489D773C797D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_828E092C32052E7C13C489D773C797D0" xlink:to="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EDBD9B39E702ABD0E5B689D773C7EAF1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_F5E04429C5584FAF980789D773C7A51F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_C7A3FF6E51302C74F24F89D773C79315" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_F5E04429C5584FAF980789D773C7A51F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_66F99F514B9233BECEC689D773C7BA7B" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_C7A25D1884852F9A776E89D773C7742E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52B6A46C62B7AAADA13089D773C73699" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_C7A25D1884852F9A776E89D773C7742E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_EE1024F548BA20050F4189D773C78B36" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_131E48EA24BB63C4F6AE89D773C8DF18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_131E48EA24BB63C4F6AE89D773C8DF18" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_7FA554BED636B920E2EA89D773C81621" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_CaremarkL.L.C.Member_7FA554BED636B920E2EA89D773C81621" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_EAD1C8E00F356B431C1C89D773C8AF53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_AccredoHealthIncorporatedMember_EAD1C8E00F356B431C1C89D773C8AF53" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_8C834BA66DDDB955770789D773C8C198" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_8C834BA66DDDB955770789D773C8C198" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_MerckMember" xlink:label="loc_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_585D119F32DFB57EA22D89D773C7B8AC" xlink:to="loc_exel_MerckMember_70573B2573EF2286DE6789D773C8A0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1142605EC0E27BD32FED89D773C87175" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_134D963F76868127BC9789D773C74469" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1142605EC0E27BD32FED89D773C87175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_959AE1BA69ED4180898389D773C84E74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1142605EC0E27BD32FED89D773C87175" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_959AE1BA69ED4180898389D773C84E74" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0404A03605B0AD71D84E89D773BFD1F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0404A03605B0AD71D84E89D773BFD1F6" xlink:to="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_98BAC8EA54F9E4E89BF989D773BF856B" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B24F7F7A396641C2483589D773BF0EAD" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_220D6043406CCB8CDBB289D773BF29F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_84D336935642A2F6761B89D773BFF060" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_FF0B8C4DBA44599BC23D89D773BF2E0B" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_0CC5C6C5267E743BB0F489D773BFACB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_8CA38F3B5E5C44B9F98A89D773C0ABA7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:to="loc_country_US_A698E8A78B4C8923E7F789D773C0D3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:to="loc_us-gaap_EuropeMember_9CE3FCAEEE603EC2D27389D773C09F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_JP" xlink:label="loc_country_JP_2FE4BDD08B41125B4C0789D773C00415" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_E01CAEC331088E8F5EEB89D773C0D62E" xlink:to="loc_country_JP_2FE4BDD08B41125B4C0789D773C00415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_D5F58EDA192DCB47ACDE89D773BFDD44" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DCB175DC9C2A949B721289D773C0D7B7" xlink:to="loc_us-gaap_ContractsRevenue_F376BEC2FE1AB129676589D773C071E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_D22A2AF7C581F57566EA8550E7ABD60F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_D22A2AF7C581F57566EA8550E7ABD60F" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_DBF3394F6E9B95FA83958550E7ABE6C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:to="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F44430ACBFB84C626A189D775C0A34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="loc_us-gaap_ShortTermInvestments_C95A5BB68066384DE4F189D775C07122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="loc_us-gaap_ReceivablesNetCurrent_933D60259A4A6406F4B589D775C009FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="loc_us-gaap_InventoryNet_BC0684DC3A097120CC3889D775C0422A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_44C76B4B4827DFE2B7E989D775C0FB3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22F25EFC49F86CF04D4D89D775C02F82" xlink:to="loc_us-gaap_AssetsCurrent_BE2EA017CC5AC7D94C3789D775C0A2E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_LongTermInvestments_61DF53A222D13112645789D775C0E8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6BC8D193AF99A302D31989D775C11662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_AB02D15FB1FC42BD90CE89D775C19422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_Goodwill_08D8E40C914B67CC0F0789D775C1BB44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_C275D4C96E41FCAE17A689D775C17B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_702CD8B901EEC405FCFE89D775C0E945" xlink:to="loc_us-gaap_Assets_C488CF4883FDA7098F7389D775C108A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0D659E62E0EDB0A4AC8B89D775BFBC35" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_AccountsPayableCurrent_67FE4E51454509C9364189D775C137CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6A2B3C624EC9CDFA710389D775C21BAF" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_5CC6FA5435DC77E5517289D775C21A09" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_4EEC0C1B6A696670FC6689D775C2E1E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_DC7E8FD0AF0822E6815489D775C25CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_NotesPayableCurrent_EDD6EC83975920EA111C89D775C2B125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_DeferredRevenueCurrent_C767FA14C444962B5E2889D775C23714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_898060D55A9C3A926BB289D775C2D5C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A485B0343D631286405589D775C1B7F1" xlink:to="loc_us-gaap_LiabilitiesCurrent_49B6DA19587EE613E81F89D775C2F35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_6DD4C3514D86130BFCDE89D775C202AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8917280DA1FBF38E999289D775C26692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_Liabilities_A8FB452FB3401E663C5789D775C2C37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F1C2792707CCBEE040E789D775C29D69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="loc_us-gaap_PreferredStockValue_67E8CB315B1F5054945789D775C3ABC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="loc_us-gaap_CommonStockValue_AF629F5ED53D2229CF5589D775C4DE25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8DA9C57520443917DD9D89D775C4AE0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75F22949E01471C2E58989D775C46C18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43B3B811823C13E297E189D775C491A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_221635F51824122B564589D775C3DDB5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50F1539504B9B3C2414A89D775C44EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_563FEC9A4B1439F2DBAB89D775C149AC" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_D987165D47712654A35389D775C45166" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C7AA1F0A4E827962DF0512B9C0BA241A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0D770F269B05C19373AF12B9C0BADB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_PreferredStockSharesIssued_C5792D22AD36A368AD3512B9C0BAE89C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_27E6EFC5BD4EBE5FD5B912B9C0BA8A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F93FA2A28A2B70249AEA12B9C0BAF9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_CommonStockSharesIssued_DCA442B9AF6668DC22B112B9C0BA4711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73A7C44E69C0A167CDA412B9C0BAC4BB" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_D7B8303B8C067F937C4E12B9C0BA079A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3079643EF772C0FD4735A345924F1922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_NetIncomeLoss_3079643EF772C0FD4735A345924F1922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_C1AE556D04456569E015A345924F649C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_ShareBasedCompensation_D82B630D78DC7FCE2515A345924FBAE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_815A546558F00FCDE465A345924F868B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_815A546558F00FCDE465A345924F868B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4A53AA193D72D8893A66A345924FDFF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_PaidInKindInterest_6EF7603BCA1E2D47CCFFA345924FEE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_E1FAB0CB980833D4DD52A345924F626D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_984AA178FD631127CCF1A345924F6125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_AC57079A8387C9F9D61BA345924FD837" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_3F5A36D765B0399DF0EFA345924FB08F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_AA4D905D22CDB6587D73A345924F8BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9E37BCC3D54F14A97766A345924FEF8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3068355ACCEA4C114E54A345924F25EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EBF50F16FE360FC805E0A345924FC3CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7D97D25E5A2316E7D6ECA345924F5F20" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_E2098EF5DEB3BB869881A345924FF33D" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_D2E57B900B2E929365A3A345924FE8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_CF89678788DBF054B7A5A345924F67B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_940EAF71463678D21C43A345924FA09F" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_DE6E4F819AAC89DEF6BDA345924F063F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8E967AFA882815A1A724A345924F765B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_028702C877C1B024745CA345924FE58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_DD3F1AB8A32D8024771BA345924F5A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_A0596F6BF3BD18F32F1DA345924FBEC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_BAFD55A16A8F309EB5D7A345924FC64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_10F8DD41DB41E7A7FE1AA345924F2E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_162BE14CDF50C845EFB5A345924F5479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F65FB9659751A64809DAA345924FBA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_50C8F2F72EA08F13D1F8A345924FB784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79CDAA0CEF3406C022E5A345924F45F9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7C3BE9F23C057D184410A345924FEBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_D01A112BE415C7E739F7A345924F26F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:to="loc_us-gaap_ProceedsFromStockPlans_709A616348512753FDE0A345924F93BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1E62FDBB86A189A1FFCBA345924F17F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5EFF77A59329A85567B3A345924F4AAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F2F49CAF07F42CA918E1A345924FBB41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C325EF3A5A31E6866E76A345924FA8D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_856AE881C4B5E5EAA8A2A345924F4867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2F41FDC942C22208B997A345924F3BA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5F1003A3FF374DD69032A345924FAD00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_316746D7A3BC29769EFBA345924F7010" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4A84F3148CFF2428421BA345924FA286" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_F60C7BECFF9D19F15521A345924FE199" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:to="loc_us-gaap_NetIncomeLoss_362BD2A2D8B6727456B6852871EAEB2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5477A0144E992F5CF1DF852871EAFAD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_CC5C3AC036283DE9E8F9852871EA5131" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F5E964E777AA883ECB63852871EA0401" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E2D9C42E42953336F0508A090163B829" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E2D9C42E42953336F0508A090163B829" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4D33918EBBFB4ECF4AD98A090166FDF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_E2D9C42E42953336F0508A090163B829" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_05D52B39E5DE850FB2358A090166456D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_EFCBC4B98CD8A062002089D775A43C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_6592B24B434B498F765889D775A4B6AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:to="loc_us-gaap_ContractsRevenue_6592B24B434B498F765889D775A4B6AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_823EB3CEDA93B10591E089D775A4E2C1" xlink:to="loc_us-gaap_Revenues_9D78BEDA20EFC78E68EA89D775A48A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:to="loc_us-gaap_CostOfGoodsSold_F53E336862C87207803589D775A576A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_48666F73AAEE2D81118589D775A5FD77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F35357CAD557A74ADAC189D775A6999F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:to="loc_us-gaap_RestructuringCharges_8F4CD71846EF797C4E0B89D775A6D7E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DA958E8D9922F1B797E989D775A5796A" xlink:to="loc_us-gaap_OperatingExpenses_94847D61350D625321A689D775A65EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_OperatingIncomeLoss_6C19BD9D7B2469E46D2B89D775A6D9E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_BD9508D1BEDB3B58E79089D775A6905E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_FCD206FCE1B6DC2CDA5589D775A7CE10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:to="loc_us-gaap_InterestExpense_FCD206FCE1B6DC2CDA5589D775A7CE10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_70385722F4118268C15F89D775A76DFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8B34CFB6A77376E52B8489D775A6E6A7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_202714E611C3057D749F89D775A7DC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_CF69741AA15D6D2A79FF89D775A71C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8B7A30AEE45FE439D1B389D775A7E8F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_NetIncomeLoss_940B5C62D19CFD353BCE89D775A74088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_D2A489B83C2CAF1EDC1D89D775A8011B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_EarningsPerShareBasic_D2A489B83C2CAF1EDC1D89D775A8011B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7FE40CC6C2B60B9BC3A889D775A8C01A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7FE40CC6C2B60B9BC3A889D775A8C01A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14BDC513F63D25012D2689D775A8040C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_AF3BD7E371B2E884FA3989D775A45C92" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_E020441DB5EEDF4860A589D775A959FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0669E067BA9308FAADCE8602EAA57608" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0669E067BA9308FAADCE8602EAA57608" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_F74CD83149F41FA86C898602EAA54036" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtDeerfieldNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5F4052C5093BD409FB5A98EBF3062701" xlink:to="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C467427E840F23382ED098EBF306D61D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_BA861256F029E6147ACE98EBF306C761" xlink:to="loc_us-gaap_SecuredDebtMember_4A1ED199B59E6CA0106B98EBF30602FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_78A906B47C8587BCE3EA98EBF3063B3D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9A96006CC8FFDA96C90F98EBF30633BD" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_FE790476438D64C94C8B98EBF306FD77" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeAxis" xlink:label="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InterestPaymentTypeAxis_8D0FCC8046D45CDA874398EBF30673E4" xlink:to="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CouponInterestMember" xlink:label="loc_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:to="loc_exel_CouponInterestMember_03A9A347D79566A6FB3698EBF306955C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_PaymentinKindInterestMember" xlink:label="loc_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InterestPaymentTypeDomain_09A4C1E83BF93E7E262898EBF306396E" xlink:to="loc_exel_PaymentinKindInterestMember_E2490E768B3B66D094D998EBF306C439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1158B3FB6D63B44D8D8398EBF306C501" xlink:to="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ExtinguishmentofDebtincludingInterestandPenalties" xlink:label="loc_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_ExtinguishmentofDebtincludingInterestandPenalties_ECC298F97356449A83C2991A51FCFF18" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ExtinguishmentofDebtIncludingPaidinKindInterest" xlink:label="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_B8664E98C5E4B4CBF7A0991975575E84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_PaidInKindInterest_6D3483A9CC89A7525DD598EBF30713E5" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentPrepaymentPenalty" xlink:label="loc_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_DebtInstrumentPrepaymentPenalty_27345D029F7ECA3F5B8A98F63E253507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_InterestPaid_99BAF2B8A80D39526CA098EBF3071B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F515DA23529E285D970398EBF3078863" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" xlink:label="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_271B6CDFC995BFCBF04998EBF307E6AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" xlink:label="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BEB84982A42629FDDFF598EBF3068E90" xlink:to="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_DD0920B435AAB866C7AD98EBF3072AE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EABD7964888F4BB8B86A8B0138359835" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EABD7964888F4BB8B86A8B0138359835" xlink:to="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5D0FDC176807642347E18B0138365CD8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_D8A8AD4C6F8CA023C3D68B0138373636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0D71C4938DD9D742F2AF8B0138369334" xlink:to="loc_us-gaap_SecuredDebtMember_D8A8AD4C6F8CA023C3D68B0138373636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:to="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_245ED5B94B6698DF09348B0138376D81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_C92F610011FE90111BCB8B013838A026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8640F4B923E9A47BBB568B0138381E70" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_C92F610011FE90111BCB8B013838A026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3BF1AD43CAD90C545F9C8B013836F551" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_InterestExpenseCouponInterest" xlink:label="loc_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_exel_InterestExpenseCouponInterest_F1B5CA5A9EF1E0CD848A8B013838C008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_5BE87F1BB31FEDC0978C8B0138395B5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_PaidInKindInterest_5BE87F1BB31FEDC0978C8B0138395B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_92557DAED89657929C1F8B01383A7507" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_92557DAED89657929C1F8B01383A7507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F25CDE43D4489AD3B0D28B0138382C63" xlink:to="loc_us-gaap_InterestExpenseDebt_7885CD009D7A37B3294E8B01383A2AE4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8FA22827EE8F5425D9D2945DBCC80007" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8FA22827EE8F5425D9D2945DBCC80007" xlink:to="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9603B9317EBEADABEB91945DBCC876BF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_5CB9CC7AE31FE58BC82B945DBCC83E0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:to="loc_us-gaap_SecuredDebtMember_5CB9CC7AE31FE58BC82B945DBCC83E0C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TermLoanMember" xlink:label="loc_exel_TermLoanMember_F4B1168243A5847D275E945DBCC8D933" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_DA2051FC98CFB4F61B50945DBCC898D8" xlink:to="loc_exel_TermLoanMember_F4B1168243A5847D275E945DBCC8D933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:to="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_85104771FA2B61E0265A945DBCC86148" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_535A37494630000E3C83945DBCC84848" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C65CA6CC0B528630A943945DBCC87F0D" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_535A37494630000E3C83945DBCC84848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F8CB2BC3FBF3908227DA945DBCC864BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_455AC6E76C78C8BA50AC945DBCC8E44A" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F8CB2BC3FBF3908227DA945DBCC864BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F8CB2BC3FBF3908227DA945DBCC864BD" xlink:to="loc_us-gaap_LongTermDebt_37770EB965B3C374F04A945DBCC89221" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89D06FB9F26E24A7230D8B013620DAD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89D06FB9F26E24A7230D8B013620DAD3" xlink:to="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_595855DF5EF8A357093F8B01362077BF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TermLoanMember" xlink:label="loc_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89FFE60C7A2C6051801C8B013620ADD0" xlink:to="loc_exel_TermLoanMember_B5207FA53DEC2923A7378B0136208791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:to="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8669EDA0DA51E9828B938B0136213E7D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_EB7C9D9FF18AA7127DB58B0136210D3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AD9ADBAFF610BD4A8BE28B0136210A76" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_EB7C9D9FF18AA7127DB58B0136210D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27E13C36DD11D9FC30B48B01362056F0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_2D42F177347B2A4533DF8B2BFACB46E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_LongTermDebt_64639B4847AF392C766C8B0136211010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_CF71201C88DDEAD9DE608B2EFF034AE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_InterestPaid_CF71201C88DDEAD9DE608B2EFF034AE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31086E2BE534948964A68B0136226DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03D1A602FCC7800FD40F8B0136221579" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations" xlink:label="loc_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations_DA722E7E1510EFBFE7168B0136224815" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_Maximumpercentagerequiredforcollateralbalance" xlink:label="loc_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_exel_Maximumpercentagerequiredforcollateralbalance_EB55F64F8D51CB407C2A8B0136228508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_057C8DCAC3980E73A5C18B0136228714" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0353D73763696853BB6F8B013621C283" xlink:to="loc_us-gaap_CompensatingBalanceAmount_057C8DCAC3980E73A5C18B0136228714" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EB095376EB4BD3354FEA8550E819ECFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EB095376EB4BD3354FEA8550E819ECFB" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_B578CD852D76399D40468550E81998C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EB095376EB4BD3354FEA8550E819ECFB" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1021F8A2422DE4FE7A7A8550E8199803" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="exel-20170630.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_DocumentType_1582C4C4EFC01F9B5EA512B9C2D867FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_AmendmentFlag_AE8A8F4B013CB63419D512B9C2D87FDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_DocumentPeriodEndDate_FE5945FBE89943595C5D12B9C2D872D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_DocumentFiscalYearFocus_D908669274142657FD2C12B9C2D848C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_DocumentFiscalPeriodFocus_F05033BA59B1C6B044C712B9C2D8782B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_TradingSymbol_D9E5D852DBDC5B8CB2D212B9C2D85AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_EntityRegistrantName_60A694E13D750E07192712B9C2D802BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_EntityCentralIndexKey_1CB7E45C4724AC76DEB312B9C2D8CF1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_EntityFilerCategory_5A2A70984C76ABAB2B9512B9C2D8BC90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_CurrentFiscalYearEndDate_02B31F7BF88F1A3A209C12B9C2D87B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_754A98C409389A94EF6B12B9C2D8A618" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8B864230402574AD573812B9C2D8A637" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4F0C398C32C1EFB5E26B8602EABAA81E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4F0C398C32C1EFB5E26B8602EABAA81E" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_342406220DF2D7C181FC8602EABA906C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26ABCD051DD5EA4A9B008550E7F9E276" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26ABCD051DD5EA4A9B008550E7F9E276" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:to="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_F1EE7455FAC1FB6836858550E7F9CD68" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_AAC315749298B3F82C758550E7F98665" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_MoneyMarketFundsMember_AAC315749298B3F82C758550E7F98665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_CommercialPaperMember_6924CBE0AFB1D7B188728550E7F9EF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_F8EDD9FF1510AEC10B4E8550E7F94AD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0867E6967F4D31DFE31E8550E7F9854C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_55A400A27740A79F79AA8550E7F97C56" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0867E6967F4D31DFE31E8550E7F9854C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B4D64B6C5C108FFAD70E8550E7FA231A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_165AF5E019D58C1424B38550E7FAB12D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B73C675EAB92420E16D8550E7FA2DB8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2EBDB1A6915694D2287E8550E7FAE944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7C952EB99C17018E4BA78550E7F96FDC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8032BA1A363C6AF2D9B98550E7FA5060" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_BF3BDD40E744CB2ADB108550E7FABF41" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_971302861F2069A5037B89D774655A7B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0EE7671E1DD9E8C0866189D774666D4C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7234EB548EA3CC3E515B8550E7C4EFFD" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4A97F3A0C0C545CD76F8550E7C4BD85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6C79D2DEEC0DC156E52A8B1CDC9078D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6C79D2DEEC0DC156E52A8B1CDC9078D0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12D3CFBEEFEA6F1E74C88B1CDC90E419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6C79D2DEEC0DC156E52A8B1CDC9078D0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_EF16776EC24D37B77B518B1CDC9036D8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ExcessTaxBenefitsSharebasedCompensation" xlink:label="loc_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6C79D2DEEC0DC156E52A8B1CDC9078D0" xlink:to="loc_exel_ExcessTaxBenefitsSharebasedCompensation_9191219101DD834342D68B1CDC91C96F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4266522B9F249006E0369938F484952D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4266522B9F249006E0369938F484952D" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_501B28E99F753AEFB23F9939800D56A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A5ADF38C82D25FE288788609B519A4A8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_DA91B0B81FDBDA9E31FB8609B51A8940" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryRawMaterials_F3DEEB90F94C55784CBF945DBCE867D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryWorkInProcess_5F7FC91078781D161855945DBCE833CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryFinishedGoods_32EDED94EE4E0B7673E5945DBCE867FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryGross_9B2E6DEB4DC882F04814945DBCE8B929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryNoncurrent_45A6B15B229866E5F291945DBCE8678C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryNet_9AE7DC010F1A6FB15634945DBCE83244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FFA84B653E3F79CD9612945DBCE89AE3" xlink:to="loc_us-gaap_InventoryWriteDown_7CFD434888561F42A7DB945DBCE86A34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_93FA12EAFB6B7940F8498550E821E21A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_93FA12EAFB6B7940F8498550E821E21A" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37D3E02C3FD441403CA38550E82118BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C62181BE74BFAE580BAD12B9C37BD318" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C62181BE74BFAE580BAD12B9C37BD318" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_155EC74CE15527BB2F7512B9C37B7C96" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FEFA59979D4BA7694A6C8986F7AE3B67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FEFA59979D4BA7694A6C8986F7AE3B67" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:to="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F7B63C0AFB9F960C13478986F7AEC91B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_D0C86FAD5DB41DC0BFC28986F7AED4E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DB4323773A6CBC3B57178986F7AE1F0B" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_DE8120685F334B1B0DED8986F7AEE843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_808E9C47D092A8C6ED5C8986F7AE1670" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="loc_us-gaap_StockCompensationPlanMember_7201DD4F30546E59762F8986F7AE8B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3E5FDFF9C7293C7A9DF38986F7AE1C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77B15F20781F045E32A48986F7AE85E6" xlink:to="loc_us-gaap_WarrantMember_FDCD9441FB5A84BDDAC48986F7AEE4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C9D68D2A33C383441FA8986F7AEE23A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A500FADC8AF90F74D96C8986F7AECBD2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E582476C821AA8C29FFE8986F7AFB21D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E0ED29F0720CFF74D5CD89D773E923F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_NetIncomeLoss_E0ED29F0720CFF74D5CD89D773E923F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_DC519BDEC3844D66A23589D773E97220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_56CCD8075ACF1C41787F89D773E999FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_84A402011E218AA6CC4E89D773E9134F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9EB6E37EFAE53D4F714389D773E9DD86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D75A20F6040D6E92FEC989D773EA7C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_360134F527353354274C89D773EAEDE8" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A3C0AB88A8129322F65F89D773EAEEF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CE226A7B7478357CC3EA89D773EA4B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_EarningsPerShareBasic_76FFF3BDAC34E4A3027689D773EA78A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B47A88E0CB3EA71FF43A89D773E91AD5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_F9060FCB8034048BDB7689D773EAD4DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5051703C4A9EAEE6534F12B9C1B48007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346592189C1FB0E71E8612B9C1B4F98E" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33F9EF63AACB06E1D35212B9C1B42AC8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40AECEDC4E9A2EA8EBCD860C38AA9AE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_40AECEDC4E9A2EA8EBCD860C38AA9AE4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_D7406A573438844F0209860C38AA739E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CC12A073FFAAFDA9C53C945DBD772977" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CC12A073FFAAFDA9C53C945DBD772977" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:to="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_B4B80BE5CE15D593CB65945DBD7767F8" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_CC19330781D0DB831288945DBD773EF2" xlink:to="loc_us-gaap_RestatementAdjustmentMember_BBD47D28A2A16B850FA3945DBD77D604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_293FD975BDEAE4E07C7E945DBD77C9C7" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember" xlink:label="loc_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_17550EB7925A427A7071945DBD77E825" xlink:to="loc_exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember_07865DBC08709B30A9B7945DBD7727D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_47700C36E60E53D943D1945DBD77E3C8" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_InterestExpense_2CAC13B462149695F869945DBD779A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_71993D5BE092A0FF4064945DBD77D664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_468930F4C25C49C2A255945DBD77D418" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4B1F88C23D08C9A2EEA945DBD77E91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_B2EB99EA195866B8E686945DBD77D557" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_503F60D87008DE8D79D3945DBD776692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_43291D368B5633F8E848945DBD77970D" xlink:to="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:to="loc_us-gaap_NetIncomeLoss_B8DB75A9DFBD9496D08D945DBD77B989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_544A490BCE721A329FF5945DBD77D3F5" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C7A7CBEC7C68C0789768945DBD7755BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3E3081D4C42AA109AC5612B9C2EC841F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3E3081D4C42AA109AC5612B9C2EC841F" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F9EA377CD21A16C51EC412B9C2ECC883" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_F59AE881A897F7D43EBC12B9C2EC5E05" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_743C388834EC73287F9C12B9C2EC9175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:to="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_465E7D55026891E0FDE812B9C2ECBC0F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8D7862AC23BB6BFBA19D12B9C2EC00FD" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_CDE1A7B08F27B74AE17012B9C2ECBCF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_0902A8D5C2919839C67512B9C2EC7C19" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3588F15F81FA4A73B47512B9C2EC201F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E152C6C388DAF23229212B9C2ECA8E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_A38EE8457EB91AAF643412B9C2EC2CFE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8E152C6C388DAF23229212B9C2ECA8E5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12D318C95353F3C8EF0812B9C2BAFF98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12D318C95353F3C8EF0812B9C2BAFF98" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:to="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_3B60E60BC904ECA8815C12B9C2BA74C4" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A9171EB239DD05F8FB5C12B9C2BA6EFE" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_DDF32D0150B934C9D91012B9C2BA2235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_17471E366426563C845D12B9C2BA8ECF" xlink:to="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_BB3148AA78FB3547EF5112B9C2C45B0C" xlink:to="loc_exel_NumberofProductsinCommercialMarket_FBF635FCAAEFA007C10E12B9C2C41CD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_800801329C1C4755B49212B9C3ADD91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E5083A86507A1929BADD12B9C3AD526D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_FiscalPeriod_78CE6CC19301EE74570312B9C3AD8AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_UseOfEstimates_BF0C95045F43E9BDECAD12B9C3ADF5BD" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock" xlink:label="loc_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock_355F5956C781D333CF7512B9C3AD869A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8E4865242445E31745C712B9C3ADBFD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_EC9EC7B9E4F5A672454B12B9C3AD2C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_393804A0BA35A600458D12B9C3AD27CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE5EA4F509DFB0F9BE2512B9C3ADC9D4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_827F5F5BEC74135923D312B9C3ADECA6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09505258CF054761E83298EBF3A1D3DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09505258CF054761E83298EBF3A1D3DA" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E1A1B2436575B8055BD1991C3114CD6D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_FCB39D426D274F83FC95991CC0F6369D" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TradeandOtherReceivablesMember" xlink:label="loc_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9F7F683366A1AF52279D991C3114D697" xlink:to="loc_exel_TradeandOtherReceivablesMember_458AD33721A37E0BA16A9921A15F4D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:to="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_547B6791C909F3EAC54798EBF3A23354" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C1F8F1AD3625C17B482F98EBF3A27EFF" xlink:to="loc_us-gaap_RestatementAdjustmentMember_F81DCC3C0E4154CF308298EBF3A2363B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0E2A3873101EA966CE9398EBF3A2DF2A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_DAF1B7CD49EE0027D85E98EBF3A2A7F2" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0E2A3873101EA966CE9398EBF3A2DF2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_0E2A3873101EA966CE9398EBF3A2DF2A" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_3B61945AEED31FF83A9D98EBF3A25944" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_793B4C5AC2308AD3E88612B9C385BB2C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_793B4C5AC2308AD3E88612B9C385BB2C" xlink:to="loc_us-gaap_NumberOfReportableSegments_67F3045615E49D932DED12B9C385D3D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_578B942C3D91F96CC41498EBF39DE2B0" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_D2A082B7B2AA6ADD4EAA98EBF39D4B7C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_AccountingStandardsUpdate201609Member" xlink:label="loc_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_126F4F298D740A3DD6B498EBF39D587C" xlink:to="loc_exel_AccountingStandardsUpdate201609Member_FAF5F25EE56E18FE4E5698F34BCC0E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E8F25EAD425CEFCDD75B98EBF39D810D" xlink:to="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1466AFBC80BE7CFD1E6E98EBF39D57D5" xlink:to="loc_us-gaap_RetainedEarningsMember_86BEDEF06DAFCF6E751598EBF39D3282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_143484F1B88FFA65416F98EBF39D057F" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_272508ABEFBBB355081198EBF39DFD8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2ADB2A1AE6173A92378198EBF39E3932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_157F12DF4707A66E324D98EBF39E23CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_139E8D023054D39F0EEC98EBF39E0A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_CADDBA32B3204374719098EBF39E5EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_200C982AF529E56B9A2D98EBF39EBE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_440FB0FE8DE476CBA95F98EBF39D9188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17DF95259717DE7B163D98EBF39E97C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_691944628E9387AA201412B9C16EAF3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_691944628E9387AA201412B9C16EAF3D" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_E96C7E1F86EE93ABEDC412B9C16E3609" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_DBAA2921AE705A638EED945DBCD8B25C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_DBAA2921AE705A638EED945DBCD8B25C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EBE729FF87D9DA382148945DBCD82B63" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_32D59106E9CC6060D8D79FB80539CF7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_32D59106E9CC6060D8D79FB80539CF7E" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_0043D4288B2118813E009FB805395D5A" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_2AD72C00D97B1C59AB2E9FB80539AA42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_8BCB6E0BA614AF46F8529FB805398B2E" xlink:to="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_2AD72C00D97B1C59AB2E9FB80539AA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0BBB0909F16C59F020D89FB805395749" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E75EF01AEC4D3FC9D1889FB805395C25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_Depreciation_E75EF01AEC4D3FC9D1889FB805395C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_4B5A43BA6B0189554F159FB80539EEA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_4B5A43BA6B0189554F159FB80539EEA8" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_DC0E363012F0F6C2D1829FB80539653F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_DC683065BF224D1666BD9FB8053943CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_DC683065BF224D1666BD9FB8053943CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9D4A9F2507AFD6EC66AF9FB80539A7DD" xlink:to="loc_us-gaap_ConstructionInProgressGross_02F5BB9969BEE9BC10EC9FB8184A2FC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86E13F867F2CBFA37FCF98EBF31357BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86E13F867F2CBFA37FCF98EBF31357BA" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_71E9C3BC20F94583AB5398EBF313B8C8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_D62BD941B5A6B580ECEE98EBF3139EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_E7B7D6877868E603889898EBF3132BA9" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_exel_LaboratoryEquipmentMember_A8BF3E71AF37205820A298EBF31406D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_456EF0EB93E79E22386498EBF314088D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4E8DC08B01F7D25F6E3E98EBF313EB87" xlink:to="loc_us-gaap_ConstructionInProgressMember_C19BF8C9807A70FAB1C898EBF314757A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_708AE19ED33016869EC798EBF31386C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2AEEC49A1380182D086998EBF31431C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_BA59D44A3B564199C27998EBF3142FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2B08ADF29D7732FBF8F498EBF314889E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2C39B7985BAE8FD2E42898EBF314A3A1" xlink:to="loc_us-gaap_Depreciation_87A8B191569A57F19E7C98EBF314DBC1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9A910799F82B06B224DD861687A104FB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6F26DDF6820BF4CE3439861687A24D22" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4217B9D43EC0AFC071388602EA86C9D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4217B9D43EC0AFC071388602EA86C9D4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1EC2858FADC62551B4B18602EA869DF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7D6843F8D4C04B01362A8B1CDC9B911E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7D6843F8D4C04B01362A8B1CDC9B911E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:to="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0623D173F5E14227433A8B1CDC9B3223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6DC30D9906EBD4D1C348B1CDC9B8C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_886580A36EB9C7F4C19E8B1CDC9BB646" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B6DC30D9906EBD4D1C348B1CDC9B8C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E1A6E020FFF0252360818B1CDC9C323D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73A3C93BA2840ACDE9008B1CDC9B2F66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E1A6E020FFF0252360818B1CDC9C323D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E1A6E020FFF0252360818B1CDC9C323D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1C167F327851B12829998B1CDC9C9B57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63F2EF655FFCAAE8620212B9C14619BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63F2EF655FFCAAE8620212B9C14619BA" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2BC042EF805E955FB2AF12B9C146FD0C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_BAC05DC8FC5946B736F012B9C1460912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_078E6338D7132A235EB912B9C1464BB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C27B79B5718750E47C3012B9C1460C80" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_078E6338D7132A235EB912B9C1464BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_B7309DD18B5B33D495C812B9C146E715" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0084B10E0A2C7307460812B9C146632E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_B5BDD94914208FB6D88A12B9C14641D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E391E70FC2A97326DD5E12B9C150165A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E391E70FC2A97326DD5E12B9C150165A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:to="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1B4195CBC5EE46E2EAEE12B9C150E159" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F6908151FB18800046C912B9C15A117B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A2C2D4D2DC27A3E0A1C112B9C150153C" xlink:to="loc_us-gaap_EmployeeStockMember_8A3890F0050910AC53C912B9C15A2D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68F32192774E06E6FC0612B9C15047FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CEEFF6FF0D9160EFB3A712B9C15A51A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6811793BBE1E2AB27B8412B9C15A1F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_71BC7266FB35A2F0166F12B9C15AD314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8C6DDEC7529F55908AF412B9C15A7480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D97422F850B5349EA60712B9C15A4F2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12D913C1564657108D188B1CDC9748F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12D913C1564657108D188B1CDC9748F6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:to="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1B2F46AD14497AB585DF8B1CDC971C24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66076DEDE1AEA5E3E07C8B1CDC9733F8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CAE96391F5A1FE62B67D8B1CDC977544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_864DEEAD9597E50882AD8B1CDC97C378" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_DBAE73F917AA7D89E5248B1CDC974A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00A75E59978ABCDA0D4D8B1CDC975675" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_6869B333B0EBFBC23FC58B1CDC97D5BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67CAC0CA67DE38188B208B1CDC985C1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BAD72857C4FF5C2AC3B48B1CDC977844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A344D928CF2426BF2BEA8B1CDC9808A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_E20B81B85B6D6A4899728B1CDC98565D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF61B8D4C28DC8EEA0AF8B1CDC98796A" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29A3CF5D2A64A2CE179D8B1CDC9891D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_227E9FDB584D84B11F7C8B1CDC983453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_234565C498F7170D88B88B1CDC980B84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_97AE60C162A42B21DF6A8B1CDC9811C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7C9C685620D0A5A6BE3F8B1CDC984676" xlink:type="arc" />
    <link:loc xlink:href="exel-20170630.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_421C56037A45DFDB68CF8B1CDC976C6F" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_31B63868D2ABF5FBB5D98B1CDC9880C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C905B5994FB370C5F2D8B1CDCA0F091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_B170597893DCDCD077408B1CDCA0540B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12D8F679155CF5E254A08B1CDCA06E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_D6DBA66A95C31043932D8B1CDCA09D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8A354B4A56C0B7F9801F8B1CDCA09087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00E2C62FF97B8A5031B28B1CDCA0590E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8AD281505A17CD2792FC8B1CDCA04F2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06CC442887ADFCF46BBD8B1CDCA0CED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5C33ECF080D2FB1583FE8B1CDCA1CA15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49CAF51F34B81722C2A88B1CDCA1A1B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0C95D50C1985C1F907C28B1CDCA14814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1CE505AEEF5084D74CF18B1CDCA0391D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_C61654C69DEC7C23E5D38B1CDCA19D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DEDBCBB4A1D2621335698B1CDCA17485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_39CB25C232CA99E929B28B1CDCA17E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_AE02C5880C136EE673AE8B1CDCA1F220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2348C306A3997BA592178B1CDCA1F62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82DFF3E29C59FF357E9B8B1CDCA0590D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_E4F9D608BD24437A6E668B1CDCA15159" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6841702928CD5460F07512B9C1F1FCE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6841702928CD5460F07512B9C1F1FCE1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E9CAAFF8FF94E5BB8C9A12B9C1F135C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6841702928CD5460F07512B9C1F1FCE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1A1096032F9399E5A27812B9C1F1D97B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6841702928CD5460F07512B9C1F1FCE1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_E6F24AECD6D7F6522C8E12B9C1F1F712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6841702928CD5460F07512B9C1F1FCE1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B0E991CA3D31FB61ADDB12B9C1F19BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6841702928CD5460F07512B9C1F1FCE1" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_330F83A83F4F2359E2C912B9C1F16170" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_914A0F27C8B591810F0512B9C37B13C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_914A0F27C8B591810F0512B9C37B13C5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:to="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_FA92E46E9F7220F2292312B9C37B7ABD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_621C9032F6B5DA33645712B9C37B43EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_621C9032F6B5DA33645712B9C37B43EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584707021DF82074931912B9C37BD42A" xlink:to="loc_us-gaap_EmployeeStockMember_B58EC9C52B2622FA5CEF12B9C37BFACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11727D8653717E25B5FD12B9C37B67AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C8E53FCB0E6B86AEE7512B9C37B0774" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11727D8653717E25B5FD12B9C37B67AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11727D8653717E25B5FD12B9C37B67AB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_B23D380B5B3C0450CC7012B9C37B7AF5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_46CE261625536B5C32C286184D7A05EE" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_EDFA33E1704B547AB7B086186635E9FB" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex101170630image1a03.jpg
<TEXT>
begin 644 ex101170630image1a03.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" .
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MT?MF?&('_DK7Q._\*J__ /CM36W[;GQEM-VWXL?$=MW7?XDO'_\ 0I#7T?\
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M4_\ P*?_ !J"?Q'J%U)NDOKR1NF6F9C_ #I_ZDO_ )_?^2_\$/\ 7!?\^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFL0ZO*VF7D$$'EWICPKVD,IS@<_,[?ABO6/^'4OPC_Y\]>_\&3?X5J?L&_\
M(,\9_P#82M?_ $WVU>_4OK^)_G?WA]1P_P#(ON/G3_AUC\'_ /H$ZM_X,Y?\
M:?#_ ,$MO@[$3NT74Y/][5)^/R85]$44OKV(_G?WL/J6'_D7W'SW_P .O/@W
M_P!"_?\ _@UN/_BZL+_P3'^"X7_D5;@^YU:\Y_\ (M>^44?7L1_._O97U.A_
M(ON1\5^+OV'?ACHG[4_ASPW#X=?^Q=0M_,GMVU&Z.]MDY^]YFX<HO0]J]?\
M^':?P3_Z$O\ \J]__P#'ZA^(O_)\'A#_ *]!_P"B[FO>Z7US$?SR^]A]3H?R
M+[D>()_P3A^"R*%_X0F'@8YU*\/_ +6I\/\ P3J^#$#[E\#VI/\ M7]VP_(R
MU[912^N5_P"=_>P^JT?Y%]R/&?\ AWM\&_\ H1[#_P "KC_XY4T?[ ?P>B0*
M/ NEX'K+,Q_,O7L%%'UJO_._O8_JM'^1?<CR*/\ 8+^$$3AAX$T?(]3*P_(M
M4O\ PPQ\(_\ H0]"_P"^&_\ BJ]8HI?6JW\[^]C^KTOY5]R/DG]L']EKX>>
MO#&@OH_A'1M/>XU$1R-'#\SKQP23TKV.S_8M^% AC?\ X0'PT6V@\V@.>/2N
M:_;O_P"14\-_]A1?Z5[I:?\ 'K'_ +@_E2^LU?YG][#ZO2_E7W(\Y_X8X^%7
M_1/_  I_X+X_\*FA_9%^%MNFU?A[X/(SGYM*A8_F5KT2BCZQ5_F?WL?L:?\
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MFOB+_@O5\)?"O@G]@Z>;1?#.@:3*LNJ(KV6GQ0,%/AS6<C*J.#Z5^A%?"_\
MP<)?\F#7'_7QJ?\ ZCFLT ?5GA+X$^"'\*:83X.\+$FTB))TJ#GY!_LUH?\
M"A_ _P#T)OA7_P %4'_Q-;?A#_D4]+_Z](O_ $ 5HT <G_PH?P/_ -";X5_\
M%4'_ ,31_P *'\#_ /0F^%?_  50?_$UUE% ')-\ _ KE2W@OPHVTY7.DP<'
MIQ\GN:\?_P""@7P8\'Z3^Q9\2+FU\*>&[:XAT65XY8M-A1XV&"""%R"/45]&
MUXO_ ,%$O^3'_B=_V YOZ4 >9_\ !*'X/>$M?_8#\!7E]X7\.WMY<'47EGGT
MZ&220_VE=<LQ4DGZU]#K\ _ JLS#P7X4#-R2-)@Y_P#'*\;_ ."1?_*/+X>_
M34?_ $Y75?2- ')_\*'\#_\ 0F^%?_!5!_\ $T?\*'\#_P#0F^%?_!5!_P#$
MUUE% ')_\*'\#_\ 0F^%?_!5!_\ $T?\*'\#_P#0F^%?_!5!_P#$UUE% '(W
M'[/_ (#NX&CE\%>$Y(Y!M9'TBW96'H1LIX^!'@=3QX-\*_\ @J@_^)KJZ* /
MSI_X(G?"WPSXD;XT?VCX=T._^R^(K**'[1812^4@TZ#"KN4X'L.*^Z3\ _ K
M.K'P7X4++T/]DP9'_CE?&G_!#3K\;_\ L9K+_P!-T%??% ')_P#"A_ __0F^
M%?\ P50?_$T?\*'\#_\ 0F^%?_!5!_\ $UUE% ')_P#"A_ __0F^%?\ P50?
M_$T?\*'\#_\ 0F^%?_!5!_\ $UUE% ')CX#^!Q_S)OA7_P %4'_Q--@_9^\!
MVL>R+P3X3C7).U=(MU&3U_@KKJ* .3_X4/X'_P"A-\*_^"J#_P")IL_[/_@.
MZBV2>"O"<B9!VMI%NPR""#]SL0#^%==10!R?_"A_ _\ T)OA7_P50?\ Q-'_
M  H?P/\ ]";X5_\ !5!_\37644 <G_PH?P/_ -";X5_\%4'_ ,31_P *'\#_
M /0F^%?_  50?_$UUE% ')_\*'\#_P#0F^%?_!5!_P#$T@^ ?@42%O\ A"_"
MFY@ 6_LF#) SC^#W/YUUM% ')_\ "A_ _P#T)OA7_P %4'_Q-'_"A_ __0F^
M%?\ P50?_$UUE% ')1_ /P+%&JKX+\**JC  TF  #_OBE_X4/X'_ .A-\*_^
M"J#_ .)KK** .3_X4/X'_P"A-\*_^"J#_P")H_X4/X'_ .A-\*_^"J#_ .)K
MK** .3_X4/X'_P"A-\*_^"J#_P")H/P$\"LRL?!GA4LO0_V3!Q_X[7644 <G
M_P *'\#_ /0F^%?_  50?_$T?\*'\#_]";X5_P#!5!_\37644 <C%^S_ . X
M&<Q^"?":&1M[E=(MQN;U/R<FG?\ "A_ _P#T)OA7_P %4'_Q-=910!R?_"A_
M _\ T)OA7_P50?\ Q-'_  H?P/\ ]";X5_\ !5!_\37644 <G_PH?P/_ -";
MX5_\%4'_ ,30_P  _ LB[6\%^%&7T.DP'_V2NLHH Y/_ (4/X'_Z$WPK_P""
MJ#_XFN9^,/[%'PJ^/'P[U#PKXD\$:+-H^IA!.MBK:;< JP=2EQ;&.:-@R@Y1
MU->I5YY^U?\ M-^&_P!C7]G?Q5\3_&"ZFWAGP=:"]U'^S[;[1<B+>J91,C=@
ML">1QDT ?,%G_P &_7P/TR"*&S\3?':SM[=2D$,'Q-U=(X$_N*/.X7IQ[5A_
MLU_\$]? /P8_X*.76C^%]5\?^*M!\)^#'N/$=KXJ\57FOV<5_>W$8L4\JY=T
M63R(;MR<9 ,9_B!KVBR_:A^+G[1GAJT;X8_"G4/!MGK-NDL7B/Q_+%;+91R+
MN65+"WDDDF;:00K/&,XW<9%>J?LW_L\:=^SGX(N-/@O[[7M;UJ\DU77]=OR#
M>:Y?R !YY,<* JJB1K\L<<:(.%H UO\ A0_@?_H3?"O_ (*H/_B:/^%#^!_^
MA-\*_P#@J@_^)KK** .3_P"%#^!_^A-\*_\ @J@_^)H_X4/X'_Z$WPK_ ."J
M#_XFNLHH \3_ &H?V*?#/QP_9X\5>#]#T+PCX?U36K(PV5\VC1-':3!E=&*H
M%; 91G:0?2OF_P#:+^,?Q,3Q5:?"_P"(]OX'FFT;5_A_XDL]0\.&Z59!/XI6
MU>*1)\]/LH8$'^,C'&:^_*_,O_@L!\+O$WQ ^-GQ:U;PW\1-5^'TW@'X-:5X
MN673]/@N)KNZT[6=3O+3]Y+_ *H)- I)4'(8^@H ^N?V O\ D7?BK_V5+Q-_
MZ6M7O=?$_P#P;S:SK'CO_@E!\._&WB37-2\2>*OB)<:IXDUO4;YE,ES=S:A<
M*Y 50JKB-> .N3WK[8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\@_^"^O_
M ">/X>_[$^U_]++VOU\K\@_^"^I_XS(\/?\ 8GVO_I9>U])PG_R,%Z,^>XH_
MW%^J.'_X)!?\G0:G_P!B[<?^C[:OTLK\U_\ @C]"9?VG=7;_ )Y^&[AC[_Z3
M:C^M?I17T>=_[S\D>!D_^[_-A1117D'J!1110 4444 > _L&_P#(,\9_]A*U
M_P#3?;5[]7@/[!O_ "#/&?\ V$K7_P!-]M7OU !1110 4444 >"?$7_D^#PA
M_P!>@_\ 1=S7O=>"?$7_ )/@\(?]>@_]%W->]T %%%% !1110 4444 >#_MW
M_P#(J>&_^PHO]*]TM/\ CUC_ -P?RKPO]N__ )%3PW_V%%_I7NEI_P >L?\
MN#^5 $E%%% !1110!YO^UE_R1.\_Z_K#_P!+(:U_V=_^2 >!O^Q?L/\ TGCK
M(_:R_P"2)WG_ %_6'_I9#6O^SO\ \D \#?\ 8OV'_I/'0!V-%%% !1110!SW
MQ<_Y)3XG_P"P3=?^B7KA/V*?^2+S?]AS4_\ TLEKN_BY_P DI\3_ /8)NO\
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MO_V:_P#L8(O_ $NLZ^^*^!_^"LG_ "=_^S7_ -C!%_Z76= 'WQ1110 4444
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M-PE"?\$3?@'@8_XE-X?_ "I7=?;M?$?_  ;B?\H3O@'_ -@B\_\ 3C=U]N4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5^0?_  7U_P"3R?#_ /V)]K_Z67M?
MKY7Y!_\ !?7_ )/)\/\ _8GVO_I9>U]-PG_R,%Z,^=XH_P!Q?JCC_P#@CO\
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MD3PS:W7QD\4>*8X_'VASBSNOAF^D)&5G)$HE*C<R=1'_ !=* /U3_P"":/\
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M: "BBB@ HHHH ***CN;J.R@:2:2.&->6=V"J/J30!\%_\$-.OQO_ .QFLO\
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M&?\ !=2UU:/]D/PSYUG^UA''_P )]H0SXPO+22P+?:#@((Y2?/\ [A/&>I%
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M.?\ P+C_ /B* /O>BO@C_A^)-_T0WQS_ .!<?_Q%'_#\2;_HAOCG_P "X_\
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M7=0:WFLY]4A>:S#PSQS!950ABK;,'![U['4=S=1V4#2S21PQH,L[L%51[DT
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M%.IR0,'$N".>E>I5X#^P4BQ:5XR5555&I6N !@#_ (E]M7OU !1110 4444
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M_!"#XC>'_AOXZ^)%WXAUS2=#M6TRTVRW]W';J^V20G!<C) ["OKKXB_$.?\
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M% !7R_\ \%C_ /E'WXR_Z^-/_P#2V&OJ"OE__@L?_P H^_&7_7QI_P#Z6PT
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M%O)9-?O[<$1",(L$S6Z]^<B+=_P+':@#W:BBB@ HHHH **** "BBB@ HHHH
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MX/\ ^^(__C5'_"E/VZ/^BD>#_P#OB/\ ^-4 ??%%? __  I3]NC_ **1X/\
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MC_\  U?_ )74?\,3?MA?]'"1_P#@:O\ \KJ^]J* /@G_ (8F_;"_Z.$C_P#
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MT66H>+;JUNX95MY4299(69,3*X4,2H!)- 'J?_!N$"/^")OP#SS_ ,2F\_\
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M]G?\&\/_ "!OBQ_UVTK_ -!O*_22OS?_ .#>2WV^&?BI-G_676F)CTPET?\
MV:OT@KY#B7_D95?E_P"DH^JX=_Y%]/Y_^E,***P?BE\1]+^#OPS\1>+M;:Z7
M1O"^F7.K7YM;:2ZG$$$32R;(HP7D;:IPB LQP "37A'M'Q!\8O\ E/7\-_\
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M1?$GP_:ZM;>&?'WCSQ!KFC/J-HUK+<VDMZ^R4*?X3@C()&5([&OJR@ HHHH
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M!V%?05 !1110 5X?^W3_ ,B'HW_7^?\ T6U>X5X?^W3_ ,B'HW_7^?\ T6U
M'LGA_P#Y -C_ ->\?_H(JY5/P_\ \@&Q_P"O>/\ ]!%7* "BBB@#C?%'P&\-
M^)]8EU(6MQI>JS',E[IER]G-*?[S["%D/NX8UR/[$>L:KKGP:NIM8UC4-;NH
M==U*T2>\<-((H;J2)%R /X4!^I->M:C*T&GW$B':Z1LRDC."!Q7A/_!._P#M
M"#X-ZI#J%Y'?-_;=U<HZ0"''GL)V! )S\\C<^E 'T[_8=K_SR_\ 'C_C1_8=
MK_SR_P#'C_C5NN5^.7QM\,_LW_"'Q#X[\9ZHFC>%_"UD]_J5XT;R>1$O7"("
MS,3@!5!9B0 "37#[27<[N1=C?_L.U_YY?^/'_&C^P[7_ )Y?^/'_ !KQCX7?
MMRV?COQMX1\-ZY\.?B9\/=<\=I+<:';^(+*RDCO+:*V:XDF-Q8W5S!%M 5?)
MED2X+2*1$4#NON5)5&]F-TTNA4_L.U_YY?\ CQ_QH_L.U_YY?^/'_&O&O&'[
M>_A+X7>!_B]XH\;:)XV\!^%_@W-Y-_K'B+2#8V6O@J"DFF.S?Z6KR,L*8VEY
M75 "67/M6GWJZC80W$88)<1K(H;J 1D9H]HWU#V:70B_L.U_YY?^/'_&C^P[
M7_GE_P"/'_&J'Q&^(>D?"?P+JOB37KI[/1]%MFNKJ2."2XDVJ/NQQ1JTDLC'
M"I'&K.[,JJK,P!^9?V5?^"S/PI_:@USXBZ+=:+\1OA;XI^%FG?VQX@\/>.]
M.F:M;V.Q&^T+;QO,S+^\C&SB0F6/"$.I*=6SLV-4TU=(^J?[#M?^>7_CQ_QH
M_L.U_P">7_CQ_P :^:/V+_\ @K1\/?VU/COXM^%]EX:^)?P[^(?@^T34;GP]
MXZT#^QM0N;-B@^T1Q>8[!!YL)Q)L<B9"%(R1%^SI_P %4]-_:?\ C98^%/#?
MP/\ VBK?0=4,TMCX[U/PA'9>$;^T16>*]AO7N,R6\Z!6A*H6D$J': 3@]M?9
MA['R/IS^P[7_ )Y?^/'_ !K.UZQBLO*\M=N[.>2<]*W*R?%'_+#_ (%_2MJ<
MFY:F-2*4=$?&WQA_;#^(NB_%K5]#T&#PK#::9+*B":VN;JXD59&C#.$X7.T^
MWY5QWC']IGXM>-_"6J:->?\ "*_9=5M9;24IH][N574J2/<9R#ZBOICQE^QW
M\,_'WB&XU;5/!^DS:E>.TEQ<HABDN&8Y+.5(W$GN:\]^.?['?PM\&_#74'L?
M"=HFLZDO]G:4%FE+M=S?)$5&[G:3O/\ LH3VKJ.4M^'?VW]/TG0+&UNM!UJ:
MZMK>.*618B%D=5 ) *YY(S5S_AN_2?\ H7==_P"_9_\ B:]E\,>&K?P[X;T_
M3UBCVV-M' #MSG:H7^E7OL</_/&/_OD4 >&?\-WZ3_T+NN_]^S_\37YW?MB^
M-(OB)^TKXJUJ&WFM8KZXC=8IAATQ#&O/Y5^PGV.'_GC'_P!\BOR4_P""@R"/
M]L;QPJ@*OVJ'@#_IWBKW,A_CR]/U1XV=_P %>OZ,^W/^#>;_ )$WXH_]?NG?
M^@7%?HW7YR?\&\W_ ")OQ1_Z_=._] N*_1NOC^)/^1E5^7_I*/J^'O\ D7T_
MG^;"O+?VX=93PY^Q?\7-0DUG7?#L=CX-U>X;5=$B\W4M,"64K&XMDR-TT>-R
M#(RRCD5ZE7DO[?,FGQ?L,?&9M6UB_P##^ECP/K7VS5+*U^UW.G0_89M\\4.Y
M?,=%RP3<NX@#(SFO#/:/@'XT?&_PQ\)?^"[4_C36M2;_ (1G1UT3[;>V-M+J
M*VOF:!XDB0LMNLC@&1T3.,!G4'&17LW[2O\ P44^$/QH^,'[.MKX=\2:E?2Z
M;\4[2>Z9_#VI6\=O'-I6J6<;.\ENJJ&N;JWB!)^]*O;FO(?@=H?BCXT?#S1?
MB%X6_P""<?P1^P>-=,MK^&Y;XDV$-S- R[XTE']E[@R;V!4_=;</6KEW^P_\
M;/C3^TA\--:L?V:?A/\  ;0_"-\D^M7=G\04U!]4@_M#3;K"Q6^G+OD1;)PJ
MN54F7[Z8Y /U$HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^??VO/"CZ
M_P#M&?L^WB^&/#>N+I?BFYF:]U'51:76C V,R^=:Q;A]HD.=I0!L YQQFOH*
MOGW]KSPI_;_[1G[/MW_PA-AXF_LOQ5<S?VG/JQLY/#F;&8?:(XA(OV@M]PH5
M< -G (! !]!4444 %%%% !1110 4444 %%%% 'P5_P %8/\ D]#]F'_L)R_^
MGWPY7WK7P5_P5@_Y/0_9A_["<O\ Z??#E?>M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/O_!4?
MQGXJ^'_[#_C+5_!NJ>)-%URT%J5O]!LC>:C:1&YB662&(1R%V$9;@(QQGBOH
M*B@#^:O3?V[?$S6,?VS]H'XW277/FM+J6K6[LV3DM&+ A#_L@X'2O9/V!/VI
MOB%XK_:ML]2^'OBCQ5\6/B%8Z)=V]IIWBC4=0N(HK)VB:=E6:W@7[R1'._J!
MQ7[Q/X;TWYF:PL?4DP+_ (5\\_ -K3]HC]LGQ)\3M'MX%\$^!=*N/ V@WL48
M$6MWKW,<NIW$1 ^:*&2V@ME<9#2+= 8"Y8 \:_X::_;<_P"B/^%/^^7_ /CU
M'_#37[;G_1'_  I_WR__ ,>K[YHH ^!O^&FOVW/^B/\ A3_OE_\ X]1_PTU^
MVY_T1_PI_P!\O_\ 'J^^:* /@;_AIK]MS_HC_A3_ +Y?_P"/5\H?MK_'#]J'
M4];^.4^L?#W0;/5KWX+BRU>V2-Q'::4+G4RMR'\T_.6>=<<X" XYK]J*^"?^
M"C'_ "4C]IK_ +-P3_TMUJ@#:_X-PB3_ ,$3?@'N_P"@3>=/^PE=U]N5\1_\
M&XG_ "A.^ ?_ &"+S_TY7=?;E !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?B
M]_P6\_Y/PU+_ + ]C_Z :_:&OQ>_X+>?\GX:E_V!['_T U]5P?\ [\_\+_-'
MS7%7^Y?]O+]31_X(S_\ )3?&G_8+A_\ 1M?H17Y[_P#!&?\ Y*;XT_[!</\
MZ-K]"*]K./\ >I?+\CQLI_W9?/\ ,****\L](**** "BBB@#P']@W_D&>,_^
MPE:_^F^VKWZO /V!K74(-(\>_P!HV/\ 9\UKXC;3C'YPEW-;6\,#-D <%D)
MKW^@ HHHH **** /!?!'_)]GB3_L&R?^@65>]5\I^,OB\GP>_;/UN];3YM4:
MYM)(?(@+F5?W5D=V%C;Y>,<XY(ZUV'_#<Z?]";KG_?N?_P",T >^45X)_P -
MQC_H3-=_[]S_ /QFC_AN,?\ 0F:[_P!^I_\ XS0![W7A_P"W3_R(>C?]?Y_]
M%M53_AN,?]"9KO\ WZG_ /C-><?M)?M-P_$OPWI]K-HM[HBV]PTPFO$N DA$
M; (,0]3F@#ZV\/\ _(!L?^O>/_T$5<KY]TK]MQ;;2[6/_A#=<;RXD7(CGP<
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M#X[_ &GFMX5GG7]FY"D9?8'/VW6N,]J^_*^"?^"C'_)2/VFO^S<$_P#2W6J
M-K_@W")/_!$WX!YX_P")3>?^G*[K[<KXC_X-Q/\ E"=\ _\ L$7G_IRNZ^W*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,^$;W]D'Q%JFL6$,ESK&H0_$/PZJ:EJ5Q*]S>W(#7.0);F::3GGYZZ;4?\
M@JMX]^%'QA\$^%/BI^S7XV\"Q^/KL66FW\'BG0]6CC;[3:VSO*D-UN6-'O(,
M[0S$,<*<''RM\5?@!KD__!6C4O@]X/\ B5X\\-Z3K4>CQI/>:Y>:F+)3I.NW
MLOEQO,H#226< +9X4&N]^,'_  3-\4?!?X]? 34]7^+VI>+CK?Q!L]$;[?I9
M>2UMDAFU:01,\[A&DDTBWC) SM9NX% 'Z@4444 %%%% !1110 4444 %%%%
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MX3ZYK%EX@N/A3XEUKPK#J%K;&W2ZB@OI"&V$D_>D;J>F*^PJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_$C_@LS_P I!_&'_7MI_P#Z10U^V]?B1_P68/\
MQL'\8?\ 7MI__I%#7U7!_P#OS_PO\T?,\5_[DO\ $OR9UG_!&FYCMO'/CCS)
M$CS8VV-S8S^\>OOS^U+;_GX@_P"_@K\T/^"9?P&T/X[>*_%=OK88QZ?:0218
MMK:;EG8'B>*0#I_" :^P/^'>?@+^[+_X*]+_ /D2O:SC_>Y?+\D>/E/^[+Y_
MF>W_ -J6W_/Q!_W\%']J6W_/Q!_W\%>(?\.\_ 7]V7_P5Z7_ /(E'_#O/P%_
M=E_\%>E__(E>6>D>W_VI;?\ /Q!_W\%']J6W_/Q!_P!_!7B'_#O/P%_=E_\
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ML >,%W1Q[KG3QN<[57_38>2>P'<^E?3U?+__  6/_P"4??C+_KXT_P#]+8:
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M='_;<;8*Y6_8'!&".G<4 =SH/Q&\/)H=D#KVB@B"/@WL7]T?[56_^%D>'?\
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M'X4TN^_;:^/TTVFV,TUO<Z"T4DD"NT1:P+,5)&1EN3CJ:^AZ^>?V9M$@T_\
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M,)YLC:E=[G;'5C@<GG@5]RU\1_\ !N)_RA.^ ?\ V"+S_P!.5W7VY0 4444
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M_@I_T/5C_P" MQ_\;H_X>1_!3_H>K'_P%N/_ (W0![C17A;?\%*_@DEPL?\
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MN/">J/*L/A_1SY$33R%_'VA1K'&O+,6:Y  'J34?_#\7P3_T#_"/_ASO#?\
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MJK*1R" :\)^!/P'\'_'O]J*^_P"$S\/V/B7^S_AEX6-M]O#2^1O2<OMR>-Q
M)/>OHW]MO_DS[XF_]BU?_P#HAZ\@_8M_Y.CUO_LF7A3_ -%ST >G?\.^_@K_
M -$V\+_^ W_UZ[[X6_"#PO\ !'PP=%\(Z'IWA_2FG>Y-K91".-I7QO<CNQP,
MD^E=)10!SWQ/^$_AOXT^$I-!\6:+I^OZ/+-%<-:7D0DC,D3AXWQ_>5E!!'0B
MO/O^'?7P5_Z)MX7_ / ;_P"O7L5% 'YL_P#!0?\ 9_\ !?P)_;/_ &<!X/\
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M"((B8@_V1;\<'_8KA?V HE@^%&H1HJHD>H;54# 4"*/ %>VZM_R"KK_KD_\
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MKS']MA6?]C;XL*B^%79O!^K +XF95T5C]CEXO2WRBV_YZ9XV;LU!1\W^(O\
M@L7'\0/VKM(^%/P;\$_\)]=ZC'$LVJZC?OHMO9W$EK?W0A:&>(3'$-@[%@NT
M^8H!)S7K.A_LP^./CEXSTGQ!\;]<T.\T[0;N/4-*\%>'4E_L6&ZC(:*YNYI<
M27DD; ,B,B1(X#;78*5^6-?8M_P<56>23A=) ]O^*;\3U^EE !1110 445X9
M^U[_ ,%*?@C^P?J.BV/Q4\=6OAO4O$"N^GV$.GWFIWMPB?>D\BTBEE6,=-[*
M%SQG/% 'SU\)S_QNV\3_ /7#6?\ TW>&Z^^*_,7]@K]JGP%^V3_P5@U[QO\
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MAYEE?^*@#]9J*** "BBB@#R[]MO_ ),^^)O_ &+5_P#^B'KR#]BW_DZ/6_\
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M(/\ A]'^S]_T-EU_X+Y?\*/^'T?[/W_0V77_ (+Y?\*]?_X8O^$O_1./!O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9F.<*SD>8OF2?-C/SMZU[M0 4444 %%%% !1110!7U;_ )!5U_UR?^1KQ/\
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M??E? ?[>_P#R?3)_V#?AM_ZFUQ0!] _L!?\ (N_%7_LJ7B;_ -+6KWNO!/V
MO^1=^*O_ &5+Q-_Z6M7O= !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P C7B?[ _\ R2S4O^PB?_14= 'NE#+N7!&0>"#WHILTRV\322,L<<8+,S'
M4#J2: """.VB"1HL:+T51@#\*=4&FZI:ZS9)<V=Q!=6\F=DL,@D1L'!P1P>:
MGH *\_\ C#_R/GP[_P"PV_\ Z2S5Z!7G_P 8?^1\^'?_ &&W_P#26:@#R?\
M:#"K^SOXLV[/^1JO<[<=?WO7 '/YGW-?0/P__P"1$T7_ *\(/_1:UX!^T,&'
M[/'BK.[_ )&F\QG/_37UKW_X?_\ (B:+_P!>$'_HM: ->BBB@ HHHH _$'Q[
M_P CSK7_ %_S_P#HQJ_9+_@B?_R8/H?_ &$[_P#]'FOQT^* Q\2_$7_83N?_
M $:U?L'_ ,$03G]A'3_;6;['_?:U[G%G_(OC_B7Y,\?A?_?G_A?YH^O****_
M,S]$"OS%_P""[O\ R=;^S_\ ]@3Q3_Z!85^G5?F+_P %W?\ DZW]G_\ [ GB
MG_T"PH _3JBBB@ KS/\ ;1\/2>+OV/?BKI,?A^Q\62:EX0U6U71+R^-C;ZN7
MLY5%M)<!T,*29V&0.I4,3N7&1Z97F/[:^B+XF_8X^+&FMX<3Q@M_X/U:W.A/
M>BR760]G*OV4SD@1"7.S>3\N[/:@#XE\8?\ *>FX_P"OOPO_ .F;Q)7Z45^/
M'_!2O]H_5?V1/^"D_P 1/B5HFDZ?KVJ>$8O"]Y!87UP]O;W)_LGQ$NUG0,R_
M>SD ]*^[]%_;C\6_"S0M+U3XS?#MO"_AG4H(93XMT"^_M71K'S%4@W:[5GMH
MQN ,KH4!Y)49( /IBBH[2[BO[6.>"2.:&9!)')&P99%(R""."".<BO,_VP_V
MO?!?["_P%U7XD>/KC4+;PSH[Q13M96C75PSRN$14C7EB6(Z4 >H45QG[/O[0
M'A/]J/X0:+XZ\$:HNL>&=?A,UI<B)XFX)5D=' 9'5@RLI (*D5V= !1110 4
M5X3^Q'^W3IO[;,7C233?#>L>'5\'ZQ+I6;^6)_MZI+-$)TV$[59H'X;D<5[M
M0 445Y;^V3^U[X2_87^ 6J?$CQNNL2>'M)N+6UE32K(WEW))<3I!$J1 @L3)
M(HZ]Z /4J^8?V>]/TOX"?M2>/OAAX@T_3XD\:ZI<>-O"%W- FS4H9@GVVT0D
M?ZVWF&XIDL4F#=.GK/C;]JOP/\,?V:#\7/%&LQ^&_ \>CPZW+>:@/*>&"6-7
MC4IR3*V]5$:Y9G(49)%?.GP5_;<^!/\ P6)UOQ-\-[70?'FF^(/ <<.L/_;6
ME2:'JNAS,Q2.XMI _FPSJ2.NW*MA@REE(!]@V_A72[299(M-L(Y$.59+=%93
MZ@XJ_7YF?M._\%#_ !M^PU^V/\&_@IH_Q:L?BMJ'C#Q[X?\ #^O66I>& U_X
M<TO4+GR@;N_MY%A%U(JL8E:-7<*[[=J\_IG0 5\I^-?^3L/VGO\ LD'AS_T9
MXGKZLK\SOV4[G4)?V\?^"B<.H2:H\MKH^EH5O+AY1&C6VKO"(PS'9'Y+QE54
M*O).,DD@'R9_P1@:3X(_\$F_@'\?;=GBA^%?Q.U+2_$;B=(4/A_5YH+*Z:0L
M,E(;@V4Y Z+"Y]Q^\4<BS1JRL&5AD$'((K\HO^#9[X.:/^T/_P $#-1\!^((
MO.T/QEJ'B#1KY0 6$4X$3,N> RAL@]B >U?;/_!+CXS:Q\7OV.=!L_%EPL_C
M[X>W-UX%\7_O!(_]K:7,UI-(Q '^N$:7"_[%PA[T >M?';XQ:3^SW\%O%?CK
M7I%BT?PCI-SJUV2X3<D,;2%03QN;;M'J2!7Y&^/OA%K'PL^(_P"PG?\ BA&7
MQM\0O$^I^./$[.B+(=1U/Q-X4NI$8KP?+5TB4]EB4<8Q7W5_P4]NF^-'B#X1
M_ &SD9F^*WB6.^U^-"C%-!TLK>7>Y6_@DD2WA]_,(KQO_@L'"EO_ ,%!_P!B
MV.-5CCCURY554850/$'A+  H _1BO@?_ ()7?\GO?M+?]AZ?_P!+[JOOBO@?
M_@E=_P GO?M+?]AZ?_TONJ /OBBBB@!LD:S1LK#<K#!'J*^:?V3_ !G#^RMX
MMD^ ?BV9=,2QN+BX^'FH7!V6VOZ.\C2I91N?E^TV6\P&'[Q@C@D&[+[?IBN8
M^+OP8\*_'KP9-X>\8Z#I_B#1YG67R+N/=Y4B_=EC88:.5<Y61"KJ>00: .GH
MKX,_:$^#FO\ [+O[8_[+ND>!_BQ\5--\*^./&M[I>L:!>ZRNJ6=S:P:3>7R0
MAKA'F ,EJJDF1F*NW.<&OO.@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OEW_ (+)1K+_ ,$^?&2L
MJLOVC3\@C(/^FPU]15\O_P#!8_\ Y1]^,O\ KXT__P!+8: /2/V$D6/]C7X9
M*JA57P[9@ # '[H5ZQ7E'["O_)F_PS_[%VS_ /10KU>@ HHHH **** "OS*_
MX+%?!R^^*GQ9^,^H6?Q$\:_#]O _P1T[Q1%)X<FM+:2[N[+5M4NK5I)Y8))H
MA%-"K@V\D+Y)RQXQ^FM? O\ P4AM8[WX@?M.0S1QS12?LX(&1U#*P^VZSU!H
M WO^#=:ZO?$?_!(?X5^*-8U;6-?\1^-/[1US6M4U2^EO+K4+R74+A7E>21BQ
M)$:CKVSU))^W*^(_^#<,;?\ @B=\ \<?\2F\_P#3E=U]N4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5^'7_!8/\ Y2+_ !$_[AO_ *;+2OW%K\.O^"P?_*1?
MXB?]PW_TV6E?6\&_[[+_  /\XGR_%O\ N<?\2_*1ZG_P17_YJ5_W"_\ V\K[
MJKX7_P""+$3"+XDO_"QTQ1]1]KS_ #%?=%>KF_\ O<_E^2/+RO\ W6/S_-A1
M117FGH!1110 4444 >!?L%:]JFNZ3\0)-6BT^.XN/%,^H*+0N4V7,44X!W<Y
M&_'^/6O?:\!_8-_Y!GC/_L)6O_IOMJ]^H **** "BBB@#'^(/_(A:Y_V#Y__
M $6U>!_L1V%]H7CG5[._L;BS:;2(=0MI',3)=V\UU<,DB%7+#N"KJI!'0@YK
MWSX@_P#(A:Y_V#Y__1;5XG\._'^E_#7QWH=YK5Q)9VM[X#TR&"7R))$D=)[@
MLN54\@,IQ[T >C^)?^3D_"/_ & =6_\ 1UA7>UXE?_'OPIKG[1G@V6WU3=#)
MIU_IRR-;RHGVB>>R$,>YE W.48 =\5[;0 4444 %%%% !1110!7U;_D%77_7
M)_Y&O$_V!_\ DEFI?]A$_P#HJ.O;-6_Y!5U_UR?^1KQ/]@?_ ))9J7_81/\
MZ*CH ]TKG?B]S\)_%'_8)N__ $2]=%7._%W_ ))/XH_[!-W_ .B7H X/]B&V
MCLO@9Y,,:QQ1ZSJ05%&%4?:Y>@KUZO!_V2?BCX=\*_">:RU+6=/L;N/6-19H
MII0CJ#=2$'!]00?QKTW_ (7GX/\ ^ADTC_P(6@#JZ\_^,/\ R/GP[_[#;_\
MI+-6K_PO/P?_ -#)I'_@0M<-\5_C#X6OO&W@*2'7M,DCMM8>25EF!$:_9IAD
M^@R0/QH XO\ :"??^SOXL^8-_P 55>CA@<?ZWT)_H?85] _#_P#Y$31?^O"#
M_P!%K7S1\<_B-HGB+X%>)+.SU2SNKJ;Q+>21Q12F1Y$Q(0P&6.,>F!["O;O
MWQM\(VW@K1XY/$6DK)'90JRF< J0@R* /0**Y3_A>?@__H9-(_\  A:/^%Y^
M#_\ H9-(_P# A: .KHKE/^%Y^#_^ADTC_P "%H_X7GX/_P"ADTC_ ,"%H _'
M/XH?\E,\1?\ 83N?_1K5^P7_  1 _P"3$;#_ +#-]_Z&M?CU\29TNOB+K\D;
M*\<FI7#*PZ,#*Q!KZ,_9)_X*P^-_V0/A+#X-T3P]X5U33(;F:[66^CN//+R$
M$@E)57 QQ\N?>OJ<^P-;%X-4J*UNGVZ,^;R3'4L+BW5K;6:_%'[;45^3EO\
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M?'SQ#I3^-M6L?!^LW?BV[T^YUC1+=XX8;F2*-@H+S)<X( RH6@#])**^$_\
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ML']G[PWJWBGQ5X]F^#_Q_P# 47A_7-<N5FOK6#7#++>:?<2(B+.Z2:7;3JY
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M_!0KXT?%AV^TZ%X 6+X7>&'$T<T)DAVW6JS)@94F>2"$\];=AVX\>_X+$_\
M*0W]B_\ [#UU_P"I#X2KZE_X)M?!J/X%?L/_  YT9K^'6-2OM*37-7U.,JRZ
MIJ-^3>7=QN7A@\\\A5O[NVOEK_@L3_RD-_8O_P"P]=?^I#X2H _1:O@?_@E=
M_P GO?M+?]AZ?_TONJ^^*_)'X*?MO1_L3?ME?'*ZD\)7GC+_ (23Q#?((=-U
MJPMKBQ\J_GYEBN)48*V_Y6&0<&@#];J*^ ?^'\%K_P!$3\:?^%#HO_R51_P_
M@M?^B)^-/_"AT7_Y*H ^_J*^ ?\ A_!:_P#1$_&G_A0Z+_\ )5'_  _@M?\
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M* -/]AK]I#X=P?L=_#5'\>>#$9?#UHI5M;M@01& 1]^O5?\ AI7X<_\ 0_\
M@K_P>6W_ ,77QA^R-_P1G^"_CW]F+P)K6J1>*KG4M6T:WN[J4ZMM\R1UW,<*
M@ R2>  *]%_X<=? G_GS\5?^#AO_ (F@#Z*_X:5^'/\ T/\ X*_\'EM_\71_
MPTK\.?\ H?\ P5_X/+;_ .+KYU_X<=? G_GS\5?^#AO_ (FC_AQU\"?^?/Q5
M_P"#AO\ XF@#Z*_X:5^'/_0_^"O_  >6W_Q='_#2OPY_Z'_P5_X/+;_XNOG7
M_AQU\"?^?/Q5_P"#AO\ XFC_ (<=? G_ )\_%7_@X;_XF@#Z*_X:5^'/_0_^
M"O\ P>6W_P 77PO_ ,%"OC?X+U/XA?M(26WB_P +W$=Y^SPEK T>JP,)YOMN
ML?NU(;YG^9?E'/(]:]>_X<=? G_GS\5?^#AO_B:^/_VZ/^"7/PI\%>(OCUH]
MG;Z\VG^&_@>OB6SAEU$N/MC76J(6;Y<LNV",;>G!]: /J3_@W$_Y0G? /_L$
M7G_IQNZ^W*^(_P#@W"4)_P $3?@'@8_XE-Y_Z<KNOMR@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OPY_X*_R++_P45^(A4[AG3AQZC3;0']:_<:OPQ_X*V_\
MI#?B-_UVLO\ T@MJ^NX-_P!]E_A?YQ/EN+O]TC_B7Y,]2_X(\>+])\+Z=\0!
MJ>J:?IQFDL/+%U<I#YF!<YQN(SC(Z>M?:G_"VO"O_0S>'_\ P8P__%5\&_\
M!*SX(Z'\8+#QPVL?VEG3Y+(1?9+Z6V^^+C.=C#=]T=>G/K7UQ_PQ5X)]?$G_
M (/+K_XNO4S;_>Y_+\D>9E?^ZQ^?YL[K_A;7A7_H9O#_ /X,8?\ XJC_ (6U
MX5_Z&;P__P"#&'_XJN%_X8J\$^OB3_P>77_Q='_#%7@GU\2?^#RZ_P#BZ\T]
M [K_ (6UX5_Z&;P__P"#&'_XJC_A;7A7_H9O#_\ X,8?_BJX7_ABKP3Z^)/_
M  >77_Q='_#%7@GU\2?^#RZ_^+H [K_A;7A7_H9O#_\ X,8?_BJ/^%M>%?\
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M:2XNK""65S</\S-&I)Z]R:O?MJ?\D<7_ *_XO_09*[SX3_\ )+O#?_8,MO\
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MM\*_&\GB3PYXC^'>CZY)O NK>WCS!O!#^4IMBD.X$@^6JY!(Z'%>B?\ $/\
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M1C&.:^V+JUCOK:2&:-9(9E*.C#*NI&""/0BO-O\ AB_X2_\ 1./!O_@JA_\
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MC^YA]:H_SK[T>W45XC_P\;^"_P#T.T'_ (+KS_XU1_P\;^"__0[0?^"Z\_\
MC5'U.O\ R/[F'UJC_.OO1[=17B/_  \;^"__ $.T'_@NO/\ XU1_P\;^"_\
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MGX->'-#\,Z1')XZ^)NHZ9 =)\&:+*LNI7;&,!9)SRMI:@_?N9]L:@'&YMJ,
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MKS7K@VXU;5(;+S\7USG;YC+NQD9QZB@#](J*\M_X;B^"W_17/AG_ .%/9?\
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MQ5_[*EXE_P#2UJ]ZKP3]@+_D7?BK_P!E2\3?^EK5[W0 4444 %%%% !1110
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MN^)Z+=>%=-T_1]#D^:#4M;CD:6^3L\5LI5E0]0TC D<[ ,$@&3^R9][XD?\
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MW?">\\1WEM<:E>M)'8Z1I5L-USK.H3-LMK2(=WDD('L,D\ UY?\ KM_TY_\
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M_P#8^_Z.!^'O_@6__P 10!];45\D_P##]_\ 8^_Z.!^'O_@6_P#\11_P_?\
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M4(SM;KT- 'GDG_!=G]CZ*1E;]H7X;[E)!QJ.>1_P&N-_9 _;G^#/QC_X*/\
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MV_\ !$WX!]3_ ,2F\Z_]A*[K[=H **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#B:/\ A1G@G_H3_"__ (*X/_B:ZJB@#E?^%&>"?^A/\+_^"N#_ .)KQO\
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M&?2XV_X0;Q,8-.^(UE$I*V@'R6VMJH_BAR(YR.L+!B#Y61^=G_!%*14_;ZT
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MTUX1_P $MO\ E'/\%?\ L4;#_P!$K0!C^//V?/C9%X'UII/VA)9(UL)RR?\
M"#Z>NX>6V1G=7Y0?%+X9>/H=5\/B7XFR3,W[(?C6]4_\(];+MLDEA\RRZ_\
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M6%]XU%Y\7)+XK\?_  7;.?\ A&+2/?<O'9>7<\-QY>5^3[K;.>IK\X/VC_\
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M EO::JMYIZ>2HE#?.?LMT 0.D3^AK]2O^&:/AQ_T3_P3_P""*U_^(H _,/\
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M\$3/^1C^,G_7];?^ENJU]\4 ?-/_  YM_95_Z(#\+O\ P10_X4?\.;?V5?\
MH@/PN_\ !%#_ (5]+44 ?-/_  YM_95_Z(#\+O\ P10_X4?\.;?V5?\ H@/P
MN_\ !%#_ (5]+44 ?-/_  YM_95_Z(#\+O\ P10_X4?\.;?V5?\ H@/PN_\
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M\$3?@'SG_B4WG_IRNZ^W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3]9O]*NKZVL(?#GBVZGMF&GWEU&D<%QJ+QQ!G7$/E(!^[-<9^P7KG[,?PV^
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M'=3(8XE6-2=H)"*JYZ 5Y+_P6=_:(O?@_P# OPOX6M=&-_;_ !.U^#0[V_\
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M&XG_ "A.^ ?_ &"+S_TY7=?;E?$7_!N$,?\ !$WX!\[O^)3><_\ <2NZ^W:
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MJN%^/GPVU3P!X3M[K6M+M;J*>Y6"!QXTUK4&M96!Q((;DF)L8/7UH ]KRO\
MPL"[^;Y_^$.B^7(Z>9+S][/_ ([^/:MO]GO_ )()X(_[ %C_ .D\=8OS_P#"
M?77WO+_X0^+N=N?,E[9QG\,^];7[/?\ R03P1_V +'_TGCH ["N?^)O@"'XD
M>%)-/:XDL;J.1+JQO(AF2QN8SNCE7W5AR#PP)!X)KH** /.;7XTZAX)A^S^.
M-!U.QFA&#J>E64VH:== ?Q@1!Y8<]2LB@+_?;K72?#7XK>'_ (P: VJ>&]23
M4[%)3"TBQO'M< $@AU![CM6UJW_(*NO^N3_R->)_L#_\DLU+_L(G_P!%1T >
MZ5\,_P#!::'=;?#>3/W6U)<>N1:?X5]S5\0_\%HH V@?#Z3G<MQ?*!]5@/\
M2O1RG_>X?/\ )GGYI_NLOE^:/F3]A/1_ ^N?M:^"8?B1<:3:^#8[Q[G4)-4O
M4L[(&*&26$32.0OEF9(P48[7!V'(8@_M7_PW?\#_ /HLOPI_\*VP_P#CM?@3
MX8\47_@S7;?4],N&M+ZU),4JJ&*94J>"".A(_&NQ_P"&J/B!_P!#)<_]^(O_
M (BNO/N'ZN.KJM3DE96UOW;_ %.?)<]I8*@Z4XMW=]+=DOT/W%_X;O\ @?\
M]%E^%/\ X5MA_P#':&_;M^!SJ0?C)\*2#P0?%NG\_P#D6OPZ_P"&J/B!_P!#
M)<_]^(O_ (BC_AJCX@?]#)<_]^(O_B*\7_4O$_\ /R/X_P"1['^MV'_DE^'^
M9]L_&;X[> O@Q\<OA_\ #;P?X]\$^*?AYX\^)>D:UX<@TC7[2\?POJ'VDM=6
M#)'(S+;S%_-AP,*QE3@;,_27P:_:4^'/P=_:\_:9T[Q=X_\ !/A74)_&6E3Q
MVNL:Y:V,TD9\+Z* X25U8J2",XQD'TK\F;+]K7XC:;?0W5OXIOK>YMG$D,L<
M<2R1,.C*P7(/N*YGQ/\ %GQ9XP\9ZMXBO_%7B:36M>DCFU&[BU:X@>]>.&.!
M'D\MU#,L44: D9VHH[4?ZEXG_GY'\?\ (/\ 6[#_ ,DOP_S/WF_X;O\ @?\
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M>)_Y^1_'_(/];L/_ "2_#_,]O^"/_!:_]E_PI\'O@GI>H?%:SM[[PK^S3>^
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MQ'MNX]ZY\7PIB,/1E6E.-HJ_7_(VPO$]"O5C1C!WD[=#]4J***^5/I@HHHH
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M[3'AGP)\<-:_X2[X/S?\*=DD3RO^$1O5_M+;:)<=?MW[O._;_%TS7P[_ ,'
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MWP;\-_BA^T+XRM_$VD7FKZ)I/@/Q'%J4=G86[VQDD*JF8XMU["%SUW8[4 >
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\ MO!7Q[GMHY&\2:?"SJ&,;ZO:;D)['&BD9'L2*?_P ()\>O^AHTO_P;VO\
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M?SO\ _LW#?R?F?'/_#FOP?\ ]#=XD_[]0_\ Q-'_  YK\'_]#=XD_P"_4/\
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M"<\X !O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0_9\_:8TOQ2_@7QEXJTO_A'-&UE9=%AMY(Q%H7B :IJ(<R3(RE+4HPPK;BX
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M=1\^(OE8]@<$TMU^P;\:K%;QIOVI=!A73V5;HOK?BQ?LQ;[H?/B+Y2>V<9H
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M#<+/_#DWX![O^@3>=/\ L)7=?;M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?@?_ ,%'KG[5^W1\4&V[<:[,G_?.%_I7[X5^!?\ P43_ .3Y/BC_ -C!<?SK
M[+@O_>9_X?U1\GQ=_N\/\7Z,^IO^"-?_ "2#Q=_V&$_]$+7V-7QS_P $:_\
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MP3M/V:?V=/ /PYL+ZZU2Q\ ^'=/\.V]Y<JJS7<=I;1VZRN%^4,PC#$#C).*
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MI\2O^Q7U+_TEDKQ#_@BG_P F'Z7_ -AO5/\ TK>@#ZSHHHH **** /@?QO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM_W;QZB6%]=!(V,"YA&T[9,X/S@<% V5&RW[2_Q&$LJCX.:PRQ^'5U9"+_\
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M'_U,]:K\/OA78?$75O'=C:_"?16\1_$*X$D>CZ8/$%UH O)#&V]3>6MW9S1
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MXL_X*%_\GPZ/_P!>?@/_ -3,4 ?0/[ 7_(N_%7_LJ7B;_P!+6KWNO!/V O\
MD7?BK_V5+Q-_Z6M7O= !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?S]_MW3-/
M^VE\5F8Y(\5:BOX"X<#]!7] E?S\?MT?\GH?%;_L;-2_]*9*^TX+_P!XJ>GZ
MGR/%_P# I^OZ'V3_ ,$<_P#DWCQ%_P!C%)_Z36]?6U?)/_!'/_DWCQ%_V,4G
M_I-;U];5U9E_O4_4Y<O_ -VAZ!1117"=@4444 %%%% '@?P'_P"3MOB'_P!<
M/_;F6O?*\#^ _P#R=M\0_P#KA_[<RU[Y0 4444 %%%% !1110!X)\;/^3P/A
M_P#]<E_]#DKWNO!/C9_R>!\/_P#KDO\ Z')7O= !1110 4444 %%%% 'BO[=
M_P#R1_3_ /L,0?\ H$M>L^$/^13TO_KTB_\ 0!7DW[=__)']/_[#$'_H$M>L
M^$/^13TO_KTB_P#0!0!HT444 %%%% !1110 RX_X]Y/]TUX7_P $\O\ DA+?
M]=[7_P!-=C7NEQ_Q[R?[IKPO_@GE_P D);_KO:_^FNQH [OX\7OV*V\*?Z5K
M5KYGB2SCSIPRTF=_R2_],3_%^%=1XO\ %]GX)TC[9?-+L>5+>)(HFDDED=@J
M(JKR22?H.2< $U1^)7@!OB-HEO9KK.LZ%);7<=VMSIDRQ3$IGY"65@5.>1CF
MK&A^ =/T/7;K5%6:XU2\BBAFNKB5I'98QA0 >%'4D* "6)ZF@ \ :%>Z!X<6
M/5)+.?5+B62XO);6 0QR2.Q/ ZG:NU-QY(0$UM444 %0WUA#J4'EW$,<T>Y7
MVNN1N4@@_@0#4U% !1110 4444 %<CK6I'P!XY_M"ZFMX=#U[R+-ECM"98[[
M+*LLCJ/N.@CCRWW3'&,X)QUU-DC69"K*K*W4$9!H \__ &F[[^S_ (8K)]KU
MZQ_XFEBOFZ0N;CFYC&T_[!Z-_LDUZ%7!:[\ +&^TFVT_2]:\1>&[&WOA?M!I
MMYM28[U<QG>&VQDKRBX'S'UKO: /S3_X*+OCQ-XH7U\5@_E8Q_XUY%^QAI4.
MN?M??"VTN(XIK>;Q9I:RQRH'25/M<196!X((R"#ZUZU_P48?'BSQ,O<^*<_^
M247^->9?L'V[7/[:GPJ5< CQ5I[\^BW",?Y5]5@-,ND_*7Y'S6-UQ\5YQ/W>
M_P"%+>#?^A2\,_\ @K@_^)H_X4MX-_Z%+PS_ ."N#_XFNFHK\I]M/N_O/TWV
M4.R^XYG_ (4MX-_Z%+PS_P""N#_XFOFZ3PEX4_8^_:NUFW\4>'_#Z_#7XPW\
M5[I&K7.GPFW\/ZX(8[>2PD8KB*&Y2&*2(\+YWG*?FE7/UO63X[\!:+\4/"&H
M>'_$6E6.MZ)JL)@N[&]A6:"X0]596X-'MI]W]X>RAV7W%?2?A;X9T'4([RQ\
M.:#9W4)S'-!I\4<D9QCAE4$<$CCUK>KY"_:._9[\9_L>?LU?$'Q9\)?C!XS\
M/Z;X+\,ZEK5GX;UN&V\0Z;$UK:23)%$]TC744?R!0BS;%' 48KTO_@G+\:?%
M/Q]_93T_Q!XTO+'4/$D/B#Q%HMU=6=I]DAN5T_7+_3XI!%N;86BMD)&3R34R
MDWN5&*6Q[E1114E!1110 4444 %%%% !17CWQI_:[MO GCO_ (07P;X<U3XD
M_$AH%N7T+2Y$A@TF%\[+C4;R3]U9Q-@[0VZ:0 F.*3:V/#OVA_VEOVBOV=?'
M_P %[CQ)<?!^WT+XD?$32_"%_H>DZ7?WEW9071?>ZZC+<1I(PV8'^AIZ^U '
M,?\ !&3_ )++^T3_ -C#;?RGK[YKX&_X(R?\EE_:)_[&&V_E/7WS0 4444 %
M%%% !1110 4444 ?EK_P<9I,?VD/V"661%@7XY:4)$*_,Q^V66T@]L?-]<BO
MU*K\N?\ @XP_Y.$_8-_[+IH__I99U^HU !1110 4444 %%%% !1110 4444
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MT_1;&UET_P 8*\$$<3L+& KD* ?^6V<<>E+^SL3_ ",/K^'_ )T?65%?+_\
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M#,0?_B9\;@>*C\4?&OXE>%+7Q(UY^TK\&;>3PI;17.J*_P .KH?8EE*B(O\
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MSK8_LV?"Z+28YI-4\0:E*=2\1:U/\UUKVI2 &:YE;J23\JCHB*B@ *!7S_\
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M_P#/N/X_YD_ZHX?^=_@?@#_PP#\;?^B5^./_  4R_P"%'_# /QM_Z)7XX_\
M!3+_ (5^_P!11_KIB/\ GW'\0_U1H?SO\#^?ZX_8)^-=LFYOA7X\(SCY-&G8
M_D%-0_\ ##'QH'_-*?B%_P"""Z_^(K^@>BG_ *Z8C_GW'\0_U0H?\_'^!_/O
M_P ,,_&C_HE/Q"_\$%U_\11_PPQ\:/\ HE/Q"_\ !!=?_$5_0113_P!=*_\
MS[7XA_JA1_Y^/\#^?*X_8E^,EJ^UOA/\2#D9^3PW>./S$9IG_#%WQB_Z)-\3
M/_"7OO\ XU7]"%%'^NE?_GVOO8O]4*/_ #\?W(_GO_X8N^,7_1)OB9_X2]]_
M\:H_X8N^,7_1)OB9_P"$O??_ !JOZ$**/]=*_P#S[7WL/]4*/_/Q_<C^>9_V
M1?BQ&Y5OAA\0U93@@^'+S(/_ '[I/^&2/BM_T3'XA?\ A.7G_P ;K^AJBJ_U
MTK?\^E][%_JA2_Y^/[D?SR_\,D?%;_HF/Q"_\)R\_P#C=-D_9,^*D*,S?#/X
M@*JC))\.W@ _\AU_0Y11_KI6_P"?2^]A_J?2_P"?C^Y'\[?_  S%\2O^B>^.
M/_!#=?\ Q%'_  S%\2O^B>^./_!#=?\ Q%?T244?ZZU?^?2^]_Y"_P!3Z?\
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M65AV[@UZC_P4MU&ZU+XI:G]HNKBX2TUN:"!))2RPI]EM3M0=%&23QU)KGO\
M@E\"W[?/PSQS_P 3-S_Y EKZC#Z95-_W9?J?-U]<RC_BC^A^A_\ PX;^!O\
M>\5_^!%I_P#(U'_#AOX&_P![Q7_X$6G_ ,C5]I45^3GZ@?%O_#AOX&_WO%?_
M ($6G_R-1_PX;^!O][Q7_P"!%I_\C5]I44 ?%O\ PX;^!O\ >\5_^!%I_P#(
MU'_#AOX&_P![Q7_X$6G_ ,C5]I44 ?G[^T+_ ,$2?@SX!^ /CG7=.D\4QZAH
MOA[4+ZU9I[4A98K:1T)'V?LR@UX5^S/^Q5\#?$W[(.K?%SXK7/B*Q!\<:CX?
M5-$L(67<VM-IUC!#;06KN69VA0!0>6R<#-?II^UU_P FH?$__L4M5_\ 2.6O
MCS]@BR:__P""=&F*EAX=U$K\;?,,>M7'D01A?&D;&6,Y&;F/&^%<_-,L:X.<
M$ P_$'_!-;]F/PS+X@2ZL_C Q\-6MO>7GD^'9I@R3A"@B*V!\YQO&Y(]S)AM
MP&TX-5_X)K?LQZ--K4<UG\8"V@Z?!J=UY?AV:0-%,4"",K8'S9/WBYC3+J Q
M(&TX]I^&G@3QU^TM\:_CE/+\8O'OAC3_  CX\/A_2]-TD6BVUM;)H^E7&/GA
M9BQEN9F))_B]J[G_ (8N\8?]' ?%K_OJQ_\ D>@#Y@O/^"9W[,EC+J"26?Q>
MW:9H<?B";;X?E;-LZJP5<6/SS?.,PKF0$$%00<,D_P"":_[,<5W-"UG\8-\.
MBKK['_A'9MOV8XPH/V#!FY'[D?O.OR\5]1?\,7>,/^C@/BU_WU8__(]'_#%W
MC#_HX#XM?]]6/_R/0!^<_P"U9^SM\*_V;?C'\$S\.8?'$%QXPO+.\N1K>BM;
MQFU.IZ<T0WO:Q&.0,I+1[@X&-R@$9_9BOS0_X*0_LI^//"GQ2^!MU!XH^*GQ
M4MY/$T<,T4]G%=0:9_IEA)YLA@B7RU*QR'<QV_)VK]+Z "OG7_@K8YC_ .";
M7QB9?O+X>E(^H9*^BJ\!_P""I_AK4_&'_!._XNZ;HVFZAK&J77AZ86]E8P&>
MYN6!4[8T7EF(!P!R: /D'X+?LC_"7]KWPKX3\7?$K4/BYXA\>>.)]4A>^DTV
M6XA46EY<KY9F:T=8HE5-L89PK  +G(K:T'_@FI^S'XCC\--;V?Q?5?%=W/9V
M/G>'IH=CPE5<S;K >0F6&'EVJV"03@UZ7^Q#^R!XVUG]EWPO?3_%KXN>#9+X
M7=T-%:*UMSIZ27<\B1^7) 77Y64X8DC->K_\,7>,/^C@/BU_WU8__(] 'RSH
M/_!-W]F'Q'!H<EO9?&)5\0ZE)I5H)O#<\)6:/&XRAK &*/D8D?:AYP3BGZ7_
M ,$V/V8=7@TF2&S^, 76M9;0K?S/#LT9%PI0%I ; >7#EQ^^?$9PWS<''U'_
M ,,7>,/^C@/BU_WU8_\ R/1_PQ=XP_Z. ^+7_?5C_P#(] 'RT/\ @F[^S"8H
MW^Q_&+;+K9\/K_Q3D^?M(SDD?8.(>/\ 7']W_M4-_P $W/V84CG;['\8L6^M
MKX?;'AR<DW+="O\ H'S0_P#38?N_]JOJ7_AB[QA_T<!\6O\ OJQ_^1Z/^&+O
M&'_1P'Q:_P"^K'_Y'H ^6]6_X)L?LPZ+;:Q--9_&!ET/6$T.X\KP[-(SW#%P
M#&%L"98OD.94S&,KEOF&4U__ ()N?LP^&X]>:XLOC$P\.:A'IEWY'AR>;?-)
MG:8MM@?.3CF2/<H[D5]2_P##%WC#_HX#XM?]]6/_ ,CT?\,7>,/^C@/BU_WU
M8_\ R/0!\NZ[_P $U?V8O#D7B5[BS^+[+X3N8+6^\GP]-+O>8L$\C;8'SU&T
M[FBW!<C)&11XG_X)J_LQ^$G\2+=V?Q@8^%5MVO?L_AV:??YX4H(=E@?.(WC<
M(]VSG=C!Q]1?\,7>,/\ HX#XM?\ ?5C_ /(]'_#%WC#_ *. ^+7_ 'U8_P#R
M/0!\0_M>?L*? ?X)?LX_%S6/"Z_%*U\1>$O#*WI>XT)_L<PEDADAC9FL@DR>
M<D+N@)VF,,P&S(^U_P#@E-IUOI'[ _@.UM+>&UM;<ZBD4,2!(XU&HW6 JC@
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MQ.\3:-XX\4?"/X@:B=:\6>"8H;_3-<:-8F\3Z-.66"Y=5PHN(G1H9PHP65'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /CG_@N=_P F-M_V,%E_*6OR
M-^#7_)7_  I_V&+3_P!'I7ZY?\%SO^3&V_[&"R_E+7Y&_!K_ )*_X4_[#%I_
MZ/2OTWA3_D7/U?Y(_.>)O^1@O1?FS]L****\(]H**** "BBB@ HHHH ****
M"BBB@ HHHH _,#_@I#_R5;6?^P_/_P"DEI6=_P $J?\ E(%\-O\ K]N/_22>
MK7_!2&Y1_C/K$:L&9=;N2<$''^BV76C_ ())_P#*0WX<_P#7:]_](+FOJ*.F
M4S_PS_4^<J:YI#_%']#]SJ***_)S]/"BBB@ HHHH \\_:Z_Y-0^)_P#V*6J_
M^D<M?'W[ NBR:]_P3ITV&+1=%UYH?C8;DP:G>?98H%B\9I(URC>8FZ:$*98H
M\GS)(T3;)NV-]@_M=?\ )J'Q/_[%+5?_ $CEKX^_8%T8:Y_P3ITV)O#]GXD\
MGXV&X^S7-]]C6V,?C-)/M:OD;GM]OGK'_P M&B"8.[% 'T!^PS_R5#]I?_LK
M$O\ ZC^AU]"5\]_L,_\ )4/VE_\ LK$O_J/Z'7T)0 4444 %%>?_ !P_:H^'
M_P"S=JGA>Q\;^)K'P]=>,[\:9HT=PKDWUP61=B[5./FD09; RXYYKT"@ HHK
MG_BM\5/#_P #_AQK7B[Q9JEOHGAOP[:O?:C?SY\NUA099VP"<#V!- '045S_
M ,*_BIX?^-OP]TKQ7X5U.'6/#^MP_:+*\B#*DZ9*Y 8 C!!&" 00:Z"@ HHH
MH **** "BBB@ HHHH **P_B7\2=#^#OP_P!8\5>)M2@T?P_X?M)+[4+V;/EV
ML*#+.V 3@#T!-5_A#\7O#?QZ^&^E^+O".JP:WX<UJ-I;*]A5E2=5=D; 8!AA
ME8$$ Y!H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\7_P""@OQ_\2?LQ?LI>)/&/A&+09?$6GO;
M0V7]M1226"/-<1Q;I5CDB8J Y/$B].N*]HKY?_X+'_\ */OQE_U\:?\ ^EL-
M 'YXZ1_P6$_:OU;38;EO$G@-6F!8BT\"V5Q;CD_ZN0^(%+KZ,5!([5L? G_@
MII\4='_:KTOXE?%"&/Q='H_AZ]\/Q6.@^'=-T626.YFMYB7E?6IP0KVR$#9Z
M\C-?J!^PL=W[''PS_P"Q=L__ $4*]6H ^"/^'\FA?]$C\=?^#;1__DNC_A_)
MH7_1(_'7_@VT?_Y+K[WHH ^"/^'\FA?]$C\=?^#;1_\ Y+H_X?R:%_T2/QU_
MX-M'_P#DNOO>B@#X(_X?R:%_T2/QU_X-M'_^2Z^;/VI/^"D6F_M$>-?BXT?@
M/Q!I%KXH^#5]X6#76I:9<-9W"QZK?+)+%#</)Y,D<,J*P4_.I!P.:_8JOR/_
M ."\&O6OA7]J;6-2U"1K;3X?A9Y,MP8G:.%Y;7Q5%&'*@A=SLJ@M@9(YH ^E
M/^#<3C_@B=\ _P#L$7G_ *<KNOMROB/_ (-PSG_@B=\ _P#L$7G_ *<KNOMR
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;D?Z."9QS^[X-?*__"9_M^?] 7P+_P"$K8__ #1T?\)G^WY_T!? O_A*V/\
M\T= '(_\%:?C[X>^)OQ-_9VM=)'B-9KW5(-6C^W>'-1TY#;RZAIH3<]Q!&JR
M?(<PL1(O&Y!N&?THK\Q?B_\ LZ?M>?M2_$'P!=?$#P_H-Q8^$]:M;J,6&GV&
ME)"AO;22>61_[8NW8+';DA$CR2<9K].J "OG3_@K><?\$V/C'_V+TO\ Z$E?
M1=>,_P#!0WX1>(/CW^Q)\2_!WA6SCU#Q%X@T26UT^UDN$MUN)L@JAD<A5SC&
M6.!F@#Y+_8LE\7:E\#_!%CIW[07Q4\.#Q%=ZPFGZ;9_"V"]LK/R+ZZ,B&[?3
M7"J-IVO-(/,/W&?(KT70M:\9>)(_#+6O[3GQJV^+KN>RT[SO@O#!^\A95D\_
MS-(7[,F6&UY_+1QDJS!21YU\+O#?[;WP0\$V_A?POH7A>/P_ILURUBE_X>T^
MYNHXI;B28+)(OB!%=E\S;N"*#C.T5T'_  F?[?G_ $!? O\ X2MC_P#-'0!T
M&@^)O%WB2#0Y+7]ISXW;?$6I2:59>=\%([<^?'C=YHDTA3!'R,2R[(VYPQP:
M?I>O^,-8M])DA_:<^-FW6M9;0;7S/@M%$?M2E ?,#:0#%#EU_P!(DVPGYB'(
M5L<Y_P )G^WY_P! 7P+_ .$K8_\ S1T?\)G^WY_T!? O_A*V/_S1T >]?\$Y
M_B[XC^+GPK\8?\)-XFOO%U]X7\:ZMX=AU6]T5='N+F"VD54+P+%$H;D_,$ ;
MJ,CFOH"OS9^$G@W]N?X,6WB"/2=*\)2+XDURZ\071N?#.GL5N+@J75,>(AA!
MM& <D<\FNL_X3/\ ;\_Z O@7_P )6Q_^:.@#[ZHKX%_X3/\ ;\_Z O@7_P )
M6Q_^:.C_ (3/]OS_ * O@7_PE;'_ .:.@#[ZHKX%_P"$S_;\_P"@+X%_\)6Q
M_P#FCH_X3/\ ;\_Z O@7_P )6Q_^:.@#Z&_X*<''_!/CXQ?]BM>_^BS5/_@E
MPQ;]A;P23R=^H\G_ +"5U7R]\:?"W[<WQ\^$_B#P7K^C^$UT7Q-92:?>FR\-
M:?%<"%QAO+=O$+!6QT)5@/0U]>_\$_OA=XB^#/[(G@_PYXLTZ/2?$5BMW)>6
M:7*7(MFEO)YE7S$)1B%D7)4D9S0![)1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+_ /P6/_Y1]^,O
M^OC3_P#TMAKZ@KY3_P""UNOV/A;_ ()Q^.M0U*Z@L;&SEL))[B9ML<2B\AR6
M/84 >J_L*_\ )F_PS_[%VS_]%"O5Z\A_8!U2VUO]B7X5WEG/%=6EUX9LI89H
MFW)*C1*0P/<$<YKUZ@ HHHH **** "OS;_X*\_L^>"_C5\4/C/?>*O#]GK5U
MX;^ $]]IKSLX^RSK>:@5<!6 8@]-P.,GU-?I)7P9_P %*W">.?V@V8A5'[.M
MSDD]/]+U"@#7_P"#<,;?^")WP#_[!-Y_Z<KNOMROB/\ X-Q#_P :3O@'_P!@
MB\_].5W7VY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X!_P
M4>_Y(CX;_P"QY\.?^G."O!?V/O\ E(+JG_8Q?$#_ -..G5[U_P %'O\ DB/A
MO_L>?#G_ *<X*^>?V6/$6G^&_P!OS4IM1OK.PA;Q)\0%5[F98E)_M#3S@%B.
M: /T%HKG_P#A;7A7_H9O#_\ X,(O_BJ/^%M>%?\ H9O#_P#X,(O_ (J@#H**
MY_\ X6UX5_Z&;P__ .#"+_XJC_A;7A7_ *&;P_\ ^#"+_P"*H Z"N+^/_P =
M]#_9Q^&5YXHU[[5-#"\=M:65G%YUYJMW*XC@M+>/K)-+(RHJ^IY( )&I_P +
M:\*_]#-X?_\ !A%_\57QK^VQ^W9\,_A!^WG\,CXZO/$%]X3\(>'=0\06#Z%X
M=U#7K>76IY8[2!W-G#*JO#:_;L!\$?:E;@A<@'K$/PN_: _: T>:_P#$/Q"M
M?@Y9ZE$RP:!X:TV#4+^PC8':9KZ<$&X7(SY2! 1QG&3V/[!G['.E_L#_ ++O
MAWX6:+KVN>)--\.O<O#?ZLZ-=2>?<23D'8 N%:0@ #H!7AU[_P %^_V;]-LI
MKFXU/XEV]O;QM+++)\-/$*I$BC+,Q^Q\  $D^@KZ8_9R_:2\&_M8_"JS\;>
MM6?6O#E]/<6L5R]G/:.)8)6AE1HID21661&4AE'3/3!H [JBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC_\
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ML\_]%"7_ ,$>I?\ R/73?\.Z/@;_ -$Q\*_^ Q_QH_X=T? W_HF/A7_P&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7]U<W$BNRHD4*L[?+&[$XP%0DX KOJ^*_P#@NZ<?L<6'_85O?_3!K% '1_\
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M(TZWU6Z^!,=U;V]U'#J.KSQK-&)%21;6,JX!!PRGD,.1VH _0']FC]J/P?\
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M1>?^G*[K[<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYO[-R+YD3;9$_P!-UKD'L:^_*^"?^"C'_)2/VFO^S<$_]+=:H VO^#<(;?\
M@B;\ ^I_XE-YU_["5W7VY7Q'_P &XG_*$[X!_P#8(O/_ $Y7=?;E !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$2Y4 X2**)%'98U X H [;X/>%/%7[3OQSTOXL>-M#OO"?AGPE%/'X%\,7X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/E3_ (+D?\H@_P!HK_L1]0_]%U\\?\$9Q(OPM_8W\QE9_P#A36I9*C _X^[6
MOH?_ (+D?\H@_P!HK_L1]0_]%U\]_P#!&W_DF7[''_9&M2_]*[6@#]+Z***
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M0 4444 ? _[7?_*9KX'_ /8+_P#:TE??%? _[7?_ "F:^!__ &"__:TE??%
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M'_X*<I<2^+?VB%M9(X;AOV<[H1O(NY5;[7J&"1WK[XKX-_X*4_\ (]_M!?\
M9NMS_P"E>H4 :O\ P;A9'_!$WX!Y_P"@3>?^G*[K[=KXC_X-Q/\ E"=\ _\
ML$7G_IRNZ^W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E3
M_@N1_P H@_VBO^Q'U#_T77YL?\$S=)_:BF^%O[-9\(ZEX=AD;X:7A\.^;:6S
M1IIWVF'S!)NF#&3<8L$@< \5^D__  7(_P"40?[17_8CZA_Z+KY[_P""-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6^+M=\,:9>W<21SRVT%](5WA.,[G8\=B!VKZTH **** "BBB@ HHHH ****
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M5YO_ ,-D_"'_ **K\-__  IK+_XY1_PV3\(?^BJ_#?\ \*:R_P#CE']G8O\
MY]2_\!?^0?6J/\Z^]'I%%>;_ /#9/PA_Z*K\-_\ PIK+_P".5<T#]J?X8^+-
M8M]/TOXC^ ]2U"Z<1PVUKX@M)IIF/ "HLA))] *4LOQ25W3E;_"_\AK%46[*
M:^]'>4445R&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO7CW_!![P_K7A/\ X);?#;3/$7AWQ'X5UBQ;48[C3=<TV73[V'_B87)5FAE
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MBB@ HHHH **** "BBB@ HHHH **** /E7_@N.?\ C4'^T5_V(^H?^BZ_,_\
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M2N_YU]O5\1_\&XG_ "A.^ ?_ &"+S_TY7=?;E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\2_\%YO^30O#?_8X6W_I%?5\=_\ !(O_ ).1UO\
M[%J?_P!*K2OL3_@O-_R:%X;_ .QPMO\ TBOJ^._^"1?_ "<CK?\ V+4__I5:
M5^U<-_\ ))5?67YH_.\Z_P"1U'Y'Z+4445\*>P%%%% !1110 4444 %?CW^T
MU_R<C\0O^QEU'_TJDK]A*_'O]IK_ ).1^(7_ &,NH_\ I5)7Z!X?_P"\5?\
M"OS/G>(?X</5G[B?L;?\FA?"G_L3](_](H:YG]M[XZ_&;X$^$M$O/@S\!_\
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M#6$]IX>T.S@C2"WM;7[03/(HCC#,\F/F<JJJJKGV2B@ HHHH **** "BBB@
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MH>7YE/ENW=6D[IVZQ3_0^'S[*,=5QJQ.%C?1=5HUZL\[_P"'R7_5.?\ RO\
M_P!S4?\ #Y+_ *IS_P"5_P#^YJ]$_P"(?'_JKG_EK?\ W91_Q#X_]5<_\M;_
M .[*]/\ M#@K^;\*W^1P?4<^_E_&'^9YW_P^2_ZIS_Y7_P#[FH_X?)?]4Y_\
MK_\ ]S5Z)_Q#X_\ 57/_ "UO_NRC_B'Q_P"JN?\ EK?_ '91_:'!7\WX5O\
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M2"-+4*I8@$X'6@#W36_^"K?P"\.:/=:A??$"TM;*SB::>:6QNE2)%&2Q)CP
M!WJ9?^"IOP'=0R^/K5E89!%C=8(_[]U\8_MI?L ?M _M#_LT^)O!G@?P/K7@
MOQ)KRP06^KZG\;+G4;.UC$\;3"6W^S?O4>%9$*\9WUTMQ^Q+_P %#C?:8T/[
M3'PUAM]/!66$:)=E;X;0HWDL2,8S\IZT ?5/_#TOX$?]#Y:_^ %U_P#&Z/\
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M0[6-%N;6W_:2^&>FSSIL2ZAT:[>2 _WE#$KGZ@B@#ZC_ .'I?P(_Z'RU_P#
M"Z_^-T?\/2_@1_T/EK_X 77_ ,;KYEA_8_\ ^"A$<*JW[0WPMD95 +'2+T;C
MZ_>J+5?V-O\ @H9J&EW%O#^T;\,+.::-D2XCT>\9X21C< S8)'7GB@#Z6O\
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M%7O^&0O^"@__ $<)\*__  4WO_Q5 'TQ_P /2_@1_P!#Y:_^ %U_\;JO;_\
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MR3D#&]@I"@GJ< "@#ZB_X>E_ C_H?+7_ , +K_XW1_P]+^!'_0^6O_@!=?\
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M?^"KW[/\&KII[_$.Q6^DA-PL!LKD2-&"%+A?+SM!(&?4U-_P]+^!'_0^6O\
MX 77_P ;KXK\0_\ !/']L#6?VP;/X@?#/7=(^#>DV?A!_#]Q;>)/&5UXODOY
MGO//9DQ'&8EVI%W/*'CGCKM'_8M_X*'Z;<WTD_[2GPSOENI_-BCDT6[5;1=H
M'EKM.2O&<MDY)^E 'U-_P]+^!'_0^6O_ ( 77_QNC_AZ7\"/^A\M?_ "Z_\
MC=?,_P#PR%_P4'_Z.$^%?_@IO?\ XJJ.G?L6_P#!0^RU;4+B3]I3X9W4-XR-
M#;/HMVJ6>U=I"$')#$;CNSR3CCB@#ZF_X>E_ C_H?+7_ , +K_XW0W_!4SX#
MJ,GQ]:@#D_Z#=?\ QNOF?_AD+_@H/_T<)\*__!3>_P#Q54;7]BK_ (*'0ZUJ
M%U)^TM\-9K>\2-8K1M%NECL]JD,48'<2Q.3N)Q@8Q0!]0:)_P5<^ /B72+;4
M-/\ B%97MC>1B6">&RNGCF0]&5A'@@^HKYB_:,^,WA[]HC]K*\\2^#KNXUC0
M;.+X;Z=-?K9S10)<CQG-(8=SJN7".C$#H&4]ZYW]D3_@GS\>/V;/V>O#_@7Q
M9X/USX@:QX9^T6?]OZ=\9KG2;74+<7$IMC':?9SY"K 8DV9."IY->@WG[)?Q
M U?5M%NM4^!.N:S_ ,(_JUGK=G!J'QTGN+=;JUG2>!VC:VPVV2-&P>#CF@#Z
M+_8"_P"1=^*O_94O$W_I:U>]UXG^PG\.?&7P]^''BJ7QUHFF^'=<\4>,M8\1
M#3K+5/[2CMH+NX,L:F81QAF /("X'J:]LH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/=2:?:?$/PZPTWQ;IEOE!!<@?+<(AZ13+\ZX) .Y<Y6ODWX%?\%F/C=\1/\
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MBQX%N%T[Q59VT7DI/NW&WO4C_A2558$# 62*0 !=N?FO]K?_ (+1_'+X^_\
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MX%\3>(-%UCX1^.-)TJW\3:A'X?BCFU6_2<V^I2PX.Z'.^WE" D+YH'.*W_\
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M$-OI]A:VQ@:.SU#4H(@;:WCBSL6*-M]W,H^5I9@"FV9L?T=4 %%%% !1110
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M0>"#WK-TCP?I'A^Z>>PTO3;&:0;7DM[9(V8=<$J 30!^8_[&_P#P;Y1>#?\
M@@[XF_9G\=:DEOXR^)DLGBC5KNWD\V#1M:/V=K4(<?,D(M+5) O$A6;!PXKX
M%_8X_P""H_[3/_!N%ILWP0^.WP:U;Q5\.-)OI)=*U&"1U6V21G)6SO-K02PN
MX+B-MK+N8X&[%?TB55U?0K'Q!:^3?V=K?0YW>7<0K(N?7# B@#^;OXN^)?VI
M/^#K3X^>#=!M_ .H?"CX">%;L7LM_/'-]C1)6*-=M+(%6[N?*5ECCC!"$OR
MY)^GO^#M+]E^X\'?\$R/V?\ X?\ PX\,:YJFC>!?$-MI-E:6%I+>RVMI;Z7-
M!%OV*3]U5!8]3[FOVKL;&#3+2.WMH8K>"(;4CB0(B#T ' I\D2RKAE5AUP1F
M@#X\^//_  3O\._\%'_^"1/A7X2^+K<Z??7/@S2I=*O9HBLVA:I%8Q^3-M^\
M-K95UZE&=>"<C\*/^#=[]C;XI?LP?\%^_!.B>-_!/B?29O"+^(--U"\ETZ?[
M#&Z:5>Q!EGV^68V;:$8'#!EQG(K^IRFB)1(7VKN;@MCDT ?S*_MG?'GXF?\
M!/7_ (.5?BU\;/#?PA\3>/K>SO?(MH!I]VEK=I-IEO$76:.-@=I!Z9&017=?
MM9?\%5?VU/\ @MU\,#\!?A[^SEKOP^TGQM*EOK6I>3>(ES:K(C-')=3QQQPP
MY ,F"69,K@@D'^BZ2UBF;<T<;-ZE0:='&L2[5557T Q0!\R_\$A/^"<NF_\
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MORTV?W=O'Y4]5VK@# '  [4 ?SU_'C]D*\_X(H?\'$_PI\8_![X?^(K7X/\
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M;8QU4U\G_P#!FM\(?%WPT^/O[0$GB3PKXE\/0S:?8QQMJ>F3V:R.+F8[09%
M+  \#D5^_%-2)8RQ554L<D@=: /QF_X/,_V9/%7QG_99^$WB;PKX9OO$#>%?
M$5S;:@=/LVN;J&.Y@7R_E12_E[HCD] 2.Y%?IK_P3J^)FN?&7]@KX-^*/$T,
MEOXEUSP=I=UJ\,EL]LT5XUK'YZF-P&7$FX8/I7LKHLB[64,IZ@CK2JH10 ,
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M^&?%^Z1+O3_#^IR:EI\*"1A%Y<TD43',84D%!@DCD<UXK_P5^_8.U+_@HO\
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M6/V<O&GQ#U1!-:^$M*FOQ 25^U2JN(H00"<R2%$& >7'!KE_V _BW\4/C?\
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M?\$:O'7_  3?_:"\%^.O ?Q:UKXA:'H?@Z_\':QI7BBV@B\C3TCENK%+46L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex101170630image2a02.jpg
<TEXT>
begin 644 ex101170630image2a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9:B@#\<?^%C?MH?]''^+/_$=M;_^0JKW'Q(_;9%W;B']HSQ(UNQ;SV?]GC7
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MW1/B=X;^)7_!4_09/#GB+0O$$=K\*M56=M-OXKL0DZOIF-WEL=N<'&>N#Z4
M?SQ?M=_M1?\ !33_ ()]CP[-\;?B5\4? MKXJ:X727;6-/O_ +8T!A\T8MY'
MV!?/CY;&=PQGG']1/[.FM7GB/]GSP)J&H7,U[J%_X>T^XN;B4YDGE>VC9W8^
MK,23[FOYZO\ @\9_:8\5^.?VQ/!OPKN/#\.G>%?!6D2WVGZNZ2AM7EO%MIYT
M#L!'^[-I"H";CECDY8 ?T$?LHM(_[+?PU:90LI\*Z674?PM]DBR* ._HHHH
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MKXP:UXKU3QAX4TC0;&;QIJ.H3:E//;RL=R2RLLGEJ&?S)%<0HC-@@%3\*_\
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M"&P>XS7VA^S1/)=?LX?#^2:22:63PWIS/)(Y=W8VL9)9CDDGJ2>30!VU%%%
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M&^O:E_P<9_M2Z+<:QK%QH-CX*T%[;3Y;V1[2WD,<662(ML4X;J .I]37Z-4
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M$&BZ-XDN_AG?:I<ZCI5SJ265U=K<BS,?D>:!$^/LSA@TBGYDVALG;[;\&?\
M@H%\6/AU\'O"?A^\_8W_ &@IKS0M&L]/G>*;0S&\D4"1L5)OP2NY3@D X[#I
M7W-39YTM8'DD=8XXU+.['"J!R23V H ^4_A;_P %+/%'C/\ :!\"^!/$_P"S
MG\7/ANOCR[N[.TUCQ#/I?V2.2WLI[QEQ;W4KDE+=A]T#GKG /U=7S?\ !G6E
M_:^_:F;XHV/[[X;_  ]L+K0/"-YC]WXBO[AT%_J4)_BMXDA2VAD'$ADNF&4\
MMF^D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO#EMH<<GAF*6"1?)<% T?V2WC551<9&YB3S7Z.T44 ?EG^U?_P $N?VS+/\
MX*<?$;X[?LV_%GX1>!=/^(&EZ?IEQ!XAMY;J[D2W@C4AHVL9XU_>(2"CY(QG
MT%?_ (9:_P""N'_1RW[.?_@A_P#O57ZJ44 ?E7_PRU_P5P_Z.6_9S_\ !#_]
MZJ/^&6O^"N'_ $<M^SG_ ."'_P"]5?JI10!^5?\ PRU_P5P_Z.6_9S_\$/\
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MF?"#XQ^&?CU\/[#Q1X1UBTUS0]14F*X@)RC*</%(APT<J,"KQN Z,"K $$4
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M$<<**,*JJ.  !@ <"K%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ/XZM&D&!-!X@(DC]UW1D9^H-3+_ ,&G'['RJ!_PC_C,X&,G7VY_\<K]+**
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MB5_X,C0!]145\N_\.QK7_HJ7Q*_\&5-/_!,2V/\ S53XF?\ @RH ^I**X/\
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M5:JIH/\ R [+_K@G_H(JW0 4444 %%%% !1110!_*G_P=IZFVF?\%==?:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;,N;?XE_#SPK\/[22*\A^+>N6NCS-%(KQRZ2BM?:B3US'+8VT\ 8<![J+GD
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MY?\ B#U_8_\ ^>?Q0_\ "E7_ .,T?\0>O['_ /SS^*'_ (4J_P#QF@#]&O\
MAH[X>_\ 0]>#_P#P<V__ ,71_P -'?#W_H>O!_\ X.;?_P"+K\Y?^(/7]C__
M )Y_%#_PI5_^,T?\0>O['_\ SS^*'_A2K_\ &: /T:_X:.^'O_0]>#__  <V
M_P#\71_PT=\/?^AZ\'_^#FW_ /BZ_.7_ (@]?V/_ /GG\4/_  I5_P#C-'_$
M'K^Q_P#\\_BA_P"%*O\ \9H _1K_ (:.^'O_ $/7@_\ \'-O_P#%T?\ #1WP
M]_Z'KP?_ .#FW_\ BZ_.7_B#U_8__P">?Q0_\*5?_C-'_$'K^Q__ ,\_BA_X
M4J__ !F@#]#O$/[1GP^D\/WRKXZ\'EC;R8 UFWY^4_[=?G/_ ,&P'QD\(^$O
MV(?'=OJWBGP[ID[?$?6Y$CN]1AA=D:;(8!F!(/8]*M?\0>G['_\ SS^*'_A2
M+_\ &:3_ (@]/V/_ /GG\4/_  I%_P#C- 'Z-_\ #1WP]_Z'KP?_ .#FW_\
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M @=(V#9)ZT ?OO\ \-'?#W_H>O!__@YM_P#XNC_AH[X>_P#0]>#_ /P<V_\
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M_!MGK\DFYOVROVE/HNK(H_2OU(HH _+D?\&VFN#_ )O&_:4_\'(_QK!^(O\
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M_P#3G<5^C-?G#_P:AR^?_P $5O ,G]_6M<;\]2GK]'J "BBB@ HHHH ****
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M _X)\_%JZT^[N+&\7P_,B3P2&.1-Q5&PPY&58@^Q-?E9_P $_P#_ ).KL?\
MK]'_ *$U?J/_ ,%8/^4<?Q@_[%Z7_P!"6OS=_8OU[1]8_:0T-=-LOLT\-\OG
M/Y*IO^]W!YY'>OSKC:36*PRMU_\ ;HGS6>O][2_KJC])****[3I"BBB@ HHH
MH **** "BBB@ HHHH **** "BBN2^.^C>(O$/P<\1V/A&Z^P^);JQ>/3I_-\
MKRICT.[^'Z]J .MHKQ;]AOP+\3/ 'POU*U^*6J3:MKDVIO-:R2WWVQDMS%$
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M;:*_)+_AC?\ X*^?]':_!#_PF[/_ .4M'_#&_P#P5\_Z.U^"'_A-V?\ \I:
M/C'_ (/%?A;XBUO]OGP'XST_2_MGA_PSX3T/3+ZX,JJ(KJ\U+67MHR"<_.+2
M?D @;.<9&?Z#?@#X8U#P3\"?!.BZM"EMJFD:#8V5Y"DHE6*:.WC1U#CA@&4C
M(X.,U_-%_P %JO@M^V5\--;N&_:,^+W@7XB6T=UX.^VKH>FP6IE66Y\0_P!G
M8V6-O_J6BU3?C&?M46=^T>7_ %%T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^5/_  =8_P#)%OV8_P#LN&B_^B+JOU6K\J?^#K'_ )(M^S'_ -EPT7_T1=4
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MJ4>5_P"DIK]:G19$*LH96&""."* *'A/Q7IOCOPOIVM:/>V^I:3JUM'>6=U
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M7^V-.D/_  =@_LHJS*K2?#35U0$_>/EZP<#\ 3^% 'ZJ4444 %?E3_P=8_\
M)%OV8_\ LN&B_P#HBZK]5J_*G_@ZQ_Y(M^S'_P!EPT7_ -$75 'ZK4444 %%
M%% !1110 4444 %%%% !1110!^&W_!UQ_P ?.M_]=_AM_P"EGC2OW)K\,_\
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M5\$Y ..#TK]8U.Y0?:OST_X.1N?V4/@Y_P!EN\)?^CYJ_0J/_5K]* '4444
M%%%% !7Y5?MDP,__  =??LGR;<I'\-]6!/H3#K6/Y'\J_56ORS_;"OEB_P"#
MJK]E>W/WYOAWJ,B_18-=!_\ 0A0!^IE%%% 'SS^WG\;?VA?@[;^&V^ _P2T;
MXQ27SSC6%O\ Q9;:%_9BJ%\HKYQ'F;R6!VGC;[U^<_\ P4;^#?[>'_!4'2OA
M/H?B+]F#PMX#TWP#X^T[Q;-=VOQ$TW4))$AWQLA0R)P%E9N"2=N .:_9ZB@
MHHHH **** "BBB@ HHHH **** "BBB@#^</_ (/'OB[XI\)_MR^#_"NEWWE^
M&]:\&:)KFJ6;6\;K/<V.IZQ':R%ROF*$^VSC:C*&\WY@2JD?T*?!'QA??$+X
M+^$=?U);5=2US1;/4+H6T;1PB66!)'V*S,RKN8X!9B!C)/6OYT?^#R>&2]_X
M*9_#ZU218EF^%T;R$C[RQ:CJ$^W\3$!7]#?[+?\ R;+\.?\ L6-,_P#22*@#
MNZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXAT\O=:)XDOY;5;NU9@N62=4X)QCOQD5^\'_  :17-S=_P#!(>QDNY(9)O\
MA+M64M%M*G!B4<K\IZ=1U^N30!^G%%%% !1110 4444 %%%% !1110 4444
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MCY\8O"?@GP_?V6J^+O'_ ((?PRV@&:SU14M0C!1)&SR1D,,D-+C@5^V7[/\
M\=M#_:.^%NG^*-!DF6&ZW07=G<(8KO2KN-BD]I<1'YHYXI R.C<@J>V">TH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^:7_@\QL9&_X*:_"Z
M\DM[IM-M_ =A#=3)&QC0R:GJ1"%@,;F5),+U(5L=#7]#W[+08?LR?#G?'+&W
M_"+Z9N26-HW0_9(N&5@&4CN" 0>M?C=_P=?2*E]JVY69FN?ANJD+NVG[5XU/
M)[<#K]!WK]S: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME\1Z7;W-E<V2PPW[)'Y3.Z%F:RY/ PQ[BLG_ (9A_P""D'_1SGP1_P#""_\
MK5^5/_!8;]I3]J+_ ()<_P#!5#X4?$GQ_P"./AY\3OBAH/@N6?0YK70'LM+C
MLY9-0MI(IH$9&DD EF=7#J!G'/ H _IBHKA?V7?BE>?'+]F?X=^-M0MX;34/
M&'AC3=;N8(5*QPRW-K%,Z*&)(4,Y !).!UKNJ "BBB@ HHHH **** "BBB@
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M=4?I!1117<=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\C?\%6_&/_"$:/X)NOL_VKS)KR+;YFS&5A.<X/\ =_6O
MHS_@C?J']K_LJZA=;/+^U:_)+MSG;NL[0XSWZU\L?\%E_P#D4/ G_7Y=_P#H
M$5?3W_!%;_DSZ;_L,M_Z16=>3D\(KB%RZV?_ *3$X<'%?VDWY?HCZZHHHK].
M/J@K\E_^#R:"UN?^"7OA);Q_+B_X6%;,I!ZR#2-6,8_&0*/QK]:*_);_ (/(
M=1_L?_@F?X!O/)^T"T^*>ESF/_GH%L-28C\<4 ??/_!,O_E'%\ ?^R=>'_\
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M1110 4444 %%%% !1110 4444 %%%% !1110!^>G_!R(-W[*7P;'_5;O"?\
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M4+K9Y?VK7Y)=N<[=UG:'&>_6OE7_ (+(7,=SX.\"&.1)!]LN^5;/\$5?4/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#PO\ X*8?\F(?$S_L%?\ M6.ORQ_X
M)L?\G.V/_7<_^BYJ_7_]K?0[/Q'^RW\1+6^MX;JV;PY?R&.1=RED@=T/U#*I
M'N!7Y2?L):]H^L?M)Z*NEV7V62*=_./DK'O_ '4N.AYZ&OSGC.36-PRMU7_I
M2/F<\?[^E_75'Z-4445W'4%%%% !1110 4444 %%%% !1110 4444 %>"_\
M!2^[EL?V./%4L,DD<B^00R,5(_>KW!!KWJO _P#@IHN_]C/Q8/\ 9A_]&+0!
MYWX!_P""6'@WQ3X&T?4KCQ?\15GU"RAN9%358PH9T#' ,1XY]:V$_P""2_@B
M/IXP^(WXZI"?_:-?0GP<_P"22^&?^P5;?^BEKI* /EU?^"47@M?^9N^(7XW]
MN?\ VA3A_P $J/!@_P"9N\?_ /@;;?\ QBOJ"B@#Y?\ ^'5/@P_\S=X^_P#
MVV_^,4UO^"4G@MO^9N^('X7UO_\ &*^HJ* /A/\ :P_8=T/]F3X*:EXNT'Q)
MXNO-2LY(85CU"[AF@"R2*I.T1#)YXY[UX'^SM^QQXT_:>M)6\(+)?W5O$9YX
M!)'$8D#[ V7D4')QTYYK[T_X*.Z+<:_^R9KUM:Q^9,T]J53<%W8G3N>*Y/\
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MP?\ %O6/C[^Q!\'?'7B&:WN-?\:>"-&UW4I;>(10RW-S8PS2LB D*I=V( /
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M>]?O3X7\,Z?X+\-:=H^DVL-AI>DVT=E9VT0VQV\,:A$11V55  ]A0!>HHHH
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MBBB@ HHHH *\%_X*7_\ )F_BO_=B_P#1@KWJO _^"FC;?V-/%A_V8O\ T8M
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MS6/%7P[FUS6/&/B35O -RLE]JVK2/]IN(+=AM9520A%;:!M7Y0,BOU8^)_\
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MD^.W_!1S_@G!XFL_$7[-M[\)? 6F>+K+3=0\5WFJN[6.H6]Q@VZV\D4;R,)
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M=Y;PW5I=1M#/!,@DCF1@0RLIX92"00>"#7YB^+OAG^VY^WC\>O@+8?%_X/\
MPP^&O@3X9_$O3?B%?:QHOB==3N2=/ANMEOY/F9(E,VS<N2I*L00#7Z@4 ?.?
M[.UA+^RA^T1=_!99IYO FN:5-XE\ ^<YD;2(X98X[_2-Y.3%"UQ;2VX/(BFD
MC'RP GZ,KY=_X*9>$/C2?^%3^-O@+X.\.>./''@/Q/<7%QIFMZJNFVLVGW.E
M7UK+F4D$XEEMW"@\E >@->'I^U!_P4G/WOV8?@B/IX[!_P#:E 'Z)45^=X_:
M>_X*2?\ 1L?P3_\ "Y'_ ,=IW_#3W_!2+_HV3X*_^%PO_P =H _0ZBOSO/[3
MW_!23_HV/X)_^%R/_CM-;]J#_@I0/N_LP_!$_7QV/_CE #O^#E&XCM?V2O@[
M)(P1%^-OA,DGL!-,3^@-?H='_JU^E?A__P %;OC/^V)\0OAI\']/^.OP5^&O
M@'P3_P +>\,2KJ>A>*/[2NC="X?RXO*W'Y64N2W;:/6OW C_ -6OTH =1110
M 4444 %?EU^U[_RM,?LO?]D_OO\ T1X@K]1:_+C]KY\?\'3G[+J^OP^OS_Y
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MEAXH#, 6U[X=@ GJ?^*I/]#7[ET %%%% !1110 4444 %%%% !1110 4444
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MRU^*UCH:Z;;_ !,;6+N74+:_,ZW#Z@%,?),X,FWJ>F:_H>HH _,?_@IIX_\
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M_&W]K? GQ!XE\8:EXE5XWLO%%O='4)TALV5VDGGO3<(KQF,>4P8'< F[R/\
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M^\5L=L'FOF*]_P"#7K]E?3;.:XN+GXIV]O;H9)99/&]RJ1J!DLQ/   R2>E
M'<I_P<G_ +$\K[5^.6E,WHNBZF3_ .D]6H_^#C+]C6497XR6[#U7P_JI_P#;
M:L?_ ()5_P#!-'X(:9^R?'>7?PQ\*>*M+UO7M4U+0+[Q5I%OJ^J-I,ET_P!C
M62XGC:1AY2J1DXVD8ZU](C_@G=\ 1_S0_P"$7_A(:?\ _&J /!9?^#C7]C6
M9D^,MJ@]6\/ZJ/\ VVJI)_P<J?L2Q;MWQRTI=O4?V+J>1^'V;-?0I_X)W?
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MR%".E4O /_!2G]DWX7>"-)\-^'_C7\']*T/0K2.QL;.W\0VB16T,:A410'P
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MZ]_X( /YO_!'?X#M_>\.(WYR.:F? >$E9^UGI_A_^1%+A^B_MR_#_(^$9O\
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M_F@+<,^"\?\ J\9YX_2BP_X-7_CAI-C#:VO[?WQ(M[6V010Q1^&[I4C11@*
M-7P !Q@5@_\ !SX\C?\ !3G]BN-!'M_MB&5RW4!=;TSI[_-7H7QM_P""^/[2
M&D?ML>//A/\ #?X$Z#XV7PWKNI:7IDEO#=RW%_'9SR1OD^<BF4(GF,B<A2QQ
MM0F@#D_^(9'XT'7O[+_X>)?$#^TQ#]H-I_8ESY_EYQOV?VQNVYXSC&:U(/\
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MU5\2>']6UR"_\+>*K[6GMC83Z?$T<L4C6^T/]O!#AS@Q$8YR/V4_X8$^!/\
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M .%CIW_QZ@#UZBO(?^'@WP#_ .BW_"'_ ,+'3O\ X]1_P\&^ ?\ T6_X0_\
MA8Z=_P#'J /Y]_\ @\(NI+;_ (*H^"5CC662Z\!V]HJL< &:>]BS^&[/X5_1
M5^RT<_LR?#G_ +%?3/\ TDBK\+_^#K[X6_!GX^3>"?CIX+^-?A?Q-XT@U+3/
M!I\.Z)K=A?K':,UY.UYB)VE#*Y1>?D&1W-?OA\,_!$?PS^&_A_PW#<37D/A_
M3;;38YY@!).L,2QAV P-Q"Y..,F@#<HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/)A>K<8ZU^R7[:W[ OPL_X*&?#W2/"OQ:\.'Q-H.AZHNLVEK]KEMU6Z6&6
M.3&RE@$GD&#QD@]0*^$OVR/^"!_['GP3^&=G9>&?@[IEQ\0_'FH)X9\'VD^J
M7C1R:C,CMY\B^9\T-M#'-=2CO';.H.YE!^N/9/SS_;Z_X+Q_!#]HO]EOXG^$
M?#L?BQM7\7?$34]=L?M&G"./[%/810QRLV[@F16!3[PQGO7WM_P1E_X+2_LN
M_L]?\$PO@WX-\9?&+PIX?\3:!H$=KJ&GW,CB6UD#,2K84C/->,?L^?\ !"?]
MFF;1O@S8:KX%&N3:MKWQ T?5;R?4)UDU./2KO4X+-WV. &5;>(_* "5Y!YKY
M\^+?_!*WX%^'=+OI++P3# UO^R#XF^):$7DY_P")_:7<207G+]55R-OW3W%
M'[$+_P '!/['+_=^/'@UOH\O_P 13Q_P< ?L>G_FNGA#KCK+_P#$5^(_Q/\
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MW_/'Q<KC_P &FB+_ %K]^J_ CQ1,(OA[_P $C5/_ "T\6*H_\&NAG^E?OO0
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M_"1ZL5/F"3@S XW#AB,XR.#B@#])J*** "BBB@ HHHH **** "BBB@ HHHH
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M?AGX8^&KK6?$GB+0_#^D6*[[B]U&^BM;> >K.[!1^)H _$G]J#_@V'M/V?\
M]G;QMXT;XH>%KJ;PYHUS>6ELOA75(WO;H1D6]NK'6F"M+,8XU)5@"XX/0_<?
M@3_@W,_9'7P1HXUCX4->:L+&'[;.OBO78EFFV+YC!!>X7+9.!TKU'^U[O_@H
M?\0] FT^QU*Q^!?A._BUA[^^MI+1O'E_"P>V6"&10YT^&0+,9F 6:1(_+W(I
M<_4% 'Q$?^#<G]C-NOP=?_PKM=_^3:8W_!N'^QBW7X-Y^OBW7?\ Y-K[@HH
M_!O_ (.0/^"0_P"SO^PS^Q'X/\:?"SX>_P#"+^);CXB:3I<EY_;NI7NZVDAN
MW=-EQ<2)RT:'(7(V\$9.?WDK\KO^#O/_ )1I^"/^RIZ+_P"D]]7ZHT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '#_M.?\ )MGQ"_[%G4O_ $EDK\>/^"9"A_VF;'//[QC_ .0)Z_8?
M]IW_ )-K^(7_ &+.I?\ I+)7Y._L!Z]HVM?M)Z,NE67V1HGE\X^2L>_,$V.A
MYZ'\Z_.>,I-8_#*W5?\ I2/F<[?^T4EZ?FC]%J***[CJ"BBB@ HHHH ****
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M^^FM'L[SP_K,GE,LQ01^>E_Y;E0/F<B-202!@XH ^JO^#C_X_>//A+_P4?\
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M>/A]!^^^&/POO(-0\9R@;H=>U==LUIH_HT4(*7-R.02;>(Y#2J+/[6V@7OP
M^(&G_'OPW:37*:#:C3O'>G6T9:35M"#%C=*B\M/9,6F7 W-$9D&3L%>I_L[?
M S2_V<?A%I7A/2Y+B[6R#S7E]<MON=5O)7,MQ=S-U:6:5GD9CU+&NU=%D0JR
MAE88((X(H JZ#KUEXIT.SU/3;JWOM/U&!+FUN8'$D5Q$ZAD=6'#*RD$$<$&O
MS$_:]/\ QU,?LO?]D_OO_1'B"OK;X 2']C[XZ2?!F\9H_ OB@W&K?#>=_N6(
M&9;W0L]O(),UN/\ GW9XP +8;OD+]L.XV?\ !U7^RO%_ST^'>I-^4.N_XT ?
MJ;1110 45\K_ /!2+]IW]HO]G?4_!T?P)^!MI\8+?5A=?VU)+J8M#IA0)Y0
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M4Z7_ ,-"?'R./4/MGAGX'^'[@"2WL9+ >(/$<B'D><Q=+2U?IE%%SP<%E.<
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M=W!_KK&=2'BGC_VXY%5Q[KB@#\[O^(9^T_Z+YXF_\(?P_P#_ "+2:;_P:Y>
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M,*B@8 'T%2444 %%%% 'GG[77_)J'Q/_ .Q2U7_TCEK\,O\ @W@_X+L?L_\
M_!/C_@GQ:_#?XD:IXDL_%$&O7U^\5II1GA$4K*4_>;@,X'([5^YG[7QQ^R9\
M4/\ L4=6_P#2.6OSW_X-2OA[H>K?\$M6DOM&TJ]F7QCJZ>9<6D<CX$B8&6!/
M% '37G_!US^R'81[I->\9;?]C0C(?R5R:AM?^#L?]C^[N8HEUWQPIE=4W2>&
MY$1,G&YF+ *HZDG@ $U^AO\ PJGPO_T+>@?^"^+_ .)K\L_^#O/P#HFB_P#!
M*FWFL-'TNQF7QAI_[RWM(XVQLF)&5 .* /TU\:?M"^%_!7PMTCQF]\-2\.Z]
MJ&D:=87>G%;E+E]3OK:QM74@X,9ENHB6!X7)YQ@^'_ /_@K[\)?VD/VIKWX1
M>&_[=?Q-87M_ILLDXLQ"+FS\PSQF);AKE!MC++(\"QL"H#[CMKR3]G3]K/X#
M_$__ ()O_#7P%XRU/7GLU\,:-YZ6>FZI;36MS:B">":&X@C5XY(IX8Y$DC8$
M-&I!KI/V0OVIOV2O@?X*DU3X9_VIIUIXJ*7US>2Z)JMS=W[A%C\V66:-Y&=M
MFYF+$LY9FRS$D ^7O^#EW_@J!X?L/V9KWX:?";XMZAHOQ.\.^/-*TKQ?I^BR
M7%G>06%S;WBO"TVQ1M9O+)\I]P*KR*^G3_P0&^#Y/_(]_M%#V_X6KK'_ ,=K
M^:;_ (+B_$G2_BK_ ,%9_C1XAT&YNIM+U#Q(!#))!+;,^R-%)V.%8<CC('KW
MK^P#]EQF;]F;X=%FDD8^&--)9V+,Q^RQ<DGDGW/)H ^:?!'_  0M^$WP_P#B
M/X5\46?B_P"-NH:AX1UNSUVS@UGQ_J&J6,D]M,LL8DMYW:-QN4=1D=00>:^T
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /%/^"B__ "91\0?^O!/_ $='7Y6?\$QSC]IFR_ZZ-_Z(GK]9
M?VZ_"UQXQ_9 ^(5C:M&LW]D2W.9#A=L.)F_$K&0/?%?E]^P+KVCZW^TEHRZ3
M9?9&BDD\X^2L>_\ <38Z'GH?SK\YXRDUC\,K=5_Z4CYG.W_M%+Y?FC]%J***
M[CJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\J_
M@%_I_P"VO<-)R)?$!W#UW7Z9K]OOB-\.]%^+?@35O#/B+3[?5=#UNV>TO+6=
M=R31L,$?7N".00".17X;SVBW_BOQ$W@=+F\\;71N!8PVUR89I+QG/E*CN"J,
M9M@#8(4D'I7$_P#"K_\ @J 3_P BI\=A[GXG6'_R/7+P%+F5>7G'\F<_#SNJ
MC\U^I^TO[!_BS6%\!>(O 7B*^N-4USX5ZW-X;-_<-NGU&S55DLIY#W=K>1%8
MGEF0L22<U[G7XE?L4^-_^"BG['DOC2YD_9TOOB%J7CB_M[^\O_%?C&.ZNX6@
MMUMU17B5 5VH.HXKW&?_ (*+?\%&HQ^[_8Q\(R^W_"4E?YM7Z$?2'ZB45\B?
M\$R_VK?VFOVC/%7C:R_: ^ =G\&;/0X;5M%N;?5!?+K$DC2B900QP$"1GM]^
MOKN@ HJOK$]Q:Z1=26D*W%U'"[0Q,VT2N 2JD]LG S7YP0?M\_\ !0^>/=_P
MQEX'CR3\K^/5##!Q_<H ^G?ACHJ?M(_MG^-O&6L*+K0_@[?+X2\*6C_-#'J+
M6D-SJ.HXZ&3;<PVJ-UC\BY _UE?15?@?JO[/7_!1Z;QUXNUG2/ 7C[PM!XN\
M0ZAXBETS1OBG:V]E:2W<[3,D:&V8[5W!1DDX45XK^V-\</V[?V$?#.F^(?BE
M)\9/!_A?4KZ/3(M6?XEV]U;&ZDCFE6+]W:%MQ2"0XVXX'/- ']+5%?E7_P &
MNW[<?Q0_;)^'WQEM?B/XVU/QM#X)U?3[31YK\1/-:Q31W,CH9D1&FZ(-[Y)V
M\8'%?JI0!4U[7;/POH5[J>H7$=K8:= ]U<SR'"PQ(I9V/L%!/X5\SWW_  5O
M^&=I=R1QZ7XSND1L++%96X20>HW3AL?4 U[7^TW_ ,FV_$+_ +%K4O\ TEDK
M\1?!'P7_ .&AOVK;7P?_ &E_8_\ ;&__ $O[/]H\KR[-ION;ESGR\?>&,YYQ
MBOB^)LZQN%Q-+#X1I<R;U5];I);H\/-,=7I584J-M5V\['Z/?&#_ (*"? ?X
M_>%CHOC+P'XD\1:;NWI'=Z;:,T#_ -^-_M&Z-_\ :0@^]?)?[5/Q<UFSUOX;
MW7[.WQ*^,?A&UT7Q1:WGBC3/$OB2:ZL;[1T=3+:V\;//M9@& 4E%YQN&:WM7
M_P"":K?L_P#@76=6A\<+JMY,(8+.V;1?*%Q<O((H8L_:#]^21%SVSGFG2_\
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MX*H?"FX0-'-XDD5NA71YB#^E*W_!4SX5H/FD\3#ZZ--_A74?L0>&--O/V2O
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M!RI(/W !@4V.19HU965E895@<@CU%.H **** "BBB@ K\I?VSI_*_P"#L?\
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MLNKF,+92(LBQ^7:+#S*&&<[-WW.^/>OVN_9E&/V;OA[_ -BUIW_I+'7Y>_\
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M@>91N:'XG::X'J1I^I&OUNK\B_\ @\^;9_P2S\&M_=^)>GG_ ,IVIT >3_\
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M  <I2NG[*?P66-C&9/CCX44D#I^\N/\ "OT1C_U:_2OSM_X.4_\ DU?X)?\
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MNCQV>GS6\^[<XU.+>,GW 'Z5S_\ PY%^)'_/K#_X-;?_  I1Q6;:\V&E_P"
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M/^"Q'[7<OQ@_X2C5G^'][HFDZ'_9^MW&FBTM6L@YBQ"R[AN)/S9ZF@#]:?\
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M;FQO+7PWIT-Q;7$9CFMY%M8PR.IY5E((([$&@#MJ*** "BBB@ HHHH ****
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M;-_N7JC/_?6*U?\ @GM_R6?4_P#L"R_^C[>OL:OQ_)<BPV+POM:M[W>S_P"
M?&X'+Z5:ESSO<^ _&W[,'C;X>^'KK5M4TA(=.LPIFF6[A<)E@H^4/N.21T'>
MO8?^"2?_ "<UJ7_8O7'_ */MZ]1_:_\ ^3<O$O\ N0?^E$5>7?\ !)/_ ).:
MU+_L7KC_ -'V]=&%RZE@L\PU.DVTVGKZM=EV+IX6%#'TH0OT>OS/T?HHHK]L
M/N@HHHH **** "BBB@ HHHH **** /S7_P"#JM_+_P""7,)/_0ZZ0/S,PK]$
MO 7_ "(VB_\ 7A!_Z+6OSE_X.OMQ_P""6=F%X+>/M"7\Y9!7Z-> 3GP+HO\
MUX0?^BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\[/^#E.
M1U_93^"RH[1F3XX^%%)'4?O+C_"OT1C_ -6OTK\[?^#E/_DU?X)?]ES\)_\
MHRXK]$H_]6OTH =1110 4444 %?EC^V'9B7_ (.K/V5[C^*'X=ZD@_X%!KO_
M ,37ZG5^6O[8-T$_X.I/V68?XI/AYJ#@?[L&O?\ Q5 'ZE4444 ?F5_P6_\
M#NLZS_P49_8).EZ3>:D&^(5RK>04RJI'#-(<,PX2*-Y#_LHV,G /Z:U\)_\
M!6;4+WP5^V9^QMXT;P[XLUCPWX-\9:S=ZY=Z+HMSJG]EPRZ1+;I)*D".ZJ9)
M5&<= WIBOJ[X)?M0> ?VBXKS_A#O$MEJUUIN/MM@Z26NH6&20#/:S*D\0.#@
MNB@X.,T =]1110 5^7__  =LVWVS_@E_H,?K\1=&/Y1W1_I7Z@5^9/\ P=@?
M\HSM S_T4+2O_2>\H _2S03G0[/_ *X)_P"@BK55- _Y 5E_UP3_ -!%6Z "
MBBB@ HHHH **** /PQ_X.E9F3PWXR78[A_&OP_7(Z)_HFOG)]N,<=R*_<ZOP
MT_X.C_\ D6?&_P#V.?P__P#2;7J_<N@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ^ _V._^"QT?C,?!;P)XJ\-^--4\
M9>/+.%+W6KK3%TJ"[GDEGC\ZSAD$9OH$\@M--:JT<*21,20QQ]^5\JZ'_P $
MEO"?A2?PVVC_ !)^-&E1^#8;FVT&*V\3*J:1#<;?-BB!A.$(51@YP%%>P?$O
M]G*3XD>%=!TM?B!\2/#QT&(1&\T?6%MKK4L(%W7+F-O,8XW9 '))H ]*HKS/
MX,_LW2?!W5+^Z?XA?$KQ9]NM_LXA\0ZPMY%;<@[XP(UVOQC//&:Y&Y_84FN;
MF23_ (77\>(_,<OL3Q/&%3)S@#R.@Z"@#WJBO-?BW^SC)\5[+184^('Q(\+_
M -BP& R:%K"VKW^0@WW!,;;W&W(/'+-ZTOP;_9SD^#\NJ,_Q ^)'BS^U(%A
M\0:NMX+/&?GAQ&NUCGD\]!0!Z317@/\ PP9/MQ_PN[X^?^%1'_\ &*[7XR?L
MYR?&";2V3X@?$CPG_9<!@*^']76S6\SCYYLQMN88Z\=30!Z317FOPF_9PD^%
M5CK4+?$#XD^)_P"VH! )-=UA;I[#AAOMR(UV/\V<G/*KZ5Q]M^PI-;W4<G_"
MZ_CQ)Y;A]C^)XRKX.<$>1T/0^U 'O5%>9_&;]FZ3XPZK8W2?$+XE>$_L-O\
M9S#X>UA;.*YY)\R0&-MS\XSQP!3OAG^SE)\-_"VO:6WQ ^)'B%M=B\H7FLZN
MMS=:;\K+NMW$:B-N<Y(/(!H ]*HKP6Q_85FLKN&4_&KX\3>2ZOLD\3QE9,'.
M&'D<@]#76?&?]FB3XQ^)8-23XB?$WPD(8!#]D\.ZRMG;2<D[V0QMEN<9ST%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5X?_P4?_Y,P\9?]N7_ *76]>X5X?\ \%'_ /DS#QE_VY?^
MEUO7EYY_R+<1_@G_ .DLY,P_W6I_A?Y,^)?^">W_ "6?4_\ L"R_^C[>OL:O
MCG_@GM_R6?4_^P++_P"C[>OL:OSGA?\ W%>K/F\I_P!W^;/-?VO_ /DW+Q+_
M +D'_I1%7A__  3?^*GAOX,_&S6M>\6:YI?AW1[7P]<"2[O[A88P?.MR%!8_
M,QP<*,D]@:]P_:__ .3<O$O^Y!_Z415XW_P2Y\&:/XT_:5FCUC2]/U6/3]'F
MO+9+NW298)UF@595# @. S ,.1DU%;_DH,+\OSD14_Y&-+Y?FSZH_9_M]4_:
MA_: ;XS:KIM]H_A/0=-GT/P#8WT!@NKJ&X>-[S598V&Z/S_)@CB1@&6*)F('
MG%1]%445^NGV04444 %%%% !1110 4444 %%%% 'YK_\'5D?F_\ !+F$>GC7
M2#^1F-?HEX"_Y$;1?^O"#_T6M?G9_P '5\OD_P#!+B$GOXVT=?S,H_K7Z)^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO<RW?_!4O3;.%49YO UL[EOX4CE><D>^(2/QK^CO]EO_ )-E^'/_ &+&F?\
MI)%7\VW_  =\SJO_  5U\.*T_D1R>$-/AF<-C:CRSJV?JI/X&OZ1_P!E69;C
M]E_X;R(RNC^%M,964Y# VD7(- '>T444 %%%% !1110 4444 %%%% !1110
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M\_X.N5S=:UQTG^&Q'M_I?C2OW*H **** "BBB@ HHHH **** "BBB@ HHHH
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MF\^)VAZYXN_X/#;K3_#]OX9NM4.K3"WB\06KW.G-_P 221F\Q$^8\9QCHV*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 ?AG_P=>W"0WFL*S!6EN?ANJ#^\?M7C4X_($_A7[F5_/\
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MO+;SO^B.XHHHKZP]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?;=_$2/^\FG-^1NO\:^>P6G$]+S3_P#2)'ET=,UCZ?HS[DHHHK]9/L HHHH
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M !Q$.?"?B#\+&1OY"H_^%"^-O^A2\1?^"^7_ .)H_P!?L1UPC_\  G_\@/\
MUBJ_\^7][_R/V.34+>5PJS0LS= '!)J:OQK;X$>-D7/_  B/B3CTTZ4_^RU'
M_P *2\:?]"CXH_\ !5/_ /$T?\1 K]<(_P#P)_\ R ?ZQ5/^?+^__@'[,45^
M,_\ PI+QI_T*/BC_ ,%4_P#\32_\*N\;1?+_ ,([XI7;QC[!.,?^.T_^(@U>
MN$?_ ($__D _UCGUHO[_ /@'[+T5^-'_  K+QM_T+WBG_P  )_\ XFE'@7QO
M9?*-&\50YYQ]DG7/Z4_^(A5.N%?_ (%_]J'^LDO^?3^__@'[+45^-+>$_&ZK
MDZ;XJ '))MY^/TJCX?D\3:_:O=:4VN7L,<AA>:T,LBHXZJ67(!'<=:/^(A2_
MZ!7_ .!?_:A_K(_^?3^__@'[245^-?V'QU_SQ\6?]\7%'V/QTO/D^+/^^;BC
M_B(G_4,__ O_ +4/]9/^G3^__@'[*45^-O\ :7CS_GX\7?\ ?=Q1_:7CS_GX
M\7?]]W%/_B(B_P"@:7W_ / #_65?\^G]_P#P#]DJ,XK\;AXI\?6H\L:EXOCV
M_P /VBX7'X9JKK&J>,/$5G]GU"X\2WUON#^5<23RIN'0X;(R/6C_ (B+#_H'
ME]__   _UEC_ ,^W]_\ P#ZE\"G_ (J?X8_]G2>+_P#TW^)Z]Z_X)UG_ (LY
MXJ_[*!XG_P#3M<U^7K^ 9+=H6;16C,-RUY$39XV3L&#2KQPY#N"PY(=N>35S
MPWIVI>#;M;C1[>^TJ>.1YEDLT:!U=R2S@K@[F)))ZG-/_B(U+K0E]Z_R'_K-
M#_GV_O/VRKX?_P""RW_--_\ N)_^V=?*(^*_Q MSO_X23QE'MYW?VA<C'X[J
MR?%/C+Q)XY%O_;>JZYK'V7=Y'VZYEN/)W8W;=Y.W.U<XZ[1Z5Y&>\:4\?@9X
M2-)Q<K:W[-/MY''F&>1Q%"5%0:O;\&F?57_!/;_DC&I_]AJ7_P!$6]>[5\(_
M![]G3XI_%3PS/J'@SXDW'@K2X;IK>6Q D_>S!$8R\>JLB_\  *TOA;:_%3X&
M_MZ>!?!7BWXD:EXLT_7=-NK^6+<PA8+#<!58,,Y#1ALC';WKT\E_W&EZ'9@?
M]WAZ'VY1117J'6<Q\3/@OX4^,MK:0^*M!TW7H;%VDMUNXO,$+, "1]0!7R=_
MP4#_ &=_!/PP@^%\WAWPWINBSWGC"UMYI+5"C/'M8[<YZ9 /X5]L5\M?\%/O
M^0?\)O\ L=[3_P! >@#ZEHHHH **** "BBB@ HHHH **** "BBB@#X2_;*_Y
M.2\2?]NO_I+#7Z<_LR?\FV_#W_L6M-_])8Z_,;]LK_DY+Q)_VZ_^DL-?8OP=
M_9N^(GAKX)>$?$GPU^+&MV]]?:)97K^&_%J)JWA^9GMT<Q1L%6[M5).U2DKI
M&O2$XQ7D<%_\C7%^K_\ 2F<.1_[W6^?YGU917EO[-?[2J_&]=:T/6M'N/"/Q
M!\(2)!XA\.W,@D>T,FXQ7$,@XGM9@K&.5>#M92%=&4>I5^GGU04444 %%%%
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MOY&OFW_@EH,?!#Q%_P!C/?\ _H8KZ2U+_D'7'_7-OY&OFW_@EO\ \D2\1_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X?_P %'_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_DS+X?_ /8-_P#:CU[)7CO_  3]0Q?L;> 5/5=.(/X2O7L5 !1110 4444
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MZC_AC;XB_P#1V/[0'_@H\$?_ #/4 ?0%%?/_ /PQM\1?^CL?V@/_  4>"/\
MYGJ/^&-OB+_T=C^T!_X*/!'_ ,SU 'T!17S_ /\ #&WQ%_Z.Q_: _P#!1X(_
M^9ZC_AC;XB_]'8_M ?\ @H\$?_,]0!] 45\__P##&WQ%_P"CL?V@/_!1X(_^
M9ZC_ (8V^(O_ $=C^T!_X*/!'_S/4 ?0%%?/_P#PQM\1?^CL?V@/_!1X(_\
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MB]20KE<X:'T^I'T)'>OJ6OE[_@H'M_X7)\!=W_0U?+]=]O\ _7KZAH ****
M"OF/_@K7)Y7[(\S?]1:V'YB05].5\N_\%>O^3/IO^PQ9_P WH ^G--_Y!UO_
M -<U_D*FJ'3O^0?!_P!<U_E4U !1110 4444 %%%% 'PE^V5_P G)>)/^W7_
M -)8:_3G]F3_ )-M^'O_ &+6F_\ I+'7YC?ME?\ )R7B3_MU_P#26&OTY_9D
M_P"3;?A[_P!BUIO_ *2QUY'!?_(UQ?J__2F<.1_[W6^?YG<4445^GGU04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?$_]H/P#\$=4T"Q\:>./"'A&]\5W?V#1+?6M9M]/EUBYRJ^3;+*ZF:3+H-B
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M?4_^P++_ .C[>OL:OSGA?_<5ZL^;RG_=_FS#^)O/PV\0?]@RY_\ 135\I_\
M!/C]E+X;_%?]F#1]<\0>#=%U74[NYNO,N+B+=(ZB9@H)SV&!7V)=VD5_:R03
MQQS0S(8Y(W4,LBD8((/!!'&#5'PGX.TGP'HD>FZ)IEAI&GQ,S);6<"PQ*6.2
M0J@#)/-?1'IGFO\ PP9\'?\ HGOAS_OP?\:/^&"_@Z?^:>^'?^_!_P :]<HH
M \C_ .&"_@[_ -$]\._]^3_C1_PP=\'A_P T^\/_ /?H_P"->N44 >2_\,(_
M!_\ Z)_X?_[]-_C1_P ,(?!__HG_ (?_ ._3?XUZU10!Y&?V#?@\?^:?>'OQ
MA/\ C1_PP5\'?^B>^'?^_)_QKURB@#R/_A@OX.C_ )I[X<_[\'_&C_A@SX._
M]$]\.?\ ?@_XUZY10!Y'_P ,&?!W_HGOAS_OP?\ &C_A@SX._P#1/?#G_?@_
MXUZY10!\4_\ !1G]E[X>_!_]GE-8\,^$='T;4EU>UA^TV\15UC8MOYSTP,GZ
M5[U^PE.ES^RKX6DC99(Y#=NC*<JRF\G((/H17=_$SX4^'?C'X<72/$VEV^L:
M:LZ7(@F+!1(F=K?*0>,G\ZO^$?".F^ O#5GH^CV<=CIFGQ^5;V\>=L2]<#//
M>@#@=0US2_A%^T*L=QJ%CI>G>.M/FNI$N)UAC-]:F)=Z[B!NDAD^;'_/NI]3
M72:[\>O _A>W274O&7A73XY&V(]QJL$:L>N 2U7/'/PH\,_$Y[)O$GA_2->_
MLYF>V74+5+A(BPPQ"N".1[5Q_C']BKX3>.M+6SO_ (?>%XX4D$H-E9+8R;@"
M.7@V.1R?E)P>..!0!H?\-7_"[_HHW@7_ ,'MK_\ %UP/[5/[2OPZ\1_LS^/]
M/T_QYX.OKZ]\/WT%O;V^LV\DL\C0.%15#DLQ)  ')-6D_P"":?P1C;<O@6W5
MO4:E>#_VM7$_&;_@DK\/_B%)8_\ ".W%WX-2W5UN$A,MZMT6QM)\Z4[2N&Z=
M=WM0!Z1_P3]5D_8U\ JP9673B"".0?->NR_:"Q_PHSQ?N&5_L>ZR/7]TU.^!
M'PHB^!GPBT/PG!>R:C#H=N8%N9(Q&THW,V2H) ^]C\*UOB#X3_X3SP+K&B&X
M:U&K6<MH9@F\Q;U*[L9&<9Z9H ^6?V&/V,_AA\2/V7/"NM:YX-TO4M4OX7DG
MN)M^^0[V S@XZ 5ZU_P[[^#/_1/]#_)__BJZ[]GCX-Q_ #X/Z/X2CU"35(]'
MC,:W+PB%I 6)^Z"<=?6NVH \;_X=]_!G_HG^A_D__P 51_P[[^#/_1/]#_)_
M_BJ]DHH \;_X=]_!G_HG^A_D_P#\51_P[[^#/_1/]#_)_P#XJO9** /&_P#A
MWW\&?^B?Z'^3_P#Q5'_#OOX,_P#1/]#_ "?_ .*KV2B@#QO_ (=]_!G_ *)_
MH?Y/_P#%4?\ #OOX,_\ 1/\ 0_R?_P"*KV2B@#Y"_82\#Z5\.OVS_CGH^BV<
M.GZ78O9Q6]M%G; OSG SSU)KZ]KR[X3?LS0_"OX[^/O'$>L37LGCIX7DLVMP
MBV?EYZ/N.[.?05ZC0!\2_L^?L\^#/CC^V)\>CXLT&QU[[#J\)MEN,_Z.7>X#
M8P1UV+^5>[?\.^_@S_T3_0_R?_XJM+X+?LRP_!OXP_$+Q='K$VH2>/[N*ZDM
M7MQ&MD4,AP&#'=GS.X'2O4J /&_^'??P9_Z)_H?Y/_\ %4?\.^_@S_T3_0_R
M?_XJO9** /&_^'??P9_Z)_H?Y/\ _%5XC?\ P6\+?!#_ (*D?"_3_"FBVFB6
M5UH%Y<316^=LDGE7:[CDGG"@?A7VE7E_B_\ 9GM_%O[4GA7XG-J\T%QX7TZ;
M3UT\6X9+@2"8;B^<KCSCQ@_=H ]0HHHH \%_;=_9M\7?'N]\"W_@[4M'TS4_
M!^HR:BLNH;RH?";" JMNPR<@\5RW_"M_VK/^A^^'_P#X '_XU7U'10!\M_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?\
M_@K%_P HLOVEO^R5>*/_ $T75?0%?/\ _P %8O\ E%E^TM_V2KQ1_P"FBZH
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M7?'OE4.I9 R%@70$L/S>^%7Q^^-_[,_[0G@GX;_M)_"SP/I7QN\&^"?$%O\
M!_XL>&+0W?AGQ1;66C>?<6%]:HT$JX6UDF*H]K\RQA((E.^7]7/B+\$_"_Q>
M^%%UX'\5:3%XC\*ZA;QVEYI^I2R727T2%6"3L[%I@2B[O,+;^0VX,<^+^,?^
M"<'@CPIX4\6:MX#\/R:C\0+KPSJ6@^&Y?%GC#5]1L-!6[A,;067VI[M=+MVQ
M&K+90*/+C1-A5%4 'R/^R3_P65^.'C'PS^R#XV^)&C_"V\\'_M4:K?>''T[P
MSI%_9ZCX9O8G=+:X^T3WDZ7$,IB<O'Y,9B!&)9-I)Z+X-_\ !7GXG-_P5/\
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MZ='_ ,%#_$@/SZ'H;?0RC_V8T?ZS8#^9_<P_M;#]W]Q]=45\D_\ #Q'Q!_T
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M .![?_$4?\/&;W_H5;7_ ,#V_P#B*?\ K)E_\_X/_(/[4PW\WX,^J**^5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)R1X_NZM><_G*:C_ .':?P<_Z%BX_P#!K=__ !RO>**G^P<M_P"@>'_@$?\
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M8G/^G>+AD_\ /]#Q_P"0:;_PZ4^&/_00\8?^!T'_ ,9KZ@HI?ZOY9_T#P_\
M 5_D']FX7_GW'[D?-.D?\$I?A9IL[-,WB;4%9<!+C4%55/J/+13GZDBM#_AU
M]\(_^@7JW_@SE_QKZ&HH_P!7LL_Z!X?^ H7]FX7_ )]Q^Y'SS_PZ^^$?_0+U
M;_P9R_XT?\.OOA'_ - O5O\ P9R_XU]#44?ZO99_T#P_\!0?V;A?^?<?N1\\
M_P##K[X1_P#0+U;_ ,&<O^-0_P##K/X3_P#/IKG_ (,6_P *^C**7^KN6?\
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M_AT[^RS_ -&T_L__ /AO-(_^1Z^@** /G_\ X=._LL_]&T_L_P#_ (;S2/\
MY'H_X=._LL_]&T_L_P#_ (;S2/\ Y'KZ HH ^?\ _AT[^RS_ -&T_L__ /AO
M-(_^1Z/^'3O[+/\ T;3^S_\ ^&\TC_Y'KZ HH ^?_P#AT[^RS_T;3^S_ /\
MAO-(_P#D>C_AT[^RS_T;3^S_ /\ AO-(_P#D>OH"B@#Y_P#^'3O[+/\ T;3^
MS_\ ^&\TC_Y'H_X=._LL_P#1M/[/_P#X;S2/_D>OH"B@#Y__ .'3O[+/_1M/
M[/\ _P"&\TC_ .1Z/^'3O[+/_1M/[/\ _P"&\TC_ .1Z^@** /G_ /X=._LL
M_P#1M/[/_P#X;S2/_D>C_AT[^RS_ -&T_L__ /AO-(_^1Z^@** /G_\ X=._
MLL_]&T_L_P#_ (;S2/\ Y'H_X=._LL_]&T_L_P#_ (;S2/\ Y'KZ HH ^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT.XGM;>UNI;)RT%R@2".-#'%(+<[B"V;K&<8P ?LA17Y _!K_@I7\;/VP/\
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MX*)^)/VROVJ-#M;7QII N-2TCPRD\'VO5]0CLQ#:A1 [1001QA$0%BQ*#<,
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M\+_A^=2@N]4DB:+3;%V5B$FN"]Q-<3)%N+>5"#E@K%"RJ1[AHG_!.CXV0_\
M!USKGQND^'^L)\*;F:.XB\2&2'[(Z#1+>W./GWY\Y&3&W.1Z<U^TU 'Y1_\
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M@5\*O$7PI\*W_C#QAX'UNZL;G3+$1+-)87L*LTQ9V7*Q2VL2A02?])8XP":
M/._^#.?X*ZMXO\$?'+]HKQ1YEQX@^)WB-K%;T2*J711VN;IO+ ^4F><<].,#
MI7Q3_P %A/\ @I#\.?BI_P '%=CKWQ-M=9\2?!GX ZA#X=;2=+TZ*\EU.2R+
MRW4;07$T<+B2_:2)GW#=#%&<,0 ?VP_88_9M\:?\$T_^")NA^$?#/AEM8^*W
MAOP;<ZBNE6D$7F76NW"/,L3@N$<QRR)&YWX*Q'!/%?(O_!M'_P $7-4^"OPK
M^*7C;]I7X6Z/-XX\;:['!8Z;XITNTU*:TM($,CW*%O,"^?-<.I!PW^BJ>A%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_H6=0_\  J#_ .*H ]"HKSW_ (7I<?\ 0LZA_P"!4'_Q5'_"]+C_ *%G4/\
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M+C_H6=0_\"H/_BJ /0J*\]_X7I<?]"SJ'_@5!_\ %4?\+TN/^A9U#_P*@_\
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M_H6=0_\  J#_ .*H ]"HKSW_ (7I<?\ 0LZA_P"!4'_Q5'_"]+C_ *%G4/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex101170630image3a02.jpg
<TEXT>
begin 644 ex101170630image3a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" -A
M!(T# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"
M! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5
M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F
M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
M  (1 Q$ /P#]_**** "BBB@#C/VB/'^H?"SX&^*O$6EK:MJ6CZ=+<6HN4:2'
MS /E+JK*64'!(#*2.,CK7P&/^"L?QBQ_JOA]_P""6Z_^2Z^X?VSO^35O'G_8
M(F_E7Y>_ /X>6?Q6^+.DZ!?37-O:W_G;Y("!(NR&208W CJH[=*_/^,,XS#"
M8JC0P4^7G7:+UO9;IGSN=8W$T:T*="5N;R7?S1ZS8?\ !5SXU03SM<-\.[B-
MY-T2KH%TGE+_ '2?MAW?7BN__P"'Q'B#_H2]'_\  R3_  J%/^">O@\-\VK>
M)&'M-"/_ &E4G_#O?P7_ -!/Q1_X$P?_ !FO&^N<3_\ /U?=#_Y$XO;9K_.O
MNC_D._X?$>(/^A+T?_P-D_PH_P"'Q'B#_H2]'_\  R3_  IO_#O?P7_T$_%'
M_@3!_P#&:/\ AWOX+_Z"?BC_ ,"8/_C-'USB?_GZONA_\B'MLU_G7W1_R'?\
M/B/$'_0EZ/\ ^!LG^%'_  ^(\0?]"7H__@9)_A3?^'>_@O\ Z"?BC_P)@_\
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M]!/Q1_X$P?\ QFCZYQ/_ ,_5]T/_ )$/;9K_ #K[H_Y#O^'Q'B#_ *$O1_\
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M_P#GZONA_P#(A[;-?YU]T?\ (=_P^(\0?]"7H_\ X&2?X4?\/B/$'_0EZ/\
M^!LG^%>+_LX_L_:/\7_C#\3/#^IW6IP67@S4DL[%[61%EE0[N9"R,"?E'W0H
M]J]F_P"'>_@O_H)^*/\ P)@_^,T?7.)_^?J^Z'_R(>VS7^=?='_(=_P^(\0?
M]"7H_P#X&2?X4?\ #XCQ!_T)>C_^!LG^%-_X=[^"_P#H)^*/_ F#_P",T?\
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M[FECDWX09 " KC&#G.:/KG$__/U?=#_Y$/;9K_.ONC_D>K?\/B/$'_0EZ/\
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M_P"!,'_QFC_AWOX+_P"@GXH_\"8/_C-'USB?_GZONA_\B'MLU_G7W1_R'?\
M#XCQ!_T)>C_^!LG^%'_#XCQ!_P!"7H__ (&2?X4W_AWOX+_Z"?BC_P "8/\
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M+-5^%.L^+O#5]J?C'7=2^V&VDECTO2;R2SL+'Y20F4(>=AW>0X)Z*HP*\?\
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MQ#8ZKXNAM]+TS2YUNK#0H)1-F=3E)KF0<.R'E47Y5;#$D@8Y_P !^--+U/\
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MOCRPMP! .(VB0E?H<GBNX^"'P#\%ZE8^)OM'AG2)?)\2:A$FZ ':BRX 'L*
M.Y\=+HWAWX-:YI^FC2[&RMM(N8X+:VV111+Y3\*BX 'L!6I\*SGX8^'/^P7;
M?^BEK'D_9N\!RQLK>$]$96&"#;#!%=E96<.G6<-O;QI#! @CCC085% P !Z
M4 ?,/PU'_&T7QZ?^I=MA_P"@5]15\N_#5O\ C:1X]7_J7+8_^@5]14 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\FX:U_V-%[_ .@Q5]24 %%%% !1110 4444 %%%% !1110!\L_\% /^2\_
M+_L:/ZQ5]35\L_\ !0#GX]_ '_L9S_.*OJ:@ KY]_P""HTWV?]B+Q=(.L<VG
ML/POK>OH*OGO_@J=_P F->,O^NEA_P"ET% 'K7P,X^"7@[_L!V7_ *(2NJKX
MQ^&W@?\ :RG^'7A^32?&7P[ATI]-MFLXY8/WD<)B78K?Z,?F"X!Y//<UM?\
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M&_MQ7OU>!_\ !3NRNK[]B;Q@MG#-<31M92[8D+L%2\@9FP.P ))[ $T >I?
MO_DB7@[_ + =E_Z(2NJKF?@K:3:?\'/"5O<0S6UQ#HUG'+#,A22)A @*LIY#
M \$'D$5TU !1110!C_$3_DG^N_\ 8/N/_1;5X?\ \$M4\K]CG15_NZAJ _\
M)N6O;_B+_P D^U[_ +!UQ_Z+:O%/^"7_ /R:%I/_ &$M1_\ 2N6@#Z$HHHH
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M%% !1110 5'=?\>TG^Z?Y5)4=U_Q[2?[I_E0!\S_ /!*(_\ &.VK?]C#<_\
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M/_D4Q_Q2_,Z>'_\ <UZL****^R/;"BBB@ HHHH **** "BBB@ HHHH ****
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MQL=O."1SQ7Z'?LM?&J;]HCX$:#XPGL8]-EUA9BUM'(9%C\N>2+AB!G.S/XT
M>@4444 >)_\ !1C_ ),J\??]>4?_ */BKLOV8?\ DW+P+_V K/\ ]$K7&_\
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M=,#(Y^\*],HH \RU#XS^++3^UO+^']W/]@U:.PML7<H^V0,SAKD?Z.<!0JG
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MYM7N/[9:)IVO[@3,/+!"A<*N.#[]!7C/Q;_Y2^_"S_L7+K_T1?U]<4 %%%%
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MN(U8!@/0G\Z^F?@U\(](^!/PWTWPKH*W"Z3I8D$ GD\R0;Y&D.6P,_,Y_"O
M_P!OJ+S?CU\!?]GQ*6_\>A_QKZDH **** /$_P#@HQ_R95X^_P"O*/\ ]'Q5
MV7[,/_)N7@7_ + 5G_Z)6N-_X*,G_C"KQ]_UY1_^CXJY7X!?MW_"+PK\#_".
MF:AXXTJUOM/TBUM[B%DEW12+$H93\G8@B@#Z6HKQ?_AX=\%_^B@:/_W[F_\
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M)_M[_P#)#(_^PG#_ .@R5P9I_N=7_"_R.?&?P)^C_(Q?^"0'_);O$W_8#/\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[41_XQJ^(/\
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M **** "BBB@ HHHH **** "BBB@#S+]LW_DU;QY_V")OY5^;?[&O_)R7AO\
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M7P5'_,T3_P#@OG_^)IR_\%1O@P_W?$MTWTTVX_\ B* /H2BOGT?\%/O@V?\
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MQ;^S=XBT_P '2:1+XFF%N; 0VTJNK"XB+D%A@?NP_P"&: /KS]D'_DV'P/\
M]@F'^5>D5YG^QM,+C]ECP'(O1M'A/(]J],H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O*OVT?C5JW[/G[/>L>*=%CLY=0L)(51;E"\9#R!3D CU]:
M]5KY]_X*@IYG[&WB1?6:V_\ 1RT 5=+NOVG-6TRVNHV^$?EW42S*#+=@@, 1
MG]UUYJP(/VGB?O?"/_O_ '?_ ,:KW#P/_P B7H__ %Y0_P#HM:U* /C+5OC[
M^U7H_BJST>3X>^&GO=06=[4)>6^VX2$H'<$S\#]XA^;!.[IP<9FC?M4?M0>(
M!HWV/X?^')O^$@BDFL/])@7STC&6/,XVX_VL9KZ@\;?\G%^ ?^P;J_\ [9UP
M?P8^Y\&_^P9?_P#H H YRZ\9?M)Z%X-&N:]-\'/"]G'&LER=5OIH199(4"20
M Q Y('#D9(&:YK_AJ/XI?]%+_9C_ /"E/^%?2WQX\$3?$;X0:]I%O##<7EQ;
M>;:PS >7+/$PEB5L\;3(B@Y[$UG_  ^\'> _B)X.L-8L?"OAWR;R/)1]*A62
M!QP\;KM^5T8%6!Z$$4 ?&/Q0^*_BKXB_M#?!M?$OBKX5Z_';>(D,"^$=4^V2
M0DO'GS@?NJ>,>I!K]#*Q]!^'N@>%KQKC2]#T?3;AEV&6ULXX7*^F5 ./:MB@
M HHKC?CY\,-1^,7PPOO#^D^)]4\'WUX\3)JNGEA<0!)%<A=KH?F *G##@]^E
M '945\*_M+?LC_$#X"? K7_%L7QY^(6I2:% LP@-W=Q>?F14P6^U,!][/"]J
M^LOV9=0OM5_9V\#W6IW4E]J-QH=I)<W$DC2/-(85+,6;EB3SD\F@#N**** "
MBBB@ HHHH **** "BBB@ KQ7]O;_ )(6O_82A_\ 07KVJO$_V^&(^!D>!UU.
M'//3Y9*X,T_W.K_A?Y'/C/X$_1_D8O\ P2 _Y+=XF_[ 9_\ 1\5?H57YZ_\
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M^-/A]I?AV;P3\/Y/B%<ZEK]GIVJVZZW;Z5_8VG2,PN-1W3<3>2H!\A/GD+
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M %%%% !7B7_!1O\ Y,H\??\ 7G%_Z415[;7BW_!1!/,_8S\<K_>MH!_Y,PT
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MG>S<@[5.!QCI77K_ ,$_?@V#_P B#H?XHW^->PP0):P)'&JQQQJ%55&%4#@
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M $&2N#-/]SJ_X7^1SXS^!/T?Y&+_ ,$@/^2W>)O^P&?_ $?%7Z%5^>O_  2
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MOC%X3\:>/-<^'7C'4;7Q+JL?A*XU?Q(/#SLQT^75+6S2XN?,:WB4R(PD=6D
MF)G9]WB_AK]G?Q=X;_8%^"NDR?!'XK6/B;P1^T__ ,)5-8Q?#75I+S1O#H+R
M32IY5JW^CG_1?EB+"1HE"AC%\O[\45NL0^W]?TR_:GXVM^Q?\1O 6N_\%!K/
MX9_"K7O#/Q0\3W_VSP%XIL]"%CYVF2F&6ZM[#4R$!DN%+YC@D+"5<N%<#/TU
M_P $/_@5JWPFT;Q=JV-<\.Z#XJTO0IY/!DOPMO\ P%IOAG5(;/R;H0P7MU*]
MQ<R(D/VFXA7R)9(U99';<%^^**B59N-A.HVK'YU_MF?M<7'C[]O/PKX7U/\
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M6(!G#'!+*,=R/8/%?BG3_!'AN^U?5;F.STW3H6GN)W^[$BC))KSC]G_3-/\
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MH_\ T?%79?LP_P#)N7@7_L!6?_HE:XW_ (*,?\F5>/O^O*/_ -'Q5V7[,/\
MR;EX%_[ 5G_Z)6@#NJ*** "BBB@ HHHH **** "BBB@ KQ/]O?\ Y(9'_P!A
M.'_T&2O;*\3_ &]_^2&1_P#83A_]!DK@S3_<ZO\ A?Y'/C/X$_1_D8O_  2
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M'JWBN.SU32]'M[:Z@-C<L8I%0!ERL9!P?0D5[I_PS5\.A_S(?@[_ ,$UO_\
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M?M8_\*G\-_V!+X(&A_V;!]@$RQ^8(/+&S=QUVXS7O'_!1C_DRKQ]_P!>4?\
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MHHK[ ]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&?\ R:IX!_[ MO\ ^@UZ97FO['2>7^RWX#7^[H\ _P#':]*H **** "BBB@
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M@D;:_/CX*ZK?>&/VEO%$.E^"M6\=-JG]JV4FALS6]Q]FD9T8G<'D5@ ,AD#
MCDY% 'V9=_M5?&_PXVCS^(/AUX7T72=8O[73TOCJ;7 C>XD5(SL4[FY8' YQ
MFO:/*^*7_/;P#_WYN_\ XJOA+X>>'_B7X-^)>FZ_??!/QYK5OHKI/9V$^HS>
M4T\8Q%/+N1E:2-<!=BQ@;1Q7T%_PW%\8O^C<_$W_ ('/_P#&* /1?C)\2_B1
M\%OA=K?BJ^7P3>6NAVQN9(((;KS)<$  9; Y(Y/0<UYWKO[5?QR\$06=YXC^
M&OAO1](NKVWLGO!J+7'E--(L:'8IRWS,.!6?XH_:]^*OC/PWJ&D:E^S7XDNM
M/U2WDM;F%K]\2QNI5E_U'<$]*\)^'_AGXD^#/B5INN77P3\>ZM9Z,R26MA+J
M,HCEDB_U,DV8V5FC'"B-(QZ@CB@#Z(_8-OIM"^)GQRN->NM-@GM_$F;R>-C'
M:H0G)!<Y"_4U]0?VK:^9&OVBWW21&=!Y@R\8QEQZJ-R\]/F'K7YL:3I_Q?T[
MXI:[XBF^">K:M:Z[J,^I2:3J5M+-:K)((PI8+M$A38<%EXW'BEN=*^,EUXN7
M4%^#NJ6VFK(^-&C@NUL5B8VA: *&R(RUKN* A<R-QB@#](+7Q/IM]!9R0ZA8
MS1Z@2+5TG5EN2 2=A!^; !Z9Z&N?^*^LV>I_"OQA#;75M<36>F7,=PD<JNT#
M>2QVL <J<<X-?GWXW\,?&+Q5X[TW6M-^$M_X4CTVWN8H['2+.ZAM_-F@EA,X
M7HD@60<J!G8*Z.]OOBS)]C_L[X&KH,L$<T,\^G6=Y'+?))#+&5F)SYGS2E\O
MDY'O0!],^#?B#XF'P[\&Z%X331UNM+\'6.KWCZ@6*SKY*JD";2-I8J<N<A>.
M#S7.Z9?/KG[:7A7Q\LT9TCQ!\/[J]M[<1 31(C6S,K-CG)E!!R>A''?Y]\7>
M(_VB=0M=-@T;P)K.BPV?AA/#$HATV1Y+B$)M9R[1D@]QC&TGCUKI++XF_'.U
MU;PWJ3?"6^:^\.^&KCP^K+83+',9O(S-L"!1@P#Y1Q\U 'OEUXY\4?$WP@FD
MZM-I=A:_$K0;F]T62S1FETU1$L@CFR</F.1267&&+#I@UH_\$\;9K/\ 8Y\$
MQ,VXQVLBY^DTE?*/PL\9?M'> _$.D7&H^ =9URRT32I=)MK:32S&J1N%P598
MP01M ^@ Z"NE^&/QM^/WP=^!=EX0T7X0ZE]JTZ!XK?4)K.:386=FW&/@'&XX
MR<=.O2@#ZZ^+7C/6M-UG0O#_ (=;3X=8\0/,R75\C20VT4*!W.Q2"S'( &>Y
M)K\\?^"K/B*\\>^)/ ^OWBVMO,^FW6E7-M#\RQ75K>21S%7ZLA8C;GIM/J:Z
MSQK\6_VLO%FLZ/J"^#=4M+S1)));>6#P^H(+IL8'=NR"IQBO'_V@[_XI77PI
MT/0?B9X5N-)M=/O9IM,U2?3$M[@EPSS1%BRA@QVL>^5R<]@#],OV0#G]F'P/
M_P!@F'^5>D5YK^QR=W[+7@/O_P 2>#_T&O2J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KY_\ ^"G?_)F_B3_KK:_^CTKZ KYY_P""I$LL7[&?B+R4
M61O/M00QQ@><O/\ ]:@#W3P;_P BAI7_ %YP_P#H K2K+\#,S^"M'9@ S6,)
M('0'RUK4H **** "BBB@#Y1_X*4MCXD? ,;3_P CK;G/_;6"OJZOE+_@I1_R
M4?X"?]CM;_\ HV"OJV@ HHKD?CI\5O\ A2?PQU#Q(-&U/Q ;%X4%AIZ;[B?S
M)4C^4=\;]Q]@: .!_P""C'_)E7C[_KRC_P#1\5=E^S#_ ,FY>!?^P%9_^B5K
MY1_:D_;>U#X[_ /Q)X1L?A/\1;&ZUJ!(DGN+',<6)$<D[03T7]:^K/V7$N(_
MV;_ BW=K-972Z%9B6WE4K)"WDKE6! ((]"* .\HHHH **** "BBB@ HHHH *
M*** "O$OV^O^2&P_]A2'_P! DKVVO$OV^O\ DAL/_84A_P#0)*\_-O\ <JO^
M%_D<V,_@3]&9O_!'S_DK?BS_ +!"?^CEK] Z_/S_ ((^?\E;\6?]@A/_ $<M
M?H'7L<"_\BB'K+\V=>0?[G'U?YA1117V![04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4/_)M7Q!_[%O4/
M_2:2OS(_8U_Y.2\-_P#;U_Z2S5^F_P"U#_R;5\0?^Q;U#_TFDK\R/V-?^3DO
M#?\ V]?^DLU?F/&O_(TPGJO_ $I'RN>?[W1^7YGW;1117K'<%%%% !1110 4
M444 %%%% !1110 4444 %1WEQ]EM)9<;O+0OCUP,U)5?5^=*NO\ KD_\C0!\
M4V/_  6 U'4K>QEM_A3KUQ'J4AAM'BD9UNI ,LD9"8=AW"Y-:O\ P]%\6?\
M1$/&O_?B;_XU6)^Q=X+M/B#\ ?A#I-X9$CGGUPQS1-MEM953*2QGLZ-R#_,$
MBOK#X2>.+W51>>'_ !!Y<?BGP_M2[VC:E]$V?*NXQ_<D .1_"ZNIY6@#YJ_X
M>B^+?^B(>-/^_$W_ ,:J+0/^"M5Q=?$G1?#>K?#76M$NM6O;>TQ=S&*2,2NJ
MA]K(#T;/O7U1\5/B'_PK[P_&UO;_ &_6M2E%II=B#AKNX;H#Z(HRS-V52?2O
MB']MWX>2>!_VCO@Z+JZ_M#6+W4(;[5;TC!NIVNT!('\*+D*J]%50* /T$HHH
MH **** "BBB@ KQ/_@HT,_L4>/O^O.+_ -*(J]LKQ?\ X*'KO_8T\<+_ 'K>
M ?\ DS#0!UW[+W_)MG@#_L7K#_TG2NZKA?V8./V;O /_ &+UC_Z3I7=4 %%%
M% !17S'^UC^W-KG[.O[0FA^&;71]+OM"NK2TOM1GD5S=0Q279MY"F'5<C*8!
M!Y;)X''TY0!XC\7M-TN7X\74WB;3O%%]H[:!91Z?_9S7?DI<"XO#/D0,!N*&
M#ENV*_/WX CQ-IG[6/B"3PCKD/A:_M6U:Z:\U>)IDM+>-G,BN&W-YFT#.<G.
M,G-?='Q1^./QM'Q=\0Z5\/O ?A[Q%X=T.6&V^VW-XD,QF:".5T*O<1YP9,9
MQ^.:^._#'P)\>:G^USXF\,^(-#MM+\4>.M,U+46M?[0B:&&.Y+MN4IYB[0RD
M;"V2!U'6@#O/A[^T_P#&3XA_$BQ\,P?$_P .VM[JW%D\^E;8Y'/*QN=OR.XY
M523N!'K7MP^$W[3X_P":C^$/_!>?_B:RM0^!GQT\5G0;77AX)NM)T74[+4A%
M96Z6EPS6KJR!9<ML)"[<[3P2*]Z_X3;X@?\ 0AZ5_P"%(/\ XQ0!XY_PJ?\
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M\9:%J_A'Q-XL;2-7N+2TFT_6VTUK=(II(B6$<3!BRJF3\O(/% 'Z_?V_8_\
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M/V(OAK\-X?L/CG1]:T8*OEVNMV>N79TBY.,*&)<FU<_W9?D)P%D8\4 ?8?\
M;]C_ ,_MI_W^7_&OB3_@MCKEG=?#'P1;Q7,,LSZG/(%1PWRK$H)X_P!X?G3?
MV??V1?ACJWP6NM2\9Q^(%U;0;1+Z]ECUFXC^UV\J&6&5$# ?,,QA1U:,^HKX
MK_:1\-W'@+XM:IHTD=Q:K8R[EM);EK@V@D4.(]S$D[58+D\G% 'ZY?L<2)+^
MRUX#:/F,Z/#M^F*]6T.[CL[MFD;:I0C.,\Y%>2_L70K!^REX!5<[1HT'4Y[9
MKTZJC*SN@V.A_MRU_P">O_CI_P */[<M?^>O_CI_PKGJ*V^L2+]HSH?[<M?^
M>O\ XZ?\*/[<M?\ GK_XZ?\ "N>HH^L2#VC.A_MRU_YZ_P#CI_PH_MRU_P">
MO_CI_P *YZBCZQ(/:,Z'^W+7_GK_ ..G_"C^W+7_ )Z_^.G_  KGJ*/K$@]H
MSH?[<M?^>O\ XZ?\*/[<M?\ GK_XZ?\ "N>HH^L2#VC.A_MRU_YZ_P#CI_PH
M_MRU_P">O_CI_P *YZBCZQ(/:,Z'^W+7_GK_ ..G_"L*[D$MW*R\JSD@^V:C
MHK.I4<MQ2DV%?//_  5(E>+]C+Q&8XWD;S[4?+V_?+S7T-7S_P#\%._^3-_$
MG_76U_\ 1Z5F2>V>!C_Q16CY&T_88<@]OW:UJ5F^#?\ D4-*_P"O.'_T 5I4
M %?)_P"W=)L_:U^ 2_WM2G'_ )'LS7UA7R-^WR2/VPOV=_\ :U6YS_W\M: /
MKFBBB@#X[_X*R^*XO FI?!W7)HI+B'0_$AU&2*,@/(D)AD95SQDA>,U]&?LY
M_'*Q_:0^#^E^,=-L[K3[/56F5(+DJ9$\N9XCG:2.2A/'8U\X_P#!6CPG'X]U
M'X.Z')-);1ZUXE^P--&,M$)3"A89XR-V?PKZ._9Q^!MG^SA\'M+\'V-]<ZC:
MZ6TS+<3JJR2&69Y3D+P,%R/H* .XKQW]O[Q7;^#?V0/&]Y=+(T;V:VP$8R=T
MLJ1+^&YQGVKV*OG_ /X*A6_VO]B;Q9".LL^GH/QOK<4 >X>$?$D/C'PII>L6
MZ21V^JVD5Y$L@PZK(@< CUP>:T*Y7X%G/P2\'?\ 8#LO_1"5U5 !1110!G^+
M/^15U/\ Z])?_0#7SW_P2G?S/V5PW][6KX_^137T)XL_Y%74_P#KTE_] -?/
M7_!*7C]E2/\ [#%]_P"C30!]*T444 %%%% !1110 5XG^WS_ ,D-A_["D/\
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M5^8\:_\ (TPGJO\ TI'RN>?[W1^7YGW;1117K'<%%%% !1110 4444 %%%%
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M+6M2OCOP_P#\%!_B-IOA^QMX_P!GGX@S+;VT<:R"VN<2 *!N'^C]#UK2M_\
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M<A_W./J_S"BBBOKCV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@+Q#;ZS\1%D\<:M<-#!H9D9K"T7S]TLP4'$?&WJ,8SGG-2:[X#\0CQ+JZ_\
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M_(@X((Y! (YK*\+>)]0^$WB"U\+^)KJ6\TV]<0Z'K<QRTQ_AM+ENTPZ(YXE
MP</]X L_\,T^%_\ GMXP_P#"OU?_ .2:Q_''PA\#?#OPY-JFJ7OC"&VAPH"^
M+=7:29SPL:*+G+.QX"CDDUZ!XW\;:;\//#D^J:I/Y-K#A0%4O),['"1QH.7=
MF("J,DD@5R?@GP-J7C/Q)#XN\70>3>0Y.CZ.6#QZ,A'WWQP]RP^\PR$!VKW9
M@#X]_:<^'FI>%?C;\&]2U";6K-=8\26TMOHUYK%UJ*Z;&MU;!=S3RR?OF!RY
M7 '"\XS7Z"5\A_\ !1O_ )+W\#?^P_#_ .E=K7UY0 4444 %%%% !1110 44
M44 %%%% %/4?$6GZ06^UWUG:[1D^=,J8'XFN#\2?%FX\?W4GA_P'-'>7TG[N
M[UI5\RQT=#U8-]V6;'W(UR,X+$*#GQ7P-X5TWQE_P5 ^)=MJUK!JEM!X?MI(
M[>Z7S8XFVV@W!6R 3DU]5Z;IEMH]FEO9V\%K;QC"10QB-%^@' H I>"?"%EX
M \):?HNG*RV>FP+!%O;<[ #EF/\ $S'))/)))[UJ444 %>!_\%#?^21:/_V&
MH_\ T1/7OE>!_P#!0W_DD6C_ /8:C_\ 1$]>=F_^Y5?\+.7&_P "?HR3_@CS
M_P E)\9?]@R'_P!&U]^5\!_\$>?^2D^,O^P9#_Z-K[\KV^!_^113]9?^E,[<
MA_W./J_S"BBBOKCV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#A?VH?\ DVKX@_\ 8MZA_P"DTE?F1^QK_P G
M)>&_^WK_ -)9J_3?]J'_ )-J^(/_ &+>H?\ I-)7YD?L:_\ )R7AO_MZ_P#2
M6:OS'C7_ )&F$]5_Z4CY7//][H_+\S[MHHHKUCN"BBB@ HHHH **** "BBB@
M HHHH **** "H=3B:;3KA%&YGC90/4D&IJ* /RY^'?@WXS?#3Q#\,[H?"'Q)
M?-\,Y;QD0(ZB_P#/8DY;80N.Q&[-?1W_  W)\</^C=->_P# N7_XS7UQ10!\
M6^-OVT/VCM5L85\/_ N^T>X63,LEW#-?+(N/NA0(]ISSG)^E>6:)\3/VH]!N
MM)FA^&=PS:-<WEU!OT28[FN<^8&_><@;CC&,=\U^DM% 'YIZ7XY_:=TS3]/M
M4^&MUY>FZ5<Z/$6T28EH9R"['#_?&!@C ]0:+[Q=^TQJ>B:E82?#FY6'5O#L
M7AB=AH<^\6L?G;6'SX$G[]\G&.G''/Z644 ?F_XD^(W[3OBFZUR:X^'4ROX@
M2S2Y\O0;@;1;,[1[,N<9+G.<YP,8HO?B3^T]>ZA=7+?#F;?=ZQ!K;!="N,+-
M$H55&7^Y@#(.3[BOT@HH _+'P[^V5\:M=O\ [1IF@Z)>2:/X@N-5F5;%QY=Y
M(KK)&X,H.T;SP.0>]&B>,/BE\5OB-\+['Q1X?L]/T7PCXGBU,7*1B#REDNHY
M)FD9I"-JA21P,>]?HGXC_9@^'7B[5&O=2\$^&;RZDX:5["/<WUXJA_PQU\*_
M^A \*_\ @ G^% '=Z#XJTOQ3%))I>I6.I)"P61K6=9@A/."5)Q5^O)_V4_ F
MA^&K#Q9JWAW2K'2='\0:W(]A':1".-[>WCCME< =5>2*:0'N) >]>L4 %%%%
M $=Q=1VJAI9(XPQP"[!<FH_[6M?^?JW_ ._@KRS]L'P%I?C?P7X>DUZ&6XT#
M2-?M[G4HXYWAQ#(DML9"RD$+&UPLC<](S6;_ ,.\_A7_ - .^_\ !I<__%T
M?.G[=7[>?Q*^!?[1^K:%X;O(1H-O;VSPYLHY%#-"KN-[*<\Y/6OFOP!^T+XQ
M\ :QXFNV\"Z/XD7Q=<F\U*V\0:+)?6[SF5I?,6,;%4[F.,@X[8K]*-(_8#^%
M.D:I#=?\(RMX]N2R)>7<UQ&#@C.QV(R,FO8#90D_ZF/_ +X% 'Y'Z]^U'KGB
M#0+ZQ_X4O\+M.:]MW@%S9^!MMQ;%E*[XV+D!USD$@@$#@T[PS^T]K'AW0+2Q
MD^#OPTU)K6,1FZO/ 2O<3X_B<K(H+>X K];?L,/_ #QB_P"^!1]AA_YXQ?\
M? H _'[XF_M)7GC_ ,(WNAS?"WX=^'VN_+S>:3X-%I?6^V19!L<RG;G;M.0<
MJS#O7G/A;QAXJ^'M]<7'AW4/$>BS7,9BE>R1K4R(>JGRR.#Z5^J&I_LU>!OB
M!^TAXOC\5>'[74KW4K:TU2PDDDD3$ C$$B*%8#Y9(MQ[CS5]16]_PP7\)/\
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MWU8_=LX?PM(O_B:_83_A@?X-_P#1/?#W_?IO\:/^&!_@W_T3WP]_WZ;_ !H
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MJ#;;>3]XH?<=R](]Y'S#D"NLHH ^3%^('[86?F\#_#?'M/G_ -NZY*V_;?\
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MD'GMQ7NE !1110 4444 %%%% !1110 4444 %%%% !1110 5\J?\%?+2Y?\
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M4 ?EOXS^)'Q@\=?%[X*VOQ0\,W.CQ:1XCLX+&]N+"6WFOF-S#NWL[$.P 7D
M$]3DDFOU(KY/_P""E;8^)?P#_P"QT@/_ )%MZ^L* "BBB@ KY1\3> ]'^)7_
M  4PU+2=>T^WU/39?""2O;S E6:.XMY$/'HR@_A7U=7S-IC?\;6-07_J2L_^
M18O\* /H'P?\/]#^'M@UKH6CZ;H]NYW-'9VR0ASZG:!D^YYK8HHH **** "B
MBB@#X%\>^(IO"?\ P5QO+ZWU#1],D6R9?/U0L+9?^)='PVT@Y/;GK7IGQ_\
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MJ_S"BBBOKCV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4CRB<^]?1U>,_P#!/7_DS#X?_P#8/;_T=)7LU !1110 4444 %%%% !1110
M4444 %%%% !117G?[46JZ]H?PDGO/#NK_P!AWL-Y;"2\^SK<>5$TRH_R-P?O
M4 >B5\^_\%/Y/*_8V\2-Z36W_HY:UO\ A2GQ>/3XP1X[?\4[!_\ %5A_$7]C
M[QU\:?"\GA[Q=\4Y-0\/W<L;W=O;Z)#!)*$8, K@G;R/2@#W3P/_ ,B5H_\
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M>&TU2%_W*\N[6D^UNV-R\8..<UZ_^U/IVI1_LY>-&EM?C&L:Z3.6.HZA:O:
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M?*>7^QIX!7^[8,/_ "-)7LE>0_L$KL_9$\$K_=M)!_Y'DKUZ@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=LC0*,XP,X')]:_)3]OSY_VX/%0_NW@S_P!\YK]?D^X/I0!QGQ[^!.C?M%>
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M^(W_ &+E]_Z(>O1J\X_;!./V5/B-_P!BY??^B'H ROV#_P#DTGP7_P!>TO\
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MX6&6SG+&-DB"MPA&#M/Y4O;T_P"9?>+VD.Z/M"BO-S^UU\.P?^1B3_P#N/\
MXW1_PUW\._\ H8X__ .X_P#C=+ZQ2_F7WH/:0[H](HKS4_M>_#E>OB2/_P
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MK_V+5I_*TKZ"^+G@2X^)'@>32[2^CTVZ%W9WL%S);_:$C>WNHKA=R;EW F(
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M^1G_  QE\5/^A#\1_P#@*:6/]B_XK2N%'@/Q%D^MOM'YDU^N5%/_ (AS@_\
MG[+\/\A_ZLT/YW^!^2?_  Q%\6/^A%US_OA?\:!^Q#\6"?\ D1=<_P"^%_\
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MLUV06UO&(XH5R3A5' Y)/XU?HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&W2>4NX^IP,U\#?M26\=I^TGX]BBC2../7[U41%VJH$[X '85]]:=_R#X/\
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M "BBB@ HHHH **** "BBB@ KY]_X*?Q++^QMXD#*K 36IPPSSYZ5]!5\]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>+-<OO%5Q92":UMYXT@LK:0'(<0H K,.S/N([<UWE%% !1110 4444 %%%%
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MX7CMXH_\$TW^%(?^"I_PM'_0T?\ @FF_PH ^D*^6/VS3_P 9I?L^?]A2X_\
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M_P";I_Q+UY_\?H ^K:*^8?#/_!5CP'XTU#[)H_AWQWJEUL,GDVNE"5]HP"V
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M^>;_  K[OKWN"/\ D3TO67_I3.[(?]RC\_S84445]8>P%%%% !1110 4444
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M$/TC_H%Z;_X#)_A1_P (?I'_ $"]-_\  9/\*TJ* ,W_ (0_2/\ H%Z;_P"
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M:0\9> M4U27P[X;M/!NM1:L;:&66[FN LD;&,OA5_P"6?7'4U]"444 %%%%
M'B7_  44_P"3//&7_7LO_H:UT?[&O_)IOPW_ .Q<L?\ T0E<Y_P44_Y,\\9?
M]>R_^AK71_L:_P#)IOPW_P"Q<L?_ $0E 'I5%%% !1110 4444 %%%% !111
M0 5X;_P4"_Y(G8_]AB'_ -%35[E7AO\ P4"_Y(G8_P#88A_]%35YN<?[C5]&
M<N._W>?H6/\ @CC_ ,C+X\_Z]K/_ -"FK[NKX1_X(X_\C+X\_P"O:S_]"FK[
MNKWN"?\ D3TO^WO_ $IG=D/^Y0^?YL****^L/8"BBB@ HHHH **** "BBB@
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M_P #C_\ %4O_  Z[N/\ HLWQ._\  X__ !5?6%% 'R?_ ,.N[C_HLWQ._P#
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M_P"A35]W5[W!/_(GI?\ ;W_I3.[(?]RA\_S84445]8>P%%%% !1110 4444
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M,4W_ *!'77>*_!ND^.M):QUC3[/4K1CN\NXB#A6[,,_=8=B,$5Y[\/?&^D>
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M==9^QK_R:;\-_P#L7+'_ -$)0!Z51110 4444 %%%% !1110 4444 %>&_\
M!0+_ )(G8_\ 88A_]%35[E7AG_!0,9^"EC_V&(?_ $5-7FYQ_N-7T9RX[_=Y
M^A9_X(X_\C+X\_Z]K/\ ]"FK[NKX1_X(X_\ (R^//^O:S_\ 0IJ^[J][@G_D
M3TO^WO\ TIG=D/\ N4/G^;"BBBOK#V HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_/Q!_P!_!1_:EM_S\0?]_!7SL/\ @EI\,A_RU\5?^#>2E_X=;?#/_GKXI_\
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MU<>)I_@G<1ZW<2&4W4)NXGC8@ E-LOR9P,[<9KC[G]M3XA6MY]GD\)ZO'/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2_\ A7_L%:C_ .TJ]#KSSQO_ ,E_\*_]@K4?_:5 '"_!3_D8/@__ -BUK?\
MZ/L*]]KP+X*?\C!\'_\ L6M;_P#1]A7OM 'G_P"U=IMSK'[-?CBUL[>:ZNKC
M1KE(H84+R2,4. H')/L*X7]D;XT>'?"OP \$Z#K-W-H6J6FFQ02PZE:RVBJX
MX*[Y%"9_&O>JKZKI%KKMC):WMM;WEM*-KQ31B1&'N#Q0!.CB10RD,K#(([TM
M>9:+:2? ?Q[IVBPR22>#O$DC0:?'(Y;^Q[P*7$"D\^3(H8JI^ZR$#@@5Z;0
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M_P#H4U?=U>]P3_R)Z7_;W_I3.[(?]RA\_P V%%%%?6'L!1110 4444 %%%%
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MKWP__P! /1__  "C_P * /GK_A[K\&O^@AKW_@K?_&C_ (>Z_!K_ *"&O?\
M@K?_ !KZ%_X5[X?_ .@'H_\ X!1_X4?\*]\/_P#0#T?_ , H_P#"@#YZ_P"'
MNOP:_P"@AKW_ (*W_P :/^'NOP:_Z"&O?^"M_P#&OH7_ (5[X?\ ^@'H_P#X
M!1_X4?\ "O?#_P#T ]'_ / */_"@#YZ_X>Z_!K_H(:]_X*W_ ,:3_A[K\&O^
M?_7O_!6_^-?0W_"O?#__ $ ]'_\  */_  H_X5[X?_Z >C_^ 4?^% 'SS_P]
MU^#7_/\ Z]_X*W_QH_X>Z_!K_G_U[_P5O_C7T-_PKWP__P! /1__  "C_P *
M/^%>^'_^@'H__@%'_A0!\\_\/=?@U_S_ .O?^"M_\:/^'NOP:_Y_]>_\%;_X
MU]#?\*]\/_\ 0#T?_P  H_\ "L'XJ> ="@^&'B1TT725==+NBK"SC!!\IO:@
M#Q?_ (>Z_!O_ )_]>_\ !6_^-'_#W;X-_P#/]KW_ (*W_P :Q_\ @DKX1TG6
M/V5I)KS2]/NYAK=VN^:V21L#9@9(S7T]_P *[\/_ /0"T?\ \ H__B: /GG_
M (>[?!O_ )_M?_\ !6_^-'_#W;X-_P#/]K__ (*W_P :^AO^%=^'_P#H!:/_
M . 4?_Q-'_"N_#__ $ M'_\  */_ .)H ^>?^'NWP;_Y_M?_ /!6_P#C1_P]
MV^#?_/\ :_\ ^"M_\:^AO^%=^'_^@%H__@%'_P#$T?\ "N_#_P#T M'_ / *
M/_XF@#YY_P"'NWP;_P"?[7__  5O_C7C_B/_ (*\>&=6^)NDZU'X2UK[/I=I
M=6I1KJ'=)YNS:W7 QMY'O7W-_P *[\/_ /0"T?\ \ H__B:/^%=^'_\ H!:/
M_P" 4?\ \30!^>W@/_@J/X?\(:AX(GD\+ZM-_P (KI6H:?,%N8AY[7$ENZLO
M/ 'DD'/]X5[WI/\ P5^^$5YI=O-=3:_974D:M+;_ -GF3R7(Y7<IPV#QD<&O
MH[_A7?A__H!:/_X!1_\ Q-'_  KOP_\ ] +1_P#P"C_^)H ^;]>_X*__  EL
MM%NIK"37+Z^CB9H+=K!HA,^/E4N3A03W/2O(8_\ @L[J\Z[SH/AFWW$GRGFN
MG9!Z%ECP?J*^[O\ A7GA_P#Z >C_ /@%'_A1_P *]\/_ /0#T?\ \ H_\* /
MAG0_^"C>N?M.>+_#_@RVTOPU!=:GK%E)#-')<J\)BG25BI9 .41EY[,17W\*
M^6_VL/#NGZ'^UI\!_L-C9V?F:O<;O(@6/=^[[X KZDH **** /"?^"E?_)EG
MC3_KC#_Z/CKT_P""C;O@]X5/_4)MO_12UYA_P4K_ .3+/&G_ %QA_P#1\=>F
M? XY^#/A/_L$6O\ Z*6@#JJ*** "BBB@ HHHH **** "BBB@ KPW_@H%_P D
M3L?^PQ#_ .BIJ]RKPO\ X*"-CX*V'OK$0_\ (,]>;G/^XU?1G+CO]WGZ%K_@
MCC_R,OCS_KVL_P#T*:ONZOA3_@C?#NUSQ_)G[L%BN/JT_P#A7W77O\$_\B>E
M_P!O?^E,[LA_W*'S_-A1117U9[ 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-_V"KK_T2] 'SW_P2&_Y-0F_[#MY_P"R5]25\M_\$ACG]E&;_L.WG_LE?4E
M!1110 4444 %%%% !1110 4444 ?-'[8G_)V/P%_[#%Q_P"BC7TO7S3^V(C#
M]JWX"-M;:VLW !QP2(N?YC\Z^EJ "BBB@#PG_@I7_P F6>-/^N,/_H^.O2O@
M2=WP4\)?]@BU_P#12UYK_P %*_\ DRSQI_UQA_\ 1\=>D? ,Y^!_A#_L#VO_
M **6@#KJ*** "BBB@ HHHH **** "BBB@ KPO_@H+_R1;3_^PS%_Z)GKW2O"
M_P#@H-_R1;3O^PS%_P"B9Z\O.O\ <:OH<F._W>?H:/\ P1M_Y"7Q"_ZY:?\
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MAWPOX\\;:IX3TNWTGP_-);:1;K;EO)O)+7SC-.,DY_>3M%D=?L_'') /,/\
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M?_)/]"_[!]O_ .BUKP?_ (*LQ^=^QUJB?WM2L!_Y'6O=_AR<_#[0?^P=;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)KGV?'F_V?\ M">,KKR\]-VS6#C\:J&*H3?+":;\FBHUH2=HM?>?3=%?/_\
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M] 45\_\ _#M/X=?]#'^T!_X?;QO_ /+:C_AVG\.O^AC_ &@/_#[>-_\ Y;4
M?0%%?/\ _P .T_AU_P!#'^T!_P"'V\;_ /RVH_X=I_#K_H8_V@/_  ^WC?\
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M /\ !6+_ )19?M+?]DJ\4?\ IHNJ^@*^?_\ @K%_RBR_:6_[)5XH_P#31=4
M>G_M$:G<:+^S_P".KRUFDM[JT\/7\T,J'#1NMM(58'L00#7X^:%H5UXFU6*Q
ML8O.NIL[$W!=V 6/)('0&OU\_:;_ .3;?B%_V+6I?^DLE?E+\"?^2JZ7_P!M
MO_1+U^4>(4>?&8>#V:?XM'R'$BO6IQ?;]0_X43XJ_P"@7_Y,P_\ Q='_  HG
MQ5_T"_\ R9A_^+KZ*HKY7^QZ/=_A_D>1]3AYGSK_ ,*)\5?] O\ \F8?_BZ/
M^%$^*O\ H%_^3,/_ ,77T511_8]'N_P_R#ZG#S/G7_A1/BK_ *!?_DS#_P#%
MT?\ "B?%7_0+_P#)F'_XNOHJBC^QZ/=_A_D'U.'F?.O_  HGQ5_T"_\ R9A_
M^+H_X43XJ_Z!?_DS#_\ %U]%44?V/1[O\/\ (/J</,^;]0^#'B72K">ZN--\
MN"WC:61OM$1VJHR3@-GH.U>G?\$UM2GL?VR/"T<,LD<=Y'>PSJIP)4%I,X4^
MHW(I^JBNK^('_(AZW_UX3_\ HMJX[_@G!_R>?X-_[??_ $AN*>!PL:&:890;
MUG'_ -*0\/35/%TN7^9?FC]4****_H _10HHHH **Y3XX?$Z?X,?"?7/%5OX
M7\0>,FT.#[2^D:))9I?W,88"1HS>7%O!\B%I"'F4E8V"[G*HWSEHO_!:7X0:
MI_P3!L/VL;BS\9Z9\/-6,T.GZ7<:="^O7]RFH3:>EK%;Q3/&TTL\+!!YNW:0
MSL@#;0#ZXHKY9E_X*Y?#?PIX$^+FI>.-#\;?#G7O@G/IMOXC\+:W;6=QJ[/J
M<2/I@MC8W-S:W'VMG,4?ESDB2.02>6%)KH?!?_!131?'_P ,_B9JFF> O'\O
MC3X/W:6?BOX?NVDQ^(M,9T29&W-?#3Y(VM7^T*Z7C*R*Z@F53%0!]"T5X_\
ML%?MK>%?^"B7[)WA3XQ>"=/\0:7X9\8?;/L=KK<$,%_%]FO)[.3S$AEEC&9+
M=R-LC94J3@Y Y/XA?\%+/"_@CXF>/M$L?!?Q(\7:'\)4C'CGQ3H&GVMUI7A:
M9[;[4;>2)KE+ZZE2W:&606-K<B,3H&(99%0 ^C**R? 7C*U^(G@71?$%C'<1
M6>NV$&H6Z3J%E2.:-9%# $@, PR 2,]S6M0 4444 ?/_ .V1_P G%?LG?]E5
MOO\ U"/%=?0%?/\ ^V1_R<5^R=_V56^_]0CQ77T!0 4444 %%%% !1110!^)
M?Q5_Y#WB3_KXNO\ T)J_2]/N#Z5^:/Q0C:;Q%XB5%9F:YN0H R2=S=*_2Y>%
M'TK\9X4VK>J_4^)R?[?J+7@7[3?P9\3?$#]ISX.Z]H^G?:M&\,7\L^JS^=&G
MV=3L*G:S!FZ'[H->^T5]<>T%%%% !1110 4444 %%%% !1110 4444 %?(O_
M  4U^!/B_P",7B/PC+X9T*ZU>.ST_4X9Y(L%8&EC5%!&<Y.2!VSUP 37UU10
M!G^$]%;PWX5TS3FD$K6%I%;%P,!RB!<X]\5X_P#$G5_B/\,_CCJU]X+^'<?C
M32]>TZUDN97UR'3%@N8C)&?]8K;R8_+Z 8"BO<** /F/QS^TK^T)I%U9QV/P
M)M(O.#ES_;\>H XQCF(($_X%G/:L7_AJ7]I3_HA]C_X&'_XNOK:B@#\T?VZ_
MVN?BAXN^'O\ P@GCKX>V/A7^V'BO(Y4F>20K%(#D<D8R,'-?HK\.CGX?:#_V
M#K?_ -%K5O6/"VF>(7C;4--L;YHP0AN+=)2@/7&X'%7(XUAC555551@ #  H
M ^>_^"IK!/V*/%!8;AYUGQ_V\QU[%\&QM^$/A4'MH]H/_(*5M:UH5CXETV2S
MU&SM=0LYN)(+F%98W[\JP(/XU8@@CM8$BB18XXU"HBC:J@<  =@* '4444 %
M%%% !1110 4444 5]6_Y!5U_UR;^1KYQ_P""31C/['VG^7C;_:%QG'K\F?US
M7TL1N&#5+0/#>G>%-/%GI>GV6FVJL6$-K L,8)ZG:H R: )]2_Y!UQ_US;^1
MKYC_ ."14L<O[)K&+[O]LW X]?+AS^N:^HB,BJ.@>&=-\*6'V72]/L=-M2Y?
MR;6!88]QZG:H R<#GVH O4444 %%%% 'S+^V*^/VM_@'_P!A:Y_]%U]-51U'
MPUINL:A:7=YI]C=75@Q>UFF@622V8\$HQ&5)]1BKU !63XT\":+\1]!DTOQ!
MI.GZUILC*[VM[;K/"S*<J2K C(-:U% 'FW_#'/PG'_--_!/_ ()X/_B:7_AC
MKX3_ /1-_!/_ ()X/_B:](HH \@\?_L5_#75? FM6NF?#WP;;ZE<6$\5I*FD
MP*T4S1L$8$+D$,0<UY+\+O\ @F!\&/B!\.]%UE;#7"=0M(Y7QJD@P^,,,=L-
MD8[5]<UYC/+<_L]^(]0N?LMU>>!]8G>\D-M$TTN@W#G,A*+EFMY&)?*@E&+<
M;2-H!YF/^"2'P:!_Y!VNGV.JR<U[U\+_ (7:'\&?!5IX=\.69L-)L=QAA,SS
M%2S%F.YR6.22>3WK3\/>)-/\6Z1#J&EWUKJ-C<#,<]M*)8W^C*<5=H ****
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M/$'_ ('6_P#\C4?ZQ9=_S\_"7^0?VGAOYOP?^1]OT5\0?\-@>(_^@AX@_P#
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M ,#K?_Y&H_UBR[_GY^$O\@_M/#?S?@_\C[?HKX@_X; \1_\ 00\0?^!UO_\
M(U'_  V!XC_Z"'B#_P #K?\ ^1J/]8LN_P"?GX2_R#^T\-_-^#_R/M^BOB#_
M (; \1_]!#Q!_P"!UO\ _(U'_#8'B/\ Z"'B#_P.M_\ Y&H_UBR[_GY^$O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKIP' N)I8NGB*U=24))[.^CO;4UP_#]6%:-2<[\K3Z]-3=HHHK],/J0HHHH
M**** "BBB@ HHHH **** "BBB@#Y_P#VR/\ DXK]D[_LJM]_ZA'BNOH"OG_]
MLC_DXK]D[_LJM]_ZA'BNOH"@ HHHH **** "BBB@#Y=O_P#@DI\.-0OIKA]:
M\;!YY&D8+>6N 2<G'^CU#_PZ(^&W_0<\<?\ @9:__(]?5%%>#_JOE3U]A$\_
M^R<)_P ^T?*__#HCX;?]!SQQ_P"!EK_\CT?\.B/AM_T'/''_ (&6O_R/7U11
M1_JOE/\ SXB']DX/_GVCY7_X=$?#;_H.>./_  ,M?_D>C_AT1\-O^@YXX_\
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M*/\ 5?*?^?$0_LG!_P#/M'RO_P .B/AM_P!!SQQ_X&6O_P CT?\ #HCX;?\
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M111_JOE/_/B(?V3@_P#GVCY7_P"'1'PV_P"@YXX_\#+7_P"1Z/\ AT1\-O\
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M_P#\.G?V6?\ HVG]G_\ \-YI'_R/1_PZ=_99_P"C:?V?_P#PWFD?_(]?0%%
M'S__ ,.G?V6?^C:?V?\ _P -YI'_ ,CT?\.G?V6?^C:?V?\ _P -YI'_ ,CU
M] 44 ?/_ /PZ=_99_P"C:?V?_P#PWFD?_(]'_#IW]EG_ *-I_9__ /#>:1_\
MCU] 44 ?/_\ PZ=_99_Z-I_9_P#_  WFD?\ R/1_PZ=_99_Z-I_9_P#_  WF
MD?\ R/7T!10!\_\ _#IW]EG_ *-I_9__ /#>:1_\CT?\.G?V6?\ HVG]G_\
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M^"/PB\&^)+!9%MM6T+P=IVG7UL)$,;A)H85=0R,RG!&58@\$UZ[110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPE\2?!]TUYX;\9:;#J=B[C;(J2+DHZ_PNIRK*>0RD4 =U117\Y_[17_!3/\
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M.X^-'ACX<_M,>'T*Z!:W,9FDU"WN%$RVDZC;][9OBPX92Y(5M^#\@^+/#?\
MP5@_X)1_#>^M]2:P^.WPKT>P5]4&^/Q+;BQ1"DENR2K'?B,1 [RB%0N26P":
M^GO^#C+_ ()$_%CXZ?&_X>_M1?LYHUU\5OABD NM+@6+[5=BTG:YM+NW1UVS
M31N61HW)WH(@JG:0?GGXC?\ !Q-^VU\9OAI??"?2?V2-0TOXFZQ!-H=[J<>F
MZE+'YC*\4IAM"B^6X^;:6G<*5R=PXH ](_9D_;'^$O[7O_!MQ^U->?#?X7^%
M/@[KFD>'=5C\6^'?#\8CLI;U[%=M[$N=_ERQHJC?DJ8F7+;=Q^*O^"(FN_\
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M  1/O?V4_$6J0WFK>)$DUK6-?M%D6--?=DDCN8E+9,<)B@B (7S$ARR*79:
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M>YGB3"0A(6:*.#G:')*@JIH ^??^"3D>GZW_ ,'<7Q^F\8RW$GB"U\0>,/\
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M!V&OZ5OV/?@_X3^ /[*_P]\&^!9ENO"'A_0+2UTJY _X_8/*4K.>GS2Y,AP
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M? 7Q]\)?">N>+KKP+=ZA:W,&C6;W=Y9RS&VG@G**#^[#6S#)_B91WH ^;_\
M@\N\(Q_#SXE?LU:#H_F&'0_#<]A8B5@SE8I8HX]QX!.%&3TKN_C9<_\ !:+Q
MI\'/$6CZGHNE_P!DZEILUO=G1CX?AO\ R#&=_DM'() Y7(&SYSG Y-+_ ,'0
M/[(WQT_:U3]F?Q'X0^&OC3QCJFG>$]VM_8-+DF>RO6\F1XYE491MV[@XZ&K.
MH_\ !:7_ (*E>)--DTO3/V4;.QO;N%X8KA/!NJ-)"2I&]=USMW+U&[(R.01Q
M0!XM_P $8_B3H.G?\$(_VV/ O@O0]:TOXT:-H-U?>)I+D!C=Z<\;PN(UVJT2
MQ0I=*\;%B"2V1NP/M;_@RRTS28/^"9?CJ\M8K4:S<?$6[BOI5 \]HTT^P,*L
M>NP;Y2N>,L^.]._X-P_^"*/CC]FKP3\5_B'^T1IMNWB;XX64FE7GAJ\"R3)8
M3&1KDW>T[0]P92#$,[57D@L5'REJ_P"Q9^V)_P &U7[47B_Q9^S[X=N/BY\#
M_%S>;<VOV-[]?LT;N8H[V*';+#<PK(RK/&-C;SP06C !^M__  7RTWP]JG_!
M'GX]IXG95TN/PV948\%;E9HC;8([F<1#\<5^(O[.>HZI>_\ !FO\?([^2Z>U
ML_BC:Q::)2=L=N;S0G81Y_A\YYCQQN+=\UZ#^T-\:/V]O^#D*+3_ (:Z3\(V
M^#WP?DU!+C4KB[M[BUM6>/'-W=SJKS*FXNL,4:ECR0Y52OW?_P %1?\ @F)>
M? '_ (-OM8_9U^#N@:WXTU/P_#I"Q6]A:M->ZO.-8MKJ]NO+4DY9S-*5!(1>
M!PHH ^"O^"1/_!2;]N[X$?L#^#?#/P;_ &6M+^(?P]TUKE=.UZ:SO'>])F9I
M.4N$4[6)'"CI7,?\$W_BCXH_X*P?\''OAO7_ -J&^U3P3\1/ #/=>'/!\>C2
MVJ6]SIADNXM-.\[[=83YUP3*&,A1P6!<9_8K_@WA^"WBS]G_ /X),?#/POXV
M\/ZIX7\160O'N-.U& P7, >YD9=R'E<@@X/8U\$_MK?L6_'CX8?\'57P_P#C
MGX/\%^)-7\">)M4T![S7=+T][FUT^Q:TBTF_CG<*0C"*.9B.H25&[T ?NA7P
M#_P=#?\ *#3XW?31/_3W85]_5\4?\'$GP7\6?M"?\$>/B_X1\#^'M5\5>)M4
M32FM-,TV SW5R(M7LII"B#D[8XW<X[*: /QL_P""0WB3_@IUIW[#'A]/V;-+
M\.W7PG6[N_[-:[316F>7S#YW_'RPEQOSC=@>G%)_P28\=^(O@'_P<B0W'[9V
MF^)+?X[>)G;3M&O9[R%[73]4O[8PVY=8-R21RV\GV>'RG\N,S+E< -'K_P#!
M/O\ ;<_X**?\$W_V7=)^%/@W]E>ZU/0='N+BX@NM6\*:E)=,TS[R&,<R*0&/
M&%'%>E_L*_\ !,S]K+_@IC_P5V\-_M3?M.>#Y?AGI/@74['619&V;3Y+N;3E
MCDLK6TM9&DD$1E6-I'<X($H#;V& "E_P>6_MCZ;XF^/7PA^ MQ?7<'A_0POB
MGQ2;2!9+B/SW,$/EY8!G6%;AMC8&6C.0#FOE;X2_\%./@O\ L[?\%Y_AW\:?
M@?#KGA7X2ZJ-/T#Q38ZMIRZ;Y-O-"EE?3O';S2B100E[@8S+&!MXR?M__@F#
M_P $Z?&W[>G_  6U^.'Q^_:2^"^I6?@N;[7)HFD^-_#$#V=^'9;6SBD@G5D:
M2&SC4EE!^=<YR:]L_P"#C7_@A_X-^*?[ BZU^S[\$_!>A_$/P7K=M?\ V7P;
MX8M["^UBQDS!/ $M8U\TJTD4WSYVK!(1C)R ?IC^U?\ LQ>%/VR_V>/%?PS\
M:V*WWAWQ;8265PN/G@8CY)HS_#)&VUU(Z%17\J7@K]C_ .-/Q*_;ETG_ ()P
MWWCXKX%T'XBWE^ZK*3:PJD#23WB KEF^R1R/'$0%$LS?=WLU?TO_ /!(?Q[X
M_P#B%_P3@^$]Q\4O#NM>&/B!INBIH^LV>K0RQW<DEHS6RW$GF?,S31Q)*QZ%
MI&K\M_@U^PY\8-%_X.V=4^*5U\-_%L'PYDUC5+M?$;V#C33%)I$T4;^=]W#2
M,JCG.2!0!^UGP'^!_AG]FGX,^&? '@W38M(\+^$=.BTS3;1.?+BC4*"QZL[<
MLS'EF9F)))-=;110!_-[_P 'ANJZEH7_  5&^!5]H]J+[5[/PS:SV-L5+?:)
MUU29HTP,$[F & >]>I?M/_MD_P#!5;]MSX.>(/A;;_LPVO@>U\96DVEZC>V-
MG]FE>TE0QS0B:\NC%&'1BI;@X)P:VO\ @YA_8>^+_P"T=_P5,_9^\3> OAQX
MM\7>'])TZQ@O;_2[![B"T>/5'D=79>%(1E;G'!K]UJ /SA_X)5?L3P_\&_?_
M  21\=:S\0-2M;[Q-:P7WCCQ5+9)YT-J\=JJQV<)P&E6-81S_%)+)C@J!_//
M\&/VJO@MXX^ _P"U'>?&F#Q+??%_XQRI?>&+RPT2&]LM'O%N'NVE,LEPDD7F
M.QA(4-MC.?F(Q7[]_P#!U1IWQ<^*O[ VD?"OX2?#_P 5>-[OX@Z]#_;CZ1IC
MW:V5C:$3A693^[>2X%OC((9$E'%>M?\ !.[_ ((J_ OX(_L0_#'PUX\^"'PF
M\4>-+#0;=]<U+7/!FG7FH37DB^;*LLLD3NQ1G,?+'A!0!\V_\&GG[:S?M&?\
M$IO$GPYU2\-QXA^"EQ/I@#L[R-I=VDMQ9.S-QPXNH55>%2V3@9%?D[_P0:_:
MW_:5_96^+7Q:F_9S^"]G\8+[5HX$UJ*X@GD&FQ)/)Y;#RI8_O,6'.>E?>O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!U70X?"5QX/O+[7KW0K22W"WS.-3C4;C.82XBV[XR< '8/T1H **_,_]H/\
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M?Q9_T&-/_P#!;_\ ;*/^$W\6?]!C3_\ P6__ &R@#UNBO)/^$W\6?]!C3_\
MP6__ &RC_A-_%G_08T__ ,%O_P!LH ];HKR3_A-_%G_08T__ ,%O_P!LH_X3
M?Q9_T&-/_P#!;_\ ;* /6Z*\D_X3?Q9_T&-/_P#!;_\ ;*/^$W\6?]!C3_\
MP6__ &R@#UNBO)/^$W\6?]!C3_\ P6__ &RC_A-_%G_08T__ ,%O_P!LH ];
MHKR3_A-_%G_08T__ ,%O_P!LH_X3?Q9_T&-/_P#!;_\ ;* /6Z*\D_X3?Q9_
MT&-/_P#!;_\ ;*/^$W\6?]!C3_\ P6__ &R@#UNBO)/^$W\6?]!C3_\ P6__
M &RC_A-_%G_08T__ ,%O_P!LH ];HKR3_A-_%G_08T__ ,%O_P!LH_X3?Q9_
MT&-/_P#!;_\ ;* /6Z*\D_X3?Q9_T&-/_P#!;_\ ;*/^$W\6?]!C3_\ P6__
M &R@#UNBO)/^$W\6?]!C3_\ P6__ &RC_A-_%G_08T__ ,%O_P!LH ];HKR3
M_A-_%G_08T__ ,%O_P!LH_X3?Q9_T&-/_P#!;_\ ;* /6Z*\D_X3?Q9_T&-/
M_P#!;_\ ;*/^$W\6?]!C3_\ P6__ &R@#UNBO)/^$W\6?]!C3_\ P6__ &RC
M_A-_%G_08T__ ,%O_P!LH ];HKR3_A-_%G_08T__ ,%O_P!LH_X3?Q9_T&-/
M_P#!;_\ ;* /6Z*\D_X3?Q9_T&-/_P#!;_\ ;*/^$W\6?]!C3_\ P6__ &R@
M#/TO]DZZT_\ X*(:Q\<&UN!K/4_A]:>"4T@6Q$D;PZA/>-<&7=@J1*JA=H(*
MDY.0!XI/_P $?-+;]E7X?>!8M1\.6_B;P5\0=/\ &\WB)-#03WZVVN'4VMR0
M1("Z'RMY8\C.".*][_X3?Q9_T&-/_P#!;_\ ;*/^$W\6?]!C3_\ P6__ &R@
M#YR^!G_!.GXY?LP?M0?$SQ9X)^(OPF7PG\4/B#>^-=1MM3\&3SZU%#=F 262
M7BW*@*$@3'R8#EFQSBONBO)/^$W\6?\ 08T__P %O_VRC_A-_%G_ $&-/_\
M!;_]LH \(_:?_P""-'A/]IO]L+XD_%:_U"ULY/B-\(;GX97-K'8@RPW,TK_\
M33S=W,BVY2 # (5/O=JQ?%G_  1.TWXD_#+]GWX>ZYXWURQ\ _ _1I2\'AZ[
MN=)U35===$7^T5NXY-\:@M<OLY;=.?FXY^D?^$W\6?\ 08T__P %O_VRC_A-
M_%G_ $&-/_\ !;_]LH ^:M,_X(Q7'@/_ ()R?%;]FSPS\0)E\'^+/$#:GX2F
MU:V>\F\,V<L]M=36DC;U:XS<I=2*Y(/^D#.2#GJ_VZ?^">_Q&^//[97PY^,W
MPW\9> /#^L^ _#VH:#]C\5^&I-:MIOM4T,OG($FCV2(8A@\D9KVK_A-_%G_0
M8T__ ,%O_P!LH_X3?Q9_T&-/_P#!;_\ ;* /%/B/_P $MI_VK/BII_B7XW:M
MX5\7)=?"6_\ ASKMGIVCO:QSWEU?07)U&U:21S;E%AP@&75FW!^,5<^%'_!-
MWQ'8_&KX'^-OB/XWTCXA:M\(/!NI^%9I[G1 DNLR3W$#6UX=SLL<L<-NBN0"
M7D+,"H.*]?\ ^$W\6?\ 08T__P %O_VRC_A-_%G_ $&-/_\ !;_]LH \N_:R
M_P""5WA7]L_X[>-/$GC:>VO-#\5?#BU\#V]JEKB]TBZ@U&ZOH]2@N,_)(CS1
M% H&&AR20<5SOB[]@7XVV7B#P#\1_!GQ<\)Z7\;M)\&IX)\8:SJOAA[[2_%U
MLCK*EP;<3(\,Z3!I 5DVGS9 1@@#W/\ X3?Q9_T&-/\ _!;_ /;*/^$W\6?]
M!C3_ /P6_P#VR@#P[X3_ /!)"W^&7BCX$WUSXL7Q(OPQD\5:AXH;4K 22>,+
M_7XE6ZE(W;(H]_F'RR&&UE7C!S6^!W_!'VP_9M_9?_:,^%/A'Q-Y/A[XS7E[
M/H2WD#SGPQ!<:?%:):DE\RQ0^7B, KMB5$YVY/O7_";^+/\ H,:?_P""W_[9
M1_PF_BS_ *#&G_\ @M_^V4 =O\'/ C_"WX0^%?#$EPMY)X<T>TTMKA4V+.8(
M4B+A<G .W.,G&:\1_P""A7_!/I?^"AD_P[T'Q!XJU;0?A_X5UJ37]8L=&N9K
M'4M6N8X'2R\NZC<&%89G\T_*261,%<9KM_\ A-_%G_08T_\ \%O_ -LH_P"$
MW\6?]!C3_P#P6_\ VR@#Y$O?^"'GB3X1_"=O"/P?^*G]DZ?H?Q3T[XH>%E\6
MVDVN?V5<16DT=Y!*WFH\PGGF:;<2&!9LDG!'3?$S_@E'\1OVX?&G@V\_:2^*
MUGK&E> EU&XTJT^'4%[X5E:]N5MXX[B67[1(Q,4*7: *5R+H\X!!^E?^$W\6
M?]!C3_\ P6__ &RC_A-_%G_08T__ ,%O_P!LH ^./%'_  ;[6?B7X&^$/A?-
M\0;RZ\!_#_4?%$WAZ&^BDN;[3[74[9!8Q"?>/GL[I?/#X&["C .2:ND?\&_E
MQX+_ &1OBQ\-=#^(&GK?_%#PKX5TJYU6_P!+DN"^J:7=WMY>W\Z^;NE^USWK
M/M+93D988Q]H_P#";^+/^@QI_P#X+?\ [91_PF_BS_H,:?\ ^"W_ .V4 >!_
M$/\ 81^/GQT_9'\6_#?QA\1/A';7ES?:5J7A>Y\.^#+C3[+29K._BO")H#=-
MYJ.T2C"E",GDYK&\=?\ !*GXI?M >$OBAJOQ(^+^AWWQ.^)'A:V^'L.JZ)X<
M:PT[P]X:-Z+B_M[>!IG=KFY5I 9G<[2D.!A"#]*_\)OXL_Z#&G_^"W_[91_P
MF_BS_H,:?_X+?_ME 'S/\-O^"/\ /^P-\0_%'C[X >,?% O-0^'M[X;?1/$M
M[)KTMY>0)NT=H9[F3$,=N^Y/*/R%'Q\N#GZX_9>C\>0_LX^!5^*4FGS?$A="
MM!XG>Q"BV?4?)7[08PH"[?,W8P /2N?_ .$W\6?]!C3_ /P6_P#VRC_A-_%G
M_08T_P#\%O\ ]LH X[]LO]C;Q9\7OBSX'^*7PL\::;X%^*/@6WN]+@NM6TMM
M3TO5--N]AGM;B!9(V^_'&Z.C@JR]P<5Y+\4O^"0GB?\ :LT+X;Z7\:?C9XN\
M66/A76M2\7:Q_8TDFB2W6LS+''8_8GB?=9VEE&;D1Q@LY,V2_6OHO_A-_%G_
M $&-/_\ !;_]LH_X3?Q9_P!!C3__  6__;* ./\ ^"=7[!/_  [Q\+^./!^C
M^)K[7O >L>(WU[P[::E)+<ZAH_GPQ_:HIKF1R9]]PCS X7!E;.223]%UY)_P
MF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME
M'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_
M^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS
M_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";
M^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4
M>MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:
M?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^
M@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5
MY)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+
M?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI_
M_@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_P
MF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME
M'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_
M^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS
M_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";
M^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4
M>MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:
M?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^
M@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5
MY)_PF_BS_H,:?_X+?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+
M?_ME'_";^+/^@QI__@M_^V4 >MT5Y)_PF_BS_H,:?_X+?_ME'_";^+/^@QI_
M_@M_^V4 5J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex101170630image4a02.jpg
<TEXT>
begin 644 ex101170630image4a02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY;_ ."I
MFF6>J>"?A2+RQL-06V^(EG<QQWEK'<1K(EAJ#(VQP5R",C(KZDKYB_X*@_\
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M^F[4* /0?^"?W_)AOP2_[$'0O_3=!7AO_!<+_DU[P_\ ]AN^_P#4;UNO<O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8O^"H/_(C?"_\
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M)2">>37T=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111F@
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M(>1EQO1#G&>.M9O_  3"_P"3<]8_[';Q)_Z=KFOHJ@ HHHS0 4444 %%%&:
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M ($C]$Z*_.S_ (>E_$C_ )]?"_\ X!S?_':/^'I?Q(_Y]?"__@'-_P#':/\
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M\;?LD_$C0_"?Q+UYO&W@7Q9=KIOA[QK<01VVH:??-_JK#5$B186\W&V&ZC5
MSCRY$#LCR?1^#7Y<_&C]MCQE\?/A9K7@_P 11Z+-H^O6_D3&*V*30,"'CFB<
M-E)8Y%21''*NBL.171V/_!2[XGV5E##]HT6;R8U3S);/+R8&,L0P&3U/%'_$
M5LE_O?<O\P_XA#GW]S_P)_Y'TU^SU_RD,_:,_P"O#PI_Z2WE?1.#7Y:^%/VT
MO&O@WXK>+?&5F^E_VUXUBL8=2WVVZ,K9I(D.Q=WR_+*V>3GCI76?\/./B=_S
MTT'_ , 6_P#BZ/\ B*V2_P![[E_F+_B$.??W/_ G_D?H[MHVX_\ U5^<+_\
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M-._\ (_\*/\ AY+\5/\ H*:=_P" $?\ A1_Q%C)>T_N7^8?\0=SWO#_P)_\
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M/E4&?DED&#D<YQD"C_B+F3_R5/N7_P D"\',[_GI_P#@3_\ D3] O^"?V?\
MA@[X)_\ 8A:%_P"FZ"O7B<5^77PN_;C^('P?^'V@>%M%OK!=%\,Z=;Z780RV
M:R-%;P1+%$I;[S81%&2<GN:ZFV_X*>?$R#&[_A'INGW[-AG_ +Y<=:VCXL9*
M]U-?)?HS&IX09]';D?I)_JD?HUU__505K\];;_@JE\1(O]9IOA63_MUF4_\
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M_P""NUT^?+\!VZ>F[5RV/RA%.7B-P^O^7_\ Y++_ ")CX9\1MV^K_P#DT?\
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MOUA;'Y&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK\HO_B:]XHH_U7RO_GROQ_S#_6S-O^?TOP_R/!Q^P-X>'_,:UK\HO_B:<O[
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M^0UK_P#WU#_\;H_X8%\-?]!K7O\ OJ'_ .-U[M11_JUE?_/F/W!_K5FO_/\
M?WGA/_# OAI7S_;6O8]"T/\ \;I?^&!_#/\ T&-=_P"^HO\ XBO=:*/]6\L_
MY\Q^XG_6?-/^?\OO/"O^&!_#/_08UW_OJ+_XBC_A@?PS_P!!C7?^^HO_ (BO
M=:*/]6\L_P"?,?N#_6?-/^?\OO/"O^&!_#/_ $&-=_[ZB_\ B*0_L#>&<?\
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M;KD8VXYH_P!7<M_Y\Q^Y$_ZRYG_S_E][/*M*_9<\5:FEB?\ A-[%?MG]L?\
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MW&6W:YX@DR<C)A^7\HZ=_P ,#^&?^@QKW_?47_Q%>[44_P#5_+O^?,?N1/\
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M^_L/_P ;H_X8'\*_]!;Q!_W]A_\ C=>Y45E+A[+9;T8_<C2/$V9QVKR^]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHDN_Q!\&\_\ 0Y0'_P <-8=O^Q9\<+BVCD_X:)UH>8H;']GOQD?]=JR/&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_"/_GX\8?\ @QC_ /C5?5U% 'P'^U-_P3T\ _LS>#M#\2^'9/$$FI#7K*V
MO+Q)(@KR8/RB-3GTYJ_^S5_R<+X)_P"PY9_^CDKV?_@I1'YOP3T5?^IDL#^3
MD_TKQS]F"'[1^T7X)4\8UFU;\I%/]*_-^*M<YPB\X_\ I2/T[A/3(L:_[LO_
M $EGZSQ_ZM?I3J;'_JU^E.K^BX['\TA1113 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /H8KVS_ (*':'-K7P4TWR6C7[+KMI</N[JI)./>O$_V6/\ DX[P3_V%[?\
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M_P#DC-Y_V$=,_P#3A;5Z%7GO[4?_ "1F\_[".F?^G"VH Y[_ (*!_P#)FGQ
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MC4(]/G) 25K<N@F"G!V%USC&17T]^W/_ ,D7C_["$/\ )J^?OV6/^3CO!/\
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MO*** "BBB@ HHHH ^7?^"3*;/V>/$ _ZFBZ/YV]L:^HJ^7_^"3GS?L]>(/\
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M3X$>+([S4M/M)&\7W;*DUPD;$>1;<X)SCKS[4 ?8%%8__"P_#_\ T'-'_P#
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M2\GN9MOF.TTS%SG8.,X'/K7IJ?<'TI:_HR.Q_- 4444P"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@#)('XU\1_\ !&^'^SXO%L,;2"*ZL[*ZD0GY?,\VZ3(';Y445]&?M:>#M/\
MB_X;T'P'?>;)'XJU:+[1'#(8Y!:P S3/D<@#:B9_O2KZT =U_P +3\+_ /0Q
M:#_X,(O_ (JKNB>,=)\2S21Z;JFG:A)" SK;7*2L@/0D*3C.*^=A_P $D_@_
MG_CRU[_P:25\]_\ !+VS_P"$+_;B\9:%8S3QZ;#;:A;^4SEMZP72I'N]2!GG
MW- 'Z/5G2^+])AD9'U33E>,E64W* J1P0>:MW]['IMC-<3,L<-NC2.Q. J@9
M)K\\OVO/V:O#WA+]D&X^)UO'J=OXK\1:K]O:?[?+Y9ANKJ21/W>[:/W3IVH
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M%;:Q-K&H-<BX>'59X8R4N98UPBL ,*H' KU)O^"67P@=LMI>N,WJ=:N?_BZ
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M-\S8 P ,5VE%% !67XX_Y$O6/^O*;_T6U:E9?CDX\%ZQ_P!>,W_HMJ /BO\
MX)DZ!XT\+>"[S7-%\-V^J6.O6D5I;W<^H);PP20W%R7WK@R$?./NJ:^N/A[\
M-;O1M<N?$'B"_CU;Q+?1" R1(8[:P@!SY$"$DA=W+,?F<@$X "CRG_@EPO\
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M2,@]B6X.?3O7A=WI]CK%V\WPBTOQ!IMU(Q)O;$_8="<^KPS#RY!G[WDH'/\
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M2^'?_0_>"_\ P=VW_P 70!VE?+'_  3'E\V;XO?[/C.Y7]37N?\ PTE\._\
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M_P"!JT >AT5YO)^V#\+HIXXV\>>&0\F=H^VKSCKST'XT[_AKGX8_]#YX7_\
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M7]B;_DZCP9_U^/\ ^BGKZ*_:T_Y-_P#$'^[#_P"CHZ^=?V)O^3J/!G_7X_\
MZ*>OSCB+_DH<'ZQ_]*/T[AO_ ))O&^D__2#]4!THH'2BOZ+/YI"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#X=_X*Y?\C+X)_P"O>\_G%7"_\$_/^0WXF_ZX6_\
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M74G@?3XWN&W,D,TL,:G 'RHK!5''0 #K7N%% 'A/_#M+X*_]"5;_ /@7/_\
M%T?\.T_@K_T)5M_X%3__ !=>[44 >$_\.T_@K_T)5M_X%3__ !='_#M+X*_]
M"5;_ /@7/_\ %U[M10!X3_P[2^"O_0E6_P#X%S__ !='_#M/X*_]"5;?^!4_
M_P 77NU% 'A/_#M/X*_]"5;?^!4__P 71_P[2^"O_0E6_P#X%S__ !=>[44
M>$_\.TO@K_T)5O\ ^!<__P 71_P[3^"O_0E6W_@5/_\ %U[M10!X3_P[3^"O
M_0E6W_@5/_\ %T?\.TO@K_T)5O\ ^!<__P 77NU% 'A(_P"":?P5'_,EV_\
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MLF!_X]3F_8-^%#*0?"-F0PP1YLG/_CU>OT4 >)_\.ZO@S_T(NF?]]R?_ !5
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M 4444 %%%% !1110 4444 >._P#!0)L?L;^/O^P:W_H2UUG[-?\ R;]X,_[
MUM_Z+6N1_P""@?\ R9QX^_[!K?\ H2UUW[-?_)OW@S_L#6W_ *+6@#MJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYA\%OC_@JIXR7_J5;4_\ HNOIZO(_B3^QUH?Q"^*DWC2W\1>,
M_"WB*ZM5L[BYT/4EM_/B7&U6#1OTP.F* /7**\7_ .&.)O\ HKOQG_\ "@A_
M^,5+^S[X)O?!/Q=\86/_  F'C+Q5ING6]I #KNH+="*X8,[!-J* 0I7/'<4
M>QT444 %>5_MIZ+>:_\ LW>)+>QM;B\G,(;RX5W/M# L<>PR3["O5*R_&UA-
MJO@S5[6W7S)[BRFBC7/WF9& 'YF@#Y__ &)_VJ9O&/[-GAR6X\)^(II-/A.G
M>;I=B9[>40?NPP8L#D@9([&O5O\ A?:_]"?X[_\ !1_]G7RS^P+X>O=-_9QL
M[6;2?B<]Q:ZA>02_V/JOV>U5UF96 7S5Y!!!XZ@U[3_9-Q_T!_C;_P"#T_\
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MJ7]?;9].4445]\?G04444 %%%% !1110 4444 %%%% 'C?\ P4$_Y,X\??\
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MID[!GMF(RK*PXDB;!*N." > 05 !TU%%% !1110 4444 %%%% !1110!YO\
MM<N$_9]\09XR( /^_P#'7S[^PM_R=?X._P"OB7_T1+7O_P"U^?\ C'W7?K;_
M /H^.O /V%O^3K_!W_7Q+_Z(EK\YX@_Y*/!^L/\ TL_3N'?^27QOI/\ ](1^
MI0Z44#I17]%'\TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\#_\%8S_ ,77\,_]
M@M__ $::YO\ X)^?\AOQ-_UPM_\ T*2ND_X*Q'_BZ_AG_L%O_P"C37,?\$^P
MW_"1>*#N.W[-; +@<'=+SZ__ *J_GRO_ ,EE5^?_ *2C^C<+_P D/1_K[3/I
M^BBBOOS\Z"BBB@ HHHH **** "BBB@ HHHH \;_X*"?\F<>/O^P:?_0EKK_V
M<./@'X/_ .P1;?\ HL5R'_!07_DSCQ]_V#3_ .A+78?LY_\ )!?!_P#V"+?_
M -%B@#M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K$\2_$SPWX,N5AUCQ!HFDS,,JEY?10,1[!F!K;
MKY+@\$Z/X^_X*E^+;76]+L=6MH?"MM)'%=P+,B-^[&0&! - 'T-_PT!X#_Z'
M;PC_ .#BW_\ BZY;X$>,-%N/BAXTT/0=8TO5-+\R'6+<65VEPENTX83+\A(4
M&1=V/5SZUT/_  SA\/\ _H2O"_\ X+(O_B:V/"'PO\-_#^XFFT/0=)T>6Y4)
M*]G:I"T@'(!*@9Q0!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %!.!17S+_ ,%:M2NM+_9!NIK6YN+67^U;
M5=\,AC8@E@02.Q]* /I;[7'_ ,](_P#OH5YW\8A%X4\9>%_%UJT:307J:3?E
M2/WUI<';AO79)L8>Y-9.C_L4?"VXTBUD?P;I;.\*,Q)?DE1_M5>L/V,/A?IE
M];W4/@[2X[BUE2>)_G.QU(96&6Z@@&@#U"BBB@ HHHH **** "BBB@ HHHH
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M $6* .THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRL4$&I0R22G<O"J&))]A70? #X_^!](^!_A.UNO%F@6]Q!I5NDD<EZBM&PC
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M4T ;="L@>"($R/\ @(JW0 4444 %%%% !1110 4444 %%%% 'EO[8^K6^G_
M35(9I%CDOI8(8%/61Q*CD#_@*,?PKQ#]@&/S?VN?!Z_]-+H_E:3G^E>J?MX@
M_P#"H]/]/[5CS_WZEKR[_@GU_P G>^#O]Z[_ /22>OSC.M>)\&O.'_I3/T[(
M].$\>_*I_P"D(_3ZBBBOZ+/YI"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\?\
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MZ?\ \.[_  #X+?\ XJ+X5W^I6Z]=1\-:Y>7/_ GM9)!,O^[&9C78_P#!)/\
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MYJ1X_P#PF@_^-U]844 ?);_\$F=%?_FI7Q$_"ZB'_LE,_P"'2&B?]%*^(_\
MX&Q__$U];T4 ?)'_  Z0T3_HI7Q'_P# V/\ ^)H_X=(:)_T4KXC_ /@;'_\
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M ,.AO"/_ $/OQ*_\&,/_ ,:H_P"'0WA'_H??B5_X,8?_ (U7UI10!\<^,/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLZWVDW]GJ=C=>))5CN+299HG^>U/#*2#TKZPKY3\"_\ !*/P[X(^)VB^*O\
MA-/%FHZAHM_%J""[,4@F:-@VUB5S@XP3UQ7U90 4444 %%%% !1110 4444
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M(4NS@<?+WH \7E_8/^%NO0:=-X<^%VI:E;7V6:YU"^FTJ.! Y4[DD!FW$#<
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M **6NQH *^?_ /@I_P#\F3>,?^W7_P!*8J^@*\!_X*??\F4>,/\ MU_]*8J
M/2OV</\ DW_P/_V K/\ ]$)7:5Q?[.'_ ";]X)_[ 5E_Z(2NTH **** "BBB
M@ HHHH **** "OC\?#GQ=J?[?7Q TNQMUTWP_KG]EZX-0GT^>:'S;818V.I5
M%D)60?,2.IP37V!10 4444 %?./_  50_P"32KK_ +"]A_Z/6OHZOF__ (*J
M3*G[)=UN95W:O8 9/7]^I_D#0!](45':WD-]%YD,L<T?3<C!A^8J2@ HHHH
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M[!*[?$^N?[6F6Y/_ '_GI/\ @ITV?VFY/^P7;@>WS/3_ -@G_D:-:_[!EO\
M^E%Q7\[X;7BW$^LOS1_2&(TX,POI'\F?35%%%?HA^;GQ'_P3E_:0\#_"7X=^
M-M/\4>*-+T>_G\87EQ'!<R%7:+R;=%8<=,HP_P" FOH;_AN/X1_]#]X?_P"_
MQ_PIUS^Q#\([RYDFF^'WAF269B[L;098DY)J/_AAGX/_ /1._"__ (!B@!W_
M  W'\(_^A^\/_P#?X_X4?\-Q_"/_ *'[P_\ ]_C_ (4W_AAGX/\ _1._"_\
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M4'/<FND_X8!^#?\ T3[0?^_;?XT?\, _!O\ Z)_H/_?#?XT 7/\ AN/X1_\
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M-??"W_H?O"W_ ('I_C1_PU]\+?\ H?O"W_@>G^-<I_P[<^"O_0BV/_@5<?\
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M .1M\3?]>5O_ .C):_G?!Z\68GUE^:/Z1QFG!V$](?D?45%%%?HA^;!1110
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M^SEH_P#PK^X\$P^%Y)KA[5-4C9KH$RMOW$''WLX]J]:^Q?M9?\_GPS_[\O\
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M<M;93]?+!_K6U^PR<Z[??]@:'_TLNZ_G;+=>*L7ZS_\ 2D?TIF6G!^"](?\
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M HHHH **** "BBB@ HHHH **** "BBB@#\S_ /@HW_R=?KO_ %PMO_1*UO\
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M .B6K\[S3_DJ<)ZP_P#2C],RO_DC\9Z3_P#24?IA1117]$'\UA1110 4444
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M^?$O_ 7_ )'IU%>8_P##87P^_P"@Y+_X S__ !%2?\->_#O_ *&!O_ "Y_\
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MKSR1W Y%?$7BC]KKXR>"M N]8U;]GW2]/T_3F:_N+F:S94@;^*8G'#>K=:]
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M\85OIN*M^8%0_P##N/XL?] .S_\ !C#_ /%5^F%&*7_$*\D_O?\ @7_ -/\
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M_P#24?I51117]%'\V!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\$WO^3,_!?\ U[/_ .C&K=_;C_Y-"^(G_8#N/_0:PO\ @F]_R9GX+_Z]G_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 Q!R21VP?HS_@G1X[U+XG? &X\0:O)'-JFJZW>37+QQB-7<.%R%' SM' H
M]ZHHHH ^,?VD? _BCX@_\%(-)T_PCXH?PAJW_")&07ZP"8[%DDW)M.1SD?E7
M7_\ #*GQZ_Z+W<_^"F+_ .)J?5TS_P %5]+;^[X+8?G))_A7TQ0!\PI^RO\
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M^TC^T9X'?XH>%KNS\?6JPQ:9J,4D^@ZM9R2(S&W*JY:0  [21SDE>.]>??\
M!%*[^U>%?B!C)$=Y:+D]\_:&_P#9J /N*BBB@ HHHH \O_;5_P"33_'W_8(F
M_E6'_P $[_\ DT/PC_URE_\ 1KUM?MLG'[)GQ _[ TQ_2L/_ ()U'=^Q]X1/
MK#)_Z-:@#VZBBB@ HHHH **** "BBB@ HHHH **** "BBB@#R/\ ;9_Y(=-_
MU^0_S->;_P#!,_\ Y.CL_P#L'W'\EKTC]MG_ )(=-_U^0_S->;_\$S_^3H[/
M_L'W'\EK\ZQW_)687UC^9^E8'_DC\7Z3_P#24?I)1117]$G\VA1110 4444
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MG/\ X[6'_P $XFW?L;>#3_>MW/\ Y$:MO]N/_DT+XB?]@.X_]!K#_P""</\
MR9IX+_Z]F_\ 0VH ]QHHHH **** "BBB@ HHHH **** "BBB@ HHHH \@_;=
ME\OX)2+_ 'KV(?3[Q_I7GW_!,J'S?VG[=L_ZO3KAOK]T?UKOOVX/^2*?]O\
M%_(UPG_!,7_DYZ/_ +!5Q_Z$E?G>,UXLPOK'\S]*P>G!N+MVE^2/T=HHHK^B
M#^;0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;-_JF^
MAIU-F_U3?0U,MF..Y^/OQO\ W/Q5\7[?EVZM>;<=L3/7*_\ !%C]ICQ_\8?V
M@M>T7Q1XLUK7-)L/#+S6UK=3&2.%UN;9%8#U"LP^A-=5\=!CXJ^,/^PM>_\
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MOSM_X)[_ +/6E_M9W'BIK>W1F\+QVTQT^%A:#44D,H9?.(8H_P H*D@C(P<
MY'W%^S5^SM\/? \%YI7@_P 4^-/"FJ7TH?4-%FU&*.\CEC4YW(\1) !/S+E2
M.0:Y\!34*$81?,NZ]3HS*I*>(E.47%NVC]$?35,FN8[8 R2)&#P"S8S7!?\
M"A9O^A\\?_\ @=!_\9KRGX_?L^?#7XD>';1?&7CCQ?XBM[&\DBL[*+4HYII;
MI1M=(XXXMS.,X(_ASSBNPX38_P""E.HV\O[&_BL+-"S9MCA7!/\ Q\1U[!\*
M_P#DF'AW_L&6W_HI:_/W]IS]@'2?AW\!]>\<6UGJGAV'2HXC8Z==7:7-U.6D
M5=\[*JB/@GY%+'U((KZJ^ O[0'B#_A1?A77M<\(R)H-UI<$GVW2KC[6UK&$
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MJ3T]&_X(DWDE_P"%/B%))LW?;+(?(BH/N3=E % 'W-1110 4444 >5?MQ_\
M)H7Q$_[ =Q_Z#6+_ ,$Y1M_8W\%_]>K?^AM6U^W'_P FA?$3_L!W'_H-8W_!
M.?\ Y,W\%_\ 7JW_ *&U 'MU%%% !17SCXS_ &<_CIK/C#5+S2?C5_9NEW5W
M++:6?]E1,;6)F)2/=LYVJ0,GTKS[]H/P!\>?@1\'=<\62_&B:^3181,T"Z=
MIERP7 /E<=: /L^BN0_9_P#$%[XK^!_A/4]2N'O+^_TJWGN)W #2NT8+,0H
MY/H *Z^@ HHHH **** "BBB@ HHHH \=_;@_Y(I_V_Q?R-<'_P $QO\ DYU/
M^P5<?^A)7>?MP?\ )%/^W^+^1K@_^"8W_)SJ?]@JX_\ 0DK\[QG_ "5N&]8_
MF?I&$_Y(S%^DOR1^CU%%%?T0?S>%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWGC+0?#^J+A/#R>(+I#=*1@M<1K)Y<2D ?N4&01EF!W+7+EM.=/#QA-6:O\
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MB;_P40L(5TW3=8NM-\)+J%O8W\"S6U\\<LA,+JP(^=-R!B/E+!ARHKZ \"_
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MGTW7K0S6\*XM[V+RK@"XMS_%&3U'5#\I]3'_ ,$7M:M;'PCXZ:[NK6U:6:P
M5Y!']R.9.Y_V0?QH ^ZJ*S_^$MTK_H):?_X$)_C1_P );I7_ $$M/_\  A/\
M: -"BL__ (2O2_\ H):?_P"!"?XT?\)7I?\ T$M/_P# A/\ &@#SK]N/_DT+
MXB?]@.X_]!K&_P""<S9_8X\%_P#7JW_H;5<_;;\1Z?=?LD?$*./4+*21]$N
MJK.I9CM[#-4?^"<1_P",-?!?_7JW_H;4 >X4444 %>*_\%%/^3,_'7_7D/\
MT8M>U5XG_P %%?\ DS/QU_UY+_Z,2@#L/V7O^3<_ _\ V!+7_P!%+7>5PO[,
M*[/V=?!"^FBVH_\ (2UW5 !1110 4444 %%%% !1110!X[^W!_R17_M_B_D:
MX3_@F+_R<]'_ -@JX_\ 0DKN?VXG"?!91_>OX@/R8_TKA_\ @F(C/^TXO^SI
M=PQ^FZ,?UK\ZQ7_)6X;UC^;/TK"_\D;B_27Y(_1RBBBOZ)/YM"BBB@ HHHH
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MIX%U+XB?\%';+3=)\1ZIX7U ^$!+%>V) ?*RRG8V>J-T.,'T.:Y#XJ^/KO\
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M_3/]GGQUI7Q(^"7AK5]%NUOM/FL4A2905!>+]TXP>>'1A^%>@>6>1#_@E?\
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M"N@1@ZJ,QMG[K=:]W_X)P2>;^QIX+;C_ (]G''M(PH ]QHHHH *\5_X*'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGZG9VNH6-R-LMO<1B2.0=<%3P:N44 0Z?IUOI%C#:VL$-M;6Z".**) B1J.
M !P /05-110 4444!<**** "BBB@ HHHH \9_;H_Y(U!_P!A*+_T!ZXW_@E[
M_P G+R?]@>?_ -&15V7[<_\ R1J'_L(1?^@O7&_\$O?^3EY/^P//_P"C(J_/
M<1_R5V&]8GZ/A_\ DC,5Z2_0_1BBBBOZ&/YP"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MON/^>LW_ 'V:/M]Q_P ]9O\ OLU#15<S)Y%V)OM]Q_SUF_[[-'V^X_YZS?\
M?9J&BCF8<B[$WV^X_P">LW_?9H^WW'_/6;_OLU#11S,.1=B;[?<?\]9O^^S1
M]ON/^>LW_?9J&BCF8<B[$WV^X_YZS?\ ?9H^WW'_ #UF_P"^S4-%',PY%V)O
MM]Q_SUF_[[-'V^X_YZS?]]FH:*.9AR+L3?;[C_GK-_WV:1KZ9U(,TI#<$%CS
M45%',PY4%%%%24%%%% 'B?[=_P#R2*R_["D?_HJ2N8_X);?\G)W7_8$G_P#1
MT%=/^W?_ ,DBLO\ L*1_^BI*YC_@EM_R<G=?]@2?_P!'05^>U/\ DK\/ZK]3
M]&I_\D7B?G^A^B=%%%?T,?SB%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(-KT[XR:M'\2M:M? .FL+J:ZGBN-;>,Y73K1'#X<C[LDC*%5>I&3T&:],H
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MH^\T[/MH>E1IU'@YSC*T4U=6WU5M3]$****] \T**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /$/V]CCX2Z7_ -A:/_T5-6!_P2L7
M_C(W4?\ L 3D>W^D6U;W[>W_ "272_\ L+1_^B9JPO\ @E7_ ,G&ZE_V )__
M $HMJ_/7_P EAA_5?DS]#?\ R1.(^?YH_0VBBBOZ&/YT"BBB@ HHHH ****
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M<HHHK]%/S,**** "BBB@ KX;_P"":'[.VC_$+P7K7BJYO]>L=2MM6O\ 1_\
MB7Z@]JLMNSPRE6V8)RP&>><#TK[DKY;_ ."2R[/V?_$7_8T7A_\ '8J /HWP
M9X#T?X>Z3]BT73[>PMV8NXC7YI6/5F;JS'U))K7HHH **** *?B+_D7[[_KW
MD_\ 037S;_P2/&S]D6)?^HS>?S6OI+Q'_P B]??]>TG_ *":^<_^"3:[?V38
MQ_U&+O\ ]DH ^F**** "H[JUCO[:2&:..:&52KHZAE<'J"#P14E% 'A?[0/[
M('A'7_AKJ4D?]L:?:Z.KZS!I]K?R)8_:(8W9&\DDH.?0"O,_^">?[..B^,_@
M3I?B:ZOM>M[NZCN=+N(+/4)+:"XACOKAU#A""W,C9!.,5]/?%W_DDWBC_L$7
M?_HEZ\A_X)C'/[(.B?\ 7]?_ /I5)0![AX6\(Z9X(T:/3](L;;3[.'[L4*;5
MSW)]2?4\UH444 %%%% '"_M.\_L\^-/^P1<?^@&N9_8#_P"3-OA[_P!@M?\
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MG\4?]@B[_P#1+UX[_P $O'\S]C?06_O7=\?_ "9DKV+XN_\ ))O%'_8)N_\
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MU,/B(1P=2E)^])JWR:/JJBBBO1/+"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6]KWEO\ ^ GZ:^(?^0!??]>\G_H)KYM_X)%C=^R##_V&;S_T):^*[S_@N/\
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MX?ZFXSV7MN:/+>V[W^X_42BOR'_X?H?%K_GP\-?^ I_QKVEO^"E_Q(/[._\
MPF2OI O?L/VH0&T!BW;L8]<?C16XLPE'EYXOWG9:+?[Q4.#<95YO9RC[JN]7
MM]Q]I_M2?\FX>./^P+=?^BS7-_L!_P#)FWP]_P"P6O\ Z$U?FAXQ_P""T/Q4
M\=^%=0T74;'PS)8ZI;O;7"I:LK,C#! (;(X/6NO_ &,?^"GWQ :XT?P#9V?A
M^RT/2[*1;<K;O),JIR 69CGJ:TJ<38:$'.2=EKLO\S*GPGBZDU3A)7>F[_R/
MU@HK\O?V@?\ @L)\4OA#\19=%L;7PW<P1P1RAY[-MY+#)Z,!7"M_P71^,1;Y
M;'P:%]#82'_VI3H\3X6I!3BG9Z[+_,5;A3%TIN$VKK3=_P"1^OE%?GC_ ,/-
M/B5_PSC_ ,)E_P 2+^T?L'VKR?L9\G=NQC&[=C\:\/\ ^'Z/QD_Y\?!W_@OD
M_P#CM10XJPE;FY$_==GHM_O+K<'XVER\[7O*ZU>WW'Z&?\%+':/]A3XE,I*L
MNEY!';]['7S#_P $#?'NN>,+'XG6NK:UJVJ6NE1Z/%90W=W)/'9H1>@K&K$A
M!A%&%P,*/05X;KO_  5'^)/[57P^\7^"?$5KX=CTO4M!O)9/L5F\<Q:*/S$
M)<_Q*.W-1_\ !*?XO^(O@B?'G]EK%;_VE_9_FBYM]V[R_M6,9Q_?/YBN'%\2
M8:G65=W48K5:7UT6EST<#POBIT'AURN4GH[NVEF[NVA^PU%?'?\ PV]XX_O:
M3_X#?_94?\-O>./[VD_^ W_V53_K[EG][[O^"/\ XAYFG]W[W_D?8E%?'?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS1F@ HHHH **** "BBB@
MHHHH **** "BC-&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA^Q/XSU1;'1_@G^S#JEXP)6"U\':'-(P'7"K"375#_@D_P#LM$9_X9J_9_\
M_#>Z1_\ (]?G+H^K7.@:M:WUG,]O=6<R3PRH<-&ZD,K ^H(%?LO!_P >\9]5
M%?;\$\8SSV%7VE-0E"VSNFG?\K'PO'7!<>'YTE3JN<:G-NK-.-K_ )H\$_X=
M/?LL_P#1M/[/_P#X;W2/_D>C_AT]^RS_ -&T_L__ /AO=(_^1Z^@**^\/@3Y
M_P#^'3W[+/\ T;3^S_\ ^&]TC_Y'H_X=/?LL_P#1M/[/_P#X;W2/_D>OH"B@
M#Y__ .'3W[+/_1M/[/\ _P"&]TC_ .1Z/^'3W[+/_1M/[/\ _P"&]TC_ .1Z
M^@** /G_ /X=/?LL_P#1M/[/_P#X;W2/_D>C_AT]^RS_ -&T_L__ /AO=(_^
M1Z^@** /G_\ X=/?LL_]&T_L_P#_ (;W2/\ Y'H_X=/?LL_]&T_L_P#_ (;W
M2/\ Y'KZ HH ^?\ _AT]^RS_ -&T_L__ /AO=(_^1Z/^'3W[+/\ T;3^S_\
M^&]TC_Y'KZ HH ^?_P#AT]^RS_T;3^S_ /\ AO=(_P#D>C_AT]^RS_T;3^S_
M /\ AO=(_P#D>OH"B@#Y/_9/^ ?@3]F[_@HW\:O#WP[\$^$O .@7'PW\#:C+
MIGAS2+?2[.6Z?5/%T;SM% B(962&)2Y&XK$@)PH ^L*^?_AS_P I3OC)_P!D
MJ\!_^G?QG7T!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%\'^&K."TTVS\;:]H?BJ#28K.:XN=5A6VEALE$L[^<X"7<S1"% %"LT?:_\
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M[AQ'%''K%NS2,3@* 'R23Q@5^%__  =Q_&KP;\0?^"@/[-?P>\>:QJGA_P
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M !R2:^>_^#KKX >'_P!E3PO^PS\-_"OVT>'?!%IK&CZ<;R437#0POHRJ9'
M9SC)( &2< =* /W?^.?[7OPI_9@;3_\ A97Q,\ _#\ZL&:Q'B/Q!:Z7]L"XW
M&/SW7?C(SMSC(K@/^'M_[*W_ $<K\!?_  O=+_\ C]?BW_P>>VRWOQ/_ &;H
M6W;9M!NT;'7!EA%?8B?\&AW[(,_@F.^N[CXFZ7FS6XGN6\2Q*MO\@9F)>#:
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MVH_X(U?!W_@JIX;^*EY\5(_%C2>#[FQAT\Z1J2V: 3+*7WYC;<?D&.1C!XH
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M_P $Q/V.[/XF?#7QAXK\/>-H-=M+73]-U?6$N&U8,6+_ &<+&DB218$N\$J
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MFS)\.? .IQQ>%]+N OEO<0_-96W0AUMU(E<@\RNO.,B@#^@I6W#(Z=C12T4
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MUI9Z9J7P\M]6L+CPH+"WMQ;-96D%S9RW&GQ31;A*;&>"0ERRNC+&4S?VR/\
M@E1X?_;-^)'PW\0ZE\3/B=X+A^$6I6NM>$-(\,1:%#IVBW]OCR[E5N=,GD<@
M*@\N21H0$ $8YS]444 >?_&W]G?1_P!HG]GK6OAKXPO-6U30_$FF#2M4N4G2
MUO;Z(A1(Q>%$6-WP<F)4 W':$XQY?:?\$^O#^B?%CPKX^\8>/OBI\2K;X4F[
MOO!NA>(9[74+7PU+)"8?.C-M9I?ZC<QV^^*.2_GO)B7:0L\[>;7TA10!^,?_
M  0__P""8$/QX_9KM=-^,]O\>/"\'P]^*=SX\A^'OB#09]!T'5;LM)]AOW:\
ML$N;@!1EK>"[$"M%&TL(>5S+]4?&_P#X-\OA7\<?BMXP\777Q$^,VBW7C+QQ
M8?$:6ST[5-.:ST[7+*.2."Z@6XL9FP$EE7RY6DCP^ H 4#[THH ^6M'_ ."4
MWA'P;^U7XR^+'A3QW\5/!6I?$P69\;:+H6JVMMI7BJ:VW;;B;-LUS;S,&(:2
MRGMR<MC;O?<_X5_\$JO!_P "/VD?'7Q!\"^./BAX/T_XG:]#XF\4^#=,U2U3
MP_JNHQLSFX^:V:\MS+*Q>5;:ZB2; CD5X1Y5?45% 'S_ /#G_E*=\9/^R5>
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M8X(XI)]S[]Z3^6IEB<LKX!R'1)% /JS_ (331_\ A#?^$B_M;3/^$?\ L?\
M:/\ :?VI/L?V79YGG^=G9Y6SYM^=NWG..:_GB_8V\?V?_!4+_@[BU[XI> (9
MM1\!>&OM=Y/J<3@1M966CC2H;L;L$I/<^057&[;-DC"L1VJ_\&??QN#GP#_P
MU.?^%*F[^T?V<(;_ "6Z^;_9OG?9?,SW\W\:_5W_ ()=?\$H/A=_P2=^",WA
M/X>VMQ?:MK#I<>(?$FH;6U'7)T#;-Y4 )#'N81PK\J!F)+.SNX!^-7_! ;XC
MZ#_P34_X+O?'GX/?$BY;P[J'BV[N] T6YU!TBCFE2]^T6H=LX!N(&1DYY+*.
MI K]^_VC?VA_!_[)_P $?$GQ"\>:Y9^'O"OA>S>\O;RY<*, ?+&@ZO*[81(U
MRSNRJH)(%?(/_!8;_@@!\+_^"M9LO$5UJ5SX!^)NEPK;0>)K&U6Y%Y;J<K!=
M0%E$JKD[&#*R;CRP^6O@GP7_ ,&@/Q9^*?B71]+^-W[35[KW@'PP5CTNPL'O
M=0N(K<,-T,*W;"*TW(,!D$@4X^1@* /-_P#@V6\+^)/C;XS_ &U/CY>:?'I^
MB^)/#&JVCJBL(S>WLDM\\<1(PRQJF#SD;TSU%?-__!OI_P $?;[_ (*C:-\2
MKJU^+WBSX7KX2FLXC'HH;_3C*LAR^)%^[LP.O4U_2Q\!_P!@KX>_LJ_L=S?!
M3X::6GA?PO)I=U8"7'GW$\UQ$R27<[G!FF8MN)) P J[4557YT_X(=?\$3F_
MX(YZ#\0+23XA#QY)XVN;:4,ND_8%M%@5P./-DW%MY],8[T ?B'_P51_X)HZM
M_P $0OVX?@3XLU[QS8_&K1/$E^UY;IXJL6F\I;&>V\^&X1Y'5XS]I5E(*X.[
M@$9/]4WAS6++Q!H%C?:;+#<:??6\<]K)$1Y<D3J&1EQQ@J01CM7P_P#\%P_^
M")6E_P#!9#P+X%M_^$P;P/XD\!WMS+::BU@;Z.6VN403P&,21X)>&!@^3CRR
M,?-D?8?P+^',WP>^"/@_PC<7RZI-X6T6STA[P1>2+HV\"1>9LRVW=LSC)QGK
M0!L>-?\ D3=8_P"O*;_T!J_E=_X-L_\ @D9\*?\ @JIXQ^*5G\4&\0^1X1M;
M2:Q72[[[+\TLCABQP<\**_JJUO3O[8T>\L]WE_:H7AW8SMW*1G'XU^?_ /P1
M#_X(4?\ #G7Q!\0KYOB1_P )V?&R6\$:C1_L'V5(6=@3^]DW,=W08 QWH _+
MO_@XO_X(+? W_@E_^Q#X;^('PT_X2O\ M[5/&MIH,W]IZG]IA^S2V5],V%VC
M#;[>/GTSZU]@_P#!2;]LS_AD;_@UO^$MG8W/V?Q#\3/A[X<\)::09%<+-IL+
M7#JR$;66!)""3C)QSFOL_P#X+5_\$LI/^"NO[*6B_#6/QDO@=]'\46WB,7S:
M=]N6;RK:[M_*V>8F,_:MV[)^YC'.1\_?MT?\&Z=Q^V[\//V:/!>I?%K^S?"?
MP!\.6F@W=D-$:3_A(3%';1RS'%PHC+I;[0,,4#M\QS0!^17P4_X)L_\ !1#Q
M'_P3ANOA/X5^"6GW'P;^(DT'BIA<?V#%J5W*?*EBN1)-.MU&^R-% (5@A*XP
MQ!^\/^#;O]L__A=/_!$7XV?"/49MVM?!O3-56T5@!NTR_@N+B+!W%G9+@78)
MP JM"/I^V_AS0+3PIX?L=+L(5MK'3;>.UMH5SB*)%"HHSSPH K\V/V:?^#>%
MOV6?VW_CC\3?"_Q2CM/!_P :=,US2[CPLOAU5_LZ+47,R)'*)L!;>;:4P@+(
M@4XW$T ?DC_P;^_\$5;S_@J#\#?'WB2U^-'C+X8KX9UV+339Z*&\N\W6ZR>8
M^)%^89QWX%4OVY_V$=9_X(._\%8_@3XA\1>(;?XV^']4NK76;>X\2Z?YI=(K
MOR9[:19'D#21*T<B2C&UI$(4%,G]TO\ @B'_ ,$?9/\ @CQ\&O&?A63QTOCI
M_%VLQZL;A=+^P"U"0K%LQYDF[.,YXQ6#_P %OO\ @B''_P %@G^%]]:_$!OA
M_K'PUGOC%,=)^WI>1W7V9B"/,0JR-:H5Y(.]O:@#\[O^#Q;P9;_$3]N?]EWP
M_>230VNO6D^G3218\Q$FU"WC8KG(W ,2,C&:]F^(?_!F9^SOI7PZU34H/BI\
M2M!DLK"6Z_M"_N;%K.UV1EO,F!A7]TN-S?,OR@_,.M>[?\%B_P#@W[U;_@K1
M??"G4KSXO+X<UCX=:$^D7ET^@?:/[8F<QL]SA9U\HET)V?-C=UXKY#/_  99
M>(-;9;;5OVH-0FTYN9%_X1J28Y'3"->!3WZGB@#Y]_X(<?&SXE?M7_\ !+?]
MKC]EJQ5=>TS2?!%SKGA8A OV:5Y<36RMM#,)3AU#<A@V!\Q%?:G_  9Q_MH^
M&_%?['7B#X%7U]I^F^.O NM76IV^ER/Y=W?V%P5=IU5L;O+F+QN%R4'EEL;U
MS]\?\$K/^"3OPV_X),? ^Z\)^ VU+5-4UZ2&Z\0:[J+#[3J]Q&A53L7Y8HEW
M/LC&=H<Y9SEC\6?\%)_^#4;P7^TI\9[[XI_ [QM<?!CQU?7+:C/8Q6[-I,MZ
M6#>? T3++9L6W.=F]2Q&U4YR >[_ /!R=^V1X/\ V6?^"5WQ)T/7-0M?^$B^
M)VE3^&-!TKSPMU?23@)+*B=3'#&Q=VX ^5<Y90?RQ\)_ [5/A#_P9X^*-3U:
MUN+.3QQXKAUNU25@1):F\BBBD7!. PC)YP?:OI;]EO\ X-%+OQ!\;;/Q_P#M
M3_&C4OB_>6DZR3Z3;RW4RZLL>WRTN;^Y?SS'P5:-44E>!(M?H[_P4S_X)T6/
M_!0#]@O6/@=I.M6W@*QNA9)8W$&GB>"PCM71DB6$,@";5"@ C Q0!^+W_!(?
M_@W/U+]NO_@GEX!^*EO^T1\0/ T?BC^T-NB::K_9;+R-0N;;Y<2K][R=YX'+
MFN:_X)+?"&Y_X)5_\'*S_!GQ=)IOCZ[U03:19^([W3@+HR36GVJ*ZA:0N\+D
M!HW(8EAD9Q7[P?\ !+S]A[_AW!^PSX'^#/\ PD7_  EC>#UO-VI_8_LGVEKB
M]GNCB/>^T*9]OWCG;GC.!\Z?M;?\$-;S]H3_ (*U^ ?VJ/#OQ07PCJ7@\6 N
M=(;0Q=?;!;%PV)?-7'F12%#E3MX//2@#]#*^&?\ @Y'_ .4,7QJ_[!T'_I3%
M7W-7A/\ P4C_ &-?^'@/[%_C?X2?V]_PC+>+K5(%U+[+]J^S,LBN"8]R[@=N
M/O#K0!^'7_!$_P#X-I?@S_P4G_X)[^&?BQXR\6?$+2=>UJ_U&UFM]*N+9+5%
MM[J2%"HDA9LE4!.3UKC/A]\+)_\ @@;_ ,'%O@7X8_!_QQ?^//#_ (M;2=,U
MS3Y5AEOUM[]]LEA<B,!?/7;'<(0JD)+"2#R3[U8?\&6?BK1-/^RV/[3UQ:VZ
MY*PQ>'9HXP3UX%WCGZ5]8?\ !*G_ (->?AC_ ,$Y?CI#\3O$GC"_^+7C?2?F
MT.:^TM;&QT:8C#7 A\R4RSCD([. F20N_:R@'YZ_\'('C+X@?\%._P#@L9X;
M^ GP;T%_'6J_"W3?*328Y46WFOB!<W1F^T,D*A$$<;%F"M@+DD@'P/\ X*5Z
M'^W-^S_^TE\+_P!J?]I#P/I_A;6O">K:9H^BZO8G1UCGGM9)[V")X;&9]S;$
MF^9UQL0+G 45^X/_  38_P""%O\ PP_^WI\4?V@?%7Q(N/B+XP^(!NDM=^GO
M:?V;'<W'G2AF,S^:2$B09 VB/CK@>^_\%3_^"?6F?\%.OV*O%'PBU+5AX=EU
MJ2VN[#5Q9K=/IMS;S)*CA"5X8*T;88'9(X!YH ]:^!/QAT7]H_X'^%/'6A.M
MQH?C+2+;5K7+K)MCGB5]C%25W+N*L 3AE([5_-O\2/\ @FM\*T_X.R['X(KH
MJK\-=2U^#7Y]%&/L[;M(_M9[0+C MVF&S9_SS)7/>OWN_P""67[$VN?\$[OV
M+O#/PCUKQN/'W_"+2W"V&H+I:Z>(+:20R+!L#N6V,SG<QR=V.PKPGQ)_P0];
MQ!_P7&T_]L?_ (6(L<5FL>?"_P#8_P S,FD'31_I/F]#D2?ZO_9]Z /OVW@2
MU@2.-52.-0JJHPJ@<  =@*EHHH _ +_@]7T0^)OC-^RKIHF:W_M ZY;"51S%
MOGTM=P^F<UZ/9?\ !G#I/BRTLX?%'[2?Q+UC1Y-DEQ:"V3Y^ 1M\QW4$'H2I
MQ7UW_P %F_\ @B7)_P %:/B/\'_$$?Q"7P3_ ,*KGNY&@;2/MW]H+/+:2'#>
M:FPK]EQT.=_;'/WK:0?9K6./[WEH%SZX&* /BOQ/\._A9_P;]?\ !(SQY-X
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M^':?PZ_Z&3]H#_P^OC?_ .6U'_#M/X=?]#)^T!_X?7QO_P#+:OD?^(;\/_\
M/C_R:7^9]C_Q$SB3_H)?_@,/_D3RG_AT-)_T4%?_  2?_;Z/^'0TG_105_\
M!)_]OKU;_AVG\.O^AD_: _\ #Z^-_P#Y;4?\.T_AU_T,G[0'_A]?&_\ \MJ/
M^(;\/_\ /C_R:7^8_P#B)G$G_02__ 8?_(GE/_#H:3_HH*_^"3_[?1_PZ&D_
MZ*"O_@D_^WUZM_P[3^'7_0R?M ?^'U\;_P#RVH_X=I_#K_H9/V@/_#Z^-_\
MY;4?\0WX?_Y\?^32_P P_P"(F<2?]!+_ / 8?_(GE/\ PZ&D_P"B@K_X)/\
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M5=T[G!)S7J% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOX^^+7AC_A,O"VD7,5[8NY,ZM!+<(J+<*!QG: <]* /TUHK\KM3_ &C?#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex101170630image5a02.jpg
<TEXT>
begin 644 ex101170630image5a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KXM_9_\ ^"L_B3]HOXF0Z7HGP'\51^'[R#6;NTUF;Q'I
M*BXATZ>6V=O(\_S%,EQ$(U# $>8&.%#$?:5?$O[ EU\8+A_#I\7:.UK VD>)
M#,YTZU@_??VQ,+,9C QN@VG X;JW.30!-\,/^"I_Q&^*5OX9CL?V:?%R:AX\
M\*3^,O"T#>+M#V:K86\^G17!=_M.('0:G;,%?!8;QU4U8\.?\%1?'WCSP/\
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M_&OD^,N(JF2X!8RE!2?,HV>FZ?;T/L.".&:>>YB\%5FX+E<KI7V:77U/O_\
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M=G@S_H;O#'_@T@_^*H_X79X,_P"AN\,?^#2#_P"*K\E/^$/U?_H%ZE_X#/\
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M_HO_ ('1?_%5^1'_  A6L_\ 0)U/_P !7_PH_P"$*UG_ *!.I_\ @*_^%/\
MXBYC/^@+_P F?_R(O^(-8+_H._\ )5_\D?KO_P +*\._]!_1?_ Z+_XJC_A9
M7AW_ *#^B_\ @=%_\57Y$?\ "%:S_P! G4__  %?_"FOX1U:,X;2]17ZVS_X
M4?\ $7L7_P! ?_DS_P#D0_X@S@_^@[_R5?\ R1^O/_"RO#O_ $']%_\  Z+_
M .*H_P"%E>'?^@_HO_@=%_\ %5^0I\*ZH/\ F&ZA_P" [_X4?\(IJG_0-U#_
M ,!W_P *7_$7L7_T!_\ DS_^1#_B#.$_Z#?_ "5?_)'Z]?\ "RO#O_0?T7_P
M.B_^*KX1_P"">OA/0? 5SX<:3XI:!K'DZ+XHA*(M[#O\_6II0_\ I$:8\K.S
M#89L90,F&/SG_P (IJG_ $#=0_\  =_\*%\):LY^72]0/TMG_P */^(O8O\
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MXT?\)-IO_00L?^_Z_P"-?C>=/N ?]1-_WP:/[/N/^>$W_?!H_P"(QU?^@/\
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M31_Q&6?_ $!_^5/_ +0/^((P_P"@W_RG_P#;G[-?VE;_ //Q#_WV*/[2M_\
MGXA_[[%?C'%"\Z;D5G4]U&13OLDW_/*3_ODT?\1EG_T!_P#E3_[0/^((P_Z#
M?_*?_P!N?M K;ER.0>01WHK\7_LDO_/.3_ODTUXFB^\K+]1BG_Q&9_\ 0'_Y
M4_\ M"?^((+_ *#?_*?_ -T/VBHK\6Z*7_$9_P#J#_\ *G_V@_\ B!__ %&_
M^4__ +H?M)17XMT4?\1G_P"H/_RI_P#:!_Q _P#ZC?\ RG_]T/VDHK\6Z*/^
M(S_]0?\ Y4_^T#_B!_\ U&_^4_\ [H?M)17XMTZ*>2 _NW9,]=IQFC_B,_\
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M_P"W^-'_  DVI?\ 00OO^_[?XT?\1FA_T"/_ ,#_ /M _P"('S_Z#%_X+_\
MMS]EJ*_&G_A)=2/_ #$+[_O^W^-)_P ))J/_ #_WO_?]O\:/^(S0_P"@1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHHH **** "N8^-7_)(/%'_8+N/_ $6U=/7+_&LX^#_BC_L%W'_HMJ /)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_2OES_@F9C/Q5Q_T-ESG_O[+0!]24444 %%%% !1110 4444 %%%% !1110
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M-G+/Y3 ;9-J%MI^;H<8KXO\ V;HVE^-NA6=O9B2XO+JU2(0%CYG^D0MGYFZ
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M-/NU$NI6\0ZR02C!E*]3&^2P&%(/!_-GPS=S:G^T7IFBPV-[_:,>J6FFM"4
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M?8U !1110 5\M?\ !6X9_9RT7_L9;/\ ]!DKZEKY>_X*S+N_9UT?_L8[4_\
MCDM 'TW8?\>,/_7-?Y5-4-A_QXP_]<U_E4U !1110 4444 <[\7G$?PI\2LW
M1=+N2?\ OTU?FK_P2'"S_M96HFC_ 'L6B790NI/R[H\,"?Q Q7Z5_%O_ ))9
MXD_[!ES_ .BFK\]O^"8Q_P",NO#O_8D/_P"AK0!^E54[CP_87=RTTUC9RS2
M!I'A5F8#IDXSQ5RB@#.'@_25N&F&EZ=YK+M+_9DW$>F<=*?_ ,(QIO\ T#['
M_OPO^%7J* */_",:;_T#['_OPO\ A1_PC&F_] ^Q_P"_"_X5>HH %7:N , <
M #M5:^T>SU.2-[FUMKAH\A&EB#E,]<9'&:LT4 9TGA#29I(W?2].9HCE&-LA
M*'ID<<4__A&--_Z!]C_WX7_"KU% %'_A&--_Z!]C_P!^%_PH_P"$8TW_ *!]
MC_WX7_"KU% %'_A&--_Z!]C_ -^%_P */^$8TW_H'V/_ 'X7_"KU% %'_A&-
M-_Z!]C_WX7_"F?\ "(:3]H\[^R].\W;LW_9DW8],XZ5HT4 5+;0+&RN5FALK
M2&905$B0JK 'J,@9JW110!570[)+KSEL[43;MWF")=V?7.,YJU110!3G\/:?
M=7+S26-G)-)C>[0JS-CIDXR:A7P?I"W+3#2]-$S*$9Q;)N('0$XSBM*B@"C_
M ,(QIO\ T#['_OPO^%'_  C&F_\ 0/L?^_"_X5>HH H_\(QIO_0/L?\ OPO^
M%6[>WCM(5CBC2.-!A51=JJ/84^B@"&^TVWU2-4NK>&X1&WJLL8<*WJ,]_>JE
MQX/TF[3;+I>G2*"& >V1AD<@].U:-% %'_A&=-_Z!]C_ -^%_P */^$8TW_H
M'V/_ 'X7_"KU% %'_A&--_Z!]C_WX7_"K%G80:?&4MX88$)R5C0*"?PJ:B@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYQT ?I#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y
MMU^TE?BW7[25\CX+_P#,9_W#_P#;S[3QP_Y@O^XG_N,****_<C\#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=GX^HQS]: /JZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ),Y^U?*T:XP#\V[!P<&N'_X)H2>;^V#X?;^]X(8_P#CRT ?I-1110 4444
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MCA_S!?\ <3_W&%%%%?N1^!A1110 4444 %%%% !1110 4444 %%%% !1110
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M:]4\<Z"OE_\ X)L#;>_%O_L<+O\ ]'35] ?\+6\+_P#0Q:'_ .!T?^-?-/\
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MX8_Z&+1/_ V/_&F6_P 7_"EU")(_$FA.C9PPOH\'''K0!T5%<_\ \+7\+_\
M0Q:'_P"!T?\ C2_\+6\+G_F8M$_\#8_\: -^BL'_ (6IX9_Z&'1?_ V/_&HH
M_B_X4EGDB7Q)H320XWJ+Z/*Y&1GF@#HZ*P/^%J^&/^ABT3_P-C_QI@^+OA4S
MF+_A)-#\Q5W%?MT>0/7K0!T5%8'_  M7PQ_T,6B?^!L?^-,/Q?\ "BW*P_\
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M- '045S_ /PM?PO_ -#%H?\ X'1_XT?\+6\+_P#0Q:'_ .!T?^- '045@?\
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M2OD?!?\ YC/^X?\ [>?:>.'_ #!?]Q/_ '&%%%%?N1^!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M9?\ P47_ .3N_$W_ %SL_P#TEBK]-*_,O_@HO_R=WXF_ZYV?_I+%7Y7XO?\
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MPE\<^#]3N+[1;XSQZ[K%@CQWSJ5B@U&Y@B [9$<:#/J,UV$?_!*SX,I&J_\
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MWP1^)?A:/48-*\0VLRNUO>6DNIMYMC<)Q)"_'53W[@@C@BO7/VIO^1N^$?\
MV.MO_P"D]Q6G\1+23X/>,F\<6,;MH]X%A\2VT8SA!PEZH_O1]']4Y_AH \O_
M .'1OP;'_,/U[_P9O_A1_P .C?@W_P! _7?_  9O_A7TQ;7,=[;1S0R++#,H
M='4Y5U(R"#Z&L7XD^/[7X;>$YM2N(Y+B3<L%K:Q#,U[<.=L<,8[L[$ >G4\
MF@#XX_:!_P""<?PL\)Z3<:3X9T_5F\326$]_YLNH/)#IEO$A8SR+CG) 15[E
MO0&O4?\ @DQ_R97H?_7]>_\ H]J]"/P_NO"GP7\9ZIK4D=UXHU_3+FYU.9.4
MC/D/LMXS_P \HA\H]3N;JQKSW_@DS_R97H?_ %_7O_H]J /I2BBB@#XX_:J^
M"WA_X[_\%#_!.@>)+62ZTRX\.3RR1Q2&)G9'8KEAS@9Z5WH_X)8?!E?^9?N_
M_ UZS?B1_P I0? ?_8L77_H1KZ<H ^=Q_P $M?@VO_,OW7_@6U.'_!+KX.C_
M )E^X_\  IJ^AJ* /GK_ (=>?!W_ *%^X_\  HTA_P""77P=/_, N/\ P*:O
MH:B@#YW;_@EK\&V_YE^Y_P# MJ:W_!*_X,M_S+]W^%Z]?15% 'SG_P .K/@S
M_P!"_>?^!\G^-'_#JOX,_P#0OWO_ ('R?XU]&44 ?.?_  ZK^#/_ $+][_X'
MR?XT?\.J_@S_ -"_>_\ @?)_C7T910!\Y_\ #JOX,_\ 0OWO_@?)_C3)?^"4
MOP9EDC;^P]07RVW874),/['VKZ/HH ^=?^'5WP9_Z%Z[_P# ^3_&HY_^"5'P
M9G0+_8-]'@@Y6_D!..W6OHZB@#YU_P"'5_P9_P"A>N__  /D_P :CN_^"4_P
M9NK=H_["OXMW\<>H2!E^E?1U% 'SO'_P2S^#<7W?#]U^-XY_G3C_ ,$NO@Z1
MC^P+C_P*:OH:B@#X%UW_ ()$>$[#XN>'_#__  E.O-!K.G:C?/)Y,0:-K>2T
M55 QC!%PV?\ =%<[X _X)<^&/%L'P_:7Q-KD9\8:9/?3A8H_W#1HC +[$L>O
MI7VUXN_Y.=\#?]@#6_\ T=IE<)\$_P#CV^"'_8OWG_HJ&@#D/!W["G@G]D_Q
MQ\.M:T\7EUJ$&IM8W>HSR8,S31R",E!\J\X'']:^K*QOB!X(M/B-X0OM'O3(
MD-XF%EC.)('!#)(I[,K ,/<5QVD_&B;X<1+I?Q"7^R9[<;(]=$;?V7J*CI(T
MN"+=S_$DI49SM9AT /DO]O#X:6'Q9_:VU>UU(R-);Z3IUG:29S]E$J7KDA>^
M'4-SWSZTWXN_\$B[/X>?#K4M5TWQ<UU+9Q;G2\T] I7Y0=I4Y#9SR>.:U?CS
MXMTKQK^UUK%]HVIZ?JUDUMI*BXLKE+B(D17V1N0D9%?6?[27_)"_$W_7F?\
MT(4 ?.?P6_X)I_!_XF_#G3]2NM)UNWU%0;>_@_M$Y@N8SMD4\<?,,X]"*ZC_
M (=&_!O_ *!^N_\ @S?_  KT[P@3\/?C0]DWRZ;XWL5U"W_NI>PHB3K[;XS&
M_J2'/8UVWQ \9VOP\\$ZIKEYN-OI=L]PRJ,M)M&0JCNS'  [D@4 ?GW^T!^Q
M3\._!'C#Q-;Z#I^I#3_#GAZ]DDDFO6D$FH+!YRJ./^62;"1W\Y?2OKG_ ()^
M#'[&?P^_[!G_ +4>O-/V@_!=UX,^#,%OJ6UM:U#P_KNH:JRG(:[G@\R4 ]U4
MG8O^Q&H[4?L7?MB?#/X?_LQ>#=!UCQ=I]CK&EV'E75J\<IDA;>QP<*>Q% 'N
MWQ"\<ZI>>*8?"?A;R5UN:$75[?3)YD&C6Q8JLC+_ !RN58(F>=K$X Y\R_:K
M^!.D^'OV:?&VL7=WK&MZ]:Z3-,FH7U](SHX&0512(UP>@"\>]=O^RWKUC\0O
M"^N^,;&X2]C\5:Y>317*J0);>"5K:WQG!QY4*G'JQ]:;^VK_ ,FF_$+KQHEP
M3@=@N30!XI_P3-@6'XD?%S:JKNU*V)('7,63^I)_&OKNOC__ ()>ZO;:_P",
MOBC?6<OG6MU>VDD4@4J'7R<9&0#VK[ H **** "BBB@ KY6_:HAW?\%!?@7)
M_<-P/S27_"OJFOEG]J9\?M__  /7^\T__H$U 'U-1110 4444 %%%% 'YMU^
MTE?BW7[25\CX+_\ ,9_W#_\ ;S[3QP_Y@O\ N)_[C"BBBOW(_ PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *_,O_@HO_P G=^)O^N=G_P"DL5?II7YE_P#!1?\ Y.[\3?\ 7.S_ /26
M*OROQ>_Y$M/_ *^1_P#29GZWX,_\CRI_UZE_Z5 ]F_8]_P"3?=%_W[C_ -'R
M5Z=7F/['O_)ONB_[]Q_Z/DKTZLLB_P"1;A_\$?\ TE&O$'_(TQ'^.?\ Z4SS
MO]K5MO[-'C8_W=)F/Z5YQ^R_J)TS]@CX>S#41I67TJ/SS;F?._4(5\O: ?\
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MF!_O9YZ5Z5XV_8G^%/C^QAM]0\"^'UC@D\U3:6XLVSC'+1;21[$XKRCX'_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQB_^X* /JBBOE-_AE^UX?N_$3X:K];<G_P!LJ9_PK#]K_P#Z*-\,_P#P%/\
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MC.Q4J0V]'!&#V KP_P#X<N_#L?\ ,U>/!]+JV_\ C% 'UG_PE6E_]!*P_P#
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M=\T+*MR!VCEP$?T;:W<Y\;_X(E?\D/\ %_\ V'1_Z3QT ?:=%%% 'POX7/\
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MW1?]^X_]'R5Z=661?\BW#_X(_P#I*->(/^1IB/\ '/\ ]*84445ZIXX4444
M%%%% !1110 4444 %%%% 'RI\8?^4K?PM_[%RZ_E=5]5U\J_&$?\;6/A:?\
MJ7;H?^.W5?55 !1110 4444 %%%% !1110 4444 %%%% 'RO^QE_R>?\>O\
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M<R_TEKZQHH ^4&_X)?S$?\E:\=K]+J;_ ./5"_\ P2UNG/\ R6+XA+["Y?\
MK)7UK10!\9^._P#@E_-IO@C6+F;XM^/;R*WLIIF@FG9HY@J%MK O@@XH_P""
M+MH+'X.^-(58L(]> R>_^CQU]7?%/GX8^(_^P7<_^BFKY5_X(SMN^$OC8_\
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M=/KW_8J:;_Z5W]>,?L8C_C,?X\?]A&'_ -!%>SZ3_P G3Z]_V*FF_P#I7?T
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M (Z/\*/[<NO^>O\ XZ/\*J44>TGW8>SAV1;_ +<NO^>O_CH_PH_MRZ_YZ_\
MCH_PJI11[2?=A[.'9%O^W+K_ )Z_^.C_  H_MRZ_YZ_^.C_"JE%'M)]V'LX=
MD6_[<NO^>O\ XZ/\*/[<NO\ GK_XZ/\ "JE%'M)]V'LX=D3W.I37D>V1]R@Y
MQ@#FH***ER;U9226B"J?B#_D WW_ %[R?^@FKE5-?_Y 5[_UP?\ ]!-(9\X?
M\$J/^3=]5_[&.^_]#%?35?,G_!*5MW[.FJ'U\17W_H8KZ;H **** "BBB@ H
MHHH **** "OD+QS_ ,IC_!O_ &*DG_HN\KZ]KY"\<_\ *8_P;_V*DG_HN\H
M^O:*** "BBB@ HHHH *^6OVI?^3_ #X(?[TW_H$U?4M?'/[?/Q'L_A'^U[\(
M_$>H0W=Q9Z2DTTL=K'YDSC$BX5>YRP_#- 'V-17S#_P]:\!_]"_XZ_\ !2?\
M:/\ AZUX#_Z%_P =?^"D_P"- 'T]17S"/^"K7@'_ * /C@?723_C4B_\%4_
M3?\ ,#\:?CI1_P : /IJJ/BC_D6=1_Z]9?\ T U\Y_\ #U'P$/\ F">-/_!6
M?\:IZ[_P5-\!WFC7D"Z'XVW30.@)THX!*D<\T > U^TE?BW7[25\CX+_ /,9
M_P!P_P#V\^T\</\ F"_[B?\ N,****_<C\#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\R_P#@HO\
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M@ HHHH ^7/BZ?^-HOPR_[ 4__HN\KZCKY;^+QQ_P5(^&/_8!N/\ T"\KZDH
M**** "BBB@ HHHH **** "BBB@ HHHH ^6OV,C_QF#\=O^PE%_Z"*]ETG_DZ
M?7O^Q4TW_P!*[^O&/V,3_P 9C_'C_L(P_P#H(KV?2?\ DZ?7O^Q4TW_TKOZ
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MMK:W*-IFH/=K()S, IW(N"/))Q[CUKTZ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *J:__ ,@*]_ZX/_Z":MU2\2.8_#M^RKN9;:0A<XS\IH ^<O\
M@E.V?V;[[_L/7@_\>%?35?%G[!7C'Q[\+/@_J&EZ?\.;KQ% =7N+C[5!JL$*
M_O-K;</SP".?>O:[K]H+XD6=K)-)\'-36.%"['^W+7@ 9/>@#VBBL/X9>,V^
M(OP\T77FLY-/_MFRBO5MY'#M$LBA@"1P>"#QZUN4 %%%% !1110 4444 %?)
MOC0_\;;_  G_ -B[_P"T-0KZRKY*\:OC_@KSX27U\-$_^0;_ /QH ^M:***
M"BBB@ HHHH *^4_VJO\ E(=\"/I=?^@25]65\G_M7::MQ_P4/^!<IDF5BMRN
M%?"C:';I[YP?44 ?6%%%% !1110 5F^,KE;/PAJLTF[9%9S.V!DX"$GBM*L?
MXA_\B!KG_8/N/_1;4 ?GG7[25^+=?M)7R/@O_P QG_</_P!O/M/'#_F"_P"X
MG_N,****_<C\#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?(?CA\?\%C/!R]CX5<_^0[W_ !KZ\KY"\<_\IC_!O_8J2?\ HN\H ^O:***
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MB>^'?^_)_P : +OP$U73])\8^,/"NE7EG=:3I<T.J:>MM,LD=K#=^86A7:<
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MHHH **** "BBB@ HHHH **** "J?B#_D WW_ %[R?^@FKE5-?_Y 5[_UP?\
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MTE?(^"__ #&?]P__ &\^T\</^8+_ +B?^XPHHHK]R/P,**** "BBB@ HHHH
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MXV1H!U)9B!@5YIX-_P""?WPMMO"&F1ZMX'T6ZU-;:,W<KQ[F>8J"Y)SS\Q-
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M?#.G?M(:Q?>&=!T?2K/P[I:Z9/+8VB0B2ZE?S'3*@9VH(\^A.*]CH ^5)?\
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M?^**UR;=JL"\C1KESC[4@[0N2!(!]UB'Z%L>5_\ !(ZY%U^SOKK*0R_\)+=
M$'@@10C- 'U11110 4444 %%%% !1110 4444 ?+/[;";OVNO@$?[NL/_P"A
MQ5]35\,_\%@;I[3QA\+WC&Z07,A0;MN2)H#C/;ZU].1_%_Q9Y:_\4-&>!S_P
MD-IS^M #)/$OCCQ=\2_%6FZ'J'AG3M.\.W%O;(+S3IKB:4R6T4S,669 !F3
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MZI;*?^_KGH8JL>'_ /DY?Q)_V K'_P!&SU?^ $FCO\(-#&AK<1V,<!1DN/\
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MBBB@ HHHH **** "OE'_ (*02%/BW^S^!_%XQB!_[_VI_I7U=7R?_P %(_\
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MZ_,6_P#9J_;_ . G_)"_!?\ V ;'_P!)XZ_$?3@HL=-/\7VJ;/\ WS'7[<?
M3_DA?@O_ + -C_Z3QT =97P7I$V/^"VEU'_>+-^6B_\ UZ^]*_/XZQ9Z#_P6
MQNKJ^NK:RM8P^^:>58XUSHP RS$ 9) H ^I?A1>1:?\ M$?&"XGD2&&#^RY)
M)'.%11;2$DGT K6^#UI+\0/$=]X^OHW1=0C^QZ'#(,&VL V=^.S3,-Y[[0@[
M5XCJ/Q'T#Q/^TW\0/#$GB31;'1=<?3+O4[V34H8XIK2*%PT".6^9I'*JP'1=
MU?0EO\=O %I;QPQ>,O!\<<2A$1=7MPJ@<  ;^U &/=_\6;^+RW0_=^&?'5PL
M<_\ <L-5P%1_9;A5"'_IJB=Y2:^??VY/"FF:YXH^,E[>:?9W5YIO@&Q>UFEB
M#R6S&ZGR4)Y4^XKZ'\<_$SX;_$'PEJ&BZAXR\)O9ZA$8GVZS;JR'JKJ=_#*P
M# CD$ U\C?%OXMVOB[0OC5;ZAK.DWFK6'@JSTB2YAO(GCU62.XE831%6PV^-
MT8J/NL67L* -S]F[_@ES\+_BO\!_"GB35/\ A(UU'6M.CNK@0WZI&'8<[1L.
M![9-=PO_  1Z^$*_Q>*OQU%/_C=>L?L6$-^RGX#*_=.DQ$?3FO4* /EG_AS_
M /",=_$__@='_P#&J#_P1^^$9[^*/_ ^/_XW7U-10!\K'_@CO\(2?O>*O_!B
MO_QNO)/V@?V*?!?[*GQA^$MWX5_M@S:OXA6&X^VW0F7:NUAM 48.>]?H)7RO
M_P %%SCXF_!'_L9\?HM 'U11110 4444 %%%% !1110 4444 >0_M*?\) ?B
M3\*O['^Q_8O^$A/VWS0#(1Y#XV9(_A\S/X?2O7J\A_:4FU^/XD?"H:1':26;
M>(6%Z96PZCR'QL_X#YF?H*]>H *^=?\ @J<-W[&VO#UN;;_T:*^BJ^=_^"I(
MS^QUKG_7U:_^C10!WO[&O_)J/P[_ .P!:?\ HI:]+KS7]C?C]E/X>_\ 8!M/
M_18KTJ@ HHHH **** "BBB@#'\?>/M(^&'A&^UW7;Z'3]+T^,R332'@#L .I
M8G@ <DG%8OP.^(>L?%+P8=<U;P_-X<AO9W?3K:>3-S):<>7+*N/W;L.=G.!B
MO(Y8X_BY^V7>:'\0I&M;7PR$O?"&@R)BSU@;<O?,Q.)I8V^41_P?>P<YKZ.H
M **** "BBB@ HHHH *^8_P#@F^<WWQ?_ .QTN?Y5].5\Q?\ !-S_ (_/B_\
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MU.W$UM-#<1-T>-PZG\14U 'PU%_P2#\40GCXU:@?][1W;^=U4P_X)(>*@/\
MDLUU^.A'_P"2:^WZ* /A]O\ @D?XJ?\ YK/=_AH9'_MS4/\ PZ"\3%]S?&C4
M3[?V3(H_2Z%?<U% 'Q#%_P $C/$"?>^+EU)]=-N?Z7M2'_@DCKQ'_)6+C_P7
M7?\ \G5]M44 ?#L__!(;Q'*/E^,5]%_NZ9<'^=X:A_X<^^)O^BUZI_X*I?\
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M(=6\,Z;=3:;JS37-K%+(?M[<LR G^=7'_P""27P;<_\ (-UG\-2<5]"^!?\
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M8(/S(I';)KF='_X*,>$-5\>7&AOHWBBUCL[^XT^XOY;1?LL3PALDD,2<E5
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ML[NP^S?NE8EP&&Y%5]I&5WX[4 ?2%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7YF_\ !1S_ ).X\1?]<;/_ -)HJ_3*OS-_
MX*.?\G<>(O\ KC9_^DT=?E_BW_R)(_\ 7R/Y2/UCP;_Y'LO^O<O_ $J)ZW^Q
M=_R0>Q_Z^9__ $,UZO7E'[%W_)!['_KYG_\ 0S7J]<?#_P#R+*'^"/Y(ZN)/
M^1KB/\<OS"BBBO8/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT65;75K2*\A64!7"2('4, 2 <$9P36A78G?5'"U9V85^;/QJ$A_X*XW?ECQ
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MY& B[<>O- 'W)X$_Y$?1O^O&#_T6M:U9/@/_ )$?1?\ KQ@_]%K6M0 4444
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M\YX-5_&__!*JS\?^%/$VG:A\6OBD]QXTA2UUV]%Y!YVI01H$AB8>5@*@W8(
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M4_!7C:7XD?#?[/\ \)'L5=<T3S0EOXH@7L>RW*#[DG?[IR#7?_"#XUZ#\:_
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M3*%3^-<5K/B74?VQK.'2-!LM1TGX;W15]5UN]@-M-K4(PWV:TA<!PCY >9U
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M$GQ0JJ  /(AX _"KND_\$O[K0)&:Q^*WC"S9AAFACBC+#W('-?6=% 'RV?\
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MVYK?_1:?B'_X$#_&E'_!-[7!_P UH^(7_?X5]444 ?+(_P""<>N#_FM'C_\
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M_%NOVDKY'P7_ .8S_N'_ .WGVGCA_P P7_<3_P!QA1117[D?@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?F]_P4V_Y.FN_P#L'6O_ *":_2&OS>_X*;?\G37?_8.M?_037YCXM?\
M(C7_ %\C^4C]6\'?^1\_^O<OSB>B_L3_ /)#(/\ K\G_ )BO7*\C_8G_ .2&
M0?\ 7Y/_ #%>N5P<._\ (LH?X(_D=W$O_(UQ'^.7YA1117LGAA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7P/^W3\+/A[IG[?_PE\16-
MQ9MXVUKQ38-K,:ZEOE1H9M.2VW0[OW>8LX&T;ASSUK[XK\C?VM/^4Y.F_P#8
MW^%__1.GUY^8UHTX1<HJ5Y):]-]3T\KH2JSFHR<;1;TZ[:'ZY5TUA_QXP_\
M7-?Y5S-=-8?\>,/_ %S7^5>UA=V>%BMD<'^UA^T;I'[(G[-OC7XF:]:WM]I/
M@G2IM4N+:S ,]R$'$:;B &9B%R2 ,Y/ KSGX1?MPZEJ?ART\1?$?P_X)\$^
M[S0'\1)X]TKQW;ZSX0\DS6L4,!OY8+4K.YG=COB6+:B>5+.3*L/H_P"U3H'B
M;Q7^S_XETOP?I6@Z[K^I0):PZ;KFS^R]0B>5%G@NMZ2#[.\)E63".VQFVJS8
M!_/;P=_P2@\3:+XK^/5E\)_A]XD^ OP]^)'PHU[PQJ/A+6?%%KJ.B^(/$U^C
MQ6]]86]M=7'V>") P:6;R&"21)';HIEV>K3C!Q][^OZ^9Y-24U+W?Z_KY'WI
MJ_[;WPEM],U)M/\ B=\,]2U'3_#K>*A9KXML(V?3?*$B7C,9,1VKJR$7#?NP
M'5MV"*\C^'7_  5Z^&^LZW\$?"_BS5O!?A?X@?&:Q>_71[7QE8:Q9Z2@#I&H
MOX&\BY:>X"0PB,CS6,FW)C(/Q3\%/V&/VA_#GQ?\%ZWJOP/\1V6G^&?V69/@
M_+CQ'H$LLNM1"X=<*M_@0RL0J/D_?0OY?SB/KOV&?V!OCI^S_P#$K]C/Q%JO
MPQEA'PU\&:[X1\70/KVF!]%FN+D&*Z=HYY!-"\3%E\CS9,Q[72/(-:^QII;_
M (^3,O;56]OP\T?IAX4^._@?QY\0-<\)Z'XR\*ZUXJ\+[?[9T:QU:WN-0TG=
MP/M$".9(<]MZC-=57YF_\$I?^"<?Q2_9J^-'AYOB5:_$:YO_ (:ZGXJCTW7C
MKN@'PKK6GZK.LTDRQPQMK$UW/,EO(8KUA''Y+N)@0MO)^F5<]6*B[1=SII3E
M*-Y*QA^)?^/Y?^N8_F:^5?BE_P $NO!OQ:_:RC^+FI:UKW]K+J-AJ+Z<H@:Q
ME-HD*+&P9"Q1Q NX9YW'I7U5XE_X_E_ZYC^9K\>?VV->\1Q_\%E#9Z!J#0Z@
MWB3PZEA'<2O]E$[6]AL\Q0?N;R-P Y&:^7S>I3A9U(\WO+Y/74^JR6E4J<RI
MRY?=;VO=::'Z%_$KX/GX$I<>./AS:KIDFGYN=8\/VPV:?K5N /,VPCY8KA5&
MY70#<5PP.<CUWPQXCM/&'ANPU:PD$UEJ5NES X_B1U#+^AKY_N-$_:<N[>2&
M6_\ A;)'*I1U,,^&!X(/%>K?LV?#W5/A3\#_  [X=UJ6SFU+2[<Q3-:9\G[[
M$!<\X ('X5V'"=Q1110 4444 5=;T[^U]&O+3=L^U0O#NQ]W<I&?UKR7X6_L
MS^(O!GPVT7PKJ7CV^DT?1K1+1(=)LDL9)448P\Q9V.?50A]Q7LE% &7X/\%:
M5X T./3='L8;&SC);9'DEV/5V8Y9V/4LQ))ZDUJ444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  &/QY/O1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 !&X8-%%% !1110!\)_\ !:WY
MH?ANN67<=1&1_OV-?2WC[X&SVW@;6Y3XZ\>2;+"=BCWL&U_W;<']ST->,_\
M!2KP;I_Q%^.?P%T#5(Y)--UG5[NTN4CD,;,CRV((##D''<5]1?$C_DG>O?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=N*U_P O5G;]1G&G&I-I*3LM5MU?HNI^@-%?D?\ \,I?MT?]!3XE?^'$B_\
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MX?\ ^@9??+_,I>(G$:_YBI?='_(^/;;_ ()%Z6MO&)O&VH22A1O9-.158]R
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M_ VL_P!N:39^&H-/FG^R3VVR=;JZD9-LR(QPLB'(&/FZY!Q^QOPYX^'N@_\
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MC"C$4:G'EQKTVJ!G&3G@UT8_X+W>-#_S*6A#_@3G^M>O_:V$_G_!_P"1XO\
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MM>=7_P!L"BBBOUH_' HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;O<Z;H]O:S/&65BA=$#%2RJ<$XRH/85V5%%5&*BK11,I2D[R=PKY9^.>/\
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MJS6Y11NYPJX7\*^Z*^6/A?#C_@JQ\19/[WARW3'T2U/]: /J>BBB@#$^)?\
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MNS7L'AGU#7P=_P %R],L]7\*?#6&^8+;MJ=WDE]G\$0Z_0FO2_\ AA7XM?\
M1R?B[_P6-_\ )-?(?_!7+X ^,/@OX$\&S>*/B=K/Q!CO[^=+>*^M3"+(K&I9
MES*^=V0.WW:Y<;44*$I25TEL=F IN>(A"+Y6WNNA^E?[.7PV\)?"'X,Z-X=\
M"S1W'A73_/\ L,D=Y]L5M\\DDF)<G=^\=QUXZ=J[>OFS_@D-_P H[_A[_P!Q
M+_TYW=?2=:8:2E1C)*UTM.VAGBHN-><6[M-Z]]=PHHHK8YS\X_C%^U-J'PU_
MX+6V>FP:79W4=Q-I'A0O)(RD17J6S/+Q_$OGG Z':*_1ROR/_:M_Y3H:7_V.
M/A;_ -%:?7ZX5YN7UYU)U5-WM)I>AZV98>G3IT7!6YHIOU"BBBO2/).8^(GQ
M0M_ ;V=G#:76L:[JFX6&EVFWSKC;]YV+$+'$N1ND8X&0!EB%/E7[0'[-'C3]
MJWP9::1XCU[0/#>GPW\6H"UTZRDNYD9 P5&GD=0WWLY$:].E,\!?M)> =*^(
M?C+6/$7BK2++6Y-3ETJ*&>;#VMI;,4C0#L';?(?>0UVMM^V)\+KJ[BA7QUX<
M629MB"2[5 Q],G H ]'MHOL]O''NW>6H7<1UQWI]&:* &7$$=W \4BK)'(I5
MU89# \$&LSP3X#T7X;Z!'I6@:78Z/IL3M(EM:1"*)68[F(4<9).:UB<"FQ3+
M.FY&5U/0J<B@!U%%% !5'Q1_R+.H_P#7K+_Z :O51\4?\BSJ/_7K+_Z : /R
M!\8_M0ZAX9_:$A\&1Z79R6LE]9VAN&D82 3"(DXZ9'F''TK^@ROYHOBO_P G
MTVO_ &&=*_\ 0+>OZ7:\7PIP].G3K."MS1I-^OOGO>+V(J5*E!3=^655+R7N
M!1117Z\?C(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%Z$W[$.E?&FPD\3/\7+J:>.0VRZ2DOV3>N/,,Q_T<L,',8^8Y^4\#O[%\0O
M>E_$OPA>:/J^GZ?JEG=)_J+V!9H2XY1BK @[6 /3J*VJ*[CSSX#A_P""7?Q0
M63]YJWPE=1UVZ!"K-_Y*$#\JTOV"OA=JGP3_ &\/&7AG6)M)FOK+P\LLC:9"
M(;4AVMV&U51 .#SA!SGK7W57RK\+A_QM@^(Q[?\ ",6P_P#';:@#ZJKQS]KC
MXPW'@"V\/>'[;7])\'?\)=<2VT_B+4+A(8])AC3>YCWX4SL/E3<0 3GG&*]C
MKS?]HOX0^'/B!I5CK?B+5#H\7A,37<=U)';S6\0=-KF6.>-T8;?8$'H: /-/
M#_[7_P"SY^SYX=D\):7XTL88[.#S);FQ2:^:Y>3&Z4W$2.LLQ9MS$,6!R2!@
MX\R\)?M%^#?'/P@OO .C^)/@[]ATZS-NNKZ_/=:;)>%E8+*;:>W4&8D;G=)G
MPQW8^8+7L'[.'@_1?B9X(O\ 5_$?PR\)K8H[-I6I'0+:&;6K09VS-;;6:(G&
M0I)W @C&<5S<JVLOPIF\;:3\//@M:Z/<V#WEM9W4<4=VB["R"0K#L\T=&C!X
M.1N)XH X']A>S_L_]B/XN0"XM;KR;_48Q-:R^9;RXBQNC; W(>H.!D$&HO\
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MAFV@9/)Y-?7-?)OQ_P!'@N/^"GGPEF97,G]FW#CYS@%0^.,X[GZT ?65%%%
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M%)&-/FG&Z8R%F;=$O*X R2 *Y#QM_P %-_ ^I>-KC6M)N-<L5N]+CTV:VO-
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M\8ZYXY:.2/3]2AATS11(I5I;.%I'-Q@]!-+*Y7/6..(_Q8KT2D50BA5 55&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;A+:W$WF^?&0Q+E@Q'7C%?>%?+?QR&?^"EWPK]M(N?YM0!]24444 ?,O_!7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX<^ ]+O%4H)[30+2&0 ]1N6,'!K.EA\:IISJIKJK+_(TK8C .#5.DT^CN_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(.%+;!G)X"@<]* /1J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#%^(T:S?#[7%D561M/G#!AP1Y;9S7@O\ P2?MX[?]
MCS33'&B>9J-VS[1C<=^,GWP /P%?1VI:=!J^GSVEU&LUO=1M%+&P^5T88(/U
M!KS/0?V1/"?P_P!+^S^#9-<\%LK&2,Z;JD[0JQZDP3,\+9P,Y3)QU% 'J5%<
M-\//'6J6WBFX\)^*/L[:W;Q?:;.]@3RX-7MLX,BJ2=DBG =,G&002"*[F@ H
MHHH _$7XC_"7Q)JO[7UOKEOH]Y-I"ZIITQNE4>6$C6 .W7H-K9^E?T=5_/GX
MQ_:AU#PS^T)#X,CTNSDM9+ZSM#<-(PD F$1)QTR/,./I7]!E>'X3RK.%?VJ2
M7+2M;JO?/H?&"-%3P_LFV^:K>_1^YL%%%%?L!^+!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7YS_ /!:/PW)XQ\?P:3%(L,FI>%#;+(PRJ%Y
MKA03],U^C%?FS_P7(U>YT'Q$U[9S/;W5KX1:6*5/O1L)K@@BOS[Q-N\D:COS
MP_,_1_"MI9\G+;DG^1Y'_P $J](\,_L6Z)XT7QAXX\.VEUXDGM#;V\CF&14@
M6;+_ #=0QFP,=T-?6G_#:'PI_P"A^\-?^!8KXE_X(V^"M'_:A\/^/KKXA:5I
MOB^YTBXLHK.74K9)GMT=9RRJ2,X)4'%?:W_#$?PC_P"B=>$__!?'_A7C9$IK
M 4U4=W9W];L]OB&4'F%5TU975O2R)/\ AM#X4_\ 0_>&O_ L4]?VR/A:_P!W
MQUX=;Z70J#_AB+X1_P#1.O"?_@OC_P *3_AB'X1?]$[\)_\ @O3_  KUCQ2V
M/VP/AB?^9WT'_P "*P_B=^V/X&M/AMXAET+QAHESKD>F7+:="EP TMR(F,2@
MG R7VCDXYK2_X8B^$8_YIWX3_P#!>G^%87Q0_8=^&]Q\-/$4>A> /"]OKDFF
M7*Z?*FGQEH[@Q-Y3#(QD/M/- 'DW@3_@I'I/P^\$:3HEIX%O([72;2*TCSKM
MCDA%"Y)W<DXR3W))KO/@?_P4;T#XQ?%.Q\(R>']3TG4M44FT=;J"\A<J"6#-
M&WR8 [YKA_ O_!-OP_X\\%:3K=GXCT][75K.*\B/_")Z9]UT# ']UU&<8]:[
MCX*?\$Y]!^#_ ,6;#QA_;EU=WVEHR6]O;:=:Z?;G<""76)!N//'(H ^C****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K
MK6JQZ'H]U>R*S1V<+S,%^\0H)./?BOC=/^"R.A7,DC1^&1;QJ^$6[U+RY67
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M&%G2GAY2M[TJK5O^W-PHHHK]@/Q8**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *_-?_@O%&H$S8^9O",H)]A)-_B:_2BOSR_X+,^(=/\,^/]+O
MM2 DLK/P\9;A GF$IY\O\/?.#^5? >);:R232O[\/_2D?HWA:D\^BF[>Y/\
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MH?S/^%'_  C5Q_>A_,_X5N44?5H!]9F8?_"-7']Z'\S_ (4?\(U<?WH?S/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?F+_P7KD$.K7K'OX.1>/>YN1_6OTZK\V_^
M"V?@Z3X@?$2+189H[>74?"T,2R."50_:KDY('TKX/Q(DEDLI/93@_P#R9'Z'
MX7IRSV,8[N$U_P"2L\8_X-^8&7X<?$B3C:VI6:CUR(I#_45^A=?&O_!&[X#7
MGP,^''C2*[U"VOO[2U*!D\E&79LB(.<^NX?E7V57@Y'4C4P-.<-4[_FSW>(*
M<J>85(35FK?D@HHHKUCQPHHHH *^4_CU;QM_P4V^$K%%+?V7='..>-V/YU]6
M5\K_ !Y_Y28_"7_L%W?\FH ^J**** "BBB@ HHHH **** "BBB@ HHHH ***
M* -#PU_Q_-_US/\ ,5N5A^&O^/YO^N9_F*W*]##? >?B?C"OEO\ X+"_"'X@
M_'G]BS4O"OPOU/0X_&FI:E;36N@:M>_9+7QQ#;[[FYT1VWIN6YMX9=Z;U5XX
MY%=DC9W7ZDKSW]HK]F?P_P#M.Z-X=L?$-UX@LX_"^M1^(+&71]3ETVX2[B@G
MBB?SHB) $,Y?:K ,R*'W1EXWZZ<N629R5(\T7$_,WX$?ML:3\,_^%X7WAWX0
M7G[+WQU^#7PLUS7A\+=<T^2Y\':K;VTZSR:AID=M):Q?O#9B*:6%(Q-YT$BO
M<+;N3Z=^R[_P5J^,'QR_:H_9K\#ZE9?#:UTGX[?"R;QK=RVVBWHN-)OTAN2$
MC9KXJ\!DA5MA4/M)7?G#CZ@TW_@F[X1UG7O&6M>/O$GC+XK^)/&_A*?P)>:O
MXD>P@GM=#GWF>QMX].M;2"-9&D9FD\HRL0H+[551Y?\  _\ X(=^"/@%\7OA
MKXXT?XJ?&>ZU[X3:!+X6\.M?WFCS06VFR+*OV=HQIRJVWSY"'P)"2 S,%4#I
M=2DT[[_\#_,YE3JIJVW_  ?\NQ^<7A?]KGXD/^PS\!=/\ _\(/\ #"Q^(G[2
M?]AZY;Z78ZI?1:A<)J$%PLKF[U&69;=YU$DUO',IEPJ+)"GF++]F?M _\%D/
MBEX%_:C^)'P\\"> 9/B!>? U/#\7B#3-&\"ZYJVH>-Y[[9)=FQELWE@TA(8#
M(Z?;C-YK+L4G:S5Z+X=_X(*_#'PQ^S_X?^'UMX^^+/V7PCX^C^).@ZL]WI1U
M'2=74'+)_H'D21,WSE)H9.1@$+E:])UG_@EKX/C_ &H-6^+7A3QM\4/A[XF\
M4Z);>'_$\>@ZS"T'BFU@$:1M=-=P3SK<>5$D?VJWEAN%7<5E5W=VJ56DWKY_
MG_D3"C62^[\O\]3UW]HCX!Z)^U3\(K[P3XFN-:C\*>(5$6LV>GWTVFRZM9D'
M?9R31%)HX9>%D6-D9TW1L=CNI^*/^"*O[%4?P_\ A#\=+#2]5\96O[/?C[Q?
M--\,;%/$5Y9W<&D1LX>^L[JWE2YAM[F3!AD$BO+##'*2PFWR?8/[7W[+=O\
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MXO8BI4J4%-WY954O)>X%%%%?KQ^,A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7YJ?\%W+R]\+:DNL6-RUM<IX85873[\;)<RDG_Q\?D:_2NO
MS0_X.!V*^'(\<?\ $@(_\F:^%\1DGDLD_P">'_I2/T#PSDUGD6OY*G_I#. _
MX(6?$77/B#\-?'S:UJ5SJ36NIVPB,QSY8:)\X^N!^5?=U?E%_P $D?@_\1OB
M5\-?%D_@7X@)X*AMM3BCNXS9^>;IC%E3G(QM&1CWKZYC_94^/Q7YOCT%/MH^
M?_9Z\')8J."@HK37\V>_GTG+'5'+?3\D?4E%?+O_  RI\?!_S7K/_<&_^SIZ
M_LL_'H#_ )+K&WUTAO\ XY7J'D'T_17S"/V6_CS_ -%RA_\ !0__ ,=H/[+?
MQZ_Z+E%_X*'_ /CM 'T]7RM\>3_QLS^$O_8+NO\ V:K+_LK_ !\;_FNZK]-'
M/_QRO,])^&?C7X;_ /!13X;P>-O&K>-KR?3[B2WG-M]G%L@# H%R>IYS0!]V
M4444 %%%% !1110 4444 %%%% !1110 4444 6M(OEL+EG<,05V_+]16E_PD
ML']V;\A_C6'16L*THJR,I48R=V;G_"2P?W9OR'^-'_"2P?W9OR'^-8=%7]9F
M1]6@;G_"2P?W9OR'^-'_  DL']V;\A_C6'11]9F'U:!N?\)+!_=F_(?XT?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<G<0/QP?RKZNKY3^/,$,G_!3?X2LR1M(-,NCD@9! ;']<4 ?5E%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ$&7(H_UCRQNRK1'_JQFMK^PD>^45\__ /#R_P"%W_00N/\ OY;?_'JO7_\
MP4&\ Z59BXNAK%M;L0!++'"B'/3DRXYH_P!8\L6]:(+AG-7JJ$CW*BOG_P#X
M>7_"[_H(7'_?RV_^/58T[_@HK\/M:D9;'^UKYHP"_P!G6WDVY]<342XCRQ*[
MK((\,YHW94)?@>\45\]WO_!37X8Z;=R6]Q=7UO/$=KQR26BNA]"#/D5#_P /
M0OA7_P _]Q_W_L__ (_1_K%EO_/U?C_D+_5G-/\ GR_P_P SZ*HKP?4O^"B/
M@'1K%;J\AUJUMF( EF6WCC.>GS&;'-9O_#T+X5_\_P#<?]_[/_X_4QXDRQZJ
MLOQ_R'+A?-5HZ+_#_,^BJ*\"T;_@H_\ #OQ$\BZ?_:M\T8!<6_V:4H#TSMF.
M*JZC_P %-OAKIEW);S7%W#-$=LD<TUK&Z'T(,V1^-'^LF67M[9?C_D'^J^:V
MO[%_A_F?0]%?./\ P]$^&/\ S^2?^!5I_P#'JT-5_P""C'@70M/6[OH-4L[5
MB )IVMXXR3T^8R@<T?ZRY8G9UE^/^12X6S5ZJB_P_P SWF]LH=2LYK>XC2:"
MX0QR1N,JZD8((]"*\\L_V4?!OARUV^&[6^\(S*Q>.;1;Z6U\MCW\O<8GZ='1
MA[5YG)_P52^%H1MNH*S8X!OK0 GZ^=7*V7_!3F\\4:C<+H6C^$]0AA.0L>NM
M-(BGH6V1D#O0^),M2NZJ_'_(4>%\T;LJ+^]?YGT%\/?&>KZ1XNF\(^*9(;G5
M(X#=:=J44?E1ZM;@X8E,D+,A(#J..0PP#@=Y7PWXF_X**V^L?$#PS<:PO@[2
M7\-ZF9KGRM<#77DM$Z20A'51D[D."1]P5Z?)_P %4OA</N7Z-ZYO[0?^U31_
MK)EMK^U7W/\ R%_JOFE[>Q?WK_,^E:S_ !6K-X7U(*P5C:R@$C(!V'M7A>L?
M\%'_  5X=TU;S4+:^L;-B )[B>"*,D]/F9P.:XO6O^"L/@F^M+NWA;P^8YD>
M-'?Q) K$$$ D;3CZ9-*/$V625XU5]S_R*EPKFL7:5%KYK_,_-KXK_P#)]-K_
M -AG2O\ T"WK^EVOYL/$WAVZ^(?[84>M:#]GUG2[;4].N);BRN8YTCC180S'
M:Q( *MU]#7])]=/A;)>SK1ZJ-*_EI,Q\6HOVE&71SJV\]8!1117ZP?CH4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY3_^3/R#^.W_  25^.GQ(^$=KH>F^';"&^AD@9GFUBV2,A%(/(<GOZ5X@/\
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M1G8I!QMR>_I7B'_$.Q^T!_>\%_\ @V/_ ,17[N45CAO#G+*$.2G.=KWWC_\
M(FV*\3LUQ$^>I"G>UMI?_)'XZ_LP?\$2OC=\$=6U:XU*W\,W2ZA%'&@M=4#%
M2I).=RCUKD?BA_P;]_';QW\0M8UBVF\%PV^I7+3I'-JC"1 >QQ&1GZ$U^W%%
M$/#G+(UG74I\S5GJO_D15/$S-948T'"GRIW6DO\ Y(_"G_B'/^/W_/UX%_\
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M-DOB$?O?$KP:OIBTN3_05^S%%7#@7+()17-9>?\ P#.IX@9K-N3Y;O\ N_\
M!/R[^/\ _P $0OB3\2/A7::!IOB3P;YT,T3/)+-<* J*1D#RNYQWKPO_ (AK
MOC%_T-G@/_O_ ''_ ,:K]N**SP_ &4T8\E)22W^+_,TQ'B-G->7/5E%O;X?\
MC\D_V9O^"$/Q8^"7B*^DO->\#W5KJ2)%(\=W<*T 4DY"^2=V<],BOULHHKVL
MGX=P>63J5,*G>I;FN[_#>WINSQ,ZXDQN:0IT\6U:GS<ME;XK7]=D%%%%>X>
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\/7_ (B?] 7P7_X"7/\ \D5^??\ $5,A_FE_X"S]'_XA'Q#_ "P_\"1]#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^!=!:X2T&I>(=7M]+LS,X8K'YL[JF]@K$+G)"GT->5_\/8OV6?\ HY;]G_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXHYM8MK:X\ART!RLGEG: 7 8+(,'M0!X3_P4]_X-\[G_ ()8_"30?VDOV/\
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M&'[*?_!$OX=?$YM'D\*_'CXM6<>DV.FZI8F)]*NT3_3KX02@%XXL#9D%2]Q
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MB8/"'B34T/BG2;9&CL[:^E7_ $F&8)P+:^3>>F$F#$8)B \M_P"#<+XNZ?\
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MAUO!_P#P5(^-6DM<-=MI?A2[M#.WWIC'J=NF\^YQG\:\J_X*U?MI^+/VHO\
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M%:O_ ,$P/VD(])\)#2O&FDV\\&N:VUP9CK$,EC</;JJD9B$>V0%1\I)#=<X
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MCO(N0.<'BOZ6/#GB*Q\7>'K'5M,NH;[3=3MX[NTN8FW1W$4BAD=3W!4@CZT
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MOS"&3/U;_P '(/\ P66L_#/[&O@WX9_ _6&U[QE^T=IL,]E<:5(_VFWT2Y
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MP>$_X*D_#7XB?%__ (.I_$WASX4>)E\&_$'5-8TB+1M:,IC_ +/F_L:T/F9
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M-F@#^JSXU?%G2_CA_P $W_&/C;097;2?%7PYO]8L7+#>L<VFR2*#M) 8!L$
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M@C_YH:/^(,?]1G_E/_[</^(X?]07_E3_ .YGYMT5^DG_  V1\1?^C3OV@/\
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MT- 'T!17S_\ \-D?$7_HT[]H#_P;^"/_ )H:/^&R/B+_ -&G?M ?^#?P1_\
M-#0!] 45\_\ _#9'Q%_Z-._: _\ !OX(_P#FAH_X;(^(O_1IW[0'_@W\$?\
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MTOP7XF\47%QJ^N:+JE[);$WTKB6X\A_*ECG@N9,N\%P%17W88HRI'D_LP?\
M!OK^T=^UQ^VSX<^.7[<7Q*TOQ,/"LL5[IOAO2KPS,TL;AT@81Q1V]K;B15=D
M@W;SD$KDD_ME10!\Q_\ !9']D;Q7^W9_P34^*'PG\#MI,?BCQ=:V45@=2N&M
M[4&&_MKA@[JKE?DA<#Y3S@<#D4?^")G[&?B__@GY_P $R_AM\)/'DFCR^*O"
MIU-KYM+N&N+7_2=3N[N,*[(A)$<Z _*,,"!D8)^JJ* "OQU_X*M_\&]7Q4\0
M_MHR_M/?LB^.K?P3\3+F1K_5=)N;U['[5=;"'DM9U5ES, %>"8"-BS$N 2M?
ML510!_/C\3_^"7/_  5._P""J=Q8^ _V@O'6C^#?ARLD4FHM)?Z>MI<(DT;;
MC9Z8/]*F3'F(LQ1<I_K$)!K[+_X*=?\ !";6/B1_P1V^'_[,_P !)M+4^ -4
MMKN.7Q%?O";\9F>XF>14?]Y)-,\FT *-Q5< **_4.B@#^>KX5?\ !&W_ (*L
M_ _X<Z/X1\(_'32/#_AK0+<6FG:=9^-;B."SB&2$1?LW &3Q7V#_ ,$A_P!B
MO_@H1\!_VOH==_:*^,5CXR^&?]D75O<Z8?$4NI/)<-L\EDC>!0I5@3NW XR.
M<X/ZJ44 ?AS_ ,%,/^#8[XG>&OVL=4^/_P"QMXVA\(>(]0NYM8N/#KZB^EW%
MG>2;FF.GW2@ILE8Y\B;8B%GQ)L*HOF$__!$#_@H5_P %9_B'H%M^UM\0H_"7
M@'P[<1M);2:G9W<SJ!AGM;2QW6YG*_*99F4C=G#X*G^A6B@#YY^,W_!,#X2?
M'#]@!/V;=6T6:'X<V>D0:3IRV\NV\THVZC[/<PRL#B>-E#;F!#'<&5E9E/XX
M^&_^"+__  4F_P""4.N:EH7[,?Q.L_&?P_U2>9X+:WU.VM%B,BH&GEL-0/D0
MS':!OADD;" Y&<#^A2B@#\6?^"9'_!M-\09_VJ[?]H']LKQM;_$;QM93PW^G
MZ(+^35 ;F,*8I+VXE4!O)(^6&,% 54[R!MKT?_@Y0_X(M_&#_@J]XH^%5Y\+
M;CP?#'X3M[VVU$:WJ,EH4,KQ%&79%)N'RMGN,=#FOU?HH \Z_:4_9C\+?M;_
M +-GB3X7^.-/BU+PYXKTMM-O8R/FC)4;98S_  R1N%=&'*LJD<BOR2_X(7_\
M&Z_QH_X)A_\ !2;4OB%XMUGP3JW@6PTS4=+T^ZL+V4WM^LI"PNT!B C)4;F4
MN0IR 6ZG]LJ* /Y__P!I+_@@%^V_I'_!2[XL?&[X&>-/"'@MO&FL7T]AJ%MX
MEFL[XV5Q(KF.0" XSM4E<D94<U9L?^#:C]LS]N_Q]X=C_:S_ &C(=2\!Z+.;
MDV=GKEWK6H)ED$B0130QV\+R1J1YQ,A4A<QN,BOWWHH Y'X!_ GPK^S%\&?#
M?P_\#Z1;Z%X3\)V*:?IMC"2PAB7N6.6=V)+,[$LS,S$DDFNNHHH _*;Q_P#\
M$9OB_P")_P#@Y0TG]JRWG\'K\+;.2VED5M1D&I_NM"^P,/(\K;DS#CY\;3G.
M>*_5FBB@#\L?^#E3_@CK\6_^"K5A\+_^%6S>$UD\(27GV]-9U![3B41["A6-
MPWW3G..U?*=A_P $L_\ @KMIEC#:V_[1%I#;V\:Q1(OCBX 15& !_HW8"OWZ
MHH _/7]EK_@F#\5OVC?^"6'C#X&_ML^*H?'WB/Q)K5S/9:Q8:B;VZTJU\NW-
MK(D\D2?OHKA9W&58;6"DE25'Y[Z!_P $:O\ @I5_P2LUK4_#_P"S-\3;7QE\
M/=2EF%K;PZK:VRVZR!09I+'4/W,,QQC? [GY0<CH/Z$J* /QA_X)@?\ !M7\
M0+/]JJQ_:$_;"\>Q_$3Q_I=W#J6F:,E_+J:BYC"F*:\N95&]HF VPQ@H#&IW
ML/E'WI_P5R_X)-^!/^"M_P"S9_PA?BB:30_$6BR/>^%_$EO$)9]#NV7:<ID>
M;!( HDB)&X*I!5T1U^JJ* /YYO"/_!,/_@K)^Q+X7F^$?PM^(MOK7P[N$%K9
MZC8>);40:1 7;'D_;0MU:$9W,MNI )X+5]D_\$1/^#='_A@/XI7GQJ^-7B6Q
M^(WQPU!IFMKB"26XLM#:;(FF2695DGN9 S RLJ[5=E .2S?JA10!^2O[<W_!
M$WXQ?M#_ /!?;X7?M)>'[KP:OPY\*:AX?OM06[U&6/4%6PE#3*L0B*LQ"C;\
MX!+#)'-?IQ^T5\)XOCQ\ _&G@N;R=GBK1;O2\S?ZM6FA9%+<'@$@]#TKLJ*
M/S-_X-MO^"6OQG_X)3_#3XF^$?BDO@N;3_$FKP:KIEUHFJ2W<CNL7E2!U>)
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M//\ X-M/^"5/QO\ ^"4OA/XL>&/BG?>$[KP_XEU&RU'0DT;4)+HB=4EBN9)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT]O([G5?$,\4]],&.0K-''&I"]!\O2OGW2O^"/WPX\,?L%ZI^SKHFJ>)='\
MWVO2ZW;F"6%KK3E?41?BUC9XR#$C 1C<&?9U8GFNZ^.G[/?Q%^(O[8_PC\:>
M&_B)JWA7P-X+COSXGT""Z8V_BCS4"P1/!MV_(V7\PMD8 "\DT >[5^<7B/\
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M#W%.KF/@I\,X_@M\'?"O@^+4M0UF'PKI-KI$=_?E#=7B01+$LDI154NP4$D
M DGBNGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex101170630image6a02.jpg
<TEXT>
begin 644 ex101170630image6a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+72H?#WP[M]$\1Z;K&CR:CJ,UC#<ZH;J,QWEJ"J2*^FNXEQLW1-*F.W\"_\
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MO]5?\.T_AU_T,?[0'_A]O&__ ,MJ/^':?PZ_Z&/]H#_P^WC?_P"6U?&.H?\
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M_A]O&_\ \MJ/^':?PZ_Z&/\ : _\/MXW_P#EM7T!12&?/_\ P[3^'7_0Q_M
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M  \L^'7_ $+G[0'_ (8GQO\ _*FOH"BI*/G_ /X>6?#K_H7/V@/_  Q/C?\
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M_$;_ )2F_!O_ +)5X\_]._@R@#Z HHHH **** "BBB@ HHHH **** "BBB@
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MRTNM3.,DVTO+\4I+[TT^^MG9W1] 4445)04444 %%%% !1110 4444 %%%%
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M:2*Y@Q*@,!$8#;'A'_@F?_PBND:/:_\ ";?:/[)^"?\ PIW=_8^WS?\ 5_\
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MV6?^CEOV?_\ PX>D?_)% 'T!17S_ /\ #V+]EG_HY;]G_P#\.'I'_P D4?\
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M4^*/B7H?A&23XC>'=<\2+=/IJ^*/AGXE\.6MRMK UQ<-]IU"P@@41PHSL6D
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M\[^S+NW\_'EKM\W?LR^W;O?=W_\ P[3^'7_0Q_M ?^'V\;__ "VH_P"":?\
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M@C_YH:/^&R/B+_T:=^T!_P"#?P1_\T-4W?\ K^OZU%;K_7]=/):'T!17S_\
M\-D?$7_HT[]H#_P;^"/_ )H:/^&R/B+_ -&G?M ?^#?P1_\ -#2&?0%%?/\
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MB/NM..C6WE=\WW\WO+LTFM4-N\>5[?\ #K\FUZ-K9L_,OX+?M,?LV_%WX?\
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M%Q]I.BJ+'RVE^:(*7D"[M[<A5]TK?V%/^5?<91J2:ZG.ZO\ #:#6_MWG:_\
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M7WP]M_"+?"-M.M;6;6M<CFCEFO8XWWWWV97BMHX%FAFD\N>8>3(&+(=RK/\
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M6K[I6OM9IMM/4%1DKI-:VZ=FI)^>J6^EDE8^"_AI^R'I_P <_ 'Q<^'7P_\
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M<F:[^T6NH37:S65A8%@533;:&2>W4R N$AM@J*-RCF_@U\/?CUX=_:%^*/Q
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M_P +6T30_ WB#Q/KZ>']&AT36Y?$6F:S+);M<PO;W7V6WD"M&DH)GMX0KPN
M64QN]7XA_ME>&/#%Y#::7J&DWUY!X]L/A_J4=^U[9BUO[J.*811M':3>;+Y,
M\3*#LA8OM:>,@XTN^:RW;BOG>%D^S3E#?5.4;V;1G*45"\OALWY6M*[^:C+U
M49;V9U@_9N^':^+_ !1X@'@'P6->\<68T_Q'J7]B6WVSQ!;!!&(+R79ON(P@
M"[)"R[1C&*J_ []E7X7_ +,4.I1_#7X;^ ?A['K#1M?KX9\/VFDK?&/<$,HM
MXTWE=S8W9QN..IKRCX(_\%0O GQ4TWXO:EK&G^*O!&C?"'5[BPO]1UWPUJ^G
MVUS;Q1P,)5>YLX5\]GFV"T0R3\1L%(E3/J/P$_:H\%_M*/K4/A>ZUV+4?#LD
M4>IZ7KWAS4?#NJ60E4O%(]GJ$$%P(I &V2^7Y;F.0*Q*.%FG\*<-G&+7^%ZK
MY:[/9W6]QR:NXRW4FG?^9:/YZ?-6MI8Q=)_X)]? 30/B>GC>Q^"'PALO&D=^
MVJIK\'@[3H]46\9R[7(N5A$HF+DL9-VXDDYS74?#S]FKX<_"+Q/XDUSPG\/_
M  3X8UKQE*9]?O\ 2=#M;*ZUR0L[E[J2-%:=BTDC9D+'+L>I->5ZY^V'X]^'
MG[37@CPCXP^%^DZ+X/\ B7KU_P"'?#FL6OBX7VL&XMK2YNTEN].6T6*&":&T
MF96BO)W0-%YB1EG$>)I/_!2YM!\*?M!:YX^^'>L>"+/X"VMMJ%Q8_P!J6VI:
MIJ<,]@+Q(VC@S;Q7!R(Q''<3(2RGS1D@3S)0\K/3RTNK=]KQWVT+Y9.IR=6U
M\]79W[73L]K]3W/X+?LZ_#[]FW0+O2OAWX%\&^ =+U"Y-Y=6?AS1;;2[>YG*
MA3*Z0(BLY55&X@G"@9X%=E7@O[,W[6'C'XC_ !AUCX>_$KX?:/\ #_QE8^'K
M'Q5:0:1XH_X2"SN["YDEA*M*UK:O'<0S0LLB")H\/&4E?)"^]5I*^C>OSOLW
M'\&FO)JQG&2=[?U=*2^]-/SO<****DH**** "BBB@ HHHH *H^*/"^F>./#6
MH:+K6G6.L:/JUM)97UA>VZ7%M>P2*4DBEC<%71E)5E8$$$@@BH?&VLZAX=\'
M:I?Z5H]QX@U2SM9)K33()XK>34)54E(5DE98T+MA=SD*,Y-> _#+]M+X@ZQ\
M0/B1X#\4?".QC^(G@/2](UJ#2_"7B^/6+'5;34I;F&)OM=[;:?Y+Q/:3M*CQ
MD^6@:+SF(CJ96LT^VOI^OGY:O0I75I+O]VJ2]-6DF^IZMX\_9S\,_$35? ,M
M];R1Z?\ #?4EU;1])MPD6G"YCMY(+=I(@N&$"R,\2@@)($<#*(5Z;0_ .@^&
M?$FM:QINBZ3I^K^))(IM7OK:SCAN=4>*,11-/(H#2LD:JBER2JJ%& ,5P?[%
M?[1LW[7'[+G@[XC7&AQ>&KCQ39M<2Z9'?F^2S=97C*K.8HC(,ID,8TZ]!7D/
MP#_X*8?\+K_:6^('@N:/X-Z/IGP[U+6++4;=?B6UUXRCM]/D,9O7T,:>OEV[
MMM.XW1"JX/S$A34IJ,Y1D];2D_2/+S.^W\OKIV)C&\5-+2\8KYW<5;?OILG?
MN>X^$/V4/A;\/M=\5:IH'PU\ :'J?CH2+XEN]/\ #UI;3^(1(79Q>.D8:XW&
M1R?-+9+L3U-3_!#]F3X;?LRZ5?6/PW^'O@?X>V.J2K/>6_AK0K728KN11M5Y
M%MT0.P' + D#BOE6/_@LA?>"/AA9>/OB#\)YO#?@?Q?X'U+Q_P"#9M-\21ZE
MJNIV-FL,WDWUK)!;QV-S);W,,H5)[F-1YH>5"GS>X?LU_M4>*?B-\8?$GPY^
M(G@O0?!/C;0=#T[Q/%#H7B=_$&G7NG7LES#&PGDM+.19DFM)EDC,)0!HF61]
MS!*C3E%\B5G:UMG9.6EM]&FVMTO>M9W%*2:YWJKWONKOE5[K37FBK[-NU[IH
MH_$;_E*;\&_^R5>//_3OX,KZ KY_^(W_ "E-^#?_ &2KQY_Z=_!E?0%2,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /G_P#X)I_\FZ^(_P#LJOQ'_P#4WUVO3OCYIWBK5OAC?VW@[2O!NOZK
M.5BETGQ3--;Z7JUJQVSV\DT44S0[XRP#F"=<\&-@21YC_P $T_\ DW7Q'_V5
M7XC_ /J;Z[7T!4RCS*S_ *_1^CT?4J,K._\ 7]>:U['PIX$_X)R?$3X9?"X7
MGAC2_A7X5UK1_B9:>/\ P[\.-,U>^3P;H<$=J;.XL(+W[&)(?M"RW%T7AT](
MTGDV^0P+ROJZ)^P3\6/$MG)J?BS4/A[;^(-3^.>D_%2[M])N[Q[.TT^VL[.!
M[..22$/+<(;=E#E8TEP)"(-_DQ_:U%:4Y<DN>/>+^<72:_\ 3-.][[>;OG5@
MJD'"7523])*HG_Z=G\WK>RM\5?%C_@GIX_\ BYX(^/'@>]N/"=KX:\=>.++X
MA>%]6M-?U"UU%KNW?39_L%Y'!!&]I&9+ J+NUNWE590ZQJZ 'T/]A;]E/5?@
MAXN\6>)/$_@VS\/^)-<M+/31?K\9?$OQ(N+VT@>>1(FEUJWA:V2.2>1E6+<&
M,KD[2!GZ2HJ:?[N*A'9)+[HJ*_\ )8J/:RVNVW4_>O?JW)^K?,__ ":\O)[:
M))?(_P //@Q^T'-^V[J'Q$\?^%_A#XCT>WNY])\*7-IX]U*"3PAH4CKO>+36
MT8QS:C.J(9I7NU!"K%&8HPWF<5J7[#GQM^/.I_M*:3X\T?X5^$/#O[06DP6L
M6HZ!XSO]<OO#MS:Z>+2W?[--I-I'<(TBK(P\Z/:!MP^=U?=M%2H)14.R:^_K
MZWUOU=V[W*4FINHM[I]]NFO396[))6/GO]FOX(?$N?\ :%UKXI?%>W\$Z+KD
MGA>R\(:;I'A76;O5[1((9YKF>[DGN+6U(DFEE11"L)$:P9,LI?"?0E%%:.6B
M2V5_Q;D_O;;]7IH9QBD[KR_!**^Y)+OIK=W84445)04444 %%%% !1110!@?
M%27Q1#\-->;P1#H%QXQ6PF_L2/7)IH=,:\V'R?M+PH\HAW[=VQ2VW..:^9OV
M1OA'^T%\!? /C&Z\1>!?A#XA^)7BAH]5U/7V^)VI2?\ "4:EF.(I+G0$^P6<
M-N&6"*%)P@C1"I9Y)S]<45/*KOS5OE_P=+][+LA[V\G?^OE==U=V>I\9_LA^
M$/C]^R%^SW\'?A/J7@_X?W&I6_B%=.U#5M&U?4-:TZ'1 +F[O+J9Y+.S-K<$
M[(($_?J\DBYPNXIM?$']EWXM_M:?%WP$WQ4TWX8^&_"GPVU/4=4@U+PMKM]?
MZMXB>>PNM.CB,,]E NG1-#>22RHMS=[FC2/)7,E?65%%2$9IQFKI_P"27KI:
MZ\V_0(RE%WB[.UOEK?[T[/R2ZZOXI^!O[$/Q<\)V'P]T[QI9?"WQ%I/P'\#:
MAX0\+6T6M7FSQY+/;P6B7&J(]CY>G1FVMMKPQ+?9:Z<AML867KOV!/V X_V:
M/BUX[^(-UX&^$_POOO%]E8Z-9^$/AQ"!HFE6MJ9I&G>?[)9FZN[B6=B\AMH]
MD<,$8W;"[?5%%:^TDZCJOXFG=]=6VWZN[79)M))$<L5#V<5:.FG32UEZ+E3[
MWW;/G_XC?\I3?@W_ -DJ\>?^G?P97T!7S_\ $;_E*;\&_P#LE7CS_P!._@RO
MH"H*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#Y__P"":?\ R;KXC_[*K\1__4WUVM#_ (**?!$_M)_LHZYX
M#A\5:)X4U#Q-<V=O8/K.7TW5YTN8YETRZB62-Y[:[$36\L*-N>*60 -]TY__
M  33_P"3=?$?_95?B/\ ^IOKM>R?$?X9^&_C%X*U#PUXN\/Z'XJ\.:L@CO=*
MUBQBOK*\4,&"R0RJR. RJ<,#R >U9U(\RMZ?@[^?XIKNFM"Z<N67-_7]?->J
MW/AOX)_'E/@?%X<\ >%? ?A#X(WVB_&FQ\'^-]!\)WD&H>%Y3>:.]T@T]S!"
M+=)\V3-&MO;2B=GRK-*9)6_$O]J35OBGX@NH_P"U_#?BG1_#_P"U%H7@W36D
MTO3]1AL+1+2Q>:&-FB8+<174EQ^^!\^)]RAUVX'V!;_LE?"FT^"$GPRB^&7P
M]C^&\QS)X33P[9KH;GS1-DV?E^0?WH$G*?? ;KS5SPY^S7\.?!WA^QTG2/ '
M@G2]*TV_MM4L[.ST.U@M[6[MHHX;>XCC5 J311111HX 9$C15("@#:F[5%.>
MMI0?RBZ#:6KLK4II):+VC6BO?"M3<J3A#2ZDOO59)WZN]2-[Z_NT[MVM^?\
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MM\J[IJ+3EJUS0MM(JI'XE%]4EZ+XGV:;32ZVDGNG;'^(W_*4WX-_]DJ\>?\
MIW\&5] 5\_\ Q&_Y2F_!O_LE7CS_ -._@ROH"D 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/\ _P $T_\
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M .IOKM>R?$?X9^&_C%X*U#PUXN\/Z'XJ\.:L@CO=*UBQBOK*\4,&"R0RJR.
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MLTNSYF\._L*_LF_LY?&3XJ>/OAW\2/!7P3\3>,M+BT>^G\-3^%[*'PE;Z?\
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M7 TVTAU"&QT_4IV"QW,KW,:R7?E&=45+J),90D^T?\$[/V@OB'\0/VY?V@?
M,WQ$U?XR?"7X:_V;IUEXMU?2]-M;JTU\QLU_I0FTZUM;:Y$*F-G(AWQ-($9B
M:Y/Q_P#\$XOV+]%^.>I?$3PSXL^'OP2\3:5X2U7PF)O!%[X>T!?#^XZC]JU.
M+_1RUOJ4":5K$?VG(,2:=? @&WE*>D?L8?#OX2_\$Z_ D7A'3?VEO[6\$^$=
M/N;"#P_XAU+PI:6FCF!]0>YN'DL;"TN&G5M(U@S23RN2UAJ#R9>"5TBCRJ,4
M[^[&2UUO><[<SZM1<=4E>5FVHQ<75:[<G'[4HO3HE&/,EY.2>[=H\V\FI'>?
M$;_E*;\&_P#LE7CS_P!._@ROH"OE_6/BSX5^('_!6;X5Z=H/B;P_K>H:/\*O
M'OV^UL-1AN9K+'B'PM9GS41B4Q=6-[ =P'[VSN$^]$X7Z@J1A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\2
M_L0?\DL\8?\ 95?B'_ZFFM5ZAXR\7Z;\/O"&JZ]K%TMCI.B6<M_>W#*S+!!$
MA>1R%!)PJDX )XX!KR_]B#_DEGC#_LJOQ#_]336JP?\ @J,FH:G^PQXZT73=
M/\6:C+XJAM_#UPOAS2KC4]1M[2\N8K:[GC@MXY)7\NWDF<[48X7[IZ5[W/*.
M'O#>RM?:_3JNOFO5;G%",95K3VOK;>W7\#LO@7^V'X#_ &C/$-]I'AFZ\1Q:
MK86$&J/9Z[X6U7P_<2VDS.D=Q"E_;0--$6C9=\090< D;AGO_%/B.W\'^&[_
M %:[COYK738'N94L;&>^N75 6(C@@1Y97P.$C1F8\ $G%?G#XT^'/C#7_ 7Q
MI\06MA\6OB-X5US2_"WA6VUGQ3X/ETSQ2]@NIL=6M[72K>RM)6M(;:;S,K8K
M+,[2#?,L:;.R^*VA^+?VEO\ A>VMIX#\;:7I?Q"O/"'PUT."^T:ZM+R[T+[0
MD]_?O"5\R"W,>IW>[S C((&658Y%9%V]HY>[!:_YNT>VCO'6]G>33:B[94XZ
MMSVTV]$Y:^7O?<DTFS[)^'/QQTCXH^.O&&@:;;ZFESX)GM+6_EN8!#&TMS:1
MW:(@)\P,L4T18.B$%P.>:H>#/VE-!\<:YJUC:6/B3=I/BB;PDTZ:3-<P2W<5
MND\C[X!((;==QC,T_E+YB%,Y*;OB"]^&%WK'Q:TO5/B5\+_&WB[X;^,_%7C+
M6[WPU_PB]WJT.J:G%<V>FZ"M_:&,QQPG3[:22&2[V6R,4D=T*I(N/X4^#WCC
MX:?LK_#+^S/ASXTTW6M!\%>-?B$NCP6-Y<RZ7KVH+Y&F:<2%)-Q'#J,\8C/S
M(L#': .,%B)\GM(QO[M^7KS:2<6]DTHS2WT<)?:2>BHWFJ3:3YK-]+>]%/T<
MN5W[<RW1^G%%?G?JO['VL?LACQI'\%?!NOVOBCPC\!+C3H=>M;5VN_%VN3R8
M@\RY8?Z9=VRV.41MQB6Z1$"JP2MK]@GX7^ )?V\+B^\ _#K5/!6F> _AO:6]
M]?:QHEQHNI>)-1U*[8->7-M<HER]PJZ;,K7-RHFE,S'+QE'?IC+FFH+^]KZ.
MHE\G[-6;M\<=]S!W5/VC7;\53?WKVFW]V78^IOC'^V7\._@)XPAT'Q-K&H6^
MHM:I?77V+0[_ %*#2+5Y#&ES?36T,D5C S*X$MTT49$4A#8C<KT7@3XT:5\0
M_B+XT\-:?#??:_ EU:V6HSR(@MY)KBUCNE2,ABQ*Q2QEMRKC>,9ZU\S?%W6-
M2D_;&L=>^%>A_%C1?B9/K-AX>\66.H>&+I/"/B308+@F2[FOY8C9*T-M+/);
MO:7*W#/(L4D4F&B3S_3?V39O%GC71?B'=> ]=N/B!X[^/,NK'5]1T^7[9X1T
M33YI5CDB,B9LH;JSTNVB8C9YXNHE8N!&HSHU)3<+[2=K^3G!)^:Y9N3>BO"2
M=K:Z5H\BFXZ\JVZW492:?SA9:/24'=W/T'HK\QO%/P:E^.GCZ&SU[X.^.-0^
M+6M_&-QKWC:?PW=P0^&_#5OJ<C6\-MJ<R 2V,^GVT<7DVK/ #<R&4(\@\SH?
MB_\ LS>)M8_9D^+'Q(TKPYX@LOB5\0OB'=13:I/H5YJ&O>'?#!U2'3YC8VD1
MBO1'+IMHDCQ6CQS2QR95BRQ[<Z>(<H*I;1^>E_W=E?:WOOFELN26]BY4U&HZ
M;>SMYVO.[2Z_!HMWS1VNC]&**^:/^":/[/?A_P"#O@3Q/KN@PVVFKXRU&.6X
MTO3?AU??#W2;)K>$0*UOH]Z6GB=U ,DSNWG, 00% 'TO75V]%^*.>,FUJ%%%
M%!04444 4/%/B.W\'^&[_5KN._FM=-@>YE2QL9[ZY=4!8B."!'EE? X2-&9C
MP 2<5X_X<_X**_"?7_$FJ:3<ZOXF\+WVBZ4-;O1XL\':UX9C@LVG6W27S-1M
M($.^9A&BABSMD*"0<>H?%/Q\OPM^'6L^(FTK7-<_LFU>X73M'L9+Z_OF ^6*
M&&,%F=FP!Q@9RQ"@D?/>F7^J?L?? ?Q5\1O&6A^)O%'Q@^(PDO[^S\,>'M1\
M0-!<I;R&QTB+['!,T5K;H!"LL@2-I'ED)#3$'EKUG34I](QOMJWK9+O=]$GM
M9V<HFL*?-RQ6[=O*VEV^UEU\[V:3/=_@A\;O#7[1GPPTSQEX0OKC4?#NL>;]
MEN)["XL9'\N5XG#0W"1RH1)&ZX= >/2N?'[7G@>Y^*\_@NQN/$NM:U9W7V&\
MET?PKJNIZ9I]R%W-!<:A;VSV=O,JE2T<LRLNY=P&Y<^;_L)^,_\ A!_V8?A)
M\/\ 3?"/CU-2B\$/+<7^J>&;S1[.TOK0013PW7VM(I8YI[B9WC!C/FK'+(#M
M )^??V _A[XB\ ZQ\)'TNQ^/&BZAX5T?4-2^,)\3'Q!_8UY>RVTA>UL;&ZQ:
MW5P^H.TZSZ;"X*0N6=FN%\SHK7A5<;KE5]>]FU=>2Y7=]+QWNKY0]ZESK?33
MUZ-=&[JR]=59M?1GB_\ X*F?"7P/<QVFIQ_$_3]2N[>XN+"RU'X9^(],DU0P
M*&>.![NQBB9R61 "X!>6-<Y89Z7P;^VMHOC#P5!?'PQXNT[Q%<:_/X97PI.E
MG/K OH"/.4FWN9;7RXXSYKR_:/+1>&8/\E>7)\)5^+WPT\;?%3XM>!_%FN:K
MX^MX-+T'P?81W$.KZ%I*W*/8VBM&\;V=Y-<"*ZN)S)$('\L22HEH)!Y)HOP-
M^*'[.G[3'A_2_#,GBBPU;44TBX5]+\/OK6AW5O<ZO)-K5G>:O>V\SQ)!:Q&=
MII+J"\O[NY\QB^(((LZ?M'5C">BE9?X9-WU_[=^+?E;N]%[]54N1SI]'?U5K
M-_\ @35MN9+S?)]F^&?^4IOPN_[)5XW_ /3OX0KZ\KY#\,_\I3?A=_V2KQO_
M .G?PA7UY7CXW^,_E^1VT?@04445RFH4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\2_L0?\DL\8?]E5^(?_J::U7L
M5>._L0?\DL\8?]E5^(?_ *FFM5>_;C^.$W[-O['OQ*\=6EQ%:ZAX;\/7=U82
MRF,(EWY96W+&3Y,><T>=_P N.O%>_&HJ>']H^D;_ '+SLOO9PQIN=7D75VU\
MV>J45^?_ (6_;LUSX/7_ (K\1:!\4=4_:A\ ^%_!/VW5[JWCT=X(O$DEW;0V
M6EV-]I=G! \EP)IC)$XGDB MV.P2 2>ZW7[6OQ,U/QY)X&T'X7>$[[X@:?I:
M>(M7LKWQO+:Z7HVG3RRQ6:37B:=*YOYFAF/V=(&B18)";DCR_,UE4A%7;[OK
MT<D__26_\-GLS&-WKZ?BHOY?$EK]K3<^BZ*^3;3_ (*/:-XV\->"?&TG]O>$
M_!L/P_U#XG^(W6>UD:&TMRD"V,J-;RF97>2:1)+>:%F-HF"ZNRUS?PO_ ."P
M]OXW\*>(==F\(^']6TNSTS3KG2&\%>-(/$S76HZA=K:6FB7DBP16]IJ3R2PD
MQ)-.B*78R;5#._:1<N5/77;79RCT[RC));MK2]U>N1K5^7EOROKY2BWT2=W;
M6WUY\1/A]H_Q7\#:KX;U^S^W:-K5L]I=PB5X6=&&#MDC*O&XZJZ,KJP#*00"
M,7X,?L^^%?@#I^H0^&[74O/UB=;C4+_5=7O-9U+4'50B&:\O)9;B4(@"H'D(
M11A0!Q7SM\?OVC_VB]'\6_"7POI/@7X=>&_%'BSQ;+%=P_\ "<R7=EJ.FVM@
M][*B3-I#2HC[6BDD-NCQ.(PF]9?,C[W]O?XE>.OAMX#\)WF@S>*=!\-S:NH\
M:^(/">D0Z[K/AS3Q!(PFMK2:"<2H;@0I(XM9F2%I&$8P9(X]I&*=1JVJCTV=
MG?\ PW?7:S=MFQ1<FH+71R7KJK6WYG;16UNO.WT!17Q+XP_:'^(FB?&;X5V'
M@S6+?XRV^D?#W6/&.IZU+JJ^'-#UBUFFMDTZYO9+6*="YMTNRODVS)),-ZQP
M1EC%Z*_[>/B#Q[8^%X?AW\/M/U[6]4\#V?C_ %FVUWQ+_8MOH5A=*?(A\U+:
MX>6ZD9)@JF)(]L#LTJ94-7M8I.3Z-K[G-/\ ]-S].5WL"BVTEU5_OY;>6O/"
MW?F1]*T5\M_#W_@H;XB^,=W\.;/PO\,5^U^./!8\>7\FM^(/[/L_#6G/<QQP
M"XECMIF::6(RNJ(A&Z$J6";I5R?V0_\ @JO8?ME?&?2='\)Z)X5U7PCKUO?W
M5OJ&D>,(]4UK1H;<@12ZOIT=OLTY+GGR@UT\I)4-&C>8L=1DG+E6_O?^2MI_
M<TUYV=KV9/V>;II_Y,DU^#3\KJ]KH^NJ***H HHHH **** "BJNN17UQHMY'
MIMQ:VFHO"ZVL]S;M<0PRE3L9XU>-G4-@E0Z%@" RYR/B?P#^TE\6-1^$FFZ"
MWC9-8\:_%7XKZUX1\/:\VBVL(T'1[![D7=U%;*@C8QII]T8!.9CNGMQ*TX#!
ML_:>]R6?3T=Y1C;R?O)ZV5DW?1E.-H\[VN[^5HRE?TM%[7=[*VJ/N*BO _V$
M/B#XM\5-\6=!\5>)KWQI'X!\=7/AW2M=OK2TMKV_MDLK*=A.+2*& R1S7$T6
MZ.&,%8UR"<L>)\?V?Q*G_;-T?PMX)^-'Q&U6'3)#XI\8:3=:=X;;2M+TMFD^
MRZ6CKIB7(FNY%*(6N"Z0032,Y;RRPZB2A+I-*2MKHXJ6V^D=6DF]':[M<Y?C
M[Q;7S3<=]M7HKM;K;6WUE17Y_P#@SQK\>O%/@'Q-X7US7/CMI?QNG\)QZL/"
M>HIX-@TVYAENHX;R72+ZPB)62 %TA^V7<;;I(G=<$NM7X%_M00Z3=Z?\._%?
MBOQUX7\-3>)YIEN)=1U3Q%JJI-J(MK+2+C68C="&);@K'/=O=^4;@O9P32"&
M<QJ%3FFJ=M9+3;5\W*UINU9WM?9KXK)JHN6+EV=GY7CS)^CTM>VZ>UVOL;PS
M_P I3?A=_P!DJ\;_ /IW\(5]>5\A^&?^4IOPN_[)5XW_ /3OX0KZ\KQL;_&?
MR_([J/P(****Y34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _-']FC]NKX(_!O0/'WAOQ?\8_A7X5\1:;\5?B!]KT
MO6/%EA8WMKO\8:Q(GF0RRJZ[HW1QD#*LI'!!K3^._P"V3^RS^T)X'@\/:Q^T
MA\([/3XM6T[5I!8?$#2(VN6LKR*[2&0M(P,+O"JNH )0L RDY'Z-T5WQQTHI
M*VUOPV_(P=!-MWW_ %/SF^-W[9O[+/Q[\*:?HNL?M'?""WL+'6M.UQDL_'VC
MK]JDL;N*[ABDWR-F(RPQE@N&(& PS7 ?&/XJ?LM_%CXL:QXNLOVP?"?@>\\4
MZ-;>'_$5MX<^(WAZ&'7K*WDG>*.1YTFGMV N9U\VTE@D D)#A@K#]6**4L==
M<KBK7;MT;:Y7?O=*S3T&J+6S?3\'=?-/6^^W8_&OX<_%W]EKXG2?%>P\4?$W
MX-^!_ _B+POIOPUT#13\1]"-[::-IZ7)$\<EM>3)"KRW;&)2Y<"!&D56.T=[
MXE^,W[.7Q ^$<WA7Q5^VUX9\43QZM8:WI.N7?C;PA;ZEH%W93)/ ]O\ 9K6&
MW?$D8+"XAF# LI&"17ZKT57]H2>LE=Z:W=[I\W-Y2YO>NK:O0GZNOZ[64;>:
MY4HV=U9)'Y9?\+R_9IE\6_#_ ,17'[97A6]\3> 9KY_[5N?B'X;DEUV*\:$W
M%O=1&/R$B801*!:16[(%.QE+,3K_ !O_ &K/V?/C#KD=YI_[:GAGP'#)8MIU
M_9>'OB'X;-KJ4)8G++>1W!AD 9U\VV,,A##+G9&4_3:BIEC;KE<5;MTVM:VU
MK=-M]-6"H6V;_IWO?O?6^_F?E*OC3]C'3_"/C#0=)_:+^%NAZ3XN\#6?P\6W
MLOB+H_\ Q)=)MH[N.-;1Y'=Q(?MDS,\K2$L%/;G(^,6I_LA?%O6-6FM_VM/"
M/@W3?$GA.V\%ZWI?ASXE:#:6^KZ?:BX^S"25P]S&\7VF7!AFC#K\D@D0LK?K
MC114QGM+\\;WWWU^+?O\4M^[[E1I.-K/;;R^'\N2-NW*NQ^8_P /_P!H/]D+
MX=^(]5U"W_:&^$%Y'JOA73/!C6=UX_T=K:VTVP6Y$4<8216!?[5*7)8Y.W 4
M#%1_LS?M-_LY_LQ^'[;0[7]LKP7XJ\,Z5I\.EZ/H^N^./"S0:+;P@+$D4MM#
M!<2%8PJ;KB:5B%R26RQ_3RBM'F4W-S:U>_GN]5L]6VNUW:UV9K"Q45'HK6\K
M)+3Y12\TDGLCX7_X><?LV?\ 1PGP/_\ "[TO_P"/T?\ #SC]FS_HX3X'_P#A
M=Z7_ /'Z^Z**/[2EV*^K+N?"_P#P\X_9L_Z.$^!__A=Z7_\ 'Z/^'G'[-G_1
MPGP/_P#"[TO_ ./U]T44?VE+L'U9=SX7_P"'G'[-G_1PGP/_ /"[TO\ ^/T?
M\/./V;/^CA/@?_X7>E__ !^ONBBC^TI=@^K+N?GO\3O^"@W[/OC[P=<:7I7[
M6'PO\$WLS(R:MHOC7P[+>0!6!(5;P7$&& VG=$QP3@J<$>$>#)OV5_ 7PF\'
M^&=/_;5\/I??#W5Y]8\,^(6\=>$3JFC-<0S0W$*C[+]FFBE6XF+?:()7W2;@
MX*KM_7^BL_KS;OR_B^EG\MNGZL/8+:_?\='Z[GYB?!_]H7]E+X(:KH=QHG[4
M7P^\G2;74EN[.;XFZ4UKK][?W,5S<ZG?1K(!->&5'*N-J1BXE5452H67P9^T
ME^RKX&^'_BK1[/\ :A^'/]K>--1GU?5?$H^)&D0ZU/>2%?+E\V)TC A2.&*.
M/R_*$4*1LCKN#?IM15/'-JW*MFM--&[M:=+I:=+*VR#ZOK>_6_?7:_KJ_6[O
MNS\I] ^*O[+M@/$U]JW[8OACQ+XK\76]MINH^)[WXD^'[75!ID+[_P"SK?[&
ML$%I"^Z7>]M%%.3,S^<)%C>.3Q1\1_V/?$?Q8TCQ)#^TG\*]%TO3+72+2;PQ
MIOCKP_!HVHII-Q+<Z9YHP;A!;3RF14@GBC8H@='4%3^JE%$<P:LU%:.Z]5L_
MO;?^)N6[;!X>Z:;WT?X?Y)>B2V2/@O\ 9S_:<^&O[1O_  5-\ ?\*]^(7@?Q
MY_8WPJ\9?VA_PCNNVNJ?8?-U?PEY?F^0[^7O\N3;NQNV-C.#C[THHKCK5'4F
MYLVA'E5@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **^3_@KXV_:2_:4T3Q)XET+XB? _PMHEIXU\4>&]/T
MV_\ ACJFJW4-OI.OZAI43RW*>(+=)9)$LED8K#& 9" N!D]A_P *Y_:F_P"B
MR?L__P#AF]7_ /FGH ^@**^?_P#A7/[4W_19/V?_ /PS>K__ #3T?\*Y_:F_
MZ+)^S_\ ^&;U?_YIZ /H"BOG_P#X5S^U-_T63]G_ /\ #-ZO_P#-/1_PKG]J
M;_HLG[/_ /X9O5__ )IZ /H"BOG_ /X5S^U-_P!%D_9__P##-ZO_ /-/1_PK
MG]J;_HLG[/\ _P"&;U?_ .:>@#Z HKY__P"%<_M3?]%D_9__ /#-ZO\ _-/1
M_P *Y_:F_P"BR?L__P#AF]7_ /FGH ^@**^?_P#A7/[4W_19/V?_ /PS>K__
M #3T?\*Y_:F_Z+)^S_\ ^&;U?_YIZ /H"BOG_P#X5S^U-_T63]G_ /\ #-ZO
M_P#-/1_PKG]J;_HLG[/_ /X9O5__ )IZ /H"BOG_ /X5S^U-_P!%D_9__P##
M-ZO_ /-/1_PKG]J;_HLG[/\ _P"&;U?_ .:>@#Z HKY__P"%<_M3?]%D_9__
M /#-ZO\ _-/1_P *Y_:F_P"BR?L__P#AF]7_ /FGH ^@**^?_P#A7/[4W_19
M/V?_ /PS>K__ #3T?\*Y_:F_Z+)^S_\ ^&;U?_YIZ /H"BOG_P#X5S^U-_T6
M3]G_ /\ #-ZO_P#-/1_PKG]J;_HLG[/_ /X9O5__ )IZ /H"BOG_ /X5S^U-
M_P!%D_9__P##-ZO_ /-/1_PKG]J;_HLG[/\ _P"&;U?_ .:>@#Z HKYO^&_Q
M(^-'@+]M#PK\.?B-XJ^%_C#1/&'@KQ!XD@G\-^"K[P]=6%QIE]H=NJ,T^K7R
M2QR)JTA("(5,*_,02*^D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_<_9;F2&9WA0I&%(#S,DGDB,L=O]I7Q7\5/VA;=(].^$7[9WPS\RPN-,O?\
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MF1+B.2#4+:.TS=&2VF2*4&W220% 1&X#"LZDG%77E^?R7WM+NTM2Z<4Y6?\
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MTN_TVU95N+^SOKV"&VO+6/>C-/;2R1A)$?=M96/:_L_?M)^"_P!J3P;>^(/
MNL-K>D:?J=SH\]PUC<6FVZMVVRH%GC1F4$@AU!1P059@0:^ ?^";^G^(?A=\
M6O ^K77A?XMW.D>'?ASJ*^*-,\2>!=<M;3X53^9!<'2/#37$9DOX99/,B\J
MZA(8[&U6.X2%(8&]\_X)1_$5-=3XPZ;-X9^)'AZZU/XC:]XGLSXE\":UX?BN
M]/N[D&WECDOK6%'9@,F)6,BCEE6M(Q3GR?W)2TUU5116JNFG"\M&_A;3<15)
M)1YH[<ZCKV<&[VT::DDG=+XDFD[7[SXC?\I3?@W_ -DJ\>?^G?P97T!7S_\
M$;_E*;\&_P#LE7CS_P!._@ROH"I&%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME:7X-L[34-4BUOPWJNC:@MM=DK9S0V5W;17-Q'<N#' T$4@FD'EQEW^6N^^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^?_ /@FG_R;KXC_ .RJ_$?_ -3?7:W_ -O#PCX4\>?LS:WI'C;0/'.O
M>&[R>U-P?!UK=7.MZ3(EQ')!J%M':9NC);3)%*#;I)("@(C<!A6!_P $T_\
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M97T!4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,KZ J1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\_\ _!-/_DW7Q'_V57XC_P#J;Z[7T!7Q!^Q+^P]X+^,'
MPP\9>(M6UKXP6>H:C\5?B'YL6B?%CQ5H=@FSQGK48\NSLM1AMHLJ@)\N-=S%
MF;+,S'U__AVG\.O^AC_: _\ #[>-_P#Y;4 ?0%%?,>N_L0_!7PMXST/PWJ?Q
M$^,FG>(O% G.C:7=?M"^,H;W5A @>?[/"VL!YO+1E9]@.T$$X!K<_P"':?PZ
M_P"AC_: _P##[>-__EM1TN!] 45\_P#_  [3^'7_ $,?[0'_ (?;QO\ _+:C
M_AVG\.O^AC_: _\ #[>-_P#Y;4 ?0%%?,?CG]B#X*_#"#39?$WQ$^,GAV+6=
M0@TC3WU/]H7QE:+?7LYVPVL1DU@>9-(W"1KEF/ !K<_X=I_#K_H8_P!H#_P^
MWC?_ .6U'2_R_K[U]X'T!17S_P#\.T_AU_T,?[0'_A]O&_\ \MJ/^':?PZ_Z
M&/\ : _\/MXW_P#EM0!] 45\_P#_  [3^'7_ $,?[0'_ (?;QO\ _+:C_AVG
M\.O^AC_: _\ #[>-_P#Y;4 ?0%%?/_\ P[3^'7_0Q_M ?^'V\;__ "VH_P"'
M:?PZ_P"AC_: _P##[>-__EM0!] 45\__ /#M/X=?]#'^T!_X?;QO_P#+:C_A
MVG\.O^AC_: _\/MXW_\ EM0!] 45\_\ _#M/X=?]#'^T!_X?;QO_ /+:C_AV
MG\.O^AC_ &@/_#[>-_\ Y;4 ?0%%?/\ _P .T_AU_P!#'^T!_P"'V\;_ /RV
MH_X=I_#K_H8_V@/_  ^WC?\ ^6U 'N6H>&--U;6=/U&ZT^QNM0TDR-8W4L"O
M-9F1=DAB<C*;E^4[2,C@\5>KY_\ ^':?PZ_Z&/\ : _\/MXW_P#EM1_P[3^'
M7_0Q_M ?^'V\;_\ RVH ^@**^?\ _AVG\.O^AC_: _\ #[>-_P#Y;4?\.T_A
MU_T,?[0'_A]O&_\ \MJ #XC?\I3?@W_V2KQY_P"G?P97T!7R!X2_9I\._L[_
M /!4WX7_ /"/ZE\0-0_MCX5>-_/_ .$G\=ZYXH\ORM7\(;?)_M.[N/(SYC;O
M*V;\)NW;$V_7] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!^8?Q>_9/\5?MD?L(Z7X7\$^)/ ,'B+2?V@?'
MGB./P?XV>4^'OB'#9^-M?DETV]BB)DEA7*SE1'(NZ%-R@?.N-^P]_P %+;KQ
MO\:_V6_"7A#PM:_ OX;^([CXAZ+XD\$K<6FH:7'J.CA)52QOO+ -M&\DK(MJ
M8XE&Y I2-:]D^ U[X+^(7[,WB[P?XZ^"DGQ@T.Q^*7Q#U);.]TW1=1T^:Y'B
M_P 52HB1:A<Q@3J;>&$.R*@?5+;#^6MU);>F_$+3OA7XI^'&F^#=6_9BA\4^
M$?!+RR^']#GT#PW/IMF]NNI+"UE;SW8C@,BVD"QG;'M&L68?RPM[]DJC0JQY
MM'RR;>SW<5'FZ;+51=TVDTXN]YK3A+EN]8_DFW;YMZRT=KQLU:WYP? S]I/Q
M]^W9\5_V ?%GBGXJ/I/BSQ+KGQ2TV+Q78Z?IBW @BVPVZVT;P&S,AAC1%9X)
M0>I5R<UH_#_XN?$C]NGX\_L(^+/%'Q/\2:?JB>-_B#X5M?$^A:;HT4.KQZ?;
M7<46IPK+9SP>;=Q1>5( IA(5C#'$V'K]"/&OA[X1ZQX9N-%OOV6[/Q%H^FG5
M#:V#>'?#4EK<?:);Z:X\J.:Z55^VRZ?9R-O";WU6Q:;88[PV=GQ_:_"[Q-\,
MM/\ !6J?LRQ^*/!O@V2270=!FT'PW-IEJ]LNI+ UG;378B@+K:0"([8RHUFS
M#^7MO?LFM.C.#A[K]W]97;VWLVK;-N[5TF.K5C-35TN937HI<]EZ>_'T4+*Z
MDTOC[6/^"AWQX/@+7OC-;_$*2&XTW]H=?A19_"9M%TW^S;C3Q?QZ;Y#S>0VH
MG465C>>:MTL0/ A,>%.+^R5\0-4_9!\(_MF>)K[XL?$Y;JY^/]UX4LM/L- T
M/4+^_O[YM+CAN;:.2V@B34)ED\J-[B46$>%=[=]K!_MS5(?A?I/QNO/B9;_L
MSK??$BS-P8?%=MH7AM=<O#'#J,">7>27:3CSH;*VC3>Z835[)9/+"7HM*OQ(
M\-_"'QEXA\9:OK7[+-EXMU;Q1;R6>MWMSX<\,W%QXI@MFO'@BGDGN@TR.VEV
M#1+<$!3J.G%Q$8KO['G1P]6"5TV^3E;MK_RYO9V=[NG*5VG9U+V?+[SJ582;
MLU;F4DNFCJVTTV52*T:<E"S:YKK\^O&/[5_C_P#:5^$/AW1_B%J.O:MJ7PO_
M &S_  SX5L;C7H=(BUF.UCEAD6"]_LC_ $!KB)Y)$9K?Y3@ \@U^U]?+-EH_
MPG^'?AV31]!_9?MXM)T?5%URQLM+\/\ AJWMY=0L4OH[.\@C-VBI<;-.LU@E
M8(\:ZI8!C$([S['Z1J_[6,^F_;O)^&GQ U#[+]H\K[/-HZ_;?*_M'9Y?F7ZX
M\[[%;;/,V8_M>R\SR]E[]DUC1J1H^SY7>Z;=MW[*E!OU;IN7S[W,Y3BZG/?2
MS6^RYZDDODII?+L>O45Y#J_[6,^F_;O)^&GQ U#[+]H\K[/-HZ_;?*_M'9Y?
MF7ZX\[[%;;/,V8_M>R\SR]E[]D-7_:QGTW[=Y/PT^(&H?9?M'E?9YM'7[;Y7
M]H[/+\R_7'G?8K;9YFS']KV7F>7LO?LD>PJ?RO[BO:1[GKU%>0ZO^UC/IOV[
MR?AI\0-0^R_:/*^SS:.OVWRO[1V>7YE^N/.^Q6VSS-F/[7LO,\O9>_9#5_VL
M9]-^W>3\-/B!J'V7[1Y7V>;1U^V^5_:.SR_,OUQYWV*VV>9LQ_:]EYGE[+W[
M(>PJ?RO[@]I'N>O45Y#J_P"UC/IOV[R?AI\0-0^R_:/*^SS:.OVWRO[1V>7Y
ME^N/.^Q6VSS-F/[7LO,\O9>_9#5_VL9]-^W>3\-/B!J'V7[1Y7V>;1U^V^5_
M:.SR_,OUQYWV*VV>9LQ_:]EYGE[+W[(>PJ?RO[@]I'N>O45Y#J_[6,^F_;O)
M^&GQ U#[+]H\K[/-HZ_;?*_M'9Y?F7ZX\[[%;;/,V8_M>R\SR]E[]D-7_:QG
MTW[=Y/PT^(&H?9?M'E?9YM'7[;Y7]H[/+\R_7'G?8K;9YFS']KV7F>7LO?LA
M["I_*_N#VD>YZ]17D.K_ +6,^F_;O)^&GQ U#[+]H\K[/-HZ_;?*_M'9Y?F7
MZX\[[%;;/,V8_M>R\SR]E[]D-7_:QGTW[=Y/PT^(&H?9?M'E?9YM'7[;Y7]H
M[/+\R_7'G?8K;9YFS']KV7F>7LO?LA["I_*_N#VD>Y:_;H^'TGQ<_8L^+7A*
M'5=%T.X\6>#]5T6#4-8N?LVGV<MS:2P))/* Q2,-(I9@I(&< GBOA#]BNX^"
M7P9T+XX?L^_%W]G+X$^%Y/@3X(T#7?'VJ:#8VFNZ%XO@BM'G2YO?,TZU?[4A
M1YEBGCD;,K,KG[S?;_BC]J 3:?JMI+\+?'6M6OEW4)A5M&:/4D0:B JK+?J-
MLXL[<*)-HQJ]GYGE[+W[)Y[HNC?"?X4_"WQ1X'\,_LOVUEX)UIKIM3\/Z/X?
M\-6FE^(BJWZ R6WVJ.*0SK86BKYZCC5;$2>6([S['D\-72J<B:YHI;7U7-RO
MR47*_6^S2LFM/;4WR*;TBV]^C<>;UNHV6UMT]T_$O^"$/@[P=^R_^PHOQ6\5
M0^!_A/<_M,>+7\46&DB6VT?3[**^?9I&EVL>(HMYME0I'&H9VE;@G-?)?C_X
ML2_%[_@M;^SG\4/B#X4^*>@^(/$'C[Q!X;TS0-<^'^MVJ:/X;M].EM;&-#):
M"&Y>YFEN+VX>!Y5B2Z02LL<.1^BW[0&G>%?C-JOP_;5?A?\ $N\T?X.ZXWB+
M0M"TR;0K?3-2O+.'4XK%FC>[5MJ&UMY+="T*J^JV!E"B*[%GVOCWXN^'_$?B
MO3=>U/X(^(O$VN>"9;V?P_J,MKH4UW9R;-1C+V4LUZ'@:Y2RME!S&2NKV0DV
M!+W[)TNC+V\:B@^6+22U?N)02U?VK)Q;ZQ>_O,QC-*C.G=7FI-O^]+GOI_+>
M49+JFE;;7\Q_&?@/PSX;^+_[<OQ^^ /@3P7\.=)_9M^']_\ #CPE<^#]%M='
M^T:]]G-SJVH$6\2!Y;;='"I;=@)E<9KZ0_X(S:W:?"/]H[5?A/:^#?@V4U#X
M5>&_'J^,_!/AE]*U+4DNFEC6WUF=[FY>^NCS,MRTJF7=,^P%SCZD\._%/PS\
M'O#NM:/X4^!NO:;I,]S?WLUEHEGH-E;ZM.[:BTDOE_;8U:2Z:SMSNE"DG6+,
MRE-E[]DS/A1KO@#]E71-:TSX8_LZW7@_39I[BZFM/">D^'M(@U:6)=06.39'
M>1*SRK8VH1I0I U:R#^7LO/LD8>C5IV4HM^[%/1ZNU1R]$ZDU-6Z14/A>AB)
M0G?E=O>;^5Z:CZM0@XOSDY;K73^(W_*4WX-_]DJ\>?\ IW\&5] 5\HI\69/B
M/_P5F^&-K_PC/B#18=+^%7CS9=W[V9AOO^*A\+P#RA#/)(,QVT5P/,1/W5[;
M@XF6>&#ZNK.46G9FB=]4%%%%2 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\2_L0?\DL\8?\ 95?B'_ZFFM5V7[07
MQALOV?/@3XR\=ZC&LUCX/T6[UF:(R^5YX@A:7R]V#M+;=H.#R1P>E<;^Q!_R
M2SQA_P!E5^(?_J::U1^WM\%O$_[1'[+^N^#?"=MX8OM0UNYL4NK3Q!>2VEA?
M627D,MU;O)%!.R^; DD8/E./GY!%>][WU>T-'9)/LWI?9[;[/T>QQ0Y?;7GJ
MKZ]+KJOF<;X _;SU;0_%GC#2_B]X3\.^ X_"'A.Q\87=YH/B*Z\206MK=33Q
M+#<J=/M9(KC,!*1HDOF /@Y7!]&^-G[57ACX/:#X\:34M._MKP%X;C\37]K?
M_:K>U@MIC<);F6>&WG91)):S+MBCEE&W(B;*AOF4?\$U_&-G\-_B,_A?P[\)
M?A?>>,+GP\UMX!\+WL\?A5DTR_6ZN)9[E+&$BXO(\PO)'8Y1(803+C*]9J?[
M%7Q0^)</Q*U3Q=J7@M=<^)GBGPO//:V%Y<R6>C^'M+EM9YK".22 /-,T@OE#
ME(TE\X.5AW&)-N:<O=2MY^KT?79-7ZVC+F2;2>5-)-RD[K3RV2YO/5J5O-JS
MDDSL=(_;\T?P_P".?B!;>,)H+73O#_B.T\+:%::'I=]K6JZS??V5;W]Y'#;6
MT<EQ<^5YY!,5NNQ(79P "1G_  :_X*$VGQ/L[36/M'A;_A&O%'CC5- \.W$T
MEY93SZ9I]C)-<7)3R)=TRRVUSN67[*BH "PD 23DO#O[%/Q9^&WQ:\-^/M$N
M/A[JOB2.^\8MJ<&J:C=QV>GKK>IV]S;WD!CMB]S+;VUK#$T#^0LG($Z8#5DW
M'_!.OXH1?L_>$_#<?B+PC=>)-#^'7B?2+S49)YX8[GQ+KDD+37JJL!Q F;P@
MX#DRJ-@&<8*59PYXI<W+:SV4])/7=I\C2:M95%'XD[:*G3YU"4O=4OBZM>]%
M.WS4FN\7T:/?/@G^WY\)?VA]46U\)^*9+X3:,_B&VNKK2+[3[+4-/1D66YMK
MFYACAN(XFD1)3"[^4S!7VMQ3_@[^WA\+_CWX_L_#'A?7-6O-9U+3Y-8L([GP
M[J=A#J=@C(IO;::XMXXKBU+21A9XG:)RZ[6;(KQ;]L7]D6XM_AA\2[L:YX;\
M'^!]+^"EQX"T.Y,,\G]BF4N;N>XBBB(2U$4-D-T>XJL<K%0%&6?L">)]<_:+
M_:A\2?$"^O? >I>%O"'@[3_"'AV;P3JKZUX?6:2>6>_2#47BA^UN%M]/WE(T
M6(L(L,\;N_3&2E5Y.GO-][7J*+^?+3TU^)[6L8RYE3YWOI^*IMKU7-/Y0\SU
M'XE_M=^)[+]I#5?AOX \":1XTU3PIHMEK^OQ7WBA=%O#:W4TL<:Z?"UO*EU(
M!!*6,TMM"K-$OFY9MF3X1_X**>%YOVH?'_P_UZ_CM8_#_B73O"VDR66CWUT@
MN[BRMIBE]=Q));6IDGN1#")FA\QHI%7>5.*7QU_9H^)'[1GQF\+3:SHWPMT7
M3? OBF'6]#\=:=J%V_BFTLHYDFDL([1K4)#]I1!;3R"^>.2,LQ@.X1)!H/[$
M?BI?#'AJSO[SPS#/<?%V\^)'BUK=Y)!?6XN;NYL8(B8E,DD;#3$8OM 6W?!;
M"ALZ/.W!SVOKWLYPU\N6#FK.[O&]FFBZUDIN&Z6BZ749??>48]5\=M.5G?>/
M_P#@H)\)?AAXYOO#^L^)+Z&\TN^BTJ]NH-!U&[TRSOI0ABL9;Z&![5+MQ)'M
MMFE$Q\V/"?.N;FJ_MT?"O1/%/B[2+KQ3Y4W@ 3'Q+=?V;=G3M ,4,<[+=7@B
M^S0N8Y4*(\@:0[E0,R,!X/I/[$'QDNI=+\(:GJ'PZ'PZT_XK7'C_ %.]^W7=
MYK/B>U?5)]3M[>2)K9(;5X93;*0LDPE6(8:(*5DU/B3_ ,$^?$_C[]COQ3X/
MDNM _P"$L\4?$63QYJ45OJUYIMGK"#6UO8;.2_MXA=0'[)%;P^?'&SQO"I4,
M% .=.I5<%.2M\GO^[UMO9<T[JW,^167O%RC!5'%:J_WJ\^NUWRPM?1<^M[,]
M^^!?[3O@_P#:-.M1^%[K6A>>'98H=2L-9\/ZAH5_9F6/S(F:VOH(9MCIDJ^S
M8VUL$E3CT"O)_P!D7X(2?!CP'??VEX9T[P]XDUB[,^I20>,]2\8SWVQ0D33:
MGJ4,5W,50;51U*QJ-JG%>L5U=O1?D<\;VU"BBB@H*"<"BLWQ?=:O9>%]0FT"
MQTW4M:C@=K&TU"^>QM;B;'RI).D4S1(3P76*0@<[3TI2=E<:U=CYZM/^"B,^
M@V?QHU#QA\/-6\+Z;\)9M-M((%U2WO\ 4]<N[V)'AL_*B_T>*X9IK551;F53
M]JB+.AW*N+/_ ,%'_$W@KQ1XB\$^,/ACI^G_ !0M9=#M] T/1O%7]I6.N3:O
M]K%NCWDEI;M!Y7V"[>X(AD6.*$NAF.$KE[?]C?XV^,O GCIO$FF_"VQ\4:M\
M3=+^)FF)9^*KZ^LM0:RGM"FFW3MI<+0(EO90HMPB3$O\YB&W:U[6_P!B+XHW
MOQLTKXX^7X!U#XHP>)EU2?PS/KEW#H=MIT>D7.F06D.HBR>9I8S<S7!E:R&Y
MIY(]JJ%>L(.?)&4VT_<NK;*T7*UK^\VYQZI*'-:TDI7*RYHQ5_BL^[3=D_[K
M236J?OVO>+M[C^RE^TAJGQ\MO'%AXC\-6/A3Q1\._$DGAO5[2PU=M5L))1:V
MUVDMO<O!;NZ-#=19WPQE6#C! #'R.U_X*D"TU;POXCUKP9::/\&?'5QJ\&@^
M+&U_S-0GCTZRNKU[R?3_ +.$BM)8;*Y:)UNI)&7RBT2>80G7?!']F;Q]\.]/
MUK3-2U7PI)9_$@ZYKWC*^M1<&^M]9O7@2UAL<A4-I;VJO$7D D<P0L$3>X'B
M/B#_ ()C?$GXY?LT^'OAWXUOO ?AVW^&/@&Z\(^%6T2^NM1@U>^FLX[,:C>)
M);6YMHQ!$Z?9HS/Q=RYE.Q=Q)U.1/:7)'S7-9J;T[2BN5+XE.Z5DVG#DYK/9
MREKLTK^Y]Z=W=:<MF[LZ;QS_ ,%2?%GP]\.WEQXD^&6D^#VUSP5-XU\*3WWB
M5KI8[1;RSM,ZQ&MM&+%H_P"T+::18I;A%19@95*9/6?LW_MA>-?CWX9AT729
M?!_B7Q4VJ7#2>)=/TNYM?#IT..X:.'5$A-S,[?:=DB6\8NCYXC:=7$0-:7AS
MX&_%S5/B/K?Q-U:'X=:'\0'\/6_@_P /:9:ZK>:MH^AV9N1/=W\DS6MK+<S.
MWEL+81Q*1:1IYZ^:TB>?_$3_ ()>WGB#]HGP]K%K#X9UG1+6XT?5KCQ-KM[+
M+XFTK4K/46O;VZM8UMBCS:BL=G:R2BX@\F"!8TC:*..&M(1?M(WV=T_)<\FI
M?*'*I6Y=VE>=N7*5Y4V]FK/_ ,EBI+O\;DXZO:^VDOH[PS_RE-^%W_9*O&__
M *=_"%?7E?(?AG_E*;\+O^R5>-__ $[^$*^O*\7&_P 9_+\COH_ @HHHKE-0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#XE_8@_Y)9XP_[*K\0_\ U--:KV*O'?V(/^26>,/^RJ_$/_U--:K,_P""
MF/C2^\$_L)_$IM)5I-;US2CX=TJ-"@DEO-1=;&!4WNBES)<+@,ZC.,D#)KWE
M4<,.I15W;1=W;1;/=Z;/T9PQBI5>63LF]7V\_D>ZT5^;_B#X.>)/V6=+\3?$
M?X4?"?2_V<67PQ9_#_1-*N(-)%QXEUS4=3LK>VU*]M=+EN+5UM2Y6-I)9)6-
MQ<91$P9/7/$OCGQLGQH\9?#[5?COKW@[0_A?X1M?&GB'Q:NEZ''?W,E]->JL
M*">RDM8=.MH[*1CNA:X8R1!K@A&,NE2M&$>=WLN:_P#V[S.V^_*E+6UE)+<S
MITY2Z=OQY5\_>ERZ7U3>Q]B45^>LO[:?BZ?X6>'_ (B^-M!TO5]:^%GP5D^)
M5_ID^BP1XUJ]+0:=,))$:2R=K>WO@ZQ2+L6XD#951B_;_&O]I;X-_#J^U[Q1
M=^(+>X\6G0O"NE0^-;+P]Y>F>(-2U**V>\M(M&D<#3(8YRRQ7EU)<.\<:;N6
M=].;W_9V=VVEI;7FE!+6VKE%I>L6[7T.5)7;Z)_+EC)O2^BC)-OR=KVU^^Z*
M^%_VA?@QXH^(_P =/@?\.9/V@O''B!H_%>I^))M0@T_PXE]9+I=@N!+ML# \
ML-[<6^Q1;J EPXD61ECD3U'_ (*'_">7XR>"M%M[6Y\!^+A\.KA?%7B#P+XP
MN5ATOQ9IX@GB'VPJD@A5'#SQ226\L/G6PR@VAX\95U&FZDMK_P#DMDW+Y>]=
M*^BO?5I5&FY245V_\FNTH]M7;6^[L]M?HB_\4Z7I6N:?I=UJ5A;:EJPD-C:2
MW")/>>6H:3RD)W/L4@MM!V@@G%7Z_.&;6[/QKK/@WQ/\--=UCX,_#7X6_!"Z
M\<%(;*"\U71HM8F^T0VT*WBW-M"D<>ES)M,<B)"3'"J*4>/M_%/[5WC36_#T
M:>*?BE)\';/X=_";1_'7B_6;'3-.>74=3U 3(D/^FPS1+;JUI*&CAB6622>)
M5E3&UZJ5E34W4TY6[^23J*__ )2D_.ZM>X1IN3BH_:2_'V=E\_:P_&^Q]ST5
M\1?!GXT?&7XO:MX$L=<\>3>';?1?A39>/?'+Z)HMD]]>WU_</);6L N()8XH
MUBL[J-EV%RK#!WE95L_\$^_BO^T%^TGXE\&_$;Q,OB?0_ ?BO2+C6=0TK54\
M.G0_)N52334T=K%YM19T0@RR7\JAP6*Q(65(M=>=P:::NGY6E*.O^)PER]TK
M]5?+F7*I=[6\[QC+\%*-^UUOJ?:E%%%,84444 %%%% !1577=(A\0:)>6%P]
MU';WT#P2/;74EK,JLI4E)8V62-@#PZ,K*<$$$ U^>WP8^(#?LZ?L2RW'P_T?
MQ?8Q_&WQ_P"(K\>(=$\*ZIXD_P"$6TTWD\*ZG)':P3S27#6MO 8S,#YEQ-YD
MA*B0G&I6Y&^;:UUKN[I).^R=[WV5G>VYI&%TK=[/R5F[Z;VM:V^JM?8_1.BO
MDK_@CYJ?@CPK^QGX/T;P_J5[:S>*[G6?$NG6>N1W5KJNH6T]^]P;A4O MQ=1
MK'=6P:Y 9'+JV\[A7A7PH^$GB+X"?M_>!]+\167PQTWQ9IECKWB3QG\2[+6Y
M;O5_$%G>,UGI\>JB>R@%NLMS+!]GM1=S1K]@9(P%B4U52HXR4;-W3:Z7:5VE
M>VR3U=M%MNE$5>+EV=ODW9/3OII;=V;[_I%JVK6N@Z5=7U]<V]E8V433W%Q/
M((XH(U!9G=FP%50"22< #-<SX9^/_@/QK\-%\::-XV\(ZMX.D8HNNV6L6]QI
MC,)/*(%PCF+/F?)C=][CKQ7Y^^#?V-O#/PLNOB)\']<E_9_AU?P[X M-;UGX
MIZ9\/HM*U#3O],#O#KJO=RFY6\2V>:0BYM]Z)-\@!1Q>^'_Q&\6_"OXQ6,_B
MCPJOB[3U\0:7XAN8=1NSH,EM>>(=6-A::G#IS0W&ZX4))Y-E+<H;.UA5I)9+
MF5E@FG4E.I&'26B?3FYG&VR[-*_+=I6O%N475CRQDU]EZ^CBFG_Y-&]F[)][
M)_;WAG_E*;\+O^R5>-__ $[^$*^O*^0_#/\ RE-^%W_9*O&__IW\(5]>5X^-
M_C/Y?D=M'X$%%%%<IJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ? _P ((/C!^S_:^,?#LW[./Q4\31S?$#Q?K=GJ
MNCZUX3%E?V>H^(]2U&UEC%SK,,ZYM[J(E9(D96W CC-;GBCQE\0?'%C!:ZU^
MR#\7M8MK6Z@OH8KW4? ]Q'#<02++#,JOKQ DCD571QRK*""" :^W**ZXXVK%
M)+I;\-C%T8O4^(_$OC/XA>,[>UAUC]D'XOZM%8W<5_;)>:EX'G6WN(F#Q3(&
MUX[9$8!E<892,@@US/Q(\%:C\9/%NDZ_XO\ V%?'7BK7?#Y4Z7J6L+X OKO3
M2KB1?)EEUQGCPX##:1AAGK7Z!44_KU3RWOMUVOZV#V$?T^78_.+X4^%_C!X=
M\8_$+Q%XR_9J^+7B[6/B$T-G<I _@NRL(-+MXY([>R\B3Q+.9,":=I'9\2-,
MV$1<(+/ASX+V_@[X>ZUX1TC_ ()_^)]+\*>)&1]6T6SL_A[!I^J,F-IG@76Q
M'*5P,%U.,"OT4HJ?K<[6TVMMNO/O\^NNX_8QO?SO\_+L?GW!X#OK71O"NFQ_
ML)>-X]/\"W'VOPU:JG@ 0^'IMV[S;-/[<VV[[N=T04YYS3OBQX*U#X\ZKI=]
MXY_85\=>-+[0RQTVXUU? &HRZ>6*LWDM-KC&/)12=I&2H/85^@5%5]>JWOI>
M]_GM?U\Q?5X6MTM;Y=O3R/A76+OQ?XB;7FU#]C#XH7S>*K1-/UHW%UX%E_MB
MV175(+G=KI\Z-5DD 1\J [#')SD>//!FI?%/Q98Z]XH_85\=>)-<TVU>PL]1
MU1? %Y=VENZNKPQRR:XSI&RR."BD AV!')K] :*F6,J/>WW#]C%;?UM_DON/
MA_0_$WCSPQK%UJ.F_L=_%K3]0OH(+6YNK:_\#0S7$, 801NZZ\"R1AW"*20H
M9L8R:YOX7>!+[X'^(M4UCP5^PGXX\'ZMK@QJ-]HB> -/N+_YB_[Z2'7%:3YB
M6^8GDYZU^@E%5]>J\W/I?77KKO\ ?U%]7A;EZ?Y;?<?&O_"Y/BQ_T:K\</\
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M]-!%%'IVHW<G^KTZY9F=44849);%?8M%%<U2HYRYI;FD8J*L@HHHJ"@HHHH
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M+<VVNZBVO?$:>XU5?):!'E:1F+2QQL5BE/[R'@QLA (H>$/V_P#_ ()3^"O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex101170630image7a02.jpg
<TEXT>
begin 644 ex101170630image7a02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
M   ! 0   %$1  0    !     %$2  0    !          #_VP!#  (! 0(!
M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,
M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" +
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MJXZX3WYKRS1]'T_X>ZU=7&MZH-*CUJWDM?,=V"XQO#$(#D JN,<Y Z=:]/\
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MO'5Q:K=Q:NT@M+/0)@-V]F=BTNUMOSLRC&>.<UJ? [X@SZ[=:AX-\6:EI?\
MPF7@_6+KPY=3BY"PZQ]F$92[A+'++-')'(.YWG .UL?./Q+^&OQX_P""W7B3
MX;IHOQ T?4-)L?#]HNHV3:BUK;Z*\3+%<336V?\ 2KAW9W/##:44D#:38_:9
M_8EU#]BKQ;X?^%/Q!O(_$'A?Q5I5E8V6K6=JFFG4+Z-I#"0VYC&(I&:W<M@>
M7>Q-SM*COJ44X69X].J[GNG[5'[7/A_X!? G4-8L;^WU+5IKG^S+"/3+]?-+
M'YI")0&"A-OS,H8 E1G)X^%OVH-.C\'?%+0OB/#I:V.D_$RQ36[JP,?EQV=X
MP_TJSV]@"0R@@$HR-@53EU[^SK6+QKXCT6*VU5K<V7@KPG:VJBUM8HW=5N)D
M<'=%'*" A&^:7).0&SOWG@:\\7^'O$/@OQ5JEWKGQ4UZY/BJ>SS&8M,EMX)&
M>V9EP/M,\14%$^6/RT7@Y%.C%4WIL$WSZL]\_P""?/\ P3J^'OQD^!&L:C9Z
M6EP+J^;2+Z9HO/EAF(+1% <;,JZE2.I&.*Y/X&:?J7P]T_QM\,=6@8ZQ\/=2
MDAM3,IRT+,2,\9VG&[.,88<]*]+_ ."(GC34/&G@?XE>!?#6K2:7XBUBQAGA
MB.I2V0CV959EDC4O\H?#IW51QGKR'[<6AQ_L"_$;0;.SUR'Q-XRUBTF?Q79R
MRFZ$D+OF(F9@9%<'>06);)STP*WS"*KTN2VO30G!U'3J\TMCK-#:QTSP]_Q,
M55KQ_+E94(!WQ[MOE],8#$_C7&_%G^UOB';6\K6-CHZQDQ3:KYJ/F-,85W9"
MHSA@"1@AARI&6\R\0?M_V-O9/#H7@Z6:^8&)9-1O#-$N0!_JU4%F!R/O8/'T
MKBOC;X5^+5_X!NO%7B[3=4T_0[&6W5K:Z7[']GBN,".06Z +M;@!G )XZ]:^
M6ED-2<+1]U>GS/8JX^$59,[+QAX[T7X?V,5U;VLWB*X;=Y3"06\-GE=N/[^2
M&Y4*JD9Z]N#U3]JC7O#OBS3=2L]/L;>UL7C::V";TN /O,QP#R#]*\]=7$$?
MF3S2A<!1N) ]_P @!]!70?"?X1:I\<?B5IOA/2L1WFJ/MDG<>9':Q $N[X[
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M$&.\\/RR_P#"+^)+6+6=)+ [O)D+*\?4_P"JG2>+D_\ +(UEW 5L;=L>W!!
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M "Q<6SQR*K*3C:!_GMBJ6JNQ>9I:EHDGA_5+S2+U%^T:3,]JZE.I0X!SUP0
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M2?'S3-)8&/,HW^9=&C[1W;/G_P *_"SQ!\6;R.+1[60QLH>28J4CC4'!)/\
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M\2M.\1R7?E-,WV;:$=A_K<^@_3FO5?AQ^SCXJ\:J+J]^P^"].:UFO(KK7C)
M]]##&TTIMH0N^;;&CME1M^1LL,&OGWX5?%2[^!OCZ;5O#_VBQU#2\I!=LBR3
M1Y.S(5AM5@2,'&1UZ\U]IW7@?5O$?Q*\/^.M>U6/3M,U+P"+;^WM78I:7<DN
MGR6X"MM)D?>5.$W,#AF!R09^'<RG=%;X<V/@KP?9_#?4_#WA^W\37WBKQ ^E
MRZGXLM(9A $>V4[; M) $<2MAI=Q&W/RU7TBP^)'CGX6?$R\U#6_LUH/%VGM
M;:[JNIBTL8([/[<K"S>0JIV,\2B.'+'(&,X!R[#XW^'?AUX?\/Z1X9TN/Q-K
M7A6]N=1L-<U6 VR65U)Y(\V&&.0B8 PJRF?.1@%/E '"^/?&?B#XFZ^VJ>)-
M<O=:U"1G=GE"Q1QEB=VR.,*B DGA5 ]JB6UXDQU6I[=X>\8^&_C6]GX;O_$%
MK=>(M'\J\CUO[*;6TUN>(D,G[PACD$%7*JSY.54UU/C[P9J_Q!D\+7$7G0Z]
MX8U6.RN9,C!LY" VX'KD8P>>GM7RLT>],?>"X KZ _9>_:B.DZR-,\17BPM)
M!+#!J%W\L$G[KY8[D[2^,H KCE2W(P21XF8X.4J?-!:H^@R?'*E4Y:C]U_AV
M?R.@^,NE+^S=\*-7U+3&L[[6+R5GCM$M?)AD?<S/*Y11F0\GYF.=W))Y/P#\
M3OB?XJ^)<\TVLZM<>7=%=]IO\F%<<#$: +_"IZ<MD_>))^H_VHOB/XPU*^?2
M?$5O/I&FVUL7BTV!3'YJLA"2[^C@]0P.TCIQG/@WQ/\ AC')X7M;G35FNK>.
M-(IICCR4)0-E'&0PX&>G. .I(Y,'-T8\M9:L,UK4\35YJ.R_'S\SR_PSKC:)
MK,-U;S+:W-NV8Y=@*HPSM;GOT//>G:)I6HZMXAEFNO.U"^F=I$>611]HQN+?
M-(<9.._J/6O2O!_A"/PEI),%O#)=3*(;EB"ES"A/+HQX7[H(P2>.@)->DZ1X
M6AU?4+R"V:^T6/2X@R7,_FPS3#@$J,,&!).0S$G(ZCBIQ&>1I-\JO;\CS8X6
M^[/.?@WXSLOA%\>=)UC6+:ZM] UBV;1/$%MYOEO-87*8<=2N0&)![,N*B^,_
MP<OOAE\4KSPU>7/[NWF#PE7_ '-PI4-',A&<K)$4<="5<<=JZGXU?"BQ\3^$
M'N[<6=K?RQ.,0E55S&<%=@8[=ZG?SM &?4X?K#+\:?V7O#GB5+B1O$W@F>/P
M]JS@8:2$1YL)F!&YOD5X6)X BB'\6*^FX;S*EB)0J5-KVDNQRXFFX72.3^$?
MC*Z_9_\ CMX<\0>7<2:/,[:=JT$<NU;JTF^292.5;*,Q *G! [X(^E/@GXW\
M/_LF^//BOX+U+PW9^)%\<:>L'AW420;JR9T9[66&41ELLCH2P(PRD9&*\'U_
M0[#Q1I:PW%L85D*R"(L-RN!D\CC'49[\5U/B/6[/Q/X%\.P^2;77_#V^P$HC
MXN[)CYD66S@-&Q=0,$D,,GY<5[6=QPD:_-A7=/\  QHN37O%72-%F^"OQ*T7
MQ3;R6-Y?6^6O+ RL_FQ!E(BE8 J5D4R(P!)QU%7?B\3\/6\11^$[A=:T6X9-
M2TU8W"^= ZAURJY9653MP?3WJC (XX\;EW8!)VC::;,B_9BR1\J/G"#[V3S_
M $X]Z\5&NCV(=(U-GCM;U&N(W51-"PRLB[ATZ@\CC'UJ0QAHA\K;8QP*S_#4
M170D\D>8L,CJ3G;MP3U[],>M6-:UJWT;2);BZF(*0O*2.R@9)^@XJ):;C+ P
M8UX565B1ALX]LTV1?+?+_=89#' 8XZXKA/%7BRZA@CDM&DFCO&CE2%)/FCP,
MDD^A Z#&.>:@M?B1::4L@DN@TV!-'SYB8P6QS@J-S'\L9Q5J[5T&J9W$)^TL
M5D+NW3"\*O?D]^U2/:++;CRWV[?48"CFLOP]XC35?L[;QNOUWB,.IV#:" >>
M_)&.E:B1N'V.%Z $ ].I.?Y4[>Z/KH211I=/&K9'3D=R#3'C4P3XW))D@ @X
MW ]<_6I9O.AVB-E 5L@$8[=:A2\DWX217DY)<#Y14Z7$>Z?#3]B70_$/PITG
MQ-J7BV2:?Q99A=,$,(CMX;YS(D<!/[QYB)XS'(-L?EC+9(VAO!+?4_L=D\VI
M0QV7V R)=),_$+(2K XZ\@$$5U?A?XM>,?!'A5M#T7Q%>:3I<DSS#["_E3(7
MQO E7#A6QR V,9'\1SPR_!&_^//B+1?".CWQL_[0NC/=WESEE0J,[@JGYN-W
MWN#GL<4I\LFF@C='G7C/X\3ZQ)<6NDRR:?9(&/FQL$EN>PY(RH[\<UE>!_AM
MJGCNZMY;?S%M9Y%BEN&!F4,^0 =IX;@]2.HXKUOPM\./"?P0^,=EI_BW28M9
MTG0/$*6NOB[CVR/"Q,9D!3!"JP5P!PV.<@D']5OVB_ WP'^ OP(N]-UKQ9X9
MTVUUC33)8Z9IA@6Z,<T1\N8C</)4C#!W .>G-*HHPNK:OJ%W)Z'YKV?[-OB[
M3=(A\&VTU]JVE:W82#[4D#_N60AX8Y%"NT:0W"J7.#^[GDQTRK?AAXC\"?L.
M>']4T/Q_XN_MC6-:NXIKO2/"Q:[_ +)FA61</<JR(&*R[71&<%D4$@QC/T%^
MSQX^\)?&/P_KWP]M_&EQK4\@F^R7NI6J6S7T;AD#0A0JL5 CR0,G SR<GX[_
M &D?A*T5NNLO:I#>:?J$N@Z\H4?O;^(;A<X)R?/C)8D(!NC8DEGYYJ52+E["
M>B?E_6_^1Z$%-+VL'K'\NOW;_>SZ_P#'CZEIO@5H]S1ZIJ^]I_-FSY )!"A0
M2.R\_@#6;8>")]1T!=+BOC'K=BHE749G66!H1E2@[@D'/()X_&H=<\2:EK\/
M]IP^'-!FEBD$YCO9L>?'NVK$1T;<PR,?W!SBDTZ:SLM#M4M['[-K$,3M=#?Y
MEN\AR<(Q/8<#@=:X]$RHR90UF[TKPUJ]W''&R:&D:VF%SYDF069PQ.=QQCT&
MX<=AFZ?;PW[VN@V"S^3<.)KYPV)$C[ ], DXSUP:9K%Q-<ZR[7C1Q^2 WE(X
M>,/D=#CJ !^5-\%:C)9ZC>!9E9]:.YI%7,ZH,@\D_=X;C -)WW16ZL:FO^-?
M*L;K4K5C)#Y31+&V&;Y>, 'MSZYJ[\,K^\\3ZK]HB8*NER*0NU@+D#!)_N_+
MECQW&*J6LMS/'LL;1+Z.("WM_-&PN@)W,Q/&X#'3N?PKT_P=X>L="\.VNR/<
ML VI\NUCD[L9Z@_,:GK8/-FK;R6MWK1LUA;[/<?/< H%WHOS*Q;W/;OBO2-+
M?[):LJ,9&N%RR#D(O8<\G-<]H^EFXND>>/<)D.?X0.F!CZ9'_P"NNI@LX85;
MS"VYF*H-F B@\?\ ZZPF]3.30V.T67;-&5+8VDYS@$5POQ]^(%O\/?AWJM^R
M_;VMT4-;PR#<_F.L8#=@I9AD\D#. 2,5Z!&T=I V_?'&2"?-.U3GTKYG_;]D
MTVXT;18&D6.]NM46ZMU6,DS)##(C@'&W@S1C!()W'&<'&4;V;!1U/G6[O?\
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MQ\6:AH.CZSI-LT!LM:A2&Z21-R_)(KI(OHP((!]'8=ZS8;3SH,,S1[>G'?\
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M/D6%O>S7C-.MR1&DJ[HVRNTJ !Z<\]#S7E5\8=/'F.NYU=\L^"KL#T7')/\
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MC5([SQ9JD.\>;?'%N"X4$B+)'8XR3PW.2 1[1?F6_:./[JQ@1*@X5%'W0!T
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M&^(&G7+VC75I:M--9-NDV*,A .>OWAS^E5H!YC>SK87-P8WA\QR#+)%NP2@
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M.[L?@WXTT=+19+S6;:UM%F8X:VMENEGD"=\LZ1CKC:7X.ZN\^,/A:\TJ_B\
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M#QP@ SCCFOD,PXDPU*3]G[S\MOO_ .'/I\OX7Q5=*4URKSW^[_.Q\4_L^_\
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M-N<%XV4U\4_M*?MQ>/OVD=*FTOQ!JL>E^&8I 8_#6C1M;:>2ARKS*6+W$BD
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M^E<@;>T\O[/"759H_+DD*DDA<@#VS_,5] ?LO>"M0U_PYIM@I.V:XDAM2_\
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M/RX;A&,+R/PK \J?;D=?6NF34-\RIM.S=N! XS53Q;HG_"1Z1&L,;/<6<RW
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MDMY[V]53]YYXY)(XT.!P S$'JIXKVZ.'J54M#].QF<83"PYZLM>W4^?/@3X
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M[KBM"\TQGB:\+0PO"ZK&,C#;B>N3^-:7[)/P!\4?'7XDZ;9^%_"&M>,M/-]
M-2EMLV]C%"LO[PF9L<@ 8.>/FX.:_1*7_@BGX$\*^.9+OQIXLU34M*AN4GLM
M LYTF6W5@?-BEE4*),-R"FP$8^AJ55;RW,N9Q5D?G?\ #3P1K'Q3UT:3X:T7
M4/%&I':A@TY?EB)[L^UE5>O)P"1@$U]I_L]_\$<KR[MH=6^,'BA?#MG*%:3P
MWH$HDN0N<B.2?YE_B8$KOXZ.>"OV+X9L_#/PJ\+IHO@GPSI7A/1X.%$";KB7
MTW,, G&,G&3Z] *OB_Q;HO@G1)=8\4:]I_A_3P"5GOYPDER5&2L:GYI&QSA
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MW^?Y'V&7<(U)+GQ4N7R6K_R_,^8?A7_P3.T/P[%#>>,M1FO+A55C8Z:YAC#
M]))?O.-O4#:,GOC)^@?"]KI/PHTC^Q_#NDV6AZ4HXBLX1'NZ\DCELYZL23GF
MM6Y8MC)^63) /6L/5XVN&RQ!P0"1V^GYU\KB,PQ&*=ZLK^73[CZK#Y;0PD?W
M,4GWZ_>6)O$#++YD;;-K;F_VNW^?85J6.O9&T,JECG.?7_"N/CN%BFX/F9/!
M_NGT_P#K>U;G@30M2\2-(L<*I@J..<_YY^E<LX67,=$:CN=O9W_FH';[WW2.
MH)]OPYJ]86SZC?+#'&S[B#@#TY_^O],UY1\;_P!KCX:_LO64MOXDUQM8UR)=
MZZ'H\7VJ\;'0/@A(AD<EV!QR >E?%/[5'_!4KQO^T/I\F@^%]/?X?^$Y<I*D
M#YO[V/;@B6< 84C/R)@<\D]:ZL'DN)Q+O"-H]WM_P3AQV<8;#*TI7EV7]:'V
MQ^T+^VO\,?V:XIX-<UA-8UJW3<NBZ+LNKC><$)*P.R(X(/)R 3QD8KYA^)O[
M<GQ*_:$,]GX7AF^'.@R((9H-*?=?3KCDO=85DSZ(%^N*^,;*QAAM\[/FD.<N
M<LS'/->TV_C2^\4>%;)EO-L)@16@@78H( SN"]^._P#6ON,!P[A<.N:2YY=W
MM]VQ\/CN(,57O&#Y8]EO]^Y9C\(Z'X83[1A=6U#>2\D4HEW,.#YDQ)9OHN>G
M45#J&OS:BBKE884)\N"(;(QC^?U.36;-=1:=&DC.ODL0O/'/^<U3?5UAN]D3
M-)&V6)SG STQUKW](Z(\-1;U9I73>>%96^8#YEZC-<EX^M38:BLRM&D=TK.R
M?Q*XZMT[Y'J2<^U=&LR3L=OWFPP ]*AUO2SXDTJXL_+W3[?,@&X#,BC*C).,
MD%EYZ;LU7Q$R5E<\]#1QSRF62-44@%]F77YOZ5O'2[62T/R,TF[8[R9!.?7M
MCT]*P+XK;3_-'MF(Q\I)+'J01CZ_E6GX?ULWEDZM-MGCBR#)\L:G(ZD_EG/&
M:<=&3N8;Q-<HT+-Y<D!X?OZ'/K1ITGF76)(T5E(9@@SO5>C>W !^@JSIT4OB
MC7+>QTJ*;5-2OIA!':6$)FFF<] H'+'KT!''!.>/O#]G_P#X(9>+/&T5KK?Q
M9U%/A5X4N8UD.EQW*R:I=!A(4WI\PC.=O^L!8C(^4XK/1*YGS6=CX7M'F\9Z
MQ%:6,<FJ:I=R[8-.M$:62X(/ #*"<D=E#].@[_9_[-G_  0B^+'QQTVSUGQU
M=:7\&?":_.?[69I-5F3/(%L,88XX$A7J"%/2OT(_9^^"/PK_ &1](M;#X8^
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MCSWCUZ'+7?(U)#?%+-=ZO!%YGEVH/RJ.LC#M_P#KJ]:01V,2_)YC-@$<9/\
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M\Y*\9''RCWK7^)%Q95.*6AU7P/\ "U]X[\6V>DZ6NI232S)N-O;LZR+@Y5L
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M*R[B0 ZY_&M30O#NC^,8]4AU_P 16?A[3;73Y9KJ>6WDEEE3 &R)5ZN20>2
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M:U+FY8PEE.Y3C. ?E ZG\L\U1T>U;5+GR84GDN,%?*A0EO?IGTSTZ5W7PO\
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MNSCMD&IC"I/X2>8^G/&?C.[\:VUKM TS1]-@\C^S[4"&QMXQC;A> ,!>@X
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MFR\*?#K7I/'36.BQS76O0WGV,Z;;6TDUR\VXJ8_*56+G(((7)/.!7V-\/?\
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ME23]Q=2XQ2=V?JMHFOVOB'PI L:_9HVB1XU5< +@$# _S]*_/_\ ;Z^&UQX
M^)L&M:/9,L.LJ\]TD-OUN$8!\G'W6RK >YKNO@Y_P4B\.W/PBAM=2/\ 8.M:
M':0PS23+YB7>T;6>-5P=WR@D' Y)'2O _C;^VT_C[6U:QTV:[M;>42"74)3O
M!Q@[57 4$9'(./2N>5&I)66YKHE<F\'>+;+6])74-3OK'3X&5AMO+<R-!M^\
MR)M+-R.,#.<=\5Q_Q<^+>GZ?J^GS>&Y;S5+6SB(CN-9M(U>61@=^R-6;" YQ
MN<GD$A2<#S#Q+XIN/%_B>:\9)(Y%&V)=_P J+[#H/H*RI)3+M:;YF4G!;^$U
MZ$</&R4CGN:6J^*+[7KYKZ\FDN+I\/N<84'@<#H. /RJ/65C/DR6ZX6X7/JH
M?NHJLJK>21*K^4A/+L"=ON0 3@>P)] :OS6C:1)MS'-"Q\R&7:?F RNX9''(
M/4"NBGII$7J5X-&$DS><HC$:AB2?GS["MC3->O/#^LKJ5A>21WEN,><IPS#&
M,''4$#FO3/@_^R)XN^*MU:WEWINHZ3I5Y&7^WW42[\&WBGB;RG=&,4B3PE)/
MN.I8H9"A6OH3X9_L1>"_ ^C1R:]"WBC5I)(YO-9Y(;:(H7.U$4KN1@R;A(&)
M,8Q@%E//6S*AAG=OWET6_P#P#UL!D>+QJO"-H]WHO^#\CYALM(\9?M':C"%M
M)FMXI I>*)Q;(V4!+$9+%0ZL0N6 .<$5]!?!W]B*S\*C3]5O)YI-7M91.LEX
M$9(G(4 I;*2 T9W,'>612<'RU(S7NEAI]AX="V]A96MG;1#"PVT*QQJ@'
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MPBYGW>WW;O\  ^@/VEO^"D_BG]HFPO-&\-V__"$>#;B-H9HQ-YE[J4?&1(^
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M]A'QK9:WH[>+['4M)TW4F>&6WTIX+F]LW&W:MP7=(X0REFSO9L#[N2!7WO\
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M&.H 13SST+EB/6O.[4LT:QQVBLTQ"*@&YI">P'.:]6^''['/BCQ6\=YKLO\
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M R*] CM8Q/FWB:9L?,YZ#VS_ (5Y7K\<NFWEGJUN+4W&G%\F?[IC8#=EL@*
MRQN20?EC(Q\V1ZMINI?VAI-O<JT5O%.N\(KYVG."IXZ@C'U%8[.QG65O>///
MVOOV;[#]JSX 7WAF\E9M>TQ_[5T9HTW&.ZB#%5XZAU+H0?[P/&!C\^?V!?BX
M?@=\8H]!U.-[/1OB%=)I=S;RL8S8:D"RPLP(&W)W1,#@Y=,_=K]3[&XN-.F$
MEI"D?S%F>0]CU./\:_)O_@JW\";KX7?'G7YL2+H/BX'4M.ECA:-1,NUW12"0
M?FVG(Q_K",<5U8:5[TV13GW/LRU^**3^-M8\+S0_9=<T.[2!XI25$D,BEH9E
M)'S!L,IQG#QNN3MR?GK_ (*'_#'Q!\!/B/X,_:$^'Y>+Q!I.I06>K+%#MCN9
M-P:)CR<JX)B;(Y&VO.]-_:VO?C_X*7XHW&L#2?&7AR]M_#NH6JVOG0WMG<D&
M.=1U#JZET))4!9$P#R?N70?!^G_M'_L]V]SYGG0:["+CR)256.]AD.#MZ*JS
M1G;CL ><G/54]U6D;SE9GEG[:?\ P5!^&/Q9_9P31M8T76M5_P"%D::TW]AQ
M0^5-8./D\PO( %V2!2C<[@ 0"#S\<_\ !.CX_P!]^SY\3=<T:QUB\AD-BMUI
M&G3#;:W]\&"^4QY*AD=B  ,X#$@+AOH7_@K7^Q7I_AKQ_H/Q0\-:4UK'XDF%
MOXA6*Y+1QW,BQE-B\K'ETE! P.4 %?'/[07[/FL_#BST/Q+?V=QI=MK :&W:
M,X99$^8'.=P;;SD^E'+S4KW"'*U<_<3POXPM?B+X0T7Q!:1R*NK6J7$<3X C
MW#!!/3@@BMRVBFEU"W=G7S;9@P"Y 3\?P_&OS!_88_X*\^&_V8_V4-0\,_%)
M?%'BSQ%I5_-/X>73H8]US!(BD02R,PV*LH<E^3M? &0,\?X"_P""LWQD_;9_
M;+\/^%=FC^%_!.O--''X>T]0@F\J%W5I9CN>20$!CDA<*<*._'&F[AR,]H\7
MZ;??LM_\%4/%'_"L8+/Q!)XYTN'7&TV*;R5TB9;A/,DSR79"LK"- 2?-_A
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M1220V2+96^\[<#,T@[=L"L>5VLBHQ>YZMK'Q)TOPI9RB:X:+=\D2@@22#Z<
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MK!>1V7F3K'*&W&- 0NXD;F#$@$ANAQG]$M'L;7PYH\.EZ+86>BZ9;C;#9Z?
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M:LR[69 9,@@ANA_+%9RHV:?<E23V"\D5I-NW:K,<@'C'KGTH@@99]NU=\@W
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M (DCT[P?H-X@EM?$.LW16WDB(W;8K>/=/.Q4J?W2/CH>H%6-(\=>#_AND/\
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M7?O?\ PC*/0^E_BW\<O!'P/L)&\7:Y%:WC1[Q8Q2B2\<^BH#G/UQ7R%\</\
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MID7$X/."H(VQ]3]Q5Z#K7H6HW=Q?LS,TDA8YW/V[XJHREXUSM5E)'J6XQ_\
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MQ,!SP%C7) R>_P!%ZY\)_!?P+.D^ _ ]QI6E_;LM"7@BMIKQQYAD^S6YYVX
M;S0=X\LDL1D#FK8R_P ""--[L^)/@7_P35TWQ#X.FU;X@:UK$UY9S7$3Z#I<
M+Q) (KGR-\LWWG1GVE6&Q2&&"Q(%?8/PX^&VG^'-,?2]/MK?PSH^D.\<.G:
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M$%]Y;:M:@:;JJXRINHE +C_?7:^.V_':OG_]L+PAJNJ_%J%=)C-Q<7FES:G
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M[YU5<'*L.2>>P^E<Q^RK9P^*2OA.^UJRTK[/.1;W-TS+&5<,8U+8P,M\NYB
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M001D9.'"YMF7;M^;[Q'W?QKMO$Q7P_X3U"WF6&#4-1FBC>S=29;:*,;P2P;
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M@D;L'GVWX W'PUU36]>AL[/6/%5]X9NRAN[RW\NUN%.?*N!:G+I#(W.&!D'
M;'%?3_@W6[7Q9X8MYM/FMX7\A1<0P2;E63 !P,Y[8YY&,=JWE*G#2"U[LY)5
M9]3R;X0?L3>&?A%%')="#4;F#YF3R=RE\DG?G<&/^\3^'0>T:=IMOH\:PZ?:
MV]G"X^<Q1A6<_P"T<<_CZ57_ 'B7>/G4C*.I'3T__75I-/NKB?8N?W8WJ!_$
M164I-N\F8:(G\3_M+7G[(G@O5/&VGZ3:ZU>:5$(_L<]QY*7 D8("6P?NLRG
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M,YF...2!A>G;-?C=_P %LKNT\)?&UI-!\6:-JUSXHTTIK]A87JW,J30D /,
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M^8^OO@W\8K'XX? ;PSXV66.-M6LU-XD)RL5RIV3)P.,2=@.A!Z5UB#R8UVC
M(')&<U\A_P#!-_Q]'X5^)GB7X9F&.2R\49\0:.$0;(I@JK*H S@&.(?7R?<5
M]>7D9A9DE<2,C$?*#M/^?>N2M%QE8ZJ<KJXR'7)=%U>UO+=S]ILYED0G.UL=
M5SP>1D<5^9W_  5N_9M'P,_:)N/$6CPNOAKXE(=<LB 6CAN&=Q<PD\ -O5GQ
MDG#= "*_3"ZCS;[&VJO49[5Y[^V)^SR/VM?V1_$7AV&%I/%'@>,^(_#4L3[7
MD=#B>#'?<C,0/7Z44I-,4NZ/QY\ ^*=/\)>-+"\UJVNKK0VD$%_'"XBN(D)
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M7C>T@9B6"LK;<YX>-AG)X^3O%'[/^K_#:[TVU$<ETN_'EVZEHW<D ;!P206
MS@9/:OJG]@GQ=<?&'X">)O!$C-8W6ASI>Z5=%_WRR/(\Z-SU"3(">V'P>M7*
M*1S\]V8O[$^HM\*-5\;?">ZDMWO-$U&;4(9<X^UQ96"1P H 4%8G!)RWVH#
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M^<?[ ?[5-K^SA\7Y+/6YI+3P7X@#)?Q(I989E*[)FQSP%P<#ICMBOH'XO?\
M!57P;\.-9N[CP"UQXLNKM&CF6XBDMK4L-JI*"Z;B0.P49&.:7L&IV6Q*E9:G
ML?[<&FWVJ_L>>.;:U1FS9+*R*F[>$E1^!C/;M7Y<W%CJFF:3+NCC4VL9\[#A
MQ"JKEBQ!P !D'G@C!P< _8-G^U@WB+X/:IXB^-WB2ZM]&\6L!X>\.6,*QS0V
MP8,MUMC4-)T!5I"44 ,!O:-EZ_\ 9,_X)&^ ?CUXFLOC19?$35]4\'Z@[BQT
M.QVEC$HV2VT\S<QJS*5:,(&VD_,"0U5&7)'0F4K:O8^:OV _@%I?[8YOKBRD
MU7Q%>:3<I;OH\47E[5;.V9GZK&<$ACM(*\GM7Z>?!_\ X)_:#\/]"AC\1O'"
MHP4T;2 8XUS@GS9C\S$]"%P?]HUZU\)?A5X7^"/@JWT#P5X?TOPOHL)+_9-/
MA$*EB!EFQRS' RS98XY-="M@V[/+-G=S67.WN<M2I=Z;$?A\P^$_"W]CZ%I]
MCI.F*Q(AMHMF_( RQ[GCJ>3[T6QF@FC99&7O\O;GI5AY(;9SN.3C[J\FLOQE
M\1]+^'-O8?VA:W\UWJKLEE9V\15IB.N9&Q&OT+9.>,T- KWT/+_B79:Y\*_V
MKO"OB+P3X6DO8_%DCGQ#=LLUS$OS6\6!&F%C/EJ6+DG..0 "3QO[0_['5KJ'
M@WQIK$D>CZOK UB#4="U:=9!>:=,;_S2BY+;HD5Y,HI&_9T( %:W[8W[1/CS
MX>?LX:QX\\/ZAI?A6Y\*HA%B8A=1ZC))(D2Q2[D8KN=E4%2 I8%G"AL\+X _
M::\1?M._"#2?$%Y"^EVGB 23Q684+Y$1D9%0$#D$(&R<L0P!) %/WDKFT5)N
MQS*>'[>XU&6;3I_MEFTK>5<-QY@!(!QSCUQV/%<K\:?@]I]UJ=GXUNM,T_7'
M\,V,L-Y8WP=H)H&*-YP'F(H:$JS$,0K)(^XG:HKTW0/#=Q8^-)+'[+(;&\1K
MN$+U$NX>8N.R_,"  .IJ[XO\7^"O#^HKX7\6>)/#>GS:X!8OI=S=I]HNDF^0
MJ8\D[6#8R1CGFG3FT[FDJ=_0^'O'7A?5OA!X1\-^.-(M]:M;SPW?->V[72;6
M(BD64H&WX9?**@G)+")L#YL5]X_!SXT6?[0/POTWQAI,:V]MK"DW,)/F-9W0
M)\V#/&X*WW6XWJ58 9Q7#_#GQ?XJ_:Z^#&I>#_$WA:S\.W&NV5MJOAUFOXFF
MEU&-':+,?G+M256DA!<?(+AV(.U37SS^PM\=M.^!W[15]\-6N+FQ\-^+/*DM
M%N87\NTOW0>5Y87>65W!M=Y_Z8[RJQG'557M$TMT8TI.-K[,^Y/[-CN'\R3:
MF<#!XS5OPYK-QX,\26=_:Q[4MG_>!OF#QD$.#^!_,4>2+>3YF:8]]WK45X H
M#;U;<H^4=:XK'6?EA_P5@_9LA_9Z_:HU>728IO\ A%_' ;Q-H=R8UCC"2L7N
M+957) BD+ 9/*\D#-?-'@SQ9)X"\20ZM#&\DEU&\$J)(1O+#$;#W5@/RK]=O
M^"B7P$;]I']C[5&LXDO/$WPWE.LZ6FP&26T/%S#G!)4*=VW_ &3UZ5^/\UJD
M,TUNO[Q5;<F1C/?\.F<5TTY7B7$S?#_A)M7UC=?2,K2R$L6.2SD]2<]VKK;'
MX=Z]XPU VMCH\EQ/;XMYDBBV0P-SMWO@(N[!Y) X)S@''9_L^_!Q?BE/<ZQJ
M6I^'O#?AW2Y_*O%U*^:WDG?R2P\D)'([DL/NJIY&"1G=7K7A[Q9X-^$EO-#X
M4L;_ ,7:G,ZS2ZKXHB"V,<L2LD;P6,;[)"F^4J;EG #D^6&Y!4FD[";TT.(^
M&/[(OBO6M.T_5[/38=2TO3YRAU*62.QTJUEPSLC7=PR0C R268#@\UKZUI"Z
M/XDN[+^T--U1+4*C7%C*9K>0[?F"/@;]IXR.#V)J+XM>./$OQ<OSKFN:UJ6M
MZC:M')^^F"Q/$N2T21)MBC&&. J@ XXXJ/4A;^'[!+EY(H89&1.6"A2Q[9K/
M63N(J16D9F6%O.50?E;H6SGT[58L;CR9F5HMS-P$!.W&/_K5->QR(ZN=S*JD
M*I&.*A>&8O;RB1L=<8[#CKC]*.HR:"/;;"5F^:0?=Q^&34,$DGF,J+O.<C(Z
M]^*L)Y< 9I&!DP=NX$@#\NM1N/(&YURC'YO5?<>^:L95U&+[3;.K*)^JD,>#
MW^G%>@0?''3[(V]U;:5<>)O$EO;HLVM^)'65+9A\P2VM$XPI+#+ELGG"YQ7#
MWICAC 56\H$@E>#G)Y/USFJ,VI?V?&]Q<,R11J<GV^E.+=M">5/5ESQ'XHU;
MQ_J_]H:YJ<^K7BD^7)<,2(1TVHOW44#^$ #GZUF:A=Z?#+%'<:E:6\TD@1(W
MEVEOIZ=Z\H\=?&C4O%$DEKH[26.G[MAF8 ._N3SM'7H>]<_H>B-!=1W$EX;J
M\C)$),I5$;W/7C.>*.1O4%%(^LOA1X-M?&?CFRM5>UO(M+#7^H%)QY26\0\P
MF3!XSMQC*\$G(ZUTWB?XIZI\-%\2-HVBV<,GB1DBEOOL(2:)I$RC0[0ICVD<
M$$DDGD@UXC\#?B*%L(]/N[B33[[3I'?[9!*T4<8+%ED?:02$^]N/(VG\?IKX
M">)]3NO&]G;Z](UU#(J36%Q;%8YK>X5 T$X8\2X )"$Y(;@@#%?*U*U2.(Y:
MAU4^5QL>'_%/PYK6A>'I-8\;7MU<:O>)]I(DD,EY?1\J#<22%BHSRN!GBOJ;
M]A7_ ()P?"KQ1^VEXB^&?BSQ#X@U+5]/T>VU.WCL%%E8W@NHHYX;B"=?WDZ;
M9-K;UC)<;=I&2?3_ -M']C[3/B?\#['QI>>)OA[HJW DN7O-7N$L1J"R ?NL
MJS,\@*287#%BW!XKYLUK_@I/IG[+GPAT3P_X/U#0_$GCC2=-72(O$5G91)<O
M8K,SPVIF969A&K8SB-\]V &?6PDIQFUTZ'/4U5CW;_@L5^R%X=N4^$NL^&XM
M!\.^+?!8N?#VMZ*)!;-=V2Y-M,B'DXE1MI ^;[0/0"OC;Q1X'U;P;#;6^JKI
M=OJ# F:QMKN.ZFL\=/-:,L@+ YVABP_B"UYUXC\5?&+]KVZ:<R:@=/T>VEN1
M/+<"UMK& 9=]SX1!P,D@ ''MQTEG^RQXT_9C^$^@^)]6.BZOX*\<%IM,U#1;
M]+Z 3Q_*Z.R_=<KV_P!@YY%>H^9ZLQCIL:7@;XFZ]\+KJY_L&XMH])U(;;[1
M;J'[5IUZA&&#1,2!WP1@C/!%;C>!O"OQ;GFN?"=U_P (KX@D;_D7-5G6.RN"
M2@9+2Z8]<LS!)MN%7 =B0#G>.?A'JW@'2O[8AFM?%GA:21?)US2V+6N&QA94
MP'A<'^"0*<^O!/-32I=P,LD8N(Y"-R<[5 '8#OUKE6C.F5UN:'B?PMJW@3Q#
M-HNO:?>Z7JEJ=MQ:7<;12)D!@>>H((((X((/(-0I!''YCMN;< ,@YR*M:EXE
MUGQ#H-G9:IJEQJ-GI((LQ<$.T"'JH<_/M_V<X[UGM*8X 550JMQSR<T;DW[C
MH&CEW#^+GZ'UIK?Z.F/F99/DP.I)Z?C3I;S$9;RQM;@<X^M.,/GJK+E64_=7
MJ/3\:KX=Q.5R-;=MC+M9F7!VGYNG:GLN[]X1N=AG;Z=L&ITC^8L&9?+'/^T*
MB<22?,FQ6S]TCBE+N@MU$59<(6*1MC &1@5#J&G/,V6#2$#,9Q]QCCH>WX5T
MG@W5?#FCW<B^+-#O-6TZ[\N/[587C6]]IC*2?,A!S&^<C*..>Q7K63X[M]-\
M-ZI<?V#K2^+-*AMS<K=0VQMIHSWCFA8Y1P0<E2Z\ [N>$U97!#O%?Q#7XA>&
M&\%>*KO3[RXFB!L=;NE":GIQ4A@@F)'F1G:1MD+8!^7%<CX;^&&DZ<SBS6.\
MCMKHBXU"Z(FA88^Z!PCG.!P#DGVQ63J'@2\\2:#<7UU<7D+73/<P1/$^3*,K
MY:CJ1T ;T4'(SBM#X-^"]:\0W,VGK=:I:V,NV/:;,2IYW1 2W&.3T_&O%Q&*
M4DY0GHNGZG11I3J24(*\GHK=6]E\SWS]F7X<0V5T^KK9P6MO9Q&TM50L9)')
M^=GW'J!A1UZM1^UUJTMYX>CT^.6Y^QV96\U".U!,T@# 1J/8'+'/HI[5Z5;B
MU^&G@'=/L\G2[4RSM#$%\U@,NP5?XF;)P.I:OG:'QWJWC:WN]8O!'I?]HAGA
MBC7SA=@#< "PXPN!CVKXG+8SQV.ECK>[';]/\_)G]+<:U(<)<(8?AJ@[5ZZO
M4:[:.>W=V@N\4SZ#^"/Q+_X3GP5I>N6;7-O=1$!BXV2Q31G[WL<@,,>HKW;2
MO%"^%/VC8]09HX/#?QOT]=4@7<%6VUNU_<WD2C/'F95P,#A4ZYR?D/\ 9M\8
MR27YM5FLYM+OT=XG5\2><IZ8 VD%<\@YR%XYKZ6TOPY-\8_@EKOA>S9$\4>%
M+A?&WA&5D+LM]:@&>% .2985!QT/D8[UTY34_L[-7AY?!4V^>WZHQXNI_P"M
MW ='.8^]B,)I/NTK*?WKEJ>23/?!)]D^9E[A0S'WZU#)8*\LBOU8AEYZ>HK#
M^$GQ$L_C+\*]!\4PKMCURSCE>%>?*EQMDC/?<KAE(/0@BN@_U(+1J%9>Y'^>
M:_1]C^5Y1L<-^T3\-W^(OPGU#3[.T^V7$K1RQ1;]K%D.<J21@@9_#ISBOBKX
MMZ5J7PW_ &8?&VGW6AZA#'H_C%;;4P9 \EFCVEIY9=2VX 2&X3)&W[PSD$5^
MB$%Q&\P DV[OF0^AZ4>$?!7A_P !:G>1W6AV=QX3\7++IWB33HAY,=\MRQW3
M,5_B\QM^[J6YSUK2-9J-O.Y5.R=V>0_\$SOC;_PLS]ERRT6.:&;4O O^@76&
M)8V[$M"_)[C<O']VMKXX:7_PA_Q0TCQ\M[?100+;Z-J5I&K20"!I)&6<*H.T
MB20!B/O?NQU S\?_  )36/\ @F5^W_)X$\37:G1+Q_[+OYDDW0WEK*-UM<JP
M^5@&*GCI\Z]0:_0?Q[X,M_&WAC5-"U&2XMK74[>2QEN+;:9K8.,>;'N!7>AP
MZ[@5W*,@C()?EJ<_1A4CT/$?^"A?P]D^)_P"C\0PPP-/X%D-TP<C<]I-MCG^
M0 [N1$W/0(?7G\\/V8_C*_[*?[3?A_Q"WVA;'1=31KL"-6-SILWR3  D@EH'
M;'!PV#P5X_2OX'>)G\:_#[7/!NJ26\FM>$WN/#VK+#EK<[&>'Y"Z*7CRDD89
MERXBW$?,*_*S]H+P?J'@[7-0TG4(FAUCPO<2Z;>(#RH5L _0?^S=JZ*<M7%D
M4X\NB/V[E\9H;N'[/;S7,,LBCS 0 $;&']QR/0^U/\=Z9-XBT9%LMEOJ&FR+
M?6-TRK(;>=,E6"LI5NN,'MG&#@CY3_9>_P""@_A+0/V)O"/BCXDZJ\.MVZS:
M/Y-M&LMWJHMG*1RK&,=(_+5B>,C.1FO*?C__ ,%F_$?CFVFL?AKH/_",VX38
MNJ:F([B]E&<#;%AHT.#GDO\ 7L>&-"5[,ZI?#H?K!X;UU?%OARSU2.UDT\7T
M6Z2-AN>!P=K(2<!MI!&1P<9'!%<?^U=^S[9_M=?LM>+OARX66\UBW673)V +
M6][$PD@<'C + *<?PNPY!(/C?[!/[;'AOQS>M\'[K7(_%&K:9I<&HZ?K>#&=
M78D"X#*20&#.&P#D;B,87-?4"W\FDSJZR>28B/E RRU.L7H<6S/S3_X)9W.K
MZ[\(K[PKKUQ/INL?#CQ'/876FS1E;JS 0[X9 >B^8T@'?Y#Z"OT"\(:U'KFD
M1P[X86M80N(Y=\BQC(7=GD=".>PR*^-OVH#:_L1?\%0M%^("K);_  Y_:(M_
ML.LE!N%EK<9 +8XZ[XVSV\Z4]!S](P:['X,UJSU3<B6?E"5Y'^4"W?&6/0C
MYQZK2J:N[-IVZ'I$8-O !#&S+DY=\XQVKYQ_X*X?#8?%3]F/2_$%E;R76H^
M[YKR\GC"[H[*12DB,#S(@?RVV@\;2>A85](6]Q'J<*R27$<ULX#*8F7RW'YE
MCGWK-\?^/-/\'65WI=YI)U@:M8R1-8,?*ANHY$8%&?& &&0?KVS6E%OG5C.T
MNI^/_P"P=\<YO@A\?;OP3>7!C\+^-%:.*/G9#<D9MY%)Y!;!B/J2,_=X_9C_
M ((>(8[CXJ*W56TH'\[VOY]?VC(_$7@/X@I:76B?\(_/HEQFV>-G\R#:X>)@
M2<<9X(ZYZGBOWI_X-X_$=QXQ^&GB_5[K;]JU33- O)MO3?)%=NV/Q)KYWB2/
M_"KE\E_-4_\ 3<C"M_O%#UE_Z2S[^^)OQ0\-_!;P%JGBKQ=KVD^&?#>BPFXO
M]4U2Z2UM+./(&YY'(5020!D\D@#DBOF[X/\ _!97X-_&+_@GCXE_:>AD\2:%
M\+O"\E[%<2:M91QWT[6\HA BBCE<$S2,BQ*S*Q,BA@G./</VA?V7?A[^U?X8
MTK1?B1X3T?QIHNBZK%K=KIVJ1&>S-W$DB1O)"3LF4+*_R2!D)()4D C\4/@K
MXHTSP-_P:2_'*74/"_\ PDUE-XGUJQCM!-)!'8RRZU#'!>LT1#A;65HY]J_>
M,(4_*QKUY2L>S&-]#]0?V"/^"O\ \.?V_?'/B+PGIWA;XH?#+QIX<TN#7I?#
MWQ!T :+J-WI<VT)J$"K+*KVY9E&[<#\RG&T@GF_V)/\ @M?X;_;T^)VA:'X1
M^!/[3>E^'?$7VLV7CG6_!,=OX2=;=926-_'<R+AVB:-,*<R%5.#G'YY_LG^/
M;C1_VM?VAK+4OC;!^UMKMY^S-+);?$SP-I=M)/X/MH6G1]'6RANDM;B=B8IQ
MOFCF=XE5BAD8TW_@E?X\T']F;]J/]CKP;^S?^T_\0/C;X1^*FAZDGCWP)XCU
M6&\M?"%M#9K<K+'80F0:-(MPT@\HR.6*D>:Z%F;7V;4U'O\ YM?H'*[-_P!;
M+_/K^9^J6G?\%3/A+XA_X*&1?LS:+J=UXA^(J:+<ZUJ$NF&WN--T7R'*O:74
MHEWQW7&[RA&Q4%2Q7(!O?\%%O^"B?A/_ ()I?!O0O&GB[PWXZ\66_B3Q':^%
MM/TSPEI\-_J5S>W,<SPJD4LT0;=Y+* K%BS* ISQ\3^&_P!EGX=_LA_\''WP
M7\*_#7PCHW@_0Y/@UK-Y/!80[7O+A[^7?//*Q,DTK *#)(S.0JC.  .B_P"#
MIBXFM/V/O@E+;>*+/P1<1_'#PV\7B*[BBFM] <17I%[(DI$;)"<2%9"$(0AB
M!DU-/WI*/=I?C;KH3+R/5_@5_P %U_ OQ7_:*\'_  S\6?!O]I+X'ZU\0))K
M7PW>?$SP-_86GZU=QJK&TAE$\A,Q5LC*A>@+!F16^W:_"?XI_$?6-*_;K_9)
M\0^+/VU_A9^W(EC\3(-+L_!GAW1M(TN^T.6\@>,:PJZ3<2^;]F95?%P @. #
M\Y(S-6_:N^&GP)_94_X*M> O&7CKPOX;\;^)_B'XK;1M O\ 4(X=2U@7D AM
MS;0$^9,&?@F,-L'S/M7FKLG!RZI/YZK3\?PVZETX\U2,9.R;6O;S^1^O?[0?
M[=>D_LV>(/'%OKW@/XGW&B^ ? =SX^O_ !)9:(CZ'<P0.ROI\-T\J*VH;5,@
M@;:-GS%Q7HWP)^,&F_M"?!'P?X]T6"^M='\;:)9Z]8PWJ*ES%!=0)/&LJHS*
M'"N P5F .<$CFOPXUK_F.?\ :.JU_P#:=6?$^@_![XY_M(_L=_#_ /:Q\2)H
M7P'LOV:-%UWPQ:ZKXGE\/Z#?>(?+CCEDGN4DAVS);CY<2J<K&.CE7RZV_KK_
M )#E'W5)?UI!_P#MS/U&^$O_  5:\)_'33+J[\)?#OXP>((=-^*]Q\(]1.GZ
M##=?V3?6Y FU.Y\JX81:6FY<W#889&8Q7U%7\Z'[&;Z#)^S7\(6\*ZUJ'B3P
MRW[>\1TG5K^9IKK5+3R8O)N)7;YGDD3:[,V"Q8D@$XK9\9_\$_/AO^TA\!/^
M"FWQ4\66_B*\\8_"OXH^+-2\(S0:]=VMKH5W;QBX^T1VT<BPO+(0B.\B.2D:
M!2A7-.*;3?97?X+\V4Z?-55.'5V6M_M22U^6Y_0M17X5_%+6_AW^U3^V=^R-
MHO[8GCJXT_X2S?L[Z5XPT>;6_%4^@Z9K'BJ14\^ZN+U)H2ET(_F#>:K%A&/^
M6F'^I/\ @UV.DG]E'XZ?V#K.K^(]$/QQ\2&PU;597FOM3@\NS\NXG>3YWED7
M#,SX9F8D@$D4?U^-C'[*?I^*;_#9^9^F%?SU_M ?!Z+QA^S=-XNMTD_M/P;J
MN)@F3YME<B*-\J!EBDH@(/15:4_3^A2OR%_8XT*S\5>$_$FDWUN9[/5X9["Y
M&<!HI8/+89SGHQZ?G7SN+ERY]@G_ ':W_MAY&._WJCZ3_P#;3\X/V)/BNW[.
MW[84>E2:[?>'O"?CX):WTMLJM(,E@BKD?(3-A=R_,J'.>U?J3!X5T_PK-=C3
M[>&UN)TV_:V'F3S==ID=LL^,Y^8FOR'_ &K_ (/ZM\*/$>L:+J6_^WO!>I2
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MVAW#21WD<=M>_9F7#.@9HG;U4JS(&R/XD]*^K-:UC[?YECN#1L@VL/2OSP^
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MQU*6?Y3Y<CB$S9&!QQ)@#N17[<_\.5OA9_T'_B!_X'6G_P C4?\ #E;X6?\
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M?BG_ ,%BOA_;_#+XG_V38M?3Z7X<\2:IHD,DJ;W*K+MC:1U 7>5@/  W$G
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M5?V@/&-IX0_;)^(\EQY;3-XEU=XTDE6*/:MX^YG9B JC(R2>XKY_,-<XR_\
MQ5/_ $U(\?,/X]'UE_Z2S!^%G[%GPF^ VJ:)!I_A>36=C+&^HZO)]KN)9=HV
MN5&(U^;)P%]#U&:]$^,7[2G@G]G:VN;/QMXJM+&\MY?M-A8VP62\GB.?+C2"
M,%B <J"0!P,G@FOBGX]_\%#]:T#Q1K'AGPSJT=QILMNT2:UI:F1DN?F#>3*Q
M7<HW*1(G (RI((9OF8A6NKO4+AIKB\O)/.NKNXD,UQ<R'^)Y#\SL<=37Z$YV
MT1T1HJ6Y]V^$?^"I_@GQ_P#%/3=&70M<TNUU2Z,,>IZ@8UC$I8A-X!)0'Y><
MG&<<]O<=>U;[/XGM9X8VO+[3[@7,$Y VVTBM_#N!&,C!QSBOR#\0:[!XBN(=
M+LT>:^G=%@6(!I&D)&P >N['Z5^M&FZ=KUK\-/!LWBEY8]432;=+T!?+C28(
M-PXX!+9SGOQ[5C>^C"45LCY*\&_&O7_!^MZ'\3+[P;'X>D;69]4N["TM\D::
MEQ>6MQ%!LPJV^WS'P5(7[/&>-F:_01+RUO;2'4--GCU#3]0B2XM;Q%(6XB<!
MD8 ],J0<=LU\G_'OX<V>J:1?6,>M6']EQ075S;Z4]YN9I'97O(X1N 0[7,SC
MD\#;C.*V_P#@G3\5#>_"/4_ .L:@LNL_#VXQ9QNQ\RYTV4Y23J<A&8+@$[%9
M <# K"M337-U1T49):'T#JV)YE;>S,W7G(J]X:U&+1Q=6]Y&LUEJMN]A>QL,
M^;;R#:Z?BIZUEF-C&K1JJ1Y/SL>13G=9U\OYICCYC7,XZ612EK<_&W]L+]FF
M^_90_:$\4^![F-O[-LYS/H]R6W"\LI<M"X[9"D X[C'8D_K!_P &XW[2?PW\
M2_L1>._!GQ'UCP_H_P#P@<LD-Z=7GBM;:?2;U&^_)(0&3>)D8=AMR>0!X'_P
M6;_9\F^)G[-.@_$_2H9;C7OAG?K8ZU'''^]ET64$I)CH1%,6Y])CS\HQ^8MW
M;,6^5C#YY6-I=WR*"V#N/]WOQFM(WE"SW-.5-:'Z2>%_^"JVA?\ !)'X@?%7
MP'\"]>TOXO>&]8E-[HUS<QF/3].OG"YFB9-WGJD>Q"%V!VBZXP3\NS:;\9/V
MUOC#JGC#QQKVNZAX@U:'?JEU;61DFBMXDVYD6-5BCB5 %P[9^Z,<U]I_'W_@
MCYX4_9K_ ."9G_"R/AOJW_"4>*%BL->E\226V]9-/E3<&MHU) 0M)$V>257/
M<X^M?V1OCI\$?A=_P34\'^-O%FO>'?"4DFE/9^((%MS+=WNI1*$N48#+2,9
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MDD6.ULMD:Q >8S;[ED"] A'WO$?%?[1/B+7K@G2YM4TJ9K403:S<W[77B*]
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MQ,+-M,TZXM9U?R;K9/NAX7*B-6!;+;9.K8! ]:Z^#XG:/<.MC9O>WUK<*(A
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M*DVTQ#(7>"1DX!)!KF]$_;Q^)'B?6K?3=,\/^';_ %&Z=8X;:"RN'DD9CA5
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MD&0DC\9+XX9LX?'(Y.?0?A'\&M:_:!O(;BYU31M'LKR69XD^5-S@@OB.,?(
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M&@F?]X Y.,@]=V=HR!G/%?"O_!2W]F+5_@C\4D^),D=C;^'?&FIRND<<C?\
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M>,(HGNKA(82><*7<A1GIDD 9[=:MZ]H6M?#[Q1)INN:5J&@ZE"2AAO82A8=
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MV\4_M*2>#]&L-4FTV>'2KHSFWF79"C^1&'=<;@,@,#C//3Z>4_\ !7']G)?
M/Q=T_P <6UG):V7Q$CDCGNQN?[-J,*@XW9)7?&%*J,#,#G&233_V _C[I?[6
MO@S4_@_\6-)T?Q VAS/);+=*5N)DP5\Z.0$21S+N(\R$HVQE[Y8^G&=Z:FD"
MIIRLV>;?\%!/!=E\1/A[I/Q?\.QPWFDZ]E+YX;7:RNQ8;I<9^<L&5F;^)2#G
MC/@W_!-C]H-OV?OV@FT#4/\ D!>+)$M'#.$6"8MF";YL#&<J?][CD8/V%^R!
MH6AW_B+QU\%?%&[68;&^NH@+V(QQ2^4P@9@-V%$J>5.B+G D=^,Y/P)^TO\
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M@VSZ._X*2?LK:'\7O@OJWBS3K&%?B-X?*ZC#+90$S:Q !ME@F5<!OE*N'(+
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M274#,JD?*PCY&[?\N0P92$'!(!'SKXP\9:MXXO=UQ!>72W+G[);QAFSDE0$
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M,[^@VK@-U[FK_P#P3^^(UCXJ^&NN>!]::-7T_%S9R,V'$$KA7[CY(I2LAR<
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MD,EQ8:Q$+BWF!_@(Z^Q'0CL01VIUV]SJ>K?:[R:YU2\<@-++(9. , 9)Z
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M^9'+<2%,A8]^0N]L Y)P-U>"^$Z&K^L5M/\ I]/_ #,WE\4OXD__  -E-O\
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MUC]1/@;XSN-4T1(M;E8R3)YT6W+-AN=AXZ@>U=S&\CSA885MHVR6=SEA]/\
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MO'^G^ ;J;1=<NH;SQ1IXM7OM-TMC<3VGVE-\0D1L-'D9 WXSC@GK7R?\1_\
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M )PI!C7T'WN #P3Q\T>-O'_B#XH:W)J7B?7-6U[4)#E[F\F,C8R< #HH&<
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M#QAJNK>+)OA[X;73KGP;\/Q=6UMJ5N]\U^'O9)57SYVCC7"LWEC9RNU%&XD
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M%;(Q_">*T/&6LZ3\//#=QJ?B;6M-T#3HP7:6\G$;2@<X )R3[*"37R/\?_\
M@K7X?\,I-IOPRT!O$%X?E.KZM"\-FA]4A.'?_@13\:XXQ<GH:JR/?-6\+?\
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MKB-&Y83?ZO9(A8,W*N @&2W)'WXN'^1E47+*_<^TYH#;)M5/,9NK,>@/?/\
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M2/3;!;RXAMR]S':0D?9B.WRC82 1D>O<Y->$Z!\2IO 6M++;V-NK8"NXB+R
M9^8@_P .0,5]O_\ !/[]I_3_ (*ZEXOUSXI^$[=O!NL:-CPW%JLC6$M_>Q7
M!EC$8-P+<E7BD>..0-L*8(WK7B8O*)SJ<L?@[?Y&W-IJ=O\ \$O/^"5FA_\
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MNM3L8UDAAD 8!-L80D*7!YY8D@=,#' .17V/^SIX F^'WPQLH;PJ=0O +BX
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MM_ _I7'B,#%0<TM>P72]3Z;_ &9/&CV^JW6AW,?DK>)]KM\C&9!Q(OU(P?\
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M/PWXB:..VN('A,=G?7()'GP,"=K,,95B!D\"M)0<KM(TE'HC[U-ND-S_ */
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M:23R$VQ+GY84_N1KT1?15  ]*Y-V5RDG[.WB.VUWPG<)?PZAJ&L7T?FZB^O
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MW@40[9-P#+*,*6 )QN&&/;RSX(_M6^+OV89X?#NZQGT>QU&2[;3WME:YM7.
M^US@_-CE=Q^Z>F3G] O"_P 4'^*?PI^",/C"-9_$'C)Y]1>%)4A6$K:33OL5
M@?W:A84('WC)&2>,U\'_ /!2G]G%O@UXJTOQ-;WJW]MXF+)?*+A9&MKE0" V
MT8^:/!'7[K<UU4:?N<W5?YD\[E/E>Q/\<O\ @HK\2/C6=4L[74E\,Z1J*M$\
M6GP;KWRV!!438+(I!Q\F#_M'K7&?"W1M#OK'/B+5]0TJ29X[:SAT_26O[J[D
M/&&#R1*/KO)R>G>NG_84_99NOC=H_G1Z;XGFU2\N"D$5@7031#&"=HSMSNRQ
M( '/ YK]!_@A_P $I]/^'&JQWWC+[/X;$WR?V=8+]HOIQQQ)<,60<X/!;&>>
M:FI4Y=9,AM7M%'PUX6^">H>*=7^RZ3IMQIJR@0!)Q'?:C<EE9&*C:(80X;>%
M'F21$ !R5W'N]:_X)&>.KK4](UR.WO-%T=MB7TVKRKLLI PQ((>'8D <B, $
M?>&:_53X9^ /#WP>TZ:S\-Z#I^GQS<-+Y?F7$@R3EY&RQ/)Z$#VK6N?"\WCK
M3[C1Y[I85U6)[/SI(O.\DNI56 )&=K$'&>W;K7/]9UND9<S>Y\3_  ,_96\-
M_L\VL>HZ+:-KVO2,(;K6+B%A\C$*?+3.R)0>3CG&<G &/G__ (*.?M<Z;X@N
M[CX?^!-7\R/3P)-4U'2W1K>6XW$&U616!^49+.N1N.WL37@'Q9^(GQ6\2>-=
M>\+^//%GB"35-#U.YL+VPBO/LMK#*CE'14BVJ5R"!U! '45P=DUKI430PK';
MM&NW:IP0:[HU%)%I-.Y[OX'_ &T-8^*>O>%?!?Q/DN+WP@U["L=]9_95OK-^
M(FED=T9F^3:2 44[1PW;UK_@KS\#_@S\/_!/AC1? _C728OBAX;GD^V:7:W/
MVJ;4+ J#))<2Q@!74KN5&(R)#L4*IKX@\.>"?$/Q*UNZ@\-:/J&L7$/+M:1;
MA&.$4L_09+<=SVK[%^#O_!"[XK?%KQ"/$GC>_P!'^%VBS2M=WHDF^V:D%*MY
MD@13L4N<DB20%5DY#$%:QJ-)+73L4HV=V?)?[.'QJ\5_ SXB377@W6=>TB\U
MVTETB:XTAG:Y$<A!!50"7PZI\N"<#CGFOIG]F_\ X(2?&[]JB\A\7?$[56\
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M*$DY&?/JGU-8R;=SYCUW_@K)\/\ 4=9M5B\)>*KJWMY!(&:2*-6.1R5#'<,
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M\'_V>/"D?B#QD_BC79+-'NX])CEEOKWL#,I;]WA?E.X@$H3WKE?V<_VW]/\
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M00-*;>Y6CC9GHW_!7?\ 9%ATNSL_&>A1JMOK+"*_\R8NT=ZH^67#<XD& <'
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M8Y7YDW=6':LJZN_)99&_U<B[>#U-0:;XVM?&_AZRU6SN([NUEC1XITQLEC8
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M@?A]^R=X1DU?XD>+M(\+VBD"*":3S+Z[9@2HBMUS(^<=< #') R1\"?M,_\
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MKKX'?M.P^)&T^(:/XR"7]NR1*D8N-ACND(!^9RT8F9L#YKA>IS7;_P#!3?\
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M-%W/'/VLO@)-^TM^ROXJ\'PPFZ\0:.C^*O#4H $D5Y;C=+&,_P#/2$,#U)(
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M%UARL@9=P1N=I<#!. N.>!VXS0/!NL_$_5EATF%6A8;KF63$=M > S%O4_*
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MVFOZ7!XNF;1;[3;[1_%6_7-'DTZX6ZMP6.+N!70E<PW'F)M'W<8(!&*Z&RN
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MH).#Q2BTE?H<\Y>\DCCOV?\ X;:/XD_95\&^"_$JR:IHVH6-I_:-J7?>KQ%
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MX3K7H27V7LO^AH5!RJPH?WGKM8O]#7T/!\3YK#P?INB>%K6#1-!M+9(X$2-
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M))4$>Y%0%F/R#&\FIDG=21$HW/RI_8C\9ZK^S5^V%;Z+K"R:#K'VN31;I9&
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MM;NZG&YO-DVL&^>0LV#O8D=,DX !Q7#4Q5E=;^9O3H*3T/LKP#XA\$_MB_\
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M'J1M)HZZWM)"C!0L:M@C/\53K"L4$B)YCS+RK#C!/OV_"H$OEMY_*^9Y&Y"
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MO&N68G9&JCDECTX_2HE-O5G*UT,N*PB2<MN9W9>,9&VK=GH5YXAE:&&UDG9
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MGTM(!_K/L4Y*1ON ^9'\R-QC!(..#7%4BVTX[+\#MINVC+?[:O\ P27\4_\
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M[1(5!&5:,Y((QR'@W]JR\OK*X6^FL]+N&17\U.89E+'((V,Q(XXYW<\C KZ
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M;6 XF;RH&+11@;0Q(W';DCY:^5_!/[,ZV7Q2:3Q!:MJ^B6F]2C7 6"1N<;%
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M#<4# DYV!MV.N!FI[[]G?5G\1PZ9ILB7\TUK+<I*P$44^QU78C;C\Q#!L-@
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MDPV^J7$&FPQMOWEA<7!.23@#"J.0 =S$<Y':N+,,VIT;JK-)_C\EO^!T</\
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MX/VM1?;E=?\ DTDY^J2BNS/<OBC^W=X3\!7/V33;>\\17S=%@(@@SZ>8_?\
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ML0S;EC4 !<$#WY^M6OV"+'Q)\-?'$UW;Z9<77AG5B%OM[!5C8 8D0G&[&,$
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MWT<C+>6,J2;?*8C(9#_#D'\B:[J$DXG(X\K-*3Q%9^'YO)9OWK9*("7=NG
M[\C_ #S6E>:!)X]@B@FCCTUK:5+NVN)PEQ/;R(V01&044XX(W$X)P0:C\$^
M])T>"2_ACDAEU#:TX#LWF$+MY+98\#UZ\\GFNBO],F^V>='A%*_,#U./05T>
MSEU6AFIK8\V_;,^%NH>(O@EJ7B#0)DM_'7PI$OB[PY)N?=="!0]Y8*-P3;=6
MT>6!!:1K:%%Y;!\,_;$\ :3^UA^SAH7Q+\)[K^Q;2O[0*B7<_D-_Q]*"?^>;
M*21U!B('>OKB7Q4VDW%BWG-:WTDI%O.SJNZ11O55!Y+A5=N,\(3QCGB?V'/
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M6_D\2:K''N\C3?WJ(<' >0?*.G/4@'I3COJ'4]OB+7_[N)1'&/O$C_.:\_\
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MQ9W%JY6=E/\ KD0_>;CAFSG\#5?3+'1[CXA-K4BM&MTKQB*5]ZH<MG/'S#H
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M\&:#HC#V7[OL OK4OQN\57'A;Q/X?NY4EFATT/Y.R,,S0'(DB+9X"[ACT#@
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M-9@?ST9;^]_X^+HO#*L<B;DMY!'&1 I%<=7,(Q?+#5G13PSGN?97QU^,5SX
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M94.3A>/;/7G%;TY6FI!"6EC[:TF"UM8(8_+$DELBQ#9C<V /UKX\_:?\8?\
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M5ZVV?FF>-^.O!\<VMPZI\6/&]YXY\2:/9Q:?8Z-9Z@L\EO!$-BQ7-PH,4(0
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M7!EC+*VW;CM@'/6G-;;X%W87=CK_ !'T_E6@$C*L54[67K[BJR6ZW:/GY<#
M.>,__7HY;[%(^H_V6?VXM#\+? +3_A7XRAU20V^L-)8:MY:-!IMLZYPQ+!CM
M<D8 X5CR  *]M\1^.?#/PO\ "O\ ;&N>)-)AT[</LZVDXO+B[)S_ *J./);H
M>N ,<FOSSA0\1LJG!)(Q]X]N:]I_9S_9P\-_%#P?#XD\1:Q=65E+=RVA@T]
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MC<AL'!!(X!SN7GBO)?!_[:7Q"UW0[ZPNHO#=W90P.U[/<6@BNID*.JH"OR$
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MZU[M?!J%I4TDET1^(UL=6Q-5UL3-SG+=R;;?JWJRS=FY+6JS+'=2+&86:*,
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MT5/"?BK4+74(VCNK&=E;:V[YD;G![COFOL2R\01:_;:7KVFL&L=5B6:+8?\
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M)/VCOVJ/ .LZS-%X)M[VZOH]&\FSOM-@1+&PN54] V Q&02!D_=XYKYP\/\
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M$MUI7P[_ +)77-.U?3GT633; 1PW%RDLNXW##(&,;@6. !DGUKOO@W\1)?\
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M=KH]CJ>GK\SRQWRK(&P>BOM'IW'6IPV/PLI-*HK>;M^9\OC/#7B?#_'@IO\
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M77B:)KN%8K6SC?9->W#>7!$S=!GDGZ $^U6[>XTO1I=UE#)?38V^==1A8_\
M@,?)Q_O$\]JK:IK%QKET'O)FN. O8*@''"] ..PHBHI:ZE2>IZU^R'XHT[PK
M\2+CP?-J4DB^+H7M$N^%LXKM1O@D&</SM>+) SYHX'6O9C9R7<-YIMS*J31
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M!/\ X*)>!?VD?V7/$?P^^+FN:1X#N;ZX;3H6L+'RH8_M4C/!/;HBD0I;E6#
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M(9;DJH95V<G[C-QGMT%/4#.U)66VDE$8:1@9#O?G([9)]:K1P\1^8?FC4/@
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M 9'S9&W#8XY]?:NPTOXQZ4T=K;SZ'?;YX6191<JQ.T?-_#V'/?G->[1?LK^
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M,[@,C?M([,I'4$#\\_#V@Z/XMUJ/3]'3Q5XNU3>L<4&D:>ZHS'C.TJS\D'C
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M\RP3S?WET(&*E\0K(0A.6/3'%<PK?9[(L2=L?"J&'!/;_P#75GP;XJU*RO\
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M;*RQ]@?E[C%;8BC3FXM+0(2:U3/7!^W9\/;B_6.;PUXHLX8?GE=/L]Q*B\]
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MW"F:%@)8'/"E >&;)Z5H/HEF^KPR7U[<:?K%K"))8IIY(UNLD(F[<-BEE(!
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MEFO)ED^W1&TEMHK$.$3>2N3C&3D$\@?K7.2>&9].NF:\O+.,R8"$(/W><%N
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M)VR>;+:QDG"DEUSSTZL*[3XO_LG>(_@OX8DU/6+K2VV/$K6]O)))(!)D!N4
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MFA56B54?;),I<%L\ E>"?RKR/QQ?-\)?'<\5OJ%E=0W5I#*T4#M_HA=QA6!
M 8 ;@5+ HZ'()('K\-XA5*\J<7=VO]S2W^956-D>Z?%/PQ#X*^-'C+38H1Y5
MGKUY'&YZF,2ML[D\K@]>]6?@5(VF?M!^#F7<LUUJT-LK*O"^:WEC_P!#SU[5
MQ@^--E\6/&D]\1Y>H:N?M4\<08QH2!TW<_\ ZZV+=Y;?4;>XMW>*\L)$FAE!
MPR2*05([9!&:^UC3<=3G\S-GU36="U#2++[/JEYI*7+_ &S3@Y:UCN8&V 21
M[L$[ G)'0XYR:]B\"6C1:M>>,6\(23>%?"MNM]K=M9 QI:V[';M9LC#L2<#(
MYQTKS>[M/$OB+X;>*K3P_>VT?B!KR"^=)"(9+B"5V%PYF8K&BHRP'&02';@C
M.WF=5T_QQ\1= N8-9^(L>@Z7K%G#9:CHVAVLBQW$2X8)*B;8FVLJY^9L%<XZ
M;O'EE\IU6UHMSLIXA16IH?V*-$UBZLXRTEM;Y6 L/O0YS&1P,@IM(..00:Z3
MP%XDM-+\-^-=,O998X==T=8+9=@=5GCNH95^F55AG&/<'::Q=>URQO-2@$<_
M%AIUI8-+)$D#3>3 D7FF)"53=L!V@D#Z<4)PBY D9_N97AAZU["C:/*<?J5X
M]T]J<K]T[<@8QUYK0TSQ>UAX'\0:";=FM=:N;.Z,BM_JI+<R8XQSE97';&1[
MBJ2.UO.S*P6-ER3GH1_DT@4,?OF3S!R0O3CC/IBB5FA7[$*VC-*S; ,XQS_2
MI/.GCTF/2OM5P^G+=-?"V*C8D[($+YZY*@#\*=F11(\?_+3 P1WXYZ?6A"H.
M^0HJ]2<GC'?GO4Q1+W)IY?WB[_E51D'^[V^E:.E^,IK>#RXY&#)(D@\L!=Q7
M[HQTQZ_4UY)\3OC1;Z<?LMA=>=)E)%"#  W<C..O'3^AI)/C[!-96\EO:732
M;VWQ[1RH]P.IZXK.OA:=6-JBNC6,FCV+4_BA>7 W1QQPWBX!F7"D]."<>W2L
MN[\:7E\MPDDB^7-M#M"NTO@?Q#H>O7'%<M\/M8/B3PM'=1R22F?+ R)M;=GY
M@>3P*UGLO*5OW;;O4*=I]3FN.CE&$I3YX05RI5IO1LFC16*LOW2=S8;IWY)J
MJ&-O,VUAW&1Z9S_6IV<_98U;RU?H.V>W3_/6H@?+=5/E].HX_/\ *O0\K$>8
MUE\P-+LWM]X<<&G*DK/PK*VX#('_ ->FK.H5E9=XW;L9Q5R")7B7S&V]D51G
M=TP>/QIV8GY#8;!9=H=68 ' =>GK_C1%;B$,8U;=NPJC&36?\3K.ZO?#"M:W
M;:?):W4=PKKG#JI&4;'8UM02,9+B$;8&DC'ERRQ;_+;KR.>.H/!J91L!"@6=
M"W[PJIPZKUSTYZ#]:D\A8[X;/N*H.2H'&#V_#KTXJX]M&$\N&ZDONA:4Q^67
M;HWRD].GZU1+1P%'4[6&.'X^7ICOW[4HQ82B1SV\0+A%V[@-QV]<>_L*=%:)
M+&T:@XV!E<#@_4?K4UJDDK?ZM2-IW9^[6;XSUC^P="D91$+K&0,X5P.N!6BE
M8%$L6S1F3RY/](8+\S*>G;Z?K57Q!XEM]$TV2:9G55X);GK]/IVJAX4\0"#2
MY+F>:/[.P\PR;\;>.1^'%<1^T5XJBTK5M&MU43)-"TVT$C>K$#YNQXS4J+;*
M5^AU/A[5AJ'CR^FCV_-;( RM\K'UQWR.]="+K%XISO=0588"_3FO"?!/B!=%
M\30O#=-'9JX:1OF&Y <X[9XS[5Z5J/QS\.V.D+=WDQW.S(8HXRS <_-C'H/\
M*T:MH'4[0&0?O6.W.3AUY)([&O*_CI\++S6?$ECJ6DV%YJDTT#Q2+"Q7RU5@
M1VZ?-TS7J'@#5X?BUX/U/6-$\NXM_#\:RWZ3#9/$GF(@8*3RN77)]QZXKR7X
MI?';7]"\7W.GZ=-;Z;;69"[O+1FF)&<Y;(Q@C@8QSFIC>]B;]C6\&>!X?#=G
M9K<:LUO"SEIK:)"_FEL )N RW&3\H)^@&:T_^$6_M'4K2]:2.WMK'?#'F5>?
M,!RV<%2QX'3"[<_-T&^EC<6T4H:XCOY#O,HDAPCC!PK'H!CLO&<Y[U'HUBEF
MMU?W44<C6L@:TCA8EF?@@]Q@$$GI]U0<FOBGC)7<[Z_YG1T':C:6VA64EM&S
M*;@QLRNK9+?-P?0?,>.N20<XXY[XU7TGD:99VFZ2/#ED4<,V$",<8X!+?B!7
M6^'=(;4(X5DD8+&O\;;GS_A_C7/?&G1Y]+DT5E$GDL)DDGCP/+#A<K]<+D9_
MNGWKSJ-1O%PCO:_Y&G+I<\QO="&G+IS&)[B6=!(&AC*H%QELMSMD7)'0CDX/
MIZ+X%\0/X?M9+K4KQKK3;.-<J4 8[GQY?]\.<G X!VG@\ X8NU58;6&X>#E
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M:*ZFDNE4LA@*H5 XW-C!7 &,9/ KKE6E&%ZF^P<J>QRVDZ0WVV159OLR/P0
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M;/I7&:K;0Q0J\/F+:L^_YAOV9XW<=N#^55R]RHGI7ASXP26FGP1S21WAM2I
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M^]<;KEE%INLW<"^9^[D98RV,D!B.3ZUFX:!L#JF]2O&.,576!MC;H=V_Y3D
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MT]XJ^,^D7&GZDFD0V6I7L>H7/V5)%8LBE0HW.P"\YX Y'IQ7HNO^!/@S\7O
MFO>+]'L]6\)+8Z*LFGZ99HT\%U>H"LL92,2O'AL,0VW&1DH/O_.D00(K[?+4
M ,,GE1@<54:_-I$CDTU1UGA/XU^+? NDKI.C^(-2TG3O,+K;VLS1JY88);'7
M(R.?4^]9$OBK5;[7_P"UVU"\DU6-U>.[D;]XCH0P.?4&J<S>9*K1KB1<KZ8'
M^34@14CW*.&YR3QGIQ3YI;,CD1L^/?BSXE^)MM%;^(/$6L:M'#)YL45Q)F-'
MQC(7& 3D\^_O6+/'\N[S?W<8&XL?NKT_PI8$\V;Y77+#DXR:XKXC?$E= M9K
M.Q:/S55MTC] !Z<TGS2$HI=!WBWXK6OARTOSN69D?9$D;Y<]\CC_ #Q7A^OZ
MU)XFU*6[G\YOE:4!E'&,9!QQ5&_U.ZU.6:2X4337$GF/C[N<\U"9?L<[%F5X
MVRBH6V#)_P#KUO3I\JLS1;$A/E[<M)YDAV97CKVQ_6NX^#G[27C#]GV:_;P=
MJYT*XOP([F:*"%[K&3\J3,OF("3DA&7.!G.!7"Z@KW.W:R[002H[D]>>M20"
M$72R!BPC3 7],YZ<?TK2VE@/8O"/[3C:SJL-]XNOM9OM2NK]9;W42AF98!L#
M.,M]_:,\*?\ 5@8(8UZ+X:\<^#Y+:VNH]8L--N)H$EEB%S'&%WD,<*QW @]4
M _B^N?F2W63B3Y3&S;(QD!CQWYQ2LBQ2;ML:^5D$C()![8/3G%?-9APWA\3?
M5Q?E_6QI&HUH?4FN?%KP!X3TZUU&;4K?Q%?2(3;I&(KN2-T*EB5#,(E.[.&.
M<@@ XP/F7QCXP;Q'XUU#5I(1&=0NGG"'#B%6;<J X ^4?+G X'05B-)Y1&9)
M).H8!=W?O_C0;?'DKT4_-\WH<<?_ *ZWR?(:.7MSA)R;TN^WDBI5')6.J\!Z
MDEMK$/VB0Q0Y#R.6P=N<XXQW _*O;O GC6/QA8S2)'MFA812#[NW.<'OS7SC
M+?&!%C4C]XP&2,[1Q^O-;'@KQ7>>%=<62&X95W RJSG9+M!(##(SU]>]>W.)
MC*+/HS4[D6=G-)))( L9W#.=P]/7\*XN]^*=KX>@D2XC>%HAO7 Y?/W??GFN
M-\4?%N^GU))H9C;-)%_I"AOW<GJ #GC 'O7#:KKMQKY:25EZ *JGDXR1GVY_
M6L?9OH%NIIZ[XYO-0N)IU9HY)G,A&_<6!SU%>K?!CXF-XHTX0311C[-%L<G)
M8XSCZ]1[UX+]LVQ*JQA&W$9P"%.>02._M6KX:\;7WAB0/:3+"K,5( ^9ATQ^
M@[57L[+0IL^DS.MM:PM)<>6SD[>< XP,53U+Q/I>GSQ^9?1;KB39&@P"S<8Z
M=O>OGW4?$]_XAND/VIEF5FD+9*D%N3G\OK6>J[)4^T'<"Q7[QQ[<_6L^5WL9
MV/J:/Y4C*$GGKGH:JZ[)+I/AZ^OMJ[K=2[9&[Y!U)]0!DX]JY;X+^.8]3\).
MM].L<UK*(27!;<S$ *..^>I]*I?'CQ3JWAO1HK?3(VAL[@_O)XU#88%MRDGI
MGY?3H11%7T*2/*/$>LV]WJ[36]NVZZ(RG. Y)^[GG:>OKC%9P:2$P^2S1LF0
MSL2<X[=J)K"ZNXY+EMK*SCS'Z;<DC/H*JSB1T4.REE! !'S$#M6GLU8;.KLO
MB_K&G:7!9Z>W]FVMOC:GE!CMSDC)[$Y/&.M:^F?M%^(+*\A6ZDAN+92/,9$6
M/<#VS@X/OSTKS6*/RSN_U,4A!1LXW=SU_P \5)J064'RR)(P<_*01GGKWHY5
M8$CZJBU2/5[&WOK%UFMIDWK,@RO7IS39;+SM[+"S-(O']W\*\K_9^\?/;13Z
M7?31K9$#[.)&XW_,2,]O\:S?%/QBU2#Q?=?9[V2&WMV7R8A)N1D#8+8/&>/R
MJ53N]0ZV/7K6;=<J-NWY@"/3M5'XI^,U\#>%%:UE*WEPQ\MA%Y@49YS^8'%>
M(I\;M>U2[F\ZZVHR@JJH%4+SQC\:-7\7W&IVRQW%RP93GRR2RXZ\')QGT[54
M:?<N,5U.]\3?&Z1/##0S6?EWFH,?*0#.V' *D^YZ5V/PO\>6_P 0["99-RW-
MGMWJ6YD1^0WX$$'\*^>=>,;7$MPTAACV M_L]O\ .*M>#_&UUX<U)KRWE$;M
M;&V=F382H'RG'L0.G..U4XZ-6*Y>Q])>/-9A\%:')?3-(/(GC12G4;B%YYZ#
M->=_%SXTKMCT_2R!+:S%IW.&WJ NWMD'(;OSZ#OYCXS^)NK>,4BCO[Z1D7D)
M&#L! _B'&?QK+26.>UDD VW#3?O#DX(/ /XG ]JA4U>XO9NYZQX9_:8CBO[.
MUO;9I$D=83+OVB,Y(W%1UZXZ]JV/VE_&2Z7\/M+N[=1YNJ2O';.(\L5!PQ4'
MD\C'3M7D?@SX0ZM\0->\FWDM;%A"US]HO&9(@H. 1M5F))Z  YQGI7I7P]^/
M\W@\^%;[5-'T_5[[X>RWUA);7R 1RK<*#&3W)25'.>P*CCG)HGH7*C*,.?IT
M.$\(>(-?T*#=JFFW*Z7K,HMXVN(VB3S.2@5CP&*YZYZ ]J[/]J'X97OAGQ_I
M=KJ4B&XMM$M;N-X')6[MKF))X'4]<%'R>.#GM@U)XW\>?%#XC?"S5+.[L[AO
M">1J86:V7R[(HSLKP$@,H'(R,\$\X;%<KXO\?-XJ\%>$;J[2&XU#2E;299T9
MFNI%#M(C.<_=V2>4/00BM:M%PDK'/&I?<R]*U?\ X5_XDL=0BALG2&3(6\MD
MNXW[D-'(&5EP3C(Z],'!KN/V:O@5HW[0?C:Y@\5>)8?#FDZ.(XY+A  [1%B2
M?;"G()ZYQG->:^(XVN;&;R]HDC42*)#P4/O[9!J/PMJ\=M=[;V2:.QU:-+6Z
M$3?<"LIW#^]M(!P>,BG3Y?:6EL*LWT/T UW]ESX:_L3_ !QTF[^'_P 2++Q[
MX!\2Q/H_B2"-TEGTM)E*+(X#;6 =E?G/S*GU'S!\7O@'<:-\1M:MKVZVW5G?
M3VCS*A:.01.8U*!@N4955E;!!!!!(.3]7V?[!'AOP?\ \$[/&'Q(\.WWB#6?
M$>BW$+74ES<"2W6Q9H@7*8P-@:1B1R .N1S\1_$'XZ:IXN\0_P!IWDUW,LT,
M:%9+QIE>55VN^6[DJ3CL& R<9J:M/DGROH1=O8]<$QOGDCDD20Y"1DIM4YY(
M!X#$XQA<_I4UK821RF-MVW>7D*N1Z  9SCIT&![>OH'B_P" 'BSX66PU#6M$
MN["WG0"/4&3S5/&2N]<@'U&>,<CBN3CNFU%O+#L'B7< 3E7Y^;/N:_*JU5P?
M+RM'I1C<A6"%/^/?]V[DLH;YL=L BK.J![N)K.Z5I(=H+LQP",?S!Z8]*J26
M,<DQ);R57N4.&/X?SJ'^UKA&6- LV%PV]OF'X>GM7'K)\RW"5DCB/&W@R&.\
M^SR+YUF?WJ3(S1E200<* <-]..,]SBGIK2VXF29K9HWB,*J[G=C."5)SM.!C
MKS[UZ#K]M_;&G?O!Y;2%1&2N?*;! (]\'I7&>+[6^BN&D6.SECA4Y3)69C@_
M,C?\!)Z=CSUKU\+BN?W6]3'4Y2UU/[- RVMN;>1 $0)_ N['+?Q?+]",9JQJ
M?G7.F306T=K9?9PKJ\@7S&9RYPI7.,<=3GC-2VBRMI[7AC:%++ 99!NV#!.,
M_>[YYZ_6J6JVVGZO%;_:8RR,WRK;N4"[LE?F],_Q>_/&:]6G=/0&6H/%U\]I
M';ZA)/YDSHBVR((X9&P$5B>0,]21@?-TJ_IDMGK"20W5K;6L0^1F6<L=RGD9
M/ Z5F74UQ<6RV\<+320LFS!W<+A<,.X(Z^_-9<OA6[U2\M;A_.LX8Y/(.,H7
M/4EB.PP!D_SKIE'E7,F',TC6U_QC<V6O6\,-K:06<<2I(ZJ660 <IO\ OEB<
MC/3G/'6LN;QW?:M<6_V>2\\E57?;1*%6)>B OUQT/M^=7K/POJ3:U?V<<UPT
MOEB6'80V3N RQ/8C/ (/M3=*\(W&D:--I]K;_9-4N&4S3R3K\N3A0O/09.3[
M&L%!3]Y[C3)HWA>+;;K;W#-O:2R:106<[L[2.IY4<8'WC@'K?%RLEJY9;-HP
M540O.JE .#_"0<=B<$>IZ5Q-IX:U+2/$EB9)I&5;O;"V2""CX+?0Y/S=>I],
M^OMX?N_'^M0Z?H]NUU>,W[Z58QA8^-SN_15!(RQ]1U)Q6-5V<8(7DCD(F^Q6
M#6L[QFUO+DF-$97C]0=YVL#D=#D8JY?>;J\-C,;BYLM1MW,:ED&T8&!DY&[Z
M]>WO5!M"U32M3M7N@T%K>7CVT,7VF*;>N"0NZ-W5<$%>3R>N<-6CXC\(ZKH&
MB?VE<6T,>ASSK%+-*RM$C'H"JGY3ROSD=>X K.52,9*+:N&O4Y;Q!%"(K59+
MB&&]M9L>8B%4D.XY8$CZ?K4ABFUN2.\U#]W"[D2.5"[PN1C)'?W]*EDU*2^6
M6W^WR0M!N5;?YA"K'H>.F>>XSGUI+2SDL9FAD6Z4K\RG)W,_RD ],CM@_P#U
MZZHQDK<P1:;)S9QZ,=EG#LV1H$9L^:WI(PXX[$#H,<5!?ZEJ$D8$BR6]K:EY
M/M!!19B!C=C!R.0,#-2+<1F\MVGDB&YSLN,,H+@ ;>^!CIG\JT+N2\"Q^7-I
M\48EQ.T<1\R1. %R?F ZG (SFMJG+%V94M-BEI]\X9=EO-*R'RE#?=BXQD<C
M!.>S9JAJ%Y:+!-]NC5[4$+%!! 6:0X(#;F.0,_49]:ZRWET[0;YH[DWDT9CD
MO#Y9_=VZ@??)!!!],<]*X^UUE?%KW<4MNUBK7(<0LQ!GB."&!/3('.>Y!]JB
M-Y*]OF'-T)M."PP2HRWRR23&9C;AQ(-V-H/Y-Q_L@TVVU1]#MB,V_G3Q!8Y%
M7#.Y/1@3@$=<]34TNMM'.T-G,LDRC" ,3&Q'())P.""?ITZUFQ:@_P!N?S88
M9+A5(PJ8A+8&W!STZC'3BM>>RLR9%J72(9+N28WIN)N%V.-S2XYP2.W;BIO"
MOA;Q!K&MK&J_:+5T7[5!:NK+ C-LW.5)'? #<FIO">F:IXFO%;4[;4]+T:59
M&^V16@6 $9 "!@-P+8[Y/;M7=I\#=8\/>")(Y-06RO;Z3[?<2).(O)TY%7:^
M[<54DLWR$DYZ]!7+4QD(M0D]2>5/4\D^)R6</C*WN=+TNXTV.TVQ[X2(RVSY
M3)M.=K<<C)Y]ZQ_$6B+XOM+J\O=[0PXQN="\I. "6(+9SVKJOB#8S:WJ2M8Z
M;#8V-A&D92.1)&N&"YS+(O#.6;)'0'([5@6-]'I&OFVCVS@PAF@8%V#'&>,=
M>P Z UW4>>24D3*21P+_  VM&TZX,<S?:(UW-^]_=XW?=&0/FQUK,\0>#8;&
M*WCBS,EU&624_*%(ZX[_ )\<UZYXCT6*76[.\9DMXK\$G"A%B4< %1U('4D'
MFL6\M9(]-GFM;2X:2$GS9FA*^4G8G.<9[ 8Z5Z?MFM;F?*>43Z=J'A>969F;
M:00&X89Z>_Z5U>F_%2XU=88;Q((63"*5&&/.!QS^E1_$KP3JEE-;W4MO?30W
M4>89%3<Q"J/O#J!R#GH>Q.#C+\#^$[[4[UGFL[E3!'YZ;HCCY>_3C'7\*WIU
MHRAS-DZIV.U1!? >7(JL#G).!GZU9T^2:Y;;$DTDD8QL:/#'!QP0?UYK)\*^
M%;K4LM!Y,*2;]C-\JR$#))]  #R,Y_6NMMO"=PMJS01-]IC5-OS,NQSWR?NX
M[9(ZBHJ8B,6D6FTA]Q?ZE':2RRPM(R .RJH9FW<  'W!_(U331[F:U2Z:.01
MJH+'?@[O3Z>W6MB/3;UM)66ZN98Y(HQ;=(]T(!(7^'.<CJ#GG.>:S;76M4N]
M.969KJ.1@/FYF8*=Q ;OU[Y]JR6*J-733L+FL]2*SO(YXVV':V-HR#\WX]L5
M+?67GW4JR;'CPJ*H'R@"BQOK&VDCM[J&XMTY=]\?0D' ZYQG'./RJ2QOH9EG
MV26I5 6V2-LW*.?E+$<GIBMJ>*DW::^97M+C3;++%M"AFP%&/2C49U\YD7YM
MH"#CT&*KQZ[;6A\R-F<KTCZG-1_;;=5\V8R N"0B89F/8>W-;2J65T'-V&2K
MF167\:@UB[6*$*N=S=&7^M7M*A@OKR7S)9=W*PPQA7:4G&!N!X(R3^5=%<PZ
M;HMBMI<6,D&H1+YCF4;FDW#<%"X&!TP>>M<]3&):)$W.%TJ*:YF8Q1R3>4IE
MD !.%'4FMCX:>'F^*/BF&QTV0M<3!CM+;-Q')'YX_,4Z&=EAN(UMUC34 ()8
MA]]T#!CTZ#(&3[5>L;(QJL>CV-U;W,<3F7Y1&T8Q@].2&SUSC!JOKT8-.2!Z
MK0T=7\-ZG\-_%K:7J]C+I]_IQ/FP7"F.0/MRN0>YRI&>,8KFK/39OMGF_.?.
M.3Q@*?7/;I4OBWQ!KVH:J]WJUQ>ZA=L@!N)F,C8(V@;N3G QSV%5M%U:61(=
MJ<':WDL2%?GG.#GGV-;>WA4?NCC>UF==I%C#!X622UCN)9+B0)(RLS/(IR[J
MH.% [$8SQM)X8GF[[PY9W=W&;Y8[F10"L$8+-&3T7 Z=!QG%=-IWC>]N8H["
MSC?_ $5F:"-8XVV$!BPD<\# )&01D"HH_%&EZ7H\NKC[/-J:^6EY:,ODR(W(
M!0'@I@#)&2"1G&17D<U2,K=W_7H;QIQY;F=8^!4U?5]DEO-%]H!FFD%PTA"\
ML2>>^<D')YK#U>SAL+R2*-6AD?:# '\PCY1D@GH&Z@$Y QGU.A'\06LM0.J1
M^9"T<H>**20LJJ?4\ C&<FL<7]QXBOWO;VYD:>0AHW"[!VYQV&.P_7K7HX7V
MBE[[T,I25]"UIMF\>DI<R>6%DN#&A8_.V.>>>^<9_P#K5!J4RV]T#'#)EB3R
MV"0<=*Z/P5X(_P"%@:HNFW&J)I*VML9XVF3<)I&8$!>0 ,8.3SQCG/$GQ6^$
M&K?#^RL[JXO=/OK>^D\M9(#CD G!'3IZ'M7L1H5.3VL=A<RO;J<O<RVZOY2C
M=YS+A2/E;M_^JB.5I0JE1(T?!S_%W_D#1XAMX8;R$0L?-A1 T8S]_KQ^8IJR
MW$TL01&57!"C.%<]2 <=>M',M2@1VCE5MZB-E& O);FNHT7XHZAX5TJ.V@3=
M,8S%YN[@9?.0/7&/QS7+ZK+'9W\UN&9Q$^T<<CU'X'-/CMY+V_CB9O+G=]J*
M,EB>*B>J [VU^/&K>&-*BC7S)Y&RP9QNW9;."3^/;I7:>%?C[#J_@FZOKP6\
M.I6[[%@ *^8.W7OU]NE>&WUPURS 22?,P0;NHQ_^J@---:L5'W!O5N=HZ \&
ML/9I._4D]P^%WQ/6>]B_M&\VQW3&V3S22^>6 SW/3G%=G\31;6ME'-#?6<,D
M?^L@G(/F!AQQG@]3GVKY:TJ2>YN1*3,JK)O3:<+O7OZ?EVKH&UN6_FDDNFF9
ML@OYAWL3@8'?VJ=%J!H:[#$NH;46:ZC10V7;HQY(Z\@'^58<=VT,<<BR*9H6
M'W>5&TY'X>WM4\]UO61ON-(,9&>1T(S52UMA+NMVD:T90S"217V;L;E7Y0>3
MT'8^HHE."UD4-\WS+G:"T>6+-@_=W<G&*HW$+RH6$S.JOD;^#C)[]<UI0Z;8
M"VAD74FAU,;$FL98&"QAMWS!\%0!A>"<C))P!69K)DANB5?<NS,BD$>7@G/\
MLUI&<6[(G0^@= ^*ZV7P[@2WC:2]@M@L:SGEQP!^G?V]Z[3PW>MJ^BVMT6^6
MXA$C#T)!W5\DPZE<+:1^5+(PV_,%;"\GI^E>P1?$F:]^$DBVL<MFTCB$SYVH
M^ !(%[C^O-9U$XR6A7F7/$OQEG77[BVMGMXK14=48CYF;^\.V!^M;?A7XYZ9
MK&EH;_9#=*^&C,>U0"<KSGL._P#^NO!I=7DMIMK1A]G"$]J)M4G^65E0,Q7>
M5Y! X'6MO8LGE/JRUGL]0MFFMIHY891P1RP./_KTY8GF7:IP%&"Q[5X;\)_C
M?)H6CW<$MN]XPE-VS A ,A5(.![=JZ;3_P!HM=0U.UA@LY9(VE'VESSL0]\<
MG/\ A7.Z=F&IZ@R?:0K+NSR,8Z>M1S.T8P< ]<9KA_'7Q>M].TZWDL9)F;S/
M,;C'R<C]./2N@\(^,K;Q7I-O,K!6FV]L88Y_G@T[-!>QLM;HT 8;N""JCUI&
MTUFC_>/B7.\!3VZ=*PYOC3X=\.ZK-:ZLTMMY095?:3\XXY ZC([5XO\ $#XP
MWGB&ZAAANF:WAF+12P@QL_/'/;_Z].,'(#WN\TA))5./O'GG^5,BT$)-(%7Y
MCR#WQ57X<QW4'AZ'[=/+/(6.)'D#;B2?\\_UIOCK2KR74?#*V][+ T>JH6VL
MW[Q-CED./4#&3Q]<UC9BDVF7I=%AD*^8N47D<=:\;^.>M)X<O&CL6C29B0P1
M?F3CC/MD_IBO5/B%\0+'PWH5U,UQ&URLA6"%>=Q#$,/T/-?-_CG59M>\:75P
M^[R;A@\:@?>R!QSZ9K:EHUS#CJ9\MY+JUQ!'=LTC1CDER<>P]LY./>K,5I]H
M589)%\O!7@9;IWI8]$NC=>6%+-*G&>N3T-+!:S:*JO)'M4':<#@]. :ZI=RK
M=$>K_L]^++>RBO+*X*FX\Q%@=G^9@001ACC P.E>GVUW!>7.(YHO,8$>6K!F
M''7'7N*^</#^DKJ6M6=K"\D-Q=R!(V8<H3_^NIO WC*3P%X_L[J9I)+>%GBF
M0'=D,"&Q[\#\JQE36Z#2Y](3YABYSM7'.,9QS3Y9'W;E^Y]W .#3=.6/5[:&
MZMY]UO>1B5.><$9'\Z5(\9P2ZYZ'&3BL1'6_"6^B74+RVRRO(BR E?EPI(Z_
M\"';UKF_$4#3>(;[<T>S[7( &&?XS6_\+H!+XCN&+?-]G8;3_O)63XQL3I_B
M2^5G7<TK2*.WS?,.?Q%9ZN5@,C,9DVEM_)&W/)J6-M@V[64-@ACW--A4M'@+
MN;&3ST]:YWQ)\6/#GAK6UTZ\O<3"-I)-J%A#CD!L#@G)Q].<9%.$&GH!T%]J
M-KHMM)-<RA8XU+%VP%/UKPGQ=\7]2O+R0V=P/+FD\T+'@H0.!QQST_2JWQ.^
M-,GCO4(X;/;9Z;#DJDN \[=F;G'T'M7%7E^9=5:0-*%FRSI]T Y!QQQ5J*0D
M:FKZM>>(+Y;R_N)IIG."SG.!SC\*G\"!;3QSI4D3';'(#N;@'((/X#KZU2>9
M[B+S&5I&D/!8_*".O\Q4EN%CC$F_RVC)5%4$8]>*WV#J1W-K';7-U&W+?:&7
MY6S@@GOZ=ZOVWBG^R]%BCVW+20G>DBS8"# ' QD>IY/:J$LK+-'YS-C>"Q([
MGIS]/Y5%;Q[$56D8*V0,GY2<YR._3\J=]+"2/JWX%?MSV^E>'[SPWKG@S2/$
M7]H6'V*UNIM1N8W@N2H47LA#EGF&#@JR#!VD$5Q_BKXAV_AG39+>XA,<FTQ(
M0P5I/]WZ5X'I-U]@NHY NT0X8<Y)(_D>WY5T/CGQ1<>+;>W:Y'VIH')4XZ'W
MX&.G2LU1]ZZ$W<]4\.?$&WD\,WVVZ!D:W\Q<EO,3L5).><YZ=JQ?!WC1O^$L
MMU;4F\N63 61F^Z?7V-><:?K/]G;4\YE9E.Y%/RMU[>QS5BXUEK@1SV+-N51
M'*7PKG.,]/0T<NMV'30^BM<\36.CPS"6X$4C1EDQ][TXKYK\4ZG<:MJLGVQI
M)G7=@!CM13_+)J34-=>^B5KB\FDFMR!'D_*5ST]#QVK+FDN+YI)-\?F[B6)4
M?/DG_(R.U%.VXT[,BDD:.=1(56, A0#R"<'/TJ6*-IHY-[!I%&5R/N^U9=N6
MDMUE82229P,CYF_ 5HS6C16#><R13J '4>OI]<5HG<?4GM-D#22LT?"^7R.<
MGN/PI(I(5EC5Y"1DA54#//3!J.UN=X7,8>/B/!Z[N/2DD=9O^6:R%3D#NA]/
MIQ5*-]62:4<JWEKM:.62*-<$B3;L(/7 /MC\:CUZ^\^.WCVR*I7S-ZI]_  Y
M/<\5)IZPQ6*,LGES2R[651\JH0".G?.?TJJTWG6RQ_*1&VW<R[21U&TY[DFL
M^8-BO;%9K1CN8EPQ!'!?'ZU7>*-A%]\,N"Q4$ESR.G]:EM':\W)Y.-I) 7Y2
MQ/4'T'-78["6XN&16#9;8P<X[]O:CVB3L45[:-KB51)-"IW?='4X/45880Q%
MI%G20[]I#'YE/3I^!YJO*Z%OE500^T!AAAUW8J:2YC5?WC[9. H5<<<T1=P(
M;MFG1F:-GD"=-IP ,@?RID(MQM9E8*R!#CKC.3_.II;9VMHYF;N0E0W:O+"%
M16.WG:HSSST/K5+L*Q&[1HVU4\OS&!Y^ZW;@?X59N+'9;O,H!;(!*X7<,9X]
M^_%1W#K83[E7"Y"L[L#[_P ^]-*?O=JG:JD,$09)'<G_ !J?0=F21SR12Q_O
M&,*<B/&5YZ_7/-,N$=G>2)1SMP"Q'KD_EQS2Q^7(JQG:J\X(7[O''?\ SBG2
M?ZZ2)9."F/D)R,XP#Z]C4Q[D[FEH>J2::\K'<T*RKYBH^&;C(PN><9ZUVT?Q
M4N=5\/+I<,VG6RP1F1S>N&DN1][@-@;L@\#/7MU/%^'= U#Q+.L&GVZW%PJY
M5 VUGP.V>IYQU[UBW6L:OK.GPPQ6JM'"[-&QC"JC'AMS=>,=#2T6Q70VM3TX
M^(K/4)_M5M8V\;KY:*"//8D?*HSSSD__ %A5C0O"FE7C6J_VA.TDX,/ER1G8
MTBY#*&QCDA2,$_>'X5_!FDC5K>QAG\ZYU**Y8R-'\L<4>%*^GJQ)] O3FO0K
M72X+R);HZ>HU#19HY4W$M;N@ 8Y*\!05 *D>AZBO QV,=*?*F]?33^NY48M[
M'!7?@*6Y@N+B2X5%CB=G621 (4SA03D_-RH*CGFL:/P_=:?;HTB+&SLH*JP;
M '(R >/Q]:]3\0Z')XA@C336MI+?4+N!7B0$>6\H:1D/5B%^7+8Y''!Q5GQ?
M\-K?2-)L&\0;OM5YJ#)(R,"NQ"8T6-AT 8,3SSN7CBIHYI.%E)K4GR/(9[:Z
ML+IHV"QQR,)&4-RS9(Y'MS4-I;)%>0QM<QJ^T!E9L @YQ@8Z@]J[Z#X/WFJP
M7%U,UQIXCB;;/+;/);(Z$($+@':N6C7GH3TQR-3Q'XHT/P_'9^%;[2[&2ZN+
M6-);^VF;%O.W <AHT!&<$X! #8W9W >M@\93Q$N1/W@5SS&9(TE\EU#;&,4F
M#T(.,D^F0:NZ-=!-6"WBCRY_E=-G!!7'7MV/I5*%)+75/,^:-=@;CI(W()QV
M&0?R]ZDNGE5VG;S&95&]MA!R?_KFN_8K6,K$NGV$.JW<D;2KB%3][YL =0?P
MJIK-A!9WL<<)1H9(RA;<223_ )[59N-.DM?$=U!)(86D&Y2IY*L,_CU_&F^*
MHH)[#=#;K:^45#,>-Q'!XZ=?Y5:DGZ%1[D&B:BDL[6\=O^^=6)8G:0>A_#BB
M<+YR+(K31S1>4K@=,< C/IQ[\4FF::][JEF%C$TCD(L<39DD#<'TY)/YU;\6
M36]AJ4VGRPO;WFGRO#+"3Q#(APRDC(X/!K.^MBWN6?AYXH.@^(1);R9"E-X*
MEERIZ'UXR.O:F?$&]2^\3WUT\D(FOP9I I)\M\\J>ISQG/\ M"LQ;F/2+V2:
M!5F>4,&41GRU&W /OZTP7+QI']J:-UA(0X0;AG^\>_7'K@5BY)3.IU/W7LY=
M[GN'@S]HW6-(^&FDQOX@\-Z5H:69LM2BN8S=:A,F[#;8\/D-&PQD(.#AAW\(
MB@MQ>74EO-+-I^YFM79EC>9%D(4NN3AMN25Y(]^M=#X3/AK4=.D.J6?G7D#%
M</))Y;)T!&T@9 ]?0<U!X[U33=3UJW&GV?D^6I01QX4%1CYN/85V5JG-%-N[
M.#V:6QC+*8Y%:23S),[]AW.H49QTZ =P.N*AE'"KYL<<.]G1<%OO'KGH.O\
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MG?P+N55F&2Q"[@<X/4^X'Z5].>/?^";6D>*[!M4^&/C""XAE+LNGZK.!EAC
M2X0;3T/WPN./K7S_ /$+X->-/@U>K;^*/#]]I49?8LLB;H9#@G*R E6R 3P>
MQ]#7BUL%6HRNU;S&E<\[T[P3]AUBZ:2_C_TQ%0I*NY'49"@].F!@YXY'(-<_
MXE\&+8274GG/<CSO+DB5]IB;!&=H(Z#N3Z>E=CJMI'JDRJRM*(SO4H=K ]._
M!')R",'N#TKF/B??ZIX8\)ZK/9Q+(]TNTW('S1[R 2>>",$#&>2OO7=@L3SR
M4&]63)-(\KNM>;3[V:U9V\VQ<)YD;_, 1D9XZ8&/KDXXYZJ<7<=[N:YAG>Q_
MUOE%EDC8]0.<X.,]/Y5P/A&SLXDBMY&9]['S25R22.@/X"NVTSQ!9QV4W^D?
M9YE9BQE+;6)/RD@9(Y[D _S/T%:U[(RCYCO^$HFNOFFAN+>%7 CFR90V 2#V
MZ'IQW_.&RTN6\CM[>;4+]OM#>>T?WO.5>.C'(Y],BKT6HV>K,!->11S0\H4_
MC;: >3[Y IQTRX^U-^_61(T.822SH3_=V@X/7-<TKQ7NFAI:)I4_RM'#<74V
MTB,'YFB0?> ]!ZGT[BEU'4KC3M(U.QM8[X:9Y!O[]+.)6\S80D32NQQY7FR'
MDD?,R<,R+BAIUC>.L:;9K.Q@C1;J1+P1R0HV=R@$DG.>>F3D=JZ[5M"\/KX9
MCTNUT^:;^T#$;VZ,P;[0L<VY5SC(7&T$ ] >YS7-S0C-.;^XE>1K?"C1?#OC
M'P)JW_"70WVD137 O=)FTW;)<03'+8=&(#Q_*,J,'YCM.>#UOANVB\3> M0T
MF^N8Y-/OH'B:-XU#)GA<@<Y&,_4=ZY*Q$_A?P5J#6MO'(^G100P1X\QMG 8#
M'.=HR,9R>W&#9LM0AAT&XO+IOL<4-L;F<,"61%7+9 &<@ \=>/I7S^83G4=H
MZ6>EOE_P#;F7+8\"DT>;PCXC:R"P7EU9E8;AHRREB/F53G /R;"" ?O$$GH#
M7=>U!@LGD7D>FSB.-?,CQMXY"D<YSG'/(7-3>%X[KQ3IUUJEP\<DVI3-<2>6
MWSJIR%5"22JC:5')X"CIS5.(QWFL_9M2N)YFMWD40A-BVZ$$!]_? /3'7&3B
MOM>9J"4]6M_7J3%=30L->NM)@MHYI#=6W$(D:?RRC%B"3Z8YZYQBMRQ1;"2Z
M>YCD:)WB)! ,C#D[L#KD D]^>M8MI MI(UK;0V\DTT:O#+*/.#[@#DJ>-PP2
M/_UU1L;QM,GB@:XFDN8U/GHL8W1@GJ !U.><GI6%:,9L)6+FMW__  EEY,\T
MDUA8QLRRPJW[P]2,ACSQ@9Z#(P#TJCX7U57VS1VJM)%!RR1??;H"3V_Q_&KG
MC"XLUT"WDALYYIKB,_.C9V'/!8=3U//':L^W\-ZEIVG^="TR,V5D7!C;JO"D
M<#@G'-=E/E=&W;06B9I:9#;:9IAAN2Q\SYEP0#(#T)'?&#^57M/:UTC3/)N+
M?[98NJ_NC(4RV<Y5OX.!C<<XS5/0;NYN+9(9K- 6))\S:RM&IZY['))Z'UK1
M2:]M[G[.MK(\>P*"I0XR"-PXQ@C/'.:XZEI.PY2TN>^V&E?\)/I7ESRG0]6/
M[Z+S+S[4TT3+N",\C'!;<Q8@$X*GH,UF7&B7&I:%<11W<D=O.L<:Z>MCYGVI
M8RV&Y<HJEP!N)&<=*\HLM1U#1M'T^UM=2U*XNM,N?MD$/VEFCB! 3![+M4[0
M!ZX[5N>%/%OVC7[>R5;K28;IO,D>^N_]'NI@V-Z' )&1VQ@_G7SN(P$XMSC+
M07,:WQT\!QZ!H]K>+I^@Z/-"%MWM])D8&[^4$RF-BV&!ZA20 !]3YRMO/9S*
MRQQ[(TDD99,-(R[<$Y7KDX^G%=)\9?#NK:9KADLU7SK$NZ3029#$A<G<<?*<
M[<8'ISVY.VGDMY'9UD-WRS0^7N3YS\^3C Z]?7TKU,#4E&FDW=BE9JQ:TZ;3
M] CC>,K->S92".Y3S%=S@",<9XSU[&FWN[4KF&&::V\Q5V2+&V[>.IPF,$J<
M\G%27!TO6;1[79<6]I=2"T26&)2@?()R"1U*GJ<\55^RVME?3RHQMYY&VV\+
MG]ZR(P!7/3)'IQG(%>A)S:O<S4;F3X\,M]I2V4,;23V]R+<2KF,RI@89@/E&
M21W'TQ5K0?#RPZ.]U>VMQ:LH$0D16>2=3DMC!VY"J0<CH0>>VI;^/H;FR9Y+
M,Q7%M*,O%#\H7. 6/KTX-.M=7NI6FFT^;[#'YC.[2$O$^X<NJKZ'CKC-11K.
M"Y>A5C(\#^(+C4-473[.WM8;=9DD>544.GSC;N8]><'!],UNZT6CU2ZAO;AI
M([=W\\P*NR0'(Z=3C(Z'@C-<9::Q9VMRTEG'<3W4RA)GC0[)7R?FQ@<GWY%=
MQIS"6&%I-,1I(@)&FG8?+N'.T,I#8&>/IZUIC*CTE8E6,-M-;Q%;01S:A-)]
MFD:4V)(!6),;78GKE3Q_CFMS1O!DFG7F)+R&UM5A22W(D$L4CY;"L.S8P#CC
MY<]\54O=+-A>PWET)O,3.Z2W(/G1@DC( PN !D=S5J&?^RK2XU"^G6:2X#S1
MVD-KYHCW@I]W !;#+R<8KSO:MZ)EVON9$F@))XCD6ZMUFM881([#YP-Q]>HZ
MX'/7/6N0\90VMOKMQ_9_F26O#J'4*8AT*GH,C^7O7HQU%M!$EO;Z',9+@"0O
M,X,L80#!*\\$YXSZUP^L(R6\UQ=1^7;K-FY20*)&8GYLA2>O(QGCVKUL)B+:
MMF7+%Z,S]"T=M1L?M4:^9)YRI&AQMP0221WQQ[>O%=+I'AR6*YNO[2L5N%MX
MA)#+G$<;'G"HA //7@@8'3BF:'?1G4?,TVT2.[\MI&"@^7G(VA4/<9(^HKHM
M?U756AM87CAMEW';',@ 5!DJ7#G#,5P6R!_#W-/$8B;E9;%<JMH9^AZ_I]QY
MAOK417SA52["+N@"D84#^Z-H V\CWYKGK[6)IYA-M5DN',>]% FD0#!(!'"[
M< YP#GOAL=7'I,WBG5CFUC7=$9FAM)/+1,#[RE1Z\C;D8SVYKC/&#QZ=XLDN
M+6UFA55$L8EBP4/J"1RH/&?0&IHRBG;J2;=[>KJWA]AILFH30O &N' >.VD/
M.%7H6VX.2ZX!!.3DFN1O+^\TZ9^9(9EVJ5$> NX<#\O2N[\$^&+R3PJTD8DD
M&H/FZ\MR2I/0!5/\6XD@_P!ZNMM?"NDZQIA6*:&3.Z2:*1=TG8':?7V]%[5$
M9^S>JT#V?-L>#W-UK6G0[H=2NK=5; 7S<1N 0>5'RD9/<?GS69%KE]&54MMD
MB)(P-K-DYZ#C'T%=[\2?A_+H]I-<:>ZS:5=*XBCF.R6%DQNSR0<\GJ>JCK7%
MQ^&+Q],:2XMVMURJPB7(:0D9PN?\X_"NRC6IR]Y?\$S<9(WO#OCC[+H;QR2R
M1R32-*5C^Z7.<L0W?D?F:H>=)=K)AH1%T?*#YOH/RKD+AVMW\X-T.1DY ZC%
M:FF:I&UI']LG15QNV@?<8_J>F>IQFO0CRI:#YKFTMG"]S&\DGG+&% !.=N.W
MX5O1^5>-(8_W>]"F3@XR,=/;FLBX:S32K6_6]M;B:1MH@2X1F"C&25#;E/7[
MP%1VNM*UR?\ EA'-D.01E1US^8K2A6B]BHV._P# ^C6%[K&W5IF%E#&D2&,[
M6)4 9;((Q].<5C?$EM/TZY%GIMQ)):PW1(Y+9./X2>N!CK5KPMX=U#7O#=Q=
M,;2#3P,F\NIO+1,'!P!U).!@^M;7PX^!4/Q,BU:^AUZPCC\.1I<7!N(RD)#.
MJ=0=Y!=D VJ2=W0<L#%9YA<-1<IO2+U=F]]+:(7*[W..U.W6ZU!Y'B7,Q+]?
MF4?AWJ#2-\>L6\K+\L+D[>=N,=SZ^]7]>\*WO@?76M+V.W:94$LZP3;H[??R
M$W<@_*0V5)&&'.:;;1W&J)<)'$YCM;>:618E^7"*3R?R^IXZD"NBEB85(J2>
MA9DZ;<;)[B:13(N_=A0 V<Y_6M#3KV*PUR.ZA,D9A1I60$J6&#D%JKZ"H32]
MP559R'D:7MC.%P::)TO?MDRD+#'!CRQG+[B -OXFNGETN/H-:YC-K'L5854!
M^3N9L=:M>'I(I(;SC9(L&'_ND,RK@_4'C^N*JK:K'8JNW.\\ D<=?_U_C3;9
MVBM)[A9\/&Z111;.'4@EB6]MO0>HJ)+070]>\)_"S5/$>AK-#=:/:16\)6,3
MJ=^P+\VXX[\#G/.!QW\[U/4S*SR*JM)-$BR'Y?E))&1[X'Y5[EI6K6B_#Z93
M;:;)>:?IN\VWGK]H67RU) CQNWC=NP<D>XKQWPEJD.AZY$]Y;"X@N99@4> R
M,<I'\H08)8[V &1\Q'(YKLS##T*4(1I[VNS"E4E*]S,U&&XGL;B.,><(XS&0
MJG*_= ).TC^(=<9 /(. ;VGZ)J&K>')H;"\MI[&9T8S/'MDMPIR K=5&,9)_
M2NF\77.H1RW,+6MG:3QNC7-O8VJ6ZQF/"&-$C&W,839N?<S_ #,S$M@:OA7P
MQJ&H^%((]L=O9WWFN958MNA/S2%W'& " V . ._7Y"MC+/2V^AT1CU.-O="E
M\9:HZVFF[9YH4:%K6+Y;ABQY?;D;L<<!0 O;%6[/2)OA_;&T\1Z7(VGWQ$H=
M8=MU;E0<,A)&5/&021Z<Y!ZRY>*WT&&"QL[RR2,(T;3%5)WYVHYSN(V\@CCV
MY KI_ ^I-:O<?9UDN8UC*RP3L)X+B4\E1Y@&01G@$CGWKEJ8R487:_KUZ%<B
MN>"?$+0M.\,Z^W]EZC%JEKB.=+A 8UDC;^$J<?,&!!&.H-3V>L*GA_R+F&8P
M^:9%@D4H%^7[P(]<G\JYOQG?6]]\2-4:TC$=JDSN(%0*L0.-P4=L,3P.,#VK
M<UV>.?58)$,@5;>,&!L;0RHJC@<8R*^@PDFZ:<FWMON1U(;&Z:&-%VN))E V
MMR&Z=<^E6[FV@ABF5;JW6=0H$2DMO/4\_P#ZZ33=2_M3Q%']K_=I;VDS9\K<
MK.L3;%/(XR!G')^M4M N9?/2:-XUX\J5YSN49 ]\]J[U+2Y4=R?3?*T^9?WC
MPLQVY W!!U!_,?E6E!>MI2S2_:%F:[5ES&1N1L_*WY9Z>M5M+TA;[5UM[B>%
MEC)9MK?.PZGGCC';VJE+/_HV&D_=W!+(P..<\XQCGC&*'%/5BZDFIW]S?/'Y
MUPT,<?S*D?'&>I_+OBFVGB:XTJX5H9&5LJP"GB,CT^HQ1HT$-_/=+,SJL-I(
M\&<G,G&W/ZU1\EOLJ[F\O9_#^7.:GD3!:NQ:U_Q--KVIM-=R-</C[['H3U'T
M[8%1VUPS0"(*GE+@*/XOK^M0A1%93%7C;E0PV=03SGWZ'\#3X;@(9/FW+P<,
M/O#/;Z]*JRV#0] \.?%>XTCPE81R-YD=O*J>1NVY4\8/\L_2F>+/C7=ZG<"Z
ML4DMYFG22-<_+ JJ ,#ZYR.G3K7"L85M1?1R,L7F&$PR$Y' .1^?Z5),)0FZ
M3:B_>P.=P]CTK-4U>X10R_O6O0S>8[-N)'.,$GD@?6JES<M<.L32O)A>H'7!
MSC/YTZ:[\L>9\VV8$JQ'RD X/UY%-^TK)$S?-(RD_." ].4KK0<F=))X<^U6
M,DEF%O([= \LD:<P\CCKV.![YJ350L6APCR\Q[R "",8 _\ K^M4[OPW>:7H
MS/'=QLEQ&)&1)POEY!.UER#G&#@C-:TVGV\-I#]JDNVFD55V0KP5*;@P9B$*
MG'8^AZ<UYU3,J4/AU('> )6C\:Z-)Y0D_P!+C8 'MD9/X#TK+NT1KB[:5.1.
MRKGOR15C2I/[%UZRN(]1CD^RS+N# J4S^'S 8Y(R!^IJW4XFNOF<,K2,Z@'/
M4FNJGB(U(W0]S0\'>(I/!GB&QN+7S&NA*%"D\*&;#*H/'S9ZU]01I'>:5;W4
M,;1K=*',<BA7C^N#Q^%?+*PKJ&V:,PRLV8RK=5SDY'H17T%\$M?;6_AE:HS>
M?+:L;4REP[2!3QTYX Q^%:2ONA'??"UEL_$DBLZ;G@9%&<%FRIX]3@$_A5'X
MB?-XON6/*_(0<?>PBU8\%YC\56>Y2.7/U^1JY?\ :/\ 'TWPQU:246[2R:DH
M-L0A900H&6/0#(/7GCTYK'E]XHX'X[_$^^\#+:V.EW"V]Y=(9)7"@M&O!&#V
MS]*\+>[NM5U.>YG:22XNF,KS.0WF'OS]36AXLU_4OB%KMSJ%](NZ2,(!TVX(
MZ#\,?2G6FE2+&FY6^<;%(0\CV ST]ZN.FI)GV%H)I5"H9+C!WX7[O^'X5H)I
M'V=HV<E9I2=I<?*%]*<8I(-0AC\^.)9F*R*Q V^G.< =.3BM32;2&W\17%E<
M:I875Q J@HCD1YSS\[ 1!L \$@GMDD9RK8B,%>VO8##MFWNRJK2,S#Y5?"CM
MQVY%7HXOM,TS&-%F7&(VSA6X_I5O6-&DBE5].T&[AL48%K@RL5E!Y^^5VY/H
MI8\'KUK'U+7[6":1&\R$N?E9^<@8Y)'?K]*BAC%45_\ @BZENZ/DJ9$VJQ(4
MEOF[_P L9JA<V[>9&JKN9&+,R+\J@=.2/IQ4CZDMQ8-);LKQY*AU/!)_6G"!
M6$+L[!G#'Y>-V#MY_*NW1E7(II5EW3-'F:9MPZ8^7@?0_2I&C:<(\VZ21E"C
M=P5!![=:;)M!97_=\?.3C*=^#[\4V_FDM2RMM^?:R<;CC@[OKCBI,A5VQEFW
M".%4"A_\15RSDYAYQR-A)P&],U2A=6T\JRNRNV& X(Z9%6A;R:;=7"R>3+Y+
M[651@#''X^M&FY70=,[12-YRJL6[G:<GCI^M4U*2Q,5\SY>K*1M8DGGCV/:K
M%K']KU5+<,H\YR2A!Z_R[=JIM<- 641C"\C X'UHC'L"C?4EMI0+R*1(V1H0
MV2?NY'\_6E^TR3%C\K'=D CB7G[V3ZT0P^=;7 ;YE6)Y!M/IR/SJ.PU&98I(
M9"J))MDR6R6&.F/\*IM;%>@T>8MK\\<FY6:106VCMU^GO3[6<R0_O1%N88R#
MAB!R/KTI\5PD\MQ(6?R;=E;8.&E4'#;0?0?GQ6J;S2])UY9I-.ENC RR(Q8+
M#G(8+@'++@X(R/3WI\VE@,JVFAMT\RW&YL>8HDYV]>#S^G7%36\9O(%;RS&6
M&<*,<@\8%==XQT*W\%:7>:08+>Z$=S%?)?HOSI')"#Y7X9!/^37'Q3&1=DDD
M?DYPLK_> )&>!UZ9SZ5E*6]R6C2M]"D&GPR6ML\D\D#7$@4EOE'5R/Q'7O\
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M:CFY=&&YKV9A7PZT<T,8N(I"T97;F0D#&[OQCCM64$72[SYMNUF$A)7(8<9
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M#MQP>_%0Z4+.35;Z/=))/)M+M.JK'NW94*1@G'KQTJ%+]KC7DL=0DD-LLKK
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M)<PI'&Z+"NU"4(;)V]@"20!C/>DTK^Q;?S&T6.>^O%&PE(SY,BC#/E3]W )
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MNV]F:2+RYOFW*6 54.3C@=._Y5]%1C[NAG?J:6CW@V7SF..XC:V9%\Q?N,Q
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M0-C?Y_"O+?V\=6M[EM(M2[+=##QE6^94S("<?E^5=MX=N5GU^P^;YFN8@?\
MOH5Y)^VJMU%\7=/N)(;A;-;,01JV&! =B2H'J3GGG'Y5?-=ZAU//-/BC"J9
M\LTB#8S854&?\\'FI()%OG\N91(/,(.YOFR,=/3GBI;_ %*WB@RR,PX*C;D#
M&#C/;D9[]:IVFIVZZC"IVPIOWO(6)VJ.?>B4^5%:%ZX\-Q0Z+*TWF;^<*D9V
M^9C"QENX&<L<@ # R>*U_!5U8Q7D<>L:?I-E#96Z1NJV*^9=-G!=^1SU)/7\
MS6W836W_  C-G-?6LRA;D&SA5O,7^$[I>_4DE1T((;' *Z[\1]&OF="MI=6D
MDGEW6Z+<XR22RD?,R@+R5SC/N,?.XBM.JWI\R8ZLF;Q/'X7TZZM=8ATZ^78\
M]O;6^5>T+1G#,^,.V  %/&X#!(.:\V\2A?$%NL<,,:M'#Y>_&)6X()/;.T@=
M\4A\31VDVI01PLWVN821LSG]T ?E(!_V>!GH#["J.F7:K?\ EW,C*D;$1OG#
M+Z@#N#_6NC#T_91NRM+:F79:+)HFW@L%.1NP<_7L?I6E)J/]HAEE58_,;.(Q
MA5'7IU_^OZ57O- MY;B2\CN7G*QELNZJ%R>&YP /8 DD8! .17AF6[@4X W
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MWGW=O*NPQPJ HE)[=]H QDX_#%9-CXO&J3"+['#^[8E;9)&.T!?E)W,=Q//
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MH;QC;0Q;E:* (JH#D=203GUSP!BGZ1X/.HZ>LDBR:9"\C.RG)0C&2,CN>.G
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MQP7 RKMMX!!/-=AX!U*W.FPR:FS+=1MMC)9ES@$;O0\']*XZW$GVHJS_ +Y
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M('ID,X''&,XS;FTADDDVJZQ[MWRD,Q''\JKSM]I7=)'Y10[E(/!Z\?C35A=
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MAN)83=8@>82,N5'5%Q@JV  2?ZU&@Y2&6KPZC%+)92R0P_ZN*WD83J%&>ID
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MN2,9'(P,YSBNF36O[/T.&'YKFX8+ I,(5UW#)P#C QFJE34)7-(4^IY]X/\
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MSN/\)['VIDEBYE9O,+>7R1G)],YKGG@J;?-#W7Y#N=!J'PWN(-_V*=;@!?\
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M!GNKBXLX6AEPD=LJCD =PO;&?7M5/0Y;?QEXM-QHUHNEPQVQ:;[1B15;J,8
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M0"8^NT=@&)Z 5ZL<=.*W,I85/H?2FI>-M'TO4$M_$%OJ7@NXD4HJZG"5@G8
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M\D#20EMV[ '=<>F?QJY+<R1R1K%Y<1V$%<'#$_2F+>?96D$T3('8$#L> /\
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M."<\N>HQDG KL=$_;/\ CK%\+H/LGQ8\8^=;HQ$]Q>>=(0KDG)(.X[!CGO\
MG7E/PK076@>-?,3R6L]"*,),+L;[7;J!M(ZX+=,$8^@KH-&F4_"J5?E#QP3I
MD-ED/S'G\"#^-53=JDEZ&DH^ZK$O_#>W[0E]<3LWQB\:I;S-EHEG6+DG)8;0
M.Y8X QS2>.?C?XV_:,^$GB2W\>^-O$OC%=%BLI+:VOI@T-NQN(T,@ 'WRH*Y
M8G(8DDG!KS.^GD22,+MZ'!_G72?#Z+=\+_B8SR"%38V$9*\@N;M""WT /;WS
MQBN?,8_[.V%.T3R@>'K/5]?U&S86Z# O(6Z21HV0RMCK\P)P1C(SUQ56[\&I
M-:%K>::.15;+L<X/8@#OTZUV,_P[UBQUK3=8^R;H=6TAY!()0/,6&4Y!)XW<
ML0,YQDXP0:HW!2*US)]Z3[H5?FSUP0:^4E)J5[FVAXY>^/M)^PWD3K<"\MYQ
M:R/(,E&^<=>ISM)Z<$_A7(^']"O+S7Y/+DF:2-'"R;_FW'@*<\\Y^N,&NIA\
M SV_C;59"L=[']L-Q(LK[%60KO.>F/O?D/I4.FRS1>)DU&_LA%8[!""P^4$$
M -@<[<>_OTKWH5%"_L^J3^](S5S&UG3I-:DL_P#EWU*]GW"%5"P_PX&3_$.^
M>F<=:U_!OPMU"\\33>)-)%O-#IL,C>7M?9\A "$< $Y)QQG:W)J3Q3:S:N]B
M0RS7%A<F.!D.U5'RD9[\DCGV[Y!KH)=/6RT22TT_4;J*XU E9;B6ZV"")<$J
M5. <EB #QG.?2MZ==*"N**[E+X-?$(Z_=6^GM8+]J:#A'&=[KG(7HOS8!W?6
MNE\2:EI,5B+BZ6UAF\KR[B*,DVZ8)^4G&3R<\5RL'ANZ\$:O8P1I&FQ=R2?:
M!O9=P!!P, [0>.0>GKB/QC']ON)+=;AK>U!C(&>"Q&-I]\]/P]*YJ\8.KSP>
MX]4K&A:IH<VAQ_9[66:.-MS)O#-R<*2ISC.?KQS5'4[ACJ7V>*ZGDN)F$!A"
M+MA0,#DH,\\=2>^*32_#=UX5@DDMUCENKB3"VT<J^8X!QD$@GGCT'7KUJI#X
MON-!OPL.AW(M'96N5E0O(VTX+$@C/.>O%8.+=^5W!>9U$FC7$\UO9MJ&H6_V
M<'8S(/+E4C&T=\C';WJC>>-(?#6N_98;NV55'[Z:X!D=CTVCGY5'7'<CTJO+
MXG74[B\NM.N9FB90=WE92%0-I./8G'0CDU7NO"$VNRKJ$:V\=\PQ/'QB?_;)
M_#IU_.L:<+RO(KD+VK-'J&BSSPW,,UQ=2;)))55(U Y V^G0^O/2N7T_QFD6
MLPKJ&CV%U;VOWX8V9E&_@'!QD_*>,D#K6N?"Z^(X;>S2U>WNK7<S1F7'FY!(
M ]^.A'-=/X9^&:R:/:WEJMG#.J8FC?+,ZDX4MG(!R?;&*]"G4A"'+(##A\?:
M?K%](MK;_P!DZ:J);QP2ON1NQ "@9Q^>!4VLW<]O&UNMP\DD7,487!*YQP>_
M!!-99^']S:O,]M:AH)G,S,RG:6!X'MVJG-=:I8^,Q:K;7BF!<-"$^^3SD<X9
M>^??ZU,>79 =9%80K'$+RSDAO)9  T(#)(O;(_7/U^H$6 13;I%-O'N6/>P^
M8G_9X)5>1C]<4T7E]L$TEU?*JN$NSL#8B.?D*]<9/4>G-7=4UIHKJ,E5>7A8
MU=D9X01Q@8R0,# ;H1]:Y)+4&RAIZ7+K-'(+6:12/+D;<Q(_A'.5P, X^G7K
M75Z1/>7+QVUQ#'>/(@C+&-%V ="!QC_]0S7.:)/:K=R_O/WENH;<XW$GOQGV
M_2KNEW]UIFGR7MJ(6A=P\DTGS&0EOF&[.?E''4XQ]:YY[V"+[G1QV5SX8O)'
MAMX)9XV#F%W7Y6'=LG;5C3=!.LP/>WERDUPQ"2DG.PXZ*,$8_P#UUA^*M5EU
MV*../RS#'C=E<8;!/X]:YZ^\37FL3K8:7,[00X:=X2&9C_=]<8JZ<9&G,7_B
M)XGT[P/;S0MIJZC#<2B)@TWW"%R/4C YZBL";^S?%:0J+>VN)+J4B,J=HA!&
M&&1P6&!QU/)J,>&K:9[AKBS:X:X^9II)2)%?D9SU8D$C\*MZ$T/@R.01VL,$
M'#LW_+1<<;@&R1D?0<YQ76IQTY=S.UU<S+'PS<:3'/;^8WV.WF%Q+/Y3?. ,
M;!SD_6O/+SQ==>'_ !E>0OFX6V8(J(<?N\ H?J1@D=CFO:H?B1HWB^T6*UGM
MUMXP2T;MB57PW7D?*,@D=Z\*^(.LR>(_&=]=1QQJI9HD90BY4$[3QP2?Q)_E
MVX6\DW-$=;':: T_BK459((["$*\UT4+-(!M!9\=""<#ZGG%7-*FC8Q0Z"LR
MPSR_/=2)M;G 7([=^GKS7,>!/$%[I$;32++-';Q;HLMMP,,"./X?6NOL]9:W
MT*&Z7[+&UTK\)E0J <XY/.0*YZV%=-W_ *^8I3TN8 N9KV[BT7SF^RZE.%:1
M02T$Z2-AU5N0&^7..W'O6]XAT_[+;M97NR^D4^263Y)E"C/IEEW8_.L>[T2U
MN[J.XBAFC\K!/DL7PP.1[YZ<>U;F@M>R37IUB.:-KDO)"\?_ "P+#< #PPXP
M,'KCU%5*7NV$M7<RO#_BF^TQ9(;E(=/=CL,C1$%/3COP,_2DUO2K76]8CGM[
MSSK=2QE575T##!*[3]1C/^%'B]3KMQ9Z7#\MQ%AM[-^\D48_')&?RQ6UI?A3
M3O#6K2;I+A;=%+E^&W,<-L?CJ.1FL98B4%HS3<36_A_920VJ06MY(UN,RR!P
MJS(0-NPX/TY/?M61%=76B0S1Z?-/#+:R,70, R3 !-R]\-E?R[XS77M+)8?:
M)+>2.[&UI(L1-@KQA"O^>G:N=T6)M2U*ZOFD^SZAA9 BOD%1D'[N>V.!GH.#
M1AZ\[/G=T1**W0^Q\6^.;[0I(8]2AM=/("R06<<<<S#C&X(H+#()R<GBK7BC
MPU/KXMY/[*FL9F2/,9SB0;>9#U(!/2K_ (3^.OAOPVC6MUH+66H:?F*21%W>
M8HX9<DY!SDCMS3Y/B-'X@UZ^U-5N?L\4@,5LLF=D*J/+1L< $#/'J1VYTH^U
MC4O&%EW[D\VFIAW/@73TN)(M0LYEECYF$C8#$DY QZ8_6L>TU+5[S2H8/M6I
M2:6K-$BNQ:/:NUAE?NX'.#_*NJM_B1<:K>[9;>WCN+E_,BZ@<M\NXX.0.?\
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MO/#5Y<7BW"R6MG(-LZ8D1NF,9&6/.!BNH@TVWUO3)(_LL:V2QA6!8JVT9(.
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M2;'"YBBA * ,"K#< QKTHW27<RE+N>*^,/[6A^+?QF;7K>TTW7K>:9-3MK<
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M NUCDX'RD9QQ6E>:[)=(T>5SLQ$ ,$8/WC]1D5JZ9XMDL;2YA::2.&^ 6X@
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ME6Z']W#P@ ;^]PB@@Y4G).<\?6_@SQY8Z%X;NOM>BVVK-E#$)9/*\F4(RDG
MRP&<@9 R!D&O 5TV5%5ED)VY(0<<^N*]S_8G^"<O[1/Q5M='O;J:W\/Z;"][
MK4T3B-TC'RHH)! 9Y"H^F[CCCMC"S31R\S;)_P!I+7K/2/B_K(6>-<F, $G/
M^I3)^;^9]^G2O.[SQ?I=W%E[F%<)N/S#IG&??/\ C7Z.^-O%OAOP_<):6_A'
MP'JC6L9@DN-2T"WNKB\V85"[$98E1M8G.5P/KY-?:UHYUV&9_AY\+/E(QN\*
M6I ;YMQ/8JP<@K@9.#G(%>TJT'L3).Y\6Z+XCM-3^&GQ+NK>ZMS':VUC"4#
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MML/"]Y;Z>MO)JAMVMW<E(SD7*G!7!XY&,=NGO6LFDWL"QQ[Y%FD)D$S*/W@
M& <]O?FO0-3D8AH[ZPD9)!\DN,LC=-RL._7D^I^E<UJ6AWK10W%KJ$=U:0X#
MV\JE63UVDYSV.#QQ^?3'$J6^A#V,+6XIK23*R0V;7 5F<1")0?;KR>!R3G%9
M<)^QB1KBUD%PLF Z(?WH/&[TX_K6UXQCN+J>.2SCLX6F_>33RQJ9"PP.FTKC
M _ ]JS_"^KZE%J\D5Q)+<2*K*P,@983U1P !U!8' X'.&_AWA)M[AS(K36MQ
MIUHNY+>XL[R4$D+M\QL#'0YSWXK./@R1IF55(\O=LBD_U@/.WC';-=^OAQ=/
ML+C[/;"169C(O#;2<;AGCIT_ED<UA:LS7,%O=V,S88HL4CG:T8CX(R,_=9 .
M?Q]*WIU/,+&#HO@^ZO[:XTIH9+6>0J8_,4J\I!PPCQ]Y3N)X';MBL?Q9X*U/
MP3=Z@NJ6=E'#= BW1]V]N<!AQD8Y/8CVKT+[%<:LVGZA:W$@ADN$@>)MLDEN
MQX.'^]@YX_X#Q5KXF^&)["R>;:&O+:(NRR!I)#S@+\PQGOC/XUM+$\NAG*,W
MHCS_ $6]U2X\.R:/:P_9I%A\QE4F1YU*G)"GG! YX]^.*=-!+I^@'5!;ZA:Z
MM;%=DL3$PR+D9S^ /YT326_AK4--O[B!;65Y$\Q4Q(JD?Q KG\%'/L*ZC4M1
MW^%5FDOK\PS.3']I9VW GL7Y"^P&.AYYQE*6JE);E1O;4\QOK&'4(TN/+:&:
M:/>59MS2'^]],@^]0Z9:7U_J4?DJ?*C0.K1@DX7&>!UQG.#6M>7%QHFD1R+.
M+]KN)K>,- (S%@_,H/.1G)__ %UHW%Y_PB_B)HK?3YXEN(<INCVCE?F..ASZ
MUWRJ**"ZZ'*^,YH5U&:.Q+M'-(3G:%W [>P[[MV?J!74>$O#&EZ]JJV<QDL1
M;Q*.6#(6RX8GOSMZ9&.3WXJ6/AI=3F66-9$82NP(7"@\[!SW9@![@GTKH(_
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MWCP,8ZFO=/A7^P[XA\7^%H[SQ!=:=H]K?Q&:.&5I!=0@YQO5%78W(PH;*YY
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MXG@A(\M/*WJC'[QP!QGCDD\'TKTO2?!6EZ;8.L5JLK.@603,9/,.!U!XSQV
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MAT;&<;2I!'^(KZE_86_8C^(WQ9^ ^G^,?"WC#PK;^7>-:K!JNC_;O(6-_,5
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M1X5I^I>7*S2R0RP\,TT?&>N23GGIGT%6_!=EJ_BKQA'H^E:>K,[MYTIDVI"
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E;MM,I!8 ?AS6[I_@[2YO,$UQ?32*V,Q0?)C\2*Z'*VY*5S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773459072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jul. 26, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">exel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,904,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774110016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 135,212<span></span>
</td>
<td colspan="2" class="nump">$ 151,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">214,044<span></span>
</td>
<td colspan="2" class="nump">268,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">43,125<span></span>
</td>
<td colspan="2" class="nump">40,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">5,425<span></span>
</td>
<td colspan="2" class="nump">3,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,433<span></span>
</td>
<td colspan="2" class="nump">5,416<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">402,239<span></span>
</td>
<td colspan="2" class="nump">469,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">26,413<span></span>
</td>
<td colspan="2" class="nump">55,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">4,650<span></span>
</td>
<td colspan="2" class="nump">4,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">18,684<span></span>
</td>
<td colspan="2" class="nump">2,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td colspan="2" class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">862<span></span>
</td>
<td colspan="2" class="nump">1,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">516,532<span></span>
</td>
<td colspan="2" class="nump">595,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,037<span></span>
</td>
<td colspan="2" class="nump">6,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">15,555<span></span>
</td>
<td colspan="2" class="nump">20,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">14,680<span></span>
</td>
<td colspan="2" class="nump">14,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">7,919<span></span>
</td>
<td colspan="2" class="nump">2,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">109,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term loan payable</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">31,255<span></span>
</td>
<td colspan="2" class="nump">19,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">21,225<span></span>
</td>
<td colspan="2" class="nump">16,923<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">97,671<span></span>
</td>
<td colspan="2" class="nump">268,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">253,663<span></span>
</td>
<td colspan="2" class="nump">237,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">16,687<span></span>
</td>
<td colspan="2" class="nump">541<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">368,021<span></span>
</td>
<td colspan="2" class="nump">506,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 293,727,630 and 289,923,798 at June 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">294<span></span>
</td>
<td colspan="2" class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,097,379<span></span>
</td>
<td colspan="2" class="nump">2,072,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(119)<span></span>
</td>
<td colspan="2" class="num">(416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,949,043)<span></span>
</td>
<td colspan="2" class="num">(1,983,147)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">148,511<span></span>
</td>
<td colspan="2" class="nump">89,318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 516,532<span></span>
</td>
<td colspan="2" class="nump">$ 595,739<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760909776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">293,727,630<span></span>
</td>
<td class="nump">289,923,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">293,727,630<span></span>
</td>
<td class="nump">289,923,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771965488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">$ 88,004<span></span>
</td>
<td class="nump">$ 31,618<span></span>
</td>
<td class="nump">$ 156,881<span></span>
</td>
<td class="nump">$ 40,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
<td class="nump">23,014<span></span>
</td>
<td class="nump">10,962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">99,008<span></span>
</td>
<td class="nump">36,252<span></span>
</td>
<td class="nump">179,895<span></span>
</td>
<td class="nump">51,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">3,014<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">6,217<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">28,214<span></span>
</td>
<td class="nump">22,984<span></span>
</td>
<td class="nump">51,424<span></span>
</td>
<td class="nump">51,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">40,727<span></span>
</td>
<td class="nump">35,823<span></span>
</td>
<td class="nump">74,987<span></span>
</td>
<td class="nump">70,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (recovery) charge</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">71,895<span></span>
</td>
<td class="nump">61,388<span></span>
</td>
<td class="nump">132,596<span></span>
</td>
<td class="nump">125,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">27,113<span></span>
</td>
<td class="num">(25,136)<span></span>
</td>
<td class="nump">47,299<span></span>
</td>
<td class="num">(74,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other, net</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,259)<span></span>
</td>
<td class="num">(10,451)<span></span>
</td>
<td class="num">(8,679)<span></span>
</td>
<td class="num">(20,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(6,239)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,239)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(8,876)<span></span>
</td>
<td class="num">(9,702)<span></span>
</td>
<td class="num">(12,228)<span></span>
</td>
<td class="num">(19,790)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">18,237<span></span>
</td>
<td class="num">(34,838)<span></span>
</td>
<td class="nump">35,071<span></span>
</td>
<td class="num">(94,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
<td class="num">$ (94,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income (loss) per share, basic (in shares)</a></td>
<td class="nump">293,188<span></span>
</td>
<td class="nump">229,310<span></span>
</td>
<td class="nump">292,029<span></span>
</td>
<td class="nump">228,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income (loss) per share, diluted (in shares)</a></td>
<td class="nump">311,219<span></span>
</td>
<td class="nump">229,310<span></span>
</td>
<td class="nump">310,759<span></span>
</td>
<td class="nump">228,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773698992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
<td class="num">$ (94,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">207<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,863<span></span>
</td>
<td class="num">$ (34,667)<span></span>
</td>
<td class="nump">$ 34,653<span></span>
</td>
<td class="num">$ (93,700)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other comprehensive income consisted solely of unrealized gains or losses, net on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income during those periods.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758820800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustments to net income (loss) resulting from realized gains or losses on sale of securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive income, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65896914&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774503824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 34,356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (94,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">6,239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and debt issuance costs</a></td>
<td class="nump">182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Accrual of interest paid in kind</a></td>
<td class="num">(11,825)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on sale of other equity investments</a></td>
<td class="num">(639)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="num">(2,581)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,087)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(4,779)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseAccruedClinicalLiabilities', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">549<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseinAccruedCollaborationLiability', window );">Accrued collaboration liabilities</a></td>
<td class="nump">5,873<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">28,159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">195,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="nump">7,457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,346<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">74,393<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">131,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,312)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale of other equity investments</a></td>
<td class="nump">639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments', window );">Proceeds from maturities of restricted cash and investments</a></td>
<td class="nump">5,650<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchase of restricted cash and investments</a></td>
<td class="num">(6,150)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sale of investments</a></td>
<td class="nump">37,294<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">200,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(154,809)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(199,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">81,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(143,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">12,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(2,331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of convertible notes and term loan payable</a></td>
<td class="num">(185,788)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(172,086)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(16,474)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">151,686<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">141,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">135,212<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">129,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow disclosure - non-cash investing and financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Construction-in-progress deemed to have been acquired under build-to-suit lease</a></td>
<td class="nump">$ 14,530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseAccruedClinicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) accrued clinical liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseAccruedClinicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseinAccruedCollaborationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseinAccruedCollaborationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with funds and investments that are not available for withdrawal or use (such as assets held in escrow or contractually limited as to use or disposition) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764224768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the commercial marketplace. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;tablets approved for previously treated advanced renal cell carcinoma (&#8220;RCC&#8221;) and COMETRIQ</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is a formulation of cobimetinib, a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The condensed consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the United States (&#8220;U.S.&#8221;) dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended June 30, 2017 and July 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended June 30, 2017 and June 30, 2016, and the years ended December&#160;31, 2017 and December&#160;31, 2016, respectively.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating results for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Correction of an Immaterial Error</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the third quarter of 2016, we identified errors in the Consolidated Balance Sheets and Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for 2015, 2014, 2013, and 2012, and in the unaudited interim Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for all prior interim fiscal periods from September 30, 2012 through June 30, 2016. Specifically, in 2012 we incorrectly calculated 1) the allocation between Additional paid-in capital and Convertible notes of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$287.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> aggregate principal amount from our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Convertible Senior Subordinated Notes due 2019 (&#8220;2019 Notes&#8221;); and 2) the amortization of the debt discount associated with the 2019 Notes during 2012 and all subsequent periods.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Having evaluated the materiality of these errors from a quantitative and qualitative perspective, management has concluded that although the accumulation of these errors was significant to the three and nine months ended September 30, 2016, the correction of these errors would not be material to any individual prior period, and did not have an effect on the trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 99, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Materiality</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and Staff Accounting Bulletin No. 108, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Because management has concluded that these errors are not material, we will correct them prospectively when the consolidated balance sheets, statements of operations, comprehensive loss and cash flows for such periods are included in future filings.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Comprehensive Loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These errors did not affect any other caption or total in our unaudited condensed consolidated financial statements as of and for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. See &#8220;Note 1 - Organization and Summary of Significant Accounting Policies&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the amounts of the corrections and the amounts that should have been reported for 2015, 2014, 2013, and 2012 in the affected line items of the statements of operations, statements of comprehensive loss and statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in accrued product sales discounts payable to our customers as of December 31, 2016 from Other current liabilities to Trade and other receivables in the accompanying Condensed Consolidated Balance Sheets. We have also reclassified the related balances between the Changes in assets and liabilities line items in the accompanying Condensed Consolidated Statements of Cash Flows for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We operate as a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">single</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reportable segment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-09,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"> Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-09&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, and no prior periods were restated as a result of this change in accounting principle, with a cumulative adjustment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to accumulated deficit and additional paid-in-capital as of January 1, 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-09, we also recorded an increase to the federal and state net operating losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for excess tax benefits previously not included. The resulting increase to the deferred tax assets of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is offset by a corresponding increase to the valuation allowance, resulting in a net </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impact on our income tax expense and our Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on our Condensed Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in cash provided by operating activities by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> along with a corresponding increase in cash used in financing activities in our Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2014-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASU 2014-09&#8221;).&#160;In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which delays the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, but allows us to adopt the standard one year earlier. We will adopt ASU 2014-09 in the first quarter of fiscal year 2018. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have substantially completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of revenue from product sales. We do expect that ASU 2014-09 will impact the timing of recognition of revenue for our collaboration arrangements. We expect to reclassify deferred revenue to retained earnings (a concept known as lost revenue) for amounts associated with certain of our collaboration arrangements upon recording our transition adjustment to accumulated loss on January 1, 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration arrangements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758474512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement (the &#8220;Ipsen Collaboration Agreement&#8221;) with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ipsen Pharma SAS (&#8220;Ipsen&#8221;) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the commercialization and further development of cabozantinib. Pursuant to the terms of the Ipsen Collaboration Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ipsen </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan (the &#8220;Ipsen Territory&#8221;). The Ipsen Collaboration Agreement was subsequently amended in December 2016 (the &#8220;Amendment&#8221;) to include commercialization rights in Canada in the Ipsen Territory. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the Ipsen Collaboration Agreement, Ipsen paid us an upfront nonrefundable payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in March 2016. Additionally, as a result of the Amendment, we received a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> upfront nonrefundable payment from Ipsen in December 2016 and, as a result of the approval of cabozantinib in second-line RCC by the European Commission (&#8220;EC&#8221;) in September 2016, we received a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone in November 2016. We are receiving a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> royalty on the initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of net sales by Ipsen, and are entitled to receive a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> royalty on the next </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of net sales by Ipsen. After the initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of sales, we are entitled to receive a tiered royalty of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">22%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> on annual net sales by Ipsen; these tiers will reset each calendar year. We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the Ipsen Collaboration Agreement; global development costs for additional trials will be shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">35%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of such costs, provided Ipsen opts in to participate in such additional trials. Pursuant to the terms of the Ipsen Collaboration Agreement, we will remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities. As part of the collaboration agreement, we entered into a supply agreement pursuant to which we will supply finished, labeled product to Ipsen for distribution in the Ipsen Territories at our cost, as defined in the agreement, which excludes the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (&#8220;GSK&#8221;) on Ipsen&#8217;s Net Sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Ipsen Collaboration Agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Ipsen for all development and commercial activities, research and development services, and participation on the joint steering, development and commercialization committees (as defined in the Ipsen Collaboration Agreement). We determined that these deliverables do not have stand-alone value and accordingly, combined these deliverables into a single unit of accounting and allocated the entire arrangement consideration to that combined unit of accounting. As a result, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, received in the first quarter of 2016 and the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> upfront payment received in December 2016 in consideration for the development and commercialization rights in Canada are being recognized ratably over the term of the Ipsen Collaboration Agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the European Union. At the time we entered into the Ipsen Collaboration Agreement, we also determined that the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone we achieved upon the approval of cabozantinib by the EC in second-line RCC was not substantive due to the relatively low degree of uncertainty and relatively low amount of effort required on our part to achieve the milestone as of the date of the collaboration agreement; the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was deferred entirely until the date of the European Medicines Agency&#8217;s approval of cabozantinib in second-line RCC in September 2016 and has since been recognized ratably over the remainder of the term of the Ipsen Collaboration Agreement. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestones for the first commercial sales of CABOMETYX in Germany and the United Kingdom were determined to be substantive at the time we entered into the Ipsen Collaboration Agreement and were recognized as collaboration revenues in the fourth quarter of 2016. We determined that the remaining development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. Reimbursements for development costs are classified as revenue as the development services represent our ongoing major or central operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the three months ended March 31, 2017, we reclassified </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of deferred revenue to Accrued collaboration liabilities and Other long-term liabilities, and accordingly adjusted our amortization of the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as a result of a change in operational responsibilities for certain clinical programs in the Ipsen Territory. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> toward the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of reimbursements due to Ipsen for these clinical programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;Note 2 - Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for additional description of our collaboration agreement with Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of upfront payments and deferred milestone</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of supplied product</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty payable to GSK on net sales by Ipsen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues under the Ipsen Collaboration Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the Ipsen Collaboration Agreement was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$219.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement (the &#8220;Genentech Collaboration Agreement&#8221;). Under the terms of the Genentech Collaboration Agreement for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. The profit and loss share has multiple tiers: we are entitled to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of profits and losses from the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of U.S. actual sales, decreasing to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of profits and losses from U.S. actual sales in excess of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$400.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In addition, we are entitled to low double-digit royalties on ex-U.S. net sales. In November 2013, we exercised an option under the Genentech Collaboration Agreement to co-promote in the U.S. In 2015, we began fielding </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 3, 2016, we filed a Demand for Arbitration before JAMS in San Francisco, California asserting claims against Genentech related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&#8217;s commercialization in the U.S. Our arbitration demand asserted that Genentech breached the Genentech Collaboration Agreement by, amongst other breaches, failing to meet its diligence and good faith obligations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 13, 2016, Genentech asserted a counterclaim for breach of contract seeking monetary damages and interest related to the cost allocations under the Genentech Collaboration Agreement. On December 29, 2016, however, Genentech withdrew its counterclaim against us and stated that it would unilaterally change its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy, both retrospectively and prospectively. The revised allocation approach substantially reduced our exposure to costs associated with promotion of the COTELLIC plus Zelboraf combination in the U.S. However, other significant issues remained in dispute between the parties as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Genentech&#8217;s action did not address the claims in our demand for arbitration related to Genentech&#8217;s clinical development of cobimetinib, or pricing or promotional costs for COTELLIC in the U.S. and it did not fully resolve claims over revenue allocation. In addition, Genentech&#8217;s unilateral action did not clarify how it intended to allocate promotional costs incurred with respect to the promotion of other combination therapies that include cobimetinib for other indications that may be developed or are in development and may be approved. As a result, we continued to press our position before the arbitral panel to obtain a just resolution of these claims. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 8, 2017, the parties settled the arbitration, which was dismissed with prejudice. The settlement does not provide for payments in settlement of the asserted claims; as part of the settlement, on July 19, 2017, we entered into an amendment to the Genentech Collaboration Agreement (the &#8220;Genentech Amendment&#8221;) which provides for a revised revenue and cost-sharing arrangement, effective as of July 1, 2017, that is applicable to current and potential future commercial uses of COTELLIC. See &#8220;Note 13 - Subsequent Event&#8221; for a further description of the Genentech Amendment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. losses included in Selling, general and administrative expenses</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,630</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,923</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">A portion of the accrual for losses for </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;"> were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech&#8217;s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S. losses under the Genentech Collaboration Agreement include our share of the net loss from the collaboration, as well as personnel and other costs we have incurred to co-promote COTELLIC plus Zelboraf in the U.S.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Royalty revenues from the Genentech Collaboration Agreement are based on amounts reported to us by Genentech and are recorded when such information becomes available to us. For prior periods, from the launch of COTELLIC through December 31, 2016, such information was not available until the following quarter, meaning that historically we recorded royalty revenues on a one quarter lag. Beginning in 2017, such information became available to us in the current quarter. As a result of this change, during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in addition to the royalties reported to us for that period we also recorded </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in royalties for the sales activity related to the three months ended December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2017, we entered into a collaboration and license agreement (the &#8220;Takeda Collaboration Agreement&#8221;) with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the Takeda Collaboration Agreement, Takeda will have exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The companies have also agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration will be governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the Takeda Collaboration Agreement, Takeda paid us an upfront nonrefundable payment of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2017. We will be eligible to receive development, regulatory and first-sales milestones of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$95.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to second-line RCC, first-line RCC and second-line hepatocellular carcinoma (&#8220;HCC&#8221;), as well as additional development, regulatory and first-sales milestone payments for potential future indications. The Takeda Collaboration Agreement also provides that we will be eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;associated with potential sales milestones. We will also receive royalties on net sales of cabozantinib in Japan at an initial tiered rate of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">24%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;on net sales for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of cumulative net sales. Thereafter, the royalty rate will be adjusted to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;on annual net sales.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Takeda will be responsible for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the costs associated with the global&#160;cabozantinib&#160;development plan&#8217;s current and future trials, provided Takeda opts to participate in such future trials, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the Takeda Collaboration Agreement, we will remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration. As part of the collaboration, the parties will enter into appropriate supply agreements for the manufacture and supply of cabozantinib for Takeda&#8217;s territory.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of upfront payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues under the Takeda Collaboration Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There was no such revenue during the comparable periods in 2016. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the Takeda Collaboration Agreement was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Takeda Collaboration Agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> following the first commercial sale of cabozantinib in Japan shall constitute a material breach of the Takeda Collaboration Agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the Takeda Collaboration Agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the Takeda Collaboration Agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the Takeda Collaboration Agreement upon </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">twelve months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Takeda Collaboration Agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Takeda for all development and commercial activities, research and development services, and participation on the joint executive, development and commercialization committees (as defined in the Takeda Collaboration Agreement). We determined that these deliverables, other than the commercial supply and joint commercialization committee participation, are non-contingent in nature. The commercial supply deliverable was deemed contingent, primarily due to the fact that there is uncertainty around approval in Japan, which is dependent on successful bridging study results. We also determined that the non-contingent deliverables do not have stand-alone value, because each one of them has value only if we meet our obligation as a whole to provide Takeda with research and development services, including clinical supply of cabozantinib under the Takeda Collaboration Agreement. Accordingly, we combined the non-contingent deliverables into a single unit of accounting and allocated the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> upfront fee to that combined unit of accounting. We also determined that the level of effort required of us to meet our obligations under the Takeda Collaboration Agreement is not expected to vary significantly over the development period of the Takeda Collaboration Agreement. As a result, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, received in the first quarter of 2017, will be recognized ratably over the development period of the Takeda Collaboration Agreement of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We determined that the development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Bristol-Myers Squibb Collaboration - First-Line Advanced RCC, Bladder Cancer and HCC Combination Studies </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with Bristol-Myers Squibb Company</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(the &#8220;BMS Collaboration Agreement&#8221;) for the purpose of evaluating the combination of cabozantinib with nivolumab or of cabozantinib with nivolumab and ipilimumab in various tumor types, including, in RCC, HCC and bladder cancer. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To date, a phase 3 trial in first-line advanced RCC and a phase 2 trial in HCC evaluating the combination have been initiated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the terms of the BMS Collaboration Agreement, each party will grant to the other a non-exclusive, worldwide (within the collaboration territory as defined in the BMS Collaboration Agreement), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts will be governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the supply agreement entered into between the parties in April 2017, and costs for each such trial will be shared equally between the parties, unless two Bristol-Myers Squibb Company (&#8220;BMS&#8221;) compounds will be utilized in such trial, in which case BMS will bear </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two-thirds</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the costs for such study treatment arms and we will bear </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one-third</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the costs. Unless earlier terminated, the BMS Collaboration Agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. Ipsen has opted in to participate in the phase 3 pivotal trial in first-line advanced RCC and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at their choosing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The Roche Group Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2017, we established a clinical trial collaboration with The Roche Group (&#8220;Roche&#8221;) for the purpose of evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the mater clinical supply agreement entered into by the parties in February 2017. Based on the dose-escalation results, the trial has the potential to enroll up to four expansion cohorts, including a cohort of patients with previously untreated advanced clear cell RCC and three cohorts of urothelial carcinoma, namely platinum eligible first-line patients, first or second-line platinum ineligible patients and patients previously treated with platinum-containing chemotherapy. The trial was initiated in June 2017 and is open for enrollment. We are the sponsor of the trial, and Roche is responsible for supplying atezolizumab. Ipsen has opted to participate in the study and will have access to the results to support potential future development in its territories.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GlaxoSmithKline Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In October 2002, we established a collaboration with GSK to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under the terms of the product development and commercialization agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. As a result, we retained the rights to develop, commercialize, and license cabozantinib, subject to payment to GSK of a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> royalty on net sales of any product incorporating cabozantinib. The product development and commercialization agreement was terminated during 2014, although GSK will continue to be entitled to a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> royalty on net sales of any product incorporating cabozantinib, including COMETRIQ and CABOMETYX. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties earned by GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Royalties earned by GSK are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen in the accompanying Condensed Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in contract revenues from a milestone payment received from BMS related to its ROR gamma program, and during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in contract revenues from a milestone payment received from Merck related to its worldwide license of our phosphoinositide-3 kinase-delta program. There was no such revenue during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. See &#8220;Note 2 - Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for a description of our existing collaboration agreements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764291888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsAndInvestmentsTextBlock', window );">Cash and Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CASH AND INVESTMENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our cash equivalents and investments are classified as available-for-sale. The following tables summarize cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">214,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">214,044</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">380,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">380,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">268,234</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">268,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">479,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">479,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under our loan and security agreement with Silicon Valley Bank, we were required to maintain compensating balances on deposit in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or more investment accounts with Silicon Valley Bank or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its affiliates. The total collateral balance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$81.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is reflected in our Condensed Consolidated Balance Sheet in short-term investments; as a result of our repayment of the term loan with Silicon Valley Bank, the compensating balance requirement was terminated as of March 29, 2017. See &#8220;Note 7 - Debt&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information regarding the collateral balance requirements under our Silicon Valley Bank loan and security agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following tables summarize our cash equivalents and investments by security type as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were nominal or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> we did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> investments in an unrealized loss position with gross unrealized losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and an aggregate fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$133.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The investments in an unrealized loss position comprise corporate bonds with an aggregate fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$117.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and securities issued by U.S. Treasury and government sponsored enterprises</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> with an aggregate fair value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The unrealized losses were not attributed to credit risk, but rather associated with the changes in interest rates. Based on the scheduled maturities of our investments, we concluded that the unrealized losses in our investment securities are not other-than-temporary, as it is more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the fair value of securities classified as available-for-sale by contractual maturity as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mature within One Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">After One Year through Two Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,986</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash is excluded from the table above. The classification of certain restricted investments is dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. Therefore, certain long-term restricted cash and investments have contractual maturities within one year.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsAndInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsAndInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764321760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventory consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,568</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: non-current portion included in Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We generally relieve inventory on a first-expiry, first-out basis. A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and, therefore, was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">; the amount of such write-downs was nominal for the comparable period in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The non-current portion of inventory is expected to be sold in future periods more than 12 months from the date presented and consists of finished goods as of June 30, 2017 and a portion of the active pharmaceutical ingredient that is included in raw materials and work in process inventories as of December 31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764313776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction-in-progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,828</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> during both the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Build-to-Suit Lease </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with Ascentris 105, LLC (&#8220;Ascentris&#8221;), to lease </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> square feet of space in office and research facilities located at 1851, 1801, and 1751 Harbor Bay Parkway, Alameda, California (the &#8220;Premises&#8221;). See &#8220;Note 10. Commitments&#8221; for a description of the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Lease, we received a tenant improvement allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Ascentris, for the costs associated with the design, development and construction of tenant improvements for the Premises. We are obligated to fund all costs incurred in excess of the tenant improvement allowance and certain indemnification obligations related to the construction activities. We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises including the building shells did not qualify as &#8220;normal tenant improvements&#8221; under Accounting Standards Codification topic 840, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Accordingly, for accounting purposes, we are the deemed owner of such portions of the Premises during the construction period. As such, we will capitalize the construction costs as a build-to-suit property within property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. The capitalized construction costs will also include the estimated tenant improvements incurred by Ascentris. We will also recognize a corresponding build-to-suit lease obligation included in Other long-term liabilities for the same amount. As of June 30, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of costs were capitalized in construction-in-progress with a corresponding build-to-suit lease obligation recognized related to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once the construction is complete, we will consider the requirements for sale-leaseback accounting treatment, including evaluating whether all risks of ownership have been transferred back to Ascentris, as evidenced by a lack of continuing involvement in the leased property. If the arrangement does not qualify for sale-leaseback accounting treatment, the building assets will remain on our consolidated balance sheets at their historical cost.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764217520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DEBT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amortized carrying amount of our debt consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Secured Convertible Notes due 2018 (&#8220;Deerfield Notes&#8221;)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;Note 7 - Debt&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for additional information on the terms of our debt, including a description of the material features of the Deerfield Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Deerfield Notes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. The repayment amount totaled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$123.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> which comprised </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$113.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in principal, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of interest paid in kind paid through the repayment date, a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prepayment penalty associated with the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">early repayment of the notes and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in accrued and unpaid interest. As a result of the early repayment, there was a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> loss on the extinguishment of the debt which comprised the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prepayment penalty </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and the unamortized fees and costs on the date of the repayment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our early repayment of the notes, the outstanding principal amount of the Deerfield Notes bore interest at the rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per annum to be paid in cash, quarterly in arrears, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per annum to be paid in kind, quarterly in arrears, for a total interest rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per annum. The following is a summary of interest expense for the Deerfield Notes (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stated coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,484</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The balance of unamortized fees and costs was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which was recorded as a reduction of the carrying amount of the Deerfield Notes on the accompanying Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Silicon Valley Bank Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 29, 2017, we repaid all amounts outstanding under our term loan with Silicon Valley Bank. The repayment included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$80.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in principal plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in accrued and unpaid interest. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> gain or loss on the extinguishment of debt as a result of the repayment of the term loan. Prior to our early repayment of the term loan, the principal amount outstanding under the term loan had accrued interest at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;per annum, which was due and payable monthly. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with the terms of the loan and security agreement, we were required to maintain an amount equal to at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, but not to exceed </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">107%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, of the outstanding principal balance of the term loan on deposit in one or more investment accounts with Silicon Valley Bank or one of its affiliates as support for our obligations under the loan and security agreement. We were entitled to retain income earned on the amounts maintained in such accounts. The total collateral balance as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$81.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and was reflected in our Condensed Consolidated Balance Sheet in Short-term investments as the amounts were not restricted as to withdrawal. As a result of our repayment of the term loan, the compensating balance requirement was terminated as of March 29, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758591216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and there were no transfers of financial assets or liabilities classified as Level 3 during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The carrying amounts of cash, trade and other receivables, accounts payable, accrued clinical trial liabilities, accrued compensation and benefits, and other liabilities approximate their fair values and are excluded from the tables above.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing, which are Level 2 inputs.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764217520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,014</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value of our stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of stock options and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ESPP</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We considered implied volatility as well as our historical volatility in developing our estimate of expected volatility. The expected life computation is based on historical exercise patterns and post-vesting termination behavior. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is presented below (dollars in thousands</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,999,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,242,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,269,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">426,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,181,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.72 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">24,237,774</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares were available for grant under our stock option plans.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of restricted stock unit (&#8220;RSU&#8221;) activity for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is presented below (dollars in thousands</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,469,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758591216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax expense consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recorded income tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which comprises our computed income tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reduced by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of excess benefits associated with equity compensation. The income tax expense for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764321760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COMMITMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On May 2, 2017, we entered into the Lease with Ascentris for an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> square feet of space in office and research facilities located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California. We also have the right to make certain tenant improvements to the space leased on the Premises. The Lease has an initial term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> with a target commencement date of March 1, 2018 and rent payments will begin upon the target commencement date. We have </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">five</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year options to extend the Lease and a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-time option to terminate the Lease without cause on the last day of the 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> year of the initial term. We are obligated to make lease payments totaling </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> over the Lease term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">170,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> square feet of space, as that additional space becomes available over the remainder of the initial term at 1601, 1701, 1751, and 1801 Harbor Bay Parkway, Alameda, California at a market rate determined according to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are deemed, for accounting purposes only, to be the owner of portions of the Premises, including </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> building shells, even though we are not the legal owner. See &#8220;Note 5. Property and Equipment - Build-to-Suit Lease&#8221; </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for a further description of the accounting for that portion of the Premises.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the aggregate future minimum lease payments under our leases are as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other financing obligations</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other financing obligations includes payments related to build-to-suit lease arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense and sublease income were as follows for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross rental expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(895</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net rental expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> Letter of Credit</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We obtained a standby letter of credit in May 2017 in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which may be drawn down by Ascentris in the event we fail to fully and faithfully perform all of our obligations under the Lease and to compensate Ascentris for all losses and damages Ascentris may suffer as a result of the occurrence of any default on our part not cured within the applicable cure period. As of June 30, 2017, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the standby letter of credit amount has been used.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;Note 13 - Commitments&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for a description of additional letters of credits that were entered into prior to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760985264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares of common stock outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The 2014 Warrants are participating securities and the warrant holders do not have a contractual obligation to share in our losses. See &#8220;Note 8 - Common Stock and Warrants&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> filed with the SEC on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;27, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for a description of the 2014 Warrants.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth potentially dilutive shares of common stock that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deerfield Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Deerfield Notes were repaid in June 2017. The 2019 Notes were converted and redeemed between August and November 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764321760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONCENTRATIONS OF CREDIT RISK</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially subject us to concentrations of credit risk are primarily trade and other receivables and investments. Investments consist of money market funds, commercial paper, corporate bonds with high credit quality, and securities issued by the U.S. Treasury and other government sponsored enterprises. All investments are maintained with financial institutions that management believes are creditworthy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Trade and other&#160;receivables are unsecured and are concentrated in the pharmaceutical and biotechnology industries. Accordingly, we may be exposed to credit risk generally associated with pharmaceutical and biotechnology companies. We have incurred no bad debt expense since inception. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">19%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">17%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of our trade receivables are with Diplomat Specialty Pharmacy, Caremark L.L.C., affiliates of McKesson Corporation, and Accredo Health, Incorporated, respectively. All of these customers have historically paid promptly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. We have operations solely in the U.S., while some of our collaboration partners have headquarters outside of the U.S. and some of our clinical trials for cabozantinib are also conducted outside of the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows the revenues earned by geographic region. Net product revenues are attributed to regions based on the delivery location. Collaboration revenues are attributed to regions based on the location of our collaboration partner's headquarters (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Japan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recorded losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> relating to foreign exchange fluctuations for both the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764308384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SUBSEQUENT EVENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 19, 2017, we and Genentech entered into the Genentech Amendment. The Genentech Amendment was entered into in connection with the settlement of the arbitration concerning claims asserted by us against Genentech related to its clinical development, pricing and commercialization of COTELLIC, and cost and revenue allocations arising from COTELLIC&#8217;s commercialization in the U.S. See &#8220;Note 2 - Collaboration Agreements - Genentech Collaboration&#8221; for additional information on the Genentech collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Genentech Amendment sets forth the parties&#8217; confirmation and agreement that we have exercised our co-promotion option and that, as such, we have the right to co-promote current and future Genentech combinations that include COTELLIC in the U.S. Pursuant to the terms of the Genentech Amendment, we will continue to be entitled to a share of U.S. profits and losses received in connection with the commercialization of COTELLIC, which share will continue to decrease as sales of COTELLIC increase in accordance with the profit share tiers as originally set forth in the Genentech Collaboration Agreement. However, effective as of July 1, 2017, the revenue for each sale of COTELLIC applied to the profit and loss statement for the Genentech Collaboration Agreement (the &#8220;Collaboration P&amp;L&#8221;) will be calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. While we will also continue to share U.S. commercialization costs for COTELLIC, the Genentech Amendment expressly sets forth that the amount of commercialization costs Genentech is entitled to allocate to the Collaboration P&amp;L will be reduced based on the number of Genentech products in any given combination including COTELLIC. The Genentech Amendment also provides for more detailed communication requirements for the parties related to COTELLIC research, development and commercialization activities and clarifies meeting and escalation procedures for the joint steering committee and the joint commercialization committee, each a body established under the Genentech Collaboration Agreement to coordinate activities with respect to COTELLIC.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761371168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The condensed consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the United States (&#8220;U.S.&#8221;) dollar. All intercompany balances and transactions have been eliminated.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Fiscal year 2017 will end on December 29, 2017 and fiscal year 2016 ended on December 30, 2016. For convenience, references in this report as of and for the fiscal periods ended June 30, 2017 and July 1, 2016, and as of and for the fiscal years ended December 29, 2017 and December 30, 2016, are indicated as being as of and for the periods ended June 30, 2017 and June 30, 2016, and the years ended December&#160;31, 2017 and December&#160;31, 2016, respectively.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of our condensed consolidated financial statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations, the amounts of revenues and expenses under our profit and loss sharing agreement, recoverability of inventory, certain accrued liabilities including accrued clinical trial liability, and stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock', window );">Correction of an Immaterial Error</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Correction of an Immaterial Error</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the third quarter of 2016, we identified errors in the Consolidated Balance Sheets and Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for 2015, 2014, 2013, and 2012, and in the unaudited interim Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, Comprehensive Loss and Cash Flows for all prior interim fiscal periods from September 30, 2012 through June 30, 2016. Specifically, in 2012 we incorrectly calculated 1) the allocation between Additional paid-in capital and Convertible notes of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$287.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> aggregate principal amount from our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Convertible Senior Subordinated Notes due 2019 (&#8220;2019 Notes&#8221;); and 2) the amortization of the debt discount associated with the 2019 Notes during 2012 and all subsequent periods.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Having evaluated the materiality of these errors from a quantitative and qualitative perspective, management has concluded that although the accumulation of these errors was significant to the three and nine months ended September 30, 2016, the correction of these errors would not be material to any individual prior period, and did not have an effect on the trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 99, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Materiality</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and Staff Accounting Bulletin No. 108, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Because management has concluded that these errors are not material, we will correct them prospectively when the consolidated balance sheets, statements of operations, comprehensive loss and cash flows for such periods are included in future filings.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Comprehensive Loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These errors did not affect any other caption or total in our unaudited condensed consolidated financial statements as of and for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. See &#8220;Note 1 - Organization and Summary of Significant Accounting Policies&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the amounts of the corrections and the amounts that should have been reported for 2015, 2014, 2013, and 2012 in the affected line items of the statements of operations, statements of comprehensive loss and statements of cash flows.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to current period presentation. We reclassified </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in accrued product sales discounts payable to our customers as of December 31, 2016 from Other current liabilities to Trade and other receivables in the accompanying Condensed Consolidated Balance Sheets. We have also reclassified the related balances between the Changes in assets and liabilities line items in the accompanying Condensed Consolidated Statements of Cash Flows for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to conform the presentation of those line items to the corresponding presentation of assets and liabilities in our accompanying Condensed Consolidated Balance Sheets.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We operate as a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">single</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reportable segment.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-09,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"> Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-09&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, and no prior periods were restated as a result of this change in accounting principle, with a cumulative adjustment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to accumulated deficit and additional paid-in-capital as of January 1, 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASU 2016-09, we also recorded an increase to the federal and state net operating losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for excess tax benefits previously not included. The resulting increase to the deferred tax assets of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is offset by a corresponding increase to the valuation allowance, resulting in a net </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impact on our income tax expense and our Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on our Condensed Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in cash provided by operating activities by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> along with a corresponding increase in cash used in financing activities in our Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2014-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASU 2014-09&#8221;).&#160;In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which delays the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, but allows us to adopt the standard one year earlier. We will adopt ASU 2014-09 in the first quarter of fiscal year 2018. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have substantially completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of revenue from product sales. We do expect that ASU 2014-09 will impact the timing of recognition of revenue for our collaboration arrangements. We expect to reclassify deferred revenue to retained earnings (a concept known as lost revenue) for amounts associated with certain of our collaboration arrangements upon recording our transition adjustment to accumulated loss on January 1, 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration arrangements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting Changes and Error Corrections, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccountingChangesandErrorCorrectionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=d3e5291-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764313776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Following are the amounts (in thousands, except per share amounts) that should have been reported for the affected line items of the statement of operations, statement of comprehensive loss and statement of cash flows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statement of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,451</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,741</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted, overstated by $0.01 and $0.02 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Comprehensive Loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss, overstated by $2,177 and $4,301 for the three and six months ended June 30, 2016, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of debt discount and debt issuance costs, overstated by $4,301 for the six months ended June 30, 2016</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">The error did not impact our net cash provided by or used in operating activities, financing activities or investing activities for any of the periods presented.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761343392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of upfront payments and deferred milestone</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">811</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of supplied product</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty payable to GSK on net sales by Ipsen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues under the Ipsen Collaboration Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. losses included in Selling, general and administrative expenses</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(781</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,630</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,923</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">A portion of the accrual for losses for </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">June&#160;30, 2016</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;"> were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech&#8217;s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of upfront payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues under the Takeda Collaboration Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties earned by GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764227168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-Sale Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following tables summarize cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">135,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">214,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">214,044</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">380,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">380,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">268,234</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">268,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total cash and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">479,862</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">479,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of Cash Equivalents and Investments by Security Type</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following tables summarize our cash equivalents and investments by security type as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,344</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">460,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Securities by Contractual Maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the fair value of securities classified as available-for-sale by contractual maturity as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mature within One Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">After One Year through Two Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,986</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764217520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventory consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,568</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: non-current portion included in Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773713680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,646</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction-in-progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,828</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656146496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amortized carrying amount of our debt consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Secured Convertible Notes due 2018 (&#8220;Deerfield Notes&#8221;)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Interest Expense on Notes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of interest expense for the Deerfield Notes (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stated coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,083</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total interest expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,484</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758580064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6932703456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recorded and allocated employee stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,014</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options and ESPP purchases. The weighted average grant-date fair value of our stock options and ESPP purchases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of stock options and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ESPP</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of All Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is presented below (dollars in thousands</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,999,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,242,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,269,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">426,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,181,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.72 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of All RSU Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of restricted stock unit (&#8220;RSU&#8221;) activity for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">six months ended</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is presented below (dollars in thousands</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,469,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258,272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,543</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774523248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax expense consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656141360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June&#160;30, 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the aggregate future minimum lease payments under our leases are as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other financing obligations</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other financing obligations includes payments related to build-to-suit lease arrangements.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of Rent Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense and sublease income were as follows for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross rental expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(306</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(895</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net rental expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,546</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761200304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,246</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares of common stock outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth potentially dilutive shares of common stock that are not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive (in thousands):</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deerfield Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6658775920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows the revenues earned by geographic region. Net product revenues are attributed to regions based on the delivery location. Collaboration revenues are attributed to regions based on the location of our collaboration partner's headquarters (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Japan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758572960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Organization) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember', window );">Products Derived from Cabozantinib [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6660509296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Error Correction, Narrative) (Details) - Senior Subordinated Notes [Member] - Convertible Senior Subordinated Notes due August 15, 2019, 4.25% [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 287,500,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt, interest rate (as a percent)</a></td>
<td class="nump">4.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774373776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Error Correction) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">$ (4,259)<span></span>
</td>
<td class="num">$ (10,451)<span></span>
</td>
<td class="num">$ (8,679)<span></span>
</td>
<td class="num">$ (20,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(8,876)<span></span>
</td>
<td class="num">(9,702)<span></span>
</td>
<td class="num">(12,228)<span></span>
</td>
<td class="num">(19,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">17,656<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="nump">34,356<span></span>
</td>
<td class="num">$ (94,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statements of Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">17,863<span></span>
</td>
<td class="num">$ (34,667)<span></span>
</td>
<td class="nump">34,653<span></span>
</td>
<td class="num">$ (93,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statements of Cash Flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="num">(34,838)<span></span>
</td>
<td class="nump">34,356<span></span>
</td>
<td class="num">(94,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">6,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember', window );">Restatement Adjustment [Member] | Correction of Amortization of Debt Discount Associated with the 2019 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statements of Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statements of Cash Flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,301)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=exel_CorrectionofAmortizationofDebtDiscountAssociatedwiththe2019NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773548928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Reclassifications) (Details) - Reclassification Adjustment [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued product sales discounts, reclassified</a></td>
<td class="num">$ (1.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_TradeandOtherReceivablesMember', window );">Trade and other receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued product sales discounts, reclassified</a></td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_TradeandOtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_TradeandOtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758540032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Segment Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773910848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Stock-Based Compensation) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Increase in cash provided by operating activities</a></td>
<td class="nump">$ 74,393,000<span></span>
</td>
<td class="nump">$ 131,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Increase in cash used in financing activities</a></td>
<td class="nump">$ 172,086,000<span></span>
</td>
<td class="num">(627,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Increase in federal and state net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Increase in deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Net impact on provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Increase in cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Increase in cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Accumulated Deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=exel_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776762928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Ipsen Collaboration) (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">$ 19,665,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,255,000<span></span>
</td>
<td class="nump">$ 19,665,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 31,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">237,094,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,663,000<span></span>
</td>
<td class="nump">237,094,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 253,663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GlaxoSmithKline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentOfReimbursementsFromCollaborationArrangement', window );">Reimbursements of certain clinical programs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 219,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member] | Reclassification Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue reclassified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member] | Initial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member] | Second [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember', window );">Collaborative Arrangement with Ipsen, Consideration for Commercialization Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember', window );">Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member] | CABOMETYX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember', window );">Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | CABOMETYX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved', window );">Number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember', window );">Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | United Kingdom [Member] | CABOMETYX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember', window );">Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | Germany [Member] | CABOMETYX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentOfReimbursementsFromCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Reimbursements From Collaboration Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentOfReimbursementsFromCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Number of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueRecognitionMilestoneMethodNumberofMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_SecondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_SecondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenConsiderationforCommercializationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenFirstCommercialSalesofProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760879920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Ipsen) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product supply agreement revenue</a></td>
<td class="nump">$ 88,004<span></span>
</td>
<td class="nump">$ 31,618<span></span>
</td>
<td class="nump">$ 156,881<span></span>
</td>
<td class="nump">$ 40,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of supplied product</a></td>
<td class="num">(3,014)<span></span>
</td>
<td class="num">(1,560)<span></span>
</td>
<td class="num">(6,217)<span></span>
</td>
<td class="num">(2,245)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues under the collaboration agreement</a></td>
<td class="nump">11,004<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
<td class="nump">23,014<span></span>
</td>
<td class="nump">10,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Amortization of upfront payments and deferred milestone</a></td>
<td class="nump">4,741<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementDevelopmentCostReimbursements', window );">Development cost reimbursements</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product supply agreement revenue</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of supplied product</a></td>
<td class="num">(811)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,802)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable to GSK on net sales by Ipsen</a></td>
<td class="num">(328)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues under the collaboration agreement</a></td>
<td class="nump">$ 5,494<span></span>
</td>
<td class="nump">$ 3,592<span></span>
</td>
<td class="nump">$ 10,024<span></span>
</td>
<td class="nump">$ 4,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementDevelopmentCostReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementDevelopmentCostReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774925264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Genentech Collaboration) (Details) - Genentech [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce', window );">Percentage of share of the Company in promotions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Profit Sharing Tier One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Profit Sharing Tier Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember', window );">COTELLIC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">$ 1,367<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
<td class="nump">$ 1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember', window );">COTELLIC [Member] | Q4 '16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Optional Percent of Total Sales Force</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementPercentOfProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Percent of Profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementPercentOfProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementProfitThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Profit Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementProfitThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodGeneratedAxis=exel_Q416Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodGeneratedAxis=exel_Q416Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761715376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Genentech) (Details) - Genentech [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossfromAgreement', window );">U.S. losses included in Selling, general and administrative expenses</a></td>
<td class="num">$ (781)<span></span>
</td>
<td class="num">$ (4,630)<span></span>
</td>
<td class="num">$ (1,407)<span></span>
</td>
<td class="num">$ (11,923)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">COTELLIC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues</a></td>
<td class="nump">$ 1,367<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="nump">$ 3,665<span></span>
</td>
<td class="nump">$ 1,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossfromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossfromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776746176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Takeda Collaboration) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,255,000<span></span>
</td>
<td colspan="2" class="nump">$ 19,665,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,663,000<span></span>
</td>
<td colspan="2" class="nump">$ 237,094,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum pre-specified payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredRevenueRecognitionPeriod', window );">Deferred revenue, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractTerminationPeriodforWrittenNotice', window );">Termination of collaboration agreement, period for written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda [Member] | Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_InitialMember', window );">Initial [Member] | Collaborative Arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Cumulative net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_InitialMember', window );">Initial [Member] | Collaborative Arrangement with Takeda [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_InitialMember', window );">Initial [Member] | Collaborative Arrangement with Takeda [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_FinalTierMember', window );">Final Tier [Member] | Collaborative Arrangement with Takeda [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_FinalTierMember', window );">Final Tier [Member] | Collaborative Arrangement with Takeda [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractTerminationPeriodforWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Termination, Period for Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractTerminationPeriodforWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=exel_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=exel_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772058768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Takeda) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues under the collaboration agreement</a></td>
<td class="nump">$ 11,004<span></span>
</td>
<td class="nump">$ 4,634<span></span>
</td>
<td class="nump">$ 23,014<span></span>
</td>
<td class="nump">$ 10,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Amortization of upfront payment</a></td>
<td class="nump">2,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementDevelopmentCostReimbursements', window );">Development cost reimbursements</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues under the collaboration agreement</a></td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementDevelopmentCostReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementDevelopmentCostReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931112336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Bristol-Myers Squibb Collaboration) (Details) - Collaborative Arrangement, 2 BMS Compound Utilized [Member] [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementShareinCostsPercentage', window );">Share in costs, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=exel_BristolMyersSquibbMember', window );">BMS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementShareinCostsPercentage', window );">Share in costs, percentage</a></td>
<td class="nump">66.67%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementShareinCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Share in Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementShareinCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=exel_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=exel_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761940832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (GlaxoSmithKline Collaboration) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 2,962<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 5,363<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GlaxoSmithKline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758781056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Other Collaborations) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember', window );">BMS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember', window );">Merck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773970688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Balance Sheet Line Item) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 380,438<span></span>
</td>
<td class="nump">$ 479,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments', window );">Gross Unrealized Losses</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecurities', window );">Fair Value</a></td>
<td class="nump">380,319<span></span>
</td>
<td class="nump">479,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">135,212<span></span>
</td>
<td class="nump">151,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecurities', window );">Fair Value</a></td>
<td class="nump">135,212<span></span>
</td>
<td class="nump">151,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">214,172<span></span>
</td>
<td class="nump">268,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments', window );">Gross Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments', window );">Gross Unrealized Losses</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecurities', window );">Fair Value</a></td>
<td class="nump">214,044<span></span>
</td>
<td class="nump">268,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_LongTermInvestmentsMember', window );">Long-term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">26,404<span></span>
</td>
<td class="nump">55,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments', window );">Gross Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments', window );">Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecurities', window );">Fair Value</a></td>
<td class="nump">26,413<span></span>
</td>
<td class="nump">55,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_RestrictedCashAndInvestmentsLongTermMember', window );">Long-term restricted cash and investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,650<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsandAvailableforsaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,650<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsandAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Available-for-sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsandAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Available-for-sale Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Available-for-sale Securities, Gross Unrealized Loss Accumulated in Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_RestrictedCashAndInvestmentsLongTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_RestrictedCashAndInvestmentsLongTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773897200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>account </div>
<div>investment </div>
<div>affiliate</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtCollateralNumberOfRequiredInvestmentAccounts', window );">Number of required investment accounts | account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtCollateralNumberOfAffiliateBanks', window );">Number of affiliate banks | affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Gain (loss) on sale of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairment charges on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear', window );">Number of investments in unrealized loss position | investment</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">$ (160,000)<span></span>
</td>
<td class="num">$ (160,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (322,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, aggregate fair value</a></td>
<td class="nump">133,200,000<span></span>
</td>
<td class="nump">133,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(308,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, aggregate fair value</a></td>
<td class="nump">117,500,000<span></span>
</td>
<td class="nump">117,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Treasury and government sponsored enterprises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, aggregate fair value</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember', window );">Silicon Valley Bank Term Loan and Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensatingBalanceAmount', window );">Collateral balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtCollateralNumberOfAffiliateBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Collateral, Number of Affiliate Banks</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtCollateralNumberOfAffiliateBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtCollateralNumberOfRequiredInvestmentAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Collateral, Number of Required Investment Accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtCollateralNumberOfRequiredInvestmentAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774213648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Security Type) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 368,344<span></span>
</td>
<td class="nump">$ 460,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">368,225<span></span>
</td>
<td class="nump">459,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">303,877<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(132)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">303,786<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">152,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Treasury and government sponsored enterprises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">15,664<span></span>
</td>
<td class="nump">70,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 15,636<span></span>
</td>
<td class="nump">$ 70,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772042064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Available for Sale by Contractual Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature within One Year</a></td>
<td class="nump">$ 343,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After One Year through Two Years</a></td>
<td class="nump">24,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">368,225<span></span>
</td>
<td class="nump">$ 459,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature within One Year</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After One Year through Two Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature within One Year</a></td>
<td class="nump">281,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After One Year through Two Years</a></td>
<td class="nump">22,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">303,786<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature within One Year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After One Year through Two Years</a></td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Treasury and government sponsored enterprises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature within One Year</a></td>
<td class="nump">13,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After One Year through Two Years</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 15,636<span></span>
</td>
<td class="nump">$ 70,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762550816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">3,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">5,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Less: non-current portion included in Other assets</a></td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">5,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761086736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 41,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,953<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(22,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,882)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">18,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">13,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">4,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">4,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,310<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment gross</a></td>
<td class="nump">$ 16,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762595184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Construction-in-progress deemed to have been acquired under build-to-suit lease</a></td>
<td class="nump">14,530<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember', window );">Capital Lease and Other Financing Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in Progress, Gross</a></td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758492784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Schedule of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 189,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured notes [Member] | Secured Convertible Notes Due June 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember', window );">Term loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762249344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Deerfield Notes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,825)<span></span>
</td>
<td class="nump">$ 3,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,239<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured notes [Member] | Secured Convertible Notes Due June 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ExtinguishmentofDebtincludingInterestandPenalties', window );">Repayments of notes payable</a></td>
<td class="nump">$ 123,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ExtinguishmentofDebtIncludingPaidinKindInterest', window );">Repayment of principal, including paid in kind interest</a></td>
<td class="nump">113,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">13,900<span></span>
</td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">$ 4,151<span></span>
</td>
<td class="nump">$ 3,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentPrepaymentPenalty', window );">Prepayment penalty amount</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued interest paid</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection', window );">Interest rate after extension option election (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses', window );">Balance of unamortized closing fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured notes [Member] | Secured Convertible Notes Due June 2018 [Member] | Coupon Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection', window );">Interest rate after extension option election (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured notes [Member] | Secured Convertible Notes Due June 2018 [Member] | Payment-in-kind interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection', window );">Interest rate after extension option election (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instruments, unamortized closing fees and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ExtinguishmentofDebtIncludingPaidinKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of Debt, Including Paid in Kind Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ExtinguishmentofDebtIncludingPaidinKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ExtinguishmentofDebtincludingInterestandPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of Debt, including Interest and Penalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ExtinguishmentofDebtincludingInterestandPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InterestPaymentTypeAxis=exel_CouponInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InterestPaymentTypeAxis=exel_CouponInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InterestPaymentTypeAxis=exel_PaymentinKindInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InterestPaymentTypeAxis=exel_PaymentinKindInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762064064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Interest Expense on Deerfield Notes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,825)<span></span>
</td>
<td class="nump">$ 3,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">6,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured notes [Member] | Secured Convertible Notes Due June 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InterestExpenseCouponInterest', window );">Stated coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,259<span></span>
</td>
<td class="nump">$ 4,057<span></span>
</td>
<td class="nump">$ 8,484<span></span>
</td>
<td class="nump">$ 8,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InterestExpenseCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coupon Interest on Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InterestExpenseCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761909616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Silicon Valley Bank Loan and Security Agreement) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain or loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,239,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(6,239,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember', window );">Silicon Valley Bank Term Loan and Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensatingBalanceAmount', window );">Collateral balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember', window );">Term loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember', window );">Term loan [Member] | Silicon Valley Bank Term Loan and Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Principal amount repaid</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued interest paid</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain or loss on extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt, interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations', window );">Percentage of security deposit on outstanding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_Maximumpercentagerequiredforcollateralbalance', window );">Maximum percentage required for collateral balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of collateral security deposit on outstanding obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentPercentageOfCollateralSecurityDepositOnOutstandingObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_Maximumpercentagerequiredforcollateralbalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage required for collateral balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_Maximumpercentagerequiredforcollateralbalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=exel_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761979776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on a Recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">$ 368,225<span></span>
</td>
<td class="nump">$ 459,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">319,972<span></span>
</td>
<td class="nump">388,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">48,253<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">303,786<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">303,786<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Treasury and government sponsored enterprises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">15,636<span></span>
</td>
<td class="nump">70,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Treasury and government sponsored enterprises [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Treasury and government sponsored enterprises [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">$ 15,636<span></span>
</td>
<td class="nump">$ 70,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758448128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,027<span></span>
</td>
<td class="nump">$ 3,558<span></span>
</td>
<td class="nump">$ 9,740<span></span>
</td>
<td class="nump">$ 14,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">6,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="nump">$ 2,393<span></span>
</td>
<td class="nump">$ 6,662<span></span>
</td>
<td class="nump">$ 8,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6660480176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Weighted Average Grant Date Fair Values) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 10.07<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 10.01<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.65<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762535968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">4 years 2 months 8 days<span></span>
</td>
<td class="text">4 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.94%<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762091888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Summary of All Stock Option Activity) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">24,999,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">674,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(3,242,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(161,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">22,269,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">16,181,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">20.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">7.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">5.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at end of period, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period, Aggregate Intrinsic Value, in dollars | $</a></td>
<td class="nump">$ 426,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period, Aggregate Intrinsic Value, in dollars | $</a></td>
<td class="nump">$ 331,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761251984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">24,237,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762193184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Summary of All RSU Activity) (Details) - Restricted Stock Units (RSUs) [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">2,469,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">258,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(280,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(85,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares) | shares</a></td>
<td class="nump">2,361,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">20.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">4.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">10.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at end of period, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue', window );">RSUs outstanding at end of period, Aggregate Intrinsic Value, in dollars | $</a></td>
<td class="nump">$ 58,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6932199616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Computed income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ExcessTaxBenefitsSharebasedCompensation', window );">Excess benefits associated with equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ExcessTaxBenefitsSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess Tax Benefits - Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ExcessTaxBenefitsSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771967200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Schedule of Future Minimum Lease Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Capital leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">Remainder of 2017</a></td>
<td class="nump">$ 1,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">2,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears', window );">2022</a></td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix', window );">Thereafter</a></td>
<td class="nump">3,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Future minimum payments due, capital</a></td>
<td class="nump">10,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=exel_FinancingLeaseObligationMember', window );">Other financing obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">Remainder of 2017</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">1,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears', window );">2022</a></td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix', window );">Thereafter</a></td>
<td class="nump">10,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Future minimum payments due, capital</a></td>
<td class="nump">$ 17,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Leases, Future Minimum Payments, Due After Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalLeasesFutureMinimumPaymentsDueAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Leases, Future Minimum Payments Due in Six Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalLeasesFutureMinimumPaymentsDueinSixYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=exel_FinancingLeaseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=exel_FinancingLeaseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762635712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Schedule of Rental Expenses and Sublease Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Gross rental expense</a></td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="nump">$ 3,194<span></span>
</td>
<td class="nump">$ 3,771<span></span>
</td>
<td class="nump">$ 5,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">less: Sublease income</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(895)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Net rental expense</a></td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">$ 2,299<span></span>
</td>
<td class="nump">$ 2,546<span></span>
</td>
<td class="nump">$ 3,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774838112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option </div>
<div>property</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby letters of credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember', window );">Capital Lease and Other Financing Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in sqft) | ft&#178;</a></td>
<td class="nump">110,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract', window );">Term of lease contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesNumberofRenewalOptions', window );">Number of renewal options | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm', window );">Renewal option term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesNumberofOptionstoTerminate', window );">Number of options to terminate | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Future minimum payments due</a></td>
<td class="nump">$ 24,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty', window );">Option for additional area of lease (in sqft) | ft&#178;</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember', window );">Capital Lease and Other Financing Lease [Member] | Building shells [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of leased properties | property</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalLeasesNumberofOptionstoTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Leases, Number of Options to Terminate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalLeasesNumberofOptionstoTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalLeasesNumberofRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Leases, Number of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalLeasesNumberofRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Leases, Option, Additional Area of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalLeasesOptionAdditionalAreaofRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Capital Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeLeasingArrangementsCapitalLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeLeasingArrangementsCapitalLeasesTermofContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Capital Leases, Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeLeasingArrangementsCapitalLeasesTermofContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfRealEstateProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of real estate properties owned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfRealEstateProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_BuildingShellsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_BuildingShellsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774015792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Reconciliation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="nump">$ 34,356<span></span>
</td>
<td class="num">$ (94,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income allocable to common stock for basic net income (loss) per share</a></td>
<td class="nump">17,596<span></span>
</td>
<td class="num">(34,838)<span></span>
</td>
<td class="nump">34,239<span></span>
</td>
<td class="num">(94,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Adjustment to net income allocated to participating securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income allocable to common stock for diluted net income (loss) per share</a></td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="nump">$ 34,246<span></span>
</td>
<td class="num">$ (94,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding (in shares)</a></td>
<td class="nump">293,188<span></span>
</td>
<td class="nump">229,310<span></span>
</td>
<td class="nump">292,029<span></span>
</td>
<td class="nump">228,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</a></td>
<td class="nump">18,031<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities (in shares)</a></td>
<td class="nump">311,219<span></span>
</td>
<td class="nump">229,310<span></span>
</td>
<td class="nump">310,759<span></span>
</td>
<td class="nump">228,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763158976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Potentially Dilutive Shares) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="nump">119,645<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">119,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding stock options, unvested RSUs and ESPP contributions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="nump">30,637<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">30,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member', window );">2019 Notes [Member] | Convertible debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,118<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member', window );">Deerfield Notes [Member] | Convertible debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762800144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange fluctuations loss</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Diplomat Specialty Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Caremark L.L.C. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Affiliates of McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Accredo Health, Incorporated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762714976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk (Revenues by Customer) (Details) - Customer Concentration Risk [Member] - Revenues [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Diplomat Specialty Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Caremark L.L.C. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accredo Health, Incorporated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Affiliates of McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Merck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762230560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Credit Risk (Revenues by Geographic Region) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 11,004<span></span>
</td>
<td class="nump">$ 4,634<span></span>
</td>
<td class="nump">$ 23,014<span></span>
</td>
<td class="nump">$ 10,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenues [Member] | U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">89,371<span></span>
</td>
<td class="nump">32,192<span></span>
</td>
<td class="nump">163,046<span></span>
</td>
<td class="nump">45,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenues [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">5,494<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenues [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,825<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^-V'?6K=W_]CX*JAJ^'47Z@M02P,$%     @ "X("2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MUP_RA5)!I$?1D_2EECUZ6K3D(M0TEW-F&I59"#J,31A,_P3*OU!+ P04
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M^KH\4"J(M.H]R1.4RYG>+TIR$.HUEN^LG6SM0M"F&]J@_^<P_P]02P,$%
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M9!5TS,_#2<L\X++"C"+31S!9!9"5-5D%'/-=)KE&*]2Y(C:C!>-5 %[-<4M
M#NI=ID-T!RK3.]D:U24N.YNWE[8Q@P4P6&<**[%H#=.13+*%= $@T<&-/$D5
MB[O8SB*8F (>#)@#YR3*+P+H->O70!8SH]E[^2\FH5@2FJ0%:#*=P29GC^MW
M=?LRO@GI9H_-V[X?AN3L[NEMRRT-C_O5_95;KAVZ3\L[I+^5;+D.70<E)/]\
MH9/\:^GX.NBWJGW9[+O90]/WS6Y\??#<-'T=NIM^"1%_K:NGT\6V?NZ'GWGX
MW1Y?PQPO^N8PO6)*3N^Y;OX!4$L#!!0    (  N" DNF)UTGKP$  -(#   8
M    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5/;CIPP#/V5*!^PF<G0BT:
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M]KV(5[P_<IQ-%8-I%.D?BO<8O9;[C.?L&HGFG-.4P]<Y2P9#]J4$WRIQXO_
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M+QO[WR Z\*DD-WZ$.O_!%D-"X\+QSI_--&:3X;"??Q!;OG'Y!U!+ P04
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MKN>6DKGX+W %B>%!">:HC'1Q)=7@O%$S"TI1_'G:A8[[.-WLLQFV#4AG0+H
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MP19#0N/#\0;/=AJSR?"FGW\06[YQ^0902P,$%     @ "X("2W^R9-RT 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL?5-A;]P@#/TKB!]0
M[DAZJTY)I%ZK:9,VZ=1IZV<N<1)4"!F02_?O9TB:9ENT+X"-W_.S,=EH[(MK
M 3QYU:IS.6V][X^,N;(%+=R-Z:'#F]I8+3R:MF&NMR"J"-**\=WNP+20'2VR
MZ#O;(C.#5[*#LR5NT%K87R=09LSIGKXYGF33^N!@1=:+!KZ!_]Z?+5IL8:FD
MALY)TQ$+=4[O]\=3&N)CP \)HUN=2:CD8LQ+,#Y7.=T%0:"@](%!X':%!U J
M$*&,GS,G75(&X/K\QOXQUHZU7(2#!Z.>9>7;G-Y14D$M!N6?S/@)YGIN*9F+
M_P)74!@>E&".TB@75U(.SAL]LZ 4+5ZG779Q'Z>;))EAVP ^ _@"N(MYV)0H
M*G\47A29-2.Q4^][$9YX?^38FS(X8ROB'8IWZ+T6^T.:L6L@FF-.4PQ?QRP1
M#-F7%'PKQ8G_ ^?;\&1381+AR1\*;[<)TDV"-!*D_RUQ*^;P5Q*VZJD&V\1I
M<J0T0Q<G>>5=!O:>QS=Y#Y^F_:NPC>P<N1B/+QO[7QOC :7L;G"$6OQ@BZ&@
M]N'X <]V&K/)\*:??Q!;OG'Q&U!+ P04    "  +@@)+;Z9QZK8!  #0 P
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MO/=G,P[9:#CLIO_#YD]<_ %02P,$%     @ "X("2PZE=""T 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL?5/;;IPP$/T5RQ\0L^PVFZX
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M\PYM.Z[9Z'C332^(S<^X^ !02P,$%     @ "X("2Z K2]D5 @  U08  !D
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MU:4)S7P2'7OVEH6N]">];_A?N3[7C8D.RKK>%CK022D+KI;DP7U,E7MCQH6
MD_73I9OKOM'V"ZO:X1$AXTM6_ 902P,$%     @ "X("2VNIX>O2 0  G 0
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MV;T:6W\TC.RFJ4;GT5K^ 5!+ P04    "  +@@)+1T_.7;8!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6QM4]MNW" 0_17$!X1=[*31RK:4
M354U4B.M4K5]9NWQ1>'B %XG?]\!.XZ;^@68X9PS%X9L-/;9M0">O"JI74Y;
M[_L#8ZYL00EW97K0>%,;JX1'TS;,]19$%4E*,K[;W3 E.DV++/I.MLC,X&6G
MX62)&Y02]NT(THPYW=-WQU/7M#XX6)'UHH&?X'_U)XL66U2J3H%VG='$0IW3
MN_WAF 9\!/SN8'2K,PF5G(UY#L9#E=-=2 @DE#XH"-PN< ]2!B%,XV76I$O(
M0%R?W]6_Q=JQEK-P<&_DGZ[R;4YO*:F@%H/T3V;\#G,]UY3,Q?^ "TB$ATPP
M1FFDBRLI!^>-FE4P%25>I[W3<1^GFR29:=L$/A/X0KB-<=@4*&;^57A19-:,
MQ$Z][T5XXOV!8V_*X(RMB'>8O$/OI>#I/F.7(#1CCA.&KS ?"(;J2PB^%>+(
M_Z/S;7JRF6$2Z<DZ^LWUMD"Z*9!&@?2?$OFG$K<PR:<@;-53!;:)T^1(:08=
M)WGE70;VCL<W^8!/T_XH;--I1\[&X\O&_M?&>,!4=E<X0BU^L,604/MP_()G
M.XW99'C3SS^(+=^X^ M02P,$%     @ "X("2QD:-A7& 0  -P0  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL;53;CML@$/T5Q <L";&3*+(M;7:U
M:J56BK9J^TSL\47+Q04<;_^^@+VNF_)B9H8SY\P XVQ4^LVT !:]"RY-CEMK
M^Q,AIFQ!,/.@>I!NIU9:,.M<W1#3:V!52!*<T,UF3P3K)"ZR$+OH(E.#Y9V$
MBT9F$(+IWV?@:LSQ%G\$7KNFM3Y BJQG#7P#^[V_:.>1A:7J!$C3*8DTU#E^
MW)[.J<<'P(\.1K.RD>_DJM2;=SY7.=[X@H!#:3T#<\L-GH!S3^3*^#5SXD72
M)Z[M#_:7T+OKY<H,/"G^LZMLF^,C1A74;.#V58V?8.XGQ6AN_@O<@#NXK\1I
ME(J;\$7E8*P2,XLK1;#W:>UD6,=I)Z5S6CR!S@ET23@&'3()A<J?F65%IM6(
M]'3V/?-7O#U1=S:E#X:C"'NN>..BMX(F249NGFC&G"<,76&V"X(X]D6"QB3.
M]+]T&D_?12O<A?3=6GU_B!,D48(D$"3_M)C>M1C#[.,B:50DC1 <[D1BF..=
M"%E=G #=A"=K4*D&&<9E%5VFXC&\%/(7/HW45Z:;3AIT5=8]GW#)M5(67"F;
M!U=+ZZ9X<3C4UIL'9^OI+4^.5?T\IF3Y5Q1_ %!+ P04    "  +@@)+I5^S
M\\(!   W!   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6QU5.UNVR 4
M?17$ Q2'Q&L7V9::5M4F;5+4:>UO8E]_J'QX@./V[0?8<:V,_0G<ZW//.1>X
MR4:EWTP+8-&[X-+DN+6VWQ-BRA8$,S>J!^F^U$H+9EVH&V)Z#:P*18(3FB1?
MB&"=Q$46<D==9&JPO)-PU,@,0C#]<0"NQAQO\"7QW#6M]0E29#UKX!?8W_U1
MNX@L+%4G0)I.2:2ASO']9G](/3X 7CH8S6J/?"<GI=Y\\+W*<>(- 8?2>@;F
MEC,\ .>>R-GX,W/B1=(7KO<7]J?0N^OEQ P\*/[:5;;-\1U&%=1LX/99C=]@
M[B?%:&[^!YR!.[AWXC1*Q4WX1>5@K!(SB[,BV/NT=C*LX\Q_*8L7T+F 7A60
M22@X?V26%9E6(]+3V??,7_%F3]W9E#X9CB)\<^:-RYX+NON:D;,GFC&'"4-7
MF,V"((Y]D: QB0/]IYS&R[=1A]M0OEVKWR9Q@EV48!<(=FO]-+EJ,8;Y3Y-I
M5"2-$- KD1AF>R5"5A<G0#?AR1I4JD&&<5EEEZFXI^'B/^'32/UDNNFD02=E
MW?,)EUPK9<%926Z<E]9-\1)PJ*W?WKJ]GM[R%%C5SV-*EO^*XB]02P,$%
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M\65C_VMC/& JNQL<H18_V&(HJ'TXWN'93F,V&=[T\P]BRS<N_@!02P,$%
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M;YMTLY+C=#\^&C*]W.H;4$L#!!0    (  N" DN M>&ZB ,  '0/   9
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MV7#:G! 3Q_9$DS8& HHP]7: Z B(WLP)'?$[=,0)'?$A.L) 0+T-$3KBB(Z
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M0) #$@X(<D#" 4$.2#@@R $)!P0Y(.& ( <L'##D@(4#QFM<.&#( 7?+'W+
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MYLAIQ?6ODY^YH/6@(JW4^*-_EHU^=H/^E68GP($ 1X+,?8^ !@+Z) 1W"<%
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M'(5:QG+-^EG:;P1MA]\$&O]5^5]02P,$%     @ "X("2W'+-DXK @  E 8
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MC*EB:IL(C?7"&.L"8)PG,\<O)'5L@I#?F!JFMH_0V&0#O,;!!-L,139C2G@
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M[2"E$CJD?Z=#GO1I?ICDXJ#,,-+CNCO2=A,EJ_ZX[@W_&3;_ %!+ P04
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M2"*"="2J6JF5HJO:/CMD$] 93&TG7/^^MB$< >=T+\%>9F9GUV&=M(R_B@)
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M@!\E)#TA>920]H34(D1=LDSVGXDDTS%GYX!W!=027:=PE*KUW>A!LYSFFUH
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MSFIBE!3V5NI!@22S=U,7E>,<VSNJ!P40LJQ%@_-$WSE^$KXO&Q&LF51'DSE
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MZ;-7]?^M4]HV!;ECC9F[]F;G7?=94VW=W'W9\)BO@I>6:,#<]QAZA:&WB"U
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M@]9&-93ANX;RJ-+]Y2)7!].>QLUYU6_ ]!=&GX;-I>"RP[7Y#U!+ P04
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MF\@]ZZ9W9PC:] \3&E['["]02P,$%     @ "X("2PR@TP7/ @  (0P  !D
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M2'#/''=?L.H3X\CRX:G(^J%(Q\T 7*S V(>=Q<*P0 @*A$8@Z @$L$ $"D2
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M40C%=3K:Q&%PUJW=-*GY49EAIL?]T-\,$R6ZL7>+I@9R^P]02P,$%     @
M"X("2_6'^>JM 0  H ,  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL
M;9/M;ML@%(9O!7$!)<&X;B/;TM)IZJ15BCIM^TWLXQB5#Q=(W-W] +M6VOF/
MX1S>\YP/3#D:^^)Z (_>E-2NPKWWPXX0U_2@N+LQ ^APTAFKN ^F/1$W6.!M
M"E*2T,WFEB@N-*[+Y#O8NC1G+X6&@T7NK!2W?_<@S5CA+7YW/(M3[Z.#U.7
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M/)?%D-#YN"W"WDX_S61X,\SO@2R/LOX'4$L#!!0    (  N" DOVM:#=C@(
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MPPP&!\8D5=6[+ZKNDYI&ZTU*#U(O([7FY4A6;B0KJG'3J6?>V7]02P,$%
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MIV+ZB3UCDJK8_2=UJIEJ8KM)0?=2#V,UYDTGUTPDJ]LNU>M:Y<4_4$L#!!0
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M]5AT%X=NHGC;7XJ2X6:V^ =02P,$%     @ "X("2Y-AK+L3>   !O$! !0
M  !X;"]S:&%R9613=')I;F=S+GAM;.R]>7/;Z)4O_/=]/P4JUSU7K@(9 MS=
M,ZF29=FMM+>(<CJ9J5NW0!*4T"8!!@ E,S4?_CW;LV$A*=GNS$PE56F+)/"L
MYSG/67_G7XNB]+YLUFGQ;[^[*\OMB]__OEC<Q9NHZ&;;.(5?5EF^B4KXF-_^
MOMCF<;0L[N*XW*Q_'_9ZH]]OHB3]G;=+D[_MXHMLEY;_]KM1?_J[/_QKD?SA
M7\L_O,H6NTV<EMYYNO0NTS(I]]Y5RFTF6>IUO.(NRN/B7W]?_N%??X_O\'LC
M[UV6EG<%O+.,E]5?_[A+NUZ_YWMA+QC7?UQWO7#4_..Q\?S'^;PH\VA1_M_6
M-V_VV[CZ8]#K_*GZW3D\O:0W7J^CV^JOJVA=U)K1?7R,\R3# 2Z]5U%9>T[-
M___[7__KX"1?)\4B6GM_C:/<>PU?UI:Y^J3TV_CLG\+J-S=YM$S26V^VW\RS
M=?77^$M<^TY6_#J^37"9H>/WT:8VO<N_7+Z]^LO5S/>NWE]T6]JX@&'G,.0K
M() OWL_QON6YU\DZSKT+6,7;+*\]]#;*;V/O?+&(X2EX9LG/5Q^[V.5Y=4';
M-J?3"<)..&T;=K;9 )W-RFSQV?=F1/S>AUU9E%&*BUGK.8/YI04,#/XJLG6R
MI%&^C-91NHBA 3B+!1RC3[-7WMFSY]XS+TF]F[ML5T![]?V.%T X 9V-4?7'
M_PAJ1*_F'14%=/.B]G-4W'G0C[? /^*_[9+[: W/U_J=W65YV2GC? /#NX^+
M<M/T%-)33.UEY1UL6AXO8FAQOJ[SARMH)2UA0WTOC<OJKQ_S>!LE2R_^LL6U
M*ZPV%\Z,:B/(2MC>P\^\S=+;HU,Q#\'^EGFRP$U;J.4Z\.+''/AN#H2"S^&*
M;O&QQEF^R;+E0[*N';(/--&U'L&AJ3;_IK9]G43S9)V425S?>S@SR.X+;QOM
M<8L:?L]W..EL@YO [!4G-8_3>)74.]4OK),TP5,&RP;_M<;0WL5Z'<VSG/LX
M\ (<H7M8W 2&ZZ5967_@!M=KG45IVZS4RFR!GK&S;.4MXU4,7RYAIX$F=[57
M/CAT=V!T+O$=>- 0UZ.'8:CBZ$ .KN-FDS32+\H2+XIMM(C_[7<@+!1Q?A__
M[@]>C1\@^[O+ULLX+_[E?T_"8/PC$7M98]!PE&5>!;/,9[UNKQ? _N0>,)M=
M['M!S^_UZ/\B3'C1K@2&D_P=WD**2S/U0U(4N[HX(3RYI8,?O4'O0 \_2J/,
M8PPC?^&%T[X_#L?^J-^C'\/)U)^&\-UTXD6E!Y=XK(48>@"X<[R9PRXI#NTC
M]]C&BS*YC]>UI3E?+A/<?=@KY'8=8/R+:)O WC4<E-UFMZ:;0]@@G,H\OH.#
M"4T#511-ATN_ [25+)(: V(Z*4[>RQI=T:P?\?Y=# -7]^'"O@_G<A^2; I<
M#4]$;3F]._AA'L<I3"B'>2^]59YM/%@0V$]82_PB2:&=A*8%#1.)2W/E'6P:
M]E:32$Z[H\\^1GBP[^(2N=MSN+.?>;]O$7]GJG/L^+4>T\>L2(Z(J;7SHNG8
M.P,"62*KS(%IP[)0U\^/-E"C^%/?..6P/79T[MM'A];X^"GCDD>S1PMF,T,V
ML'4?MC'?2K:(IH9AR6G^$;FM?[(Z5)/JKODZJ%_@[^&@;/-LN5N4ZLYH8/3V
MS=KV%)_KME]E#4!/4.)878[,"J+T6Y!H"@\6LS;%:[A*HGS!XM,2>EIG)!C5
M#DZ\!O'AUO=N0<I ]0"?CY8;$"GPP" C;6BZS&$1=CF.\0R$S@R$A/US;W&'
MRD'S9+/:I.H2*O!8(&ODK<^9T62:&IHO9VF*A+W:&EVE<&W#4(%.J&$MTC;*
MAOII:;,N0A1 H"G\C)/8)<6=XC;+>-["Z+/:( _/>1Z#7AVK\9;1E]9%@M_:
M!HI4FMC-'GW < \?KH4B69S(6@XVM$S6.SS>IS4E:MT.N0/>RG#9[HA8TM,&
MRQSB&S5K#[VEX9-XV84C,JBM?DO=G:I_.O=:8X/M-]N'!L&%)]W RFO/M%!/
M>Z,D7P#3P&LM6X/XA4/>I7D<K4FPO(T2X.I93L)37-!YP!,5W4?)&E6'#E!_
MIP!]V"MB$.I%X,F3 G=LR=P&18\MV5R G%!<AF.[[,+ZP>'U'O _:0:\"P]?
MCF(L,*<UJ&P)B&.B4"U_W8DFZ959 R% H[LU$0FQH+;AX\AQ,#1>F*@]9& T
M)0\(!"$81%([M- L"XHPA";Y4M[0D\X*/>U3A:G3:;$N9YU&F]??<VWKZWHZ
M)?JXU$];)C0XO%YG#Z=;B-P3:MYO/Y?G[C+A_0G2*FK8M063520["(@>]\D2
M1?>]=9M&J.LT&QQ>Q; R( 9K0T*T0>WW[_1%HX+9 8Y:M4"T7#/G5EOJ%@3.
M68B-@Z4.^ IE1Q+J%R"R-!LD\+"N8.)R 9,A"E;\<Y+6I)HW0"@V=<@-2\K/
M(2,1T4J-(NZB]);E2K;JT*@/F7"T$:V^U(\Q:5 WI]@5WC?M_9E<9\\;J:#1
MXK@BBJ0SQXMTA'(^[D!RC.@DKK#O!@-;@QEN$<=+Z47MS]>\>^K>NF]OHE+Q
M86CCL;9$F?=37FV<PQ.'?<(0CSUWA'2:R. 8Z8BJ?X1TG&G%7^)\D?""DJ((
M--LHSU=>VVS7V3Z.Y9VMVI;M.JHQKAL4DYEI6)<J<DV2W> "*<NU9M!"3M%#
ME#==:-MHKYY<5$V??*\?LW?J=3=K;>] TQHV-;&,%W [%C&)K:<Z#5J]"V@]
MF\>W29IBSS"Y/>B&CWH[1N6I^;W9;KOE!49CK*(9N@O@$MO!%G1@ =,._631
M7;JLK\:^0=--6=L$JNDD:0<6\Q:.9@$K!'W27M]%</.3E2I:P*B1#>_@KL^]
M^2Y9+SMEUBE@T[TUKF>-,>>W4:JN,1S2;+?91#G)KK/D-B7A!KV?;+S'H7X$
MV6'1)(]83?F6D*%:_LCBJKXQC97*DD$.2//7;\[?7_W[^<W5A_?>^?M7WNS3
MNW?GUW_U/KSV9E=OWE^]OKHX?W_CG5]<?/CT_N;J_1OOXX>W5Q=7ES//F>7E
MEWB=?$E   <QL.N=H0DQ[/VHOZ;/P8^>?/\05[_)=KGZ!D0V^7)7R'? 6X!B
MO'F2;>'\;:)%O".YDJ2**-WCOYNDE'.*(C1)#6A!\&U#!9,B/(L<!.5$O7!I
M_.#!UL,FI#%)4,D&CQB(&'C>Q:J,4A1P$QC@-LZ /KV'I+R#)T 4R;NPM2B2
MP$3@B1U9J_"@!=/I &3'NQPXCQAZ"CTZ-%B7>O&8Z!0QXESN\FQW>V><,=94
M?'',D7QPBR9B$"&\:(NCCM8^7XXD_I#B8,T:[H7\<UP"WUO$H.4\9!Y.T3'&
M+J)Y]O<(23.98U,PD;MDGD 7N%8;E+=Q^N4^ST"1BE&LHNL#5F"]HYG_^?+-
M:]][=WGC>^=_>4NCN;Z\H3%OH9GBA7=Q_O(#_/[7O\!N!^/!CR!? ^M#SD!S
MP*'@0H/PDX"4#)I?"<P+=SA:WN.*X[Q1)UO$:V01,#70TB)->M<7%YIXL/<+
M[.SZZD^JMT6T!;TAKG7'BP]+X0,]E!$:H),%DL8.[0TPBCN8=++4NX[F\/(N
MR9=J=^&8?KBY? NG1'7E,_5B? /NDU#<(ILGT(,L,0EY>4$W@[/8[RY_]F7'
M- ^**LXV(L,W<8K[O8!;(H+QDLV=#.:Q=YTMX+]O@)BVSYDR$FO>$=YT.=U/
MV/!F#ILIEL9;&&%*1PK7WJS\!BY%7.VN]S("]9R509LW'7 2-!KWF7!B]@(H
MGR:TJH\&Z[\9W_IXQA[N8 GVG>PA1=O ;EXDRP3T^KB@+8'G8G3UPV?ES5CM
MTH4X:EAF7NQQ&;#'3VFBU;9"4]"G[JRK28C-35WO'(B-M K%><3G(2/,(U!Q
M%FQK-E<(S 'M!V15T OFL.X;F3>UB>=GERIGR&.6T72Y1>=[SB8J;#A?DL)$
ME!*9>V>;P\KC62Z4K18.&OP.AY3?I>6!A:#301-/-E;?B16U@PL 4A6J9B72
MS&OXQ<.8'/KE',2>!1!WT,/)7S/+PM=FG;\H.IVY]H[++PO2IBA< W0^?%IM
MSNQ2'^\N7:0YLIWU'EEMO(?M0OE*DQ5,2_51'?$JRTH6Q?)8+GH0J6C*#2O2
MO'2X-KAWP+[BQHWIPK5(5)MMX;SC58XCLDT;9V+H(EDJ93M7B@-%DS[2*PDT
MYH7G;!E;$G]/@:L6!7(G' EPFBC)E25+\QN</-M*B/R,&=S(9R*70QN-)C&+
MO&1A@9Y_B?GK:)GQ"GG#L(-W^+#?>8CCS[ >%*V#4IZW13%GSTX\L[H@!VK3
MU^L<Z!ON<Y#R4&\',K(<B+"B7E>%_U"#Y+7%\ L6)E/S=#BU?+HK]Y41/AV[
MSRO/31?IE@7U- $F$>-%"XIX3(><3D2"M().?_%),AGQHDE/:NVXG[J3^8\[
MF+?V+Y,=I:TI'+1JJ'EVM3GX=*,G((,L^,9$ARL14*V3XP,UW\A(\;7&08F'
M]R0W>M<S'BE%E6I,1?+%V["GK7%89) M-=4GZ[V:*YKK*J1.M+8!DIK'9'8B
MY5OU1 01LZQ6GT:6\WD"+K_:E:AT\&JI&Z;934VA#LA/BKMLM\9(&[1)BJ\@
M_55N(>;$+)@=X^JF2;( PYFHCK]A%T8H=L@IQ;Z1^YRG*1K&KIEX81"*1?\,
M':_A.3TH8*_T>SS/=\A7PK&L2=?[Q'?P)?"J#=V7>'?Q=:-Y#7;VF'L+GD"N
M3(+WDVZGA[L$!!_AX 7L=QK=LGX.+6ZBS['WZVYY2YWY7JR'S@>OV&W8@,#$
M$JU60"5"1+A2,5DYE4C"9CW?-K'YRD3'4K?X(OFT*/N!45WA-OB =P\L\&V&
MTT274^';@X[1&T\C3*!3,UXM7_N@AY9T"E"T8+W'%P')LEBH8:$Y&/1.UB*-
MD ZDL1-A16SG[#SVSHH=>GF1S\VQ8U_<L/-H\1D^H"4*?X,S(=<'?P/[DSV0
M-/3<M[@+&>WBG.Y=8JAP;<$&:Q,_67K7<'9SBC+D1>05D)\W0)U%F:%J1B0J
MG(0\'41JEC1<<-?6CNEIV;LCHC2^#G+P*E$6U*(@&P]Q2U %8JUK930^W/&]
M,I-)["/H 67$<A9%PMFQ-6:QH\.1=7O?Q.$TF,SIHIV3&1%&;"@"U@?N(Q@'
M-8F3R^G68I4U]>YA*J ^B>&3]8@.+AXNOQ/EN88EYW!+]S@\X)6_3F -<;F9
MFQ4@1J.FPFM(7"S)%[L-AFDL8MD!2]C@XXD$0+\0P1,3@Z.):Z,/IP?;N..S
M!RI=3J(P1:981Z]J49=3*[<"\EJ\$4"](0^4./UID@6LW0+/W_FBW)%DQ2-<
M$*->)G#P<4@HY!*KD< D/%1ZQ;L@C8+VL%"D">?X:J/>\2[S'&;URO@5637\
M&S#1DO4QO@IA4=4A@(V.\:U",;1#X4NDR9X2Z>)7O',4:D!O&V\2;@ ,9TBL
M?4#_[3,5PE^A*(H\)J..*!W@M' K&>]C8G1.'3E*T'!!.&J)(WO1[LWPKK"%
MHU!;51S1INO-Y%#@SB.3Y(<?V/]'.PX4 ;\N)!PO>,Y\!GB>\+%Y7#Z@<-P>
M$JC6HV($%I'E63@9=X?([-:DG=P"_[F%OM0]B.\35Q.:!D8PZ(;#'YP69R"V
MPIK,=G-2B6BH[ZF7)5P$,*>IUJ'H _VF5*D?>?>?*P[J>./(K&9[Y/ \9N@+
MM"4'TZCR--,ZTDT+.X::.MS2%+TKOF?OI^B>8GCDTF,)4QTI8;<EZ_1\4&CZ
M$9XJU/%9[,,.X(NU^@RM*VG3N5HQ^A!]HRP8,>M8PQE'BA#KP\XVTS@=H^^]
ML"RX8FQDZQZ):6@-<V37&@&.?!'[;"[B]D+L")G9W*P#B48I2[KWR1+9%U,_
M+R.?UF7"[[%&EGHQBS*B6Y6Y6-R-#"8<$)W;G]E@:20P8>(D4NESJH1#.+VK
ME6W!?KE;K]&:!7O?]::@GKRS-I",X ??"'H3MF^C2JN8YR4-7ZPE.%=*^7B7
M%);H^ !\POL34<**K@OW9VA>18MS DZ3@;SKO8P7T:Z(CQ"*LTOJPE$;1$R=
M5%'96GQ\@\*%T7IXM#6IWXF;1?G*88V9Q1KK$<--VCM);XH-LBIH% %194#@
MA]4J4-U%J8TDE#QV1*<S8OXZ.#+^@H*W"6I2SSWGQ1%UQ]@(M/"LM!46K$E
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MC,I$406_U>5,],[+B/NQ(F6O4N^/4<HV^%XP)B5#N=HLWC?#_"@,/_,^;7&
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MLG$@AK9Q"9_;BM,WXS8QBK4D(N8,@^J@ONZJ4P%X>8R Z+6]XK#2=+>*%L1
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M0&W[3@2]>2]CL8BEP:K.DA*EP&*?*@=)EQPQ,5\59I/4Z\#7*+F6%>7PKZ:
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M\U[O\C31"?BKY$M)18$1Z"T SAT.>F3Z*G/VF':2M$/^,MRR8 0"Q]@#%C\
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M#$MEUSX;6J/9FM]!0:(@YR;!EBOWUH(R4EI,PLD:6%XBSK*A2H[XVRZ5(?*
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MS->BEKN**QXKL'?X\1ZFDNT*<;^Q5[*#BX?+[SCFUK#DJ%Q4C\-#K!Q\8NU
M"P+(C&@ -T+](LD7NPTZ[A<*]-*Z)?EX4K@F_L( 1Z0M19]Q;?3A1'20'9\]
M#88BP"+ZZ/%&66OLQ$# Z);HRHVV*+BA(0 IFR<IZ!THZ5"@BAKA@F(<E@D%
M=RIX66A#H$OP4.D5;_"(@^2LH0_A6%]M-$+M99YG^:-?L#/5"(1$&1,D$'Q$
MABAUB-"QBV_I\-EV6#.="V5^MZ)FH/$/6IKA&B1Y? <$B!8;C'CDMU'">:TE
M'!C.D.Z5 ?VW[RO;=NB+QYS&9.1P)?R> L.FQ]OTY->.'$5'CO\T\K@C,]#N
MS_"NL2_UT%,XN\Z5W&7/WXJ]FY2?0@\_<. V[3A0E&4Y"IXSG])&91.,82Q!
MZ"7M)+H"DUH/C5'-(K>(I<_"B5,\4:<QU) 9^4P (\&4YQ^<%F<@;L&:S'9S
MI8 O723LJ58>3(R)TB%^Y-U_KCBP@WW*7BP'_[0!<]@*7!&$)5I' 8 AM5;\
M'[)/7>^GZ-Y"<8]9,E)'2M@U.Z3EH-#TJ6HH*L2,@((=<,P%?X;6E93D7,T8
M5%VIMH@.6HV\K$O=F%F;CM$_4ECF!V5XUMF8:9+&KN.H1H CA0]H<Q&W%V)G
MR SG%EHVBE8IA4H@/@2R/Z9^7D9?0AL=T"ZQV&JH[IR$>QLP2S@H#(D9.9>[
M80E.+@'+Y*7TT\L+/+VKE6U^>;E;K]%.!7O?]:8@5K^S-I L. ??"'H3G_@#
MZG**>5[2\,5,@'.E=)EWH ,;WD%UT/Y$E+"BZ\;]&2N+B<N!7FZ,-^QZ+R5L
M[C"A.+ND+BRU0;9W@;86']^@<&*D=56U+3X$T>_;DK6CHOJ<H*Q9XUJQQHK:
MRE5'A VR"F,""\7K@N$&Z6V!:II&BI$B)DKT.C6XG!>GN".R-<JQ%KZ5CL2"
M.0E8<$K@-C'>&F/WKTS8^:%E]NXS>BD.>[49O>>0:WMD2,2]H5X8$&F11GU*
M,BP8D1I3P$,_&+/^]FS@]WO!8Q.W*UH>U=;N^8-A0 '!9V'/'W,L,"-0D'2D
MQT*%7+[_@*;^N,<EJ,\"!%M0V4NX+[]%_U:0NYM@P+6,J_'95DI%;72$TD2#
M@[_";S V';NM@K9=::<NX;RH?/<;+N)H-)9%[,..]NJ#-7(7Y@*^:-]D=U"'
MAX(R@F$1]A92Y-2C ->_Z4!&_B (VE,AT5I"-X"^;+& .%ZR((ZAJY 8D+B4
M:#3P*"9P43"[3J@V3A'?RJNT7"69*O1<^9ZA"'3V><TZJ7T%?$NI08I11%=!
M1XF4USC7!0%H"D^SN-<-8J>2I->0V.9UO*]P /WCTPW4?6=,&*[$9Y(RU",G
MW*#MFII.WCSA?JU)%.XOQV[8PKUB:\KT=>SB0=>LC[4'O NQOMC2K%X7G0CQ
M%.=/'EO(KQQ)SB:,3(>A2'>VDZ K867FU6>!57K%LA.I4$ VGBDFI6%<M75+
M1]&VH9^3/L,YUFI@CGTD.QB'K7;_L248K+AG5>',6JX[8XC4_D"EX)*5@GQ2
M[(9O-NM85/B((;;>/2=R<WN?[^(&]P]:@ZRAZ2*)=B&TZELM,Q1^\825KX7Z
MQ60_ \%2N^5.>(02O>DLQYS3C,$L:V7VEK0D>NMDV%CTT/TQ2CDO2H<8BD^J
ML8CBIRVAN^CZIA8L&2IVN"F=WM1W>I$ 3DX5<[H_NZ$RC.-@\AS$[ I:C4%X
M)8C:ES9$K34XWQZ,&H >5->SOB6,X00S:23@I2!X0]NT76#P$V%+;Y4R:KGT
M%5:%@;2UT'-5A0#;A^Z[)F6[C17#C*&+P;?!GY#GD<V$3+-UP/V(898P=I-+
M<0NBE N#[:NP$N?MM*Y^6>R]%F)'E"#=6LMHXOXVS*>\>"W&C3*3&%U[>EH/
MWG/B/>*)Q/=HZ$;;6RM,+9I?6@*$9 WL4MOW5(Z$<"\6EF'!JFEI!B3XW>QG
MEUB!JA-+N2YNJ2>.)S83PO,GQT05L=Q0>=$8?4BEL0(PS$V$04%D,<J<FT_G
MA8DT6X,J0.2>@\/T=6U'L6.14UGG+G. =%_?9VSOL:H[ VV(,R6JV3$[VH[)
M 8#"*,1?V5@B[!#%Z,*:@A%MXAN%W%;Q4B,>,VA9'6U,@KZ'(ZO0&IU(AEW#
M Z2AU[::RIQ\2U7Y!\?-5C!W&,M8"D5B8PICOHI7]"P,[&)J^,0*PRVI>*1[
MO53;-[XR[8'SG>% "SCQO\=YIM6-5$KVUC#B2$HXL5!*X7)#V1#QPI)0RNH,
MU:?+L!LB[1U<HQ*A0B=YF8A]'$D/$XP992C2P6DP//LGC6DTCROH_%%=&]JK
MN1Z3&%R!P>4I#TY';"!3>#5(S)JD;.[W!)Y +5OFN":^T,P.ZIEOYF18LIFJ
M5LQY4T@B$MUDG1ZI(>=JH0VJ)QL5K&R)"+.#FFO#UAI7.FVC]GJX5D_+CITJ
MXC5I'7%%%\RS%/Y>--?'.?8\"D&"C#-@:[W1&QMEH)<9_*.ECM?GLY=:W)!\
M3SQE(@X-B/U=JU!I2D"0['MQCU]HC4'$H5%O]+PJU PLH88"JR0'F/5$&C2,
MHZ'_80=G]>C^7X#B@FPPTC%DESH>G+!>563[$M2&/4<AFHAQA0!H#9ZH,F5=
MNFO_0.D$T8:VWM> ;J:M%5E4E%+!P'.6A[42I#3A6(N(T:,XIYA.I))\: _U
M2*A86H*H9[K\,SUL#_S4GIU92:PQ@L&A-/N0>9L8V.B2KQ*Y)5^XS&%-F'T4
MDLM" DOVQ((<S15V^ QAE2J\A7MX[GOTJMNP25<P<H+R%ZT4-!X[XM=[Y9&Y
MW25+J62ETSE%<E8[K$#U!!:)I7KRZ#6+0S+&0^MM@O0/MB$,.\MCBT%7:"Y1
MX08I1]/NE=7%U/=603=TLR6E56L&DU@H(>8VHWW+/0S>HXP LBFH4^.4G!-.
M357,"NW[06E40VSPN:$#PV-B,;:HIJ<D=NZ:KJ%2&XQ+=BC18>!-Q!B911EO
M.7:\D'"M.XX-(<G27;L(2XDB;GO&M5-\=HIA/6HQ$< M7B025,-IY=B""@>1
MD'45ZR*9W#K U,+0:@AT,H.$"9N7.&0E_B)!HB=%J-J\W1@]T!5=1@IT0 6N
MLNP4@="[IPCEM$V*Y3.=BKW.@GETGB>*MG!6M#O7B'$\?S-O$_'$S-DQ,W'I
MLDPHA-?<'A#U)VV3&1;#M&^YS>8NI,**FS[J8O3]$NO^+#/1WLC%JC%=/Q"#
M6A2(UEG$&8%PJ#^GB!D7(?IMH5-HG[--6RQ^U9@"%9S5F.5J#Y,18UEF4A4&
MZ.CRE",'OLE6>53Q35>;F?@6KH0@&)^TH'8J(S#F-9Y[]M8+8B9P18Y@<[+M
M['KT!/ET-&%$5D0EQ'2MN!,4(%6,S-&%\P_/J[(!U7'E',*>P<)947X<D26L
MJ@%N#\/:&#'/X87Z>K%-\A9Y=^NT;JLLML9JQ6N*?*Z(0A.K997YM@DH-V28
MK:6?S!9W\7+'=Q('BEU47 (<Y<!1XQ;@6+W XS]]]O_TV?_39_]/G_T_??;_
M(WSV]1#C%C2!MJO%>@$(\=S<[BQ$76VA(^\_WI'?L88SH4P!UW:6P3LT/H)$
MW+%"^^V&"^\_WN*5<(570AVZPKKJW+%=JV#^3R3(M\RT5KW0CJ@^L?2%!NGP
M*\*/SB<PX>^\0&WYK%4(ZN\'GG=>B;G=;4$%L"LD\&D2.5$+7 BJ0K<+%>XC
MN)6I ELA+G^=[0G42,D^B'6I4%0&%K[**TNZ6[",GFSFN[R0/9^,0@L8+YB:
M5CXJ+66']@(+4T)U.0DL)$\"-E>?L.XD>=IV @Z@-)XS?,=&?Z77S!=J5I;#
M_<WL9Y3E*6>?W/)PF'ESS_KAQ&YL-!I8'UNP>$ZED&<"8V/67Z!L9 ,>>5Y-
MBG7;F?W* Q%_Z9#FG+MT(6!_^(NX5AZ3]OW;'9/KZK"S5$^I$35#*Q,M^XP0
MZ_T1(_3W!E0O6DJ< 96/0V=)[.8>49N3;V*X-,<3D0CA&B?(=Q3&J.8S_QGX
MTQ K3+5>9^?5H@@4D()%GC.%T"KWZ(DA6.)RQ/N8IV7R(^EG-(0]Q.HQRB5:
M*GW0!8O%*B-*800)@,LG,5!$10O4Y*1!=W9I@IHS&W)$=10\(.4CT6[HM8U^
MI7%I#&9^!>"G47FF*!9%(]OUKO#^/5XC::P<. F4TZ-M4XFB@T?X)OH<+Z-O
M>GY/N,>DU^]Q0FD(1X[ID>N+*A=,^CWFBO#\L>L&#F70AW>"WN0XASXR]V<"
M)?:,0<1.WD[QB;Q91U\R;[;!OW\F9?@[L69FR8F#18>W6AL4EV%W[RYOKJ\8
M9N#B_"5^_.M??G.F7!\X;OIT1#()221#X+14"\\/@TEM&U 2QQG8Z*RG&%3.
M5;T?K#O6F45K&T>A^B(J!!4PP$(J+Z('8*$&07^@;>D>VDNY3)(>ELH/UD4:
M]6M."?2]F]YA#"D:1:E*"/4 P>JF-9ZZF"MX2[&23VD>([N#;]\@VEK]Z[=\
M4U@E&B_:YHV[U1_"?H5.?3[SE_IU=@=#Z5 ])7L1PF! UR@HV&<!E4_$;WJ#
M 0PBO6UX'A2ZW@#^@<?Q6L3/P C,P\=6':[6H8%PUI(N?<OVE\;7X-J?]/Q!
M'RM?DS1]%HSXAL;O^R TU_?FMUG](5;Z&;6MOOS:MOJCB1_V!X@;>A:0Q('?
M8"F%YM4?#D%DA<U"&Q&*V_!Y!*KY8U8_:%S]X-CJ#\93?T*L(AB0I2-D8Q5^
M/QP.ZF"*VB9+BW=IK5F5A\ Y%'ZP]V[VVUK-CR,L@4SHU7UI..N%ZJ.$/AYQ
MPMEWJ:RXQJL;?V'H%NR;'=D*S,7NV(VAJ8WS-V(?[VK(V;AU0'O#?@OARH\7
M%7AM&%O?GXS'> :!8I$&\!L$#;VHX&X/&P@-OZL#:Q^#U(93Y*-.J!5$4A?Q
MR_Y(J+;"*N 0]0>#.JO XQ8.OR>K:%SI,2@1PW'+2LN/M94.1G =CX>U-53?
M5]<[&(8@N85>'PM9\0*%I+L\8<''/:KG$> FHRZ.G\-QXUH/1CT_' _JC&$X
M!=EB=( Q')0+\,3:Q8??126=WA.8@^$-[-0GL"&".N"@8=U%);[-&0[!(R(<
MMC6&C8RAD7E43S(-.%:>] _P*&6YGE/4J_ZH,MYO'C+ZXDFGMNVLAI/ '\+=
MCO6X87/:#JI].)]Z0/O^=()5[? 6/W0P!\ ]J&1*. "Y86#.9+V2LH" G"1B
MZJ?;FSF]E++>5X=-7$</.D2 BD.'*(I@[>A?LORSEYBH"%@+K%<#'*B/T6D,
MTL>A(($?A($W!BF&5V?H#T<3? 'E+2I*EV9I1Z? B"W!-FMP+HI$NHK$=C:B
MPG57!C<%C6QD^ J'9##I]VOB?$N9R+;5=AZ/]>.RJFQT>,JR7G EY]QJDY2R
M;%4^2.TD()E>G__ E:.B<QBNZI;,1;5U" HD5E=\R^HB;KMI=N"'0*(#*B+T
M>I>G%!XNV%E?.%0<[3L!EO(;]"@LLLP9Q ?CJZ&K6X3CQ,KTX\D8<>4'<+R
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M#6[SN(,XMIQFV*;]N-.5(A=6F0+3PAH'H]WT*CV.]:(FB\&(@TN/*1"^6X.
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MY/ BP-5DUTJ.S(0U6IO+K-489<P$L'N+J[MT^O:E;;7]^:P%YTZ;'X*5#HQ
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M\4V^J8,Q0T((V(U0EOKS!(&F_X!Y_G_P_>Z&ZNAKY=RQ>%)6C.?2*HJ()O^
M??;W(9RIM[._:\1T:U6N:_&LW8)"(@<$S!(8KR9.?5\UP?S]^G!&"Y$ 0F8!
M0+^' <5$6@B9M8 Q0XH)5QGLRXSV0$0<^25D09^8$*DCY%YHM$0D.T1W3"&1
M0$)F@7R$)JUD2!TALSK:8Y163&23D-DF3;#2"H5\$C+[I"-JV7-23.24D-DI
M7=%+RX.,K!(R6X4&,6VW.D)JB9C50J*95C;DDXC9)R"L:5@I)O))Q)^VZ@YM
MQ!'%A'DK9I] .T<QQ41&B9B-@C%IZBI">HF8]8(Q:?(J0GJ)F/6",6GZ*D+"
MB?I,8$6G%!,))V(6#L8\HYA(.!%W+JLSP!TMW6&*&JDG9E=/%^;F",5$%HK9
M2R==F'\I<SB:R$)Q;ZL:?R2FQ9,862AF+Y]T+[X6*J>8L'["7D!!HTDM%",+
MQ>PEE"[,&ZL=S5_$R$(Q>\JL\Q$JY%M%,9&%8F8+=6,^UG-E*2:R4,R=2FM-
M#.Q5-*&8R$)Q#Q45<?0@;3.^:[HZ2Y"%$FX+H=%,:&XM019*N"W4BGF]EKKX
M::V;( LES!8B^:"Q[RY?%:H)CO;-%!-9*&&V4%=R:,=,,9&%$F8+=6'N'B**
M">OXS!;:YK#H_6Y:CL71G:K][Y-B(@LEOR75=J>4G6E5Y.*AJI7[H*19K019
M*&&VT!9S9&IE_8,N[M^:O)8?52,VZ!0362AAMM#NINM"3SW:BRP*]2YNI%F(
MKY4T=$=1@BR4,%NH,Y6Y_;G232;(0BFSA;I3F1M.BHDLE#);J!OS'Z5?YQ03
M62AEMA <S92NA5)DH9390@"S"3\H)K)0VM,F@9V'*":R4,IL(3B:Z<%V,KB?
MC-E"A]6 PR#)'Z&8R$(I^UJ(U 4HY9=5O3K85I B"Z7LVPHZ,)]]DZ2A1XHL
ME+)GY CFQQ*H+4+*D(4R9@O!@LLSO>D9LE#69UWHB:83,F2AK,^Z4$8ME"$+
M9?P;F@$FK0MER$(9_Y9F@$DS<AFR4+:QT'!SLKNZR-5,&Y4_^*]POGTJB^F3
M%<W+=AMCG#0;DF:KHKCU;8_&Q[9-^Z:/_7\0KOX#4$L#!!0    (  N" DMN
MQ0CI9@(  /8L   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%VDUN
MVS 0AN&K&#I :,Z0PZ2(L^HFV[07$&SZ![$E0521Y/95O:D*)/JZ,#YM;!@V
M9MZ-'PB4'E_RN1Y.;5..IZZLWB_GIFRJXS!TWYPKVV.^U.6N[7(S?K-O^TL]
MC!_[@^OJ[6M]R$[6:W/]=$;U]#B=N7K>;:K^>>>KU<^Z/^1A4[GWLWMK^]=R
MS'DH[OKF[\8%XT\^NOP_Z]O]_K3-W]OMKTMNAD\J_BZHW.=!,A\D]""=#U)Z
M4)@/"O2@.!\4Z4$V'V3TH#0?E.A!]_-!]_2@A_F@!WJ07P,9U_PDA#5?:P^X
M]GRO/0#;\\7V@&S/-]L#M#U?;0_8]GRW/8#;\^7V@&[/M]L#O#U?;P%Z"U]O
M 7K+ M?:Z&*;K[< O86OMP"]A:^W +V%K[< O86OMP"]A:^W +V%K[< O86O
MMP*]E:^W KV5K[<"O76!LQ)T6,+76X'>RM=;@=[*UUN!WLK76X'>RM=;@=[*
MUUN!WLK7.P"] U_O /0.?+T#T#OP]0Y [[# 63<Z[.;K'8#>@:]W 'H'OMX!
MZ!WX>@>@=^#K'8#>@:]W!'I'OMX1Z!WY>D>@=^3K'8'>D:]W!'K'!>Y5HIN5
M?+TCT#OR]8Y [\C7.P*](U_O"/2.?+T-Z&U\O0WH;7R]#>AM?+T-Z&U\O0WH
M;7R]#>AM"SQK@AXVX>MM0&_CZVU ;^/K;4!OX^N=@-Z)KW<">B>^W@GHG?AZ
M)Z!WXNN=@-Z)KW<">B>^WFFB=SG6?=[]&/I3<RBW+OEG^)<U$[C+\''.M\^X
M3OUR_T3I8=R2W?7UYG_QZ]0_$6Y:49Y^ U!+ P04    "  +@@)+WPG))!0"
M  #I*P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VLU.XS 4!>!7J;)%C>O?
MP(BR&=@.2#,O8)+;)FH26[9ARMOC!!AI4)% M-+9-$VN<^]):GVK7OYY\A07
M^Z$?X[IH4_(_&(MU2X.-I?,TYLK&A<&F?!JVS-MZ9[?$Q&IE6.W&1&-:IJE'
M<75Y31O[T*?%SY?K4^MU8;WON]JFSHWL<6S>-5V^-BP#]?.:V'8^GN4%Q>)F
MG[O$?&U=Y&HLV"<FO+]Q.L_WW3Y2"%U#7XKF-INNIL;5#T.^I8P^D&UB2Y2&
MOHRM#=3\3J$;MZ]Y[VQ(O^R0&[-]S_Y;4)XN1WKJZ7" N7+,R2EO"SHT:BZ\
M?/)O#7S;#;4+M/0A5T/J#CQ>CG27JY%-"X_YB#1MG8::3PW/K4_WP_YU83=_
M/_3"_Q4CFP_?>^O'RR% <DB0' HDAP;)84!R5" YSD%R7(#DX"N4("BB<A12
M.8JI' 55CJ(J1V&5H[C*46#E*+(*%%D%BJP"15:!(JM D56@R"I09!4HL@H4
M606*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL$D56B2*K0I%5H<BJ4&15*+(J
M%%D5BJP*15:%(JM"D56AR*I19-4HLFH4636*K!I%5HTBJT:15:/(JE%DU2BR
M&A19#8JL!D56@R*K09'5H,AJ4&0U*+(:%%D-BJP5BJP5BJP5BJP5BJP5BJS5
M"66=C^5@N_&C)/?.[=[FL_D?OE?/4$L! A0#%     @ "X("2Q\CSP/
M$P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%     @
M"X("2V;S"V""    L0   !               ( !Z0   &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  +@@)+,&&?Q>\    K @  $0
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M965T-"YX;6Q02P$"% ,4    "  +@@)+\T$R<XH"  !%"   &
M    @ %X&   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M"X("2YP*#845 @  308  !@              ( !.!L  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    (  N" DL?W5TY5 4  /,:   8
M          "  8,=  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    "  +@@)+IB==)Z\!  #2 P  &               @ $-(P  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ "X("2R.SHV.P 0  T@,
M !@              ( !\B0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    (  N" DL/<!YYM0$  -(#   9              "  =@F  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ "X("2Y-NQK.T
M 0  T@,  !D              ( !Q"@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    "  +@@)+;)*2<+0!  #2 P  &0
M@ &O*@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  N"
M DL*"483M $  -(#   9              "  9HL  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ "X("2TV)ZBBV 0  T@,  !D
M         ( !A2X  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    "  +@@)+^XO+J;0!  #2 P  &0              @ %R,   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  N" DM_LF3<M $  -(#
M   9              "  5TR  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ "X("2V^F<>JV 0  T ,  !D              ( !2#0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  +@@)+#J5T
M(+0!  #2 P  &0              @ $U-@  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    (  N" DMZ;;/OM $  -(#   9
M  "  2 X  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M"X("2R!+=?:U 0  T@,  !D              ( !"SH  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    "  +@@)+"M')MB("   $!P  &0
M            @ 'W.P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    (  N" DOS?\=WLP$  -(#   9              "  5 ^  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ "X("2Z K2]D5 @
MU08  !D              ( !.D   'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    "  +@@)+:ZGAZ](!  "<!   &0              @ &&
M0@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  N" DLV
MJB<0MP$  -(#   9              "  8]$  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ "X("2^RE&:&W 0  T@,  !D
M     ( !?48  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  N" DL9&C85Q@$  #<$   9              "
M 6-0  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ "X("
M2Z5?L_/" 0  -P0  !D              ( !8%(  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    "  +@@)+[T# :K@!  #2 P  &0
M        @ %95   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   (  N" DNAJ^[FV@$  +<$   9              "  4A6  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ "X("2S"\9$2L 0  Q0,
M !D              ( !65@  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    "  +@@)+@+7ANH@#  !T#P  &0              @ $\6@
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  N" DM1+::]
MQ0$  (4$   9              "  ?M=  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ "X("2Q)<KS.X 0  T@,  !D
M ( !]U\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  +
M@@)+;JW:.)L"  !'"0  &0              @ 'F80  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  N" DO(+-%3BP0  ,<8   9
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M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ "X("2W:
MEA%<!    !4  !D              ( !<G(  'AL+W=O<FMS:&5E=',O<VAE
M970T-"YX;6Q02P$"% ,4    "  +@@)+S=W2)VH"  "V!P  &0
M    @ $%=P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M  N" DNY'<_?TP$  +D$   9              "  :9Y  !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ "X("2^TG9%TV @  MP8  !D
M             ( !L'L  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    "  +@@)+<<LV3BL"  "4!@  &0              @ $=?@  >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  N" DLL/!"#;P,
M &H0   9              "  7^   !X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ "X("2\&ET7,+ P  [PP  !D              ( !
M)80  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  +@@)+
M1$Q=&GH#  !F$   &0              @ %GAP  >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    (  N" DN>5U+"W@(  #\,   9
M      "  1B+  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ "X("2[#<(.ZN @  ,@D  !D              ( !+8X  'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  +@@)+ \YV%2@#  #_#
M&0              @ $2D0  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    (  N" DO;F4Y>20(  /X&   9              "  7&4  !X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ "X("2Y%6/&/U
M 0  Z 4  !D              ( !\98  'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    "  +@@)+'BZ=%_0"  "5#   &0
M@ $=F0  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (  N"
M DM[F242C0(  %@)   9              "  4B<  !X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ "X("2\/PGE"[ @  8 L  !D
M         ( !#)\  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
M    "  +@@)+1;5_-X8#  #M$@  &0              @ '^H0  >&PO=V]R
M:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (  N" DM;$+#L? (  $8(
M   9              "  ;NE  !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL
M4$L! A0#%     @ "X("2]"X:R-( @  *0<  !D              ( !;J@
M 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  +@@)+#*#3
M!<\"   A#   &0              @ 'MJ@  >&PO=V]R:W-H965T<R]S:&5E
M=#8S+GAM;%!+ 0(4 Q0    (  N" DM/((1SSP(  $P*   9
M  "  ?.M  !X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
M"X("2_6'^>JM 0  H ,  !D              ( !^;   'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    "  +@@)+]K6@W8X"  "A"   &0
M            @ '=L@  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    (  N" DL"8)7^+@(  %,&   9              "  :*U  !X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ "X("2UICAC60 @
M0 H  !D              ( !![@  'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    "  +@@)+H6\,55D"   \!P  &0              @ '.
MN@  >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (  N" DOZ
M1=61>0(  #<)   9              "  5Z]  !X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ "X("2XUCSP8_ P  =0T  !D
M     ( !#L   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  N" DN38:R[$W@   ;Q 0 4              "
M <G.  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    (  N" DL6CT+3
M30(  "$,   -              "  0Y' 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ "X("2P;/9TL;!0  \C    \              ( !ADD! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    (  N" DMNQ0CI9@(  /8L   :
M      "  <Y. 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   (  N" DO?"<DD% (  .DK   3              "  6Q1 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !4 %0 _A8  +%3 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Concentrations of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConcentrationsOfCreditRisk</Role>
      <ShortName>Concentrations of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Commitments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Concentrations of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables</Role>
      <ShortName>Concentrations of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ConcentrationsOfCreditRisk</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies (Organization) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Organization) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies (Error Correction, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Error Correction, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies (Error Correction) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesErrorCorrectionDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Error Correction) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2401406 - Disclosure - Organization and Summary of Significant Accounting Policies (Reclassifications) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesReclassificationsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Reclassifications) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2401407 - Disclosure - Organization and Summary of Significant Accounting Policies (Segment Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Segment Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2401408 - Disclosure - Organization and Summary of Significant Accounting Policies (Stock-Based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Stock-Based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements (Ipsen Collaboration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails</Role>
      <ShortName>Collaboration Agreements (Ipsen Collaboration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements (Genentech Collaboration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationDetails</Role>
      <ShortName>Collaboration Agreements (Genentech Collaboration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements (Takeda Collaboration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails</Role>
      <ShortName>Collaboration Agreements (Takeda Collaboration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements (Collaboration Revenues - Takeda) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesTakedaDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Takeda) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements (Bristol-Myers Squibb Collaboration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsBristolMyersSquibbCollaborationDetails</Role>
      <ShortName>Collaboration Agreements (Bristol-Myers Squibb Collaboration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2403409 - Disclosure - Collaboration Agreements (GlaxoSmithKline Collaboration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsGlaxosmithklineCollaborationDetails</Role>
      <ShortName>Collaboration Agreements (GlaxoSmithKline Collaboration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2403410 - Disclosure - Collaboration Agreements (Other Collaborations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements (Other Collaborations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Cash and Investments (Summary by Balance Sheet Line Item) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsSummaryByBalanceSheetLineItemDetails</Role>
      <ShortName>Cash and Investments (Summary by Balance Sheet Line Item) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Cash and Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsSummaryBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments (Summary by Security Type) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Cash and Investments (Available for Sale by Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsAvailableForSaleByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments (Available for Sale by Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Inventory (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails</Role>
      <ShortName>Inventory (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Debt (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtScheduleOfDebtDetails</Role>
      <ShortName>Debt (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Debt (Deerfield Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exelixis.com/role/DebtDeerfieldNotesDetails</Role>
      <ShortName>Debt (Deerfield Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Debt (Interest Expense on Deerfield Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exelixis.com/role/DebtInterestExpenseOnDeerfieldNotesDetails</Role>
      <ShortName>Debt (Interest Expense on Deerfield Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Debt (Silicon Valley Bank Loan and Security Agreement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtSiliconValleyBankLoanAndSecurityAgreementDetails</Role>
      <ShortName>Debt (Silicon Valley Bank Loan and Security Agreement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Stock-Based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpensesDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Stock-Based Compensation (Weighted Average Grant Date Fair Values) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValuesDetails</Role>
      <ShortName>Stock-Based Compensation (Weighted Average Grant Date Fair Values) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Stock-Based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEstimatedUsingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Stock-Based Compensation (Summary of All Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of All Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2408407 - Disclosure - Stock-Based Compensation (Summary of All RSU Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of All RSU Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Income Taxes (Schedule of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Commitments (Schedule of Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments (Schedule of Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Commitments (Schedule of Rental Expenses and Sublease Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsScheduleOfRentalExpensesAndSubleaseIncomeDetails</Role>
      <ShortName>Commitments (Schedule of Rental Expenses and Sublease Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsNarrativeDetails</Role>
      <ShortName>Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net Income (Loss) Per Share (Reconciliation of Basic and Diluted Net Income (Loss) Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Reconciliation of Basic and Diluted Net Income (Loss) Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Net Income (Loss) Per Share (Potentially Dilutive Shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Potentially Dilutive Shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Concentrations of Credit Risk (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConcentrationsOfCreditRiskNarrativeDetails</Role>
      <ShortName>Concentrations of Credit Risk (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Concentrations of Credit Risk (Revenues by Customer) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByCustomerDetails</Role>
      <ShortName>Concentrations of Credit Risk (Revenues by Customer) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="exel-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Concentrations of Credit Risk (Revenues by Geographic Region) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConcentrationsOfCreditRiskRevenuesByGeographicRegionDetails</Role>
      <ShortName>Concentrations of Credit Risk (Revenues by Geographic Region) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ConcentrationsOfCreditRiskTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>exel-20170630.xml</File>
    <File>exel-20170630.xsd</File>
    <File>exel-20170630_cal.xml</File>
    <File>exel-20170630_def.xml</File>
    <File>exel-20170630_lab.xml</File>
    <File>exel-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0000939767-17-000137-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-17-000137-xbrl.zip
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M__AAZ><FH_NA-KR&47[.>O!3UKY]';RR,-V&7;9@E\$8P&[K6__J#G[Z*]B
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M*W^9]_Z:I]6P\R"@E-9HQ)#B-#AOI$"DW.;OP;6W%T3 DR4!X\YQI8)37K,
M_U#45230A"TG 3X(!1X?_GC]J$O+=:@'G]WW!_GP8V^F]_!,!\$G'::5E !C
M \_^=ZO;S1Z2R7G?;_4@$JN^.PU4-B'(Q)& WZ:7/$6*Z*@B4H*9=\@+9D-$
MMB0%#R$N(P5>2H<7 ;>*&$5V/U$QG[)>J[N\6QWP*E&GQ.MO^>P2E9+2!&O
MG?*.:>*Q5LHB'9T2U-?3"%S-AF!/P+$"ML'OO=9T]V$7<._=Q"P; #]5L?SZ
M.JA3PQ %9A3VRGH!EI=[+Y&N>#3*>ATV6PWAT]#,8'J=%3# \N2>SUF[?]/+
M'[W< Z\+)_?6>@V!HC71 D,Q4;:8!_]0V "N.?O[=,[KASZ=8_C6S@:#WUK?
M;-;+KO/A8!SY?&D-$I7O$B"MNGE9[L;.40Q<) ::)7!+N736*RRT$$PRK[@#
M5;-LO^,CR38<U<PLP 6Y&>6#VX1A_WI"\G9WE+3,IU;>F7=0EK4%'2N1MZ>M
M2JA37'KA A4,&RHC1A%4">)"*(],O=XBK9W,P;H53&OAS:OGJKM!I4^4TF+K
MIG,"V(@D4T1(2:PS6+JHE<741JFU)?5:34+54P"O!6H*,9"A2#U,?3;Y>W7;
M]U4K'JO7'E.9&><15 1A#%2G+,\2\ YC9&M<\Y9,N*:<T^8CV\EDENB5N541
M)!$/CE O*!5:">RF^0FF9:ULF3.]TZF,]XJL[@R_-7&L\2)&$R17AA/.,5.E
M]Z60DJ*F)P7B?/6$GAC=[F;U!)64QQ8QBDB0S@#CJ<A"9:\1X[5]JEQ)NHM9
M302L-.3S684G%VI/01?-53$B!7(:$3B,\ TEX7^XY'06_9+B.CW;K&(M%B]
M;*-8YDB(J6@]-RIJYVAB/DOU-*4.?D?-TP8UI_:,F#QM'N->@CQ*KYV'2 1[
MZ73)8X(H6N\D1I"B^T?LE'DL$!JH(4P*'\'Y IM:(A:8=Z3.8PQSO"UB[\'W
MS;+4TAR\AIG88##7[+SL 9_"_$.WN7_,I&%G,9@M@BP5$)5X3YG25@@4N58L
MA22\"DFVGM66>*1'4I7K9$GB:)!XS9T5%,6((.2/R547  D6*C"(_'E:0$';
M83(_LRDL2U=A8[]X+/1]7'?]O=?)BCGS.5A10G#0]6D:20B1"&H8)\9&E]JN
MEJ7.4=K:/I2Q]GD4IUTAL CI_323591+)]?]HCU-:7V9E-*?8:Y/>V<"T4Q0
M;YQP$KQ.6?EES"JW+-?W/9+S<&^&SA33ZLR*3Y/#( =I575*GE;Q1[;2"*Q)
M'\/@C4EM\9%#%$F!!:^68"*5L_UKIV=45DN^3X]G!T.?TJQ\]&-QE15?\_;L
MTDGY4I\5(#Z=5(WB@#?_W4K+*?F7IT@)84\4)*K4;R-U@S&Q[&L$$""J\#((
MR/80E L\:1%QMEPRIM'."M.,^!^Z@GLV@(?8W4D146JRI4Q:C5.A<@&EK&^/
M)WA6GSQCLH] 3:0"GNT_I,SLQ]XOV3 =_+V21<83+N^&F+.8/[6I^UM>%3],
M@?N<OCKGN)0BN9N2@!4 +ZRU.Z4,]<@:''VT((;548G4.SR'\./*#1$5PJM0
MNB0<-[-]PJ'4B99J2846AB" LTK+^#AW/MU,Z<JIXS@YTNJ _(@4Q,9")]\A
MI+,O-"^7KU(%$)GK[S;#C^0UX;@9/_K43]0&BXS7,65MD)@*MG=V!9!'P?%=
M6LH 4W6"4FV-<^DL&FHCA(1.04AM*X]6(+1<J@D[;1@/SXS(:ZD$D0YA[R2R
M@54)Q.C3;I#U]0&G .,^=5X(C*CQ2F"T1"$CF>+5V;P!$;*\@.4XL@I!3;^W
MHYK%C< 10DH%[DG0F(*'3)5 <7IP\?QRQPSK[!.<1W7T3XA-1Q"/@J\]>)SR
MS]W6M_[5'4SPK]V\]^1A@MX:Y5T@1CN)N9 PT:FBMF'N4)L9ZF_A.4!DD(\K
M8%-2HHI%)[4SX\W#D^=_ZP];W?3@ "+N9=$P_Y7M8#%\S7:!!97!$"*!.,,M
M!+9@O32=UKJ32/1RS3M5&<^:]!.831^;7%Y='50%A(_O2%["8"Y8G+_VL>*3
M@^%+N9*<1B80438B):V9- R*3(+KL-RRK8=W$9_CP?G;+7SCP(!ZJ@D#K42\
MB)QYR;0D%:"@T)\( '8"Z/BW:>Z#VWYW=3W+:;+G7."OB9!4(N\$^+&*$Z[<
MI,M2U-)%5#O1B" TETK<"*"CP7D8]IP#U*AT(+ITS!IFO:)$RM*1I90C55N8
M9B\"]',VR%I%^[;5Z\QL(IH9>MFS8IQK'*?A!W,YFNN4]!T,!^]Z[70V>U4!
M^J1)GNZ+^SGKWQ2M^]M4!S &<EP@7SS\XR^?#N/Q*AYY$,*FH[88(HSJJL3-
M2LWILOU 51GFGL [8>*4;E/_RZ[<[@U#9!FIY5H8;2RC5G(44.5:VHA7!'<7
M3J5]^O*$.LV,L$HR3[E(^RQ*H3!*H;@\)T'YP1!?+*Z<+C=]R(:W_4Z59W]<
MA2K[\BRW#;]NM&Z0%@GNLN'#MQW&5#$O!L/'-8"Q@SM='GB*2#A$*J-D$3D4
MN1+P+S')N9/4\F-V]]5=!<3C6L0+0'PDQ"24299RAUFY?3(V,T0*Y5F$((52
M2X/7;((9XE3R)0<9SUO7F1GO"(7#9S&D=$3'8 C,VFO$/6C0,F#C,;!:N\?S
M@F SB\*"3D=96TZ54:G(5!E1K5?9)8V9:.5E?;\_& Z>L8&PW;O 76!DW-<:
M7,DRG85YJN=:42N^EA/&!>-VL6!\9G3VX?&6<MW/_-DJ.JD=W?!A9K_ V##\
M!D9DD@P8F!MP9F_ ,WD'_F'>&^3M_VYU1]GZ*HKQJVME1X_])*^&_?8?O\,L
M!Y^O?G^J,8BG2DBBA)/,IG5O&29%$P%)"";K); *SU97'AR9 ]#DOP%(D+;4
M<Z";2F:>WIKQ0H+,,[#AF#E,@S;(>8\4=K;49!AS%6<I,D@3'(#Y4TAPN7>2
MU( Y!C'R<M/)W[+\YA8NF:]9T;K)?H9/#3VP2VSEQ1(9VCW5R%QK#(' HBC%
M!'/1*FP=J588:" +O=Y@ F,T(,Y]7*TY10BG]/TMZ[52\T=X^MW=?=&?-(,<
MF&ZW_V>M>NG=3('<SDOC5B084L.XLLEE-%PIYS4XC\0+Y)32 M4JW^6LSG]J
M>E,<?K^_+F"F!BQ:Y4"6I*CO4A&_X@^M N&W%!^B6,5HCC SB@:A"=>&*%I5
MO^$0;*U*?C%GM69JSYJ^_!7'[,O>.KS-3IU;S*(BS"DKF.$2.SJMTPFB?K@"
MWVKFY0Q^K-H<P+744M:E*&Y9O>.Z S=,#$1HQ21/K"E5ZD5>UA= U,-J6X($
M%Y,-&NL'\9QAKNN=[HS7=.Q*"H2]=P8BLLDP!7>*UGPHB:C<?IAI$T:XN^_V
M'[*LVIKW+%0=D49K;+V*45#B752FVLLH$:OYO031\@CFS4;SDG&O@SGJ"'I*
M@/'0QKI@%2\3$E%$3E%]4P;GO,8.VXU[4I '2G6<BUB']H9=S'\K6IVIRH:X
M.\N_)HHOMO>:9M^NVJ!KP?C4;&YYW73^.9JT%7EJ=YUBC LDJ-5!"DLX8TQK
M@F+P7#)>WQ-:[:W;!)$](U?=, :M?-7,?K&]8\>(]#B5? I!E6/<2"0J=\5@
M5._&^!+PJJ;:/KLO8#AC%.#G;C:&H]<I3[:=-/PI^O=9,7SX!, EA9Q\F_OE
M9>7K%(+FG 8/RM;#_X01VI4M?*+R*-":FB5,*;(XOYV,^S!8K%,RFC*""+&.
M 09!4H.%KM:RF%NRED4448?$8B($X/,6V6WJK/$U>^RJ]TN6ELE;W[:T!XBE
M0[^<#^ +,JL,LJ3R!XBNJX:W#(M5,]YD=#N=V-HS35BJ0G:"* /*SVO)@ZL,
MAC2^YN.E+IX[FUBGDY?U"ZV\\ZY7NNS;40:K:,$ALXHRDXX)X<+PJJ -&5?;
M\$20!%\6S\]A^4">-=9U8.-HK+)&2*L9B5JA:,L5]=2FVM6\2H*TI%)O/58(
M,MJ)(,L#P')SUZH-IZM'+[4'36Z=)\;B%!J$<O1I^[FL=3VFG"](_4;CVMU,
MMNHQ6BW&F+G%F/(+3QUUZ4@ !]%C3<"=I50&7 J1Y43Y^G$U>-$'/V5DMNJ^
MNKK%/\0=$$%;D4KRN8UI\_ $(T]QJ,<IA&IZ/(S6;1YWX"!RSGCD,G"M4<1E
M*8>'&(&+VAX.S"0[[E0.)@@<7  O:0"5K!"$3U2+4'4+P)35>N(*2?3Y(+,;
M08C$<16%!JM%&%'83$N'05L24XN$ 3EV)(SD>H, ;J! 4FOAD&!2*8F(K P"
MA?BIGB0A\J@S.9P<<$]LRFPP&SQ"+K6*GB+#6"UW.#DI[ER0V8T<,$6YL)[3
M9#=M@)'@DGN<MC;4/$_@MB-RSUJ#X 56X-3)*,&I,PA\9U])M+>Z9A @2CHB
MM0]I#\#)U8&I5/ <HS-4R3*Z\*GM-Z^[C"F!>3;([$8./ '.I@J<1D2E$Q$;
MRJ<V4Y$:1D((\E*,9F+KC]?359%QQB61.1^L:@Y\XCUIK/#!ZH@P\MJ%8!V@
MF@XKDP:'2.J'QF*\X)AM",S.P%RG5L!<&FNI2=V]' X6TVBF?J:KKT$(AO'1
M9W.RK.$9X8XCS6G$@CGJJWV8H*JEC[4,#D'B=, ,19%J_8IBTADV/?RIR/O%
M9-'U,4D[F$G=VH>9?Y0WCM-JH_F5LNJE_>O9X4YZPU4C-(-!/^7HLDY:01O>
M)CKI,=WVDEB>I9NTP<:(F9:.4QU!E@FO*M$T,C4I> NQUC'%X,0[*H'Y91PA
MG/K?.,X(P\I,-"1RJ;2KYJL<4T$^X7=1A9-KP2FV'(.[39P@59-F$^K=H?!B
M1OX(DSE=QC#8"(,\]XA@;D- HCR"4=.H28TQ=@)F;YAW\NXH>4N/!ZF&;ZDA
M9=:9M+6XNQ\-RY>&5M&#5PZJ8I>)+MLZCZD1DE2G/M(Q@!;1VG*OM&? 1II)
M/YN)JJJA,-:"+:3L=C'V@X'Q6*'TLJ_8A^4OF&.Z&=Y-C/=XUX:-]V>>O\IZ
M8.:N1E_Z12>=X)%U*FDPHQLP()@G2P2F_:F:Q'2.N)4>=)X%-4<)Q6Y"<\4Y
M4V8)S3FX4ZHA^6%(OJG66[TX$:AC2(6TW]CI:%@,8P(+$R.1<SLQ*@)3JC1J
M"+P9@<>5B[-A95J+?8(FA@CI4E(DFHA=(HNSB28<5*XP<^><3VF"Q&+=3T.3
M533Y6RM5MCUEV W13#GG'542,Y86L%&I^CQE0BPS=V@Q'7D^1%CG,$HOE0Y6
MH("<%TH$-5FGLRBYP3Y<G.7_^YF9@3U8?NZ,,RHZS35( (M,!U.UL:**XDNS
M_.=&\A=;?IL4&T@H0R10</.0)M-V(TC[B[/\AR;P<RR_]I;(@ *QE@:((!WQ
M961N;)!L68AUUI;_T#39S/)SYFTP'&P]<22RX&RY&A^TYT0MDXRSM?Q/+%63
M=#PAXIY*2;G2- 8MRYB?T/E4T10*R<Z3'^7YA7][L/L$&\&"\=8Z1Q"%D,.7
M61[O%(EH"<4;6I^%P4=.8A<M(EZELYJDT0&/0WWPZQF>*UEM*+MO2Q\@R*<.
M,P3N-*A8Y8V<Q/@XF"C#LJVEC6+=M:&/J:44<L)BB'6"\HS9.-%UX'H9LXP(
MYPG_VF.D@N2$L!"9P(PR"D[GI/E-B!(+M]3;$92>*R>>6YRWCZ2^AB"#FF37
M2?2>FU!64@9@?CMW-M79L_U9T?K%)EYS1T":#3$..8^BDY.V(TF6B;H@$W\.
MP3R8>$*1]S2UT@\Q'<(DJ_8G6/"E)KY1K#LV\0%1<+(X^%=!IX961OOR[##P
M>NW<QMZ#2$21M=(Q%*UN&)?T5#OTCM&U <UZ0C*5*U#%&9,*RZ ,*!N!+06O
M%"D[NS5Q\*_K8<KO(ZGH#%(K)C8W^<$@6ZSP>&J;6E3,8RN=\P$90@52DX,_
MQNTJC:IM?^&:2[JP-V+\V4T&LFX/&A)"(FFYD"PM W%C9:CZ!1#BZUVM0,0I
MV6@@S]II3[5U N(V!9 0 [$="[X:C[6T5BK/!*""EXQGV5;A]<-:!Q.$,3&Q
M4% .QN\MZ,!I[PNI2&TG"T.$+*77RF%-6Z*DTIAN?P 6\W,2S=2/=#L( S 5
M)U9HCV0DJ6=)=5('8&GK^W'3 JP02\:Z;D@[F,!4!TR?M _3'_\KSXI49O[P
M/A69SVG(Z3WO>J"C!N,;\%-G+=+4MT6 9#$DG76$\DFY9Q!8:EHK&Y28<7D1
MD,R4L'_-)B66M;*PQU:*GUKW56/!U=Z8EHXZ1PE6Q%H18ZI'+L\4U-;6=->K
M ;&X3RUF,MN?GHV6/UGNCP/6*!!%:# 6_"3# ZO Q"36MG^]$C _]'O9PZ3W
M0QSU.D^A"-*-C)&2&R:%(\)Q7_:8DSSPNCE]7>+]^]7/?8B\>N-"[/M^;]"'
M:"RD8SSOBWP @=B2H&XUU-)+J[GVP9&(&4FMH*9GL$IW40Q+GBJ2#4$I;DDT
MH \Y&-'H)WMU I><^YI5H7 W6N85G!\FNS<KX(-&'83BBCG-54B;H"K&(DN.
MJDV.J.2O",SGF!?G&.7I"$V%HQ2(.!UBI1@CJBM&S DX2*\&U"W-C \*H@#$
M90"11R1:J5R%)C+BHCR?+5#<J7WAFD! 3!P.8-.I$.D\XM)3MQBB]GIG.+FX
M$?B@4._.K78>/)B@F:<T"!=2!#S5?^ *GIS^V[FR0I129I0/VA ,(2RUY1D>
M8$Y#8/6&:\=65KO3+$0CRX#^*"@&8:H'$SB=.G?U/>/'=F /I0UTVJ_+C>,*
MU&Y$2$5LJ_"(8US;P7L,;;"^-QI1$6B*:2HUQ<$)@:L]:2C6&X51H0@YM%#/
M=OX^0"Z&:QG!V2.22FII1%;Z$A/-6*SW&&.*<'H1D.S>:$@/-C)8'#&2CD4N
MG$#5IG!)<2U]^VI ?([]84)C 29'A.B-30UI3=5ZP7@2:^'<*P%S2U.&HU4N
M($NTI@)0XS9,Q9LP66/)UR7>.[6.RH!C%(W4+B*B('R&T+F$.F!O:[[R.6/\
M5"X&&7 7*=A4J24!#\IKC"OA=8C4V(YB#3>>-]_M+1?C*!<:X@M+P;1$AB(2
MMI)APT+-[:*(2G7H):1C@OFL7 RVZ4!2CHWT 50>]GIZ.AC8FWI_-(Y>#:);
MVAB(E1#GAO$0>9 8@J>R_7*R,4+6^/.5H+C;T,NGG@]6DQB8<"0='F J=HTV
M+.D=+^@Q5<#.E)]7%DLC8JK(2)5.8%5\%;-IP^N=Z(ZM_':NJ;@PV&K-4[*8
M(8.CIM.>E(21^I%-1]54NU,K07*87:#8DZ!#VAYLJ\Y]QJAZBZUCNZX'\S,9
M9]QQD' AP;6B)J"JLPZ7!.]>%7QMY=UTR$/L%^EPQ\>!;EEEQ;V0&,.8D74Q
M4(FIJ%*J6-@Z/9=4PJP<R@L&O'N=98S0WGM&+00"B$?FL:]FB@Q9TF&TGCP^
MWDR?E2S&4EOBN 3:@G*2Q)7'RGFNE)7U)MM+DL7'FO&6:BF"GXB\%HQ$SH,W
MP,JX*N@RMG[TU)+D\+%FNE,U1)*_IR6$<]0'*;U-PCW!(0&QY-"@6C)XYSBL
MK:V$T#P:92S'004%JB5,SVPCMM[??UGR=Q\#WKWZX0)S(VPZ?=U0;:EV)64"
MQ#R1;A0O'F^FS\H5>A=!)"6-7BE*];2U>4 RT U<I&--=TO= W:?4IKVDX4(
MCK"PG,0I#[/Z05U+7*)CS72GNH>!ZDUA#Q$0#Q%+295> E5L97V!;HD+]$(<
M9DY6^;GH#P:_]XJLU<W_#?]LY3V;7</TMC[(AC 9.$UMJC5Q2%L?N:A6VYDV
MM:S98N_YEXYV_U/?O;)C A&>7 \:$T-0JLI:<)]ZE]-:??4EXO4<E1FHEA!$
MI;[HQNN(TEEZ4_/-Z=+#HR\.NBW5KS16N6C3?D9@.BU<>5@]^/5.!US;=W!Y
M@.U6B^,0 <@@,$2S7F/GRMTEB051/:^]V$'[Q"%=YXP*B(L(LYH(9P)%(>5Q
M)CM8#+BBL;[J?G93WT-)*O +%UP$3PR-UB B6760$Y*NOI/F0C%[CK:':!O\
M0XH,6$BB.,<*3;%C1JRM$[\,W+94]5PRIQERR'&K;'2$>E$!YGV=V2X/L)VJ
M>I_*1Q71D@OM&6@X7>[X CBQEC5]=TIPIA,2G^G04^93"CM5QVED,?6.F,HY
M)935N(@2\F*=-3?<_<]]#\O=$1!2Q%@2F"5*(8=#E3T5+M8\TTO$ZSDZ/@K%
ME">810NACT'<D-([I0@[4COEER)UB<RV=4H%(FLGE+*6.YD.Y9;5_ER&):UE
MKB\/L)TJ^J"\M8%+3YGA6G-O,)]FQPVJ;W%Y>0KCD)"N\^DYB]XIAD#>% :5
MQ17'5<<;1Y=M&=@T"7DR<]^]LB>!(VQH2D!#($1T4*8ZMY9KJ>J+F8OM#BX%
MM&>EO0/17 IPJ!P/R/ D;644":%UO3;B\G#;4MFG#7<Q>&FECD(29\0T[,9.
M[SP,.D' =JKL(PI:@F,K#68A1*4CT=.(W*%:&G[QH/D#03HY_":UO!ILV?\D
M(F\H> >@FSAQS 5%Y71[M:E7MJ5DM-S8HLV.:U=3V8.&9F#*G7,QQG1H,&+5
MI@8@,A>FEO3<JICAB!@\*XW"D4P=ZHUCV,1@7-H:.3;Q5%."EZP[I4-W3QV+
M+96HX XC#Q+OC:(*O!W)IEO#I62U,S&W*8 X&@8[U8O.2,<C3<?B6>P\]UA,
MPW[#;<VID4C2C7W!G2.TSJ=U:7N85Q%%@G0JD?;5P?#&AACJ,:50Z0CE(TYE
M]PI0<6ZMLCC28!FH=R_=8Z[>A"7GY%(EC\?P^_4X-5?21TY-]%90K570%1;"
MT!H_;%YH<30@MM1^J=K2VQ2S&!0<0YX[5KF0S-4KW;8IP3@:!KOU"I477)%
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MW%<U6T0HA&JD/,#<WO661XZ#7T?PRW2:QM>9G<^_C!*K?KR>WE4%F"73/&G
MW_T29W<*1"'2P=4X<)KVK7-6=677U#L^ZVCG4VE[\Y/DF^"RVYG-HCE[PL<@
MCD!\L@]Y+[\;W7UJ/:0AIF."UBN/]_W>#:B#NR2 \\>'S!\5\O%+-[\9'VGR
M5#HQY9H9YIHH)RD%>TZ\TBI:8"ON6'V7@)0+Z\P;S>H0,$PM]<S['W%XLLV*
MXXQ$PP*/6 I)9?2N.K?7HR7J$JPZ/P 0[WI3S_G K"&D%3$X+*A&0;G I8[
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MM7L7WO6A]4^0T/+FP:-\F7:[R#K]_\I:W>%MPJ2L8.W4V7XV Q$8ES82[ZE
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M+LZP3G@4;$@'QAHB(-HVY39^82V5]583%.$=$^+<7;0-;)6A$CPQ)2F1G$%
MC65Y0"\X9M+'&LI"$=Z O*6M8@CC=!($BP1+<&V14V6]DM/2X7I>5E#$=AEN
M7 #,6QDK%E@4H+EC6@Z)U#(CJG C[92N XX0V:/NV*.U4@J#O=*82G#?.?B9
M!JM*2S)?/Y+Y-&>ZD;ER6''AL0X1 L9HB62L[/")P8*I6FBUK:KZFA7#_$LW
M2PTM7%H 6M%[9TW;)BZL")$9'L='6THU;?0F"5V6&<.DEAI;,HSG#'1=%R?!
M-0,_F1HOM(TH2L_+ICZ$1^/7]OO=8("#X<?KL;:XZG>7KV.NBU$-^"%)/8(=
MD@Q) 8Z]*F/4X(6K^5^8U]*\<P-XQM@.XF8:F)IT02I*,,)$!I!><#.UM@*"
MQUH&:G<37-O<PTMKM(<(2@LD3-0XE!U) J6,UP]K)8OGB+QX;(< 7T;0@48$
M8J)5S),@7'GZ)_PCFAJ/[6B"3V1GP!&WXR[,(O4%])2YLFEN\-IS6@-_B</[
MTK$= GRO$:4<1ZU]$NET=H\?<SX7\&NRI*788MS^HEFN7=L@P.8(M"-R3@EJ
M12QC#@]A;XBUB$BD=OV['=LA* ":1J3C;R3'%CPDPU LI9S+9=/$M4,&UDQS
M=#?JC@<6KJ^S]C!UR/^S+.C->S>?BKS7SN^[V;O>I-<43+'3OT_NX/I&=S/-
MJV*_6'AGOP<_MK-)$]_9HM'RCJO4HK%5= :_WW? P4RO1GJ5ZYF:& \?4I.B
M?F_ZPNJNS]FPE?>R3F@5/7CQ4P>#I[X7(2W>& &@$T$A I@P5(1H0-<2KG2Q
M'N/9:,[39&REQS,TO<[[/CC5O[6^C6M>!AFX_MEUOOU)=^!'!VFH(0IQQ;4W
MVD4AF!+&6&Z6.-FUAFB;#&MV'O/-#F$0*ULDD@U:),ZX,E=9+^\75R.0J4[>
M2W7%XZ9E?I29T0VP'>:ID1DC?(%GUIXRL.*E=8Y9:&*+'+",L/!-$J+ UONR
M542DV-=7?XF2DRJ>[V>@7874:C3?I:,KL\'P,PQTTAKYL9[MHO!U1%M+4# 0
M>Z>CTB02J!+)X,SR_:0(QK8*W77([0KOV2*R';7\7 _R^(V_P6_32YZ"5'$.
MZHU*SEGJN*0%XZI:]&)Z19G];&_NYP)ZG:4ZO4D+.= <9C#(AO53.P]E2M;T
MTG8R;<4QCH/3J;$RG)<\%[3A;MTYZ:LGN0R*I7'ZA(%PW=)MVWQQ7[X)GXOR
MN8\Q]=*7PE#@(^%MY8(9J6M5/GJQX_@"%&M0>EZ0#UZKY%%#+ IDI$HQ(Z9!
MOJJ3$FLA^+H!+@FA-QWGVA,X&%/42@@I@,FH@""9^&ES\6CJP00F?(_C/ 3K
M,([!"<'@C& K->/:4%+M@O,TU#,'3_'.<:>\,BDV.V?%DLY%%'@1/FJM=V52
M+*:NYJI6)X3QHHNY]9Q_Z4_JH[>5'$TPC#'U.(D,@@R5EMDJR5'<+EG0D6AA
M:6WE2)XYW'4"A,&:H4BDYVF/MTY'\;CJ"!N-EQPEQJE8Z,ZZA^$>0HZP(]RE
M\\C!:ADLM>>D/+Q'0>P>ZH3">M&U/\&9;R1.X'GCB(QE5%D.^@1@\%6.65I6
MLSZ4/:%"UL]\:LY7[!TXM->R@ 67VC&'0HCI !FL?:@"$0-!;9T-R HLYJ>Y
M%HAT*L!X<<ATN_T_4[/X4T,E'9'';" ,Z<A8 )EWBDLI%<.I/\HS4*G/>1ZB
M^R)M*:NG2%;D<^>\*9-.=%((8AN3-LQ$%,%41(<C*%]?/Z1U<3_([,<W']03
MB0/#??#.2R(@0&#:,FYU90B(#S77Y#F#@I^[V1C3<2_S:;_R[3/B43AEO&6.
M!(PP.%4\3G=+ZB4%?5RL'.RJ0;U\$D_D-0UF0E'-@6&]])YP%B:V+,A(O*BS
M0<V0;3>)*CM6':QD6X.\O<E*T-Q.>JV=Y\@(;K A)CB/RF)%#A[/8@'(X[E/
M;]'W>"987SJ6YPWV[ZL'"TP"_DT08#!L'!\6+>2$IP6R<O$HL+G!,KS[P=97
M&N:[G*FT54P@(:,/3$E?+G]$HH5DZT[4$GL9ZQI@E0LV.((\1,[I2$KCB)[V
M4XA(K1XK)B\=*W"XS[NCX>+)3D_S;N0!8B\*0T^[@\ ^6 I_\@"N(V@^LG+4
MF_#NXZAV,(''NHI7=73$?/,4G?HL"L6UL^#YI8-PR^-("%,\K)&&IR1W=Z1:
M(R$6M+N"N,J!SL$0FF!'4<EKEHC5Y^-MHGIV.H&&U][2=.*?B%*2@)QC*L2J
MRRK67+.XAM>>TF:;D>J9^HP12ACQX/I:G%(I*!T Q4G@F &_6?],??;" :\1
M"A)$B%8Y KXZ5LQ95YZMYY/WX.4SA>(E UYODV%\#JP%HSH2&JADAMDQPHC
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M(3/Q8!2]-,Z!>O)Z40YD?XTK)F"(--,+*)\0O7.BZB;%PWOX*HY=+'44 +5
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M-]6+=1;D:R-$SX%](P<@GR.< -D#(:@#!QK4,R\A5M>A/@'L/X_'T[UI;EA
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M!;T5I&?"O[7-A 9@T:B-PE@2JP,K3#W6)73-:[RX@7J]G]X? 637 2X&TJG
M$ER 8CG 36.EP2"' FNO?,6F7K7!(,_ . 30;?9(2ZHBK?&6@&46@G["ZF@U
MH''S>D @UOO^M9"N%OP#%GA"@B*-C$(-48HHEHM#]"^\DJ9 I&$^X=U->#=
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M![PZ4)=A9!9F>,SJ"/"&I;WOWQC!C<D2P6FGH>-,&*\UQ,T^FJV&"()5^\)
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M]R2XXH*TC?J31EV0 /RQRQ9.$S-T5N+2K 0-KA3OK,1>5N*8Z=S%!SB?1MA
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M-J*^X$YRIH,KSO2W)^5+,9M=@?KPN*4S?9WI.V%4V-Z6R,[J=5:OLWJ=U;L
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MP[$4JUONV"UW7/?QR][1UR'?(7\!R%_(3::S*[L_@?OJESON&,U=]E6Z\Q7
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M,924^HK2YDB[SDH>.1OO1F4?=3242\9W.(TK_;V:^G6;C^Z+B5#E$)[D&MQ
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MBY6F;%U-=+NB->K<Z$:NT[);JS_Z/,QP)20\%@0=+,Z7*J&;;_#:$M'4NU#
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MXP<P"D*$RU"L&FSU8>(9M(FX2'2N)</)<WC8@'-JL4G@@S;4[SUWWPG,LHU
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ME$AQ7:QY3H:]179(8-(77I&BC;#5(/N1 ;VS],O 8+EJ;*(5*[&K)V-,LR;
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M4T=V<D2R)QU).I)T9!EXE71DKJ?%FOD=MB =^<QDY6;@ODT#>P(,Z>4#? [
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MF.YHMTF6*/++A;:_"*7>,Z#IB1T%@8 '8(<!;'PCW;A=C739%]WR9NO>W.2
MKMSWMI%?9N;55)NSX[9DVR/'OJ/0L42V]8@DMULOJ TI22Y%EBOWI8?Z+:R(
M*8;Q<NJY7!:2[:ZU<G%$*2+V;C?S ]MXBC)EX06*O_=[(HH4S=$IFI;5*BJ[
M?L"*AI O=M@W<]X!,Q".%/>FUZRIG<1>OVPL Q6>B.^^1,?+?/*B$-O02E5C
MIVEV)"ZPA#='8VZ'!E3#]E3<A77^V >.-=$ZN:*[UV*5NP>OOXL<KB_0S8/O
MN:,+I$_/OGRZO/W]/[I('1O+W5Y__!=^L$Q/<'@V=LJ%9\9E\[K+8B"4P&[P
M^JX1=GOU?&QI&P_H 1OMFFZY\1="]VDT@[*P.2VF=\()=YG-?1G"POW//#F=
M1XW]!A(@3D;>@ZOBVN\1SB2& , W:[+)N*FNF3TVA+0G/+B++Y;Z3><P"IRN
M/FV H<\HZ8!MQ[^HR/<=J2GFC2([7,A&G6,=Y3"N (:QP,LB :MS$V$U>6:8
M>IXK?)X?1_U0KW5V@;2P VB$Z@,B;*X,WSE*P@>]6J9EN>'F9<8$T7*]J71!
M[,<IZT]]'NC"9=,=%5F]P$&NK8?*[_$&YV-=8AD(,E<0TF@R.]8F0V'4 4Q]
M'(%6G7>*G8+F,RJJT4PX-6VD/D+\"1_5H*L;S[JCA5+X\<+QIK@=[6K36;ZL
MW;GN$<M\4&!3;HM(^RDPMCM0FQ*GI-LJ2[6@G8)L?91^[L/BH=UT]KIUO!Y+
MIN-RW [X<?=A#8#%9F"*90"+N-WYN<.5DF-0LF>S<WA1@&:,.Y\X&K-P=@%3
MN$5NW ;@HM%I=DZ[W?/S1JM5[_>[@[.^Z31[V;OJU[N[ [BHFF]RNP#68. +
M5#1%J)7_(<8*_LQE8-K3:Y4B;%PF9"$[74CD)G[/I8/W(U[*B>+PH*$&AD@6
M&)E3KW#,>P>OC9_$OLCO5<^,HPE@HUP &XUF+@@;G<$Q@4R4[/9JC[Y2DZ](
M'5;I$J:$Y; 9RT&[G4*C!N)Y$W#-?Q<\H&P],=\.F.]T#"](F0Y\Q<"+[B;L
M]L'37^P5Y8+8\'$VK$J/X2L,W_Z-X=L+=@;HV.+2?9\@G)Q!)!M\$R$;PVP)
MB:8$NYD'#^70[EO-#J$Y[.2$18DT6>FL*&DPTF"O83?J7$)J[*C46%FXK12:
MJC3*:$?N5%D6_[6JIB)YUR))>.Y-IR*P)7>8SWVQ38+P@.%^^@VKTVOF)4=E
M6>NB+3,9X$.6B:;5;.16)DTB02)1>9%HU5M6KY];#>.AR 2EV1]SMP(?3W )
M-O2VR[$_OX#X8 J$=YE:*0N#4/:D I;J<$2LTZF3:)%HD6B1:%7.93PLS_#7
MVDV-W0:"JPC+_%RLK8%YN[KL4/F>JSPL>-3':DR/9XK!X+Y&RQI0"$9I"4I+
MS$7"ZN9G>D@B2"*J+Q$=J]LB(['#/%WET<(T#K4N+(ZK>W/SY8O \:GVB:'=
MH?\<_G&T5KME]1L%M<O8AJ*5X#Q*"97TK!II2=*211YF:%OM_ XSD)(D)4E*
MLA2\2DHR1U>RV[>:.T2ZK3;GY1B-;X:M?!JSZJ585%E,J\_BX=2V$6L-^/9K
MX+GPIRWT<[\"[>V9^7<;'*O+LUZSVZE?]=KML\Y9I],_;UQH'*N+R\%I^WRP
M,QRKEX%6X>=MF64KL"/S(SXD@0K2WV2+GC<#0%T+K+9F\S5CBXNVBDAUZ,BD
M'UWVB<\0!ZNM<3[9E72YJT^Y9ZAT$W)WQ(.18F<>_(>]30X<->L?KDYOSM*/
MC0_OF%0J$B-V>O,K^^S5]*-/Z@/K$:N>-V-H&%$[67*-T6D ^Q(!5QKM@YU'
M"A9+!(J]O?5\:;-NO;O:*2 _8B_0#>D3TR9+OMJ<3K VI]$=C!&OZ\3+ ]1>
M0^'.":Y?N0G[GEV(L0@"@S>+D[D<CX7!.40U6R#A+?8PD?:$C83#9P;33J3O
MU@B.,*+,@B!N'2@--@,35<O^8&F<NZG&*;78$'0,#F7^+$34C!!FT>#F(8@O
M^R/B 8)\:#1(A3".^%A\8A\>$86,(_B>POM"C_&1YX?Z;A4+73H2!O_O2 $C
M^@WA:APGOC@[\.>^>6%6, +E(=SE5,(*A@\>FXIP@GB5<*=^!ZI1%H@P\)1O
MINK,-*HN!ZH::.% : A+T!8QAN@<%//M.(+!+MP>O^&=Q?2MBP_6/*2!2:,I
M8A7C]8;&!L%3AE(C*7/?=V;X1KSV+I(CT%P"GF9[=Z[4,,+A'*-S?J>^#]PN
MC;?Y5F,I>R.#8KAVC(_1.U+)^Q]]1NWX+,NM!I9%&-5 @D'QG14AD\J@F'(7
M#VL@+*2:>)$SFJ]@@K!L<*0EK&; 735&Q>*#VI$J!58%+E(BN)>VT%)DIPH(
M! *>'P/BZM<%8NP(5%4&^M95$GQFPPQPIU$46D.8,1F,6!5#Q.HO'0.W*K[;
M$^[>B1A'%T&N5P:S*&<C,8;E51KM^QXE7/@I-"O*OCW1R.#A!$BS1#L-Q TO
M'7G(<,JSV 14D1T(@X8-X_4]<&2'TL%!ZXEJW-K_1J,[?3)&PV2K4") K&)3
M,/I#I.\?D<33,C'Z%3XGH7F\"IHPZ2 1!3>]"0(0T"[BNU1:[O7!G#G..8>@
MQ->8N'-'PE]PM[1@33A2(AJBNHOE&O&('8&W>E$  ^?.3 %%/#.^1"$MLQ-.
M4#]L!+>"*G-CNJ37:Q%VO=!<Q5.H7":G/D?=DLQ_/F]X19"U<PDF.(*;FN&/
MO)A##,VS ]+OBY^-#P;:(PWT,]>_ A@'9VPOH(QS,)G 97.*)>]#+/<8@76&
MK"4TT'OR,/USR#490.N[\&HPQQPY'M>%?7.]!Q?-F8/ Y_%=[_08C+0@0K#R
MP!4,8_Y@-H2K\$ <\N/#9)&OX=&!AT=ZRG"U%ETS93[Z;V3"+\/UL9J'U\!8
M]#K_D[M@NV;,8!*#G01!0$1:8(Z1F=NS")H!BY=@B1R4>\2AA64$(P5R F8
MH>QC1?00<V.B99"<2(\LKKT!>$Y*0>7_>/).G&/,'BCUH(#Q%^1GRQ#5<9XF
MG/7XO)868'E<&6A_4-H@[!XJ&UOKU%A5H?N"H/V1$R9>V#W0U6"J+NC"U)YF
M$:8S[%U;Y77M1L3:@?&4 FR4(D,C?O\=GS-%RJQ(<<2\AB%L"T"];1">#>"_
M!'?<C1?Q'$\..C!I_'#JCKX:_T5__#).XR*(A4+S]#G@-5Q] \87[+\-2BPS
M&GRS%&J;!,#59:_?:YPUSBXQ^C^[&@S.X@3 U<599]"A!, K$@!?KO]^^OGC
M_SV]_?CE,SO]?,%N?OWTZ?3Z=_;EBMU\_/OGCU<?ST\_W[+3\_,OOWZ^_?CY
M[^SKEU\^GG^\O'FU W>0],S(S]%YN)??A2/!^;'81]>N+03WZ4^9T)YE?G\0
MFWX!K9C]!0Q'YL=(+65:0)D/I;?4)4"W<W"U&P4!76S_=!P$"@LW;L B/<ND
MN4",J1B!"G.-6PW.3  /8#8V5\';O"@T(3!:.%]XZ*D:5P%-!T2J-Q)-"*KZ
M,>:KI6[1PAJ#06'I"KTTX20012844DN?TE1'F_/<3<( \V^T9P&WW8%94=HU
M-5"?-LB#7K;,DEAH^ 6$" LV/6G78QE?'L^WQR[N?/5B8$+? 798$W3F&-X]
M>$72%QD,7!%- NUYV^ P_0\C!%<.D0# 1A.(=D)/IS? ?PQUF!3.(/8&=F7?
MP%ZC8V>\%^2[?U_^_<IBGRYO+7;ZGU\T#:\O;S6E?7B,>C_O@53@S/!I*O(W
M[ "!OONPHA_G#^WY87:'M-<V>A:>MW8#)<=1IVRL=UPP-M#,&#O(/OAQTHL4
M)H7BB)2/[E$%( .C"XCX_*@V0)7 *Q=TY?7Y^8)6R_:?HH78N! V]\&+%RLK
M810,"(Z%N2>NT(&U48U'$'0$F!H $9&C5$-CG@9B_R!M>&4!]6\O?P&OAZB_
MDD?6)A<(;?*2<53F#>%)B6;2,4V@)$94"SKJT^7/5JR>T]P)7XH%M>W\NW!1
MN=L3#->GICM/'*M=>S;\^W>P'/X[8P9DA@$@N/-YH ,[?/!T"#HP;E1V!R/4
M^2TMGW/IG$*$C!+Y>-!UK.[M&==YIS%;B V/SM$UJ5Q\)3HN=DH+U#GI=J%*
MX^(D8Q WLK)-,@FHF#A%FG%-PC3.9#Q,0 QF)]X#9JLP&2A'DF.7*JV?5)QW
MA<\ITD'O X(OVW&&P33ZLF<FIRS8KZ[$T>E872U8&TQ2+IB;$0H@[O)@L@Y]
MJL1]'G('920>;29!89)$0P$"!?/!5FKP+A*@1P4HFTPY2OE!.=!\A:YHY'+P
M24,C3,\6JSG;@;\%BMZDY/#!@<G4:>NQD&V/=P_4NK1\G.[767O3.!33X=/,
MNZ6+EB[.4H(0^%&@(FZRME?P"VO43W2+4':*YAL,7J..BWUM8A:\[>;D/XGM
MNIGW#<-;+I/=$P36D^"QX&9<1E!O+A?<PIH^CZ SAYA1A0?.,/>.Z?Q$W<09
M5GS7\LC'GA?"I3K_&&]>#&?/V[!(28@T2G8FUBY0C7UTM3;S?/ %/-?2(YHG
MNT$1Q:T!=?K3A5=BD*V%"L,0T&'X0^:&=VE.%D;E"MR"01=.IY--5S8_(U?)
MY$UZ5XL=IKFY45HZRN=JPL9ZMSGI_9@T.9SOUL[9+,G\OEZW54UBDWTIO7>$
M',$ZS1-,QG1:H/G$MX7]=%_GE\T6PIR;A#M*MZRN I#K&<-LL5!:?#)M%\ON
M9:MP1]YUC5TMGE+HF6T%@8DF=TZRYB#3.7/I8$/7])!=N#YN]->MH=)"B;H7
MK@1O06":92S0<1#QF0VIXG,,<8="HSN"^$R%?E,B,.8]JZT\_QDYR;Y5U[CH
M&Q^%@TX>M'YV*W.P=&8$A '/+QB7?RBTUEAYR=,#G7\3CQ1O6S>H>=09=PE=
M'-W*SUVD[/Q QZK^R#%3='2ZZ8O1Z;#FB:*G)LW/??;N.X"BN**3DEAOW,*.
MQ1>/@"R9;'-NPYS-2)L3)\MKSH"9)'J!0]XL]$72R0N,6P.!UT+[Y20 7.L1
MHQ(R;EU\<D@?:>':MP4]_]\X0,P<*'O2R9X_4G>]!U.]3'ZX<Q_4+[)CMK6P
MR8\N[*GKXD&):V,,@82)O_\SD,U)#H1HM_[R''\O<'178AC@:9 Y29J]PAF2
MXOEU\?RO)F5SF9PC.SKCBZ&\B;X7#OYL$\;#%1B<QB?^7A"LFR.*<2"+1_E<
M;HX/X1.G_-O\T)^R,D?^C"NJHJEO D)S]M(<JS4V"&4=?<IIFK&#ZP4^Q9%<
MGRR$X-U*#^WH74@P4GB RHH/()GS5ID#/S7V19_ ]-P[?7)QB!DA*SMH@9W%
M]0CQ]/%\O.G.G3DEC484LVUF/]N*\X>9$UYKSBU:F>T_4&Y1G+_3&XKQY1"4
MJPC(R='S'^*++3PK%=P)K+*"#_JH'QZEBX(XBC;?Z%/;.D'XSLKXVT@U^$NG
M'W2((9$]]<F@A&%&P@'3'^!&FGE@3('XY\S1+:UD8T\:I[AR>"P^,)99L71:
MV=6)=QOB(VIC:?;\]6$[!7/5\<-=($2Z]^SI\9FSI/K@-#P4]Z"M] @:<&:
M10@9SL@0._DUW=P.]4'+Y.*981>8I?WM!#A"R\T4QZIGI4\YXM=ZQ'.. /I
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MJ]S[!3=IPL+0]#DB$PI^[BB/(XO _M.B]P8N+XR6NLR=Y.FG?!.+^X@+=27
MJ%?C# :[Z/SE;_BH$'[KXH,Y#_'=YGD&*J<Q&Y ?@L\"-'ME#F3 -Y/9M0\9
M>"LLG&'.XT,([##+09<K7-S)[RO=R2MVP89$6S'&M^B=>[9;GW&!.:*[O%J
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M]4=^D*7^$[VE7A9S;*W!2P[!-8RC27ZHE6<"OHP';AP"[R5?:7S[Z%:@<'8
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M9N<BZ@V2ZN9:Q<N13$U#T4311-&4432=FOK?HFBB:*)H'D)'715V[.3B15/
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MJ/*0#V7@0SPH(8!K?UW.$9]2N*6O0,7ZXX4-05NQ6N+0165??'8?UCU(6/>
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M&"HP25@1%=CN):J*V<(04G3Y:C/W8P\G84"3Y!.Y7:K5?$\N=UN3ZIJW_VN
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MS6Z4- Z"99N*I@D[.2W+$M?M"J#^E48FY(T@FJ0'=/6F)>S<L"PKB5J@>5H
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M-EI=M3M0M5[7Z&H#JY4K$'/0:@W;1U,@#12,+*$D?:2D&X YO0:+$($](+^
MQ8U"D!JV?F0:^PS^G4RB$0U(&I$GMDPDRF(8!ENB_#H0K7!$!K=?OY)I%GN/
MP W)#6% _<_%DA,W7W/RP!;]>L0D<@S+7CYPO-,S$9:_R;#\EARP_ ?>?F)H
M^$N>_(E!_9N]=(V:?$,0NJ5+*\R&:U\Z2#PV)4!^PZ8$Q]S'/VU3 @.1D1&^
M6W8MB4R*O0Z0#V5MJR&9/D16.U]6JZDI@7P;[W5NF-Y6L\6GE-V-]&X$9.B?
M1)%N*]LU'II64V_4^N$I&L$U[#YL/"]A\1 J,%1@&TEEW(CS<IO--*B_4'])
MPHJHO_9RP#148*C 4(%)Q(JHP'9O1W1CH0,F1'\U?K_T<!*RXLA3:BU9Z"!,
M_S3I.$WKQA(&'2?+0M;MTZ#K@DK@K)2 =F,).U4GRT*B$D E@$I@CTF;-Y:P
MG(@L"XE* )4 *H&]/ %;6#LZ61928(K@W0?E3WD =OM)W/PMG7#TF1_B]Y_H
MU\ -D_Q$[P[G9QVG/[0LK=_NMDS=Z?>'/:TX/SOL#S3;P0/XX0$'\%E]TC5?
M,U)=M#?9]QP/&W\.R5_=,'/C5\*84"'/E+BC:,K.!7<\+\I"=AB=W*9N. +1
M2<AO4WY ^*K$[-'5[SNWO\T^:=]_)+]&-W.KQRKJKM7VZED+T4S@IT!:KSB/
MO["F<W2AO"RM^B.YNHNFOD=LS?GXB7R>3&-P!IBF2-B1ZL%D&D2OE!(NX@6_
M%*JD0IZ:)I=/98G2I"!HE>)'I>U-G4@-E0D2/R$N/&!$W)0?AD]\6 U_##:1
M+UPT)@EERCH@;C*E7LJ1]=F%[IQOQU%,:+F("5_$>[Z(TV(14]#S":A;9A 4
MXH=>D#&97'X&_#>F?IK%-+\JFE"2NB],C2?T/QD%%0\_>(&;) LC=)^YT+@)
M@;O!FA*XV$]?"3PR\-U[/_!3G]W)SM,OWQWFLTY!W/A0X7&>FSP2YJDF;\-+
MG*.F^IK%2>:R)8OR51X50 A EPK;< WVZ#Y1,G%'<%5(:$#Y^K(;8V8,1M7E
M),^/E%,:%L7SLOB&?(WIDQ]E2?"J$(YZ4+",5U4;#.T@_[I8IS";W,/ZSM><
MOC"FA L8- --4N*.4[B <8P_ I<#. N^]2>LVU]U0#DX@_?(O!A@M2HG3N$N
MSY\&E#P#-\%D'OB;X 4+$V) #(4*SQ+.S PD C@+OHAI&D=<7, A(>X4])WK
M/>8,&$;L#<":4^X1P9-H3.$.SH*C'*4%/F5!FDL:".C;PU3R<;K$RR99X.:O
M'/T[2]*2H6M4)7]2;PP"]P;KS+I _0S4A[GG$P0JC2A(L)]R@C*I8=P"*FKJ
M^B,0F&O/G3)ERH@)TR]-KZ9PZ[M&M9Z[5'>6F>IMP7:#I!1BQI$AT\4Q=1E<
M2JX5QG24FX1PE*M.$M*T !IBO!E$29+W8*F3]5K63?L8O,?-VPO8GH1;HWL:
M O>!(9S.5!@(=5J8-3K*54M.;4:,9>(![](X9BH+'@;&B.8VE6N)%ZZIX(%U
MTDW7;O1CT,UG\QK#_,C]*U-/$<PZF4;A:!U5& Q.KO1=!FWC@JU7%H@(3V!,
M5N. _TOCJ%9Z3*;@ S%3QJ!^*OX-,V+@X7!Q8C_U(J8=\J@IY,4+7.EUW8"1
M!=QD"CQS>;Y)U6TM5!3X><P8IX_@O7*WC5D SE+N"[?)6?H8Q=S]RUV0$5SO
MI2!@S&8^0OC*KN(N:\+EG"U']:=I%D\CILONZ<QU+*WTV ]A/7(_%JPN]SC#
MMQ;PMNIE]MAPA]S+7'"&GA=>E&3>8^E&<P]WKF0K;NI[G!G^Y/DSUCHTZ_V8
M&QZ4Q8P^Q8#GMH+]N>AA\[7)!1DN8*.KV!/XF"\;!(0^>P!HBOD,"[*RQ;NO
M627>:,?0B&X0P;1*=VV]/BQ)DB4YN5:XC)'#?P^?Y0P.G%+C%!/_!=Q@C@)!
M&0I$G=2L\=D,NV*>73%4[CFNGED4]\*]@0SWSX8N)%.S^SRB3@=/3+/L SEH
M.:IF#+MJU^D,S*'>&MKFT+$TQ[),2[=U&U.FAZ1,?^O>#O[VV^#7.S+X._Q[
M<4;^2TC^FH%]UMI*)5<*CM%/X'8#:X+1XN>3N7(L?,?Y3QW0>B,.#,I-XIH?
MN)U;> )3N%$8%ND+KIQY2HBF:3#3HCQDBN_] B:8W>'1..1V.'#]2<(]^3C-
M35@&'Q]</TS2RA!BFL>N[)5@RSU8,K;S!/' $PVB*7N3,L.;Y*FJ:#*AL>?#
M"OUWENOJ?;D;_/SSYUZ1S8J2/ @&!X*&&>7.<VYX80BQS^WX.(XFL_MF>5K[
M^V3-&_P\S_+;S>T-N:5@*N9IT5\CB/-T<@VV)@C<^X)W2><AID4N][HRVX6+
M*FE4;H0J(;L_!^<MDSSSAWC5AUR>P[N)A7G("&0K.'7JQLPIJ*PL8\^Q7Y*5
M)TG*5<K]L3)[1U_8\O,$6\:R9M?@B$VB?#&FLYO9+0IS/IG/.$_]L7?S?5S&
MTK-[P1'-P+$)<[X<9RQ=MK"DDWOP:'(.Y6,IXN89AR[PX'(^$N1V,DM!KZ$-
M']TS>'+<D/E,).!.<-Z9.01YYN+GYAX_>PQ_"0R<!_1LP$7J MQ8"N9SM$D[
M;)'-YT<?1I6_964TH/AS5X]1U WR1$EE]G-'T.5^-@_Z9F_.!UL\&]8]SL,"
M6 @@:P":DP7<.7/XR_*T07)OR/]$SRS+KQ Z'I?>?IX[X[JX5,5\Q0M-P[,B
M+ILE3&%A!A G!'Y.Z<J 2^)6<NVE/[IU@.2*NZUS7;1XW5?^"_OOYX4M,DYY
M%KBY@5<D#O/(AFOS H^WX*7_9"!%-&:Y',HD#&*!/'SREM:'2U/X6M5A]['+
M$<_F\X YCS(OO4H^LBQ1XL7^/?S.U[#*YCP&8_2[(?]X]%F05K +#V^K/),O
M-^?65=9C5B#W[N<<N$$^6*X!!I3D?#+7(L7NCSMA@2/?!-GPEODS_611J'++
M,TOH;%RBV;* !<X\9C#79_A7J)GDT>,K>0#^#*N:I+*E5%)@LP/ :5L$G#G5
M)E',TG*IZP?Y#L0D"\OPM<@QY :N9-A"XU9-^FQ9@;K4C9F>K!CV#?:\$M$5
M>U,Q"_L3,J$T+=T 8!\W< LTZ@@(ELV2%3"4?T<^-S<TW^Q@[_!3^%0H[O*"
M=<M97*GD8NR2^VCTRG9+W/O 3QZ9L !7[RJAW 3PI #'FI]/K,@[\"Q"E5![
M1SR;0I9J7/-;"+H3IDA'/X'[]3.HFR_AYY!M#/$%W!M>O:>:;;W=U0<M=:CW
MVFK/4"U>'C)PVOVV=KQ8IXFN2PY2SO4MHSMS'R83X/#_YOCI/,O!I.L)%&!8
MF%]_OEC,D4XH.!,LL9:^3DN3=.RP?_6XFLB,$,RYQN?WP8UA^K0R*:W^7 97
MO;DIX;LD"=,=([:'PAT]MO *N<_FKE]UU1>SK"M,<L6=FBA+@'+)1P3 OT0
M_-8E(8%+=GNS1X^3;\KD&W*Z6;I##?/AMBX=D7Q';Z[9Q^OE94 $/EWAR,Z$
MM1W[[YIMT0UNZU%'UXN2=(^%1D% 07@OJ_T41\G;B+6G&MD\@R3E\%A:ZZ10
MORBD**0GEP+)A?1GOH>(4BJOE#8EA&'G8@D_&%MKV"(1U&&=QZE_B4+Z2B9N
M_#O;(H?9(FC^NVF)D(>[PY,XBMXR:J=7(]B&W8>@K6>"=])L5D0-MB>[\</]
MJ,90C:$:DX@548VA&D,UAFIL,[%EX38I-)4TRNA(4:$LBW^HJFG(=GR=).S-
M:KC)U)W2^#T)5'U+ K7FHH\:&GJIAN+8PEI*R++6=5MF-,!G+!,FHB&C.* X
ME/==:88NFE'FBUZ?SRE<BE8A+%%<4%S6>52VLW.#]DLQ(;BQ_E9D$D_9D5!*
M[J/]=M5W%B.AE#RI?+5:PCK6G'W4WR#Y:JZ%.A_1.F:"'T4,10Q%#$4,10Q%
M#!W$1D5EYQ5\<5"H.X89EL6O'%#D@4EQF$/%31DP+,,ZY+7JT]C?[V3"^:8Y
MM)9B629F.3#SAYF_^GP[E N4B\;+Q97NB.83W#]":3E3:6&.E8';1R("E1UC
MVF7PNL:%,'=1RJ' 9RB PN+?A?/ QO2%C**,0>H=<FR_V37?XJIPM]'V_ \4
M&):C&*:P(/+]%&T$YV$:5=+3!J@E44LVHAP5%20J2%204O J*DB1!<J6N!V_
M@\FY5VJJ$;PJ+&^%"A05*"I0^10HB\-UO75ZBC:"\P2F,K_C#2K67E_YNS(O
M[,.Q,'+LP]&8A@22W=[LT>/DFS+YAA382><.SX=[\7TX]FA"UNPJ3WF9$-'-
ML1<'"@(*PCI60YC_]Q(.>W&@D**0RBVDV(M#=BEM2AB#O3A$\A[VXI!Q*^GL
M=XIL33%;PM BF\TV[#XL-Y)PMQPU&&HP*0 X&L$[J,90C4G"BJC&4(VA&D,U
M)C_NCA2:2AIE=*2H4);%/U35-&0['GMQ'%F,-*NE&+:P,EQ9UKINRXP&^(QE
M C&54"Y0+E N4"Y0+M"'DA(^J?FQ"';?V .=3%=L35@_J+./]1LD8\VU4N<C
M7MC0%@4+!:L.C!!#%09"*Q8"1!:!1)0/E+RZ/$93Q=VA6D.U\XK(Y&C)<>*#
MQ35LTZJ*;=2$E'6YA2%HU2Y8I+2:L#E1G%"<+E"<KK2:P, WT^:R8S64M@N6
M-N8/ZN("LPLQ8-B)Y/P[D<A"SF: G$I3AVQ:JJ+;$O03D85_ZG;6,=6+Z@S5
M66W)!=1DJ,E0D\G(CJC)]MQ]U\65C!VW0X<L'(?;\ZCI4--)K^G,5EMI6\+:
M]Z+CMG>WC/+O'[[+DNL'UYU^FD,L,LA1AFCX)?P\3U'=L:?> 0FZ0>3]_N,?
M__##[,:$?AD/DM2?N"E-@(@AH]0W.O[+AV%?5S7[;_H_[_H?B#^"+UPOO;9L
M8V!KIM-IF9IJF#VSU^]K>K?=Z0_:9LOI?_AQB?)5*F[I=;%NX3:V ^%8#4PP
MEI=V04>MZ^NQ[]IO&77!E 6WYC^RAY0]0_@W5:Q /IX1]5A%OA^%GQC'%%4A
M"271F,S6XTT.VH5(A50M)UWWIYOIU$VX/+GZ2,DTIE,W)PTC1I3%C"UA% EE
M6QDAS[D#=49D[(=NR$]8)RE\P5F=73$&PB<DC8CK>: W4I@5/-6'2Z<!#.B!
MAC1V@^"5_4ZG[$E^2%)X-:_*>7[TO4<2T_]D?@Q7P\#=!_YL]L2)^SLE_\Y&
M#_QE"J$ST6$U/&Z29),I&SF\_M%-B3L>4R_ESX9913%[ESMA8TK8W.!ZRIX2
M^.Z]'_BI3^%#3)]HF%'^0/HR9?.&;]FGF 9\WB,_\8(HR6!X-^1+"+^1*'R(
MV#3OW<2'JRN#ID]ND/$1^O#2^7B!'$'&%EPA]UE*PBB%84Q\]OPT4F#(44)G
M;X29E\.*@7$?0I]-4ID_A(SH*//RF8_C:%)>GI"K) -RN@E\<\]>K!#OT8T?
M*%/K\"%QV9+$-,WB,"=B_@VL3_0,JTN3CPJGWQ3T;S1B5(._V JS'V$$C#W]
M,=B5DF%&-/#!U#"5ES^PH$#Q,W F$ %$+B'/?LH6.IGR-8H*5@L"][X0S21_
M=67%9M.JK@X!VT1C?OLTCL9^RG^%%4I( G-EY'$?8LK70^$$Y.-C*_[*'LHV
M$\(TBE^!-F C08,SSHPS('R%,RK$+G_U0/"9125IS*2@O/@U9Q>8I??[-7 $
MEYL)&RN?U0WY!V6,0OF(YQP!]'GTX::8/Y)-+O8I$)D_#'Y\@JE$&5P'-(D+
M8,YK1CQ&_OPB_@LP#9 <6&]%')[AO; Z0$-&[GO&3&X2A;QU4DY#1F[/C[UL
M B+-5E\IA"?)@GP%<O%D#,!_X0S//C+19+29"2>!9<QRV?/<.'YE/S).H!71
MRQ>J0N-<:F/*Y0%&-_*9FIB"0F*RQ#D[GV0"M/.8_'6\- -RE2,$A1,P"07!
M9T-**5L9> :_-1>J&<5OWO805JW\@K%F9AS6__=/XRA*8;CT9_A 7OA7<<1T
M\6.:3C]]]]WS\_/-RWT<W$3QPW>ZJAK?L9^_8Q=^**Y/7Z=P/>A["JLP^@"/
M+IX-_D)QR6/,G(+_CSL!JF'95LMJ=3MFWQBV'5O7+>X$#/5VMZV9Y6-!DFA0
M. [;[OE7<!\L#@?>[0(W?B#?;1U/M],QK;8^4%M:O]=W5-TLGJT-G5ZOOW8\
M6^XY:#R]?@LFU3/ZIJ.; \=I=4WV[*ZJ#LU.6UT[GBWW'#(>S1EV+<WH.H;9
MZ0_;:LOJM/*Y#KMJIZ>O&\^V>PX:S[ WZ'7:[8ZJ=7M]F*S6[^;/MEKJH#U8
M.YXM]QPR'EWM= >#+DS2[CEMX NCT\N?;;=-\&K7C6?;/0>-I]-I679+@U"K
M8PRT@:;;_9+V1J\_7#N>+?<<-)ZA;0QMK=7I]WJ];MOJZ*WBV?V^J9IK^7G;
M/8>,Q]"M84=K&X-VWVRU; <X8I@_VS$<VVZM&\^V>PX:CVG:>J=KM1P(@RRS
M;0^ 2W/>'+;:/7OM>+;<<]!XVMV>-3 UQU(=O:/V;'/0+^?:[1IKUVO;/0>-
MIV>I WWH#(R6;>O=3E?KE[I$&P 1UHYGRSV'C,<<F*WAT-9-M0_BV^VU]7:O
MM$7M@;E6OK;=<\AX+,OL#2R(J+N.WM*-@3I0V[GN-\$>6.UUX]EVSV'C:5E=
M:P!VIP4S!IUK.TYABUJV;ECKQ_/V/0>-I]WOVZUA>]"WG$[+<!RS8\V>[:RW
M[]ON.60\=@O<A4$;3'0?)*.EVIV6G3];AY=J:^FS[9Y#QN/TAJV.8PZ8OC5L
M5>OU;#WGS1;8[]9:?VS;/0>-I]_J]<%8@UY36\;0TH%)^;,'@WZGV]+6CF?+
M/8>,IZUK+55S^GIW"!-N.YVV/BQY 19DK?^S[9[#QF-KFM9N@:/0Z0V[0[4_
M:)6^0T\WULK[MGL.&H]EZ5:W[8 A,K0AT+[3S6UC'QQ/>[C6']MVST'CL=4>
MZ-JV-6AWP D&/[UO.RV] SZ@YG2[O;7CV7+/(>/IV,9 'UA6OVTX,&W;'G8&
MI6\U:/76^AO;[CEH/,.!;K4=TV[I?4NU'5#Y9FFK[:&YUIYNN^>0\71UQ]0A
MP-. ,575@H#%ZI:Z9#!T.NO&L^V>@\;3ANF!-VRI/5WO@9CH7;OT'7KFT%@[
MGBWW'#2>CF7H0'E0^C;8;$NSG4$9NQ@M=:W]VG;/0>/IM;I=B!)L"'GAR5J[
M5_I6$)]WVVO]GVWW'#*>GFIVNGVSUQ\,.RVSZW34KE[X,EV]W5HK[]ON.6@\
MN@V1IM;M.Z#8#+W? WXL>%.S@4O6CF?+/0>-QQ@:;<NV5:,W-#1+[ZE6D:M0
M@00;Z+/EGH/& _JTI0TZAMI6.[V!;C@Y+W15"+"&Z_,;V^XY9#Q]HV/W^GK;
MT%1==9R.975FN9,V4'_=>+;=<\AX(%30M:'I6, &7;MO@*O>*I_-'.1UX]EV
MSR'C&3IF7^O:/1 6M0.^.,RWT"6& 4[@6GNQ[9[=QE/F)CNQ1_A&+]^KS>]R
M8V]+GK*XXKLQ&U#YJ/)VEE%]3VXQ@IN*1UW;W98S[!A,E8' #HQ!JW"JP.FT
M['5!'0SI%!/<)UG9R GND_VL3M 8=%M,ISA&V^S:'18-VZ4;"E'-FC3*:2:X
M5SJUD1/<)S_;Q GNE?!MY 3WR2 W<H+[I*2;.,&]<MR-G. ^2?-&3G"?+'PC
M)[A/6K^)$]QKGZ")$]QKXZ&9$]QC)Z.1$]QG:Z2)$]QKKZ6)$]QK\Z:1$]QG
M-ZB) >]>VTM-7,&]]JL:.<%]-L :.<%]=M2:.,&]MN@:.<%]]OR:.,&]-A$;
M.<%]=B4;.<%]MCD;.<%]]DV;.,&]-F(;.<%]=G8;.<%]MHJ;Z&SOM??<Q!7<
M:S.[B1/<:W>\B1/<:[N]G@D6%Y5% .]YP2[GCI:)D \JIOF)*OAV$L 8PH>_
M?*#A]6^W'WYDAT(WG "]=P-V2HPDCY2R\V;L9%>?>G1R3V-B: K15<TBC_##
M/:4A@<7SG]C!T?PP%B5N-O(WGB3-'\=/A+&WW?SPW0*Y=B;@/EJR%@)^X2?6
MV!' F#X"%8$&[#!A-.%T3?R$D0"(2@-^'#&;'28G#ZX? A5B?IB1'<8+@<Q1
M2-PGUP_8L3U@Z?B:G=@D"?6R.#]$Y\9^PL^$9OSLX_ST9L(.]R8,U'YT0V!9
M8TJ>*3]L-X$%"-B+0G;2U O<))D?ZG1'_\Z*D^SLW" ;0S'\*S:NC\7A._:N
MXNSI^N&SD;/!\/'"1*M##D?L)S8@6'881/&"U'TICWE6#\-&FRDZFS0[ZE=,
M>PWK+'WS,WSX\8\_?,>6V__$_OWQ_P=02P,$%     @ "X("2T,^J70M%@
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M'OL8-%$H?(&\7\Z[$O'L-*@0\4C2/L<7(^W@!9<N5;-'34-> N\:$BI1_]@
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M($'V.GK@NP?^R2?^"HF.E ]$N-J#%<FUO+1Y>XLI4V1*Q&9=/-3UGC#RC)U
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MX;8?*<7XV55<;E.]V7L^U$!,'$<WWT3=PS8#?O8XQC;5<1)^:^:QJV6]L>.
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M*X42F)]2>Y)DGV2ZG9KQ@TO8J+#N[F!FW2N5KSJ:63=0!=Y,\D9A1+11R+)
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MF5366FB<E$Q!YPPGFRK8UJ,6YFZ?,;4.B-4)?$.F7'^GT1P)V,2;*0C78=^
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M6U\A8QWJ\]:]FL'USG1?# 3DY/2[N!Z5^70>H[R+#\'8"+\:76WSH#7H)9.
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M4HE:3IT?(:!MFTUAD)?60\&YL<!![AU8(TL8[#4EKK\04&TZ=1\".@[_08>
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M;)A)I4*8&VZQ(R9>L;HQ#IAO/MF(5TF6GG ^T21CXNJ[E5_[&V1:2",<\((
M*R'AG&*PF4)=B^*7\E6R*"F:)^)*!.E8NCRVR8!!2F %A$.6<^V"I5>YTID%
MID5V)_B>*-,8T4?6]'LIPLKZ?_:WQ8];$8ZG#R0F[(RL-L H@32QQ$5/G?,6
M<ZKKI65T%3P\[UL1B&3.,V^0=H:&>9BZ&.I[0%8R^#HOQJY-I^YO13@._]'K
MOQ6!6F4X1L9BSZ$@D!)A*T X=GU>)7;J=)S:W*AU*\)QP/9E9IVN@CWVD&@
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M/+'C #I=GACWBE*BG668!5L7..14-4[(4/, PPGRQ!HI,@$J0TL;<LI"(QP
M'E.F"88&FFKTRM,^,_5/H].T  TY#5 8@8E6C%EKM:24\XWO4A@HF\_#)\@0
M:Z;J#F!JK/!W8;>QVVO_\I&, \JQ1N$_SB,DF'5L,RH%3/.YM[/ZBXF5UQR,
M<T[EDU0J!P,;I;/!B@1""EQ)2AP?8(Y]'\D@S1$:1$;6;WEQ58YNKZ?CC_E5
M>.RU9699HX,VK9$&*4FDY@BBM4J Y;I6K=AA9V99ZJEP5D&)@K"$*V/7%KOV
MUI(^/\NFF5FUE50O,^LX1+ZSS"PIM HVI*+$2T<"+MK+"AP1K,HSR\RJK>LC
M,K..@^A\<V\T(I[[>*\N8P0:1 2FE9P@[#6&[?-,HL$CDG":H?5ZV3%(%^C0
M2'$:,CP:=<?G9AULFR$$+ ,$$\",T<)8K5$E,Y*]YO8FR,ZJK<&B6YQ>0WZ6
M(!9C)C%E!"GD&6=05Q)[P)J773]-?E9"VZ(-3J\AVR:(%;X 8K4B9'7*#6&[
M^18<./<*7K45>FS:33/<O@?&G(OY,1"BO([\+& ,-<Q0Q+CC!&L-/*FD5$:?
M@^G16''U\[..0ZDW+BQ'RY4'Y=%R&LT.6!P[VV3"*"P\UM110XB6P92O(IU
M:=7\#JC39&LU-352 =0;"1Y\9T]'>W"IV-DF<P :Y0S&$ CAA*?.Z8W?D"$W
M;*LB@>Y>LB$Q4J^3%8.T'(9$AC8D6.3C7ZZ*+[^N2DR6]P\<6/_CI?K7O\[^
MN-BBY\<_9BJ6OA&*"TV,D B[L%_?C!>; 5Z%G #[HB4,?7V[[JXL;@\79GWZ
M6!:+UOD @W,,8&>01;R*D\;2^@,L]9%.H0D Z?Z+_/</>[[(?_^0(>^(MA8$
M*L)8=92835X* *3%J=W.,K72?Y%'P]#CKCS8E^-EM3O8OPM_]FCF,6<Z$- [
MJ#1$,FQ0:241AZ[YEWF*'(\68>4VJ)PPKZ./*^<F\6J]2?AA4<RFDYB=J$>S
M41C1Q76>+T_[\@^C,@!SG2_C]]WW2#8F7%3):''M9\5?O</Q;!#%S6V97T<+
M],OZ L1806J 0QJ,WMZ'K?S#9]7A*.+UG1UW;_.\O)SFL\GOQ3)?G#JI:\=]
MI7L6IETWG.JP-A,ID"*((>FM]?[AMAT,F'"GO(KQ^8@/Y7)M>3J#D J-O6:6
M84V(%5;@2C9#09_.S;V)7*UU4Z3&8M I7&^+^=4R+V^BF#5RM[8]GAG".$'<
M"0(\PE@@9T$%AV6PSUR,H[R=K51;) >F+PO\Y5 /.K.V-\BT$BSL*Y@'2#H&
MHUO8;:#B# [;O]E.80>TWPJAU\:#07HTAZ#^4[FSQW=A2Q;'>CC8^?+9C"CH
M+)12TR"240 "IBN9 /(#+'[55CG?.*[;0=*7FI\O;@>6]6\?SKA0,@A"N!%4
M<&T<=JJ2"FO<?%'O.%LJY:+>&I;3*#N>)SLXF>]JDDDE&8A)@<)[&WXV$OB-
MA%@//.^ZC<KV:K\U0J^1"X-<VH= @6-5O^/HZWJQ,<7\2UXNIV$N>_"8W.7_
M?C?/P_-B_[G8NNTS[[@$A#."A67$2&+$9@WSEC=/6.EL66^OFJ)[H!HK_LT\
MF"SY8OEA=+]:QG;OS/<]G@D+?  "$&8)-58)3C8+'\>N^>F[CO.04BSB"8%)
MJ<:=D_'^!AF0BACH!-9>8L<=8DAL:"W90+.)TBCA@$9;(70.NAW4,CLDE292
MI2GN;HMY-8P#]7ZV/)L!K*3"A%LN*6.*>8U9-4Y)::\%N?8OGZD +])"TEAU
M:Q&F\_^8SB?U-+BG2>80D<!Q%E8:S9@%DEBY660"E8>3^].%(M,ATUB?[FMX
M_=7=='$=1U)<1DM@.A_/[B;AU]601O/)AWP^FBVG^4Z3Z.B.,F<,DL)+'L\_
M$*D$#O^6,!8K-WZ0U==2Q;IZ 2PI)=Y4 _LPFDZ>\_480NSI)M.",>*D,-01
M38SV7($@G>24<NI$<]NYLS3 SNF0#JZ^G"%QH&\.T6/WPQFSF(BPD@6;1BI.
M$;6V@H['N].&ETJ8.O[=&I3&W_US23Z4^>W#\O0P =WO^LX/-,L0QX1:$##@
MSBCLJ18JS&(,.T0Q!<U='9T5=TOZ7:>%IZ_O^-'0F4[V?,%/'\NDU,JC,'P!
M+)84Q=C,AJ::-"_8V%DAN-3?;@LX>BL&$7!9Q"2[?/%^_GS->7_Y-!5M6S&(
M0VTS3R&U"F&*I$."6LE!M1WE0K#F%&#G0H'4&"6:S2MF?APM\U6&X^2Q4MWH
M,OS-Q?R_Z(=X?QNA=[-\=<]HO4F_:>]A\H.:&>N-E%3[8,0 4FURN&-*->8+
M'SI?3H=B(D8M_IB/;HIR.?U7/C&S8A&([O-\H>83]_4V9M7NW"D>VT]FP^X7
M@3!E4J6BV6NXLI5\2+4P"L49LB0Y7IT?4'@8_P.WUV-\/W^M*<D>46,=P9:0
M8*Q;K(%%0@.(!1;(U%L!AYJ2C+6'RA)L IV H81Z:=:R,4_IX%.2:^NF1DKR
M<5B\^I3DL(/QUD#.!.",($RX@Q4< ?0^?7FM Y^U55LG)?DX8,XM%158#@V1
M6%@K+2?((^4KZ23&9)A!TC0*JY>3V@RAU\:#0054AZ3^TZB]74JR%4J$^=$P
M+XP""!MLV5HFCEF+J]'Z3DFNK9R#*<G'07(N*<F(4&>IED0S)H7U0&)22<6L
MZ/-6G9,MZJUA.<<T5,$(\*M+0YU4A&NM:45G 1T'PU[6VZBL;CYJ,X1>(Q<&
MN;0/@0*)O&Z]I20;B3R# $#HG0S_A=KH2IZPI@UP66^OFD8IR<<!U3K?<>TR
M>Y[T=2CG<6NCS$--C:)*.@\="-8L"7;+>N0&@#/*N#G6E9,<G'-)J*#:"1Y$
MTSBPU1H@N:CL'DDU;1YAZ3VKIJGWKC4H?:E:/;CU5P5'WE_ZZ7PT'T_G5Z98
M+*-[WTX7JV)3^XSXNEUD$E'*K8JW7#'*)9(&5EL?Q=LD9?2>9].4%AU!U7>"
MQGHN.Q"YW_)TQH4(R $0MKX*<XV1)*Z2"ZD69U5ZS\MI2H'VJ/02.[L87^>3
MNUG^D#_PBD)EPFBD#?;:8PD$0N$KDX1:;4PPX.H==AQJJ(Q0J@QSG)G5TJ(H
M4*:2S1'2?-GM*U165S<U0F7'8?'J0V62 :PEAMQIIZS23DM8P<&9[K.B0VNO
M6FW5U@F5'0?,N85(K$(@)NI+8;PF80.I*:BDD\**8?O4VBFL7JRD&4*OC0>#
M]*<-0?WG&"JC1DMCN')QHTF%-@+I2B;LP(#.*:92SL%0V7&0-/:>?0HRO"U&
M!ZZG?_Y4YHF&D E$L**"<(LX==78K,3-TY<[<Y8D4E=[,,XEIBDH!(1SZ!72
M##J &'TT;"%I/OV>(*;9U/IJ#<LYQK$,HT8Q8X"F2(2I(HB'-ZN5!^=79JFV
MRNH&M)HA]!JY,$@;; @4.+>8)L5484XD":\/_^-PL#$J>8AH,=OW'].LK9I&
M,<WC@.ISS_5I;=T<V&E5CV68<P["5H11C4T0R0.R^28D0@.\%#"U#ZX%'/WX
MLZ>SZ;B8_^=H-LOO]6C^9S0ZU7RR(NMT>:^NRGSEVWL]KFZ *;8<<X:99()B
MK=E##(DA:) XZU,AB#L8J,6LA=!*;S#09"T;B.5>A^[JKJV;&J[NX[!X]:YN
M*JF@U'KJO%"8<B!Q!2W@_+Q<W;556^M4R%' G)N+4TCO'0.&*V08H%  :"KI
ME+4#3Q]MI[!ZOLYF"+TV'@QRFS4$]9_2!QJV%X![%=9$9Y!$6(6EL1J;X'*
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MVM>?>MLYS#1!X)#"@N,PQ3@E&3-.8BF<]E@AZU&MZQ>_SS1!JSS4W%@BG0,
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M(TG:LL_0"P_#M\ 0-9!K(I"O9.3.^V%;BRWU5K_^<R.47B<C!FDG#H4(IR%
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MI7)<RB6RM.=#,LBMEQ11R<-/CFO(<(F"Y*:^JLNO598N1S'-#*F-R[K-=*@
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MI'P!CK<@V8%A/8O*O"V$NU(R#^SXI%%\=%UF$-<\:A10< H<X2;6'6]I!4:
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MO=5,&+\KHN#,L$H&]$?@,L\$(]8Y9265W%$@!%*VP-%@WF5G]+8#EY5%IK7
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MZUW=W.?WF2G'YD/Z^/2"K0!&2>+$$%,7LU^X?HS#(+1I1(GE8N$#1X91&*P
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M0L>2]5J<J$@Z 0H:I(!!!1PKX& ERR?-I ]+UWQ\JY59BZ9Z4ZZ;\=A<U[9
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M5F>'.!K032W4+D,'];A2&NAZ&B9D(F9R6S[P7]*RWGW,\OO/>Y8O-AJ[PE:
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M(H3[?,OWW7SZDFVW=9=/P@BZ8>2Z+LLC+2N*;#O!O1TK]H7.'JM_W;"B]9A
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M H[UEVRSWS(UC;+/[6-9-]FW7<A\_FT5NGY H\"%D>\Y&$?(0E[@NE;,L\^
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M21A24T8#3*EI8T]2\[204:&\N'PSDIMEB:4L^ MRJ<2!D&"^+?)=GFZ[N<G
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MP.M06136DZ(X*R40%SBZ,,)4,&O&T%)BR7>%,U6Q,V,P38[)^B")B =L9*/
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M#0/B/#YT!D0%GEHE(/XK+VYN*6Y  T%VD_]GM<_8TR*'Q]: R($H<L.0AO(
MN*2MJ# 8@#W'7S$RS@.N?Z=ED,&'$=B*<7*FEU<(F,NYUYC(.9AL]39;)Z-_
M]!AZT9M+!5,U7>IO&%45$:,SO*KTG5"<_?JZ 5]%\H,O>7WG;' 2^:Y+XL"&
M@><G*0CM<:;L$Q=(Q-5U@"X71_?%M<S:ZTK^$XB8YCO.F @Y=@9FXPKA4(NK
M7@M_Z_8/@\+=RD2\%-Y,\ UO./NMW!7-H2Z^'FE#0PD85A<)[%OWTM:KCUE]
M*+;%?<;JC9Y*[=$076PW& 5. G&*O-CW<1@"5J0JP5'DI4GDNO:FS&^RS@C>
MR*4=$Y?,)9W,?0>?6_+>GXJV9@-P5LSU?@I=NBJK?L?Q12LSG"45DYY M\;2
M5GU9,##UV1,+K&D=U=:(9:/.7,HOQ);%O&E&!%G.W&JE42-8DRL_G$H0@H>L
MV+=/EE4TF-U597M$\K;:4Z?T*((0(1S;40 0<9#O1'%$!A1)0O#F4!VR/9_J
MJVY;Z/#A"%->W5GM*:H4VQ:NU;3'@5GQY:\,[0L5O._SVFI8+B!8ZDNUB_AD
M?DWOB*GZ]P4>1[C,/QU@:XIX%1$7)/2"9NMRC1D2K<VZY_7&M+*X0#J.BSW[
MI4WL ]^FG<Y)72<&@,+TTP&8X_EDV82<%]4R*?FD0O[35Q7,2M"Y7:D]15?J
MOO62]-Z,'R9-[_'J2=1%?6I&'%C28'7)NAS7ZM/U 4>2PC#UHI2 -/"P3R+'
M]P8<[!%4/0D[;^NFI.R[#N\:23NWHU2G[3I\I#]Q7T78A4E5DKR+.L@,V=9H
MGW0"+\<DKR@_VY0>ZABWR_[-A^.A.60TGI0W_3H.G4"X-@EMW\9AFK@D14F/
M 40H%+R H[9M[=NX ]PW67^VI976AE5H?*+)U0FY]5-1]C_V#S$-5NP7/OU=
MSR%BVOO=*:-3:?4.JS4!N\IZB1"3%P17CT?,$%M-ME5+]&DQD6TEO'C(3YGV
M^&BO%]HLHP[<R L\+_#=R$=#@RE.8Y$[\C.:$<IEQ5<R!F23Y8G_$-/#.13R
MB=]"[(DIW4C<='T@O;[.MP?V6&;;::V7GKE9Z<WO\R1>$#D%S)NA:"H,J93W
M2@4)89^#?B>:IQ7*#?"0#6 <@]AQ$\]U21B0$4U*A)X"UX5!L\I-0 VIX'#J
MZU@^Y W+6#Y]_JVQZ,]8Z>>/'VG>6'8K->RG%">+*GPV(VU<V%UJ$L@>] M9
MY.2Y6@,RR=?)%<TI%;K+#"W6;B5/GJF<U9G3^G-X-BAUW1!$,/*CV LBA&CK
M PH?AD)'(U2WK7F=569:SP1\]WU.JWRZ+^^O61/^15RE=<J_RDJK()OBT_[9
M?C%8FE58QS?U5\2B[ NVW4)#%!)"/(@!\OS4!Y[M1N&XT! #9\[KM7PM:$Z&
MWY_?C;KJ3YDQM=Q5^WU6-Z=_%!1.27;YY%$_L6(B^/U$?Y7%S1=IN:!F\V@T
M0[-FVO#*Z[4RC,CJS["?1!([M F"L>WYMA]##$^M81\+/5TAV\::&C1LF^M0
M(6Z.Y71(![WSE6B5G.L,-0)J)$JFF7HD;,4KBB3'"J\FL=);#2AWOU%;ZT-6
ME$\6-FV0>I#$ 'MA[(/0MJ.X*VCL 6Q#G_<5JGF-Z!L[+:YV"OD$V6IK]A=Y
MNC"0U/!KQG!29$NEHP>*#2W$#"YI"VQ-F0$X/?9Z>NN5>"  Q$UB8D<X!M!#
M@3\T[8=BLP\E#6I.!)Y@;)=V4)WOBD-;^U(LU*OAET_!%J=63,B>P.O*B)X
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MM<,>CM1ZH2C9I@J:M#W<ZX)R3,F+6'IWOZ\>\_Q3OF]3G],6ZR;"282I8 ;
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M+#F?H%,4:V9S+A%PEJ1;U?)$%WB>.& $O";],P+0DFZ8&X64N$,N%KU"$V]
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MK^IM;_/=D3U02X[LJL&O15G<'>_>L;M$0PU&4M4HNR]8G1[V[:8]$_PE_W:
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M["9O%\4Q3=Q)5M3_F>V/^?00F.OY01@@/XE)Y$0VIH$B'JV$L6GGF97:IOG
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M^2D^<U)[41(O)/_:_&'&]$"?>=5"_5JP=%)^PQKZE-]7]84%4Y2D*())ZI,
MA)'K!SX<VG:1(UK22$F;VI<Q>IC6V_*ZJN\DMFL4<<NGD\N3*B:. YLC0'/4
MD8NZ"Y*HEGHS=%"Q3<\KMFA@;%ZQN.YJ;WOY:DN1%0_Y1]I]^VQVXR5>;/O
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M_,?L\=G[RTZ*W#B("< H=(/ @3YTXM!V4Q"'"29"Q]9U8]&L<6K*@6AW")\
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M1O7:_.)MM?:^-W?9>TI[KU%_ZMN5X #WL*[-X7*#>:U:>+HET#J:6E>I=\7
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M.*QPRB)#O=64$VM=A;/!M79D._.(OLH-F!H'&\)]HOW*PVG"4]Z3M!80;J6
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MD@1R:Z@G3DGGPW*/J34ELC"X,-.*D W,QOY3 9JI[W6E @ *XW5T"F@6'.F
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M89;]K>+ND@XNH[4JK.J.QT-7ID(.ZHD=<>M W\_#,)UA^[T4U?[Z(P)"H&P
M30*($/9(@@I)F98$),;(TM$LJR?48FNK_X^; &EX'9?GO\T7X?4LEOF[V=UV
MU/ML_P--LO " ^(H%YX'2]=J;P"1.+I!C!A-)I8,?QJ%%[WH8KA5>7O-QOO\
MK+B,._/%LAKY;_GFJCA_^L"_\I?N%VO?628\\Q99Z*'3%AH0O*AR)Y%)G71,
M?81ATI,R=# MM9[].BS$QR%RSAB,@"$>@O#RT3+SB 53)B4/<T1[_*/@5:>:
M2$W0JWMW'?%:6Q6F8*4ATAIR;JM149ET%\ (DS=/SX_VV+=G1-!.:'PU6Y[;
M,*,MBINMI_,@7N#L1;&ZSL_#GV\W5T$+[_/Y]:?;H(WXZVVEA/5F_>OR[#;J
M<D?QO>SJY^NRF#3/  9".ZLBV!)4:$DA4U;($>:IC("IH]!C NN/K.Z_WT8'
MO[BH/EZKH)/0:N_-L0E=9L8ZB2PS$$L/C0?BT;M.@BT\K0W/,;!W*%T-Y:'8
MG8J/W][X[,G,<H4,%0Y"PV,V N:"EO) KU/2<1IO:+RZZQO;>A=I2FCO.MR[
MV<'^?#P7KWT Z6F9W >Y]SH5S;O*;)C#I4*8&VZQ(R9>6%F9-,RG3',C#/*=
M?IKK7T<GFMY,M!E>Y.;A!ID6T@@'O"# 2D@XIQA4D[=+JA0IOS.PSE373A,G
MXED$J2G5'MIDP" EL +"(<NY=L&V+3<MF04F*>,9?*=;';JUUL8#XX:O3;_U
MEY[\;OV].'V=<N#24<$U( Q#''Q(YR")QW:<MYA++W"=%ZZOC)#779R>2.8\
M\P9I9VB8N:F+:1@[9!F<6);<P&SLOSA],_4-M=IV4YR>6F4X1L9BSZ$@D!)A
M2]DX=A.[E>V4Y*A5G+Z9.H:BVNF*TV,/B09!T<(X( R-.X0E'D21B5UVE<B)
MQ.+TS;!N7_7F0'53_=N']B5KJ\89M(H:BK$43#@IL96F0LR%WTV+-;WIN6Y-
MVK; ]T*AW_+5V9_M2?2H>2:QV=[L!I5GEF(MC?.E-$#H6@9Q5XDC0P1W3TZD
M]N!_SP[='PR Q"@&K#; *($TL<15:J(ZZ8S."/.?1F3BG5"+WTIN'Z "2$X0
MDP!1["431E53D-<3*W]X&D*EY_8UT](I@X?;%_Y[H/!P: 92[355&DG#K2,8
M> 8$I< )+J&'M:K-#38=W2XV\YM%;@,!@@T5U?OXQ3D6#&S78888\8A;:)07
M"CC*!$8E0@;CB9V)'IA5Q^>C[E7TNH)Z2'-K!;)*<F@TAMM_[F1S*JGNU CI
MUS<!:@7NFD$^_<!=4*,W!)'@Q2G(I50&PQ(/+>A$JE9VQ(G$P%TSK'N)NG1X
MJZ1%E&!,+!1"(6$894B4TMC'EZE/@CF]Z;K-K9+-H.^%2+_DR_!3?G;5GDS/
MNLA4O)&"*.E%>/N(MT+1"C(J;<HYG1'&/TY.J#3X>R'5Q]F?^?FL/:,>M\]L
M\&:)-!![YJRF COX8#=8.9'2KJ.A4P+VG7-IO>5WDZI)S7O*'-#6*^^1%P)I
MBA0G3%"-A>;*ZJ3Z;2,\-G92?G6FA1.&6P^[.G4V&]IWFAED *.4>J"AA=IJ
MYWFE#6LGMK4PL*,YF%Z&*^S4]=;,Q_S+1H?!_CEH/E_UK1DVGD/+J #,*.X=
M"?HM<4:03RS.-P0A>\_F:ZN\T^Y*1!OHR2^_IS37B2D#*8+?*H%F# :6Q35]
M6^$78@*DX]]3FEOOB5-GG'1."64)Y1PCR%B)+.,RQ4H=X<PW,!O[3VENIK[4
MBAE-KSU3##L+D))4,<T04DZY<G08XXE==G!*]1ZZ]JR9%KK@2--KSQS&GB)H
M#0#:.>HMN3\&%T>HR%1"Q6G*.7SM63,$6^NXQ;5G C(EC"6"*TS#J!C>)A?>
M4]BAB63VI*IE_[5GS?!KK=F6]V-QZ2 !+AC_''G#D #*5@)ZGZ+=4:76=JG?
M- Q?5P:#@<PKK$F\#%Y )96!%4#4HJG=LGYZ"Z!+=4P_NX%93S'01G*.A  T
MS(JBQ,/:I%H<(UJ<.N)$8G9#,ZS'OW_()3)&0D&L09P*AZBIO$ M=,K4-D+N
M]*;M5ON'S; ?+"Y>A@I^R8O+U>SF:GXV6]2]7^-YFPPC)(BG4#I!@T' K7XP
M_#!Q*7=!CW!_>D1+9U<J&8QV^>7ST1Z_9V-?F\QZBRE0FDFB-*>&<F%*&8U1
M$YO6.M#U<_9TA&SK!?"71?'IF(O^^)G,![<CR">,]\1CCG0P!,IQ 0PG=A5E
M!_HIND&RV?RPSL]^NBP^_WQ6W"XWJ[O[Z6'WC^<SP^[C[-_?O4" AU]FR@F,
M.(? X5A1B"E_?REK&"^2QJ<D]X[1.^M,\ZTA'"R_)*Z*M:^W=MX";CS@#E/,
M"&(.E]84T@9/+%-I1)9&6Q4,2J-&UUM[2;3PP'/C/(-:8(++53.\)61BQP5:
MZ._ ]=;-L!N* ^VNMY8\'D)%TE(DXDT0V-#RC<#8\XGM_+72XL'KK9OA-Q@7
M6EUO';QSI!FCA%E$(/0((5#)PN6@Y3=>"1<2\&MG59[G\T@#$G^(VB>/M!\^
MRM[DE[.%6V[FF[L]9L4+3V7.0:NTM$!ZHY#27HF*Q;'H48+F1W@?P0@,BW0E
M]$.?^^'LC4H\?R1CR!CG'';4>>Z1))*56V*8<)0R98QH^4C25M$)=*VC#/?A
MV'=7L]7U["R_W41ORA37-[/EW9OY]7R3GQ^.0-1MGREL#220*14M*0VHU*24
M1R&4<NIK9%1HI\:B?U"_%V7:7WU%$"(<T,AC"@@0!(25OD02\*0K.T=X:<D(
MEK@1:+'UI-GQE9W.A:7"8:2590( 2*D,YF5P0I4TC-B4':(138VG57C=*SN;
MZ:+SW>V=QZ"N8V32+>:7\_!N712K1]=2S9;G[_/+VT4DP=W#E3Y-]\';?U-&
M$15"4H<"X%Y*A#2NUC0N1$HYSQ$Z@J?GZ\E5V)KF+X[0Q]O2KJ_S54S+?QC3
M'\OSY_<$5"=N]I&[J_XSB[QT'F-D!(*.>R84K@PIFI1 -,)-^M-3^D2*:TWD
M#J^I5<:BL)Q0QK45SEH(<847I"[EC.X(=VE.3[6N-)%ZH*+N-;7&2N\(@TII
MC"3&1'!=CDH2.TRP3=[S8YEO)LZ.]LBWY\,T+JFE6&MM-((&$N^@45B5F^W8
M4Y\2T!FAQSP"IHY"CT/%D+JZ(T]1H(Q1'EM!'<0"5.E?!L5R-0DL;7PAZ,19
MVJDF3L2SQ#ORK.2&&,B@MDHH*#@ NI11B:0#D)._$[0;MK561N>AG-T=R_''
M-W&^7A<7#][-;JZ>+<_R\..\V'L1=S>]9X0@IA3@R#( @;42&%9BX:WX?E7H
M0"&;7M660.'EMB+"QWQU/5]N%7P_@#"<?ZSFFTV^_+W8S,_V>KNU.\B"22%4
M6 HDU]P))75PV$N)+"=)1\0G?XMH.R;VHYK69'LV83^J7G1X)CS6+G/"$L"T
MMIX+S)@/[EME8&A+DHH_?=]'>8%:'6MDH(I.U]?SS9.MNL%K-3T:0]!5?$'G
M03G+LWF^MO/UV:)8WZ[R&C69&O632:'CX5 '0+!]O-&*<"48!$;':L+U"CCT
MCL?#N.N4DCO<,/-2<PXYH3B(YPSC'L(HL?-*.@PG4K*B9S9\M5W?(>1#O_&_
MQ[.N<3X\=;6VT\P G'K%A95""B<] 5XYH+ ,6E(T?%#K2& _>+PIEI?10'EW
M&P-<Z_Q!KF.EU(ZTS( AS#*N*;. 0$L,8*R4.4 QL8,,/?&AZ!/SH2(];_(P
MU,>&4/CV(T>K]C7)H#964:@Y@U#%RW HYJ6$T*&)7>C2F;Z?\Z@;>$])H*,'
MM/<WRHA$#%$,E!(\X!7ETSLIF<=F8D5+TI5=@SVMD&T?-IG=S#>SQ78@L^7Y
M=L]E5V]R>;G]]$B)DIKM,RCBL33OL#'QZAI#@GBE/$;AB9WL[D*Q1?\P#S7M
MO%L5-_EJ<_=N,=OF++I_WLZW6W_ZKL825J-U)K ,\AG@K0<6> @$ @]RDXD5
M]^IK->L>Z9,SK-8*5Z-UAGD\^Q!S:I!"0)(PE<)2;H*2<EI&.(%URH2Z+&N-
M=NOE3]\&%,(4^N$J7RSVUW3;^VR&+*+:4DK#/ M S+_RLAPG<#PEC_@UL:*-
MYHINL1WL9%!0QWSC9V?SQ?X3J/L?SO"]=:BMY%H2!X75OI0J6) 3JZ75UTJ5
M#.QIZ')T)7KI\0Q)SY%4C#IC/21:0%--M![0B;GJ*:H]R))6: [%DP_QG,.G
MNS?Y)B+\]N)^Z$?+&QQJE@70')2, T&U4Y0+J\J7BU.LIQ8X3%+VUX7WNL)U
ML-C.WJGV38V3J#5:9S2\;"1\.Z1( X*E@H \DCOE*/P(T_Y["QEVCO10#%.K
M?/;VXGT^6[AU+%98FH,':+6O2>8@TA)3);$ ADIK'*C>(6GPQ.:F3G7^5?'C
M3B!N[4.]R=?K/(]!J&# /T[B>!RT6D?I8Z+8<M]^8.N^,BT4P$Q;IX,GZJ!7
MQ-M23H/(Q&X,[(-*0V'?29AZ_?MM7(6+0/EE_M=L\?9FFPA4)T*]IVG RWB$
M&;;>:QD,!,BL**4(MD,*@UZ53Y;(H.ZA[GE2VHTM@I$V(SWJ*!.206F5M)P1
MK7FLMUH&0#CT21>8OBHK:9#IJ#WPW<Y%.WIOBC)'=7^><;WF&4&,&L\%,V$$
M&AN%1+FG*)0'*1MF(RQ8-NR<E SW8-&CQZ/WMYO;5;XKSEA6^]A=%?B?L\5M
M_O;B]WSS[/>'8DW)G6= ,&6]-9890Z#W'*OMX3N.C=7&I-36;'R LL\[EX:P
MXP=71S<SX/V[I,[/MUG3LT5T1XIZ3F+[SC(&+:3!VM0:0V&,YLC)ZG75SB80
M;X1G(H>9'7L"?ZBY\GYR?\$3GK]86:A.LXP*19CE$@9<#=<"2EFM"L(G5:4?
MX6'(/F>W#F$>+* :A"XCOV58>5?T11>K5?%7,$S#"Q1^<S $UJ2;#$(I/#&2
M>L(HY%9J7[I'$BN4LI\\PD..?1*N1]B'R]9\LOOP]G:SCML2T1_:%ATZF+-Y
MN&G&#/4.,HD@DC(6;]:FA%5RPI/R\49XB+%7IG6+]= G2AX*:3XQ.K<V06E9
M?IN'3;P#5G&LC89: LUU//[G%47*2&!1K>SF?O"P^:?-K\&!7=W6.6#RPM,9
MUL@&KT!8:#RV(!AP6I>R!2$G=K=63WK_JHY#*LY#[A4'U*_CB.L<(GGA\8QR
M 9D-\M @&D7 ,6Y+R:#G$\M*2=+M"SO B7">BBC'#XN\V""#P(05U")N 48X
M_.D$>(!*IM0P&B%9TA1\A"VM$#U%P/+MI\7\<E;OMN2#[;(P'6NL!?<(2LRI
M\XB@4E9'55+%C?&SIZG"#\054Z%M'3)\>ECE81B'4ZX/M\J<148:)P%V+KY.
MC!-:O5% IM!BI!O_'="B>V"'JW/V> E^4R.I;4^+3!E#H="2 "Z98%Q2J$KY
MA!4IVQ8C)$Z7IDLWB(YG^^Q]'E^B\QB9],$1F"W^;SZKNTXUZ#$#*+C[0BB%
M"*%.DWAQ6O5&N:E=1IC,DL9;8UV@/AY6VMO\U^7'OXHH1-H.[I.>,BF!9Q C
M0Y02R,8[=WB)!^-H8I?L#L_"%+3'QK[PG7E7_*OZRCAPR""D&>?<!? 1U[!:
M=RA(67E'F&EW*@:VQ7MD'/3%[:HC"E9=99I9"KDT5EN/* RFKJJP)VEU3T:8
MGG<B!K:%>VP$G'_N:@ZLNLJX9L 8IRT!D )$J255' AC-[&;2$]%P)9P=Y,3
MM6]<\^6'^9=]A&K33<90<-\\5!X@Q S1%GNVDR[X<RYE-AOA#09=D6D J/LE
MDKH(8,=AA=$E4>EQ1QE'5 %%#7 4 DD(,;R$41.$4HRS$2;5#4^F!+!'M3"F
MKH9A3K;.0(!,\,ZI%,;'ZKH[V37T*340FJ?5%7&\KX%H?6)\NJ23][&OA?MR
MDR^#.&IY_N'VTR**]NLR-/Q&RYQZ:ZT6S# O$)$>2,1CA4OMD=#8UW-2^LI)
MBY7-XI6,C]1V,!'MA><S+9G#,M9ND)XSC AF@:.>.2=4S+685CBT)]V_6$PP
M#>FAEIFW-WFL8KS;?XJGN#:[ 9=O_[T4:WB 6O4[R9SA0!&@J>1$:(H%\BR@
M$#YDWHND.I7U Y_5A727LTU^_G$BM.M-"Z?GXN_YH1G]8+M,00 @P"HLNT0H
MCB1%,<<X_!!>/:=2KI9K'NCLW<0Y-=6:(SZTP;/==OW6S!AK57"7O6)*6 R\
MH=(@(;D%$!,77.C3F3%UDI[C7;Y/2A]$%=:YTR&]\\QHI["!2"/@C()<.&-+
MY)1%$RN7VQ.KGM=T&EHM@]4.>^),[:;$%FS=VSH#<0?=,$(HL$9+#0Q10AJI
MG(B;2Q,KL3(T';O"?: U;1GO7-W=8EX>>GD_7_]YLL4M?GG4U!]A9*O-;+Z,
MAPIK+&8'VP7L'8['P"QF@B@&0#!28D4E@Y4%NE[*3E^+^2,51"&:7CETO'GF
ML:+*HV!  6Z%TMA04DI/F)I8PG9'3/CJHJ'.@3[Q*SZ:VX?Z>>4M]$1Q0*V@
M++H2G!MR[YA@(%2]96Z@5_[8F:^7&V3.6J"PUI+%\A":H^"([22$B.J4R/NK
M>ZUK:_O8:]T&VL$V=)X/MM:5"P=:Q0I>0'(@/=6(2\M$D+&4$VH^N=AMFK*/
M<:<UL"<C4*UC8 =:90P00R"!#GGHA%2*$UK*&6O73)Q ;31^= 9JB^Y@++I=
M;XKK?/75R(^?##O<,E.:,$N#0P2]@DQC#&-0^5Y>9T5*4>+7P*8VFG_.IDX1
M/N'"IH./?G4]6_W9?'5[TC3CQ@N-O!"4![M<.8EY);&V27<TC#+<T?<2EX+N
MZ?A4#KKY8O>L:4:H$HP0%B9Z3X#46'E52NR5F-A1^>X(<)1923@/Q2QU=A;+
MP*S?YV?Y_'-\MXXN>ON:9!AAQ[3G!%#&M:;A;UO-Q;+>CLIK9E);A3^OF=X-
MOD,QZ+?9?Q6K<IE>'UG=OGXX\X:Z8%P2(8T+$%$A8HI9.97#%!MIA*=N.E[/
MDO$<K #B[#I_>_%DN$>7KKUM,B.D-8!PP9#6 !'I("YE%&AJD:(4)3^O=-@1
MI*TSR.W\9A&^<//A)C^;SQ:;NW=7L]7U[.SN<+&%(\VR[05,+JS/3E+F(?;Q
MCM'=Z!G"*1DM(R1$!UHL>@,WX7#!*H_+YYN?WOQD?CIVM>_7SV8"<HP]4?&N
M6DNM)I[P:L&U=F(E-SHF00>(MM:\NKB8+^:S3;XN+GX[^X]\O2Z6IEC=%*L:
M=5AJ-<ZLHH)2!P(V7#B*]*,X < FA1LCM#(ZYD8?$+<GR]E9 +KX__,P4UW%
M//S[<>3G1VARN%F&I0;*$HZ=H(@"'_]9CAZ3I")@(SQZVS5!.@7W9%&5-S7*
M]NQOE$E O!>.80:Q"RLE-:J:+:F6*4?41DBAOB-S;7$]&7O>Y:OXP>PR/W0P
MX%"S3%@H37#PL6=42FWB(8B=I(A[ZZ9EQG:A\F,L:H_N4#SRQ2J?7R[-;=#,
M\NSNXVJV7,_.XOA_"?/QFV*]UOE%>.;C[*73M"UZR11D7$>[3E)OL/1,D#*W
M 'FKA[&3GQXX>6T\ZP_N$R=1O<\_Y\O;?*WO*KM@DME4 @D')#(8 8H<-Q ;
M$BP?SK'A,3_V]6=3!</*2H8]9X()B+@VP2S?21BCTM-:2SK2=KULJF;0OMYL
M*F>UE1I+QP%2V@)'-2OE=,I/+,\V5=D-LJF: ?MZLZD,5]A[YBC$  6X/"*^
M>N_""CMQ K71>(-LJF;HOOYL*D\=( 1)0ZD@7@7;'51OHJ)P\LF=+33?,)NJ
M&<)3R*9BS$OI*21:(HRU,\Y4[Z5621=%C'#/H/\E+@7=*613T7CRC3##D.9*
M*:O"&UI*C)F<F-7='0&:9E,UPWFPPZZS13SZOW6A?RF*\W6\!_78LK>_49SG
M$;4P;O13Y*7BG+E22D[0U..!K97^_#1K5PB_EIPJYR ()@$E0JN@" H\@:54
M0N.44PPCW.WL>%5+QO-UYE11$=X#*#U&UFL:G!*$;#55"S6Q2]=2E%P[IZH9
MI&/+J8(8.B+"H(G6#!OBF2JG1F$]G%B270=:;))3U0S<T^54<:\H)=I9AEFP
MX8!#3I7CA REA !'Z!]U3((.$!U;FHQ3%AKA /"8,DTP--"4HU>>3BQ;NV,^
M= ONF-/MA!&8:,58K*8F*>6\"B0) V7*VC'"5)BN:=(#Q*W)\EN^.ML?NGW^
M2,8!Y5BC\(?S" EF':M&I8!)62]&>(% QXIO#^1K39F#D" &J#-A&>3:8N1=
M"9/@D*=L$(UPGN@[_-H6U]><,B>I5 Z&>5 Z&_PU(*3 I:3$\8F=_.A"Y4U2
MYIJA.YK<I5_RXG(UN[F:G[W/+\-CT\QA @00!7!0>LRNYM &E=PK1WL+?:TH
MW[ASF"SU5#BKH$36:,*5L0\26C*QE[LC;=?+86H&[>O-89)"J^!3*4J\=!$Q
M[64IIPA>UK0HE*KL!CE,S8!]O3E,&A'//5=8,D:@041@6LH)@L<^<0*UT7B#
M'*9FZ [%H@?[H7D6T]&V&4+ ,D P <P8+8S5&I4R(SG]M,H6VB_ZQ7@*F4R"
M6(R9Q)01I)!GG$%=2NP!F]B]\?TO="GH3B&3*8@5WAMBM2)D>UP*85N]00Y,
MW7!J38"FF4S-<'ZMF4S &&J8H8AQQPG6&GA22JF,GOJ:UUKI]3.9FB$\&(^"
MNO)X6\'#DCU;'%GJ]K;)A%%8>*RIHX80+8/]6>Z= J55RO7$(]Q]['B-ZPK6
MP:B37SX?[=%5;6^;S %HE#,80R"$$YXZITL9+9M:*F4'NG[.GHZ0;<:>=7[V
MTV7Q^>=M1;S5W3UY=O]XSIO=Q]D?'UX@R,,O,Q6KD@C%A29&2(1=\$"J\6(S
ML13M#O16)$(XU(3A;E?%S?'ZE8\?RV+]-!]@<(X![ RRB)<;'+'T]<1J1G5'
MA@[ ['\F^/=W!V:"?W^7(>^(MA8$&L-8G(28*H4" ))T/'&$YD3W,T%C"%]K
MFD*PLR"GUDB#E"12<P11!1#7*7;GZTE3Z"RVTA;7 =FSW7(K':W#G'GR:.8Q
M9SI,?=Y!I2&2C#-:2L2A2UE/1FA<=*':K]F2@NB)4Q!.?)-J3S=/(:20\MQ0
M 3WEE#&G!*7 Q;J@#-0Z=]V3B[B[IC#JX+%.WE[<A_#BGSZ(4*R:7#;9H+?,
M:H^Q))XYJ27U2F!)2VP<,Q,[)-$13_9<-MD?[D/-"N?QFLQX*>>Z6,S/8V:W
MGBUF0:0/5WF^.=V\4(4#WE[X^3(,:#Y;O"O6\RWCCD\/=9IGP5*DT@5K$3BK
M@2+*B'LCDFJO#:YE3/<CO5JO _@UY'SZ8,8!,E9H":!SA@#JC;\W>*@!3I*)
M52_I5LG/[S1(078HN^]^D/<UW3:UZ?+L^0PACZCSAD@OF/& 6&)+V9 7$[,
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MCX634E:3*V-R8EE9O=.I,Z1/L(S56[\R);PF%'F-"8".,6RJ+$9D<%).1?/
MSI +5^\;5@VA'2Z@<WT]OT\YC ?\BN5FOKS,EV>'*7.@5>:A05PB#K@QVCE
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M*4?Q1WB"9%@:M8+X9!1Z>[M9;V;+&.]JPJ-'S3++M<  :V$ X^'-"3"Z4E+
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M15HVN+H^-*P@'L3( (.1@<YKZA +:@#(!9NO1#/7*I^T3>X=#XXK,$$$,(2
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M^IL<HG4)W[AW"2J=G<*D1N,+YR'CG#F#B VN#>>:PEIVS))RS =X"-<%J[K
M^3C']A3S<O]<E<NP4?MG^[O+=>K0U\DR]A:ORUY6KUT_G3*\D%!"%/X/!&]5
M8(()LFPK#322I?3K'.#Q5YNLZ1#FW-Y%S\<![?L1!#%&$8K->HD$@+DP,Z7$
MPA-!)&UVT=6-K ^.7.1'-8^G,8^<NJ>VYHSZI2>_M:  :B2<E)Y3K)S7"/N
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M */WNXBV#RLD]@HBI[QFFLO8I95LPDT%@@XU2SWL^BYB]_W;*] S+AX.OZ+
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M/ WPM"PSPY(KDIRMJ"PV+)C>L.RO?H:OC[<RW^\>)7-D-T[UQ\2R:JO'7]3
M\!P=6P2'6L6>F<IQ0!6+'3NM)-1J8X5&M,=0][W?;J?+JUFUO%^438S(*:\I
M@OO&D?1><"NMP@)!(FHTD&9X7$:C17:\["34%>B]&8#WD\5B?4W0=SA[MP8!
M(TLE!,Q)8QA@P K+I8\U7; TGC=JV]>UE[%7BI/:JQYX10&TUB!F=$-FJ/0
M!1QJ%"@G(_,>6F3%H0ZJ[0&>:T_]>SE9EBK,^_GM)O\U_/J1R+I]0PH "+8$
MB6 X8=C]0>S"]K66T-*17=^VK_BJ$YS[9-+1@+K]@PJAC6:Q8@V#1'G"O*"H
MEC)(/K+NJNG*;L">LY ].R#<3+Y/XZ%]_)"Z0-'NB&?]KX=CPIN.CY?)'!D
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MPG'-+1.<"R8< U@(*6HYD58INZQ+.G=,8%3[*)]M>P)VU2(JZ.=.L,,F9^^
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M2P$"% ,4    "  +@@)+0SZI="T6  !7^P  $0              @ $*A $
M97AE;"TR,#$W,#8S,"YX<V102P$"% ,4    "  +@@)+DD6&;6DD   YAP$
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E,#$W,#8S,%]P<F4N>&UL4$L%!@     &  8 B@$  &F  P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
